| Level/ Type |
Code |
Display Name |
Code System |
Designations |
Description |
| 0‑L |
A
|
ALIMENTARY TRACT AND METABOLISM
|
WHO Anatomical Therapeutic Chemical classification |
|
ALIMENTARY TRACT AND METABOLISM |
| 0‑L |
A01
|
STOMATOLOGICAL PREPARATIONS
|
WHO Anatomical Therapeutic Chemical classification |
|
STOMATOLOGICAL PREPARATIONS |
| 0‑L |
A01A
|
STOMATOLOGICAL PREPARATIONS
|
WHO Anatomical Therapeutic Chemical classification |
|
STOMATOLOGICAL PREPARATIONS |
| 0‑L |
A01AA
|
Caries prophylactic agents
|
WHO Anatomical Therapeutic Chemical classification |
|
Caries prophylactic agents |
| 0‑L |
A01AA01
|
sodium fluoride
|
WHO Anatomical Therapeutic Chemical classification |
|
sodium fluoride |
| 0‑L |
A01AA02
|
sodium monofluorophosphate
|
WHO Anatomical Therapeutic Chemical classification |
|
sodium monofluorophosphate |
| 0‑L |
A01AA03
|
olaflur
|
WHO Anatomical Therapeutic Chemical classification |
|
olaflur |
| 0‑L |
A01AA04
|
stannous fluoride
|
WHO Anatomical Therapeutic Chemical classification |
|
stannous fluoride |
| 0‑L |
A01AA30
|
combinations
|
WHO Anatomical Therapeutic Chemical classification |
|
combinations |
| 0‑L |
A01AA51
|
sodium fluoride, combinations
|
WHO Anatomical Therapeutic Chemical classification |
|
sodium fluoride, combinations |
| 0‑L |
A01AB
|
Antiinfectives and antiseptics for local oral treatment
|
WHO Anatomical Therapeutic Chemical classification |
|
Antiinfectives and antiseptics for local oral treatment |
| 0‑L |
A01AB02
|
hydrogen peroxide
|
WHO Anatomical Therapeutic Chemical classification |
|
hydrogen peroxide |
| 0‑L |
A01AB03
|
chlorhexidine
|
WHO Anatomical Therapeutic Chemical classification |
|
chlorhexidine |
| 0‑L |
A01AB04
|
amphotericin B
|
WHO Anatomical Therapeutic Chemical classification |
|
amphotericin B |
| 0‑L |
A01AB05
|
polynoxylin
|
WHO Anatomical Therapeutic Chemical classification |
|
polynoxylin |
| 0‑L |
A01AB06
|
domiphen
|
WHO Anatomical Therapeutic Chemical classification |
|
domiphen |
| 0‑L |
A01AB07
|
oxyquinoline
|
WHO Anatomical Therapeutic Chemical classification |
|
oxyquinoline |
| 0‑L |
A01AB08
|
neomycin
|
WHO Anatomical Therapeutic Chemical classification |
|
neomycin |
| 0‑L |
A01AB09
|
miconazole
|
WHO Anatomical Therapeutic Chemical classification |
|
miconazole |
| 0‑L |
A01AB10
|
natamycin
|
WHO Anatomical Therapeutic Chemical classification |
|
natamycin |
| 0‑L |
A01AB11
|
various
|
WHO Anatomical Therapeutic Chemical classification |
|
various |
| 0‑L |
A01AB12
|
hexetidine
|
WHO Anatomical Therapeutic Chemical classification |
|
hexetidine |
| 0‑L |
A01AB13
|
tetracycline
|
WHO Anatomical Therapeutic Chemical classification |
|
tetracycline |
| 0‑L |
A01AB14
|
benzoxonium chloride
|
WHO Anatomical Therapeutic Chemical classification |
|
benzoxonium chloride |
| 0‑L |
A01AB15
|
tibezonium iodide
|
WHO Anatomical Therapeutic Chemical classification |
|
tibezonium iodide |
| 0‑L |
A01AB16
|
mepartricin
|
WHO Anatomical Therapeutic Chemical classification |
|
mepartricin |
| 0‑L |
A01AB17
|
metronidazole
|
WHO Anatomical Therapeutic Chemical classification |
|
metronidazole |
| 0‑L |
A01AB18
|
clotrimazole
|
WHO Anatomical Therapeutic Chemical classification |
|
clotrimazole |
| 0‑L |
A01AB19
|
sodium perborate
|
WHO Anatomical Therapeutic Chemical classification |
|
sodium perborate |
| 0‑L |
A01AB21
|
chlortetracycline
|
WHO Anatomical Therapeutic Chemical classification |
|
chlortetracycline |
| 0‑L |
A01AB22
|
doxycycline
|
WHO Anatomical Therapeutic Chemical classification |
|
doxycycline |
| 0‑L |
A01AB23
|
minocycline
|
WHO Anatomical Therapeutic Chemical classification |
|
minocycline |
| 0‑L |
A01AC
|
Corticosteroids for local oral treatment
|
WHO Anatomical Therapeutic Chemical classification |
|
Corticosteroids for local oral treatment |
| 0‑L |
A01AC01
|
triamcinolone
|
WHO Anatomical Therapeutic Chemical classification |
|
triamcinolone |
| 0‑L |
A01AC02
|
dexamethasone
|
WHO Anatomical Therapeutic Chemical classification |
|
dexamethasone |
| 0‑L |
A01AC03
|
hydrocortisone
|
WHO Anatomical Therapeutic Chemical classification |
|
hydrocortisone |
| 0‑L |
A01AC54
|
prednisolone, combinations
|
WHO Anatomical Therapeutic Chemical classification |
|
prednisolone, combinations |
| 0‑L |
A01AD
|
Other agents for local oral treatment
|
WHO Anatomical Therapeutic Chemical classification |
|
Other agents for local oral treatment |
| 0‑L |
A01AD01
|
epinephrine
|
WHO Anatomical Therapeutic Chemical classification |
|
epinephrine |
| 0‑L |
A01AD02
|
benzydamine
|
WHO Anatomical Therapeutic Chemical classification |
|
benzydamine |
| 0‑L |
A01AD05
|
acetylsalicylic acid
|
WHO Anatomical Therapeutic Chemical classification |
|
acetylsalicylic acid |
| 0‑L |
A01AD06
|
adrenalone
|
WHO Anatomical Therapeutic Chemical classification |
|
adrenalone |
| 0‑L |
A01AD07
|
amlexanox
|
WHO Anatomical Therapeutic Chemical classification |
|
amlexanox |
| 0‑L |
A01AD08
|
becaplermin
|
WHO Anatomical Therapeutic Chemical classification |
|
becaplermin |
| 0‑L |
A01AD11
|
various
|
WHO Anatomical Therapeutic Chemical classification |
|
various |
| 0‑L |
A02
|
DRUGS FOR ACID RELATED DISORDERS
|
WHO Anatomical Therapeutic Chemical classification |
|
DRUGS FOR ACID RELATED DISORDERS |
| 0‑L |
A02A
|
ANTACIDS
|
WHO Anatomical Therapeutic Chemical classification |
|
ANTACIDS |
| 0‑L |
A02AA
|
Magnesium compounds
|
WHO Anatomical Therapeutic Chemical classification |
|
Magnesium compounds |
| 0‑L |
A02AA01
|
magnesium carbonate
|
WHO Anatomical Therapeutic Chemical classification |
|
magnesium carbonate |
| 0‑L |
A02AA02
|
magnesium oxide
|
WHO Anatomical Therapeutic Chemical classification |
|
magnesium oxide |
| 0‑L |
A02AA03
|
magnesium peroxide
|
WHO Anatomical Therapeutic Chemical classification |
|
magnesium peroxide |
| 0‑L |
A02AA04
|
magnesium hydroxide
|
WHO Anatomical Therapeutic Chemical classification |
|
magnesium hydroxide |
| 0‑L |
A02AA05
|
magnesium silicate
|
WHO Anatomical Therapeutic Chemical classification |
|
magnesium silicate |
| 0‑L |
A02AA10
|
combinations
|
WHO Anatomical Therapeutic Chemical classification |
|
combinations |
| 0‑L |
A02AB
|
Aluminium compounds
|
WHO Anatomical Therapeutic Chemical classification |
|
Aluminium compounds |
| 0‑L |
A02AB01
|
aluminium hydroxide
|
WHO Anatomical Therapeutic Chemical classification |
|
aluminium hydroxide |
| 0‑L |
A02AB02
|
algeldrate
|
WHO Anatomical Therapeutic Chemical classification |
|
algeldrate |
| 0‑L |
A02AB03
|
aluminium phosphate
|
WHO Anatomical Therapeutic Chemical classification |
|
aluminium phosphate |
| 0‑L |
A02AB04
|
dihydroxialumini sodium carbonate
|
WHO Anatomical Therapeutic Chemical classification |
|
dihydroxialumini sodium carbonate |
| 0‑L |
A02AB05
|
aluminium acetoacetate
|
WHO Anatomical Therapeutic Chemical classification |
|
aluminium acetoacetate |
| 0‑L |
A02AB06
|
aloglutamol
|
WHO Anatomical Therapeutic Chemical classification |
|
aloglutamol |
| 0‑L |
A02AB07
|
aluminium glycinate
|
WHO Anatomical Therapeutic Chemical classification |
|
aluminium glycinate |
| 0‑L |
A02AB10
|
combinations
|
WHO Anatomical Therapeutic Chemical classification |
|
combinations |
| 0‑L |
A02AC
|
Calcium compounds
|
WHO Anatomical Therapeutic Chemical classification |
|
Calcium compounds |
| 0‑L |
A02AC01
|
calcium carbonate
|
WHO Anatomical Therapeutic Chemical classification |
|
calcium carbonate |
| 0‑L |
A02AC02
|
calcium silicate
|
WHO Anatomical Therapeutic Chemical classification |
|
calcium silicate |
| 0‑L |
A02AC10
|
combinations
|
WHO Anatomical Therapeutic Chemical classification |
|
combinations |
| 0‑L |
A02AD
|
Combinations and complexes of aluminium, calcium and magnesium compounds
|
WHO Anatomical Therapeutic Chemical classification |
|
Combinations and complexes of aluminium, calcium and magnesium compounds |
| 0‑L |
A02AD01
|
ordinary salt combinations
|
WHO Anatomical Therapeutic Chemical classification |
|
ordinary salt combinations |
| 0‑L |
A02AD02
|
magaldrate
|
WHO Anatomical Therapeutic Chemical classification |
|
magaldrate |
| 0‑L |
A02AD03
|
almagate
|
WHO Anatomical Therapeutic Chemical classification |
|
almagate |
| 0‑L |
A02AD04
|
hydrotalcite
|
WHO Anatomical Therapeutic Chemical classification |
|
hydrotalcite |
| 0‑L |
A02AD05
|
almasilate
|
WHO Anatomical Therapeutic Chemical classification |
|
almasilate |
| 0‑L |
A02AF
|
Antacids with antiflatulents
|
WHO Anatomical Therapeutic Chemical classification |
|
Antacids with antiflatulents |
| 0‑L |
A02AF01
|
magaldrate and antiflatulents
|
WHO Anatomical Therapeutic Chemical classification |
|
magaldrate and antiflatulents |
| 0‑L |
A02AF02
|
ordinary salt combinations and antiflatulents
|
WHO Anatomical Therapeutic Chemical classification |
|
ordinary salt combinations and antiflatulents |
| 0‑L |
A02AG
|
Antacids with antispasmodics
|
WHO Anatomical Therapeutic Chemical classification |
|
Antacids with antispasmodics |
| 0‑L |
A02AH
|
Antacids with sodium bicarbonate
|
WHO Anatomical Therapeutic Chemical classification |
|
Antacids with sodium bicarbonate |
| 0‑L |
A02AX
|
Antacids, other combinations
|
WHO Anatomical Therapeutic Chemical classification |
|
Antacids, other combinations |
| 0‑L |
A02B
|
DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD)
|
WHO Anatomical Therapeutic Chemical classification |
|
DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD) |
| 0‑L |
A02BA
|
H2-receptor antagonists
|
WHO Anatomical Therapeutic Chemical classification |
|
H2-receptor antagonists |
| 0‑L |
A02BA01
|
cimetidine
|
WHO Anatomical Therapeutic Chemical classification |
|
cimetidine |
| 0‑L |
A02BA02
|
ranitidine
|
WHO Anatomical Therapeutic Chemical classification |
|
ranitidine |
| 0‑L |
A02BA03
|
famotidine
|
WHO Anatomical Therapeutic Chemical classification |
|
famotidine |
| 0‑L |
A02BA04
|
nizatidine
|
WHO Anatomical Therapeutic Chemical classification |
|
nizatidine |
| 0‑L |
A02BA05
|
niperotidine
|
WHO Anatomical Therapeutic Chemical classification |
|
niperotidine |
| 0‑L |
A02BA06
|
roxatidine
|
WHO Anatomical Therapeutic Chemical classification |
|
roxatidine |
| 0‑L |
A02BA07
|
ranitidine bismuth citrate
|
WHO Anatomical Therapeutic Chemical classification |
|
ranitidine bismuth citrate |
| 0‑L |
A02BA08
|
lafutidine
|
WHO Anatomical Therapeutic Chemical classification |
|
lafutidine |
| 0‑L |
A02BA51
|
cimetidine, combinations
|
WHO Anatomical Therapeutic Chemical classification |
|
cimetidine, combinations |
| 0‑L |
A02BA53
|
famotidine, combinations
|
WHO Anatomical Therapeutic Chemical classification |
|
famotidine, combinations |
| 0‑L |
A02BB
|
Prostaglandins
|
WHO Anatomical Therapeutic Chemical classification |
|
Prostaglandins |
| 0‑L |
A02BB01
|
misoprostol
|
WHO Anatomical Therapeutic Chemical classification |
|
misoprostol |
| 0‑L |
A02BB02
|
enprostil
|
WHO Anatomical Therapeutic Chemical classification |
|
enprostil |
| 0‑L |
A02BC
|
Proton pump inhibitors
|
WHO Anatomical Therapeutic Chemical classification |
|
Proton pump inhibitors |
| 0‑L |
A02BC01
|
omeprazole
|
WHO Anatomical Therapeutic Chemical classification |
|
omeprazole |
| 0‑L |
A02BC02
|
pantoprazole
|
WHO Anatomical Therapeutic Chemical classification |
|
pantoprazole |
| 0‑L |
A02BC03
|
lansoprazole
|
WHO Anatomical Therapeutic Chemical classification |
|
lansoprazole |
| 0‑L |
A02BC04
|
rabeprazole
|
WHO Anatomical Therapeutic Chemical classification |
|
rabeprazole |
| 0‑L |
A02BC05
|
esomeprazole
|
WHO Anatomical Therapeutic Chemical classification |
|
esomeprazole |
| 0‑L |
A02BC06
|
dexlansoprazole
|
WHO Anatomical Therapeutic Chemical classification |
|
dexlansoprazole |
| 0‑L |
A02BC07
|
dexrabeprazole
|
WHO Anatomical Therapeutic Chemical classification |
|
dexrabeprazole |
| 0‑L |
A02BC53
|
lansoprazole, combinations
|
WHO Anatomical Therapeutic Chemical classification |
|
lansoprazole, combinations |
| 0‑L |
A02BC54
|
rabeprazole, combinations
|
WHO Anatomical Therapeutic Chemical classification |
|
rabeprazole, combinations |
| 0‑L |
A02BD
|
Combinations for eradication of Helicobacter pylori
|
WHO Anatomical Therapeutic Chemical classification |
|
Combinations for eradication of Helicobacter pylori |
| 0‑L |
A02BD01
|
omeprazole, amoxicillin and metronidazole
|
WHO Anatomical Therapeutic Chemical classification |
|
omeprazole, amoxicillin and metronidazole |
| 0‑L |
A02BD02
|
lansoprazole, tetracycline and metronidazole
|
WHO Anatomical Therapeutic Chemical classification |
|
lansoprazole, tetracycline and metronidazole |
| 0‑L |
A02BD03
|
lansoprazole, amoxicillin and metronidazole
|
WHO Anatomical Therapeutic Chemical classification |
|
lansoprazole, amoxicillin and metronidazole |
| 0‑L |
A02BD04
|
pantoprazole, amoxicillin and clarithromycin
|
WHO Anatomical Therapeutic Chemical classification |
|
pantoprazole, amoxicillin and clarithromycin |
| 0‑L |
A02BD05
|
omeprazole, amoxicillin and clarithromycin
|
WHO Anatomical Therapeutic Chemical classification |
|
omeprazole, amoxicillin and clarithromycin |
| 0‑L |
A02BD06
|
esomeprazole, amoxicillin and clarithromycin
|
WHO Anatomical Therapeutic Chemical classification |
|
esomeprazole, amoxicillin and clarithromycin |
| 0‑L |
A02BD07
|
lansoprazole, amoxicillin and clarithromycin
|
WHO Anatomical Therapeutic Chemical classification |
|
lansoprazole, amoxicillin and clarithromycin |
| 0‑L |
A02BD08
|
bismuth subcitrate, tetracycline and metronidazole
|
WHO Anatomical Therapeutic Chemical classification |
|
bismuth subcitrate, tetracycline and metronidazole |
| 0‑L |
A02BD09
|
lansoprazole, clarithromycin and tinidazole
|
WHO Anatomical Therapeutic Chemical classification |
|
lansoprazole, clarithromycin and tinidazole |
| 0‑L |
A02BD10
|
lansoprazole, amoxicillin and levofloxacin
|
WHO Anatomical Therapeutic Chemical classification |
|
lansoprazole, amoxicillin and levofloxacin |
| 0‑L |
A02BD11
|
pantoprazole, amoxicillin, clarithromycin and metronidazole
|
WHO Anatomical Therapeutic Chemical classification |
|
pantoprazole, amoxicillin, clarithromycin and metronidazole |
| 0‑L |
A02BX
|
Other drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD)
|
WHO Anatomical Therapeutic Chemical classification |
|
Other drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) |
| 0‑L |
A02BX01
|
carbenoxolone
|
WHO Anatomical Therapeutic Chemical classification |
|
carbenoxolone |
| 0‑L |
A02BX02
|
sucralfate
|
WHO Anatomical Therapeutic Chemical classification |
|
sucralfate |
| 0‑L |
A02BX03
|
pirenzepine
|
WHO Anatomical Therapeutic Chemical classification |
|
pirenzepine |
| 0‑L |
A02BX04
|
methiosulfonium chloride
|
WHO Anatomical Therapeutic Chemical classification |
|
methiosulfonium chloride |
| 0‑L |
A02BX05
|
bismuth subcitrate
|
WHO Anatomical Therapeutic Chemical classification |
|
bismuth subcitrate |
| 0‑L |
A02BX06
|
proglumide
|
WHO Anatomical Therapeutic Chemical classification |
|
proglumide |
| 0‑L |
A02BX07
|
gefarnate
|
WHO Anatomical Therapeutic Chemical classification |
|
gefarnate |
| 0‑L |
A02BX08
|
sulglicotide
|
WHO Anatomical Therapeutic Chemical classification |
|
sulglicotide |
| 0‑L |
A02BX09
|
acetoxolone
|
WHO Anatomical Therapeutic Chemical classification |
|
acetoxolone |
| 0‑L |
A02BX10
|
zolimidine
|
WHO Anatomical Therapeutic Chemical classification |
|
zolimidine |
| 0‑L |
A02BX11
|
troxipide
|
WHO Anatomical Therapeutic Chemical classification |
|
troxipide |
| 0‑L |
A02BX12
|
bismuth subnitrate
|
WHO Anatomical Therapeutic Chemical classification |
|
bismuth subnitrate |
| 0‑L |
A02BX13
|
alginic acid
|
WHO Anatomical Therapeutic Chemical classification |
|
alginic acid |
| 0‑L |
A02BX51
|
carbenoxolone, combinations excl. psycholeptics
|
WHO Anatomical Therapeutic Chemical classification |
|
carbenoxolone, combinations excl. psycholeptics |
| 0‑L |
A02BX71
|
carbenoxolone, combinations with psycholeptics
|
WHO Anatomical Therapeutic Chemical classification |
|
carbenoxolone, combinations with psycholeptics |
| 0‑L |
A02BX77
|
gefarnate, combinations with psycholeptics
|
WHO Anatomical Therapeutic Chemical classification |
|
gefarnate, combinations with psycholeptics |
| 0‑L |
A02X
|
OTHER DRUGS FOR ACID RELATED DISORDERS
|
WHO Anatomical Therapeutic Chemical classification |
|
OTHER DRUGS FOR ACID RELATED DISORDERS |
| 0‑L |
A03
|
DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS
|
WHO Anatomical Therapeutic Chemical classification |
|
DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS |
| 0‑L |
A03A
|
DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS
|
WHO Anatomical Therapeutic Chemical classification |
|
DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS |
| 0‑L |
A03AA
|
Synthetic anticholinergics, esters with tertiary amino group
|
WHO Anatomical Therapeutic Chemical classification |
|
Synthetic anticholinergics, esters with tertiary amino group |
| 0‑L |
A03AA01
|
oxyphencyclimine
|
WHO Anatomical Therapeutic Chemical classification |
|
oxyphencyclimine |
| 0‑L |
A03AA03
|
camylofin
|
WHO Anatomical Therapeutic Chemical classification |
|
camylofin |
| 0‑L |
A03AA04
|
mebeverine
|
WHO Anatomical Therapeutic Chemical classification |
|
mebeverine |
| 0‑L |
A03AA05
|
trimebutine
|
WHO Anatomical Therapeutic Chemical classification |
|
trimebutine |
| 0‑L |
A03AA06
|
rociverine
|
WHO Anatomical Therapeutic Chemical classification |
|
rociverine |
| 0‑L |
A03AA07
|
dicycloverine
|
WHO Anatomical Therapeutic Chemical classification |
|
dicycloverine |
| 0‑L |
A03AA08
|
dihexyverine
|
WHO Anatomical Therapeutic Chemical classification |
|
dihexyverine |
| 0‑L |
A03AA09
|
difemerine
|
WHO Anatomical Therapeutic Chemical classification |
|
difemerine |
| 0‑L |
A03AA30
|
piperidolate
|
WHO Anatomical Therapeutic Chemical classification |
|
piperidolate |
| 0‑L |
A03AB
|
Synthetic anticholinergics, quaternary ammonium compounds
|
WHO Anatomical Therapeutic Chemical classification |
|
Synthetic anticholinergics, quaternary ammonium compounds |
| 0‑L |
A03AB01
|
benzilone
|
WHO Anatomical Therapeutic Chemical classification |
|
benzilone |
| 0‑L |
A03AB02
|
glycopyrronium bromide
|
WHO Anatomical Therapeutic Chemical classification |
|
glycopyrronium bromide |
| 0‑L |
A03AB03
|
oxyphenonium
|
WHO Anatomical Therapeutic Chemical classification |
|
oxyphenonium |
| 0‑L |
A03AB04
|
penthienate
|
WHO Anatomical Therapeutic Chemical classification |
|
penthienate |
| 0‑L |
A03AB05
|
propantheline
|
WHO Anatomical Therapeutic Chemical classification |
|
propantheline |
| 0‑L |
A03AB06
|
otilonium bromide
|
WHO Anatomical Therapeutic Chemical classification |
|
otilonium bromide |
| 0‑L |
A03AB07
|
methantheline
|
WHO Anatomical Therapeutic Chemical classification |
|
methantheline |
| 0‑L |
A03AB08
|
tridihexethyl
|
WHO Anatomical Therapeutic Chemical classification |
|
tridihexethyl |
| 0‑L |
A03AB09
|
isopropamide
|
WHO Anatomical Therapeutic Chemical classification |
|
isopropamide |
| 0‑L |
A03AB10
|
hexocyclium
|
WHO Anatomical Therapeutic Chemical classification |
|
hexocyclium |
| 0‑L |
A03AB11
|
poldine
|
WHO Anatomical Therapeutic Chemical classification |
|
poldine |
| 0‑L |
A03AB12
|
mepenzolate
|
WHO Anatomical Therapeutic Chemical classification |
|
mepenzolate |
| 0‑L |
A03AB13
|
bevonium
|
WHO Anatomical Therapeutic Chemical classification |
|
bevonium |
| 0‑L |
A03AB14
|
pipenzolate
|
WHO Anatomical Therapeutic Chemical classification |
|
pipenzolate |
| 0‑L |
A03AB15
|
diphemanil
|
WHO Anatomical Therapeutic Chemical classification |
|
diphemanil |
| 0‑L |
A03AB16
|
(2-benzhydryloxyethyl)diethyl-methylammonium iodide
|
WHO Anatomical Therapeutic Chemical classification |
|
(2-benzhydryloxyethyl)diethyl-methylammonium iodide |
| 0‑L |
A03AB17
|
tiemonium iodide
|
WHO Anatomical Therapeutic Chemical classification |
|
tiemonium iodide |
| 0‑L |
A03AB18
|
prifinium bromide
|
WHO Anatomical Therapeutic Chemical classification |
|
prifinium bromide |
| 0‑L |
A03AB19
|
timepidium bromide
|
WHO Anatomical Therapeutic Chemical classification |
|
timepidium bromide |
| 0‑L |
A03AB21
|
fenpiverinium
|
WHO Anatomical Therapeutic Chemical classification |
|
fenpiverinium |
| 0‑L |
A03AB53
|
oxyphenonium, combinations
|
WHO Anatomical Therapeutic Chemical classification |
|
oxyphenonium, combinations |
| 0‑L |
A03AC
|
Synthetic antispasmodics, amides with tertiary amines
|
WHO Anatomical Therapeutic Chemical classification |
|
Synthetic antispasmodics, amides with tertiary amines |
| 0‑L |
A03AC02
|
dimethylaminopropionylphenothiazine
|
WHO Anatomical Therapeutic Chemical classification |
|
dimethylaminopropionylphenothiazine |
| 0‑L |
A03AC04
|
nicofetamide
|
WHO Anatomical Therapeutic Chemical classification |
|
nicofetamide |
| 0‑L |
A03AC05
|
tiropramide
|
WHO Anatomical Therapeutic Chemical classification |
|
tiropramide |
| 0‑L |
A03AD
|
Papaverine and derivatives
|
WHO Anatomical Therapeutic Chemical classification |
|
Papaverine and derivatives |
| 0‑L |
A03AD01
|
papaverine
|
WHO Anatomical Therapeutic Chemical classification |
|
papaverine |
| 0‑L |
A03AD02
|
drotaverine
|
WHO Anatomical Therapeutic Chemical classification |
|
drotaverine |
| 0‑L |
A03AD30
|
moxaverine
|
WHO Anatomical Therapeutic Chemical classification |
|
moxaverine |
| 0‑L |
A03AE
|
Serotonin receptor antagonists
|
WHO Anatomical Therapeutic Chemical classification |
|
Serotonin receptor antagonists |
| 0‑L |
A03AE01
|
alosetron
|
WHO Anatomical Therapeutic Chemical classification |
|
alosetron |
| 0‑L |
A03AE03
|
cilansetron
|
WHO Anatomical Therapeutic Chemical classification |
|
cilansetron |
| 0‑L |
A03AX
|
Other drugs for functional gastrointestinal disorders
|
WHO Anatomical Therapeutic Chemical classification |
|
Other drugs for functional gastrointestinal disorders |
| 0‑L |
A03AX01
|
fenpiprane
|
WHO Anatomical Therapeutic Chemical classification |
|
fenpiprane |
| 0‑L |
A03AX02
|
diisopromine
|
WHO Anatomical Therapeutic Chemical classification |
|
diisopromine |
| 0‑L |
A03AX03
|
chlorbenzoxamine
|
WHO Anatomical Therapeutic Chemical classification |
|
chlorbenzoxamine |
| 0‑L |
A03AX04
|
pinaverium
|
WHO Anatomical Therapeutic Chemical classification |
|
pinaverium |
| 0‑L |
A03AX05
|
fenoverine
|
WHO Anatomical Therapeutic Chemical classification |
|
fenoverine |
| 0‑L |
A03AX06
|
idanpramine
|
WHO Anatomical Therapeutic Chemical classification |
|
idanpramine |
| 0‑L |
A03AX07
|
proxazole
|
WHO Anatomical Therapeutic Chemical classification |
|
proxazole |
| 0‑L |
A03AX08
|
alverine
|
WHO Anatomical Therapeutic Chemical classification |
|
alverine |
| 0‑L |
A03AX09
|
trepibutone
|
WHO Anatomical Therapeutic Chemical classification |
|
trepibutone |
| 0‑L |
A03AX10
|
isometheptene
|
WHO Anatomical Therapeutic Chemical classification |
|
isometheptene |
| 0‑L |
A03AX11
|
caroverine
|
WHO Anatomical Therapeutic Chemical classification |
|
caroverine |
| 0‑L |
A03AX12
|
phloroglucinol
|
WHO Anatomical Therapeutic Chemical classification |
|
phloroglucinol |
| 0‑L |
A03AX13
|
silicones
|
WHO Anatomical Therapeutic Chemical classification |
|
silicones |
| 0‑L |
A03AX14
|
valethamate
|
WHO Anatomical Therapeutic Chemical classification |
|
valethamate |
| 0‑L |
A03AX30
|
trimethyldiphenylpropylamine
|
WHO Anatomical Therapeutic Chemical classification |
|
trimethyldiphenylpropylamine |
| 0‑L |
A03AX58
|
alverine, combinations
|
WHO Anatomical Therapeutic Chemical classification |
|
alverine, combinations |
| 0‑L |
A03B
|
BELLADONNA AND DERIVATIVES, PLAIN
|
WHO Anatomical Therapeutic Chemical classification |
|
BELLADONNA AND DERIVATIVES, PLAIN |
| 0‑L |
A03BA
|
Belladonna alkaloids, tertiary amines
|
WHO Anatomical Therapeutic Chemical classification |
|
Belladonna alkaloids, tertiary amines |
| 0‑L |
A03BA01
|
atropine
|
WHO Anatomical Therapeutic Chemical classification |
|
atropine |
| 0‑L |
A03BA03
|
hyoscyamine
|
WHO Anatomical Therapeutic Chemical classification |
|
hyoscyamine |
| 0‑L |
A03BA04
|
belladonna total alkaloids
|
WHO Anatomical Therapeutic Chemical classification |
|
belladonna total alkaloids |
| 0‑L |
A03BB
|
Belladonna alkaloids, semisynthetic, quaternary ammonium compounds
|
WHO Anatomical Therapeutic Chemical classification |
|
Belladonna alkaloids, semisynthetic, quaternary ammonium compounds |
| 0‑L |
A03BB01
|
butylscopolamine
|
WHO Anatomical Therapeutic Chemical classification |
|
butylscopolamine |
| 0‑L |
A03BB02
|
methylatropine
|
WHO Anatomical Therapeutic Chemical classification |
|
methylatropine |
| 0‑L |
A03BB03
|
methylscopolamine
|
WHO Anatomical Therapeutic Chemical classification |
|
methylscopolamine |
| 0‑L |
A03BB04
|
fentonium
|
WHO Anatomical Therapeutic Chemical classification |
|
fentonium |
| 0‑L |
A03BB05
|
cimetropium bromide
|
WHO Anatomical Therapeutic Chemical classification |
|
cimetropium bromide |
| 0‑L |
A03C
|
ANTISPASMODICS IN COMBINATION WITH PSYCHOLEPTICS
|
WHO Anatomical Therapeutic Chemical classification |
|
ANTISPASMODICS IN COMBINATION WITH PSYCHOLEPTICS |
| 0‑L |
A03CA
|
Synthetic anticholinergic agents in combination with psycholeptics
|
WHO Anatomical Therapeutic Chemical classification |
|
Synthetic anticholinergic agents in combination with psycholeptics |
| 0‑L |
A03CA01
|
isopropamide and psycholeptics
|
WHO Anatomical Therapeutic Chemical classification |
|
isopropamide and psycholeptics |
| 0‑L |
A03CA02
|
clidinium and psycholeptics
|
WHO Anatomical Therapeutic Chemical classification |
|
clidinium and psycholeptics |
| 0‑L |
A03CA03
|
oxyphencyclimine and psycholeptics
|
WHO Anatomical Therapeutic Chemical classification |
|
oxyphencyclimine and psycholeptics |
| 0‑L |
A03CA04
|
otilonium bromide and psycholeptics
|
WHO Anatomical Therapeutic Chemical classification |
|
otilonium bromide and psycholeptics |
| 0‑L |
A03CA05
|
glycopyrronium bromide and psycholeptics
|
WHO Anatomical Therapeutic Chemical classification |
|
glycopyrronium bromide and psycholeptics |
| 0‑L |
A03CA06
|
bevonium and psycholeptics
|
WHO Anatomical Therapeutic Chemical classification |
|
bevonium and psycholeptics |
| 0‑L |
A03CA07
|
ambutonium and psycholeptics
|
WHO Anatomical Therapeutic Chemical classification |
|
ambutonium and psycholeptics |
| 0‑L |
A03CA08
|
diphemanil and psycholeptics
|
WHO Anatomical Therapeutic Chemical classification |
|
diphemanil and psycholeptics |
| 0‑L |
A03CA09
|
pipenzolate and psycholeptics
|
WHO Anatomical Therapeutic Chemical classification |
|
pipenzolate and psycholeptics |
| 0‑L |
A03CA30
|
emepronium and psycholeptics
|
WHO Anatomical Therapeutic Chemical classification |
|
emepronium and psycholeptics |
| 0‑L |
A03CA34
|
propantheline and psycholeptics
|
WHO Anatomical Therapeutic Chemical classification |
|
propantheline and psycholeptics |
| 0‑L |
A03CB
|
Belladonna and derivatives in combination with psycholeptics
|
WHO Anatomical Therapeutic Chemical classification |
|
Belladonna and derivatives in combination with psycholeptics |
| 0‑L |
A03CB01
|
methylscopolamine and psycholeptics
|
WHO Anatomical Therapeutic Chemical classification |
|
methylscopolamine and psycholeptics |
| 0‑L |
A03CB02
|
belladonna total alkaloids and psycholeptics
|
WHO Anatomical Therapeutic Chemical classification |
|
belladonna total alkaloids and psycholeptics |
| 0‑L |
A03CB03
|
atropine and psycholeptics
|
WHO Anatomical Therapeutic Chemical classification |
|
atropine and psycholeptics |
| 0‑L |
A03CB04
|
methylhomatropine and psycholeptics
|
WHO Anatomical Therapeutic Chemical classification |
|
methylhomatropine and psycholeptics |
| 0‑L |
A03CB31
|
hyoscyamine and psycholeptics
|
WHO Anatomical Therapeutic Chemical classification |
|
hyoscyamine and psycholeptics |
| 0‑L |
A03CC
|
Other antispasmodics in combination with psycholeptics
|
WHO Anatomical Therapeutic Chemical classification |
|
Other antispasmodics in combination with psycholeptics |
| 0‑L |
A03D
|
ANTISPASMODICS IN COMBINATION WITH ANALGESICS
|
WHO Anatomical Therapeutic Chemical classification |
|
ANTISPASMODICS IN COMBINATION WITH ANALGESICS |
| 0‑L |
A03DA
|
Synthetic anticholinergic agents in combination with analgesics
|
WHO Anatomical Therapeutic Chemical classification |
|
Synthetic anticholinergic agents in combination with analgesics |
| 0‑L |
A03DA01
|
tropenzilone and analgesics
|
WHO Anatomical Therapeutic Chemical classification |
|
tropenzilone and analgesics |
| 0‑L |
A03DA02
|
pitofenone and analgesics
|
WHO Anatomical Therapeutic Chemical classification |
|
pitofenone and analgesics |
| 0‑L |
A03DA03
|
bevonium and analgesics
|
WHO Anatomical Therapeutic Chemical classification |
|
bevonium and analgesics |
| 0‑L |
A03DA04
|
ciclonium and analgesics
|
WHO Anatomical Therapeutic Chemical classification |
|
ciclonium and analgesics |
| 0‑L |
A03DA05
|
camylofin and analgesics
|
WHO Anatomical Therapeutic Chemical classification |
|
camylofin and analgesics |
| 0‑L |
A03DA06
|
trospium and analgesics
|
WHO Anatomical Therapeutic Chemical classification |
|
trospium and analgesics |
| 0‑L |
A03DA07
|
tiemonium iodide and analgesics
|
WHO Anatomical Therapeutic Chemical classification |
|
tiemonium iodide and analgesics |
| 0‑L |
A03DB
|
Belladonna and derivatives in combination with analgesics
|
WHO Anatomical Therapeutic Chemical classification |
|
Belladonna and derivatives in combination with analgesics |
| 0‑L |
A03DB04
|
butylscopolamine and analgesics
|
WHO Anatomical Therapeutic Chemical classification |
|
butylscopolamine and analgesics |
| 0‑L |
A03DC
|
Other antispasmodics in combination with analgesics
|
WHO Anatomical Therapeutic Chemical classification |
|
Other antispasmodics in combination with analgesics |
| 0‑L |
A03E
|
ANTISPASMODICS AND ANTICHOLINERGICS IN COMBINATION WITH OTHER DRUGS
|
WHO Anatomical Therapeutic Chemical classification |
|
ANTISPASMODICS AND ANTICHOLINERGICS IN COMBINATION WITH OTHER DRUGS |
| 0‑L |
A03EA
|
Antispasmodics, psycholeptics and analgesics in combination
|
WHO Anatomical Therapeutic Chemical classification |
|
Antispasmodics, psycholeptics and analgesics in combination |
| 0‑L |
A03ED
|
Antispasmodics in combination with other drugs
|
WHO Anatomical Therapeutic Chemical classification |
|
Antispasmodics in combination with other drugs |
| 0‑L |
A03F
|
PROPULSIVES
|
WHO Anatomical Therapeutic Chemical classification |
|
PROPULSIVES |
| 0‑L |
A03FA
|
Propulsives
|
WHO Anatomical Therapeutic Chemical classification |
|
Propulsives |
| 0‑L |
A03FA01
|
metoclopramide
|
WHO Anatomical Therapeutic Chemical classification |
|
metoclopramide |
| 0‑L |
A03FA02
|
cisapride
|
WHO Anatomical Therapeutic Chemical classification |
|
cisapride |
| 0‑L |
A03FA03
|
domperidone
|
WHO Anatomical Therapeutic Chemical classification |
|
domperidone |
| 0‑L |
A03FA04
|
bromopride
|
WHO Anatomical Therapeutic Chemical classification |
|
bromopride |
| 0‑L |
A03FA05
|
alizapride
|
WHO Anatomical Therapeutic Chemical classification |
|
alizapride |
| 0‑L |
A03FA06
|
clebopride
|
WHO Anatomical Therapeutic Chemical classification |
|
clebopride |
| 0‑L |
A03FA07
|
itopride
|
WHO Anatomical Therapeutic Chemical classification |
|
itopride |
| 0‑L |
A03FA08
|
cinitapride
|
WHO Anatomical Therapeutic Chemical classification |
|
cinitapride |
| 0‑L |
A04
|
ANTIEMETICS AND ANTINAUSEANTS
|
WHO Anatomical Therapeutic Chemical classification |
|
ANTIEMETICS AND ANTINAUSEANTS |
| 0‑L |
A04A
|
ANTIEMETICS AND ANTINAUSEANTS
|
WHO Anatomical Therapeutic Chemical classification |
|
ANTIEMETICS AND ANTINAUSEANTS |
| 0‑L |
A04AA
|
Serotonin (5HT3) antagonists
|
WHO Anatomical Therapeutic Chemical classification |
|
Serotonin (5HT3) antagonists |
| 0‑L |
A04AA01
|
ondansetron
|
WHO Anatomical Therapeutic Chemical classification |
|
ondansetron |
| 0‑L |
A04AA02
|
granisetron
|
WHO Anatomical Therapeutic Chemical classification |
|
granisetron |
| 0‑L |
A04AA03
|
tropisetron
|
WHO Anatomical Therapeutic Chemical classification |
|
tropisetron |
| 0‑L |
A04AA04
|
dolasetron
|
WHO Anatomical Therapeutic Chemical classification |
|
dolasetron |
| 0‑L |
A04AA05
|
palonosetron
|
WHO Anatomical Therapeutic Chemical classification |
|
palonosetron |
| 0‑L |
A04AA55
|
palonosetron, combinations
|
WHO Anatomical Therapeutic Chemical classification |
|
palonosetron, combinations |
| 0‑L |
A04AD
|
Other antiemetics
|
WHO Anatomical Therapeutic Chemical classification |
|
Other antiemetics |
| 0‑L |
A04AD01
|
scopolamine
|
WHO Anatomical Therapeutic Chemical classification |
|
scopolamine |
| 0‑L |
A04AD02
|
cerium oxalate
|
WHO Anatomical Therapeutic Chemical classification |
|
cerium oxalate |
| 0‑L |
A04AD04
|
chlorobutanol
|
WHO Anatomical Therapeutic Chemical classification |
|
chlorobutanol |
| 0‑L |
A04AD05
|
metopimazine
|
WHO Anatomical Therapeutic Chemical classification |
|
metopimazine |
| 0‑L |
A04AD10
|
dronabinol
|
WHO Anatomical Therapeutic Chemical classification |
|
dronabinol |
| 0‑L |
A04AD11
|
nabilone
|
WHO Anatomical Therapeutic Chemical classification |
|
nabilone |
| 0‑L |
A04AD12
|
aprepitant
|
WHO Anatomical Therapeutic Chemical classification |
|
aprepitant |
| 0‑L |
A04AD13
|
casopitant
|
WHO Anatomical Therapeutic Chemical classification |
|
casopitant |
| 0‑L |
A04AD14
|
rolapitant
|
WHO Anatomical Therapeutic Chemical classification |
|
rolapitant |
| 0‑L |
A04AD51
|
scopolamine, combinations
|
WHO Anatomical Therapeutic Chemical classification |
|
scopolamine, combinations |
| 0‑L |
A04AD54
|
chlorobutanol, combinations
|
WHO Anatomical Therapeutic Chemical classification |
|
chlorobutanol, combinations |
| 0‑L |
A05
|
BILE AND LIVER THERAPY
|
WHO Anatomical Therapeutic Chemical classification |
|
BILE AND LIVER THERAPY |
| 0‑L |
A05A
|
BILE THERAPY
|
WHO Anatomical Therapeutic Chemical classification |
|
BILE THERAPY |
| 0‑L |
A05AA
|
Bile acid preparations
|
WHO Anatomical Therapeutic Chemical classification |
|
Bile acid preparations |
| 0‑L |
A05AA01
|
chenodeoxycholic acid
|
WHO Anatomical Therapeutic Chemical classification |
|
chenodeoxycholic acid |
| 0‑L |
A05AA02
|
ursodeoxycholic acid
|
WHO Anatomical Therapeutic Chemical classification |
|
ursodeoxycholic acid |
| 0‑L |
A05AA03
|
cholic acid
|
WHO Anatomical Therapeutic Chemical classification |
|
cholic acid |
| 0‑L |
A05AA04
|
obeticholic acid
|
WHO Anatomical Therapeutic Chemical classification |
|
obeticholic acid |
| 0‑L |
A05AB
|
Preparations for biliary tract therapy
|
WHO Anatomical Therapeutic Chemical classification |
|
Preparations for biliary tract therapy |
| 0‑L |
A05AB01
|
nicotinyl methylamide
|
WHO Anatomical Therapeutic Chemical classification |
|
nicotinyl methylamide |
| 0‑L |
A05AX
|
Other drugs for bile therapy
|
WHO Anatomical Therapeutic Chemical classification |
|
Other drugs for bile therapy |
| 0‑L |
A05AX01
|
piprozolin
|
WHO Anatomical Therapeutic Chemical classification |
|
piprozolin |
| 0‑L |
A05AX02
|
hymecromone
|
WHO Anatomical Therapeutic Chemical classification |
|
hymecromone |
| 0‑L |
A05AX03
|
cyclobutyrol
|
WHO Anatomical Therapeutic Chemical classification |
|
cyclobutyrol |
| 0‑L |
A05B
|
LIVER THERAPY, LIPOTROPICS
|
WHO Anatomical Therapeutic Chemical classification |
|
LIVER THERAPY, LIPOTROPICS |
| 0‑L |
A05BA
|
Liver therapy
|
WHO Anatomical Therapeutic Chemical classification |
|
Liver therapy |
| 0‑L |
A05BA01
|
arginine glutamate
|
WHO Anatomical Therapeutic Chemical classification |
|
arginine glutamate |
| 0‑L |
A05BA03
|
silymarin
|
WHO Anatomical Therapeutic Chemical classification |
|
silymarin |
| 0‑L |
A05BA04
|
citiolone
|
WHO Anatomical Therapeutic Chemical classification |
|
citiolone |
| 0‑L |
A05BA05
|
epomediol
|
WHO Anatomical Therapeutic Chemical classification |
|
epomediol |
| 0‑L |
A05BA06
|
ornithine oxoglurate
|
WHO Anatomical Therapeutic Chemical classification |
|
ornithine oxoglurate |
| 0‑L |
A05BA07
|
tidiacic arginine
|
WHO Anatomical Therapeutic Chemical classification |
|
tidiacic arginine |
| 0‑L |
A05BA08
|
glycyrrhizic acid
|
WHO Anatomical Therapeutic Chemical classification |
|
glycyrrhizic acid |
| 0‑L |
A05C
|
DRUGS FOR BILE THERAPY AND LIPOTROPICS IN COMBINATION
|
WHO Anatomical Therapeutic Chemical classification |
|
DRUGS FOR BILE THERAPY AND LIPOTROPICS IN COMBINATION |
| 0‑L |
A06
|
DRUGS FOR CONSTIPATION
|
WHO Anatomical Therapeutic Chemical classification |
|
DRUGS FOR CONSTIPATION |
| 0‑L |
A06A
|
DRUGS FOR CONSTIPATION
|
WHO Anatomical Therapeutic Chemical classification |
|
DRUGS FOR CONSTIPATION |
| 0‑L |
A06AA
|
Softeners, emollients
|
WHO Anatomical Therapeutic Chemical classification |
|
Softeners, emollients |
| 0‑L |
A06AA01
|
liquid paraffin
|
WHO Anatomical Therapeutic Chemical classification |
|
liquid paraffin |
| 0‑L |
A06AA02
|
docusate sodium
|
WHO Anatomical Therapeutic Chemical classification |
|
docusate sodium |
| 0‑L |
A06AA51
|
liquid paraffin, combinations
|
WHO Anatomical Therapeutic Chemical classification |
|
liquid paraffin, combinations |
| 0‑L |
A06AB
|
Contact laxatives
|
WHO Anatomical Therapeutic Chemical classification |
|
Contact laxatives |
| 0‑L |
A06AB01
|
oxyphenisatine
|
WHO Anatomical Therapeutic Chemical classification |
|
oxyphenisatine |
| 0‑L |
A06AB02
|
bisacodyl
|
WHO Anatomical Therapeutic Chemical classification |
|
bisacodyl |
| 0‑L |
A06AB03
|
dantron
|
WHO Anatomical Therapeutic Chemical classification |
|
dantron |
| 0‑L |
A06AB04
|
phenolphthalein
|
WHO Anatomical Therapeutic Chemical classification |
|
phenolphthalein |
| 0‑L |
A06AB05
|
castor oil
|
WHO Anatomical Therapeutic Chemical classification |
|
castor oil |
| 0‑L |
A06AB06
|
senna glycosides
|
WHO Anatomical Therapeutic Chemical classification |
|
senna glycosides |
| 0‑L |
A06AB07
|
cascara
|
WHO Anatomical Therapeutic Chemical classification |
|
cascara |
| 0‑L |
A06AB08
|
sodium picosulfate
|
WHO Anatomical Therapeutic Chemical classification |
|
sodium picosulfate |
| 0‑L |
A06AB09
|
bisoxatin
|
WHO Anatomical Therapeutic Chemical classification |
|
bisoxatin |
| 0‑L |
A06AB20
|
contact laxatives in combination
|
WHO Anatomical Therapeutic Chemical classification |
|
contact laxatives in combination |
| 0‑L |
A06AB30
|
contact laxatives in combination with belladonna alkaloids
|
WHO Anatomical Therapeutic Chemical classification |
|
contact laxatives in combination with belladonna alkaloids |
| 0‑L |
A06AB52
|
bisacodyl, combinations
|
WHO Anatomical Therapeutic Chemical classification |
|
bisacodyl, combinations |
| 0‑L |
A06AB53
|
dantron, combinations
|
WHO Anatomical Therapeutic Chemical classification |
|
dantron, combinations |
| 0‑L |
A06AB56
|
senna glycosides, combinations
|
WHO Anatomical Therapeutic Chemical classification |
|
senna glycosides, combinations |
| 0‑L |
A06AB57
|
cascara, combinations
|
WHO Anatomical Therapeutic Chemical classification |
|
cascara, combinations |
| 0‑L |
A06AB58
|
sodium picosulfate, combinations
|
WHO Anatomical Therapeutic Chemical classification |
|
sodium picosulfate, combinations |
| 0‑L |
A06AC
|
Bulk-forming laxatives
|
WHO Anatomical Therapeutic Chemical classification |
|
Bulk-forming laxatives |
| 0‑L |
A06AC01
|
ispaghula (psylla seeds)
|
WHO Anatomical Therapeutic Chemical classification |
|
ispaghula (psylla seeds) |
| 0‑L |
A06AC02
|
ethulose
|
WHO Anatomical Therapeutic Chemical classification |
|
ethulose |
| 0‑L |
A06AC03
|
sterculia
|
WHO Anatomical Therapeutic Chemical classification |
|
sterculia |
| 0‑L |
A06AC05
|
linseed
|
WHO Anatomical Therapeutic Chemical classification |
|
linseed |
| 0‑L |
A06AC06
|
methylcellulose
|
WHO Anatomical Therapeutic Chemical classification |
|
methylcellulose |
| 0‑L |
A06AC07
|
triticum (wheat fibre)
|
WHO Anatomical Therapeutic Chemical classification |
|
triticum (wheat fibre) |
| 0‑L |
A06AC08
|
polycarbophil calcium
|
WHO Anatomical Therapeutic Chemical classification |
|
polycarbophil calcium |
| 0‑L |
A06AC51
|
ispaghula, combinations
|
WHO Anatomical Therapeutic Chemical classification |
|
ispaghula, combinations |
| 0‑L |
A06AC53
|
sterculia, combinations
|
WHO Anatomical Therapeutic Chemical classification |
|
sterculia, combinations |
| 0‑L |
A06AC55
|
linseed, combinations
|
WHO Anatomical Therapeutic Chemical classification |
|
linseed, combinations |
| 0‑L |
A06AD
|
Osmotically acting laxatives
|
WHO Anatomical Therapeutic Chemical classification |
|
Osmotically acting laxatives |
| 0‑L |
A06AD01
|
magnesium carbonate
|
WHO Anatomical Therapeutic Chemical classification |
|
magnesium carbonate |
| 0‑L |
A06AD02
|
magnesium oxide
|
WHO Anatomical Therapeutic Chemical classification |
|
magnesium oxide |
| 0‑L |
A06AD03
|
magnesium peroxide
|
WHO Anatomical Therapeutic Chemical classification |
|
magnesium peroxide |
| 0‑L |
A06AD04
|
magnesium sulfate
|
WHO Anatomical Therapeutic Chemical classification |
|
magnesium sulfate |
| 0‑L |
A06AD10
|
mineral salts in combination
|
WHO Anatomical Therapeutic Chemical classification |
|
mineral salts in combination |
| 0‑L |
A06AD11
|
lactulose
|
WHO Anatomical Therapeutic Chemical classification |
|
lactulose |
| 0‑L |
A06AD12
|
lactitol
|
WHO Anatomical Therapeutic Chemical classification |
|
lactitol |
| 0‑L |
A06AD13
|
sodium sulfate
|
WHO Anatomical Therapeutic Chemical classification |
|
sodium sulfate |
| 0‑L |
A06AD14
|
pentaerithrityl
|
WHO Anatomical Therapeutic Chemical classification |
|
pentaerithrityl |
| 0‑L |
A06AD15
|
macrogol
|
WHO Anatomical Therapeutic Chemical classification |
|
macrogol |
| 0‑L |
A06AD16
|
mannitol
|
WHO Anatomical Therapeutic Chemical classification |
|
mannitol |
| 0‑L |
A06AD17
|
sodium phosphate
|
WHO Anatomical Therapeutic Chemical classification |
|
sodium phosphate |
| 0‑L |
A06AD18
|
sorbitol
|
WHO Anatomical Therapeutic Chemical classification |
|
sorbitol |
| 0‑L |
A06AD19
|
magnesium citrate
|
WHO Anatomical Therapeutic Chemical classification |
|
magnesium citrate |
| 0‑L |
A06AD21
|
sodium tartrate
|
WHO Anatomical Therapeutic Chemical classification |
|
sodium tartrate |
| 0‑L |
A06AD61
|
lactulose, combinations
|
WHO Anatomical Therapeutic Chemical classification |
|
lactulose, combinations |
| 0‑L |
A06AD65
|
macrogol, combinations
|
WHO Anatomical Therapeutic Chemical classification |
|
macrogol, combinations |
| 0‑L |
A06AG
|
Enemas
|
WHO Anatomical Therapeutic Chemical classification |
|
Enemas |
| 0‑L |
A06AG01
|
sodium phosphate
|
WHO Anatomical Therapeutic Chemical classification |
|
sodium phosphate |
| 0‑L |
A06AG02
|
bisacodyl
|
WHO Anatomical Therapeutic Chemical classification |
|
bisacodyl |
| 0‑L |
A06AG03
|
dantron, incl. combinations
|
WHO Anatomical Therapeutic Chemical classification |
|
dantron, incl. combinations |
| 0‑L |
A06AG04
|
glycerol
|
WHO Anatomical Therapeutic Chemical classification |
|
glycerol |
| 0‑L |
A06AG06
|
oil
|
WHO Anatomical Therapeutic Chemical classification |
|
oil |
| 0‑L |
A06AG07
|
sorbitol
|
WHO Anatomical Therapeutic Chemical classification |
|
sorbitol |
| 0‑L |
A06AG10
|
docusate sodium, incl. combinations
|
WHO Anatomical Therapeutic Chemical classification |
|
docusate sodium, incl. combinations |
| 0‑L |
A06AG11
|
sodium lauryl sulfoacetate, incl. combinations
|
WHO Anatomical Therapeutic Chemical classification |
|
sodium lauryl sulfoacetate, incl. combinations |
| 0‑L |
A06AG20
|
combinations
|
WHO Anatomical Therapeutic Chemical classification |
|
combinations |
| 0‑L |
A06AH
|
Peripheral opioid receptor antagonists
|
WHO Anatomical Therapeutic Chemical classification |
|
Peripheral opioid receptor antagonists |
| 0‑L |
A06AH01
|
methylnaltrexone bromide
|
WHO Anatomical Therapeutic Chemical classification |
|
methylnaltrexone bromide |
| 0‑L |
A06AH02
|
alvimopan
|
WHO Anatomical Therapeutic Chemical classification |
|
alvimopan |
| 0‑L |
A06AH03
|
naloxegol
|
WHO Anatomical Therapeutic Chemical classification |
|
naloxegol |
| 0‑L |
A06AH04
|
naloxone
|
WHO Anatomical Therapeutic Chemical classification |
|
naloxone |
| 0‑L |
A06AX
|
Other drugs for constipation
|
WHO Anatomical Therapeutic Chemical classification |
|
Other drugs for constipation |
| 0‑L |
A06AX01
|
glycerol
|
WHO Anatomical Therapeutic Chemical classification |
|
glycerol |
| 0‑L |
A06AX02
|
carbon dioxide producing drugs
|
WHO Anatomical Therapeutic Chemical classification |
|
carbon dioxide producing drugs |
| 0‑L |
A06AX03
|
lubiprostone
|
WHO Anatomical Therapeutic Chemical classification |
|
lubiprostone |
| 0‑L |
A06AX04
|
linaclotide
|
WHO Anatomical Therapeutic Chemical classification |
|
linaclotide |
| 0‑L |
A06AX05
|
prucalopride
|
WHO Anatomical Therapeutic Chemical classification |
|
prucalopride |
| 0‑L |
A06AX06
|
tegaserod
|
WHO Anatomical Therapeutic Chemical classification |
|
tegaserod |
| 0‑L |
A07
|
ANTIDIARRHEALS, INTESTINAL ANTIINFLAMMATORY/ANTIINFECTIVE AGENTS
|
WHO Anatomical Therapeutic Chemical classification |
|
ANTIDIARRHEALS, INTESTINAL ANTIINFLAMMATORY/ANTIINFECTIVE AGENTS |
| 0‑L |
A07A
|
INTESTINAL ANTIINFECTIVES
|
WHO Anatomical Therapeutic Chemical classification |
|
INTESTINAL ANTIINFECTIVES |
| 0‑L |
A07AA
|
Antibiotics
|
WHO Anatomical Therapeutic Chemical classification |
|
Antibiotics |
| 0‑L |
A07AA01
|
neomycin
|
WHO Anatomical Therapeutic Chemical classification |
|
neomycin |
| 0‑L |
A07AA02
|
nystatin
|
WHO Anatomical Therapeutic Chemical classification |
|
nystatin |
| 0‑L |
A07AA03
|
natamycin
|
WHO Anatomical Therapeutic Chemical classification |
|
natamycin |
| 0‑L |
A07AA04
|
streptomycin
|
WHO Anatomical Therapeutic Chemical classification |
|
streptomycin |
| 0‑L |
A07AA05
|
polymyxin B
|
WHO Anatomical Therapeutic Chemical classification |
|
polymyxin B |
| 0‑L |
A07AA06
|
paromomycin
|
WHO Anatomical Therapeutic Chemical classification |
|
paromomycin |
| 0‑L |
A07AA07
|
amphotericin B
|
WHO Anatomical Therapeutic Chemical classification |
|
amphotericin B |
| 0‑L |
A07AA08
|
kanamycin
|
WHO Anatomical Therapeutic Chemical classification |
|
kanamycin |
| 0‑L |
A07AA09
|
vancomycin
|
WHO Anatomical Therapeutic Chemical classification |
|
vancomycin |
| 0‑L |
A07AA10
|
colistin
|
WHO Anatomical Therapeutic Chemical classification |
|
colistin |
| 0‑L |
A07AA11
|
rifaximin
|
WHO Anatomical Therapeutic Chemical classification |
|
rifaximin |
| 0‑L |
A07AA12
|
fidaxomicin
|
WHO Anatomical Therapeutic Chemical classification |
|
fidaxomicin |
| 0‑L |
A07AA51
|
neomycin, combinations
|
WHO Anatomical Therapeutic Chemical classification |
|
neomycin, combinations |
| 0‑L |
A07AA54
|
streptomycin, combinations
|
WHO Anatomical Therapeutic Chemical classification |
|
streptomycin, combinations |
| 0‑L |
A07AB
|
Sulfonamides
|
WHO Anatomical Therapeutic Chemical classification |
|
Sulfonamides |
| 0‑L |
A07AB02
|
phthalylsulfathiazole
|
WHO Anatomical Therapeutic Chemical classification |
|
phthalylsulfathiazole |
| 0‑L |
A07AB03
|
sulfaguanidine
|
WHO Anatomical Therapeutic Chemical classification |
|
sulfaguanidine |
| 0‑L |
A07AB04
|
succinylsulfathiazole
|
WHO Anatomical Therapeutic Chemical classification |
|
succinylsulfathiazole |
| 0‑L |
A07AC
|
Imidazole derivatives
|
WHO Anatomical Therapeutic Chemical classification |
|
Imidazole derivatives |
| 0‑L |
A07AC01
|
miconazole
|
WHO Anatomical Therapeutic Chemical classification |
|
miconazole |
| 0‑L |
A07AX
|
Other intestinal antiinfectives
|
WHO Anatomical Therapeutic Chemical classification |
|
Other intestinal antiinfectives |
| 0‑L |
A07AX01
|
broxyquinoline
|
WHO Anatomical Therapeutic Chemical classification |
|
broxyquinoline |
| 0‑L |
A07AX02
|
acetarsol
|
WHO Anatomical Therapeutic Chemical classification |
|
acetarsol |
| 0‑L |
A07AX03
|
nifuroxazide
|
WHO Anatomical Therapeutic Chemical classification |
|
nifuroxazide |
| 0‑L |
A07AX04
|
nifurzide
|
WHO Anatomical Therapeutic Chemical classification |
|
nifurzide |
| 0‑L |
A07B
|
INTESTINAL ADSORBENTS
|
WHO Anatomical Therapeutic Chemical classification |
|
INTESTINAL ADSORBENTS |
| 0‑L |
A07BA
|
Charcoal preparations
|
WHO Anatomical Therapeutic Chemical classification |
|
Charcoal preparations |
| 0‑L |
A07BA01
|
medicinal charcoal
|
WHO Anatomical Therapeutic Chemical classification |
|
medicinal charcoal |
| 0‑L |
A07BA51
|
medicinal charcoal, combinations
|
WHO Anatomical Therapeutic Chemical classification |
|
medicinal charcoal, combinations |
| 0‑L |
A07BB
|
Bismuth preparations
|
WHO Anatomical Therapeutic Chemical classification |
|
Bismuth preparations |
| 0‑L |
A07BC
|
Other intestinal adsorbents
|
WHO Anatomical Therapeutic Chemical classification |
|
Other intestinal adsorbents |
| 0‑L |
A07BC01
|
pectin
|
WHO Anatomical Therapeutic Chemical classification |
|
pectin |
| 0‑L |
A07BC02
|
kaolin
|
WHO Anatomical Therapeutic Chemical classification |
|
kaolin |
| 0‑L |
A07BC03
|
crospovidone
|
WHO Anatomical Therapeutic Chemical classification |
|
crospovidone |
| 0‑L |
A07BC04
|
attapulgite
|
WHO Anatomical Therapeutic Chemical classification |
|
attapulgite |
| 0‑L |
A07BC05
|
diosmectite
|
WHO Anatomical Therapeutic Chemical classification |
|
diosmectite |
| 0‑L |
A07BC30
|
combinations
|
WHO Anatomical Therapeutic Chemical classification |
|
combinations |
| 0‑L |
A07BC54
|
attapulgite, combinations
|
WHO Anatomical Therapeutic Chemical classification |
|
attapulgite, combinations |
| 0‑L |
A07C
|
ELECTROLYTES WITH CARBOHYDRATES
|
WHO Anatomical Therapeutic Chemical classification |
|
ELECTROLYTES WITH CARBOHYDRATES |
| 0‑L |
A07CA
|
Oral rehydration salt formulations
|
WHO Anatomical Therapeutic Chemical classification |
|
Oral rehydration salt formulations |
| 0‑L |
A07D
|
ANTIPROPULSIVES
|
WHO Anatomical Therapeutic Chemical classification |
|
ANTIPROPULSIVES |
| 0‑L |
A07DA
|
Antipropulsives
|
WHO Anatomical Therapeutic Chemical classification |
|
Antipropulsives |
| 0‑L |
A07DA01
|
diphenoxylate
|
WHO Anatomical Therapeutic Chemical classification |
|
diphenoxylate |
| 0‑L |
A07DA02
|
opium
|
WHO Anatomical Therapeutic Chemical classification |
|
opium |
| 0‑L |
A07DA03
|
loperamide
|
WHO Anatomical Therapeutic Chemical classification |
|
loperamide |
| 0‑L |
A07DA04
|
difenoxin
|
WHO Anatomical Therapeutic Chemical classification |
|
difenoxin |
| 0‑L |
A07DA05
|
loperamide oxide
|
WHO Anatomical Therapeutic Chemical classification |
|
loperamide oxide |
| 0‑L |
A07DA06
|
eluxadoline
|
WHO Anatomical Therapeutic Chemical classification |
|
eluxadoline |
| 0‑L |
A07DA52
|
morphine, combinations
|
WHO Anatomical Therapeutic Chemical classification |
|
morphine, combinations |
| 0‑L |
A07DA53
|
loperamide, combinations
|
WHO Anatomical Therapeutic Chemical classification |
|
loperamide, combinations |
| 0‑L |
A07E
|
INTESTINAL ANTIINFLAMMATORY AGENTS
|
WHO Anatomical Therapeutic Chemical classification |
|
INTESTINAL ANTIINFLAMMATORY AGENTS |
| 0‑L |
A07EA
|
Corticosteroids acting locally
|
WHO Anatomical Therapeutic Chemical classification |
|
Corticosteroids acting locally |
| 0‑L |
A07EA01
|
prednisolone
|
WHO Anatomical Therapeutic Chemical classification |
|
prednisolone |
| 0‑L |
A07EA02
|
hydrocortisone
|
WHO Anatomical Therapeutic Chemical classification |
|
hydrocortisone |
| 0‑L |
A07EA03
|
prednisone
|
WHO Anatomical Therapeutic Chemical classification |
|
prednisone |
| 0‑L |
A07EA04
|
betamethasone
|
WHO Anatomical Therapeutic Chemical classification |
|
betamethasone |
| 0‑L |
A07EA05
|
tixocortol
|
WHO Anatomical Therapeutic Chemical classification |
|
tixocortol |
| 0‑L |
A07EA06
|
budesonide
|
WHO Anatomical Therapeutic Chemical classification |
|
budesonide |
| 0‑L |
A07EA07
|
beclometasone
|
WHO Anatomical Therapeutic Chemical classification |
|
beclometasone |
| 0‑L |
A07EB
|
Antiallergic agents, excl. corticosteroids
|
WHO Anatomical Therapeutic Chemical classification |
|
Antiallergic agents, excl. corticosteroids |
| 0‑L |
A07EB01
|
cromoglicic acid
|
WHO Anatomical Therapeutic Chemical classification |
|
cromoglicic acid |
| 0‑L |
A07EC
|
Aminosalicylic acid and similar agents
|
WHO Anatomical Therapeutic Chemical classification |
|
Aminosalicylic acid and similar agents |
| 0‑L |
A07EC01
|
sulfasalazine
|
WHO Anatomical Therapeutic Chemical classification |
|
sulfasalazine |
| 0‑L |
A07EC02
|
mesalazine
|
WHO Anatomical Therapeutic Chemical classification |
|
mesalazine |
| 0‑L |
A07EC03
|
olsalazine
|
WHO Anatomical Therapeutic Chemical classification |
|
olsalazine |
| 0‑L |
A07EC04
|
balsalazide
|
WHO Anatomical Therapeutic Chemical classification |
|
balsalazide |
| 0‑L |
A07F
|
ANTIDIARRHEAL MICROORGANISMS
|
WHO Anatomical Therapeutic Chemical classification |
|
ANTIDIARRHEAL MICROORGANISMS |
| 0‑L |
A07FA
|
Antidiarrheal microorganisms
|
WHO Anatomical Therapeutic Chemical classification |
|
Antidiarrheal microorganisms |
| 0‑L |
A07FA01
|
lactic acid producing organisms
|
WHO Anatomical Therapeutic Chemical classification |
|
lactic acid producing organisms |
| 0‑L |
A07FA02
|
saccharomyces boulardii
|
WHO Anatomical Therapeutic Chemical classification |
|
saccharomyces boulardii |
| 0‑L |
A07FA51
|
lactic acid producing organisms, combinations
|
WHO Anatomical Therapeutic Chemical classification |
|
lactic acid producing organisms, combinations |
| 0‑L |
A07X
|
OTHER ANTIDIARRHEALS
|
WHO Anatomical Therapeutic Chemical classification |
|
OTHER ANTIDIARRHEALS |
| 0‑L |
A07XA
|
Other antidiarrheals
|
WHO Anatomical Therapeutic Chemical classification |
|
Other antidiarrheals |
| 0‑L |
A07XA01
|
albumin tannate
|
WHO Anatomical Therapeutic Chemical classification |
|
albumin tannate |
| 0‑L |
A07XA02
|
ceratonia
|
WHO Anatomical Therapeutic Chemical classification |
|
ceratonia |
| 0‑L |
A07XA03
|
calcium compounds
|
WHO Anatomical Therapeutic Chemical classification |
|
calcium compounds |
| 0‑L |
A07XA04
|
racecadotril
|
WHO Anatomical Therapeutic Chemical classification |
|
racecadotril |
| 0‑L |
A07XA51
|
albumin tannate, combinations
|
WHO Anatomical Therapeutic Chemical classification |
|
albumin tannate, combinations |
| 0‑L |
A08
|
ANTIOBESITY PREPARATIONS, EXCL. DIET PRODUCTS
|
WHO Anatomical Therapeutic Chemical classification |
|
ANTIOBESITY PREPARATIONS, EXCL. DIET PRODUCTS |
| 0‑L |
A08A
|
ANTIOBESITY PREPARATIONS, EXCL. DIET PRODUCTS
|
WHO Anatomical Therapeutic Chemical classification |
|
ANTIOBESITY PREPARATIONS, EXCL. DIET PRODUCTS |
| 0‑L |
A08AA
|
Centrally acting antiobesity products
|
WHO Anatomical Therapeutic Chemical classification |
|
Centrally acting antiobesity products |
| 0‑L |
A08AA01
|
phentermine
|
WHO Anatomical Therapeutic Chemical classification |
|
phentermine |
| 0‑L |
A08AA02
|
fenfluramine
|
WHO Anatomical Therapeutic Chemical classification |
|
fenfluramine |
| 0‑L |
A08AA03
|
amfepramone
|
WHO Anatomical Therapeutic Chemical classification |
|
amfepramone |
| 0‑L |
A08AA04
|
dexfenfluramine
|
WHO Anatomical Therapeutic Chemical classification |
|
dexfenfluramine |
| 0‑L |
A08AA05
|
mazindol
|
WHO Anatomical Therapeutic Chemical classification |
|
mazindol |
| 0‑L |
A08AA06
|
etilamfetamine
|
WHO Anatomical Therapeutic Chemical classification |
|
etilamfetamine |
| 0‑L |
A08AA07
|
cathine
|
WHO Anatomical Therapeutic Chemical classification |
|
cathine |
| 0‑L |
A08AA08
|
clobenzorex
|
WHO Anatomical Therapeutic Chemical classification |
|
clobenzorex |
| 0‑L |
A08AA09
|
mefenorex
|
WHO Anatomical Therapeutic Chemical classification |
|
mefenorex |
| 0‑L |
A08AA10
|
sibutramine
|
WHO Anatomical Therapeutic Chemical classification |
|
sibutramine |
| 0‑L |
A08AA11
|
lorcaserin
|
WHO Anatomical Therapeutic Chemical classification |
|
lorcaserin |
| 0‑L |
A08AA56
|
ephedrine, combinations
|
WHO Anatomical Therapeutic Chemical classification |
|
ephedrine, combinations |
| 0‑L |
A08AA62
|
bupropion and naltrexone
|
WHO Anatomical Therapeutic Chemical classification |
|
bupropion and naltrexone |
| 0‑L |
A08AB
|
Peripherally acting antiobesity products
|
WHO Anatomical Therapeutic Chemical classification |
|
Peripherally acting antiobesity products |
| 0‑L |
A08AB01
|
orlistat
|
WHO Anatomical Therapeutic Chemical classification |
|
orlistat |
| 0‑L |
A08AX
|
Other antiobesity drugs
|
WHO Anatomical Therapeutic Chemical classification |
|
Other antiobesity drugs |
| 0‑L |
A08AX01
|
rimonabant
|
WHO Anatomical Therapeutic Chemical classification |
|
rimonabant |
| 0‑L |
A09
|
DIGESTIVES, INCL. ENZYMES
|
WHO Anatomical Therapeutic Chemical classification |
|
DIGESTIVES, INCL. ENZYMES |
| 0‑L |
A09A
|
DIGESTIVES, INCL. ENZYMES
|
WHO Anatomical Therapeutic Chemical classification |
|
DIGESTIVES, INCL. ENZYMES |
| 0‑L |
A09AA
|
Enzyme preparations
|
WHO Anatomical Therapeutic Chemical classification |
|
Enzyme preparations |
| 0‑L |
A09AA01
|
diastase
|
WHO Anatomical Therapeutic Chemical classification |
|
diastase |
| 0‑L |
A09AA02
|
multienzymes (lipase, protease etc.)
|
WHO Anatomical Therapeutic Chemical classification |
|
multienzymes (lipase, protease etc.) |
| 0‑L |
A09AA03
|
pepsin
|
WHO Anatomical Therapeutic Chemical classification |
|
pepsin |
| 0‑L |
A09AA04
|
tilactase
|
WHO Anatomical Therapeutic Chemical classification |
|
tilactase |
| 0‑L |
A09AB
|
Acid preparations
|
WHO Anatomical Therapeutic Chemical classification |
|
Acid preparations |
| 0‑L |
A09AB01
|
glutamic acid hydrochloride
|
WHO Anatomical Therapeutic Chemical classification |
|
glutamic acid hydrochloride |
| 0‑L |
A09AB02
|
betaine hydrochloride
|
WHO Anatomical Therapeutic Chemical classification |
|
betaine hydrochloride |
| 0‑L |
A09AB03
|
hydrochloric acid
|
WHO Anatomical Therapeutic Chemical classification |
|
hydrochloric acid |
| 0‑L |
A09AB04
|
citric acid
|
WHO Anatomical Therapeutic Chemical classification |
|
citric acid |
| 0‑L |
A09AC
|
Enzyme and acid preparations, combinations
|
WHO Anatomical Therapeutic Chemical classification |
|
Enzyme and acid preparations, combinations |
| 0‑L |
A09AC01
|
pepsin and acid preparations
|
WHO Anatomical Therapeutic Chemical classification |
|
pepsin and acid preparations |
| 0‑L |
A09AC02
|
multienzymes and acid preparations
|
WHO Anatomical Therapeutic Chemical classification |
|
multienzymes and acid preparations |
| 0‑L |
A10
|
DRUGS USED IN DIABETES
|
WHO Anatomical Therapeutic Chemical classification |
|
DRUGS USED IN DIABETES |
| 0‑L |
A10A
|
INSULINS AND ANALOGUES
|
WHO Anatomical Therapeutic Chemical classification |
|
INSULINS AND ANALOGUES |
| 0‑L |
A10AB
|
Insulins and analogues for injection, fast-acting
|
WHO Anatomical Therapeutic Chemical classification |
|
Insulins and analogues for injection, fast-acting |
| 0‑L |
A10AB01
|
insulin (human)
|
WHO Anatomical Therapeutic Chemical classification |
|
insulin (human) |
| 0‑L |
A10AB02
|
insulin (beef)
|
WHO Anatomical Therapeutic Chemical classification |
|
insulin (beef) |
| 0‑L |
A10AB03
|
insulin (pork)
|
WHO Anatomical Therapeutic Chemical classification |
|
insulin (pork) |
| 0‑L |
A10AB04
|
insulin lispro
|
WHO Anatomical Therapeutic Chemical classification |
|
insulin lispro |
| 0‑L |
A10AB05
|
insulin aspart
|
WHO Anatomical Therapeutic Chemical classification |
|
insulin aspart |
| 0‑L |
A10AB06
|
insulin glulisine
|
WHO Anatomical Therapeutic Chemical classification |
|
insulin glulisine |
| 0‑L |
A10AB30
|
combinations
|
WHO Anatomical Therapeutic Chemical classification |
|
combinations |
| 0‑L |
A10AC
|
Insulins and analogues for injection, intermediate-acting
|
WHO Anatomical Therapeutic Chemical classification |
|
Insulins and analogues for injection, intermediate-acting |
| 0‑L |
A10AC01
|
insulin (human)
|
WHO Anatomical Therapeutic Chemical classification |
|
insulin (human) |
| 0‑L |
A10AC02
|
insulin (beef)
|
WHO Anatomical Therapeutic Chemical classification |
|
insulin (beef) |
| 0‑L |
A10AC03
|
insulin (pork)
|
WHO Anatomical Therapeutic Chemical classification |
|
insulin (pork) |
| 0‑L |
A10AC04
|
insulin lispro
|
WHO Anatomical Therapeutic Chemical classification |
|
insulin lispro |
| 0‑L |
A10AC30
|
combinations
|
WHO Anatomical Therapeutic Chemical classification |
|
combinations |
| 0‑L |
A10AD
|
Insulins and analogues for injection, intermediate- or long-acting combined with fast-acting
|
WHO Anatomical Therapeutic Chemical classification |
|
Insulins and analogues for injection, intermediate- or long-acting combined with fast-acting |
| 0‑L |
A10AD01
|
insulin (human)
|
WHO Anatomical Therapeutic Chemical classification |
|
insulin (human) |
| 0‑L |
A10AD02
|
insulin (beef)
|
WHO Anatomical Therapeutic Chemical classification |
|
insulin (beef) |
| 0‑L |
A10AD03
|
insulin (pork)
|
WHO Anatomical Therapeutic Chemical classification |
|
insulin (pork) |
| 0‑L |
A10AD04
|
insulin lispro
|
WHO Anatomical Therapeutic Chemical classification |
|
insulin lispro |
| 0‑L |
A10AD05
|
insulin aspart
|
WHO Anatomical Therapeutic Chemical classification |
|
insulin aspart |
| 0‑L |
A10AD06
|
insulin degludec and insulin aspart
|
WHO Anatomical Therapeutic Chemical classification |
|
insulin degludec and insulin aspart |
| 0‑L |
A10AD30
|
combinations
|
WHO Anatomical Therapeutic Chemical classification |
|
combinations |
| 0‑L |
A10AE
|
Insulins and analogues for injection, long-acting
|
WHO Anatomical Therapeutic Chemical classification |
|
Insulins and analogues for injection, long-acting |
| 0‑L |
A10AE01
|
insulin (human)
|
WHO Anatomical Therapeutic Chemical classification |
|
insulin (human) |
| 0‑L |
A10AE02
|
insulin (beef)
|
WHO Anatomical Therapeutic Chemical classification |
|
insulin (beef) |
| 0‑L |
A10AE03
|
insulin (pork)
|
WHO Anatomical Therapeutic Chemical classification |
|
insulin (pork) |
| 0‑L |
A10AE04
|
insulin glargine
|
WHO Anatomical Therapeutic Chemical classification |
|
insulin glargine |
| 0‑L |
A10AE05
|
insulin detemir
|
WHO Anatomical Therapeutic Chemical classification |
|
insulin detemir |
| 0‑L |
A10AE06
|
insulin degludec
|
WHO Anatomical Therapeutic Chemical classification |
|
insulin degludec |
| 0‑L |
A10AE30
|
combinations
|
WHO Anatomical Therapeutic Chemical classification |
|
combinations |
| 0‑L |
A10AE56
|
insulin degludec and liraglutide
|
WHO Anatomical Therapeutic Chemical classification |
|
insulin degludec and liraglutide |
| 0‑L |
A10AF
|
Insulins and analogues for inhalation
|
WHO Anatomical Therapeutic Chemical classification |
|
Insulins and analogues for inhalation |
| 0‑L |
A10AF01
|
insulin (human)
|
WHO Anatomical Therapeutic Chemical classification |
|
insulin (human) |
| 0‑L |
A10B
|
BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS
|
WHO Anatomical Therapeutic Chemical classification |
|
BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS |
| 0‑L |
A10BA
|
Biguanides
|
WHO Anatomical Therapeutic Chemical classification |
|
Biguanides |
| 0‑L |
A10BA01
|
phenformin
|
WHO Anatomical Therapeutic Chemical classification |
|
phenformin |
| 0‑L |
A10BA02
|
metformin
|
WHO Anatomical Therapeutic Chemical classification |
|
metformin |
| 0‑L |
A10BA03
|
buformin
|
WHO Anatomical Therapeutic Chemical classification |
|
buformin |
| 0‑L |
A10BB
|
Sulfonylureas
|
WHO Anatomical Therapeutic Chemical classification |
|
Sulfonylureas |
| 0‑L |
A10BB01
|
glibenclamide
|
WHO Anatomical Therapeutic Chemical classification |
|
glibenclamide |
| 0‑L |
A10BB02
|
chlorpropamide
|
WHO Anatomical Therapeutic Chemical classification |
|
chlorpropamide |
| 0‑L |
A10BB03
|
tolbutamide
|
WHO Anatomical Therapeutic Chemical classification |
|
tolbutamide |
| 0‑L |
A10BB04
|
glibornuride
|
WHO Anatomical Therapeutic Chemical classification |
|
glibornuride |
| 0‑L |
A10BB05
|
tolazamide
|
WHO Anatomical Therapeutic Chemical classification |
|
tolazamide |
| 0‑L |
A10BB06
|
carbutamide
|
WHO Anatomical Therapeutic Chemical classification |
|
carbutamide |
| 0‑L |
A10BB07
|
glipizide
|
WHO Anatomical Therapeutic Chemical classification |
|
glipizide |
| 0‑L |
A10BB08
|
gliquidone
|
WHO Anatomical Therapeutic Chemical classification |
|
gliquidone |
| 0‑L |
A10BB09
|
gliclazide
|
WHO Anatomical Therapeutic Chemical classification |
|
gliclazide |
| 0‑L |
A10BB10
|
metahexamide
|
WHO Anatomical Therapeutic Chemical classification |
|
metahexamide |
| 0‑L |
A10BB11
|
glisoxepide
|
WHO Anatomical Therapeutic Chemical classification |
|
glisoxepide |
| 0‑L |
A10BB12
|
glimepiride
|
WHO Anatomical Therapeutic Chemical classification |
|
glimepiride |
| 0‑L |
A10BB31
|
acetohexamide
|
WHO Anatomical Therapeutic Chemical classification |
|
acetohexamide |
| 0‑L |
A10BC
|
Sulfonamides (heterocyclic)
|
WHO Anatomical Therapeutic Chemical classification |
|
Sulfonamides (heterocyclic) |
| 0‑L |
A10BC01
|
glymidine
|
WHO Anatomical Therapeutic Chemical classification |
|
glymidine |
| 0‑L |
A10BD
|
Combinations of oral blood glucose lowering drugs
|
WHO Anatomical Therapeutic Chemical classification |
|
Combinations of oral blood glucose lowering drugs |
| 0‑L |
A10BD01
|
phenformin and sulfonylureas
|
WHO Anatomical Therapeutic Chemical classification |
|
phenformin and sulfonylureas |
| 0‑L |
A10BD02
|
metformin and sulfonylureas
|
WHO Anatomical Therapeutic Chemical classification |
|
metformin and sulfonylureas |
| 0‑L |
A10BD03
|
metformin and rosiglitazone
|
WHO Anatomical Therapeutic Chemical classification |
|
metformin and rosiglitazone |
| 0‑L |
A10BD04
|
glimepiride and rosiglitazone
|
WHO Anatomical Therapeutic Chemical classification |
|
glimepiride and rosiglitazone |
| 0‑L |
A10BD05
|
metformin and pioglitazone
|
WHO Anatomical Therapeutic Chemical classification |
|
metformin and pioglitazone |
| 0‑L |
A10BD06
|
glimepiride and pioglitazone
|
WHO Anatomical Therapeutic Chemical classification |
|
glimepiride and pioglitazone |
| 0‑L |
A10BD07
|
metformin and sitagliptin
|
WHO Anatomical Therapeutic Chemical classification |
|
metformin and sitagliptin |
| 0‑L |
A10BD08
|
metformin and vildagliptin
|
WHO Anatomical Therapeutic Chemical classification |
|
metformin and vildagliptin |
| 0‑L |
A10BD09
|
pioglitazone and alogliptin
|
WHO Anatomical Therapeutic Chemical classification |
|
pioglitazone and alogliptin |
| 0‑L |
A10BD10
|
metformin and saxagliptin
|
WHO Anatomical Therapeutic Chemical classification |
|
metformin and saxagliptin |
| 0‑L |
A10BD11
|
metformin and linagliptin
|
WHO Anatomical Therapeutic Chemical classification |
|
metformin and linagliptin |
| 0‑L |
A10BD12
|
pioglitazone and sitagliptin
|
WHO Anatomical Therapeutic Chemical classification |
|
pioglitazone and sitagliptin |
| 0‑L |
A10BD13
|
metformin and alogliptin
|
WHO Anatomical Therapeutic Chemical classification |
|
metformin and alogliptin |
| 0‑L |
A10BD14
|
metformin and repaglinide
|
WHO Anatomical Therapeutic Chemical classification |
|
metformin and repaglinide |
| 0‑L |
A10BD15
|
metformin and dapagliflozin
|
WHO Anatomical Therapeutic Chemical classification |
|
metformin and dapagliflozin |
| 0‑L |
A10BD16
|
metformin and canagliflozin
|
WHO Anatomical Therapeutic Chemical classification |
|
metformin and canagliflozin |
| 0‑L |
A10BD17
|
metformin and acarbose
|
WHO Anatomical Therapeutic Chemical classification |
|
metformin and acarbose |
| 0‑L |
A10BD18
|
metformin and gemigliptin
|
WHO Anatomical Therapeutic Chemical classification |
|
metformin and gemigliptin |
| 0‑L |
A10BD19
|
linagliptin and empagliflozin
|
WHO Anatomical Therapeutic Chemical classification |
|
linagliptin and empagliflozin |
| 0‑L |
A10BD20
|
metformin and empagliflozin
|
WHO Anatomical Therapeutic Chemical classification |
|
metformin and empagliflozin |
| 0‑L |
A10BD21
|
saxagliptin and dapagliflozin
|
WHO Anatomical Therapeutic Chemical classification |
|
saxagliptin and dapagliflozin |
| 0‑L |
A10BF
|
Alpha glucosidase inhibitors
|
WHO Anatomical Therapeutic Chemical classification |
|
Alpha glucosidase inhibitors |
| 0‑L |
A10BF01
|
acarbose
|
WHO Anatomical Therapeutic Chemical classification |
|
acarbose |
| 0‑L |
A10BF02
|
miglitol
|
WHO Anatomical Therapeutic Chemical classification |
|
miglitol |
| 0‑L |
A10BF03
|
voglibose
|
WHO Anatomical Therapeutic Chemical classification |
|
voglibose |
| 0‑L |
A10BG
|
Thiazolidinediones
|
WHO Anatomical Therapeutic Chemical classification |
|
Thiazolidinediones |
| 0‑L |
A10BG01
|
troglitazone
|
WHO Anatomical Therapeutic Chemical classification |
|
troglitazone |
| 0‑L |
A10BG02
|
rosiglitazone
|
WHO Anatomical Therapeutic Chemical classification |
|
rosiglitazone |
| 0‑L |
A10BG03
|
pioglitazone
|
WHO Anatomical Therapeutic Chemical classification |
|
pioglitazone |
| 0‑L |
A10BH
|
Dipeptidyl peptidase 4 (DPP-4) inhibitors
|
WHO Anatomical Therapeutic Chemical classification |
|
Dipeptidyl peptidase 4 (DPP-4) inhibitors |
| 0‑L |
A10BH01
|
sitagliptin
|
WHO Anatomical Therapeutic Chemical classification |
|
sitagliptin |
| 0‑L |
A10BH02
|
vildagliptin
|
WHO Anatomical Therapeutic Chemical classification |
|
vildagliptin |
| 0‑L |
A10BH03
|
saxagliptin
|
WHO Anatomical Therapeutic Chemical classification |
|
saxagliptin |
| 0‑L |
A10BH04
|
alogliptin
|
WHO Anatomical Therapeutic Chemical classification |
|
alogliptin |
| 0‑L |
A10BH05
|
linagliptin
|
WHO Anatomical Therapeutic Chemical classification |
|
linagliptin |
| 0‑L |
A10BH06
|
gemigliptin
|
WHO Anatomical Therapeutic Chemical classification |
|
gemigliptin |
| 0‑L |
A10BH51
|
sitagliptin and simvastatin
|
WHO Anatomical Therapeutic Chemical classification |
|
sitagliptin and simvastatin |
| 0‑L |
A10BJ
|
Glucagon-like peptide-1 (GLP-1) analogues
|
WHO Anatomical Therapeutic Chemical classification |
|
Glucagon-like peptide-1 (GLP-1) analogues |
| 0‑L |
A10BJ01
|
exenatide
|
WHO Anatomical Therapeutic Chemical classification |
|
exenatide |
| 0‑L |
A10BJ02
|
liraglutide
|
WHO Anatomical Therapeutic Chemical classification |
|
liraglutide |
| 0‑L |
A10BJ03
|
lixisenatide
|
WHO Anatomical Therapeutic Chemical classification |
|
lixisenatide |
| 0‑L |
A10BJ04
|
albiglutide
|
WHO Anatomical Therapeutic Chemical classification |
|
albiglutide |
| 0‑L |
A10BJ05
|
dulaglutide
|
WHO Anatomical Therapeutic Chemical classification |
|
dulaglutide |
| 0‑L |
A10BK
|
Sodium-glucose co-transporter 2 (SGLT2) inhibitors
|
WHO Anatomical Therapeutic Chemical classification |
|
Sodium-glucose co-transporter 2 (SGLT2) inhibitors |
| 0‑L |
A10BK01
|
dapagliflozin
|
WHO Anatomical Therapeutic Chemical classification |
|
dapagliflozin |
| 0‑L |
A10BK02
|
canagliflozin
|
WHO Anatomical Therapeutic Chemical classification |
|
canagliflozin |
| 0‑L |
A10BK03
|
empagliflozin
|
WHO Anatomical Therapeutic Chemical classification |
|
empagliflozin |
| 0‑L |
A10BX
|
Other blood glucose lowering drugs, excl. insulins
|
WHO Anatomical Therapeutic Chemical classification |
|
Other blood glucose lowering drugs, excl. insulins |
| 0‑L |
A10BX01
|
guar gum
|
WHO Anatomical Therapeutic Chemical classification |
|
guar gum |
| 0‑L |
A10BX02
|
repaglinide
|
WHO Anatomical Therapeutic Chemical classification |
|
repaglinide |
| 0‑L |
A10BX03
|
nateglinide
|
WHO Anatomical Therapeutic Chemical classification |
|
nateglinide |
| 0‑L |
A10BX05
|
pramlintide
|
WHO Anatomical Therapeutic Chemical classification |
|
pramlintide |
| 0‑L |
A10BX06
|
benfluorex
|
WHO Anatomical Therapeutic Chemical classification |
|
benfluorex |
| 0‑L |
A10BX08
|
mitiglinide
|
WHO Anatomical Therapeutic Chemical classification |
|
mitiglinide |
| 0‑L |
A10X
|
OTHER DRUGS USED IN DIABETES
|
WHO Anatomical Therapeutic Chemical classification |
|
OTHER DRUGS USED IN DIABETES |
| 0‑L |
A10XA
|
Aldose reductase inhibitors
|
WHO Anatomical Therapeutic Chemical classification |
|
Aldose reductase inhibitors |
| 0‑L |
A10XA01
|
tolrestat
|
WHO Anatomical Therapeutic Chemical classification |
|
tolrestat |
| 0‑L |
A11
|
VITAMINS
|
WHO Anatomical Therapeutic Chemical classification |
|
VITAMINS |
| 0‑L |
A11A
|
MULTIVITAMINS, COMBINATIONS
|
WHO Anatomical Therapeutic Chemical classification |
|
MULTIVITAMINS, COMBINATIONS |
| 0‑L |
A11AA
|
Multivitamins with minerals
|
WHO Anatomical Therapeutic Chemical classification |
|
Multivitamins with minerals |
| 0‑L |
A11AA01
|
multivitamins and iron
|
WHO Anatomical Therapeutic Chemical classification |
|
multivitamins and iron |
| 0‑L |
A11AA02
|
multivitamins and calcium
|
WHO Anatomical Therapeutic Chemical classification |
|
multivitamins and calcium |
| 0‑L |
A11AA03
|
multivitamins and other minerals, incl. combinations
|
WHO Anatomical Therapeutic Chemical classification |
|
multivitamins and other minerals, incl. combinations |
| 0‑L |
A11AA04
|
multivitamins and trace elements
|
WHO Anatomical Therapeutic Chemical classification |
|
multivitamins and trace elements |
| 0‑L |
A11AB
|
Multivitamins, other combinations
|
WHO Anatomical Therapeutic Chemical classification |
|
Multivitamins, other combinations |
| 0‑L |
A11B
|
MULTIVITAMINS, PLAIN
|
WHO Anatomical Therapeutic Chemical classification |
|
MULTIVITAMINS, PLAIN |
| 0‑L |
A11BA
|
Multivitamins, plain
|
WHO Anatomical Therapeutic Chemical classification |
|
Multivitamins, plain |
| 0‑L |
A11C
|
VITAMIN A AND D, INCL. COMBINATIONS OF THE TWO
|
WHO Anatomical Therapeutic Chemical classification |
|
VITAMIN A AND D, INCL. COMBINATIONS OF THE TWO |
| 0‑L |
A11CA
|
Vitamin A, plain
|
WHO Anatomical Therapeutic Chemical classification |
|
Vitamin A, plain |
| 0‑L |
A11CA01
|
retinol (vit A)
|
WHO Anatomical Therapeutic Chemical classification |
|
retinol (vit A) |
| 0‑L |
A11CA02
|
betacarotene
|
WHO Anatomical Therapeutic Chemical classification |
|
betacarotene |
| 0‑L |
A11CB
|
Vitamin A and D in combination
|
WHO Anatomical Therapeutic Chemical classification |
|
Vitamin A and D in combination |
| 0‑L |
A11CC
|
Vitamin D and analogues
|
WHO Anatomical Therapeutic Chemical classification |
|
Vitamin D and analogues |
| 0‑L |
A11CC01
|
ergocalciferol
|
WHO Anatomical Therapeutic Chemical classification |
|
ergocalciferol |
| 0‑L |
A11CC02
|
dihydrotachysterol
|
WHO Anatomical Therapeutic Chemical classification |
|
dihydrotachysterol |
| 0‑L |
A11CC03
|
alfacalcidol
|
WHO Anatomical Therapeutic Chemical classification |
|
alfacalcidol |
| 0‑L |
A11CC04
|
calcitriol
|
WHO Anatomical Therapeutic Chemical classification |
|
calcitriol |
| 0‑L |
A11CC05
|
colecalciferol
|
WHO Anatomical Therapeutic Chemical classification |
|
colecalciferol |
| 0‑L |
A11CC06
|
calcifediol
|
WHO Anatomical Therapeutic Chemical classification |
|
calcifediol |
| 0‑L |
A11CC20
|
combinations
|
WHO Anatomical Therapeutic Chemical classification |
|
combinations |
| 0‑L |
A11D
|
VITAMIN B1, PLAIN AND IN COMBINATION WITH VITAMIN B6 AND B12
|
WHO Anatomical Therapeutic Chemical classification |
|
VITAMIN B1, PLAIN AND IN COMBINATION WITH VITAMIN B6 AND B12 |
| 0‑L |
A11DA
|
Vitamin B1, plain
|
WHO Anatomical Therapeutic Chemical classification |
|
Vitamin B1, plain |
| 0‑L |
A11DA01
|
thiamine (vit B1)
|
WHO Anatomical Therapeutic Chemical classification |
|
thiamine (vit B1) |
| 0‑L |
A11DA02
|
sulbutiamine
|
WHO Anatomical Therapeutic Chemical classification |
|
sulbutiamine |
| 0‑L |
A11DA03
|
benfotiamine
|
WHO Anatomical Therapeutic Chemical classification |
|
benfotiamine |
| 0‑L |
A11DB
|
Vitamin B1 in combination with vitamin B6 and/or vitamin B12
|
WHO Anatomical Therapeutic Chemical classification |
|
Vitamin B1 in combination with vitamin B6 and/or vitamin B12 |
| 0‑L |
A11E
|
VITAMIN B-COMPLEX, INCL. COMBINATIONS
|
WHO Anatomical Therapeutic Chemical classification |
|
VITAMIN B-COMPLEX, INCL. COMBINATIONS |
| 0‑L |
A11EA
|
Vitamin B-complex, plain
|
WHO Anatomical Therapeutic Chemical classification |
|
Vitamin B-complex, plain |
| 0‑L |
A11EB
|
Vitamin B-complex with vitamin C
|
WHO Anatomical Therapeutic Chemical classification |
|
Vitamin B-complex with vitamin C |
| 0‑L |
A11EC
|
Vitamin B-complex with minerals
|
WHO Anatomical Therapeutic Chemical classification |
|
Vitamin B-complex with minerals |
| 0‑L |
A11ED
|
Vitamin B-complex with anabolic steroids
|
WHO Anatomical Therapeutic Chemical classification |
|
Vitamin B-complex with anabolic steroids |
| 0‑L |
A11EX
|
Vitamin B-complex, other combinations
|
WHO Anatomical Therapeutic Chemical classification |
|
Vitamin B-complex, other combinations |
| 0‑L |
A11G
|
ASCORBIC ACID (VITAMIN C), INCL. COMBINATIONS
|
WHO Anatomical Therapeutic Chemical classification |
|
ASCORBIC ACID (VITAMIN C), INCL. COMBINATIONS |
| 0‑L |
A11GA
|
Ascorbic acid (vitamin C), plain
|
WHO Anatomical Therapeutic Chemical classification |
|
Ascorbic acid (vitamin C), plain |
| 0‑L |
A11GA01
|
ascorbic acid (vit C)
|
WHO Anatomical Therapeutic Chemical classification |
|
ascorbic acid (vit C) |
| 0‑L |
A11GB
|
Ascorbic acid (vitamin C), combinations
|
WHO Anatomical Therapeutic Chemical classification |
|
Ascorbic acid (vitamin C), combinations |
| 0‑L |
A11GB01
|
ascorbic acid (vit C) and calcium
|
WHO Anatomical Therapeutic Chemical classification |
|
ascorbic acid (vit C) and calcium |
| 0‑L |
A11H
|
OTHER PLAIN VITAMIN PREPARATIONS
|
WHO Anatomical Therapeutic Chemical classification |
|
OTHER PLAIN VITAMIN PREPARATIONS |
| 0‑L |
A11HA
|
Other plain vitamin preparations
|
WHO Anatomical Therapeutic Chemical classification |
|
Other plain vitamin preparations |
| 0‑L |
A11HA01
|
nicotinamide
|
WHO Anatomical Therapeutic Chemical classification |
|
nicotinamide |
| 0‑L |
A11HA02
|
pyridoxine (vit B6)
|
WHO Anatomical Therapeutic Chemical classification |
|
pyridoxine (vit B6) |
| 0‑L |
A11HA03
|
tocopherol (vit E)
|
WHO Anatomical Therapeutic Chemical classification |
|
tocopherol (vit E) |
| 0‑L |
A11HA04
|
riboflavin (vit B2)
|
WHO Anatomical Therapeutic Chemical classification |
|
riboflavin (vit B2) |
| 0‑L |
A11HA05
|
biotin
|
WHO Anatomical Therapeutic Chemical classification |
|
biotin |
| 0‑L |
A11HA06
|
pyridoxal phosphate
|
WHO Anatomical Therapeutic Chemical classification |
|
pyridoxal phosphate |
| 0‑L |
A11HA07
|
inositol
|
WHO Anatomical Therapeutic Chemical classification |
|
inositol |
| 0‑L |
A11HA08
|
tocofersolan
|
WHO Anatomical Therapeutic Chemical classification |
|
tocofersolan |
| 0‑L |
A11HA30
|
dexpanthenol
|
WHO Anatomical Therapeutic Chemical classification |
|
dexpanthenol |
| 0‑L |
A11HA31
|
calcium pantothenate
|
WHO Anatomical Therapeutic Chemical classification |
|
calcium pantothenate |
| 0‑L |
A11HA32
|
pantethine
|
WHO Anatomical Therapeutic Chemical classification |
|
pantethine |
| 0‑L |
A11J
|
OTHER VITAMIN PRODUCTS, COMBINATIONS
|
WHO Anatomical Therapeutic Chemical classification |
|
OTHER VITAMIN PRODUCTS, COMBINATIONS |
| 0‑L |
A11JA
|
Combinations of vitamins
|
WHO Anatomical Therapeutic Chemical classification |
|
Combinations of vitamins |
| 0‑L |
A11JB
|
Vitamins with minerals
|
WHO Anatomical Therapeutic Chemical classification |
|
Vitamins with minerals |
| 0‑L |
A11JC
|
Vitamins, other combinations
|
WHO Anatomical Therapeutic Chemical classification |
|
Vitamins, other combinations |
| 0‑L |
A12
|
MINERAL SUPPLEMENTS
|
WHO Anatomical Therapeutic Chemical classification |
|
MINERAL SUPPLEMENTS |
| 0‑L |
A12A
|
CALCIUM
|
WHO Anatomical Therapeutic Chemical classification |
|
CALCIUM |
| 0‑L |
A12AA
|
Calcium
|
WHO Anatomical Therapeutic Chemical classification |
|
Calcium |
| 0‑L |
A12AA01
|
calcium phosphate
|
WHO Anatomical Therapeutic Chemical classification |
|
calcium phosphate |
| 0‑L |
A12AA02
|
calcium glubionate
|
WHO Anatomical Therapeutic Chemical classification |
|
calcium glubionate |
| 0‑L |
A12AA03
|
calcium gluconate
|
WHO Anatomical Therapeutic Chemical classification |
|
calcium gluconate |
| 0‑L |
A12AA04
|
calcium carbonate
|
WHO Anatomical Therapeutic Chemical classification |
|
calcium carbonate |
| 0‑L |
A12AA05
|
calcium lactate
|
WHO Anatomical Therapeutic Chemical classification |
|
calcium lactate |
| 0‑L |
A12AA06
|
calcium lactate gluconate
|
WHO Anatomical Therapeutic Chemical classification |
|
calcium lactate gluconate |
| 0‑L |
A12AA07
|
calcium chloride
|
WHO Anatomical Therapeutic Chemical classification |
|
calcium chloride |
| 0‑L |
A12AA08
|
calcium glycerylphosphate
|
WHO Anatomical Therapeutic Chemical classification |
|
calcium glycerylphosphate |
| 0‑L |
A12AA09
|
calcium citrate lysine complex
|
WHO Anatomical Therapeutic Chemical classification |
|
calcium citrate lysine complex |
| 0‑L |
A12AA10
|
calcium glucoheptonate
|
WHO Anatomical Therapeutic Chemical classification |
|
calcium glucoheptonate |
| 0‑L |
A12AA11
|
calcium pangamate
|
WHO Anatomical Therapeutic Chemical classification |
|
calcium pangamate |
| 0‑L |
A12AA13
|
calcium citrate
|
WHO Anatomical Therapeutic Chemical classification |
|
calcium citrate |
| 0‑L |
A12AA20
|
calcium (different salts in combination)
|
WHO Anatomical Therapeutic Chemical classification |
|
calcium (different salts in combination) |
| 0‑L |
A12AA30
|
calcium laevulate
|
WHO Anatomical Therapeutic Chemical classification |
|
calcium laevulate |
| 0‑L |
A12AX
|
Calcium, combinations with vitamin D and/or other drugs
|
WHO Anatomical Therapeutic Chemical classification |
|
Calcium, combinations with vitamin D and/or other drugs |
| 0‑L |
A12B
|
POTASSIUM
|
WHO Anatomical Therapeutic Chemical classification |
|
POTASSIUM |
| 0‑L |
A12BA
|
Potassium
|
WHO Anatomical Therapeutic Chemical classification |
|
Potassium |
| 0‑L |
A12BA01
|
potassium chloride
|
WHO Anatomical Therapeutic Chemical classification |
|
potassium chloride |
| 0‑L |
A12BA02
|
potassium citrate
|
WHO Anatomical Therapeutic Chemical classification |
|
potassium citrate |
| 0‑L |
A12BA03
|
potassium hydrogentartrate
|
WHO Anatomical Therapeutic Chemical classification |
|
potassium hydrogentartrate |
| 0‑L |
A12BA04
|
potassium hydrogencarbonate
|
WHO Anatomical Therapeutic Chemical classification |
|
potassium hydrogencarbonate |
| 0‑L |
A12BA05
|
potassium gluconate
|
WHO Anatomical Therapeutic Chemical classification |
|
potassium gluconate |
| 0‑L |
A12BA30
|
combinations
|
WHO Anatomical Therapeutic Chemical classification |
|
combinations |
| 0‑L |
A12BA51
|
potassium chloride, combinations
|
WHO Anatomical Therapeutic Chemical classification |
|
potassium chloride, combinations |
| 0‑L |
A12C
|
OTHER MINERAL SUPPLEMENTS
|
WHO Anatomical Therapeutic Chemical classification |
|
OTHER MINERAL SUPPLEMENTS |
| 0‑L |
A12CA
|
Sodium
|
WHO Anatomical Therapeutic Chemical classification |
|
Sodium |
| 0‑L |
A12CA01
|
sodium chloride
|
WHO Anatomical Therapeutic Chemical classification |
|
sodium chloride |
| 0‑L |
A12CA02
|
sodium sulfate
|
WHO Anatomical Therapeutic Chemical classification |
|
sodium sulfate |
| 0‑L |
A12CB
|
Zinc
|
WHO Anatomical Therapeutic Chemical classification |
|
Zinc |
| 0‑L |
A12CB01
|
zinc sulfate
|
WHO Anatomical Therapeutic Chemical classification |
|
zinc sulfate |
| 0‑L |
A12CB02
|
zinc gluconate
|
WHO Anatomical Therapeutic Chemical classification |
|
zinc gluconate |
| 0‑L |
A12CB03
|
zinc protein complex
|
WHO Anatomical Therapeutic Chemical classification |
|
zinc protein complex |
| 0‑L |
A12CC
|
Magnesium
|
WHO Anatomical Therapeutic Chemical classification |
|
Magnesium |
| 0‑L |
A12CC01
|
magnesium chloride
|
WHO Anatomical Therapeutic Chemical classification |
|
magnesium chloride |
| 0‑L |
A12CC02
|
magnesium sulfate
|
WHO Anatomical Therapeutic Chemical classification |
|
magnesium sulfate |
| 0‑L |
A12CC03
|
magnesium gluconate
|
WHO Anatomical Therapeutic Chemical classification |
|
magnesium gluconate |
| 0‑L |
A12CC04
|
magnesium citrate
|
WHO Anatomical Therapeutic Chemical classification |
|
magnesium citrate |
| 0‑L |
A12CC05
|
magnesium aspartate
|
WHO Anatomical Therapeutic Chemical classification |
|
magnesium aspartate |
| 0‑L |
A12CC06
|
magnesium lactate
|
WHO Anatomical Therapeutic Chemical classification |
|
magnesium lactate |
| 0‑L |
A12CC07
|
magnesium levulinate
|
WHO Anatomical Therapeutic Chemical classification |
|
magnesium levulinate |
| 0‑L |
A12CC08
|
magnesium pidolate
|
WHO Anatomical Therapeutic Chemical classification |
|
magnesium pidolate |
| 0‑L |
A12CC09
|
magnesium orotate
|
WHO Anatomical Therapeutic Chemical classification |
|
magnesium orotate |
| 0‑L |
A12CC10
|
magnesium oxide
|
WHO Anatomical Therapeutic Chemical classification |
|
magnesium oxide |
| 0‑L |
A12CC30
|
magnesium (different salts in combination)
|
WHO Anatomical Therapeutic Chemical classification |
|
magnesium (different salts in combination) |
| 0‑L |
A12CD
|
Fluoride
|
WHO Anatomical Therapeutic Chemical classification |
|
Fluoride |
| 0‑L |
A12CD01
|
sodium fluoride
|
WHO Anatomical Therapeutic Chemical classification |
|
sodium fluoride |
| 0‑L |
A12CD02
|
sodium monofluorophosphate
|
WHO Anatomical Therapeutic Chemical classification |
|
sodium monofluorophosphate |
| 0‑L |
A12CD51
|
fluoride, combinations
|
WHO Anatomical Therapeutic Chemical classification |
|
fluoride, combinations |
| 0‑L |
A12CE
|
Selenium
|
WHO Anatomical Therapeutic Chemical classification |
|
Selenium |
| 0‑L |
A12CE01
|
sodium selenate
|
WHO Anatomical Therapeutic Chemical classification |
|
sodium selenate |
| 0‑L |
A12CE02
|
sodium selenite
|
WHO Anatomical Therapeutic Chemical classification |
|
sodium selenite |
| 0‑L |
A12CX
|
Other mineral products
|
WHO Anatomical Therapeutic Chemical classification |
|
Other mineral products |
| 0‑L |
A13
|
TONICS
|
WHO Anatomical Therapeutic Chemical classification |
|
TONICS |
| 0‑L |
A13A
|
TONICS
|
WHO Anatomical Therapeutic Chemical classification |
|
TONICS |
| 0‑L |
A14
|
ANABOLIC AGENTS FOR SYSTEMIC USE
|
WHO Anatomical Therapeutic Chemical classification |
|
ANABOLIC AGENTS FOR SYSTEMIC USE |
| 0‑L |
A14A
|
ANABOLIC STEROIDS
|
WHO Anatomical Therapeutic Chemical classification |
|
ANABOLIC STEROIDS |
| 0‑L |
A14AA
|
Androstan derivatives
|
WHO Anatomical Therapeutic Chemical classification |
|
Androstan derivatives |
| 0‑L |
A14AA01
|
androstanolone
|
WHO Anatomical Therapeutic Chemical classification |
|
androstanolone |
| 0‑L |
A14AA02
|
stanozolol
|
WHO Anatomical Therapeutic Chemical classification |
|
stanozolol |
| 0‑L |
A14AA03
|
metandienone
|
WHO Anatomical Therapeutic Chemical classification |
|
metandienone |
| 0‑L |
A14AA04
|
metenolone
|
WHO Anatomical Therapeutic Chemical classification |
|
metenolone |
| 0‑L |
A14AA05
|
oxymetholone
|
WHO Anatomical Therapeutic Chemical classification |
|
oxymetholone |
| 0‑L |
A14AA06
|
quinbolone
|
WHO Anatomical Therapeutic Chemical classification |
|
quinbolone |
| 0‑L |
A14AA07
|
prasterone
|
WHO Anatomical Therapeutic Chemical classification |
|
prasterone |
| 0‑L |
A14AA08
|
oxandrolone
|
WHO Anatomical Therapeutic Chemical classification |
|
oxandrolone |
| 0‑L |
A14AA09
|
norethandrolone
|
WHO Anatomical Therapeutic Chemical classification |
|
norethandrolone |
| 0‑L |
A14AB
|
Estren derivatives
|
WHO Anatomical Therapeutic Chemical classification |
|
Estren derivatives |
| 0‑L |
A14AB01
|
nandrolone
|
WHO Anatomical Therapeutic Chemical classification |
|
nandrolone |
| 0‑L |
A14AB02
|
ethylestrenol
|
WHO Anatomical Therapeutic Chemical classification |
|
ethylestrenol |
| 0‑L |
A14AB03
|
oxabolone cipionate
|
WHO Anatomical Therapeutic Chemical classification |
|
oxabolone cipionate |
| 0‑L |
A14B
|
OTHER ANABOLIC AGENTS
|
WHO Anatomical Therapeutic Chemical classification |
|
OTHER ANABOLIC AGENTS |
| 0‑L |
A15
|
APPETITE STIMULANTS
|
WHO Anatomical Therapeutic Chemical classification |
|
APPETITE STIMULANTS |
| 0‑L |
A16
|
OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS
|
WHO Anatomical Therapeutic Chemical classification |
|
OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS |
| 0‑L |
A16A
|
OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS
|
WHO Anatomical Therapeutic Chemical classification |
|
OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS |
| 0‑L |
A16AA
|
Amino acids and derivatives
|
WHO Anatomical Therapeutic Chemical classification |
|
Amino acids and derivatives |
| 0‑L |
A16AA01
|
levocarnitine
|
WHO Anatomical Therapeutic Chemical classification |
|
levocarnitine |
| 0‑L |
A16AA02
|
ademetionine
|
WHO Anatomical Therapeutic Chemical classification |
|
ademetionine |
| 0‑L |
A16AA03
|
glutamine
|
WHO Anatomical Therapeutic Chemical classification |
|
glutamine |
| 0‑L |
A16AA04
|
mercaptamine
|
WHO Anatomical Therapeutic Chemical classification |
|
mercaptamine |
| 0‑L |
A16AA05
|
carglumic acid
|
WHO Anatomical Therapeutic Chemical classification |
|
carglumic acid |
| 0‑L |
A16AA06
|
betaine
|
WHO Anatomical Therapeutic Chemical classification |
|
betaine |
| 0‑L |
A16AA07
|
metreleptin
|
WHO Anatomical Therapeutic Chemical classification |
|
metreleptin |
| 0‑L |
A16AB
|
Enzymes
|
WHO Anatomical Therapeutic Chemical classification |
|
Enzymes |
| 0‑L |
A16AB01
|
alglucerase
|
WHO Anatomical Therapeutic Chemical classification |
|
alglucerase |
| 0‑L |
A16AB02
|
imiglucerase
|
WHO Anatomical Therapeutic Chemical classification |
|
imiglucerase |
| 0‑L |
A16AB03
|
agalsidase alfa
|
WHO Anatomical Therapeutic Chemical classification |
|
agalsidase alfa |
| 0‑L |
A16AB04
|
agalsidase beta
|
WHO Anatomical Therapeutic Chemical classification |
|
agalsidase beta |
| 0‑L |
A16AB05
|
laronidase
|
WHO Anatomical Therapeutic Chemical classification |
|
laronidase |
| 0‑L |
A16AB06
|
sacrosidase
|
WHO Anatomical Therapeutic Chemical classification |
|
sacrosidase |
| 0‑L |
A16AB07
|
alglucosidase alfa
|
WHO Anatomical Therapeutic Chemical classification |
|
alglucosidase alfa |
| 0‑L |
A16AB08
|
galsulfase
|
WHO Anatomical Therapeutic Chemical classification |
|
galsulfase |
| 0‑L |
A16AB09
|
idursulfase
|
WHO Anatomical Therapeutic Chemical classification |
|
idursulfase |
| 0‑L |
A16AB10
|
velaglucerase alfa
|
WHO Anatomical Therapeutic Chemical classification |
|
velaglucerase alfa |
| 0‑L |
A16AB11
|
taliglucerase alfa
|
WHO Anatomical Therapeutic Chemical classification |
|
taliglucerase alfa |
| 0‑L |
A16AB12
|
elosulfase alfa
|
WHO Anatomical Therapeutic Chemical classification |
|
elosulfase alfa |
| 0‑L |
A16AB13
|
asfotase alfa
|
WHO Anatomical Therapeutic Chemical classification |
|
asfotase alfa |
| 0‑L |
A16AB14
|
sebelipase alfa
|
WHO Anatomical Therapeutic Chemical classification |
|
sebelipase alfa |
| 0‑L |
A16AX
|
Various alimentary tract and metabolism products
|
WHO Anatomical Therapeutic Chemical classification |
|
Various alimentary tract and metabolism products |
| 0‑L |
A16AX01
|
thioctic acid
|
WHO Anatomical Therapeutic Chemical classification |
|
thioctic acid |
| 0‑L |
A16AX02
|
anethole trithione
|
WHO Anatomical Therapeutic Chemical classification |
|
anethole trithione |
| 0‑L |
A16AX03
|
sodium phenylbutyrate
|
WHO Anatomical Therapeutic Chemical classification |
|
sodium phenylbutyrate |
| 0‑L |
A16AX04
|
nitisinone
|
WHO Anatomical Therapeutic Chemical classification |
|
nitisinone |
| 0‑L |
A16AX05
|
zinc acetate
|
WHO Anatomical Therapeutic Chemical classification |
|
zinc acetate |
| 0‑L |
A16AX06
|
miglustat
|
WHO Anatomical Therapeutic Chemical classification |
|
miglustat |
| 0‑L |
A16AX07
|
sapropterin
|
WHO Anatomical Therapeutic Chemical classification |
|
sapropterin |
| 0‑L |
A16AX08
|
teduglutide
|
WHO Anatomical Therapeutic Chemical classification |
|
teduglutide |
| 0‑L |
A16AX09
|
glycerol phenylbutyrate
|
WHO Anatomical Therapeutic Chemical classification |
|
glycerol phenylbutyrate |
| 0‑L |
A16AX10
|
eliglustat
|
WHO Anatomical Therapeutic Chemical classification |
|
eliglustat |
| 0‑L |
A16AX11
|
sodium benzoate
|
WHO Anatomical Therapeutic Chemical classification |
|
sodium benzoate |
| 0‑L |
A16AX12
|
trientine
|
WHO Anatomical Therapeutic Chemical classification |
|
trientine |
| 0‑L |
A16AX13
|
uridine triacetate
|
WHO Anatomical Therapeutic Chemical classification |
|
uridine triacetate |
| 0‑L |
B
|
BLOOD AND BLOOD FORMING ORGANS
|
WHO Anatomical Therapeutic Chemical classification |
|
BLOOD AND BLOOD FORMING ORGANS |
| 0‑L |
B01
|
ANTITHROMBOTIC AGENTS
|
WHO Anatomical Therapeutic Chemical classification |
|
ANTITHROMBOTIC AGENTS |
| 0‑L |
B01A
|
ANTITHROMBOTIC AGENTS
|
WHO Anatomical Therapeutic Chemical classification |
|
ANTITHROMBOTIC AGENTS |
| 0‑L |
B01AA
|
Vitamin K antagonists
|
WHO Anatomical Therapeutic Chemical classification |
|
Vitamin K antagonists |
| 0‑L |
B01AA01
|
dicoumarol
|
WHO Anatomical Therapeutic Chemical classification |
|
dicoumarol |
| 0‑L |
B01AA02
|
phenindione
|
WHO Anatomical Therapeutic Chemical classification |
|
phenindione |
| 0‑L |
B01AA03
|
warfarin
|
WHO Anatomical Therapeutic Chemical classification |
|
warfarin |
| 0‑L |
B01AA04
|
phenprocoumon
|
WHO Anatomical Therapeutic Chemical classification |
|
phenprocoumon |
| 0‑L |
B01AA07
|
acenocoumarol
|
WHO Anatomical Therapeutic Chemical classification |
|
acenocoumarol |
| 0‑L |
B01AA08
|
ethyl biscoumacetate
|
WHO Anatomical Therapeutic Chemical classification |
|
ethyl biscoumacetate |
| 0‑L |
B01AA09
|
clorindione
|
WHO Anatomical Therapeutic Chemical classification |
|
clorindione |
| 0‑L |
B01AA10
|
diphenadione
|
WHO Anatomical Therapeutic Chemical classification |
|
diphenadione |
| 0‑L |
B01AA11
|
tioclomarol
|
WHO Anatomical Therapeutic Chemical classification |
|
tioclomarol |
| 0‑L |
B01AA12
|
fluindione
|
WHO Anatomical Therapeutic Chemical classification |
|
fluindione |
| 0‑L |
B01AB
|
Heparin group
|
WHO Anatomical Therapeutic Chemical classification |
|
Heparin group |
| 0‑L |
B01AB01
|
heparin
|
WHO Anatomical Therapeutic Chemical classification |
|
heparin |
| 0‑L |
B01AB02
|
antithrombin III
|
WHO Anatomical Therapeutic Chemical classification |
|
antithrombin III |
| 0‑L |
B01AB04
|
dalteparin
|
WHO Anatomical Therapeutic Chemical classification |
|
dalteparin |
| 0‑L |
B01AB05
|
enoxaparin
|
WHO Anatomical Therapeutic Chemical classification |
|
enoxaparin |
| 0‑L |
B01AB06
|
nadroparin
|
WHO Anatomical Therapeutic Chemical classification |
|
nadroparin |
| 0‑L |
B01AB07
|
parnaparin
|
WHO Anatomical Therapeutic Chemical classification |
|
parnaparin |
| 0‑L |
B01AB08
|
reviparin
|
WHO Anatomical Therapeutic Chemical classification |
|
reviparin |
| 0‑L |
B01AB09
|
danaparoid
|
WHO Anatomical Therapeutic Chemical classification |
|
danaparoid |
| 0‑L |
B01AB10
|
tinzaparin
|
WHO Anatomical Therapeutic Chemical classification |
|
tinzaparin |
| 0‑L |
B01AB11
|
sulodexide
|
WHO Anatomical Therapeutic Chemical classification |
|
sulodexide |
| 0‑L |
B01AB12
|
bemiparin
|
WHO Anatomical Therapeutic Chemical classification |
|
bemiparin |
| 0‑L |
B01AB51
|
heparin, combinations
|
WHO Anatomical Therapeutic Chemical classification |
|
heparin, combinations |
| 0‑L |
B01AC
|
Platelet aggregation inhibitors excl. heparin
|
WHO Anatomical Therapeutic Chemical classification |
|
Platelet aggregation inhibitors excl. heparin |
| 0‑L |
B01AC01
|
ditazole
|
WHO Anatomical Therapeutic Chemical classification |
|
ditazole |
| 0‑L |
B01AC02
|
cloricromen
|
WHO Anatomical Therapeutic Chemical classification |
|
cloricromen |
| 0‑L |
B01AC03
|
picotamide
|
WHO Anatomical Therapeutic Chemical classification |
|
picotamide |
| 0‑L |
B01AC04
|
clopidogrel
|
WHO Anatomical Therapeutic Chemical classification |
|
clopidogrel |
| 0‑L |
B01AC05
|
ticlopidine
|
WHO Anatomical Therapeutic Chemical classification |
|
ticlopidine |
| 0‑L |
B01AC06
|
acetylsalicylic acid
|
WHO Anatomical Therapeutic Chemical classification |
|
acetylsalicylic acid |
| 0‑L |
B01AC07
|
dipyridamole
|
WHO Anatomical Therapeutic Chemical classification |
|
dipyridamole |
| 0‑L |
B01AC08
|
carbasalate calcium
|
WHO Anatomical Therapeutic Chemical classification |
|
carbasalate calcium |
| 0‑L |
B01AC09
|
epoprostenol
|
WHO Anatomical Therapeutic Chemical classification |
|
epoprostenol |
| 0‑L |
B01AC10
|
indobufen
|
WHO Anatomical Therapeutic Chemical classification |
|
indobufen |
| 0‑L |
B01AC11
|
iloprost
|
WHO Anatomical Therapeutic Chemical classification |
|
iloprost |
| 0‑L |
B01AC13
|
abciximab
|
WHO Anatomical Therapeutic Chemical classification |
|
abciximab |
| 0‑L |
B01AC15
|
aloxiprin
|
WHO Anatomical Therapeutic Chemical classification |
|
aloxiprin |
| 0‑L |
B01AC16
|
eptifibatide
|
WHO Anatomical Therapeutic Chemical classification |
|
eptifibatide |
| 0‑L |
B01AC17
|
tirofiban
|
WHO Anatomical Therapeutic Chemical classification |
|
tirofiban |
| 0‑L |
B01AC18
|
triflusal
|
WHO Anatomical Therapeutic Chemical classification |
|
triflusal |
| 0‑L |
B01AC19
|
beraprost
|
WHO Anatomical Therapeutic Chemical classification |
|
beraprost |
| 0‑L |
B01AC21
|
treprostinil
|
WHO Anatomical Therapeutic Chemical classification |
|
treprostinil |
| 0‑L |
B01AC22
|
prasugrel
|
WHO Anatomical Therapeutic Chemical classification |
|
prasugrel |
| 0‑L |
B01AC23
|
cilostazol
|
WHO Anatomical Therapeutic Chemical classification |
|
cilostazol |
| 0‑L |
B01AC24
|
ticagrelor
|
WHO Anatomical Therapeutic Chemical classification |
|
ticagrelor |
| 0‑L |
B01AC25
|
cangrelor
|
WHO Anatomical Therapeutic Chemical classification |
|
cangrelor |
| 0‑L |
B01AC26
|
vorapaxar
|
WHO Anatomical Therapeutic Chemical classification |
|
vorapaxar |
| 0‑L |
B01AC27
|
selexipag
|
WHO Anatomical Therapeutic Chemical classification |
|
selexipag |
| 0‑L |
B01AC30
|
combinations
|
WHO Anatomical Therapeutic Chemical classification |
|
combinations |
| 0‑L |
B01AC56
|
acetylsalicylic acid, combinations with proton pump inhibitors
|
WHO Anatomical Therapeutic Chemical classification |
|
acetylsalicylic acid, combinations with proton pump inhibitors |
| 0‑L |
B01AD
|
Enzymes
|
WHO Anatomical Therapeutic Chemical classification |
|
Enzymes |
| 0‑L |
B01AD01
|
streptokinase
|
WHO Anatomical Therapeutic Chemical classification |
|
streptokinase |
| 0‑L |
B01AD02
|
alteplase
|
WHO Anatomical Therapeutic Chemical classification |
|
alteplase |
| 0‑L |
B01AD03
|
anistreplase
|
WHO Anatomical Therapeutic Chemical classification |
|
anistreplase |
| 0‑L |
B01AD04
|
urokinase
|
WHO Anatomical Therapeutic Chemical classification |
|
urokinase |
| 0‑L |
B01AD05
|
fibrinolysin
|
WHO Anatomical Therapeutic Chemical classification |
|
fibrinolysin |
| 0‑L |
B01AD06
|
brinase
|
WHO Anatomical Therapeutic Chemical classification |
|
brinase |
| 0‑L |
B01AD07
|
reteplase
|
WHO Anatomical Therapeutic Chemical classification |
|
reteplase |
| 0‑L |
B01AD08
|
saruplase
|
WHO Anatomical Therapeutic Chemical classification |
|
saruplase |
| 0‑L |
B01AD09
|
ancrod
|
WHO Anatomical Therapeutic Chemical classification |
|
ancrod |
| 0‑L |
B01AD10
|
drotrecogin alfa (activated)
|
WHO Anatomical Therapeutic Chemical classification |
|
drotrecogin alfa (activated) |
| 0‑L |
B01AD11
|
tenecteplase
|
WHO Anatomical Therapeutic Chemical classification |
|
tenecteplase |
| 0‑L |
B01AD12
|
protein C
|
WHO Anatomical Therapeutic Chemical classification |
|
protein C |
| 0‑L |
B01AE
|
Direct thrombin inhibitors
|
WHO Anatomical Therapeutic Chemical classification |
|
Direct thrombin inhibitors |
| 0‑L |
B01AE01
|
desirudin
|
WHO Anatomical Therapeutic Chemical classification |
|
desirudin |
| 0‑L |
B01AE02
|
lepirudin
|
WHO Anatomical Therapeutic Chemical classification |
|
lepirudin |
| 0‑L |
B01AE03
|
argatroban
|
WHO Anatomical Therapeutic Chemical classification |
|
argatroban |
| 0‑L |
B01AE04
|
melagatran
|
WHO Anatomical Therapeutic Chemical classification |
|
melagatran |
| 0‑L |
B01AE05
|
ximelagatran
|
WHO Anatomical Therapeutic Chemical classification |
|
ximelagatran |
| 0‑L |
B01AE06
|
bivalirudin
|
WHO Anatomical Therapeutic Chemical classification |
|
bivalirudin |
| 0‑L |
B01AE07
|
dabigatran etexilate
|
WHO Anatomical Therapeutic Chemical classification |
|
dabigatran etexilate |
| 0‑L |
B01AF
|
Direct factor Xa inhibitors
|
WHO Anatomical Therapeutic Chemical classification |
|
Direct factor Xa inhibitors |
| 0‑L |
B01AF01
|
rivaroxaban
|
WHO Anatomical Therapeutic Chemical classification |
|
rivaroxaban |
| 0‑L |
B01AF02
|
apixaban
|
WHO Anatomical Therapeutic Chemical classification |
|
apixaban |
| 0‑L |
B01AF03
|
edoxaban
|
WHO Anatomical Therapeutic Chemical classification |
|
edoxaban |
| 0‑L |
B01AX
|
Other antithrombotic agents
|
WHO Anatomical Therapeutic Chemical classification |
|
Other antithrombotic agents |
| 0‑L |
B01AX01
|
defibrotide
|
WHO Anatomical Therapeutic Chemical classification |
|
defibrotide |
| 0‑L |
B01AX04
|
dermatan sulfate
|
WHO Anatomical Therapeutic Chemical classification |
|
dermatan sulfate |
| 0‑L |
B01AX05
|
fondaparinux
|
WHO Anatomical Therapeutic Chemical classification |
|
fondaparinux |
| 0‑L |
B02
|
ANTIHEMORRHAGICS
|
WHO Anatomical Therapeutic Chemical classification |
|
ANTIHEMORRHAGICS |
| 0‑L |
B02A
|
ANTIFIBRINOLYTICS
|
WHO Anatomical Therapeutic Chemical classification |
|
ANTIFIBRINOLYTICS |
| 0‑L |
B02AA
|
Amino acids
|
WHO Anatomical Therapeutic Chemical classification |
|
Amino acids |
| 0‑L |
B02AA01
|
aminocaproic acid
|
WHO Anatomical Therapeutic Chemical classification |
|
aminocaproic acid |
| 0‑L |
B02AA02
|
tranexamic acid
|
WHO Anatomical Therapeutic Chemical classification |
|
tranexamic acid |
| 0‑L |
B02AA03
|
aminomethylbenzoic acid
|
WHO Anatomical Therapeutic Chemical classification |
|
aminomethylbenzoic acid |
| 0‑L |
B02AB
|
Proteinase inhibitors
|
WHO Anatomical Therapeutic Chemical classification |
|
Proteinase inhibitors |
| 0‑L |
B02AB01
|
aprotinin
|
WHO Anatomical Therapeutic Chemical classification |
|
aprotinin |
| 0‑L |
B02AB02
|
alfa1 antitrypsin
|
WHO Anatomical Therapeutic Chemical classification |
|
alfa1 antitrypsin |
| 0‑L |
B02AB04
|
camostat
|
WHO Anatomical Therapeutic Chemical classification |
|
camostat |
| 0‑L |
B02B
|
VITAMIN K AND OTHER HEMOSTATICS
|
WHO Anatomical Therapeutic Chemical classification |
|
VITAMIN K AND OTHER HEMOSTATICS |
| 0‑L |
B02BA
|
Vitamin K
|
WHO Anatomical Therapeutic Chemical classification |
|
Vitamin K |
| 0‑L |
B02BA01
|
phytomenadione
|
WHO Anatomical Therapeutic Chemical classification |
|
phytomenadione |
| 0‑L |
B02BA02
|
menadione
|
WHO Anatomical Therapeutic Chemical classification |
|
menadione |
| 0‑L |
B02BB
|
Fibrinogen
|
WHO Anatomical Therapeutic Chemical classification |
|
Fibrinogen |
| 0‑L |
B02BB01
|
fibrinogen, human
|
WHO Anatomical Therapeutic Chemical classification |
|
fibrinogen, human |
| 0‑L |
B02BC
|
Local hemostatics
|
WHO Anatomical Therapeutic Chemical classification |
|
Local hemostatics |
| 0‑L |
B02BC01
|
absorbable gelatin sponge
|
WHO Anatomical Therapeutic Chemical classification |
|
absorbable gelatin sponge |
| 0‑L |
B02BC02
|
oxidized cellulose
|
WHO Anatomical Therapeutic Chemical classification |
|
oxidized cellulose |
| 0‑L |
B02BC03
|
tetragalacturonic acid hydroxymethylester
|
WHO Anatomical Therapeutic Chemical classification |
|
tetragalacturonic acid hydroxymethylester |
| 0‑L |
B02BC05
|
adrenalone
|
WHO Anatomical Therapeutic Chemical classification |
|
adrenalone |
| 0‑L |
B02BC06
|
thrombin
|
WHO Anatomical Therapeutic Chemical classification |
|
thrombin |
| 0‑L |
B02BC07
|
collagen
|
WHO Anatomical Therapeutic Chemical classification |
|
collagen |
| 0‑L |
B02BC08
|
calcium alginate
|
WHO Anatomical Therapeutic Chemical classification |
|
calcium alginate |
| 0‑L |
B02BC09
|
epinephrine
|
WHO Anatomical Therapeutic Chemical classification |
|
epinephrine |
| 0‑L |
B02BC30
|
combinations
|
WHO Anatomical Therapeutic Chemical classification |
|
combinations |
| 0‑L |
B02BD
|
Blood coagulation factors
|
WHO Anatomical Therapeutic Chemical classification |
|
Blood coagulation factors |
| 0‑L |
B02BD01
|
coagulation factor IX, II, VII and X in combination
|
WHO Anatomical Therapeutic Chemical classification |
|
coagulation factor IX, II, VII and X in combination |
| 0‑L |
B02BD02
|
coagulation factor VIII
|
WHO Anatomical Therapeutic Chemical classification |
|
coagulation factor VIII |
| 0‑L |
B02BD03
|
factor VIII inhibitor bypassing activity
|
WHO Anatomical Therapeutic Chemical classification |
|
factor VIII inhibitor bypassing activity |
| 0‑L |
B02BD04
|
coagulation factor IX
|
WHO Anatomical Therapeutic Chemical classification |
|
coagulation factor IX |
| 0‑L |
B02BD05
|
coagulation factor VII
|
WHO Anatomical Therapeutic Chemical classification |
|
coagulation factor VII |
| 0‑L |
B02BD06
|
von Willebrand factor and coagulation factor VIII in combination
|
WHO Anatomical Therapeutic Chemical classification |
|
von Willebrand factor and coagulation factor VIII in combination |
| 0‑L |
B02BD07
|
coagulation factor XIII
|
WHO Anatomical Therapeutic Chemical classification |
|
coagulation factor XIII |
| 0‑L |
B02BD08
|
eptacog alfa (activated)
|
WHO Anatomical Therapeutic Chemical classification |
|
eptacog alfa (activated) |
| 0‑L |
B02BD10
|
von Willebrand factor
|
WHO Anatomical Therapeutic Chemical classification |
|
von Willebrand factor |
| 0‑L |
B02BD11
|
catridecacog
|
WHO Anatomical Therapeutic Chemical classification |
|
catridecacog |
| 0‑L |
B02BD13
|
coagulation factor X
|
WHO Anatomical Therapeutic Chemical classification |
|
coagulation factor X |
| 0‑L |
B02BD14
|
susoctocog alfa
|
WHO Anatomical Therapeutic Chemical classification |
|
susoctocog alfa |
| 0‑L |
B02BD30
|
thrombin
|
WHO Anatomical Therapeutic Chemical classification |
|
thrombin |
| 0‑L |
B02BX
|
Other systemic hemostatics
|
WHO Anatomical Therapeutic Chemical classification |
|
Other systemic hemostatics |
| 0‑L |
B02BX01
|
etamsylate
|
WHO Anatomical Therapeutic Chemical classification |
|
etamsylate |
| 0‑L |
B02BX02
|
carbazochrome
|
WHO Anatomical Therapeutic Chemical classification |
|
carbazochrome |
| 0‑L |
B02BX03
|
batroxobin
|
WHO Anatomical Therapeutic Chemical classification |
|
batroxobin |
| 0‑L |
B02BX04
|
romiplostim
|
WHO Anatomical Therapeutic Chemical classification |
|
romiplostim |
| 0‑L |
B02BX05
|
eltrombopag
|
WHO Anatomical Therapeutic Chemical classification |
|
eltrombopag |
| 0‑L |
B03
|
ANTIANEMIC PREPARATIONS
|
WHO Anatomical Therapeutic Chemical classification |
|
ANTIANEMIC PREPARATIONS |
| 0‑L |
B03A
|
IRON PREPARATIONS
|
WHO Anatomical Therapeutic Chemical classification |
|
IRON PREPARATIONS |
| 0‑L |
B03AA
|
Iron bivalent, oral preparations
|
WHO Anatomical Therapeutic Chemical classification |
|
Iron bivalent, oral preparations |
| 0‑L |
B03AA01
|
ferrous glycine sulfate
|
WHO Anatomical Therapeutic Chemical classification |
|
ferrous glycine sulfate |
| 0‑L |
B03AA02
|
ferrous fumarate
|
WHO Anatomical Therapeutic Chemical classification |
|
ferrous fumarate |
| 0‑L |
B03AA03
|
ferrous gluconate
|
WHO Anatomical Therapeutic Chemical classification |
|
ferrous gluconate |
| 0‑L |
B03AA04
|
ferrous carbonate
|
WHO Anatomical Therapeutic Chemical classification |
|
ferrous carbonate |
| 0‑L |
B03AA05
|
ferrous chloride
|
WHO Anatomical Therapeutic Chemical classification |
|
ferrous chloride |
| 0‑L |
B03AA06
|
ferrous succinate
|
WHO Anatomical Therapeutic Chemical classification |
|
ferrous succinate |
| 0‑L |
B03AA07
|
ferrous sulfate
|
WHO Anatomical Therapeutic Chemical classification |
|
ferrous sulfate |
| 0‑L |
B03AA08
|
ferrous tartrate
|
WHO Anatomical Therapeutic Chemical classification |
|
ferrous tartrate |
| 0‑L |
B03AA09
|
ferrous aspartate
|
WHO Anatomical Therapeutic Chemical classification |
|
ferrous aspartate |
| 0‑L |
B03AA10
|
ferrous ascorbate
|
WHO Anatomical Therapeutic Chemical classification |
|
ferrous ascorbate |
| 0‑L |
B03AA11
|
ferrous iodine
|
WHO Anatomical Therapeutic Chemical classification |
|
ferrous iodine |
| 0‑L |
B03AB
|
Iron trivalent, oral preparations
|
WHO Anatomical Therapeutic Chemical classification |
|
Iron trivalent, oral preparations |
| 0‑L |
B03AB01
|
ferric sodium citrate
|
WHO Anatomical Therapeutic Chemical classification |
|
ferric sodium citrate |
| 0‑L |
B03AB02
|
saccharated iron oxide
|
WHO Anatomical Therapeutic Chemical classification |
|
saccharated iron oxide |
| 0‑L |
B03AB03
|
sodium feredetate
|
WHO Anatomical Therapeutic Chemical classification |
|
sodium feredetate |
| 0‑L |
B03AB04
|
ferric hydroxide
|
WHO Anatomical Therapeutic Chemical classification |
|
ferric hydroxide |
| 0‑L |
B03AB05
|
ferric oxide polymaltose complexes
|
WHO Anatomical Therapeutic Chemical classification |
|
ferric oxide polymaltose complexes |
| 0‑L |
B03AB07
|
chondroitin sulfate-iron complex
|
WHO Anatomical Therapeutic Chemical classification |
|
chondroitin sulfate-iron complex |
| 0‑L |
B03AB08
|
ferric acetyl transferrin
|
WHO Anatomical Therapeutic Chemical classification |
|
ferric acetyl transferrin |
| 0‑L |
B03AB09
|
ferric proteinsuccinylate
|
WHO Anatomical Therapeutic Chemical classification |
|
ferric proteinsuccinylate |
| 0‑L |
B03AB10
|
ferric maltol
|
WHO Anatomical Therapeutic Chemical classification |
|
ferric maltol |
| 0‑L |
B03AC
|
Iron, parenteral preparations
|
WHO Anatomical Therapeutic Chemical classification |
|
Iron, parenteral preparations |
| 0‑L |
B03AD
|
Iron in combination with folic acid
|
WHO Anatomical Therapeutic Chemical classification |
|
Iron in combination with folic acid |
| 0‑L |
B03AD01
|
ferrous amino acid complex
|
WHO Anatomical Therapeutic Chemical classification |
|
ferrous amino acid complex |
| 0‑L |
B03AD02
|
ferrous fumarate
|
WHO Anatomical Therapeutic Chemical classification |
|
ferrous fumarate |
| 0‑L |
B03AD03
|
ferrous sulfate
|
WHO Anatomical Therapeutic Chemical classification |
|
ferrous sulfate |
| 0‑L |
B03AD04
|
ferric oxide polymaltose complexes
|
WHO Anatomical Therapeutic Chemical classification |
|
ferric oxide polymaltose complexes |
| 0‑L |
B03AE
|
Iron in other combinations
|
WHO Anatomical Therapeutic Chemical classification |
|
Iron in other combinations |
| 0‑L |
B03AE01
|
iron, vitamin B12 and folic acid
|
WHO Anatomical Therapeutic Chemical classification |
|
iron, vitamin B12 and folic acid |
| 0‑L |
B03AE02
|
iron, multivitamins and folic acid
|
WHO Anatomical Therapeutic Chemical classification |
|
iron, multivitamins and folic acid |
| 0‑L |
B03AE03
|
iron and multivitamins
|
WHO Anatomical Therapeutic Chemical classification |
|
iron and multivitamins |
| 0‑L |
B03AE04
|
iron, multivitamins and minerals
|
WHO Anatomical Therapeutic Chemical classification |
|
iron, multivitamins and minerals |
| 0‑L |
B03AE10
|
various combinations
|
WHO Anatomical Therapeutic Chemical classification |
|
various combinations |
| 0‑L |
B03B
|
VITAMIN B12 AND FOLIC ACID
|
WHO Anatomical Therapeutic Chemical classification |
|
VITAMIN B12 AND FOLIC ACID |
| 0‑L |
B03BA
|
Vitamin B12 (cyanocobalamin and analogues)
|
WHO Anatomical Therapeutic Chemical classification |
|
Vitamin B12 (cyanocobalamin and analogues) |
| 0‑L |
B03BA01
|
cyanocobalamin
|
WHO Anatomical Therapeutic Chemical classification |
|
cyanocobalamin |
| 0‑L |
B03BA02
|
cyanocobalamin tannin complex
|
WHO Anatomical Therapeutic Chemical classification |
|
cyanocobalamin tannin complex |
| 0‑L |
B03BA03
|
hydroxocobalamin
|
WHO Anatomical Therapeutic Chemical classification |
|
hydroxocobalamin |
| 0‑L |
B03BA04
|
cobamamide
|
WHO Anatomical Therapeutic Chemical classification |
|
cobamamide |
| 0‑L |
B03BA05
|
mecobalamin
|
WHO Anatomical Therapeutic Chemical classification |
|
mecobalamin |
| 0‑L |
B03BA51
|
cyanocobalamin, combinations
|
WHO Anatomical Therapeutic Chemical classification |
|
cyanocobalamin, combinations |
| 0‑L |
B03BA53
|
hydroxocobalamin, combinations
|
WHO Anatomical Therapeutic Chemical classification |
|
hydroxocobalamin, combinations |
| 0‑L |
B03BB
|
Folic acid and derivatives
|
WHO Anatomical Therapeutic Chemical classification |
|
Folic acid and derivatives |
| 0‑L |
B03BB01
|
folic acid
|
WHO Anatomical Therapeutic Chemical classification |
|
folic acid |
| 0‑L |
B03BB51
|
folic acid, combinations
|
WHO Anatomical Therapeutic Chemical classification |
|
folic acid, combinations |
| 0‑L |
B03X
|
OTHER ANTIANEMIC PREPARATIONS
|
WHO Anatomical Therapeutic Chemical classification |
|
OTHER ANTIANEMIC PREPARATIONS |
| 0‑L |
B03XA
|
Other antianemic preparations
|
WHO Anatomical Therapeutic Chemical classification |
|
Other antianemic preparations |
| 0‑L |
B03XA01
|
erythropoietin
|
WHO Anatomical Therapeutic Chemical classification |
|
erythropoietin |
| 0‑L |
B03XA02
|
darbepoetin alfa
|
WHO Anatomical Therapeutic Chemical classification |
|
darbepoetin alfa |
| 0‑L |
B03XA03
|
methoxy polyethylene glycol-epoetin beta
|
WHO Anatomical Therapeutic Chemical classification |
|
methoxy polyethylene glycol-epoetin beta |
| 0‑L |
B03XA04
|
peginesatide
|
WHO Anatomical Therapeutic Chemical classification |
|
peginesatide |
| 0‑L |
B05
|
BLOOD SUBSTITUTES AND PERFUSION SOLUTIONS
|
WHO Anatomical Therapeutic Chemical classification |
|
BLOOD SUBSTITUTES AND PERFUSION SOLUTIONS |
| 0‑L |
B05A
|
BLOOD AND RELATED PRODUCTS
|
WHO Anatomical Therapeutic Chemical classification |
|
BLOOD AND RELATED PRODUCTS |
| 0‑L |
B05AA
|
Blood substitutes and plasma protein fractions
|
WHO Anatomical Therapeutic Chemical classification |
|
Blood substitutes and plasma protein fractions |
| 0‑L |
B05AA01
|
albumin
|
WHO Anatomical Therapeutic Chemical classification |
|
albumin |
| 0‑L |
B05AA02
|
other plasma protein fractions
|
WHO Anatomical Therapeutic Chemical classification |
|
other plasma protein fractions |
| 0‑L |
B05AA03
|
fluorocarbon blood substitutes
|
WHO Anatomical Therapeutic Chemical classification |
|
fluorocarbon blood substitutes |
| 0‑L |
B05AA05
|
dextran
|
WHO Anatomical Therapeutic Chemical classification |
|
dextran |
| 0‑L |
B05AA06
|
gelatin agents
|
WHO Anatomical Therapeutic Chemical classification |
|
gelatin agents |
| 0‑L |
B05AA07
|
hydroxyethylstarch
|
WHO Anatomical Therapeutic Chemical classification |
|
hydroxyethylstarch |
| 0‑L |
B05AA08
|
hemoglobin crosfumaril
|
WHO Anatomical Therapeutic Chemical classification |
|
hemoglobin crosfumaril |
| 0‑L |
B05AA09
|
hemoglobin raffimer
|
WHO Anatomical Therapeutic Chemical classification |
|
hemoglobin raffimer |
| 0‑L |
B05AA10
|
hemoglobin glutamer (bovine)
|
WHO Anatomical Therapeutic Chemical classification |
|
hemoglobin glutamer (bovine) |
| 0‑L |
B05AX
|
Other blood products
|
WHO Anatomical Therapeutic Chemical classification |
|
Other blood products |
| 0‑L |
B05AX01
|
erythrocytes
|
WHO Anatomical Therapeutic Chemical classification |
|
erythrocytes |
| 0‑L |
B05AX02
|
thrombocytes
|
WHO Anatomical Therapeutic Chemical classification |
|
thrombocytes |
| 0‑L |
B05AX03
|
blood plasma
|
WHO Anatomical Therapeutic Chemical classification |
|
blood plasma |
| 0‑L |
B05AX04
|
stem cells from umbilical cord blood
|
WHO Anatomical Therapeutic Chemical classification |
|
stem cells from umbilical cord blood |
| 0‑L |
B05B
|
I.V. SOLUTIONS
|
WHO Anatomical Therapeutic Chemical classification |
|
I.V. SOLUTIONS |
| 0‑L |
B05BA
|
Solutions for parenteral nutrition
|
WHO Anatomical Therapeutic Chemical classification |
|
Solutions for parenteral nutrition |
| 0‑L |
B05BA01
|
amino acids
|
WHO Anatomical Therapeutic Chemical classification |
|
amino acids |
| 0‑L |
B05BA02
|
fat emulsions
|
WHO Anatomical Therapeutic Chemical classification |
|
fat emulsions |
| 0‑L |
B05BA03
|
carbohydrates
|
WHO Anatomical Therapeutic Chemical classification |
|
carbohydrates |
| 0‑L |
B05BA04
|
protein hydrolysates
|
WHO Anatomical Therapeutic Chemical classification |
|
protein hydrolysates |
| 0‑L |
B05BA10
|
combinations
|
WHO Anatomical Therapeutic Chemical classification |
|
combinations |
| 0‑L |
B05BB
|
Solutions affecting the electrolyte balance
|
WHO Anatomical Therapeutic Chemical classification |
|
Solutions affecting the electrolyte balance |
| 0‑L |
B05BB01
|
electrolytes
|
WHO Anatomical Therapeutic Chemical classification |
|
electrolytes |
| 0‑L |
B05BB02
|
electrolytes with carbohydrates
|
WHO Anatomical Therapeutic Chemical classification |
|
electrolytes with carbohydrates |
| 0‑L |
B05BB03
|
trometamol
|
WHO Anatomical Therapeutic Chemical classification |
|
trometamol |
| 0‑L |
B05BB04
|
electrolytes in combination with other drugs
|
WHO Anatomical Therapeutic Chemical classification |
|
electrolytes in combination with other drugs |
| 0‑L |
B05BC
|
Solutions producing osmotic diuresis
|
WHO Anatomical Therapeutic Chemical classification |
|
Solutions producing osmotic diuresis |
| 0‑L |
B05BC01
|
mannitol
|
WHO Anatomical Therapeutic Chemical classification |
|
mannitol |
| 0‑L |
B05BC02
|
carbamide
|
WHO Anatomical Therapeutic Chemical classification |
|
carbamide |
| 0‑L |
B05C
|
IRRIGATING SOLUTIONS
|
WHO Anatomical Therapeutic Chemical classification |
|
IRRIGATING SOLUTIONS |
| 0‑L |
B05CA
|
Antiinfectives
|
WHO Anatomical Therapeutic Chemical classification |
|
Antiinfectives |
| 0‑L |
B05CA01
|
cetylpyridinium
|
WHO Anatomical Therapeutic Chemical classification |
|
cetylpyridinium |
| 0‑L |
B05CA02
|
chlorhexidine
|
WHO Anatomical Therapeutic Chemical classification |
|
chlorhexidine |
| 0‑L |
B05CA03
|
nitrofural
|
WHO Anatomical Therapeutic Chemical classification |
|
nitrofural |
| 0‑L |
B05CA04
|
sulfamethizole
|
WHO Anatomical Therapeutic Chemical classification |
|
sulfamethizole |
| 0‑L |
B05CA05
|
taurolidine
|
WHO Anatomical Therapeutic Chemical classification |
|
taurolidine |
| 0‑L |
B05CA06
|
mandelic acid
|
WHO Anatomical Therapeutic Chemical classification |
|
mandelic acid |
| 0‑L |
B05CA07
|
noxytiolin
|
WHO Anatomical Therapeutic Chemical classification |
|
noxytiolin |
| 0‑L |
B05CA08
|
ethacridine lactate
|
WHO Anatomical Therapeutic Chemical classification |
|
ethacridine lactate |
| 0‑L |
B05CA09
|
neomycin
|
WHO Anatomical Therapeutic Chemical classification |
|
neomycin |
| 0‑L |
B05CA10
|
combinations
|
WHO Anatomical Therapeutic Chemical classification |
|
combinations |
| 0‑L |
B05CB
|
Salt solutions
|
WHO Anatomical Therapeutic Chemical classification |
|
Salt solutions |
| 0‑L |
B05CB01
|
sodium chloride
|
WHO Anatomical Therapeutic Chemical classification |
|
sodium chloride |
| 0‑L |
B05CB02
|
sodium citrate
|
WHO Anatomical Therapeutic Chemical classification |
|
sodium citrate |
| 0‑L |
B05CB03
|
magnesium citrate
|
WHO Anatomical Therapeutic Chemical classification |
|
magnesium citrate |
| 0‑L |
B05CB04
|
sodium bicarbonate
|
WHO Anatomical Therapeutic Chemical classification |
|
sodium bicarbonate |
| 0‑L |
B05CB10
|
combinations
|
WHO Anatomical Therapeutic Chemical classification |
|
combinations |
| 0‑L |
B05CX
|
Other irrigating solutions
|
WHO Anatomical Therapeutic Chemical classification |
|
Other irrigating solutions |
| 0‑L |
B05CX01
|
glucose
|
WHO Anatomical Therapeutic Chemical classification |
|
glucose |
| 0‑L |
B05CX02
|
sorbitol
|
WHO Anatomical Therapeutic Chemical classification |
|
sorbitol |
| 0‑L |
B05CX03
|
glycine
|
WHO Anatomical Therapeutic Chemical classification |
|
glycine |
| 0‑L |
B05CX04
|
mannitol
|
WHO Anatomical Therapeutic Chemical classification |
|
mannitol |
| 0‑L |
B05CX10
|
combinations
|
WHO Anatomical Therapeutic Chemical classification |
|
combinations |
| 0‑L |
B05D
|
PERITONEAL DIALYTICS
|
WHO Anatomical Therapeutic Chemical classification |
|
PERITONEAL DIALYTICS |
| 0‑L |
B05DA
|
Isotonic solutions
|
WHO Anatomical Therapeutic Chemical classification |
|
Isotonic solutions |
| 0‑L |
B05DB
|
Hypertonic solutions
|
WHO Anatomical Therapeutic Chemical classification |
|
Hypertonic solutions |
| 0‑L |
B05X
|
I.V. SOLUTION ADDITIVES
|
WHO Anatomical Therapeutic Chemical classification |
|
I.V. SOLUTION ADDITIVES |
| 0‑L |
B05XA
|
Electrolyte solutions
|
WHO Anatomical Therapeutic Chemical classification |
|
Electrolyte solutions |
| 0‑L |
B05XA01
|
potassium chloride
|
WHO Anatomical Therapeutic Chemical classification |
|
potassium chloride |
| 0‑L |
B05XA02
|
sodium bicarbonate
|
WHO Anatomical Therapeutic Chemical classification |
|
sodium bicarbonate |
| 0‑L |
B05XA03
|
sodium chloride
|
WHO Anatomical Therapeutic Chemical classification |
|
sodium chloride |
| 0‑L |
B05XA04
|
ammonium chloride
|
WHO Anatomical Therapeutic Chemical classification |
|
ammonium chloride |
| 0‑L |
B05XA05
|
magnesium sulfate
|
WHO Anatomical Therapeutic Chemical classification |
|
magnesium sulfate |
| 0‑L |
B05XA06
|
potassium phosphate, incl. combinations with other potassium salts
|
WHO Anatomical Therapeutic Chemical classification |
|
potassium phosphate, incl. combinations with other potassium salts |
| 0‑L |
B05XA07
|
calcium chloride
|
WHO Anatomical Therapeutic Chemical classification |
|
calcium chloride |
| 0‑L |
B05XA08
|
sodium acetate
|
WHO Anatomical Therapeutic Chemical classification |
|
sodium acetate |
| 0‑L |
B05XA09
|
sodium phosphate
|
WHO Anatomical Therapeutic Chemical classification |
|
sodium phosphate |
| 0‑L |
B05XA10
|
magnesium phosphate
|
WHO Anatomical Therapeutic Chemical classification |
|
magnesium phosphate |
| 0‑L |
B05XA11
|
magnesium chloride
|
WHO Anatomical Therapeutic Chemical classification |
|
magnesium chloride |
| 0‑L |
B05XA12
|
zinc chloride
|
WHO Anatomical Therapeutic Chemical classification |
|
zinc chloride |
| 0‑L |
B05XA13
|
hydrochloric acid
|
WHO Anatomical Therapeutic Chemical classification |
|
hydrochloric acid |
| 0‑L |
B05XA14
|
sodium glycerophosphate
|
WHO Anatomical Therapeutic Chemical classification |
|
sodium glycerophosphate |
| 0‑L |
B05XA15
|
potassium lactate
|
WHO Anatomical Therapeutic Chemical classification |
|
potassium lactate |
| 0‑L |
B05XA16
|
cardioplegia solutions
|
WHO Anatomical Therapeutic Chemical classification |
|
cardioplegia solutions |
| 0‑L |
B05XA17
|
potassium acetate
|
WHO Anatomical Therapeutic Chemical classification |
|
potassium acetate |
| 0‑L |
B05XA30
|
combinations of electrolytes
|
WHO Anatomical Therapeutic Chemical classification |
|
combinations of electrolytes |
| 0‑L |
B05XA31
|
electrolytes in combination with other drugs
|
WHO Anatomical Therapeutic Chemical classification |
|
electrolytes in combination with other drugs |
| 0‑L |
B05XB
|
Amino acids
|
WHO Anatomical Therapeutic Chemical classification |
|
Amino acids |
| 0‑L |
B05XB01
|
arginine hydrochloride
|
WHO Anatomical Therapeutic Chemical classification |
|
arginine hydrochloride |
| 0‑L |
B05XB02
|
alanyl glutamine
|
WHO Anatomical Therapeutic Chemical classification |
|
alanyl glutamine |
| 0‑L |
B05XB03
|
lysine
|
WHO Anatomical Therapeutic Chemical classification |
|
lysine |
| 0‑L |
B05XC
|
Vitamins
|
WHO Anatomical Therapeutic Chemical classification |
|
Vitamins |
| 0‑L |
B05XX
|
Other i.v. solution additives
|
WHO Anatomical Therapeutic Chemical classification |
|
Other i.v. solution additives |
| 0‑L |
B05XX02
|
trometamol
|
WHO Anatomical Therapeutic Chemical classification |
|
trometamol |
| 0‑L |
B05Z
|
HEMODIALYTICS AND HEMOFILTRATES
|
WHO Anatomical Therapeutic Chemical classification |
|
HEMODIALYTICS AND HEMOFILTRATES |
| 0‑L |
B05ZA
|
Hemodialytics, concentrates
|
WHO Anatomical Therapeutic Chemical classification |
|
Hemodialytics, concentrates |
| 0‑L |
B05ZB
|
Hemofiltrates
|
WHO Anatomical Therapeutic Chemical classification |
|
Hemofiltrates |
| 0‑L |
B06
|
OTHER HEMATOLOGICAL AGENTS
|
WHO Anatomical Therapeutic Chemical classification |
|
OTHER HEMATOLOGICAL AGENTS |
| 0‑L |
B06A
|
OTHER HEMATOLOGICAL AGENTS
|
WHO Anatomical Therapeutic Chemical classification |
|
OTHER HEMATOLOGICAL AGENTS |
| 0‑L |
B06AA
|
Enzymes
|
WHO Anatomical Therapeutic Chemical classification |
|
Enzymes |
| 0‑L |
B06AA02
|
fibrinolysin and desoxyribonuclease
|
WHO Anatomical Therapeutic Chemical classification |
|
fibrinolysin and desoxyribonuclease |
| 0‑L |
B06AA03
|
hyaluronidase
|
WHO Anatomical Therapeutic Chemical classification |
|
hyaluronidase |
| 0‑L |
B06AA04
|
chymotrypsin
|
WHO Anatomical Therapeutic Chemical classification |
|
chymotrypsin |
| 0‑L |
B06AA07
|
trypsin
|
WHO Anatomical Therapeutic Chemical classification |
|
trypsin |
| 0‑L |
B06AA10
|
desoxyribonuclease
|
WHO Anatomical Therapeutic Chemical classification |
|
desoxyribonuclease |
| 0‑L |
B06AA55
|
streptokinase, combinations
|
WHO Anatomical Therapeutic Chemical classification |
|
streptokinase, combinations |
| 0‑L |
B06AB
|
Other hem products
|
WHO Anatomical Therapeutic Chemical classification |
|
Other hem products |
| 0‑L |
B06AB01
|
hematin
|
WHO Anatomical Therapeutic Chemical classification |
|
hematin |
| 0‑L |
B06AC
|
Drugs used in hereditary angioedema
|
WHO Anatomical Therapeutic Chemical classification |
|
Drugs used in hereditary angioedema |
| 0‑L |
B06AC01
|
c1-inhibitor, plasma derived
|
WHO Anatomical Therapeutic Chemical classification |
|
c1-inhibitor, plasma derived |
| 0‑L |
B06AC02
|
icatibant
|
WHO Anatomical Therapeutic Chemical classification |
|
icatibant |
| 0‑L |
B06AC03
|
ecallantide
|
WHO Anatomical Therapeutic Chemical classification |
|
ecallantide |
| 0‑L |
B06AC04
|
conestat alfa
|
WHO Anatomical Therapeutic Chemical classification |
|
conestat alfa |
| 0‑L |
C
|
CARDIOVASCULAR SYSTEM
|
WHO Anatomical Therapeutic Chemical classification |
|
CARDIOVASCULAR SYSTEM |
| 0‑L |
C01
|
CARDIAC THERAPY
|
WHO Anatomical Therapeutic Chemical classification |
|
CARDIAC THERAPY |
| 0‑L |
C01A
|
CARDIAC GLYCOSIDES
|
WHO Anatomical Therapeutic Chemical classification |
|
CARDIAC GLYCOSIDES |
| 0‑L |
C01AA
|
Digitalis glycosides
|
WHO Anatomical Therapeutic Chemical classification |
|
Digitalis glycosides |
| 0‑L |
C01AA01
|
acetyldigitoxin
|
WHO Anatomical Therapeutic Chemical classification |
|
acetyldigitoxin |
| 0‑L |
C01AA02
|
acetyldigoxin
|
WHO Anatomical Therapeutic Chemical classification |
|
acetyldigoxin |
| 0‑L |
C01AA03
|
digitalis leaves
|
WHO Anatomical Therapeutic Chemical classification |
|
digitalis leaves |
| 0‑L |
C01AA04
|
digitoxin
|
WHO Anatomical Therapeutic Chemical classification |
|
digitoxin |
| 0‑L |
C01AA05
|
digoxin
|
WHO Anatomical Therapeutic Chemical classification |
|
digoxin |
| 0‑L |
C01AA06
|
lanatoside C
|
WHO Anatomical Therapeutic Chemical classification |
|
lanatoside C |
| 0‑L |
C01AA07
|
deslanoside
|
WHO Anatomical Therapeutic Chemical classification |
|
deslanoside |
| 0‑L |
C01AA08
|
metildigoxin
|
WHO Anatomical Therapeutic Chemical classification |
|
metildigoxin |
| 0‑L |
C01AA09
|
gitoformate
|
WHO Anatomical Therapeutic Chemical classification |
|
gitoformate |
| 0‑L |
C01AA52
|
acetyldigoxin, combinations
|
WHO Anatomical Therapeutic Chemical classification |
|
acetyldigoxin, combinations |
| 0‑L |
C01AB
|
Scilla glycosides
|
WHO Anatomical Therapeutic Chemical classification |
|
Scilla glycosides |
| 0‑L |
C01AB01
|
proscillaridin
|
WHO Anatomical Therapeutic Chemical classification |
|
proscillaridin |
| 0‑L |
C01AB51
|
proscillaridin, combinations
|
WHO Anatomical Therapeutic Chemical classification |
|
proscillaridin, combinations |
| 0‑L |
C01AC
|
Strophanthus glycosides
|
WHO Anatomical Therapeutic Chemical classification |
|
Strophanthus glycosides |
| 0‑L |
C01AC01
|
g-strophanthin
|
WHO Anatomical Therapeutic Chemical classification |
|
g-strophanthin |
| 0‑L |
C01AC03
|
cymarin
|
WHO Anatomical Therapeutic Chemical classification |
|
cymarin |
| 0‑L |
C01AX
|
Other cardiac glycosides
|
WHO Anatomical Therapeutic Chemical classification |
|
Other cardiac glycosides |
| 0‑L |
C01AX02
|
peruvoside
|
WHO Anatomical Therapeutic Chemical classification |
|
peruvoside |
| 0‑L |
C01B
|
ANTIARRHYTHMICS, CLASS I AND III
|
WHO Anatomical Therapeutic Chemical classification |
|
ANTIARRHYTHMICS, CLASS I AND III |
| 0‑L |
C01BA
|
Antiarrhythmics, class Ia
|
WHO Anatomical Therapeutic Chemical classification |
|
Antiarrhythmics, class Ia |
| 0‑L |
C01BA01
|
quinidine
|
WHO Anatomical Therapeutic Chemical classification |
|
quinidine |
| 0‑L |
C01BA02
|
procainamide
|
WHO Anatomical Therapeutic Chemical classification |
|
procainamide |
| 0‑L |
C01BA03
|
disopyramide
|
WHO Anatomical Therapeutic Chemical classification |
|
disopyramide |
| 0‑L |
C01BA04
|
sparteine
|
WHO Anatomical Therapeutic Chemical classification |
|
sparteine |
| 0‑L |
C01BA05
|
ajmaline
|
WHO Anatomical Therapeutic Chemical classification |
|
ajmaline |
| 0‑L |
C01BA08
|
prajmaline
|
WHO Anatomical Therapeutic Chemical classification |
|
prajmaline |
| 0‑L |
C01BA12
|
lorajmine
|
WHO Anatomical Therapeutic Chemical classification |
|
lorajmine |
| 0‑L |
C01BA13
|
hydroquinidine
|
WHO Anatomical Therapeutic Chemical classification |
|
hydroquinidine |
| 0‑L |
C01BA51
|
quinidine, combinations excl. psycholeptics
|
WHO Anatomical Therapeutic Chemical classification |
|
quinidine, combinations excl. psycholeptics |
| 0‑L |
C01BA71
|
quinidine, combinations with psycholeptics
|
WHO Anatomical Therapeutic Chemical classification |
|
quinidine, combinations with psycholeptics |
| 0‑L |
C01BB
|
Antiarrhythmics, class Ib
|
WHO Anatomical Therapeutic Chemical classification |
|
Antiarrhythmics, class Ib |
| 0‑L |
C01BB01
|
lidocaine
|
WHO Anatomical Therapeutic Chemical classification |
|
lidocaine |
| 0‑L |
C01BB02
|
mexiletine
|
WHO Anatomical Therapeutic Chemical classification |
|
mexiletine |
| 0‑L |
C01BB03
|
tocainide
|
WHO Anatomical Therapeutic Chemical classification |
|
tocainide |
| 0‑L |
C01BB04
|
aprindine
|
WHO Anatomical Therapeutic Chemical classification |
|
aprindine |
| 0‑L |
C01BC
|
Antiarrhythmics, class Ic
|
WHO Anatomical Therapeutic Chemical classification |
|
Antiarrhythmics, class Ic |
| 0‑L |
C01BC03
|
propafenone
|
WHO Anatomical Therapeutic Chemical classification |
|
propafenone |
| 0‑L |
C01BC04
|
flecainide
|
WHO Anatomical Therapeutic Chemical classification |
|
flecainide |
| 0‑L |
C01BC07
|
lorcainide
|
WHO Anatomical Therapeutic Chemical classification |
|
lorcainide |
| 0‑L |
C01BC08
|
encainide
|
WHO Anatomical Therapeutic Chemical classification |
|
encainide |
| 0‑L |
C01BC09
|
ethacizine
|
WHO Anatomical Therapeutic Chemical classification |
|
ethacizine |
| 0‑L |
C01BD
|
Antiarrhythmics, class III
|
WHO Anatomical Therapeutic Chemical classification |
|
Antiarrhythmics, class III |
| 0‑L |
C01BD01
|
amiodarone
|
WHO Anatomical Therapeutic Chemical classification |
|
amiodarone |
| 0‑L |
C01BD02
|
bretylium tosilate
|
WHO Anatomical Therapeutic Chemical classification |
|
bretylium tosilate |
| 0‑L |
C01BD03
|
bunaftine
|
WHO Anatomical Therapeutic Chemical classification |
|
bunaftine |
| 0‑L |
C01BD04
|
dofetilide
|
WHO Anatomical Therapeutic Chemical classification |
|
dofetilide |
| 0‑L |
C01BD05
|
ibutilide
|
WHO Anatomical Therapeutic Chemical classification |
|
ibutilide |
| 0‑L |
C01BD06
|
tedisamil
|
WHO Anatomical Therapeutic Chemical classification |
|
tedisamil |
| 0‑L |
C01BD07
|
dronedarone
|
WHO Anatomical Therapeutic Chemical classification |
|
dronedarone |
| 0‑L |
C01BG
|
Other antiarrhythmics, class I and III
|
WHO Anatomical Therapeutic Chemical classification |
|
Other antiarrhythmics, class I and III |
| 0‑L |
C01BG01
|
moracizine
|
WHO Anatomical Therapeutic Chemical classification |
|
moracizine |
| 0‑L |
C01BG07
|
cibenzoline
|
WHO Anatomical Therapeutic Chemical classification |
|
cibenzoline |
| 0‑L |
C01BG11
|
vernakalant
|
WHO Anatomical Therapeutic Chemical classification |
|
vernakalant |
| 0‑L |
C01C
|
CARDIAC STIMULANTS EXCL. CARDIAC GLYCOSIDES
|
WHO Anatomical Therapeutic Chemical classification |
|
CARDIAC STIMULANTS EXCL. CARDIAC GLYCOSIDES |
| 0‑L |
C01CA
|
Adrenergic and dopaminergic agents
|
WHO Anatomical Therapeutic Chemical classification |
|
Adrenergic and dopaminergic agents |
| 0‑L |
C01CA01
|
etilefrine
|
WHO Anatomical Therapeutic Chemical classification |
|
etilefrine |
| 0‑L |
C01CA02
|
isoprenaline
|
WHO Anatomical Therapeutic Chemical classification |
|
isoprenaline |
| 0‑L |
C01CA03
|
norepinephrine
|
WHO Anatomical Therapeutic Chemical classification |
|
norepinephrine |
| 0‑L |
C01CA04
|
dopamine
|
WHO Anatomical Therapeutic Chemical classification |
|
dopamine |
| 0‑L |
C01CA05
|
norfenefrine
|
WHO Anatomical Therapeutic Chemical classification |
|
norfenefrine |
| 0‑L |
C01CA06
|
phenylephrine
|
WHO Anatomical Therapeutic Chemical classification |
|
phenylephrine |
| 0‑L |
C01CA07
|
dobutamine
|
WHO Anatomical Therapeutic Chemical classification |
|
dobutamine |
| 0‑L |
C01CA08
|
oxedrine
|
WHO Anatomical Therapeutic Chemical classification |
|
oxedrine |
| 0‑L |
C01CA09
|
metaraminol
|
WHO Anatomical Therapeutic Chemical classification |
|
metaraminol |
| 0‑L |
C01CA10
|
methoxamine
|
WHO Anatomical Therapeutic Chemical classification |
|
methoxamine |
| 0‑L |
C01CA11
|
mephentermine
|
WHO Anatomical Therapeutic Chemical classification |
|
mephentermine |
| 0‑L |
C01CA12
|
dimetofrine
|
WHO Anatomical Therapeutic Chemical classification |
|
dimetofrine |
| 0‑L |
C01CA13
|
prenalterol
|
WHO Anatomical Therapeutic Chemical classification |
|
prenalterol |
| 0‑L |
C01CA14
|
dopexamine
|
WHO Anatomical Therapeutic Chemical classification |
|
dopexamine |
| 0‑L |
C01CA15
|
gepefrine
|
WHO Anatomical Therapeutic Chemical classification |
|
gepefrine |
| 0‑L |
C01CA16
|
ibopamine
|
WHO Anatomical Therapeutic Chemical classification |
|
ibopamine |
| 0‑L |
C01CA17
|
midodrine
|
WHO Anatomical Therapeutic Chemical classification |
|
midodrine |
| 0‑L |
C01CA18
|
octopamine
|
WHO Anatomical Therapeutic Chemical classification |
|
octopamine |
| 0‑L |
C01CA19
|
fenoldopam
|
WHO Anatomical Therapeutic Chemical classification |
|
fenoldopam |
| 0‑L |
C01CA21
|
cafedrine
|
WHO Anatomical Therapeutic Chemical classification |
|
cafedrine |
| 0‑L |
C01CA22
|
arbutamine
|
WHO Anatomical Therapeutic Chemical classification |
|
arbutamine |
| 0‑L |
C01CA23
|
theodrenaline
|
WHO Anatomical Therapeutic Chemical classification |
|
theodrenaline |
| 0‑L |
C01CA24
|
epinephrine
|
WHO Anatomical Therapeutic Chemical classification |
|
epinephrine |
| 0‑L |
C01CA25
|
amezinium metilsulfate
|
WHO Anatomical Therapeutic Chemical classification |
|
amezinium metilsulfate |
| 0‑L |
C01CA26
|
ephedrine
|
WHO Anatomical Therapeutic Chemical classification |
|
ephedrine |
| 0‑L |
C01CA27
|
droxidopa
|
WHO Anatomical Therapeutic Chemical classification |
|
droxidopa |
| 0‑L |
C01CA30
|
combinations
|
WHO Anatomical Therapeutic Chemical classification |
|
combinations |
| 0‑L |
C01CA51
|
etilefrine, combinations
|
WHO Anatomical Therapeutic Chemical classification |
|
etilefrine, combinations |
| 0‑L |
C01CE
|
Phosphodiesterase inhibitors
|
WHO Anatomical Therapeutic Chemical classification |
|
Phosphodiesterase inhibitors |
| 0‑L |
C01CE01
|
amrinone
|
WHO Anatomical Therapeutic Chemical classification |
|
amrinone |
| 0‑L |
C01CE02
|
milrinone
|
WHO Anatomical Therapeutic Chemical classification |
|
milrinone |
| 0‑L |
C01CE03
|
enoximone
|
WHO Anatomical Therapeutic Chemical classification |
|
enoximone |
| 0‑L |
C01CE04
|
bucladesine
|
WHO Anatomical Therapeutic Chemical classification |
|
bucladesine |
| 0‑L |
C01CX
|
Other cardiac stimulants
|
WHO Anatomical Therapeutic Chemical classification |
|
Other cardiac stimulants |
| 0‑L |
C01CX06
|
angiotensinamide
|
WHO Anatomical Therapeutic Chemical classification |
|
angiotensinamide |
| 0‑L |
C01CX07
|
xamoterol
|
WHO Anatomical Therapeutic Chemical classification |
|
xamoterol |
| 0‑L |
C01CX08
|
levosimendan
|
WHO Anatomical Therapeutic Chemical classification |
|
levosimendan |
| 0‑L |
C01D
|
VASODILATORS USED IN CARDIAC DISEASES
|
WHO Anatomical Therapeutic Chemical classification |
|
VASODILATORS USED IN CARDIAC DISEASES |
| 0‑L |
C01DA
|
Organic nitrates
|
WHO Anatomical Therapeutic Chemical classification |
|
Organic nitrates |
| 0‑L |
C01DA02
|
glyceryl trinitrate
|
WHO Anatomical Therapeutic Chemical classification |
|
glyceryl trinitrate |
| 0‑L |
C01DA04
|
methylpropylpropanediol dinitrate
|
WHO Anatomical Therapeutic Chemical classification |
|
methylpropylpropanediol dinitrate |
| 0‑L |
C01DA05
|
pentaerithrityl tetranitrate
|
WHO Anatomical Therapeutic Chemical classification |
|
pentaerithrityl tetranitrate |
| 0‑L |
C01DA07
|
propatylnitrate
|
WHO Anatomical Therapeutic Chemical classification |
|
propatylnitrate |
| 0‑L |
C01DA08
|
isosorbide dinitrate
|
WHO Anatomical Therapeutic Chemical classification |
|
isosorbide dinitrate |
| 0‑L |
C01DA09
|
trolnitrate
|
WHO Anatomical Therapeutic Chemical classification |
|
trolnitrate |
| 0‑L |
C01DA13
|
eritrityl tetranitrate
|
WHO Anatomical Therapeutic Chemical classification |
|
eritrityl tetranitrate |
| 0‑L |
C01DA14
|
isosorbide mononitrate
|
WHO Anatomical Therapeutic Chemical classification |
|
isosorbide mononitrate |
| 0‑L |
C01DA20
|
organic nitrates in combination
|
WHO Anatomical Therapeutic Chemical classification |
|
organic nitrates in combination |
| 0‑L |
C01DA38
|
tenitramine
|
WHO Anatomical Therapeutic Chemical classification |
|
tenitramine |
| 0‑L |
C01DA52
|
glyceryl trinitrate, combinations
|
WHO Anatomical Therapeutic Chemical classification |
|
glyceryl trinitrate, combinations |
| 0‑L |
C01DA54
|
methylpropylpropanediol dinitrate, combinations
|
WHO Anatomical Therapeutic Chemical classification |
|
methylpropylpropanediol dinitrate, combinations |
| 0‑L |
C01DA55
|
pentaerithrityl tetranitrate, combinations
|
WHO Anatomical Therapeutic Chemical classification |
|
pentaerithrityl tetranitrate, combinations |
| 0‑L |
C01DA57
|
propatylnitrate, combinations
|
WHO Anatomical Therapeutic Chemical classification |
|
propatylnitrate, combinations |
| 0‑L |
C01DA58
|
isosorbide dinitrate, combinations
|
WHO Anatomical Therapeutic Chemical classification |
|
isosorbide dinitrate, combinations |
| 0‑L |
C01DA59
|
trolnitrate, combinations
|
WHO Anatomical Therapeutic Chemical classification |
|
trolnitrate, combinations |
| 0‑L |
C01DA63
|
eritrityl tetranitrate, combinations
|
WHO Anatomical Therapeutic Chemical classification |
|
eritrityl tetranitrate, combinations |
| 0‑L |
C01DA70
|
organic nitrates in combination with psycholeptics
|
WHO Anatomical Therapeutic Chemical classification |
|
organic nitrates in combination with psycholeptics |
| 0‑L |
C01DB
|
Quinolone vasodilators
|
WHO Anatomical Therapeutic Chemical classification |
|
Quinolone vasodilators |
| 0‑L |
C01DB01
|
flosequinan
|
WHO Anatomical Therapeutic Chemical classification |
|
flosequinan |
| 0‑L |
C01DX
|
Other vasodilators used in cardiac diseases
|
WHO Anatomical Therapeutic Chemical classification |
|
Other vasodilators used in cardiac diseases |
| 0‑L |
C01DX01
|
itramin tosilate
|
WHO Anatomical Therapeutic Chemical classification |
|
itramin tosilate |
| 0‑L |
C01DX02
|
prenylamine
|
WHO Anatomical Therapeutic Chemical classification |
|
prenylamine |
| 0‑L |
C01DX03
|
oxyfedrine
|
WHO Anatomical Therapeutic Chemical classification |
|
oxyfedrine |
| 0‑L |
C01DX04
|
benziodarone
|
WHO Anatomical Therapeutic Chemical classification |
|
benziodarone |
| 0‑L |
C01DX05
|
carbocromen
|
WHO Anatomical Therapeutic Chemical classification |
|
carbocromen |
| 0‑L |
C01DX06
|
hexobendine
|
WHO Anatomical Therapeutic Chemical classification |
|
hexobendine |
| 0‑L |
C01DX07
|
etafenone
|
WHO Anatomical Therapeutic Chemical classification |
|
etafenone |
| 0‑L |
C01DX08
|
heptaminol
|
WHO Anatomical Therapeutic Chemical classification |
|
heptaminol |
| 0‑L |
C01DX09
|
imolamine
|
WHO Anatomical Therapeutic Chemical classification |
|
imolamine |
| 0‑L |
C01DX10
|
dilazep
|
WHO Anatomical Therapeutic Chemical classification |
|
dilazep |
| 0‑L |
C01DX11
|
trapidil
|
WHO Anatomical Therapeutic Chemical classification |
|
trapidil |
| 0‑L |
C01DX12
|
molsidomine
|
WHO Anatomical Therapeutic Chemical classification |
|
molsidomine |
| 0‑L |
C01DX13
|
efloxate
|
WHO Anatomical Therapeutic Chemical classification |
|
efloxate |
| 0‑L |
C01DX14
|
cinepazet
|
WHO Anatomical Therapeutic Chemical classification |
|
cinepazet |
| 0‑L |
C01DX15
|
cloridarol
|
WHO Anatomical Therapeutic Chemical classification |
|
cloridarol |
| 0‑L |
C01DX16
|
nicorandil
|
WHO Anatomical Therapeutic Chemical classification |
|
nicorandil |
| 0‑L |
C01DX18
|
linsidomine
|
WHO Anatomical Therapeutic Chemical classification |
|
linsidomine |
| 0‑L |
C01DX19
|
nesiritide
|
WHO Anatomical Therapeutic Chemical classification |
|
nesiritide |
| 0‑L |
C01DX21
|
serelaxin
|
WHO Anatomical Therapeutic Chemical classification |
|
serelaxin |
| 0‑L |
C01DX51
|
itramin tosilate, combinations
|
WHO Anatomical Therapeutic Chemical classification |
|
itramin tosilate, combinations |
| 0‑L |
C01DX52
|
prenylamine, combinations
|
WHO Anatomical Therapeutic Chemical classification |
|
prenylamine, combinations |
| 0‑L |
C01DX53
|
oxyfedrine, combinations
|
WHO Anatomical Therapeutic Chemical classification |
|
oxyfedrine, combinations |
| 0‑L |
C01DX54
|
benziodarone, combinations
|
WHO Anatomical Therapeutic Chemical classification |
|
benziodarone, combinations |
| 0‑L |
C01E
|
OTHER CARDIAC PREPARATIONS
|
WHO Anatomical Therapeutic Chemical classification |
|
OTHER CARDIAC PREPARATIONS |
| 0‑L |
C01EA
|
Prostaglandins
|
WHO Anatomical Therapeutic Chemical classification |
|
Prostaglandins |
| 0‑L |
C01EA01
|
alprostadil
|
WHO Anatomical Therapeutic Chemical classification |
|
alprostadil |
| 0‑L |
C01EB
|
Other cardiac preparations
|
WHO Anatomical Therapeutic Chemical classification |
|
Other cardiac preparations |
| 0‑L |
C01EB02
|
camphora
|
WHO Anatomical Therapeutic Chemical classification |
|
camphora |
| 0‑L |
C01EB03
|
indometacin
|
WHO Anatomical Therapeutic Chemical classification |
|
indometacin |
| 0‑L |
C01EB04
|
crataegus glycosides
|
WHO Anatomical Therapeutic Chemical classification |
|
crataegus glycosides |
| 0‑L |
C01EB05
|
creatinolfosfate
|
WHO Anatomical Therapeutic Chemical classification |
|
creatinolfosfate |
| 0‑L |
C01EB06
|
fosfocreatine
|
WHO Anatomical Therapeutic Chemical classification |
|
fosfocreatine |
| 0‑L |
C01EB07
|
fructose 1,6-diphosphate
|
WHO Anatomical Therapeutic Chemical classification |
|
fructose 1,6-diphosphate |
| 0‑L |
C01EB09
|
ubidecarenone
|
WHO Anatomical Therapeutic Chemical classification |
|
ubidecarenone |
| 0‑L |
C01EB10
|
adenosine
|
WHO Anatomical Therapeutic Chemical classification |
|
adenosine |
| 0‑L |
C01EB11
|
tiracizine
|
WHO Anatomical Therapeutic Chemical classification |
|
tiracizine |
| 0‑L |
C01EB13
|
acadesine
|
WHO Anatomical Therapeutic Chemical classification |
|
acadesine |
| 0‑L |
C01EB15
|
trimetazidine
|
WHO Anatomical Therapeutic Chemical classification |
|
trimetazidine |
| 0‑L |
C01EB16
|
ibuprofen
|
WHO Anatomical Therapeutic Chemical classification |
|
ibuprofen |
| 0‑L |
C01EB17
|
ivabradine
|
WHO Anatomical Therapeutic Chemical classification |
|
ivabradine |
| 0‑L |
C01EB18
|
ranolazine
|
WHO Anatomical Therapeutic Chemical classification |
|
ranolazine |
| 0‑L |
C01EB21
|
regadenoson
|
WHO Anatomical Therapeutic Chemical classification |
|
regadenoson |
| 0‑L |
C01EB22
|
meldonium
|
WHO Anatomical Therapeutic Chemical classification |
|
meldonium |
| 0‑L |
C01EB23
|
tiazotic acid
|
WHO Anatomical Therapeutic Chemical classification |
|
tiazotic acid |
| 0‑L |
C01EX
|
Other cardiac combination products
|
WHO Anatomical Therapeutic Chemical classification |
|
Other cardiac combination products |
| 0‑L |
C02
|
ANTIHYPERTENSIVES
|
WHO Anatomical Therapeutic Chemical classification |
|
ANTIHYPERTENSIVES |
| 0‑L |
C02A
|
ANTIADRENERGIC AGENTS, CENTRALLY ACTING
|
WHO Anatomical Therapeutic Chemical classification |
|
ANTIADRENERGIC AGENTS, CENTRALLY ACTING |
| 0‑L |
C02AA
|
Rauwolfia alkaloids
|
WHO Anatomical Therapeutic Chemical classification |
|
Rauwolfia alkaloids |
| 0‑L |
C02AA01
|
rescinnamine
|
WHO Anatomical Therapeutic Chemical classification |
|
rescinnamine |
| 0‑L |
C02AA02
|
reserpine
|
WHO Anatomical Therapeutic Chemical classification |
|
reserpine |
| 0‑L |
C02AA03
|
combinations of rauwolfia alkaloids
|
WHO Anatomical Therapeutic Chemical classification |
|
combinations of rauwolfia alkaloids |
| 0‑L |
C02AA04
|
rauwolfia alkaloids, whole root
|
WHO Anatomical Therapeutic Chemical classification |
|
rauwolfia alkaloids, whole root |
| 0‑L |
C02AA05
|
deserpidine
|
WHO Anatomical Therapeutic Chemical classification |
|
deserpidine |
| 0‑L |
C02AA06
|
methoserpidine
|
WHO Anatomical Therapeutic Chemical classification |
|
methoserpidine |
| 0‑L |
C02AA07
|
bietaserpine
|
WHO Anatomical Therapeutic Chemical classification |
|
bietaserpine |
| 0‑L |
C02AA52
|
reserpine, combinations
|
WHO Anatomical Therapeutic Chemical classification |
|
reserpine, combinations |
| 0‑L |
C02AA53
|
combinations of rauwolfia alkoloids, combinations
|
WHO Anatomical Therapeutic Chemical classification |
|
combinations of rauwolfia alkoloids, combinations |
| 0‑L |
C02AA57
|
bietaserpine, combinations
|
WHO Anatomical Therapeutic Chemical classification |
|
bietaserpine, combinations |
| 0‑L |
C02AB
|
Methyldopa
|
WHO Anatomical Therapeutic Chemical classification |
|
Methyldopa |
| 0‑L |
C02AB01
|
methyldopa (levorotatory)
|
WHO Anatomical Therapeutic Chemical classification |
|
methyldopa (levorotatory) |
| 0‑L |
C02AB02
|
methyldopa (racemic)
|
WHO Anatomical Therapeutic Chemical classification |
|
methyldopa (racemic) |
| 0‑L |
C02AC
|
Imidazoline receptor agonists
|
WHO Anatomical Therapeutic Chemical classification |
|
Imidazoline receptor agonists |
| 0‑L |
C02AC01
|
clonidine
|
WHO Anatomical Therapeutic Chemical classification |
|
clonidine |
| 0‑L |
C02AC02
|
guanfacine
|
WHO Anatomical Therapeutic Chemical classification |
|
guanfacine |
| 0‑L |
C02AC04
|
tolonidine
|
WHO Anatomical Therapeutic Chemical classification |
|
tolonidine |
| 0‑L |
C02AC05
|
moxonidine
|
WHO Anatomical Therapeutic Chemical classification |
|
moxonidine |
| 0‑L |
C02AC06
|
rilmenidine
|
WHO Anatomical Therapeutic Chemical classification |
|
rilmenidine |
| 0‑L |
C02B
|
ANTIADRENERGIC AGENTS, GANGLION-BLOCKING
|
WHO Anatomical Therapeutic Chemical classification |
|
ANTIADRENERGIC AGENTS, GANGLION-BLOCKING |
| 0‑L |
C02BA
|
Sulfonium derivatives
|
WHO Anatomical Therapeutic Chemical classification |
|
Sulfonium derivatives |
| 0‑L |
C02BA01
|
trimetaphan
|
WHO Anatomical Therapeutic Chemical classification |
|
trimetaphan |
| 0‑L |
C02BB
|
Secondary and tertiary amines
|
WHO Anatomical Therapeutic Chemical classification |
|
Secondary and tertiary amines |
| 0‑L |
C02BB01
|
mecamylamine
|
WHO Anatomical Therapeutic Chemical classification |
|
mecamylamine |
| 0‑L |
C02BC
|
Bisquaternary ammonium compounds
|
WHO Anatomical Therapeutic Chemical classification |
|
Bisquaternary ammonium compounds |
| 0‑L |
C02C
|
ANTIADRENERGIC AGENTS, PERIPHERALLY ACTING
|
WHO Anatomical Therapeutic Chemical classification |
|
ANTIADRENERGIC AGENTS, PERIPHERALLY ACTING |
| 0‑L |
C02CA
|
Alpha-adrenoreceptor antagonists
|
WHO Anatomical Therapeutic Chemical classification |
|
Alpha-adrenoreceptor antagonists |
| 0‑L |
C02CA01
|
prazosin
|
WHO Anatomical Therapeutic Chemical classification |
|
prazosin |
| 0‑L |
C02CA02
|
indoramin
|
WHO Anatomical Therapeutic Chemical classification |
|
indoramin |
| 0‑L |
C02CA03
|
trimazosin
|
WHO Anatomical Therapeutic Chemical classification |
|
trimazosin |
| 0‑L |
C02CA04
|
doxazosin
|
WHO Anatomical Therapeutic Chemical classification |
|
doxazosin |
| 0‑L |
C02CA06
|
urapidil
|
WHO Anatomical Therapeutic Chemical classification |
|
urapidil |
| 0‑L |
C02CC
|
Guanidine derivatives
|
WHO Anatomical Therapeutic Chemical classification |
|
Guanidine derivatives |
| 0‑L |
C02CC01
|
betanidine
|
WHO Anatomical Therapeutic Chemical classification |
|
betanidine |
| 0‑L |
C02CC02
|
guanethidine
|
WHO Anatomical Therapeutic Chemical classification |
|
guanethidine |
| 0‑L |
C02CC03
|
guanoxan
|
WHO Anatomical Therapeutic Chemical classification |
|
guanoxan |
| 0‑L |
C02CC04
|
debrisoquine
|
WHO Anatomical Therapeutic Chemical classification |
|
debrisoquine |
| 0‑L |
C02CC05
|
guanoclor
|
WHO Anatomical Therapeutic Chemical classification |
|
guanoclor |
| 0‑L |
C02CC06
|
guanazodine
|
WHO Anatomical Therapeutic Chemical classification |
|
guanazodine |
| 0‑L |
C02CC07
|
guanoxabenz
|
WHO Anatomical Therapeutic Chemical classification |
|
guanoxabenz |
| 0‑L |
C02D
|
ARTERIOLAR SMOOTH MUSCLE, AGENTS ACTING ON
|
WHO Anatomical Therapeutic Chemical classification |
|
ARTERIOLAR SMOOTH MUSCLE, AGENTS ACTING ON |
| 0‑L |
C02DA
|
Thiazide derivatives
|
WHO Anatomical Therapeutic Chemical classification |
|
Thiazide derivatives |
| 0‑L |
C02DA01
|
diazoxide
|
WHO Anatomical Therapeutic Chemical classification |
|
diazoxide |
| 0‑L |
C02DB
|
Hydrazinophthalazine derivatives
|
WHO Anatomical Therapeutic Chemical classification |
|
Hydrazinophthalazine derivatives |
| 0‑L |
C02DB01
|
dihydralazine
|
WHO Anatomical Therapeutic Chemical classification |
|
dihydralazine |
| 0‑L |
C02DB02
|
hydralazine
|
WHO Anatomical Therapeutic Chemical classification |
|
hydralazine |
| 0‑L |
C02DB03
|
endralazine
|
WHO Anatomical Therapeutic Chemical classification |
|
endralazine |
| 0‑L |
C02DB04
|
cadralazine
|
WHO Anatomical Therapeutic Chemical classification |
|
cadralazine |
| 0‑L |
C02DC
|
Pyrimidine derivatives
|
WHO Anatomical Therapeutic Chemical classification |
|
Pyrimidine derivatives |
| 0‑L |
C02DC01
|
minoxidil
|
WHO Anatomical Therapeutic Chemical classification |
|
minoxidil |
| 0‑L |
C02DD
|
Nitroferricyanide derivatives
|
WHO Anatomical Therapeutic Chemical classification |
|
Nitroferricyanide derivatives |
| 0‑L |
C02DD01
|
nitroprusside
|
WHO Anatomical Therapeutic Chemical classification |
|
nitroprusside |
| 0‑L |
C02DG
|
Guanidine derivatives
|
WHO Anatomical Therapeutic Chemical classification |
|
Guanidine derivatives |
| 0‑L |
C02DG01
|
pinacidil
|
WHO Anatomical Therapeutic Chemical classification |
|
pinacidil |
| 0‑L |
C02K
|
OTHER ANTIHYPERTENSIVES
|
WHO Anatomical Therapeutic Chemical classification |
|
OTHER ANTIHYPERTENSIVES |
| 0‑L |
C02KA
|
Alkaloids, excl. rauwolfia
|
WHO Anatomical Therapeutic Chemical classification |
|
Alkaloids, excl. rauwolfia |
| 0‑L |
C02KA01
|
veratrum
|
WHO Anatomical Therapeutic Chemical classification |
|
veratrum |
| 0‑L |
C02KB
|
Tyrosine hydroxylase inhibitors
|
WHO Anatomical Therapeutic Chemical classification |
|
Tyrosine hydroxylase inhibitors |
| 0‑L |
C02KB01
|
metirosine
|
WHO Anatomical Therapeutic Chemical classification |
|
metirosine |
| 0‑L |
C02KC
|
MAO inhibitors
|
WHO Anatomical Therapeutic Chemical classification |
|
MAO inhibitors |
| 0‑L |
C02KC01
|
pargyline
|
WHO Anatomical Therapeutic Chemical classification |
|
pargyline |
| 0‑L |
C02KD
|
Serotonin antagonists
|
WHO Anatomical Therapeutic Chemical classification |
|
Serotonin antagonists |
| 0‑L |
C02KD01
|
ketanserin
|
WHO Anatomical Therapeutic Chemical classification |
|
ketanserin |
| 0‑L |
C02KX
|
Antihypertensives for pulmonary arterial hypertension
|
WHO Anatomical Therapeutic Chemical classification |
|
Antihypertensives for pulmonary arterial hypertension |
| 0‑L |
C02KX01
|
bosentan
|
WHO Anatomical Therapeutic Chemical classification |
|
bosentan |
| 0‑L |
C02KX02
|
ambrisentan
|
WHO Anatomical Therapeutic Chemical classification |
|
ambrisentan |
| 0‑L |
C02KX03
|
sitaxentan
|
WHO Anatomical Therapeutic Chemical classification |
|
sitaxentan |
| 0‑L |
C02KX04
|
macitentan
|
WHO Anatomical Therapeutic Chemical classification |
|
macitentan |
| 0‑L |
C02KX05
|
riociguat
|
WHO Anatomical Therapeutic Chemical classification |
|
riociguat |
| 0‑L |
C02L
|
ANTIHYPERTENSIVES AND DIURETICS IN COMBINATION
|
WHO Anatomical Therapeutic Chemical classification |
|
ANTIHYPERTENSIVES AND DIURETICS IN COMBINATION |
| 0‑L |
C02LA
|
Rauwolfia alkaloids and diuretics in combination
|
WHO Anatomical Therapeutic Chemical classification |
|
Rauwolfia alkaloids and diuretics in combination |
| 0‑L |
C02LA01
|
reserpine and diuretics
|
WHO Anatomical Therapeutic Chemical classification |
|
reserpine and diuretics |
| 0‑L |
C02LA02
|
rescinnamine and diuretics
|
WHO Anatomical Therapeutic Chemical classification |
|
rescinnamine and diuretics |
| 0‑L |
C02LA03
|
deserpidine and diuretics
|
WHO Anatomical Therapeutic Chemical classification |
|
deserpidine and diuretics |
| 0‑L |
C02LA04
|
methoserpidine and diuretics
|
WHO Anatomical Therapeutic Chemical classification |
|
methoserpidine and diuretics |
| 0‑L |
C02LA07
|
bietaserpine and diuretics
|
WHO Anatomical Therapeutic Chemical classification |
|
bietaserpine and diuretics |
| 0‑L |
C02LA08
|
rauwolfia alkaloids, whole root and diuretics
|
WHO Anatomical Therapeutic Chemical classification |
|
rauwolfia alkaloids, whole root and diuretics |
| 0‑L |
C02LA09
|
syrosingopine and diuretics
|
WHO Anatomical Therapeutic Chemical classification |
|
syrosingopine and diuretics |
| 0‑L |
C02LA50
|
combination of rauwolfia alkaloids and diuretics incl. other combinations
|
WHO Anatomical Therapeutic Chemical classification |
|
combination of rauwolfia alkaloids and diuretics incl. other combinations |
| 0‑L |
C02LA51
|
reserpine and diuretics, combinations with other drugs
|
WHO Anatomical Therapeutic Chemical classification |
|
reserpine and diuretics, combinations with other drugs |
| 0‑L |
C02LA52
|
rescinnamine and diuretics, combinations with other drugs
|
WHO Anatomical Therapeutic Chemical classification |
|
rescinnamine and diuretics, combinations with other drugs |
| 0‑L |
C02LA71
|
reserpine and diuretics, combinations with psycholeptics
|
WHO Anatomical Therapeutic Chemical classification |
|
reserpine and diuretics, combinations with psycholeptics |
| 0‑L |
C02LB
|
Methyldopa and diuretics in combination
|
WHO Anatomical Therapeutic Chemical classification |
|
Methyldopa and diuretics in combination |
| 0‑L |
C02LB01
|
methyldopa (levorotatory) and diuretics
|
WHO Anatomical Therapeutic Chemical classification |
|
methyldopa (levorotatory) and diuretics |
| 0‑L |
C02LC
|
Imidazoline receptor agonists in combination with diuretics
|
WHO Anatomical Therapeutic Chemical classification |
|
Imidazoline receptor agonists in combination with diuretics |
| 0‑L |
C02LC01
|
clonidine and diuretics
|
WHO Anatomical Therapeutic Chemical classification |
|
clonidine and diuretics |
| 0‑L |
C02LC05
|
moxonidine and diuretics
|
WHO Anatomical Therapeutic Chemical classification |
|
moxonidine and diuretics |
| 0‑L |
C02LC51
|
clonidine and diuretics, combinations with other drugs
|
WHO Anatomical Therapeutic Chemical classification |
|
clonidine and diuretics, combinations with other drugs |
| 0‑L |
C02LE
|
Alpha-adrenoreceptor antagonists and diuretics
|
WHO Anatomical Therapeutic Chemical classification |
|
Alpha-adrenoreceptor antagonists and diuretics |
| 0‑L |
C02LE01
|
prazosin and diuretics
|
WHO Anatomical Therapeutic Chemical classification |
|
prazosin and diuretics |
| 0‑L |
C02LF
|
Guanidine derivatives and diuretics
|
WHO Anatomical Therapeutic Chemical classification |
|
Guanidine derivatives and diuretics |
| 0‑L |
C02LF01
|
guanethidine and diuretics
|
WHO Anatomical Therapeutic Chemical classification |
|
guanethidine and diuretics |
| 0‑L |
C02LG
|
Hydrazinophthalazine derivatives and diuretics
|
WHO Anatomical Therapeutic Chemical classification |
|
Hydrazinophthalazine derivatives and diuretics |
| 0‑L |
C02LG01
|
dihydralazine and diuretics
|
WHO Anatomical Therapeutic Chemical classification |
|
dihydralazine and diuretics |
| 0‑L |
C02LG02
|
hydralazine and diuretics
|
WHO Anatomical Therapeutic Chemical classification |
|
hydralazine and diuretics |
| 0‑L |
C02LG03
|
picodralazine and diuretics
|
WHO Anatomical Therapeutic Chemical classification |
|
picodralazine and diuretics |
| 0‑L |
C02LG51
|
dihydralazine and diuretics, combinations with other drugs
|
WHO Anatomical Therapeutic Chemical classification |
|
dihydralazine and diuretics, combinations with other drugs |
| 0‑L |
C02LG73
|
picodralazine and diuretics, combinations with psycholeptics
|
WHO Anatomical Therapeutic Chemical classification |
|
picodralazine and diuretics, combinations with psycholeptics |
| 0‑L |
C02LK
|
Alkaloids, excl. rauwolfia, in combination with diuretics
|
WHO Anatomical Therapeutic Chemical classification |
|
Alkaloids, excl. rauwolfia, in combination with diuretics |
| 0‑L |
C02LK01
|
veratrum and diuretics
|
WHO Anatomical Therapeutic Chemical classification |
|
veratrum and diuretics |
| 0‑L |
C02LL
|
MAO inhibitors and diuretics
|
WHO Anatomical Therapeutic Chemical classification |
|
MAO inhibitors and diuretics |
| 0‑L |
C02LL01
|
pargyline and diuretics
|
WHO Anatomical Therapeutic Chemical classification |
|
pargyline and diuretics |
| 0‑L |
C02LN
|
Serotonin antagonists and diuretics
|
WHO Anatomical Therapeutic Chemical classification |
|
Serotonin antagonists and diuretics |
| 0‑L |
C02LX
|
Other antihypertensives and diuretics
|
WHO Anatomical Therapeutic Chemical classification |
|
Other antihypertensives and diuretics |
| 0‑L |
C02LX01
|
pinacidil and diuretics
|
WHO Anatomical Therapeutic Chemical classification |
|
pinacidil and diuretics |
| 0‑L |
C02N
|
COMBINATIONS OF ANTIHYPERTENSIVES IN ATC-GR. C02
|
WHO Anatomical Therapeutic Chemical classification |
|
COMBINATIONS OF ANTIHYPERTENSIVES IN ATC-GR. C02 |
| 0‑L |
C03
|
DIURETICS
|
WHO Anatomical Therapeutic Chemical classification |
|
DIURETICS |
| 0‑L |
C03A
|
LOW-CEILING DIURETICS, THIAZIDES
|
WHO Anatomical Therapeutic Chemical classification |
|
LOW-CEILING DIURETICS, THIAZIDES |
| 0‑L |
C03AA
|
Thiazides, plain
|
WHO Anatomical Therapeutic Chemical classification |
|
Thiazides, plain |
| 0‑L |
C03AA01
|
bendroflumethiazide
|
WHO Anatomical Therapeutic Chemical classification |
|
bendroflumethiazide |
| 0‑L |
C03AA02
|
hydroflumethiazide
|
WHO Anatomical Therapeutic Chemical classification |
|
hydroflumethiazide |
| 0‑L |
C03AA03
|
hydrochlorothiazide
|
WHO Anatomical Therapeutic Chemical classification |
|
hydrochlorothiazide |
| 0‑L |
C03AA04
|
chlorothiazide
|
WHO Anatomical Therapeutic Chemical classification |
|
chlorothiazide |
| 0‑L |
C03AA05
|
polythiazide
|
WHO Anatomical Therapeutic Chemical classification |
|
polythiazide |
| 0‑L |
C03AA06
|
trichlormethiazide
|
WHO Anatomical Therapeutic Chemical classification |
|
trichlormethiazide |
| 0‑L |
C03AA07
|
cyclopenthiazide
|
WHO Anatomical Therapeutic Chemical classification |
|
cyclopenthiazide |
| 0‑L |
C03AA08
|
methyclothiazide
|
WHO Anatomical Therapeutic Chemical classification |
|
methyclothiazide |
| 0‑L |
C03AA09
|
cyclothiazide
|
WHO Anatomical Therapeutic Chemical classification |
|
cyclothiazide |
| 0‑L |
C03AA13
|
mebutizide
|
WHO Anatomical Therapeutic Chemical classification |
|
mebutizide |
| 0‑L |
C03AB
|
Thiazides and potassium in combination
|
WHO Anatomical Therapeutic Chemical classification |
|
Thiazides and potassium in combination |
| 0‑L |
C03AB01
|
bendroflumethiazide and potassium
|
WHO Anatomical Therapeutic Chemical classification |
|
bendroflumethiazide and potassium |
| 0‑L |
C03AB02
|
hydroflumethiazide and potassium
|
WHO Anatomical Therapeutic Chemical classification |
|
hydroflumethiazide and potassium |
| 0‑L |
C03AB03
|
hydrochlorothiazide and potassium
|
WHO Anatomical Therapeutic Chemical classification |
|
hydrochlorothiazide and potassium |
| 0‑L |
C03AB04
|
chlorothiazide and potassium
|
WHO Anatomical Therapeutic Chemical classification |
|
chlorothiazide and potassium |
| 0‑L |
C03AB05
|
polythiazide and potassium
|
WHO Anatomical Therapeutic Chemical classification |
|
polythiazide and potassium |
| 0‑L |
C03AB06
|
trichlormethiazide and potassium
|
WHO Anatomical Therapeutic Chemical classification |
|
trichlormethiazide and potassium |
| 0‑L |
C03AB07
|
cyclopenthiazide and potassium
|
WHO Anatomical Therapeutic Chemical classification |
|
cyclopenthiazide and potassium |
| 0‑L |
C03AB08
|
methyclothiazide and potassium
|
WHO Anatomical Therapeutic Chemical classification |
|
methyclothiazide and potassium |
| 0‑L |
C03AB09
|
cyclothiazide and potassium
|
WHO Anatomical Therapeutic Chemical classification |
|
cyclothiazide and potassium |
| 0‑L |
C03AH
|
Thiazides, combinations with psycholeptics and/or analgesics
|
WHO Anatomical Therapeutic Chemical classification |
|
Thiazides, combinations with psycholeptics and/or analgesics |
| 0‑L |
C03AH01
|
chlorothiazide, combinations
|
WHO Anatomical Therapeutic Chemical classification |
|
chlorothiazide, combinations |
| 0‑L |
C03AH02
|
hydroflumethiazide, combinations
|
WHO Anatomical Therapeutic Chemical classification |
|
hydroflumethiazide, combinations |
| 0‑L |
C03AX
|
Thiazides, combinations with other drugs
|
WHO Anatomical Therapeutic Chemical classification |
|
Thiazides, combinations with other drugs |
| 0‑L |
C03AX01
|
hydrochlorothiazide, combinations
|
WHO Anatomical Therapeutic Chemical classification |
|
hydrochlorothiazide, combinations |
| 0‑L |
C03B
|
LOW-CEILING DIURETICS, EXCL. THIAZIDES
|
WHO Anatomical Therapeutic Chemical classification |
|
LOW-CEILING DIURETICS, EXCL. THIAZIDES |
| 0‑L |
C03BA
|
Sulfonamides, plain
|
WHO Anatomical Therapeutic Chemical classification |
|
Sulfonamides, plain |
| 0‑L |
C03BA02
|
quinethazone
|
WHO Anatomical Therapeutic Chemical classification |
|
quinethazone |
| 0‑L |
C03BA03
|
clopamide
|
WHO Anatomical Therapeutic Chemical classification |
|
clopamide |
| 0‑L |
C03BA04
|
chlortalidone
|
WHO Anatomical Therapeutic Chemical classification |
|
chlortalidone |
| 0‑L |
C03BA05
|
mefruside
|
WHO Anatomical Therapeutic Chemical classification |
|
mefruside |
| 0‑L |
C03BA07
|
clofenamide
|
WHO Anatomical Therapeutic Chemical classification |
|
clofenamide |
| 0‑L |
C03BA08
|
metolazone
|
WHO Anatomical Therapeutic Chemical classification |
|
metolazone |
| 0‑L |
C03BA09
|
meticrane
|
WHO Anatomical Therapeutic Chemical classification |
|
meticrane |
| 0‑L |
C03BA10
|
xipamide
|
WHO Anatomical Therapeutic Chemical classification |
|
xipamide |
| 0‑L |
C03BA11
|
indapamide
|
WHO Anatomical Therapeutic Chemical classification |
|
indapamide |
| 0‑L |
C03BA12
|
clorexolone
|
WHO Anatomical Therapeutic Chemical classification |
|
clorexolone |
| 0‑L |
C03BA13
|
fenquizone
|
WHO Anatomical Therapeutic Chemical classification |
|
fenquizone |
| 0‑L |
C03BA82
|
clorexolone, combinations with psycholeptics
|
WHO Anatomical Therapeutic Chemical classification |
|
clorexolone, combinations with psycholeptics |
| 0‑L |
C03BB
|
Sulfonamides and potassium in combination
|
WHO Anatomical Therapeutic Chemical classification |
|
Sulfonamides and potassium in combination |
| 0‑L |
C03BB02
|
quinethazone and potassium
|
WHO Anatomical Therapeutic Chemical classification |
|
quinethazone and potassium |
| 0‑L |
C03BB03
|
clopamide and potassium
|
WHO Anatomical Therapeutic Chemical classification |
|
clopamide and potassium |
| 0‑L |
C03BB04
|
chlortalidone and potassium
|
WHO Anatomical Therapeutic Chemical classification |
|
chlortalidone and potassium |
| 0‑L |
C03BB05
|
mefruside and potassium
|
WHO Anatomical Therapeutic Chemical classification |
|
mefruside and potassium |
| 0‑L |
C03BB07
|
clofenamide and potassium
|
WHO Anatomical Therapeutic Chemical classification |
|
clofenamide and potassium |
| 0‑L |
C03BC
|
Mercurial diuretics
|
WHO Anatomical Therapeutic Chemical classification |
|
Mercurial diuretics |
| 0‑L |
C03BC01
|
mersalyl
|
WHO Anatomical Therapeutic Chemical classification |
|
mersalyl |
| 0‑L |
C03BD
|
Xanthine derivatives
|
WHO Anatomical Therapeutic Chemical classification |
|
Xanthine derivatives |
| 0‑L |
C03BD01
|
theobromine
|
WHO Anatomical Therapeutic Chemical classification |
|
theobromine |
| 0‑L |
C03BK
|
Sulfonamides, combinations with other drugs
|
WHO Anatomical Therapeutic Chemical classification |
|
Sulfonamides, combinations with other drugs |
| 0‑L |
C03BX
|
Other low-ceiling diuretics
|
WHO Anatomical Therapeutic Chemical classification |
|
Other low-ceiling diuretics |
| 0‑L |
C03BX03
|
cicletanine
|
WHO Anatomical Therapeutic Chemical classification |
|
cicletanine |
| 0‑L |
C03C
|
HIGH-CEILING DIURETICS
|
WHO Anatomical Therapeutic Chemical classification |
|
HIGH-CEILING DIURETICS |
| 0‑L |
C03CA
|
Sulfonamides, plain
|
WHO Anatomical Therapeutic Chemical classification |
|
Sulfonamides, plain |
| 0‑L |
C03CA01
|
furosemide
|
WHO Anatomical Therapeutic Chemical classification |
|
furosemide |
| 0‑L |
C03CA02
|
bumetanide
|
WHO Anatomical Therapeutic Chemical classification |
|
bumetanide |
| 0‑L |
C03CA03
|
piretanide
|
WHO Anatomical Therapeutic Chemical classification |
|
piretanide |
| 0‑L |
C03CA04
|
torasemide
|
WHO Anatomical Therapeutic Chemical classification |
|
torasemide |
| 0‑L |
C03CB
|
Sulfonamides and potassium in combination
|
WHO Anatomical Therapeutic Chemical classification |
|
Sulfonamides and potassium in combination |
| 0‑L |
C03CB01
|
furosemide and potassium
|
WHO Anatomical Therapeutic Chemical classification |
|
furosemide and potassium |
| 0‑L |
C03CB02
|
bumetanide and potassium
|
WHO Anatomical Therapeutic Chemical classification |
|
bumetanide and potassium |
| 0‑L |
C03CC
|
Aryloxyacetic acid derivatives
|
WHO Anatomical Therapeutic Chemical classification |
|
Aryloxyacetic acid derivatives |
| 0‑L |
C03CC01
|
etacrynic acid
|
WHO Anatomical Therapeutic Chemical classification |
|
etacrynic acid |
| 0‑L |
C03CC02
|
tienilic acid
|
WHO Anatomical Therapeutic Chemical classification |
|
tienilic acid |
| 0‑L |
C03CD
|
Pyrazolone derivatives
|
WHO Anatomical Therapeutic Chemical classification |
|
Pyrazolone derivatives |
| 0‑L |
C03CD01
|
muzolimine
|
WHO Anatomical Therapeutic Chemical classification |
|
muzolimine |
| 0‑L |
C03CX
|
Other high-ceiling diuretics
|
WHO Anatomical Therapeutic Chemical classification |
|
Other high-ceiling diuretics |
| 0‑L |
C03CX01
|
etozolin
|
WHO Anatomical Therapeutic Chemical classification |
|
etozolin |
| 0‑L |
C03D
|
POTASSIUM-SPARING AGENTS
|
WHO Anatomical Therapeutic Chemical classification |
|
POTASSIUM-SPARING AGENTS |
| 0‑L |
C03DA
|
Aldosterone antagonists
|
WHO Anatomical Therapeutic Chemical classification |
|
Aldosterone antagonists |
| 0‑L |
C03DA01
|
spironolactone
|
WHO Anatomical Therapeutic Chemical classification |
|
spironolactone |
| 0‑L |
C03DA02
|
potassium canrenoate
|
WHO Anatomical Therapeutic Chemical classification |
|
potassium canrenoate |
| 0‑L |
C03DA03
|
canrenone
|
WHO Anatomical Therapeutic Chemical classification |
|
canrenone |
| 0‑L |
C03DA04
|
eplerenone
|
WHO Anatomical Therapeutic Chemical classification |
|
eplerenone |
| 0‑L |
C03DB
|
Other potassium-sparing agents
|
WHO Anatomical Therapeutic Chemical classification |
|
Other potassium-sparing agents |
| 0‑L |
C03DB01
|
amiloride
|
WHO Anatomical Therapeutic Chemical classification |
|
amiloride |
| 0‑L |
C03DB02
|
triamterene
|
WHO Anatomical Therapeutic Chemical classification |
|
triamterene |
| 0‑L |
C03E
|
DIURETICS AND POTASSIUM-SPARING AGENTS IN COMBINATION
|
WHO Anatomical Therapeutic Chemical classification |
|
DIURETICS AND POTASSIUM-SPARING AGENTS IN COMBINATION |
| 0‑L |
C03EA
|
Low-ceiling diuretics and potassium-sparing agents
|
WHO Anatomical Therapeutic Chemical classification |
|
Low-ceiling diuretics and potassium-sparing agents |
| 0‑L |
C03EA01
|
hydrochlorothiazide and potassium-sparing agents
|
WHO Anatomical Therapeutic Chemical classification |
|
hydrochlorothiazide and potassium-sparing agents |
| 0‑L |
C03EA02
|
trichlormethiazide and potassium-sparing agents
|
WHO Anatomical Therapeutic Chemical classification |
|
trichlormethiazide and potassium-sparing agents |
| 0‑L |
C03EA03
|
epitizide and potassium-sparing agents
|
WHO Anatomical Therapeutic Chemical classification |
|
epitizide and potassium-sparing agents |
| 0‑L |
C03EA04
|
altizide and potassium-sparing agents
|
WHO Anatomical Therapeutic Chemical classification |
|
altizide and potassium-sparing agents |
| 0‑L |
C03EA05
|
mebutizide and potassium-sparing agents
|
WHO Anatomical Therapeutic Chemical classification |
|
mebutizide and potassium-sparing agents |
| 0‑L |
C03EA06
|
chlortalidone and potassium-sparing agents
|
WHO Anatomical Therapeutic Chemical classification |
|
chlortalidone and potassium-sparing agents |
| 0‑L |
C03EA07
|
cyclopenthiazide and potassium-sparing agents
|
WHO Anatomical Therapeutic Chemical classification |
|
cyclopenthiazide and potassium-sparing agents |
| 0‑L |
C03EA12
|
metolazone and potassium-sparing agents
|
WHO Anatomical Therapeutic Chemical classification |
|
metolazone and potassium-sparing agents |
| 0‑L |
C03EA13
|
bendroflumethiazide and potassium-sparing agents
|
WHO Anatomical Therapeutic Chemical classification |
|
bendroflumethiazide and potassium-sparing agents |
| 0‑L |
C03EA14
|
butizide and potassium-sparing agents
|
WHO Anatomical Therapeutic Chemical classification |
|
butizide and potassium-sparing agents |
| 0‑L |
C03EB
|
High-ceiling diuretics and potassium-sparing agents
|
WHO Anatomical Therapeutic Chemical classification |
|
High-ceiling diuretics and potassium-sparing agents |
| 0‑L |
C03EB01
|
furosemide and potassium-sparing agents
|
WHO Anatomical Therapeutic Chemical classification |
|
furosemide and potassium-sparing agents |
| 0‑L |
C03EB02
|
bumetanide and potassium-sparing agents
|
WHO Anatomical Therapeutic Chemical classification |
|
bumetanide and potassium-sparing agents |
| 0‑L |
C03X
|
OTHER DIURETICS
|
WHO Anatomical Therapeutic Chemical classification |
|
OTHER DIURETICS |
| 0‑L |
C03XA
|
Vasopressin antagonists
|
WHO Anatomical Therapeutic Chemical classification |
|
Vasopressin antagonists |
| 0‑L |
C03XA01
|
tolvaptan
|
WHO Anatomical Therapeutic Chemical classification |
|
tolvaptan |
| 0‑L |
C03XA02
|
conivaptan
|
WHO Anatomical Therapeutic Chemical classification |
|
conivaptan |
| 0‑L |
C04
|
PERIPHERAL VASODILATORS
|
WHO Anatomical Therapeutic Chemical classification |
|
PERIPHERAL VASODILATORS |
| 0‑L |
C04A
|
PERIPHERAL VASODILATORS
|
WHO Anatomical Therapeutic Chemical classification |
|
PERIPHERAL VASODILATORS |
| 0‑L |
C04AA
|
2-amino-1-phenylethanol derivatives
|
WHO Anatomical Therapeutic Chemical classification |
|
2-amino-1-phenylethanol derivatives |
| 0‑L |
C04AA01
|
isoxsuprine
|
WHO Anatomical Therapeutic Chemical classification |
|
isoxsuprine |
| 0‑L |
C04AA02
|
buphenine
|
WHO Anatomical Therapeutic Chemical classification |
|
buphenine |
| 0‑L |
C04AA31
|
bamethan
|
WHO Anatomical Therapeutic Chemical classification |
|
bamethan |
| 0‑L |
C04AB
|
Imidazoline derivatives
|
WHO Anatomical Therapeutic Chemical classification |
|
Imidazoline derivatives |
| 0‑L |
C04AB01
|
phentolamine
|
WHO Anatomical Therapeutic Chemical classification |
|
phentolamine |
| 0‑L |
C04AB02
|
tolazoline
|
WHO Anatomical Therapeutic Chemical classification |
|
tolazoline |
| 0‑L |
C04AC
|
Nicotinic acid and derivatives
|
WHO Anatomical Therapeutic Chemical classification |
|
Nicotinic acid and derivatives |
| 0‑L |
C04AC01
|
nicotinic acid
|
WHO Anatomical Therapeutic Chemical classification |
|
nicotinic acid |
| 0‑L |
C04AC02
|
nicotinyl alcohol (pyridylcarbinol)
|
WHO Anatomical Therapeutic Chemical classification |
|
nicotinyl alcohol (pyridylcarbinol) |
| 0‑L |
C04AC03
|
inositol nicotinate
|
WHO Anatomical Therapeutic Chemical classification |
|
inositol nicotinate |
| 0‑L |
C04AC07
|
ciclonicate
|
WHO Anatomical Therapeutic Chemical classification |
|
ciclonicate |
| 0‑L |
C04AD
|
Purine derivatives
|
WHO Anatomical Therapeutic Chemical classification |
|
Purine derivatives |
| 0‑L |
C04AD01
|
pentifylline
|
WHO Anatomical Therapeutic Chemical classification |
|
pentifylline |
| 0‑L |
C04AD02
|
xantinol nicotinate
|
WHO Anatomical Therapeutic Chemical classification |
|
xantinol nicotinate |
| 0‑L |
C04AD03
|
pentoxifylline
|
WHO Anatomical Therapeutic Chemical classification |
|
pentoxifylline |
| 0‑L |
C04AD04
|
etofylline nicotinate
|
WHO Anatomical Therapeutic Chemical classification |
|
etofylline nicotinate |
| 0‑L |
C04AE
|
Ergot alkaloids
|
WHO Anatomical Therapeutic Chemical classification |
|
Ergot alkaloids |
| 0‑L |
C04AE01
|
ergoloid mesylates
|
WHO Anatomical Therapeutic Chemical classification |
|
ergoloid mesylates |
| 0‑L |
C04AE02
|
nicergoline
|
WHO Anatomical Therapeutic Chemical classification |
|
nicergoline |
| 0‑L |
C04AE04
|
dihydroergocristine
|
WHO Anatomical Therapeutic Chemical classification |
|
dihydroergocristine |
| 0‑L |
C04AE51
|
ergoloid mesylates, combinations
|
WHO Anatomical Therapeutic Chemical classification |
|
ergoloid mesylates, combinations |
| 0‑L |
C04AE54
|
dihydroergocristine, combinations
|
WHO Anatomical Therapeutic Chemical classification |
|
dihydroergocristine, combinations |
| 0‑L |
C04AF
|
Enzymes
|
WHO Anatomical Therapeutic Chemical classification |
|
Enzymes |
| 0‑L |
C04AF01
|
kallidinogenase
|
WHO Anatomical Therapeutic Chemical classification |
|
kallidinogenase |
| 0‑L |
C04AX
|
Other peripheral vasodilators
|
WHO Anatomical Therapeutic Chemical classification |
|
Other peripheral vasodilators |
| 0‑L |
C04AX01
|
cyclandelate
|
WHO Anatomical Therapeutic Chemical classification |
|
cyclandelate |
| 0‑L |
C04AX02
|
phenoxybenzamine
|
WHO Anatomical Therapeutic Chemical classification |
|
phenoxybenzamine |
| 0‑L |
C04AX07
|
vincamine
|
WHO Anatomical Therapeutic Chemical classification |
|
vincamine |
| 0‑L |
C04AX10
|
moxisylyte
|
WHO Anatomical Therapeutic Chemical classification |
|
moxisylyte |
| 0‑L |
C04AX11
|
bencyclane
|
WHO Anatomical Therapeutic Chemical classification |
|
bencyclane |
| 0‑L |
C04AX17
|
vinburnine
|
WHO Anatomical Therapeutic Chemical classification |
|
vinburnine |
| 0‑L |
C04AX19
|
suloctidil
|
WHO Anatomical Therapeutic Chemical classification |
|
suloctidil |
| 0‑L |
C04AX20
|
buflomedil
|
WHO Anatomical Therapeutic Chemical classification |
|
buflomedil |
| 0‑L |
C04AX21
|
naftidrofuryl
|
WHO Anatomical Therapeutic Chemical classification |
|
naftidrofuryl |
| 0‑L |
C04AX23
|
butalamine
|
WHO Anatomical Therapeutic Chemical classification |
|
butalamine |
| 0‑L |
C04AX24
|
visnadine
|
WHO Anatomical Therapeutic Chemical classification |
|
visnadine |
| 0‑L |
C04AX26
|
cetiedil
|
WHO Anatomical Therapeutic Chemical classification |
|
cetiedil |
| 0‑L |
C04AX27
|
cinepazide
|
WHO Anatomical Therapeutic Chemical classification |
|
cinepazide |
| 0‑L |
C04AX28
|
ifenprodil
|
WHO Anatomical Therapeutic Chemical classification |
|
ifenprodil |
| 0‑L |
C04AX30
|
azapetine
|
WHO Anatomical Therapeutic Chemical classification |
|
azapetine |
| 0‑L |
C04AX32
|
fasudil
|
WHO Anatomical Therapeutic Chemical classification |
|
fasudil |
| 0‑L |
C05
|
VASOPROTECTIVES
|
WHO Anatomical Therapeutic Chemical classification |
|
VASOPROTECTIVES |
| 0‑L |
C05A
|
AGENTS FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE
|
WHO Anatomical Therapeutic Chemical classification |
|
AGENTS FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE |
| 0‑L |
C05AA
|
Corticosteroids
|
WHO Anatomical Therapeutic Chemical classification |
|
Corticosteroids |
| 0‑L |
C05AA01
|
hydrocortisone
|
WHO Anatomical Therapeutic Chemical classification |
|
hydrocortisone |
| 0‑L |
C05AA04
|
prednisolone
|
WHO Anatomical Therapeutic Chemical classification |
|
prednisolone |
| 0‑L |
C05AA05
|
betamethasone
|
WHO Anatomical Therapeutic Chemical classification |
|
betamethasone |
| 0‑L |
C05AA06
|
fluorometholone
|
WHO Anatomical Therapeutic Chemical classification |
|
fluorometholone |
| 0‑L |
C05AA08
|
fluocortolone
|
WHO Anatomical Therapeutic Chemical classification |
|
fluocortolone |
| 0‑L |
C05AA09
|
dexamethasone
|
WHO Anatomical Therapeutic Chemical classification |
|
dexamethasone |
| 0‑L |
C05AA10
|
fluocinolone acetonide
|
WHO Anatomical Therapeutic Chemical classification |
|
fluocinolone acetonide |
| 0‑L |
C05AA11
|
fluocinonide
|
WHO Anatomical Therapeutic Chemical classification |
|
fluocinonide |
| 0‑L |
C05AA12
|
triamcinolone
|
WHO Anatomical Therapeutic Chemical classification |
|
triamcinolone |
| 0‑L |
C05AB
|
Antibiotics
|
WHO Anatomical Therapeutic Chemical classification |
|
Antibiotics |
| 0‑L |
C05AD
|
Local anesthetics
|
WHO Anatomical Therapeutic Chemical classification |
|
Local anesthetics |
| 0‑L |
C05AD01
|
lidocaine
|
WHO Anatomical Therapeutic Chemical classification |
|
lidocaine |
| 0‑L |
C05AD02
|
tetracaine
|
WHO Anatomical Therapeutic Chemical classification |
|
tetracaine |
| 0‑L |
C05AD03
|
benzocaine
|
WHO Anatomical Therapeutic Chemical classification |
|
benzocaine |
| 0‑L |
C05AD04
|
cinchocaine
|
WHO Anatomical Therapeutic Chemical classification |
|
cinchocaine |
| 0‑L |
C05AD05
|
procaine
|
WHO Anatomical Therapeutic Chemical classification |
|
procaine |
| 0‑L |
C05AD06
|
oxetacaine
|
WHO Anatomical Therapeutic Chemical classification |
|
oxetacaine |
| 0‑L |
C05AD07
|
pramocaine
|
WHO Anatomical Therapeutic Chemical classification |
|
pramocaine |
| 0‑L |
C05AE
|
Muscle relaxants
|
WHO Anatomical Therapeutic Chemical classification |
|
Muscle relaxants |
| 0‑L |
C05AE01
|
glyceryl trinitrate
|
WHO Anatomical Therapeutic Chemical classification |
|
glyceryl trinitrate |
| 0‑L |
C05AE02
|
isosorbide dinitrate
|
WHO Anatomical Therapeutic Chemical classification |
|
isosorbide dinitrate |
| 0‑L |
C05AE03
|
diltiazem
|
WHO Anatomical Therapeutic Chemical classification |
|
diltiazem |
| 0‑L |
C05AX
|
Other agents for treatment of hemorrhoids and anal fissures for topical use
|
WHO Anatomical Therapeutic Chemical classification |
|
Other agents for treatment of hemorrhoids and anal fissures for topical use |
| 0‑L |
C05AX01
|
aluminium preparations
|
WHO Anatomical Therapeutic Chemical classification |
|
aluminium preparations |
| 0‑L |
C05AX02
|
bismuth preparations, combinations
|
WHO Anatomical Therapeutic Chemical classification |
|
bismuth preparations, combinations |
| 0‑L |
C05AX03
|
other preparations, combinations
|
WHO Anatomical Therapeutic Chemical classification |
|
other preparations, combinations |
| 0‑L |
C05AX04
|
zinc preparations
|
WHO Anatomical Therapeutic Chemical classification |
|
zinc preparations |
| 0‑L |
C05AX05
|
tribenoside
|
WHO Anatomical Therapeutic Chemical classification |
|
tribenoside |
| 0‑L |
C05B
|
ANTIVARICOSE THERAPY
|
WHO Anatomical Therapeutic Chemical classification |
|
ANTIVARICOSE THERAPY |
| 0‑L |
C05BA
|
Heparins or heparinoids for topical use
|
WHO Anatomical Therapeutic Chemical classification |
|
Heparins or heparinoids for topical use |
| 0‑L |
C05BA01
|
organo-heparinoid
|
WHO Anatomical Therapeutic Chemical classification |
|
organo-heparinoid |
| 0‑L |
C05BA02
|
sodium apolate
|
WHO Anatomical Therapeutic Chemical classification |
|
sodium apolate |
| 0‑L |
C05BA03
|
heparin
|
WHO Anatomical Therapeutic Chemical classification |
|
heparin |
| 0‑L |
C05BA04
|
pentosan polysulfate sodium
|
WHO Anatomical Therapeutic Chemical classification |
|
pentosan polysulfate sodium |
| 0‑L |
C05BA51
|
heparinoid, combinations
|
WHO Anatomical Therapeutic Chemical classification |
|
heparinoid, combinations |
| 0‑L |
C05BA53
|
heparin, combinations
|
WHO Anatomical Therapeutic Chemical classification |
|
heparin, combinations |
| 0‑L |
C05BB
|
Sclerosing agents for local injection
|
WHO Anatomical Therapeutic Chemical classification |
|
Sclerosing agents for local injection |
| 0‑L |
C05BB01
|
monoethanolamine oleate
|
WHO Anatomical Therapeutic Chemical classification |
|
monoethanolamine oleate |
| 0‑L |
C05BB02
|
polidocanol
|
WHO Anatomical Therapeutic Chemical classification |
|
polidocanol |
| 0‑L |
C05BB03
|
invert sugar
|
WHO Anatomical Therapeutic Chemical classification |
|
invert sugar |
| 0‑L |
C05BB04
|
sodium tetradecyl sulfate
|
WHO Anatomical Therapeutic Chemical classification |
|
sodium tetradecyl sulfate |
| 0‑L |
C05BB05
|
phenol
|
WHO Anatomical Therapeutic Chemical classification |
|
phenol |
| 0‑L |
C05BB56
|
glucose, combinations
|
WHO Anatomical Therapeutic Chemical classification |
|
glucose, combinations |
| 0‑L |
C05BX
|
Other sclerosing agents
|
WHO Anatomical Therapeutic Chemical classification |
|
Other sclerosing agents |
| 0‑L |
C05BX01
|
calcium dobesilate
|
WHO Anatomical Therapeutic Chemical classification |
|
calcium dobesilate |
| 0‑L |
C05BX51
|
calcium dobesilate, combinations
|
WHO Anatomical Therapeutic Chemical classification |
|
calcium dobesilate, combinations |
| 0‑L |
C05C
|
CAPILLARY STABILIZING AGENTS
|
WHO Anatomical Therapeutic Chemical classification |
|
CAPILLARY STABILIZING AGENTS |
| 0‑L |
C05CA
|
Bioflavonoids
|
WHO Anatomical Therapeutic Chemical classification |
|
Bioflavonoids |
| 0‑L |
C05CA01
|
rutoside
|
WHO Anatomical Therapeutic Chemical classification |
|
rutoside |
| 0‑L |
C05CA02
|
monoxerutin
|
WHO Anatomical Therapeutic Chemical classification |
|
monoxerutin |
| 0‑L |
C05CA03
|
diosmin
|
WHO Anatomical Therapeutic Chemical classification |
|
diosmin |
| 0‑L |
C05CA04
|
troxerutin
|
WHO Anatomical Therapeutic Chemical classification |
|
troxerutin |
| 0‑L |
C05CA05
|
hidrosmin
|
WHO Anatomical Therapeutic Chemical classification |
|
hidrosmin |
| 0‑L |
C05CA51
|
rutoside, combinations
|
WHO Anatomical Therapeutic Chemical classification |
|
rutoside, combinations |
| 0‑L |
C05CA53
|
diosmin, combinations
|
WHO Anatomical Therapeutic Chemical classification |
|
diosmin, combinations |
| 0‑L |
C05CA54
|
troxerutin, combinations
|
WHO Anatomical Therapeutic Chemical classification |
|
troxerutin, combinations |
| 0‑L |
C05CX
|
Other capillary stabilizing agents
|
WHO Anatomical Therapeutic Chemical classification |
|
Other capillary stabilizing agents |
| 0‑L |
C05CX01
|
tribenoside
|
WHO Anatomical Therapeutic Chemical classification |
|
tribenoside |
| 0‑L |
C05CX02
|
naftazone
|
WHO Anatomical Therapeutic Chemical classification |
|
naftazone |
| 0‑L |
C05CX03
|
Hippocastani semen
|
WHO Anatomical Therapeutic Chemical classification |
|
Hippocastani semen |
| 0‑L |
C07
|
BETA BLOCKING AGENTS
|
WHO Anatomical Therapeutic Chemical classification |
|
BETA BLOCKING AGENTS |
| 0‑L |
C07A
|
BETA BLOCKING AGENTS
|
WHO Anatomical Therapeutic Chemical classification |
|
BETA BLOCKING AGENTS |
| 0‑L |
C07AA
|
Beta blocking agents, non-selective
|
WHO Anatomical Therapeutic Chemical classification |
|
Beta blocking agents, non-selective |
| 0‑L |
C07AA01
|
alprenolol
|
WHO Anatomical Therapeutic Chemical classification |
|
alprenolol |
| 0‑L |
C07AA02
|
oxprenolol
|
WHO Anatomical Therapeutic Chemical classification |
|
oxprenolol |
| 0‑L |
C07AA03
|
pindolol
|
WHO Anatomical Therapeutic Chemical classification |
|
pindolol |
| 0‑L |
C07AA05
|
propranolol
|
WHO Anatomical Therapeutic Chemical classification |
|
propranolol |
| 0‑L |
C07AA06
|
timolol
|
WHO Anatomical Therapeutic Chemical classification |
|
timolol |
| 0‑L |
C07AA07
|
sotalol
|
WHO Anatomical Therapeutic Chemical classification |
|
sotalol |
| 0‑L |
C07AA12
|
nadolol
|
WHO Anatomical Therapeutic Chemical classification |
|
nadolol |
| 0‑L |
C07AA14
|
mepindolol
|
WHO Anatomical Therapeutic Chemical classification |
|
mepindolol |
| 0‑L |
C07AA15
|
carteolol
|
WHO Anatomical Therapeutic Chemical classification |
|
carteolol |
| 0‑L |
C07AA16
|
tertatolol
|
WHO Anatomical Therapeutic Chemical classification |
|
tertatolol |
| 0‑L |
C07AA17
|
bopindolol
|
WHO Anatomical Therapeutic Chemical classification |
|
bopindolol |
| 0‑L |
C07AA19
|
bupranolol
|
WHO Anatomical Therapeutic Chemical classification |
|
bupranolol |
| 0‑L |
C07AA23
|
penbutolol
|
WHO Anatomical Therapeutic Chemical classification |
|
penbutolol |
| 0‑L |
C07AA27
|
cloranolol
|
WHO Anatomical Therapeutic Chemical classification |
|
cloranolol |
| 0‑L |
C07AB
|
Beta blocking agents, selective
|
WHO Anatomical Therapeutic Chemical classification |
|
Beta blocking agents, selective |
| 0‑L |
C07AB01
|
practolol
|
WHO Anatomical Therapeutic Chemical classification |
|
practolol |
| 0‑L |
C07AB02
|
metoprolol
|
WHO Anatomical Therapeutic Chemical classification |
|
metoprolol |
| 0‑L |
C07AB03
|
atenolol
|
WHO Anatomical Therapeutic Chemical classification |
|
atenolol |
| 0‑L |
C07AB04
|
acebutolol
|
WHO Anatomical Therapeutic Chemical classification |
|
acebutolol |
| 0‑L |
C07AB05
|
betaxolol
|
WHO Anatomical Therapeutic Chemical classification |
|
betaxolol |
| 0‑L |
C07AB06
|
bevantolol
|
WHO Anatomical Therapeutic Chemical classification |
|
bevantolol |
| 0‑L |
C07AB07
|
bisoprolol
|
WHO Anatomical Therapeutic Chemical classification |
|
bisoprolol |
| 0‑L |
C07AB08
|
celiprolol
|
WHO Anatomical Therapeutic Chemical classification |
|
celiprolol |
| 0‑L |
C07AB09
|
esmolol
|
WHO Anatomical Therapeutic Chemical classification |
|
esmolol |
| 0‑L |
C07AB10
|
epanolol
|
WHO Anatomical Therapeutic Chemical classification |
|
epanolol |
| 0‑L |
C07AB11
|
s-atenolol
|
WHO Anatomical Therapeutic Chemical classification |
|
s-atenolol |
| 0‑L |
C07AB12
|
nebivolol
|
WHO Anatomical Therapeutic Chemical classification |
|
nebivolol |
| 0‑L |
C07AB13
|
talinolol
|
WHO Anatomical Therapeutic Chemical classification |
|
talinolol |
| 0‑L |
C07AB14
|
landiolol
|
WHO Anatomical Therapeutic Chemical classification |
|
landiolol |
| 0‑L |
C07AG
|
Alpha and beta blocking agents
|
WHO Anatomical Therapeutic Chemical classification |
|
Alpha and beta blocking agents |
| 0‑L |
C07AG01
|
labetalol
|
WHO Anatomical Therapeutic Chemical classification |
|
labetalol |
| 0‑L |
C07AG02
|
carvedilol
|
WHO Anatomical Therapeutic Chemical classification |
|
carvedilol |
| 0‑L |
C07B
|
BETA BLOCKING AGENTS AND THIAZIDES
|
WHO Anatomical Therapeutic Chemical classification |
|
BETA BLOCKING AGENTS AND THIAZIDES |
| 0‑L |
C07BA
|
Beta blocking agents, non-selective, and thiazides
|
WHO Anatomical Therapeutic Chemical classification |
|
Beta blocking agents, non-selective, and thiazides |
| 0‑L |
C07BA02
|
oxprenolol and thiazides
|
WHO Anatomical Therapeutic Chemical classification |
|
oxprenolol and thiazides |
| 0‑L |
C07BA05
|
propranolol and thiazides
|
WHO Anatomical Therapeutic Chemical classification |
|
propranolol and thiazides |
| 0‑L |
C07BA06
|
timolol and thiazides
|
WHO Anatomical Therapeutic Chemical classification |
|
timolol and thiazides |
| 0‑L |
C07BA07
|
sotalol and thiazides
|
WHO Anatomical Therapeutic Chemical classification |
|
sotalol and thiazides |
| 0‑L |
C07BA12
|
nadolol and thiazides
|
WHO Anatomical Therapeutic Chemical classification |
|
nadolol and thiazides |
| 0‑L |
C07BA68
|
metipranolol and thiazides, combinations
|
WHO Anatomical Therapeutic Chemical classification |
|
metipranolol and thiazides, combinations |
| 0‑L |
C07BB
|
Beta blocking agents, selective, and thiazides
|
WHO Anatomical Therapeutic Chemical classification |
|
Beta blocking agents, selective, and thiazides |
| 0‑L |
C07BB02
|
metoprolol and thiazides
|
WHO Anatomical Therapeutic Chemical classification |
|
metoprolol and thiazides |
| 0‑L |
C07BB03
|
atenolol and thiazides
|
WHO Anatomical Therapeutic Chemical classification |
|
atenolol and thiazides |
| 0‑L |
C07BB04
|
acebutolol and thiazides
|
WHO Anatomical Therapeutic Chemical classification |
|
acebutolol and thiazides |
| 0‑L |
C07BB06
|
bevantolol and thiazides
|
WHO Anatomical Therapeutic Chemical classification |
|
bevantolol and thiazides |
| 0‑L |
C07BB07
|
bisoprolol and thiazides
|
WHO Anatomical Therapeutic Chemical classification |
|
bisoprolol and thiazides |
| 0‑L |
C07BB12
|
nebivolol and thiazides
|
WHO Anatomical Therapeutic Chemical classification |
|
nebivolol and thiazides |
| 0‑L |
C07BB52
|
metoprolol and thiazides, combinations
|
WHO Anatomical Therapeutic Chemical classification |
|
metoprolol and thiazides, combinations |
| 0‑L |
C07BG
|
Alpha and beta blocking agents and thiazides
|
WHO Anatomical Therapeutic Chemical classification |
|
Alpha and beta blocking agents and thiazides |
| 0‑L |
C07BG01
|
labetalol and thiazides
|
WHO Anatomical Therapeutic Chemical classification |
|
labetalol and thiazides |
| 0‑L |
C07C
|
BETA BLOCKING AGENTS AND OTHER DIURETICS
|
WHO Anatomical Therapeutic Chemical classification |
|
BETA BLOCKING AGENTS AND OTHER DIURETICS |
| 0‑L |
C07CA
|
Beta blocking agents, non-selective, and other diuretics
|
WHO Anatomical Therapeutic Chemical classification |
|
Beta blocking agents, non-selective, and other diuretics |
| 0‑L |
C07CA02
|
oxprenolol and other diuretics
|
WHO Anatomical Therapeutic Chemical classification |
|
oxprenolol and other diuretics |
| 0‑L |
C07CA03
|
pindolol and other diuretics
|
WHO Anatomical Therapeutic Chemical classification |
|
pindolol and other diuretics |
| 0‑L |
C07CA17
|
bopindolol and other diuretics
|
WHO Anatomical Therapeutic Chemical classification |
|
bopindolol and other diuretics |
| 0‑L |
C07CA23
|
penbutolol and other diuretics
|
WHO Anatomical Therapeutic Chemical classification |
|
penbutolol and other diuretics |
| 0‑L |
C07CB
|
Beta blocking agents, selective, and other diuretics
|
WHO Anatomical Therapeutic Chemical classification |
|
Beta blocking agents, selective, and other diuretics |
| 0‑L |
C07CB02
|
metoprolol and other diuretics
|
WHO Anatomical Therapeutic Chemical classification |
|
metoprolol and other diuretics |
| 0‑L |
C07CB03
|
atenolol and other diuretics
|
WHO Anatomical Therapeutic Chemical classification |
|
atenolol and other diuretics |
| 0‑L |
C07CB53
|
atenolol and other diuretics, combinations
|
WHO Anatomical Therapeutic Chemical classification |
|
atenolol and other diuretics, combinations |
| 0‑L |
C07CG
|
Alpha and beta blocking agents and other diuretics
|
WHO Anatomical Therapeutic Chemical classification |
|
Alpha and beta blocking agents and other diuretics |
| 0‑L |
C07CG01
|
labetalol and other diuretics
|
WHO Anatomical Therapeutic Chemical classification |
|
labetalol and other diuretics |
| 0‑L |
C07D
|
BETA BLOCKING AGENTS, THIAZIDES AND OTHER DIURETICS
|
WHO Anatomical Therapeutic Chemical classification |
|
BETA BLOCKING AGENTS, THIAZIDES AND OTHER DIURETICS |
| 0‑L |
C07DA
|
Beta blocking agents, non-selective, thiazides and other diuretics
|
WHO Anatomical Therapeutic Chemical classification |
|
Beta blocking agents, non-selective, thiazides and other diuretics |
| 0‑L |
C07DA06
|
timolol, thiazides and other diuretics
|
WHO Anatomical Therapeutic Chemical classification |
|
timolol, thiazides and other diuretics |
| 0‑L |
C07DB
|
Beta blocking agents, selective, thiazides and other diuretics
|
WHO Anatomical Therapeutic Chemical classification |
|
Beta blocking agents, selective, thiazides and other diuretics |
| 0‑L |
C07DB01
|
atenolol, thiazides and other diuretics
|
WHO Anatomical Therapeutic Chemical classification |
|
atenolol, thiazides and other diuretics |
| 0‑L |
C07E
|
BETA BLOCKING AGENTS AND VASODILATORS
|
WHO Anatomical Therapeutic Chemical classification |
|
BETA BLOCKING AGENTS AND VASODILATORS |
| 0‑L |
C07EA
|
Beta blocking agents, non-selective, and vasodilators
|
WHO Anatomical Therapeutic Chemical classification |
|
Beta blocking agents, non-selective, and vasodilators |
| 0‑L |
C07EB
|
Beta blocking agents, selective, and vasodilators
|
WHO Anatomical Therapeutic Chemical classification |
|
Beta blocking agents, selective, and vasodilators |
| 0‑L |
C07F
|
BETA BLOCKING AGENTS, OTHER COMBINATIONS
|
WHO Anatomical Therapeutic Chemical classification |
|
BETA BLOCKING AGENTS, OTHER COMBINATIONS |
| 0‑L |
C07FB
|
Beta blocking agents and calcium channel blockers
|
WHO Anatomical Therapeutic Chemical classification |
|
Beta blocking agents and calcium channel blockers |
| 0‑L |
C07FB02
|
metoprolol and felodipine
|
WHO Anatomical Therapeutic Chemical classification |
|
metoprolol and felodipine |
| 0‑L |
C07FB03
|
atenolol and nifedipine
|
WHO Anatomical Therapeutic Chemical classification |
|
atenolol and nifedipine |
| 0‑L |
C07FB07
|
bisoprolol and amlodipine
|
WHO Anatomical Therapeutic Chemical classification |
|
bisoprolol and amlodipine |
| 0‑L |
C07FB12
|
nevibolol and amlodipine
|
WHO Anatomical Therapeutic Chemical classification |
|
nevibolol and amlodipine |
| 0‑L |
C07FB13
|
metoprolol and amlodipine
|
WHO Anatomical Therapeutic Chemical classification |
|
metoprolol and amlodipine |
| 0‑L |
C07FX
|
Beta blocking agents, other combinations
|
WHO Anatomical Therapeutic Chemical classification |
|
Beta blocking agents, other combinations |
| 0‑L |
C07FX01
|
propranolol and other combinations
|
WHO Anatomical Therapeutic Chemical classification |
|
propranolol and other combinations |
| 0‑L |
C07FX02
|
sotalol and acetylsalicylic acid
|
WHO Anatomical Therapeutic Chemical classification |
|
sotalol and acetylsalicylic acid |
| 0‑L |
C07FX03
|
metoprolol and acetylsalicylic acid
|
WHO Anatomical Therapeutic Chemical classification |
|
metoprolol and acetylsalicylic acid |
| 0‑L |
C07FX04
|
bisoprolol and acetylsalicylic acid
|
WHO Anatomical Therapeutic Chemical classification |
|
bisoprolol and acetylsalicylic acid |
| 0‑L |
C07FX05
|
metoprolol and ivabradine
|
WHO Anatomical Therapeutic Chemical classification |
|
metoprolol and ivabradine |
| 0‑L |
C07FX06
|
carvedilol and ivabradine
|
WHO Anatomical Therapeutic Chemical classification |
|
carvedilol and ivabradine |
| 0‑L |
C08
|
CALCIUM CHANNEL BLOCKERS
|
WHO Anatomical Therapeutic Chemical classification |
|
CALCIUM CHANNEL BLOCKERS |
| 0‑L |
C08C
|
SELECTIVE CALCIUM CHANNEL BLOCKERS WITH MAINLY VASCULAR EFFECTS
|
WHO Anatomical Therapeutic Chemical classification |
|
SELECTIVE CALCIUM CHANNEL BLOCKERS WITH MAINLY VASCULAR EFFECTS |
| 0‑L |
C08CA
|
Dihydropyridine derivatives
|
WHO Anatomical Therapeutic Chemical classification |
|
Dihydropyridine derivatives |
| 0‑L |
C08CA01
|
amlodipine
|
WHO Anatomical Therapeutic Chemical classification |
|
amlodipine |
| 0‑L |
C08CA02
|
felodipine
|
WHO Anatomical Therapeutic Chemical classification |
|
felodipine |
| 0‑L |
C08CA03
|
isradipine
|
WHO Anatomical Therapeutic Chemical classification |
|
isradipine |
| 0‑L |
C08CA04
|
nicardipine
|
WHO Anatomical Therapeutic Chemical classification |
|
nicardipine |
| 0‑L |
C08CA05
|
nifedipine
|
WHO Anatomical Therapeutic Chemical classification |
|
nifedipine |
| 0‑L |
C08CA06
|
nimodipine
|
WHO Anatomical Therapeutic Chemical classification |
|
nimodipine |
| 0‑L |
C08CA07
|
nisoldipine
|
WHO Anatomical Therapeutic Chemical classification |
|
nisoldipine |
| 0‑L |
C08CA08
|
nitrendipine
|
WHO Anatomical Therapeutic Chemical classification |
|
nitrendipine |
| 0‑L |
C08CA09
|
lacidipine
|
WHO Anatomical Therapeutic Chemical classification |
|
lacidipine |
| 0‑L |
C08CA10
|
nilvadipine
|
WHO Anatomical Therapeutic Chemical classification |
|
nilvadipine |
| 0‑L |
C08CA11
|
manidipine
|
WHO Anatomical Therapeutic Chemical classification |
|
manidipine |
| 0‑L |
C08CA12
|
barnidipine
|
WHO Anatomical Therapeutic Chemical classification |
|
barnidipine |
| 0‑L |
C08CA13
|
lercanidipine
|
WHO Anatomical Therapeutic Chemical classification |
|
lercanidipine |
| 0‑L |
C08CA14
|
cilnidipine
|
WHO Anatomical Therapeutic Chemical classification |
|
cilnidipine |
| 0‑L |
C08CA15
|
benidipine
|
WHO Anatomical Therapeutic Chemical classification |
|
benidipine |
| 0‑L |
C08CA16
|
clevidipine
|
WHO Anatomical Therapeutic Chemical classification |
|
clevidipine |
| 0‑L |
C08CA55
|
nifedipine, combinations
|
WHO Anatomical Therapeutic Chemical classification |
|
nifedipine, combinations |
| 0‑L |
C08CX
|
Other selective calcium channel blockers with mainly vascular effects
|
WHO Anatomical Therapeutic Chemical classification |
|
Other selective calcium channel blockers with mainly vascular effects |
| 0‑L |
C08CX01
|
mibefradil
|
WHO Anatomical Therapeutic Chemical classification |
|
mibefradil |
| 0‑L |
C08D
|
SELECTIVE CALCIUM CHANNEL BLOCKERS WITH DIRECT CARDIAC EFFECTS
|
WHO Anatomical Therapeutic Chemical classification |
|
SELECTIVE CALCIUM CHANNEL BLOCKERS WITH DIRECT CARDIAC EFFECTS |
| 0‑L |
C08DA
|
Phenylalkylamine derivatives
|
WHO Anatomical Therapeutic Chemical classification |
|
Phenylalkylamine derivatives |
| 0‑L |
C08DA01
|
verapamil
|
WHO Anatomical Therapeutic Chemical classification |
|
verapamil |
| 0‑L |
C08DA02
|
gallopamil
|
WHO Anatomical Therapeutic Chemical classification |
|
gallopamil |
| 0‑L |
C08DA51
|
verapamil, combinations
|
WHO Anatomical Therapeutic Chemical classification |
|
verapamil, combinations |
| 0‑L |
C08DB
|
Benzothiazepine derivatives
|
WHO Anatomical Therapeutic Chemical classification |
|
Benzothiazepine derivatives |
| 0‑L |
C08DB01
|
diltiazem
|
WHO Anatomical Therapeutic Chemical classification |
|
diltiazem |
| 0‑L |
C08E
|
NON-SELECTIVE CALCIUM CHANNEL BLOCKERS
|
WHO Anatomical Therapeutic Chemical classification |
|
NON-SELECTIVE CALCIUM CHANNEL BLOCKERS |
| 0‑L |
C08EA
|
Phenylalkylamine derivatives
|
WHO Anatomical Therapeutic Chemical classification |
|
Phenylalkylamine derivatives |
| 0‑L |
C08EA01
|
fendiline
|
WHO Anatomical Therapeutic Chemical classification |
|
fendiline |
| 0‑L |
C08EA02
|
bepridil
|
WHO Anatomical Therapeutic Chemical classification |
|
bepridil |
| 0‑L |
C08EX
|
Other non-selective calcium channel blockers
|
WHO Anatomical Therapeutic Chemical classification |
|
Other non-selective calcium channel blockers |
| 0‑L |
C08EX01
|
lidoflazine
|
WHO Anatomical Therapeutic Chemical classification |
|
lidoflazine |
| 0‑L |
C08EX02
|
perhexiline
|
WHO Anatomical Therapeutic Chemical classification |
|
perhexiline |
| 0‑L |
C08G
|
CALCIUM CHANNEL BLOCKERS AND DIURETICS
|
WHO Anatomical Therapeutic Chemical classification |
|
CALCIUM CHANNEL BLOCKERS AND DIURETICS |
| 0‑L |
C08GA
|
Calcium channel blockers and diuretics
|
WHO Anatomical Therapeutic Chemical classification |
|
Calcium channel blockers and diuretics |
| 0‑L |
C08GA01
|
nifedipine and diuretics
|
WHO Anatomical Therapeutic Chemical classification |
|
nifedipine and diuretics |
| 0‑L |
C08GA02
|
amlodipine and diuretics
|
WHO Anatomical Therapeutic Chemical classification |
|
amlodipine and diuretics |
| 0‑L |
C09
|
AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM
|
WHO Anatomical Therapeutic Chemical classification |
|
AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM |
| 0‑L |
C09A
|
ACE INHIBITORS, PLAIN
|
WHO Anatomical Therapeutic Chemical classification |
|
ACE INHIBITORS, PLAIN |
| 0‑L |
C09AA
|
ACE inhibitors, plain
|
WHO Anatomical Therapeutic Chemical classification |
|
ACE inhibitors, plain |
| 0‑L |
C09AA01
|
captopril
|
WHO Anatomical Therapeutic Chemical classification |
|
captopril |
| 0‑L |
C09AA02
|
enalapril
|
WHO Anatomical Therapeutic Chemical classification |
|
enalapril |
| 0‑L |
C09AA03
|
lisinopril
|
WHO Anatomical Therapeutic Chemical classification |
|
lisinopril |
| 0‑L |
C09AA04
|
perindopril
|
WHO Anatomical Therapeutic Chemical classification |
|
perindopril |
| 0‑L |
C09AA05
|
ramipril
|
WHO Anatomical Therapeutic Chemical classification |
|
ramipril |
| 0‑L |
C09AA06
|
quinapril
|
WHO Anatomical Therapeutic Chemical classification |
|
quinapril |
| 0‑L |
C09AA07
|
benazepril
|
WHO Anatomical Therapeutic Chemical classification |
|
benazepril |
| 0‑L |
C09AA08
|
cilazapril
|
WHO Anatomical Therapeutic Chemical classification |
|
cilazapril |
| 0‑L |
C09AA09
|
fosinopril
|
WHO Anatomical Therapeutic Chemical classification |
|
fosinopril |
| 0‑L |
C09AA10
|
trandolapril
|
WHO Anatomical Therapeutic Chemical classification |
|
trandolapril |
| 0‑L |
C09AA11
|
spirapril
|
WHO Anatomical Therapeutic Chemical classification |
|
spirapril |
| 0‑L |
C09AA12
|
delapril
|
WHO Anatomical Therapeutic Chemical classification |
|
delapril |
| 0‑L |
C09AA13
|
moexipril
|
WHO Anatomical Therapeutic Chemical classification |
|
moexipril |
| 0‑L |
C09AA14
|
temocapril
|
WHO Anatomical Therapeutic Chemical classification |
|
temocapril |
| 0‑L |
C09AA15
|
zofenopril
|
WHO Anatomical Therapeutic Chemical classification |
|
zofenopril |
| 0‑L |
C09AA16
|
imidapril
|
WHO Anatomical Therapeutic Chemical classification |
|
imidapril |
| 0‑L |
C09B
|
ACE INHIBITORS, COMBINATIONS
|
WHO Anatomical Therapeutic Chemical classification |
|
ACE INHIBITORS, COMBINATIONS |
| 0‑L |
C09BA
|
ACE inhibitors and diuretics
|
WHO Anatomical Therapeutic Chemical classification |
|
ACE inhibitors and diuretics |
| 0‑L |
C09BA01
|
captopril and diuretics
|
WHO Anatomical Therapeutic Chemical classification |
|
captopril and diuretics |
| 0‑L |
C09BA02
|
enalapril and diuretics
|
WHO Anatomical Therapeutic Chemical classification |
|
enalapril and diuretics |
| 0‑L |
C09BA03
|
lisinopril and diuretics
|
WHO Anatomical Therapeutic Chemical classification |
|
lisinopril and diuretics |
| 0‑L |
C09BA04
|
perindopril and diuretics
|
WHO Anatomical Therapeutic Chemical classification |
|
perindopril and diuretics |
| 0‑L |
C09BA05
|
ramipril and diuretics
|
WHO Anatomical Therapeutic Chemical classification |
|
ramipril and diuretics |
| 0‑L |
C09BA06
|
quinapril and diuretics
|
WHO Anatomical Therapeutic Chemical classification |
|
quinapril and diuretics |
| 0‑L |
C09BA07
|
benazepril and diuretics
|
WHO Anatomical Therapeutic Chemical classification |
|
benazepril and diuretics |
| 0‑L |
C09BA08
|
cilazapril and diuretics
|
WHO Anatomical Therapeutic Chemical classification |
|
cilazapril and diuretics |
| 0‑L |
C09BA09
|
fosinopril and diuretics
|
WHO Anatomical Therapeutic Chemical classification |
|
fosinopril and diuretics |
| 0‑L |
C09BA12
|
delapril and diuretics
|
WHO Anatomical Therapeutic Chemical classification |
|
delapril and diuretics |
| 0‑L |
C09BA13
|
moexipril and diuretics
|
WHO Anatomical Therapeutic Chemical classification |
|
moexipril and diuretics |
| 0‑L |
C09BA15
|
zofenopril and diuretics
|
WHO Anatomical Therapeutic Chemical classification |
|
zofenopril and diuretics |
| 0‑L |
C09BB
|
ACE inhibitors and calcium channel blockers
|
WHO Anatomical Therapeutic Chemical classification |
|
ACE inhibitors and calcium channel blockers |
| 0‑L |
C09BB02
|
enalapril and lercanidipine
|
WHO Anatomical Therapeutic Chemical classification |
|
enalapril and lercanidipine |
| 0‑L |
C09BB03
|
lisinopril and amlodipine
|
WHO Anatomical Therapeutic Chemical classification |
|
lisinopril and amlodipine |
| 0‑L |
C09BB04
|
perindopril and amlodipine
|
WHO Anatomical Therapeutic Chemical classification |
|
perindopril and amlodipine |
| 0‑L |
C09BB05
|
ramipril and felodipine
|
WHO Anatomical Therapeutic Chemical classification |
|
ramipril and felodipine |
| 0‑L |
C09BB06
|
enalapril and nitrendipine
|
WHO Anatomical Therapeutic Chemical classification |
|
enalapril and nitrendipine |
| 0‑L |
C09BB07
|
ramipril and amlodipine
|
WHO Anatomical Therapeutic Chemical classification |
|
ramipril and amlodipine |
| 0‑L |
C09BB10
|
trandolapril and verapamil
|
WHO Anatomical Therapeutic Chemical classification |
|
trandolapril and verapamil |
| 0‑L |
C09BB12
|
delapril and manidipine
|
WHO Anatomical Therapeutic Chemical classification |
|
delapril and manidipine |
| 0‑L |
C09BX
|
ACE inhibitors, other combinations
|
WHO Anatomical Therapeutic Chemical classification |
|
ACE inhibitors, other combinations |
| 0‑L |
C09BX01
|
perindopril, amlodipine and indapamide
|
WHO Anatomical Therapeutic Chemical classification |
|
perindopril, amlodipine and indapamide |
| 0‑L |
C09BX02
|
perindopril and bisoprolol
|
WHO Anatomical Therapeutic Chemical classification |
|
perindopril and bisoprolol |
| 0‑L |
C09C
|
ANGIOTENSIN II ANTAGONISTS, PLAIN
|
WHO Anatomical Therapeutic Chemical classification |
|
ANGIOTENSIN II ANTAGONISTS, PLAIN |
| 0‑L |
C09CA
|
Angiotensin II antagonists, plain
|
WHO Anatomical Therapeutic Chemical classification |
|
Angiotensin II antagonists, plain |
| 0‑L |
C09CA01
|
losartan
|
WHO Anatomical Therapeutic Chemical classification |
|
losartan |
| 0‑L |
C09CA02
|
eprosartan
|
WHO Anatomical Therapeutic Chemical classification |
|
eprosartan |
| 0‑L |
C09CA03
|
valsartan
|
WHO Anatomical Therapeutic Chemical classification |
|
valsartan |
| 0‑L |
C09CA04
|
irbesartan
|
WHO Anatomical Therapeutic Chemical classification |
|
irbesartan |
| 0‑L |
C09CA05
|
tasosartan
|
WHO Anatomical Therapeutic Chemical classification |
|
tasosartan |
| 0‑L |
C09CA06
|
candesartan
|
WHO Anatomical Therapeutic Chemical classification |
|
candesartan |
| 0‑L |
C09CA07
|
telmisartan
|
WHO Anatomical Therapeutic Chemical classification |
|
telmisartan |
| 0‑L |
C09CA08
|
olmesartan medoxomil
|
WHO Anatomical Therapeutic Chemical classification |
|
olmesartan medoxomil |
| 0‑L |
C09CA09
|
azilsartan medoxomil
|
WHO Anatomical Therapeutic Chemical classification |
|
azilsartan medoxomil |
| 0‑L |
C09CA10
|
fimasartan
|
WHO Anatomical Therapeutic Chemical classification |
|
fimasartan |
| 0‑L |
C09D
|
ANGIOTENSIN II ANTAGONISTS, COMBINATIONS
|
WHO Anatomical Therapeutic Chemical classification |
|
ANGIOTENSIN II ANTAGONISTS, COMBINATIONS |
| 0‑L |
C09DA
|
Angiotensin II antagonists and diuretics
|
WHO Anatomical Therapeutic Chemical classification |
|
Angiotensin II antagonists and diuretics |
| 0‑L |
C09DA01
|
losartan and diuretics
|
WHO Anatomical Therapeutic Chemical classification |
|
losartan and diuretics |
| 0‑L |
C09DA02
|
eprosartan and diuretics
|
WHO Anatomical Therapeutic Chemical classification |
|
eprosartan and diuretics |
| 0‑L |
C09DA03
|
valsartan and diuretics
|
WHO Anatomical Therapeutic Chemical classification |
|
valsartan and diuretics |
| 0‑L |
C09DA04
|
irbesartan and diuretics
|
WHO Anatomical Therapeutic Chemical classification |
|
irbesartan and diuretics |
| 0‑L |
C09DA06
|
candesartan and diuretics
|
WHO Anatomical Therapeutic Chemical classification |
|
candesartan and diuretics |
| 0‑L |
C09DA07
|
telmisartan and diuretics
|
WHO Anatomical Therapeutic Chemical classification |
|
telmisartan and diuretics |
| 0‑L |
C09DA08
|
olmesartan medoxomil and diuretics
|
WHO Anatomical Therapeutic Chemical classification |
|
olmesartan medoxomil and diuretics |
| 0‑L |
C09DA09
|
azilsartan medoxomil and diuretics
|
WHO Anatomical Therapeutic Chemical classification |
|
azilsartan medoxomil and diuretics |
| 0‑L |
C09DB
|
Angiotensin II antagonists and calcium channel blockers
|
WHO Anatomical Therapeutic Chemical classification |
|
Angiotensin II antagonists and calcium channel blockers |
| 0‑L |
C09DB01
|
valsartan and amlodipine
|
WHO Anatomical Therapeutic Chemical classification |
|
valsartan and amlodipine |
| 0‑L |
C09DB02
|
olmesartan medoxomil and amlodipine
|
WHO Anatomical Therapeutic Chemical classification |
|
olmesartan medoxomil and amlodipine |
| 0‑L |
C09DB04
|
telmisartan and amlodipine
|
WHO Anatomical Therapeutic Chemical classification |
|
telmisartan and amlodipine |
| 0‑L |
C09DB05
|
irbesartan and amlodipine
|
WHO Anatomical Therapeutic Chemical classification |
|
irbesartan and amlodipine |
| 0‑L |
C09DB06
|
losartan and amlodipine
|
WHO Anatomical Therapeutic Chemical classification |
|
losartan and amlodipine |
| 0‑L |
C09DB07
|
candesartan and amlodipine
|
WHO Anatomical Therapeutic Chemical classification |
|
candesartan and amlodipine |
| 0‑L |
C09DB08
|
valsartan and lercanidipine
|
WHO Anatomical Therapeutic Chemical classification |
|
valsartan and lercanidipine |
| 0‑L |
C09DX
|
Angiotensin II antagonists, other combinations
|
WHO Anatomical Therapeutic Chemical classification |
|
Angiotensin II antagonists, other combinations |
| 0‑L |
C09DX01
|
valsartan, amlodipine and hydrochlorothiazide
|
WHO Anatomical Therapeutic Chemical classification |
|
valsartan, amlodipine and hydrochlorothiazide |
| 0‑L |
C09DX02
|
valsartan and aliskiren
|
WHO Anatomical Therapeutic Chemical classification |
|
valsartan and aliskiren |
| 0‑L |
C09DX03
|
olmesartan medoxomil, amlodipine and hydrochlorothiazide
|
WHO Anatomical Therapeutic Chemical classification |
|
olmesartan medoxomil, amlodipine and hydrochlorothiazide |
| 0‑L |
C09DX04
|
valsartan and sacubitril
|
WHO Anatomical Therapeutic Chemical classification |
|
valsartan and sacubitril |
| 0‑L |
C09X
|
OTHER AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM
|
WHO Anatomical Therapeutic Chemical classification |
|
OTHER AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM |
| 0‑L |
C09XA
|
Renin-inhibitors
|
WHO Anatomical Therapeutic Chemical classification |
|
Renin-inhibitors |
| 0‑L |
C09XA01
|
remikiren
|
WHO Anatomical Therapeutic Chemical classification |
|
remikiren |
| 0‑L |
C09XA02
|
aliskiren
|
WHO Anatomical Therapeutic Chemical classification |
|
aliskiren |
| 0‑L |
C09XA52
|
aliskiren and hydrochlorothiazide
|
WHO Anatomical Therapeutic Chemical classification |
|
aliskiren and hydrochlorothiazide |
| 0‑L |
C09XA53
|
aliskiren and amlodipine
|
WHO Anatomical Therapeutic Chemical classification |
|
aliskiren and amlodipine |
| 0‑L |
C09XA54
|
aliskiren, amlodipine and hydrochlorothiazide
|
WHO Anatomical Therapeutic Chemical classification |
|
aliskiren, amlodipine and hydrochlorothiazide |
| 0‑L |
C10
|
LIPID MODIFYING AGENTS
|
WHO Anatomical Therapeutic Chemical classification |
|
LIPID MODIFYING AGENTS |
| 0‑L |
C10A
|
LIPID MODIFYING AGENTS, PLAIN
|
WHO Anatomical Therapeutic Chemical classification |
|
LIPID MODIFYING AGENTS, PLAIN |
| 0‑L |
C10AA
|
HMG CoA reductase inhibitors
|
WHO Anatomical Therapeutic Chemical classification |
|
HMG CoA reductase inhibitors |
| 0‑L |
C10AA01
|
simvastatin
|
WHO Anatomical Therapeutic Chemical classification |
|
simvastatin |
| 0‑L |
C10AA02
|
lovastatin
|
WHO Anatomical Therapeutic Chemical classification |
|
lovastatin |
| 0‑L |
C10AA03
|
pravastatin
|
WHO Anatomical Therapeutic Chemical classification |
|
pravastatin |
| 0‑L |
C10AA04
|
fluvastatin
|
WHO Anatomical Therapeutic Chemical classification |
|
fluvastatin |
| 0‑L |
C10AA05
|
atorvastatin
|
WHO Anatomical Therapeutic Chemical classification |
|
atorvastatin |
| 0‑L |
C10AA06
|
cerivastatin
|
WHO Anatomical Therapeutic Chemical classification |
|
cerivastatin |
| 0‑L |
C10AA07
|
rosuvastatin
|
WHO Anatomical Therapeutic Chemical classification |
|
rosuvastatin |
| 0‑L |
C10AA08
|
pitavastatin
|
WHO Anatomical Therapeutic Chemical classification |
|
pitavastatin |
| 0‑L |
C10AB
|
Fibrates
|
WHO Anatomical Therapeutic Chemical classification |
|
Fibrates |
| 0‑L |
C10AB01
|
clofibrate
|
WHO Anatomical Therapeutic Chemical classification |
|
clofibrate |
| 0‑L |
C10AB02
|
bezafibrate
|
WHO Anatomical Therapeutic Chemical classification |
|
bezafibrate |
| 0‑L |
C10AB03
|
aluminium clofibrate
|
WHO Anatomical Therapeutic Chemical classification |
|
aluminium clofibrate |
| 0‑L |
C10AB04
|
gemfibrozil
|
WHO Anatomical Therapeutic Chemical classification |
|
gemfibrozil |
| 0‑L |
C10AB05
|
fenofibrate
|
WHO Anatomical Therapeutic Chemical classification |
|
fenofibrate |
| 0‑L |
C10AB06
|
simfibrate
|
WHO Anatomical Therapeutic Chemical classification |
|
simfibrate |
| 0‑L |
C10AB07
|
ronifibrate
|
WHO Anatomical Therapeutic Chemical classification |
|
ronifibrate |
| 0‑L |
C10AB08
|
ciprofibrate
|
WHO Anatomical Therapeutic Chemical classification |
|
ciprofibrate |
| 0‑L |
C10AB09
|
etofibrate
|
WHO Anatomical Therapeutic Chemical classification |
|
etofibrate |
| 0‑L |
C10AB10
|
clofibride
|
WHO Anatomical Therapeutic Chemical classification |
|
clofibride |
| 0‑L |
C10AB11
|
choline fenofibrate
|
WHO Anatomical Therapeutic Chemical classification |
|
choline fenofibrate |
| 0‑L |
C10AC
|
Bile acid sequestrants
|
WHO Anatomical Therapeutic Chemical classification |
|
Bile acid sequestrants |
| 0‑L |
C10AC01
|
colestyramine
|
WHO Anatomical Therapeutic Chemical classification |
|
colestyramine |
| 0‑L |
C10AC02
|
colestipol
|
WHO Anatomical Therapeutic Chemical classification |
|
colestipol |
| 0‑L |
C10AC03
|
colextran
|
WHO Anatomical Therapeutic Chemical classification |
|
colextran |
| 0‑L |
C10AC04
|
colesevelam
|
WHO Anatomical Therapeutic Chemical classification |
|
colesevelam |
| 0‑L |
C10AD
|
Nicotinic acid and derivatives
|
WHO Anatomical Therapeutic Chemical classification |
|
Nicotinic acid and derivatives |
| 0‑L |
C10AD01
|
niceritrol
|
WHO Anatomical Therapeutic Chemical classification |
|
niceritrol |
| 0‑L |
C10AD02
|
nicotinic acid
|
WHO Anatomical Therapeutic Chemical classification |
|
nicotinic acid |
| 0‑L |
C10AD03
|
nicofuranose
|
WHO Anatomical Therapeutic Chemical classification |
|
nicofuranose |
| 0‑L |
C10AD04
|
aluminium nicotinate
|
WHO Anatomical Therapeutic Chemical classification |
|
aluminium nicotinate |
| 0‑L |
C10AD05
|
nicotinyl alcohol (pyridylcarbinol)
|
WHO Anatomical Therapeutic Chemical classification |
|
nicotinyl alcohol (pyridylcarbinol) |
| 0‑L |
C10AD06
|
acipimox
|
WHO Anatomical Therapeutic Chemical classification |
|
acipimox |
| 0‑L |
C10AD52
|
nicotinic acid, combinations
|
WHO Anatomical Therapeutic Chemical classification |
|
nicotinic acid, combinations |
| 0‑L |
C10AX
|
Other lipid modifying agents
|
WHO Anatomical Therapeutic Chemical classification |
|
Other lipid modifying agents |
| 0‑L |
C10AX01
|
dextrothyroxine
|
WHO Anatomical Therapeutic Chemical classification |
|
dextrothyroxine |
| 0‑L |
C10AX02
|
probucol
|
WHO Anatomical Therapeutic Chemical classification |
|
probucol |
| 0‑L |
C10AX03
|
tiadenol
|
WHO Anatomical Therapeutic Chemical classification |
|
tiadenol |
| 0‑L |
C10AX05
|
meglutol
|
WHO Anatomical Therapeutic Chemical classification |
|
meglutol |
| 0‑L |
C10AX06
|
omega-3-triglycerides incl. other esters and acids
|
WHO Anatomical Therapeutic Chemical classification |
|
omega-3-triglycerides incl. other esters and acids |
| 0‑L |
C10AX07
|
magnesium pyridoxal 5-phosphate glutamate
|
WHO Anatomical Therapeutic Chemical classification |
|
magnesium pyridoxal 5-phosphate glutamate |
| 0‑L |
C10AX08
|
policosanol
|
WHO Anatomical Therapeutic Chemical classification |
|
policosanol |
| 0‑L |
C10AX09
|
ezetimibe
|
WHO Anatomical Therapeutic Chemical classification |
|
ezetimibe |
| 0‑L |
C10AX10
|
alipogene tiparvovec
|
WHO Anatomical Therapeutic Chemical classification |
|
alipogene tiparvovec |
| 0‑L |
C10AX11
|
mipomersen
|
WHO Anatomical Therapeutic Chemical classification |
|
mipomersen |
| 0‑L |
C10AX12
|
lomitapide
|
WHO Anatomical Therapeutic Chemical classification |
|
lomitapide |
| 0‑L |
C10AX13
|
evolocumab
|
WHO Anatomical Therapeutic Chemical classification |
|
evolocumab |
| 0‑L |
C10AX14
|
alirocumab
|
WHO Anatomical Therapeutic Chemical classification |
|
alirocumab |
| 0‑L |
C10B
|
LIPID MODIFYING AGENTS, COMBINATIONS
|
WHO Anatomical Therapeutic Chemical classification |
|
LIPID MODIFYING AGENTS, COMBINATIONS |
| 0‑L |
C10BA
|
HMG CoA reductase inhibitors in combination with other lipid modifying agents
|
WHO Anatomical Therapeutic Chemical classification |
|
HMG CoA reductase inhibitors in combination with other lipid modifying agents |
| 0‑L |
C10BA01
|
lovastatin and nicotinic acid
|
WHO Anatomical Therapeutic Chemical classification |
|
lovastatin and nicotinic acid |
| 0‑L |
C10BA02
|
simvastatin and ezetimibe
|
WHO Anatomical Therapeutic Chemical classification |
|
simvastatin and ezetimibe |
| 0‑L |
C10BA03
|
pravastatin and fenofibrate
|
WHO Anatomical Therapeutic Chemical classification |
|
pravastatin and fenofibrate |
| 0‑L |
C10BA04
|
simvastatin and fenofibrate
|
WHO Anatomical Therapeutic Chemical classification |
|
simvastatin and fenofibrate |
| 0‑L |
C10BA05
|
atorvastatin and ezetimibe
|
WHO Anatomical Therapeutic Chemical classification |
|
atorvastatin and ezetimibe |
| 0‑L |
C10BA06
|
rosuvastatin and ezetimibe
|
WHO Anatomical Therapeutic Chemical classification |
|
rosuvastatin and ezetimibe |
| 0‑L |
C10BX
|
HMG CoA reductase inhibitors, other combinations
|
WHO Anatomical Therapeutic Chemical classification |
|
HMG CoA reductase inhibitors, other combinations |
| 0‑L |
C10BX01
|
simvastatin and acetylsalicylic acid
|
WHO Anatomical Therapeutic Chemical classification |
|
simvastatin and acetylsalicylic acid |
| 0‑L |
C10BX02
|
pravastatin and acetylsalicylic acid
|
WHO Anatomical Therapeutic Chemical classification |
|
pravastatin and acetylsalicylic acid |
| 0‑L |
C10BX03
|
atorvastatin and amlodipine
|
WHO Anatomical Therapeutic Chemical classification |
|
atorvastatin and amlodipine |
| 0‑L |
C10BX04
|
simvastatin, acetylsalicylic acid and ramipril
|
WHO Anatomical Therapeutic Chemical classification |
|
simvastatin, acetylsalicylic acid and ramipril |
| 0‑L |
C10BX05
|
rosuvastatin and acetylsalicylic acid
|
WHO Anatomical Therapeutic Chemical classification |
|
rosuvastatin and acetylsalicylic acid |
| 0‑L |
C10BX06
|
atorvastatin, acetylsalicylic acid and ramipril
|
WHO Anatomical Therapeutic Chemical classification |
|
atorvastatin, acetylsalicylic acid and ramipril |
| 0‑L |
C10BX07
|
rosuvastatin, amlodipine and lisinopril
|
WHO Anatomical Therapeutic Chemical classification |
|
rosuvastatin, amlodipine and lisinopril |
| 0‑L |
C10BX08
|
atorvastatin and acetylsalicylic acid
|
WHO Anatomical Therapeutic Chemical classification |
|
atorvastatin and acetylsalicylic acid |
| 0‑L |
C10BX09
|
rosuvastatin and amlodipine
|
WHO Anatomical Therapeutic Chemical classification |
|
rosuvastatin and amlodipine |
| 0‑L |
C10BX10
|
rosuvastatin and valsartan
|
WHO Anatomical Therapeutic Chemical classification |
|
rosuvastatin and valsartan |
| 0‑L |
C10BX11
|
atorvastatin, amlodipine and perindopril
|
WHO Anatomical Therapeutic Chemical classification |
|
atorvastatin, amlodipine and perindopril |
| 0‑L |
C10BX12
|
atorvastatin, acetylsalicylic acid and perindopril
|
WHO Anatomical Therapeutic Chemical classification |
|
atorvastatin, acetylsalicylic acid and perindopril |
| 0‑L |
D
|
DERMATOLOGICALS
|
WHO Anatomical Therapeutic Chemical classification |
|
DERMATOLOGICALS |
| 0‑L |
D01
|
ANTIFUNGALS FOR DERMATOLOGICAL USE
|
WHO Anatomical Therapeutic Chemical classification |
|
ANTIFUNGALS FOR DERMATOLOGICAL USE |
| 0‑L |
D01A
|
ANTIFUNGALS FOR TOPICAL USE
|
WHO Anatomical Therapeutic Chemical classification |
|
ANTIFUNGALS FOR TOPICAL USE |
| 0‑L |
D01AA
|
Antibiotics
|
WHO Anatomical Therapeutic Chemical classification |
|
Antibiotics |
| 0‑L |
D01AA01
|
nystatin
|
WHO Anatomical Therapeutic Chemical classification |
|
nystatin |
| 0‑L |
D01AA02
|
natamycin
|
WHO Anatomical Therapeutic Chemical classification |
|
natamycin |
| 0‑L |
D01AA03
|
hachimycin
|
WHO Anatomical Therapeutic Chemical classification |
|
hachimycin |
| 0‑L |
D01AA04
|
pecilocin
|
WHO Anatomical Therapeutic Chemical classification |
|
pecilocin |
| 0‑L |
D01AA06
|
mepartricin
|
WHO Anatomical Therapeutic Chemical classification |
|
mepartricin |
| 0‑L |
D01AA07
|
pyrrolnitrin
|
WHO Anatomical Therapeutic Chemical classification |
|
pyrrolnitrin |
| 0‑L |
D01AA08
|
griseofulvin
|
WHO Anatomical Therapeutic Chemical classification |
|
griseofulvin |
| 0‑L |
D01AA20
|
combinations
|
WHO Anatomical Therapeutic Chemical classification |
|
combinations |
| 0‑L |
D01AC
|
Imidazole and triazole derivatives
|
WHO Anatomical Therapeutic Chemical classification |
|
Imidazole and triazole derivatives |
| 0‑L |
D01AC01
|
clotrimazole
|
WHO Anatomical Therapeutic Chemical classification |
|
clotrimazole |
| 0‑L |
D01AC02
|
miconazole
|
WHO Anatomical Therapeutic Chemical classification |
|
miconazole |
| 0‑L |
D01AC03
|
econazole
|
WHO Anatomical Therapeutic Chemical classification |
|
econazole |
| 0‑L |
D01AC04
|
chlormidazole
|
WHO Anatomical Therapeutic Chemical classification |
|
chlormidazole |
| 0‑L |
D01AC05
|
isoconazole
|
WHO Anatomical Therapeutic Chemical classification |
|
isoconazole |
| 0‑L |
D01AC06
|
tiabendazole
|
WHO Anatomical Therapeutic Chemical classification |
|
tiabendazole |
| 0‑L |
D01AC07
|
tioconazole
|
WHO Anatomical Therapeutic Chemical classification |
|
tioconazole |
| 0‑L |
D01AC08
|
ketoconazole
|
WHO Anatomical Therapeutic Chemical classification |
|
ketoconazole |
| 0‑L |
D01AC09
|
sulconazole
|
WHO Anatomical Therapeutic Chemical classification |
|
sulconazole |
| 0‑L |
D01AC10
|
bifonazole
|
WHO Anatomical Therapeutic Chemical classification |
|
bifonazole |
| 0‑L |
D01AC11
|
oxiconazole
|
WHO Anatomical Therapeutic Chemical classification |
|
oxiconazole |
| 0‑L |
D01AC12
|
fenticonazole
|
WHO Anatomical Therapeutic Chemical classification |
|
fenticonazole |
| 0‑L |
D01AC13
|
omoconazole
|
WHO Anatomical Therapeutic Chemical classification |
|
omoconazole |
| 0‑L |
D01AC14
|
sertaconazole
|
WHO Anatomical Therapeutic Chemical classification |
|
sertaconazole |
| 0‑L |
D01AC15
|
fluconazole
|
WHO Anatomical Therapeutic Chemical classification |
|
fluconazole |
| 0‑L |
D01AC16
|
flutrimazole
|
WHO Anatomical Therapeutic Chemical classification |
|
flutrimazole |
| 0‑L |
D01AC17
|
eberconazole
|
WHO Anatomical Therapeutic Chemical classification |
|
eberconazole |
| 0‑L |
D01AC18
|
luliconazole
|
WHO Anatomical Therapeutic Chemical classification |
|
luliconazole |
| 0‑L |
D01AC19
|
efinaconazole
|
WHO Anatomical Therapeutic Chemical classification |
|
efinaconazole |
| 0‑L |
D01AC20
|
imidazoles/triazoles in combination with corticosteroids
|
WHO Anatomical Therapeutic Chemical classification |
|
imidazoles/triazoles in combination with corticosteroids |
| 0‑L |
D01AC52
|
miconazole, combinations
|
WHO Anatomical Therapeutic Chemical classification |
|
miconazole, combinations |
| 0‑L |
D01AC60
|
bifonazole, combinations
|
WHO Anatomical Therapeutic Chemical classification |
|
bifonazole, combinations |
| 0‑L |
D01AE
|
Other antifungals for topical use
|
WHO Anatomical Therapeutic Chemical classification |
|
Other antifungals for topical use |
| 0‑L |
D01AE01
|
bromochlorosalicylanilide
|
WHO Anatomical Therapeutic Chemical classification |
|
bromochlorosalicylanilide |
| 0‑L |
D01AE02
|
methylrosaniline
|
WHO Anatomical Therapeutic Chemical classification |
|
methylrosaniline |
| 0‑L |
D01AE03
|
tribromometacresol
|
WHO Anatomical Therapeutic Chemical classification |
|
tribromometacresol |
| 0‑L |
D01AE04
|
undecylenic acid
|
WHO Anatomical Therapeutic Chemical classification |
|
undecylenic acid |
| 0‑L |
D01AE05
|
polynoxylin
|
WHO Anatomical Therapeutic Chemical classification |
|
polynoxylin |
| 0‑L |
D01AE06
|
2-(4-chlorphenoxy)-ethanol
|
WHO Anatomical Therapeutic Chemical classification |
|
2-(4-chlorphenoxy)-ethanol |
| 0‑L |
D01AE07
|
chlorphenesin
|
WHO Anatomical Therapeutic Chemical classification |
|
chlorphenesin |
| 0‑L |
D01AE08
|
ticlatone
|
WHO Anatomical Therapeutic Chemical classification |
|
ticlatone |
| 0‑L |
D01AE09
|
sulbentine
|
WHO Anatomical Therapeutic Chemical classification |
|
sulbentine |
| 0‑L |
D01AE10
|
ethyl hydroxybenzoate
|
WHO Anatomical Therapeutic Chemical classification |
|
ethyl hydroxybenzoate |
| 0‑L |
D01AE11
|
haloprogin
|
WHO Anatomical Therapeutic Chemical classification |
|
haloprogin |
| 0‑L |
D01AE12
|
salicylic acid
|
WHO Anatomical Therapeutic Chemical classification |
|
salicylic acid |
| 0‑L |
D01AE13
|
selenium sulfide
|
WHO Anatomical Therapeutic Chemical classification |
|
selenium sulfide |
| 0‑L |
D01AE14
|
ciclopirox
|
WHO Anatomical Therapeutic Chemical classification |
|
ciclopirox |
| 0‑L |
D01AE15
|
terbinafine
|
WHO Anatomical Therapeutic Chemical classification |
|
terbinafine |
| 0‑L |
D01AE16
|
amorolfine
|
WHO Anatomical Therapeutic Chemical classification |
|
amorolfine |
| 0‑L |
D01AE17
|
dimazole
|
WHO Anatomical Therapeutic Chemical classification |
|
dimazole |
| 0‑L |
D01AE18
|
tolnaftate
|
WHO Anatomical Therapeutic Chemical classification |
|
tolnaftate |
| 0‑L |
D01AE19
|
tolciclate
|
WHO Anatomical Therapeutic Chemical classification |
|
tolciclate |
| 0‑L |
D01AE20
|
combinations
|
WHO Anatomical Therapeutic Chemical classification |
|
combinations |
| 0‑L |
D01AE21
|
flucytosine
|
WHO Anatomical Therapeutic Chemical classification |
|
flucytosine |
| 0‑L |
D01AE22
|
naftifine
|
WHO Anatomical Therapeutic Chemical classification |
|
naftifine |
| 0‑L |
D01AE23
|
butenafine
|
WHO Anatomical Therapeutic Chemical classification |
|
butenafine |
| 0‑L |
D01AE54
|
undecylenic acid, combinations
|
WHO Anatomical Therapeutic Chemical classification |
|
undecylenic acid, combinations |
| 0‑L |
D01B
|
ANTIFUNGALS FOR SYSTEMIC USE
|
WHO Anatomical Therapeutic Chemical classification |
|
ANTIFUNGALS FOR SYSTEMIC USE |
| 0‑L |
D01BA
|
Antifungals for systemic use
|
WHO Anatomical Therapeutic Chemical classification |
|
Antifungals for systemic use |
| 0‑L |
D01BA01
|
griseofulvin
|
WHO Anatomical Therapeutic Chemical classification |
|
griseofulvin |
| 0‑L |
D01BA02
|
terbinafine
|
WHO Anatomical Therapeutic Chemical classification |
|
terbinafine |
| 0‑L |
D02
|
EMOLLIENTS AND PROTECTIVES
|
WHO Anatomical Therapeutic Chemical classification |
|
EMOLLIENTS AND PROTECTIVES |
| 0‑L |
D02A
|
EMOLLIENTS AND PROTECTIVES
|
WHO Anatomical Therapeutic Chemical classification |
|
EMOLLIENTS AND PROTECTIVES |
| 0‑L |
D02AA
|
Silicone products
|
WHO Anatomical Therapeutic Chemical classification |
|
Silicone products |
| 0‑L |
D02AB
|
Zinc products
|
WHO Anatomical Therapeutic Chemical classification |
|
Zinc products |
| 0‑L |
D02AC
|
Soft paraffin and fat products
|
WHO Anatomical Therapeutic Chemical classification |
|
Soft paraffin and fat products |
| 0‑L |
D02AD
|
Liquid plasters
|
WHO Anatomical Therapeutic Chemical classification |
|
Liquid plasters |
| 0‑L |
D02AE
|
Carbamide products
|
WHO Anatomical Therapeutic Chemical classification |
|
Carbamide products |
| 0‑L |
D02AE01
|
carbamide
|
WHO Anatomical Therapeutic Chemical classification |
|
carbamide |
| 0‑L |
D02AE51
|
carbamide, combinations
|
WHO Anatomical Therapeutic Chemical classification |
|
carbamide, combinations |
| 0‑L |
D02AF
|
Salicylic acid preparations
|
WHO Anatomical Therapeutic Chemical classification |
|
Salicylic acid preparations |
| 0‑L |
D02AX
|
Other emollients and protectives
|
WHO Anatomical Therapeutic Chemical classification |
|
Other emollients and protectives |
| 0‑L |
D02B
|
PROTECTIVES AGAINST UV-RADIATION
|
WHO Anatomical Therapeutic Chemical classification |
|
PROTECTIVES AGAINST UV-RADIATION |
| 0‑L |
D02BA
|
Protectives against UV-radiation for topical use
|
WHO Anatomical Therapeutic Chemical classification |
|
Protectives against UV-radiation for topical use |
| 0‑L |
D02BA01
|
aminobenzoic acid
|
WHO Anatomical Therapeutic Chemical classification |
|
aminobenzoic acid |
| 0‑L |
D02BA02
|
octinoxate
|
WHO Anatomical Therapeutic Chemical classification |
|
octinoxate |
| 0‑L |
D02BB
|
Protectives against UV-radiation for systemic use
|
WHO Anatomical Therapeutic Chemical classification |
|
Protectives against UV-radiation for systemic use |
| 0‑L |
D02BB01
|
betacarotene
|
WHO Anatomical Therapeutic Chemical classification |
|
betacarotene |
| 0‑L |
D02BB02
|
afamelanotide
|
WHO Anatomical Therapeutic Chemical classification |
|
afamelanotide |
| 0‑L |
D03
|
PREPARATIONS FOR TREATMENT OF WOUNDS AND ULCERS
|
WHO Anatomical Therapeutic Chemical classification |
|
PREPARATIONS FOR TREATMENT OF WOUNDS AND ULCERS |
| 0‑L |
D03A
|
CICATRIZANTS
|
WHO Anatomical Therapeutic Chemical classification |
|
CICATRIZANTS |
| 0‑L |
D03AA
|
Cod-liver oil ointments
|
WHO Anatomical Therapeutic Chemical classification |
|
Cod-liver oil ointments |
| 0‑L |
D03AX
|
Other cicatrizants
|
WHO Anatomical Therapeutic Chemical classification |
|
Other cicatrizants |
| 0‑L |
D03AX01
|
cadexomer iodine
|
WHO Anatomical Therapeutic Chemical classification |
|
cadexomer iodine |
| 0‑L |
D03AX02
|
dextranomer
|
WHO Anatomical Therapeutic Chemical classification |
|
dextranomer |
| 0‑L |
D03AX03
|
dexpanthenol
|
WHO Anatomical Therapeutic Chemical classification |
|
dexpanthenol |
| 0‑L |
D03AX04
|
calcium pantothenate
|
WHO Anatomical Therapeutic Chemical classification |
|
calcium pantothenate |
| 0‑L |
D03AX05
|
hyaluronic acid
|
WHO Anatomical Therapeutic Chemical classification |
|
hyaluronic acid |
| 0‑L |
D03AX06
|
becaplermin
|
WHO Anatomical Therapeutic Chemical classification |
|
becaplermin |
| 0‑L |
D03AX09
|
crilanomer
|
WHO Anatomical Therapeutic Chemical classification |
|
crilanomer |
| 0‑L |
D03AX10
|
enoxolone
|
WHO Anatomical Therapeutic Chemical classification |
|
enoxolone |
| 0‑L |
D03AX11
|
sodium chlorite
|
WHO Anatomical Therapeutic Chemical classification |
|
sodium chlorite |
| 0‑L |
D03AX12
|
trolamine
|
WHO Anatomical Therapeutic Chemical classification |
|
trolamine |
| 0‑L |
D03AX13
|
Betulae cortex
|
WHO Anatomical Therapeutic Chemical classification |
|
Betulae cortex |
| 0‑L |
D03B
|
ENZYMES
|
WHO Anatomical Therapeutic Chemical classification |
|
ENZYMES |
| 0‑L |
D03BA
|
Proteolytic enzymes
|
WHO Anatomical Therapeutic Chemical classification |
|
Proteolytic enzymes |
| 0‑L |
D03BA01
|
trypsin
|
WHO Anatomical Therapeutic Chemical classification |
|
trypsin |
| 0‑L |
D03BA02
|
collagenase
|
WHO Anatomical Therapeutic Chemical classification |
|
collagenase |
| 0‑L |
D03BA03
|
bromelains
|
WHO Anatomical Therapeutic Chemical classification |
|
bromelains |
| 0‑L |
D03BA52
|
collagenase, combinations
|
WHO Anatomical Therapeutic Chemical classification |
|
collagenase, combinations |
| 0‑L |
D04
|
ANTIPRURITICS, INCL. ANTIHISTAMINES, ANESTHETICS, ETC.
|
WHO Anatomical Therapeutic Chemical classification |
|
ANTIPRURITICS, INCL. ANTIHISTAMINES, ANESTHETICS, ETC. |
| 0‑L |
D04A
|
ANTIPRURITICS, INCL. ANTIHISTAMINES, ANESTHETICS, ETC.
|
WHO Anatomical Therapeutic Chemical classification |
|
ANTIPRURITICS, INCL. ANTIHISTAMINES, ANESTHETICS, ETC. |
| 0‑L |
D04AA
|
Antihistamines for topical use
|
WHO Anatomical Therapeutic Chemical classification |
|
Antihistamines for topical use |
| 0‑L |
D04AA01
|
thonzylamine
|
WHO Anatomical Therapeutic Chemical classification |
|
thonzylamine |
| 0‑L |
D04AA02
|
mepyramine
|
WHO Anatomical Therapeutic Chemical classification |
|
mepyramine |
| 0‑L |
D04AA03
|
thenalidine
|
WHO Anatomical Therapeutic Chemical classification |
|
thenalidine |
| 0‑L |
D04AA04
|
tripelennamine
|
WHO Anatomical Therapeutic Chemical classification |
|
tripelennamine |
| 0‑L |
D04AA09
|
chloropyramine
|
WHO Anatomical Therapeutic Chemical classification |
|
chloropyramine |
| 0‑L |
D04AA10
|
promethazine
|
WHO Anatomical Therapeutic Chemical classification |
|
promethazine |
| 0‑L |
D04AA12
|
tolpropamine
|
WHO Anatomical Therapeutic Chemical classification |
|
tolpropamine |
| 0‑L |
D04AA13
|
dimetindene
|
WHO Anatomical Therapeutic Chemical classification |
|
dimetindene |
| 0‑L |
D04AA14
|
clemastine
|
WHO Anatomical Therapeutic Chemical classification |
|
clemastine |
| 0‑L |
D04AA15
|
bamipine
|
WHO Anatomical Therapeutic Chemical classification |
|
bamipine |
| 0‑L |
D04AA16
|
pheniramine
|
WHO Anatomical Therapeutic Chemical classification |
|
pheniramine |
| 0‑L |
D04AA22
|
isothipendyl
|
WHO Anatomical Therapeutic Chemical classification |
|
isothipendyl |
| 0‑L |
D04AA32
|
diphenhydramine
|
WHO Anatomical Therapeutic Chemical classification |
|
diphenhydramine |
| 0‑L |
D04AA33
|
diphenhydramine methylbromide
|
WHO Anatomical Therapeutic Chemical classification |
|
diphenhydramine methylbromide |
| 0‑L |
D04AA34
|
chlorphenoxamine
|
WHO Anatomical Therapeutic Chemical classification |
|
chlorphenoxamine |
| 0‑L |
D04AB
|
Anesthetics for topical use
|
WHO Anatomical Therapeutic Chemical classification |
|
Anesthetics for topical use |
| 0‑L |
D04AB01
|
lidocaine
|
WHO Anatomical Therapeutic Chemical classification |
|
lidocaine |
| 0‑L |
D04AB02
|
cinchocaine
|
WHO Anatomical Therapeutic Chemical classification |
|
cinchocaine |
| 0‑L |
D04AB03
|
oxybuprocaine
|
WHO Anatomical Therapeutic Chemical classification |
|
oxybuprocaine |
| 0‑L |
D04AB04
|
benzocaine
|
WHO Anatomical Therapeutic Chemical classification |
|
benzocaine |
| 0‑L |
D04AB05
|
quinisocaine
|
WHO Anatomical Therapeutic Chemical classification |
|
quinisocaine |
| 0‑L |
D04AB06
|
tetracaine
|
WHO Anatomical Therapeutic Chemical classification |
|
tetracaine |
| 0‑L |
D04AB07
|
pramocaine
|
WHO Anatomical Therapeutic Chemical classification |
|
pramocaine |
| 0‑L |
D04AX
|
Other antipruritics
|
WHO Anatomical Therapeutic Chemical classification |
|
Other antipruritics |
| 0‑L |
D05
|
ANTIPSORIATICS
|
WHO Anatomical Therapeutic Chemical classification |
|
ANTIPSORIATICS |
| 0‑L |
D05A
|
ANTIPSORIATICS FOR TOPICAL USE
|
WHO Anatomical Therapeutic Chemical classification |
|
ANTIPSORIATICS FOR TOPICAL USE |
| 0‑L |
D05AA
|
Tars
|
WHO Anatomical Therapeutic Chemical classification |
|
Tars |
| 0‑L |
D05AC
|
Antracen derivatives
|
WHO Anatomical Therapeutic Chemical classification |
|
Antracen derivatives |
| 0‑L |
D05AC01
|
dithranol
|
WHO Anatomical Therapeutic Chemical classification |
|
dithranol |
| 0‑L |
D05AC51
|
dithranol, combinations
|
WHO Anatomical Therapeutic Chemical classification |
|
dithranol, combinations |
| 0‑L |
D05AD
|
Psoralens for topical use
|
WHO Anatomical Therapeutic Chemical classification |
|
Psoralens for topical use |
| 0‑L |
D05AD01
|
trioxysalen
|
WHO Anatomical Therapeutic Chemical classification |
|
trioxysalen |
| 0‑L |
D05AD02
|
methoxsalen
|
WHO Anatomical Therapeutic Chemical classification |
|
methoxsalen |
| 0‑L |
D05AX
|
Other antipsoriatics for topical use
|
WHO Anatomical Therapeutic Chemical classification |
|
Other antipsoriatics for topical use |
| 0‑L |
D05AX01
|
fumaric acid
|
WHO Anatomical Therapeutic Chemical classification |
|
fumaric acid |
| 0‑L |
D05AX02
|
calcipotriol
|
WHO Anatomical Therapeutic Chemical classification |
|
calcipotriol |
| 0‑L |
D05AX03
|
calcitriol
|
WHO Anatomical Therapeutic Chemical classification |
|
calcitriol |
| 0‑L |
D05AX04
|
tacalcitol
|
WHO Anatomical Therapeutic Chemical classification |
|
tacalcitol |
| 0‑L |
D05AX05
|
tazarotene
|
WHO Anatomical Therapeutic Chemical classification |
|
tazarotene |
| 0‑L |
D05AX52
|
calcipotriol, combinations
|
WHO Anatomical Therapeutic Chemical classification |
|
calcipotriol, combinations |
| 0‑L |
D05B
|
ANTIPSORIATICS FOR SYSTEMIC USE
|
WHO Anatomical Therapeutic Chemical classification |
|
ANTIPSORIATICS FOR SYSTEMIC USE |
| 0‑L |
D05BA
|
Psoralens for systemic use
|
WHO Anatomical Therapeutic Chemical classification |
|
Psoralens for systemic use |
| 0‑L |
D05BA01
|
trioxysalen
|
WHO Anatomical Therapeutic Chemical classification |
|
trioxysalen |
| 0‑L |
D05BA02
|
methoxsalen
|
WHO Anatomical Therapeutic Chemical classification |
|
methoxsalen |
| 0‑L |
D05BA03
|
bergapten
|
WHO Anatomical Therapeutic Chemical classification |
|
bergapten |
| 0‑L |
D05BB
|
Retinoids for treatment of psoriasis
|
WHO Anatomical Therapeutic Chemical classification |
|
Retinoids for treatment of psoriasis |
| 0‑L |
D05BB01
|
etretinate
|
WHO Anatomical Therapeutic Chemical classification |
|
etretinate |
| 0‑L |
D05BB02
|
acitretin
|
WHO Anatomical Therapeutic Chemical classification |
|
acitretin |
| 0‑L |
D05BX
|
Other antipsoriatics for systemic use
|
WHO Anatomical Therapeutic Chemical classification |
|
Other antipsoriatics for systemic use |
| 0‑L |
D05BX51
|
fumaric acid derivatives, combinations
|
WHO Anatomical Therapeutic Chemical classification |
|
fumaric acid derivatives, combinations |
| 0‑L |
D06
|
ANTIBIOTICS AND CHEMOTHERAPEUTICS FOR DERMATOLOGICAL USE
|
WHO Anatomical Therapeutic Chemical classification |
|
ANTIBIOTICS AND CHEMOTHERAPEUTICS FOR DERMATOLOGICAL USE |
| 0‑L |
D06A
|
ANTIBIOTICS FOR TOPICAL USE
|
WHO Anatomical Therapeutic Chemical classification |
|
ANTIBIOTICS FOR TOPICAL USE |
| 0‑L |
D06AA
|
Tetracycline and derivatives
|
WHO Anatomical Therapeutic Chemical classification |
|
Tetracycline and derivatives |
| 0‑L |
D06AA01
|
demeclocycline
|
WHO Anatomical Therapeutic Chemical classification |
|
demeclocycline |
| 0‑L |
D06AA02
|
chlortetracycline
|
WHO Anatomical Therapeutic Chemical classification |
|
chlortetracycline |
| 0‑L |
D06AA03
|
oxytetracycline
|
WHO Anatomical Therapeutic Chemical classification |
|
oxytetracycline |
| 0‑L |
D06AA04
|
tetracycline
|
WHO Anatomical Therapeutic Chemical classification |
|
tetracycline |
| 0‑L |
D06AX
|
Other antibiotics for topical use
|
WHO Anatomical Therapeutic Chemical classification |
|
Other antibiotics for topical use |
| 0‑L |
D06AX01
|
fusidic acid
|
WHO Anatomical Therapeutic Chemical classification |
|
fusidic acid |
| 0‑L |
D06AX02
|
chloramphenicol
|
WHO Anatomical Therapeutic Chemical classification |
|
chloramphenicol |
| 0‑L |
D06AX04
|
neomycin
|
WHO Anatomical Therapeutic Chemical classification |
|
neomycin |
| 0‑L |
D06AX05
|
bacitracin
|
WHO Anatomical Therapeutic Chemical classification |
|
bacitracin |
| 0‑L |
D06AX07
|
gentamicin
|
WHO Anatomical Therapeutic Chemical classification |
|
gentamicin |
| 0‑L |
D06AX08
|
tyrothricin
|
WHO Anatomical Therapeutic Chemical classification |
|
tyrothricin |
| 0‑L |
D06AX09
|
mupirocin
|
WHO Anatomical Therapeutic Chemical classification |
|
mupirocin |
| 0‑L |
D06AX10
|
virginiamycin
|
WHO Anatomical Therapeutic Chemical classification |
|
virginiamycin |
| 0‑L |
D06AX11
|
rifaximin
|
WHO Anatomical Therapeutic Chemical classification |
|
rifaximin |
| 0‑L |
D06AX12
|
amikacin
|
WHO Anatomical Therapeutic Chemical classification |
|
amikacin |
| 0‑L |
D06AX13
|
retapamulin
|
WHO Anatomical Therapeutic Chemical classification |
|
retapamulin |
| 0‑L |
D06B
|
CHEMOTHERAPEUTICS FOR TOPICAL USE
|
WHO Anatomical Therapeutic Chemical classification |
|
CHEMOTHERAPEUTICS FOR TOPICAL USE |
| 0‑L |
D06BA
|
Sulfonamides
|
WHO Anatomical Therapeutic Chemical classification |
|
Sulfonamides |
| 0‑L |
D06BA01
|
silver sulfadiazine
|
WHO Anatomical Therapeutic Chemical classification |
|
silver sulfadiazine |
| 0‑L |
D06BA02
|
sulfathiazole
|
WHO Anatomical Therapeutic Chemical classification |
|
sulfathiazole |
| 0‑L |
D06BA03
|
mafenide
|
WHO Anatomical Therapeutic Chemical classification |
|
mafenide |
| 0‑L |
D06BA04
|
sulfamethizole
|
WHO Anatomical Therapeutic Chemical classification |
|
sulfamethizole |
| 0‑L |
D06BA05
|
sulfanilamide
|
WHO Anatomical Therapeutic Chemical classification |
|
sulfanilamide |
| 0‑L |
D06BA06
|
sulfamerazine
|
WHO Anatomical Therapeutic Chemical classification |
|
sulfamerazine |
| 0‑L |
D06BA51
|
silver sulfadiazine, combinations
|
WHO Anatomical Therapeutic Chemical classification |
|
silver sulfadiazine, combinations |
| 0‑L |
D06BB
|
Antivirals
|
WHO Anatomical Therapeutic Chemical classification |
|
Antivirals |
| 0‑L |
D06BB01
|
idoxuridine
|
WHO Anatomical Therapeutic Chemical classification |
|
idoxuridine |
| 0‑L |
D06BB02
|
tromantadine
|
WHO Anatomical Therapeutic Chemical classification |
|
tromantadine |
| 0‑L |
D06BB03
|
aciclovir
|
WHO Anatomical Therapeutic Chemical classification |
|
aciclovir |
| 0‑L |
D06BB04
|
podophyllotoxin
|
WHO Anatomical Therapeutic Chemical classification |
|
podophyllotoxin |
| 0‑L |
D06BB05
|
inosine
|
WHO Anatomical Therapeutic Chemical classification |
|
inosine |
| 0‑L |
D06BB06
|
penciclovir
|
WHO Anatomical Therapeutic Chemical classification |
|
penciclovir |
| 0‑L |
D06BB07
|
lysozyme
|
WHO Anatomical Therapeutic Chemical classification |
|
lysozyme |
| 0‑L |
D06BB08
|
ibacitabine
|
WHO Anatomical Therapeutic Chemical classification |
|
ibacitabine |
| 0‑L |
D06BB09
|
edoxudine
|
WHO Anatomical Therapeutic Chemical classification |
|
edoxudine |
| 0‑L |
D06BB10
|
imiquimod
|
WHO Anatomical Therapeutic Chemical classification |
|
imiquimod |
| 0‑L |
D06BB11
|
docosanol
|
WHO Anatomical Therapeutic Chemical classification |
|
docosanol |
| 0‑L |
D06BB12
|
sinecatechins
|
WHO Anatomical Therapeutic Chemical classification |
|
sinecatechins |
| 0‑L |
D06BB53
|
aciclovir, combinations
|
WHO Anatomical Therapeutic Chemical classification |
|
aciclovir, combinations |
| 0‑L |
D06BX
|
Other chemotherapeutics
|
WHO Anatomical Therapeutic Chemical classification |
|
Other chemotherapeutics |
| 0‑L |
D06BX01
|
metronidazole
|
WHO Anatomical Therapeutic Chemical classification |
|
metronidazole |
| 0‑L |
D06BX02
|
ingenol mebutate
|
WHO Anatomical Therapeutic Chemical classification |
|
ingenol mebutate |
| 0‑L |
D06C
|
ANTIBIOTICS AND CHEMOTHERAPEUTICS, COMBINATIONS
|
WHO Anatomical Therapeutic Chemical classification |
|
ANTIBIOTICS AND CHEMOTHERAPEUTICS, COMBINATIONS |
| 0‑L |
D07
|
CORTICOSTEROIDS, DERMATOLOGICAL PREPARATIONS
|
WHO Anatomical Therapeutic Chemical classification |
|
CORTICOSTEROIDS, DERMATOLOGICAL PREPARATIONS |
| 0‑L |
D07A
|
CORTICOSTEROIDS, PLAIN
|
WHO Anatomical Therapeutic Chemical classification |
|
CORTICOSTEROIDS, PLAIN |
| 0‑L |
D07AA
|
Corticosteroids, weak (group I)
|
WHO Anatomical Therapeutic Chemical classification |
|
Corticosteroids, weak (group I) |
| 0‑L |
D07AA01
|
methylprednisolone
|
WHO Anatomical Therapeutic Chemical classification |
|
methylprednisolone |
| 0‑L |
D07AA02
|
hydrocortisone
|
WHO Anatomical Therapeutic Chemical classification |
|
hydrocortisone |
| 0‑L |
D07AA03
|
prednisolone
|
WHO Anatomical Therapeutic Chemical classification |
|
prednisolone |
| 0‑L |
D07AB
|
Corticosteroids, moderately potent (group II)
|
WHO Anatomical Therapeutic Chemical classification |
|
Corticosteroids, moderately potent (group II) |
| 0‑L |
D07AB01
|
clobetasone
|
WHO Anatomical Therapeutic Chemical classification |
|
clobetasone |
| 0‑L |
D07AB02
|
hydrocortisone butyrate
|
WHO Anatomical Therapeutic Chemical classification |
|
hydrocortisone butyrate |
| 0‑L |
D07AB03
|
flumetasone
|
WHO Anatomical Therapeutic Chemical classification |
|
flumetasone |
| 0‑L |
D07AB04
|
fluocortin
|
WHO Anatomical Therapeutic Chemical classification |
|
fluocortin |
| 0‑L |
D07AB05
|
fluperolone
|
WHO Anatomical Therapeutic Chemical classification |
|
fluperolone |
| 0‑L |
D07AB06
|
fluorometholone
|
WHO Anatomical Therapeutic Chemical classification |
|
fluorometholone |
| 0‑L |
D07AB07
|
fluprednidene
|
WHO Anatomical Therapeutic Chemical classification |
|
fluprednidene |
| 0‑L |
D07AB08
|
desonide
|
WHO Anatomical Therapeutic Chemical classification |
|
desonide |
| 0‑L |
D07AB09
|
triamcinolone
|
WHO Anatomical Therapeutic Chemical classification |
|
triamcinolone |
| 0‑L |
D07AB10
|
alclometasone
|
WHO Anatomical Therapeutic Chemical classification |
|
alclometasone |
| 0‑L |
D07AB11
|
hydrocortisone buteprate
|
WHO Anatomical Therapeutic Chemical classification |
|
hydrocortisone buteprate |
| 0‑L |
D07AB19
|
dexamethasone
|
WHO Anatomical Therapeutic Chemical classification |
|
dexamethasone |
| 0‑L |
D07AB21
|
clocortolone
|
WHO Anatomical Therapeutic Chemical classification |
|
clocortolone |
| 0‑L |
D07AB30
|
combinations of corticosteroids
|
WHO Anatomical Therapeutic Chemical classification |
|
combinations of corticosteroids |
| 0‑L |
D07AC
|
Corticosteroids, potent (group III)
|
WHO Anatomical Therapeutic Chemical classification |
|
Corticosteroids, potent (group III) |
| 0‑L |
D07AC01
|
betamethasone
|
WHO Anatomical Therapeutic Chemical classification |
|
betamethasone |
| 0‑L |
D07AC02
|
fluclorolone
|
WHO Anatomical Therapeutic Chemical classification |
|
fluclorolone |
| 0‑L |
D07AC03
|
desoximetasone
|
WHO Anatomical Therapeutic Chemical classification |
|
desoximetasone |
| 0‑L |
D07AC04
|
fluocinolone acetonide
|
WHO Anatomical Therapeutic Chemical classification |
|
fluocinolone acetonide |
| 0‑L |
D07AC05
|
fluocortolone
|
WHO Anatomical Therapeutic Chemical classification |
|
fluocortolone |
| 0‑L |
D07AC06
|
diflucortolone
|
WHO Anatomical Therapeutic Chemical classification |
|
diflucortolone |
| 0‑L |
D07AC07
|
fludroxycortide
|
WHO Anatomical Therapeutic Chemical classification |
|
fludroxycortide |
| 0‑L |
D07AC08
|
fluocinonide
|
WHO Anatomical Therapeutic Chemical classification |
|
fluocinonide |
| 0‑L |
D07AC09
|
budesonide
|
WHO Anatomical Therapeutic Chemical classification |
|
budesonide |
| 0‑L |
D07AC10
|
diflorasone
|
WHO Anatomical Therapeutic Chemical classification |
|
diflorasone |
| 0‑L |
D07AC11
|
amcinonide
|
WHO Anatomical Therapeutic Chemical classification |
|
amcinonide |
| 0‑L |
D07AC12
|
halometasone
|
WHO Anatomical Therapeutic Chemical classification |
|
halometasone |
| 0‑L |
D07AC13
|
mometasone
|
WHO Anatomical Therapeutic Chemical classification |
|
mometasone |
| 0‑L |
D07AC14
|
methylprednisolone aceponate
|
WHO Anatomical Therapeutic Chemical classification |
|
methylprednisolone aceponate |
| 0‑L |
D07AC15
|
beclometasone
|
WHO Anatomical Therapeutic Chemical classification |
|
beclometasone |
| 0‑L |
D07AC16
|
hydrocortisone aceponate
|
WHO Anatomical Therapeutic Chemical classification |
|
hydrocortisone aceponate |
| 0‑L |
D07AC17
|
fluticasone
|
WHO Anatomical Therapeutic Chemical classification |
|
fluticasone |
| 0‑L |
D07AC18
|
prednicarbate
|
WHO Anatomical Therapeutic Chemical classification |
|
prednicarbate |
| 0‑L |
D07AC19
|
difluprednate
|
WHO Anatomical Therapeutic Chemical classification |
|
difluprednate |
| 0‑L |
D07AC21
|
ulobetasol
|
WHO Anatomical Therapeutic Chemical classification |
|
ulobetasol |
| 0‑L |
D07AD
|
Corticosteroids, very potent (group IV)
|
WHO Anatomical Therapeutic Chemical classification |
|
Corticosteroids, very potent (group IV) |
| 0‑L |
D07AD01
|
clobetasol
|
WHO Anatomical Therapeutic Chemical classification |
|
clobetasol |
| 0‑L |
D07AD02
|
halcinonide
|
WHO Anatomical Therapeutic Chemical classification |
|
halcinonide |
| 0‑L |
D07B
|
CORTICOSTEROIDS, COMBINATIONS WITH ANTISEPTICS
|
WHO Anatomical Therapeutic Chemical classification |
|
CORTICOSTEROIDS, COMBINATIONS WITH ANTISEPTICS |
| 0‑L |
D07BA
|
Corticosteroids, weak, combinations with antiseptics
|
WHO Anatomical Therapeutic Chemical classification |
|
Corticosteroids, weak, combinations with antiseptics |
| 0‑L |
D07BA01
|
prednisolone and antiseptics
|
WHO Anatomical Therapeutic Chemical classification |
|
prednisolone and antiseptics |
| 0‑L |
D07BA04
|
hydrocortisone and antiseptics
|
WHO Anatomical Therapeutic Chemical classification |
|
hydrocortisone and antiseptics |
| 0‑L |
D07BB
|
Corticosteroids, moderately potent, combinations with antiseptics
|
WHO Anatomical Therapeutic Chemical classification |
|
Corticosteroids, moderately potent, combinations with antiseptics |
| 0‑L |
D07BB01
|
flumetasone and antiseptics
|
WHO Anatomical Therapeutic Chemical classification |
|
flumetasone and antiseptics |
| 0‑L |
D07BB02
|
desonide and antiseptics
|
WHO Anatomical Therapeutic Chemical classification |
|
desonide and antiseptics |
| 0‑L |
D07BB03
|
triamcinolone and antiseptics
|
WHO Anatomical Therapeutic Chemical classification |
|
triamcinolone and antiseptics |
| 0‑L |
D07BB04
|
hydrocortisone butyrate and antiseptics
|
WHO Anatomical Therapeutic Chemical classification |
|
hydrocortisone butyrate and antiseptics |
| 0‑L |
D07BC
|
Corticosteroids, potent, combinations with antiseptics
|
WHO Anatomical Therapeutic Chemical classification |
|
Corticosteroids, potent, combinations with antiseptics |
| 0‑L |
D07BC01
|
betamethasone and antiseptics
|
WHO Anatomical Therapeutic Chemical classification |
|
betamethasone and antiseptics |
| 0‑L |
D07BC02
|
fluocinolone acetonide and antiseptics
|
WHO Anatomical Therapeutic Chemical classification |
|
fluocinolone acetonide and antiseptics |
| 0‑L |
D07BC03
|
fluocortolone and antiseptics
|
WHO Anatomical Therapeutic Chemical classification |
|
fluocortolone and antiseptics |
| 0‑L |
D07BC04
|
diflucortolone and antiseptics
|
WHO Anatomical Therapeutic Chemical classification |
|
diflucortolone and antiseptics |
| 0‑L |
D07BD
|
Corticosteroids, very potent, combinations with antiseptics
|
WHO Anatomical Therapeutic Chemical classification |
|
Corticosteroids, very potent, combinations with antiseptics |
| 0‑L |
D07C
|
CORTICOSTEROIDS, COMBINATIONS WITH ANTIBIOTICS
|
WHO Anatomical Therapeutic Chemical classification |
|
CORTICOSTEROIDS, COMBINATIONS WITH ANTIBIOTICS |
| 0‑L |
D07CA
|
Corticosteroids, weak, combinations with antibiotics
|
WHO Anatomical Therapeutic Chemical classification |
|
Corticosteroids, weak, combinations with antibiotics |
| 0‑L |
D07CA01
|
hydrocortisone and antibiotics
|
WHO Anatomical Therapeutic Chemical classification |
|
hydrocortisone and antibiotics |
| 0‑L |
D07CA02
|
methylprednisolone and antibiotics
|
WHO Anatomical Therapeutic Chemical classification |
|
methylprednisolone and antibiotics |
| 0‑L |
D07CA03
|
prednisolone and antibiotics
|
WHO Anatomical Therapeutic Chemical classification |
|
prednisolone and antibiotics |
| 0‑L |
D07CB
|
Corticosteroids, moderately potent, combinations with antibiotics
|
WHO Anatomical Therapeutic Chemical classification |
|
Corticosteroids, moderately potent, combinations with antibiotics |
| 0‑L |
D07CB01
|
triamcinolone and antibiotics
|
WHO Anatomical Therapeutic Chemical classification |
|
triamcinolone and antibiotics |
| 0‑L |
D07CB02
|
fluprednidene and antibiotics
|
WHO Anatomical Therapeutic Chemical classification |
|
fluprednidene and antibiotics |
| 0‑L |
D07CB03
|
fluorometholone and antibiotics
|
WHO Anatomical Therapeutic Chemical classification |
|
fluorometholone and antibiotics |
| 0‑L |
D07CB04
|
dexamethasone and antibiotics
|
WHO Anatomical Therapeutic Chemical classification |
|
dexamethasone and antibiotics |
| 0‑L |
D07CB05
|
flumetasone and antibiotics
|
WHO Anatomical Therapeutic Chemical classification |
|
flumetasone and antibiotics |
| 0‑L |
D07CC
|
Corticosteroids, potent, combinations with antibiotics
|
WHO Anatomical Therapeutic Chemical classification |
|
Corticosteroids, potent, combinations with antibiotics |
| 0‑L |
D07CC01
|
betamethasone and antibiotics
|
WHO Anatomical Therapeutic Chemical classification |
|
betamethasone and antibiotics |
| 0‑L |
D07CC02
|
fluocinolone acetonide and antibiotics
|
WHO Anatomical Therapeutic Chemical classification |
|
fluocinolone acetonide and antibiotics |
| 0‑L |
D07CC03
|
fludroxycortide and antibiotics
|
WHO Anatomical Therapeutic Chemical classification |
|
fludroxycortide and antibiotics |
| 0‑L |
D07CC04
|
beclometasone and antibiotics
|
WHO Anatomical Therapeutic Chemical classification |
|
beclometasone and antibiotics |
| 0‑L |
D07CC05
|
fluocinonide and antibiotics
|
WHO Anatomical Therapeutic Chemical classification |
|
fluocinonide and antibiotics |
| 0‑L |
D07CC06
|
fluocortolone and antibiotics
|
WHO Anatomical Therapeutic Chemical classification |
|
fluocortolone and antibiotics |
| 0‑L |
D07CD
|
Corticosteroids, very potent, combinations with antibiotics
|
WHO Anatomical Therapeutic Chemical classification |
|
Corticosteroids, very potent, combinations with antibiotics |
| 0‑L |
D07CD01
|
clobetasol and antibiotics
|
WHO Anatomical Therapeutic Chemical classification |
|
clobetasol and antibiotics |
| 0‑L |
D07X
|
CORTICOSTEROIDS, OTHER COMBINATIONS
|
WHO Anatomical Therapeutic Chemical classification |
|
CORTICOSTEROIDS, OTHER COMBINATIONS |
| 0‑L |
D07XA
|
Corticosteroids, weak, other combinations
|
WHO Anatomical Therapeutic Chemical classification |
|
Corticosteroids, weak, other combinations |
| 0‑L |
D07XA01
|
hydrocortisone
|
WHO Anatomical Therapeutic Chemical classification |
|
hydrocortisone |
| 0‑L |
D07XA02
|
prednisolone
|
WHO Anatomical Therapeutic Chemical classification |
|
prednisolone |
| 0‑L |
D07XB
|
Corticosteroids, moderately potent, other combinations
|
WHO Anatomical Therapeutic Chemical classification |
|
Corticosteroids, moderately potent, other combinations |
| 0‑L |
D07XB01
|
flumetasone
|
WHO Anatomical Therapeutic Chemical classification |
|
flumetasone |
| 0‑L |
D07XB02
|
triamcinolone
|
WHO Anatomical Therapeutic Chemical classification |
|
triamcinolone |
| 0‑L |
D07XB03
|
fluprednidene
|
WHO Anatomical Therapeutic Chemical classification |
|
fluprednidene |
| 0‑L |
D07XB04
|
fluorometholone
|
WHO Anatomical Therapeutic Chemical classification |
|
fluorometholone |
| 0‑L |
D07XB05
|
dexamethasone
|
WHO Anatomical Therapeutic Chemical classification |
|
dexamethasone |
| 0‑L |
D07XB30
|
combinations of corticosteroids
|
WHO Anatomical Therapeutic Chemical classification |
|
combinations of corticosteroids |
| 0‑L |
D07XC
|
Corticosteroids, potent, other combinations
|
WHO Anatomical Therapeutic Chemical classification |
|
Corticosteroids, potent, other combinations |
| 0‑L |
D07XC01
|
betamethasone
|
WHO Anatomical Therapeutic Chemical classification |
|
betamethasone |
| 0‑L |
D07XC02
|
desoximetasone
|
WHO Anatomical Therapeutic Chemical classification |
|
desoximetasone |
| 0‑L |
D07XC03
|
mometasone
|
WHO Anatomical Therapeutic Chemical classification |
|
mometasone |
| 0‑L |
D07XC04
|
diflucortolone
|
WHO Anatomical Therapeutic Chemical classification |
|
diflucortolone |
| 0‑L |
D07XC05
|
fluocortolone
|
WHO Anatomical Therapeutic Chemical classification |
|
fluocortolone |
| 0‑L |
D07XD
|
Corticosteroids, very potent, other combinations
|
WHO Anatomical Therapeutic Chemical classification |
|
Corticosteroids, very potent, other combinations |
| 0‑L |
D08
|
ANTISEPTICS AND DISINFECTANTS
|
WHO Anatomical Therapeutic Chemical classification |
|
ANTISEPTICS AND DISINFECTANTS |
| 0‑L |
D08A
|
ANTISEPTICS AND DISINFECTANTS
|
WHO Anatomical Therapeutic Chemical classification |
|
ANTISEPTICS AND DISINFECTANTS |
| 0‑L |
D08AA
|
Acridine derivatives
|
WHO Anatomical Therapeutic Chemical classification |
|
Acridine derivatives |
| 0‑L |
D08AA01
|
ethacridine lactate
|
WHO Anatomical Therapeutic Chemical classification |
|
ethacridine lactate |
| 0‑L |
D08AA02
|
aminoacridine
|
WHO Anatomical Therapeutic Chemical classification |
|
aminoacridine |
| 0‑L |
D08AA03
|
euflavine
|
WHO Anatomical Therapeutic Chemical classification |
|
euflavine |
| 0‑L |
D08AB
|
Aluminium agents
|
WHO Anatomical Therapeutic Chemical classification |
|
Aluminium agents |
| 0‑L |
D08AC
|
Biguanides and amidines
|
WHO Anatomical Therapeutic Chemical classification |
|
Biguanides and amidines |
| 0‑L |
D08AC01
|
dibrompropamidine
|
WHO Anatomical Therapeutic Chemical classification |
|
dibrompropamidine |
| 0‑L |
D08AC02
|
chlorhexidine
|
WHO Anatomical Therapeutic Chemical classification |
|
chlorhexidine |
| 0‑L |
D08AC03
|
propamidine
|
WHO Anatomical Therapeutic Chemical classification |
|
propamidine |
| 0‑L |
D08AC04
|
hexamidine
|
WHO Anatomical Therapeutic Chemical classification |
|
hexamidine |
| 0‑L |
D08AC05
|
polihexanide
|
WHO Anatomical Therapeutic Chemical classification |
|
polihexanide |
| 0‑L |
D08AC52
|
chlorhexidine, combinations
|
WHO Anatomical Therapeutic Chemical classification |
|
chlorhexidine, combinations |
| 0‑L |
D08AD
|
Boric acid products
|
WHO Anatomical Therapeutic Chemical classification |
|
Boric acid products |
| 0‑L |
D08AE
|
Phenol and derivatives
|
WHO Anatomical Therapeutic Chemical classification |
|
Phenol and derivatives |
| 0‑L |
D08AE01
|
hexachlorophene
|
WHO Anatomical Therapeutic Chemical classification |
|
hexachlorophene |
| 0‑L |
D08AE02
|
policresulen
|
WHO Anatomical Therapeutic Chemical classification |
|
policresulen |
| 0‑L |
D08AE03
|
phenol
|
WHO Anatomical Therapeutic Chemical classification |
|
phenol |
| 0‑L |
D08AE04
|
triclosan
|
WHO Anatomical Therapeutic Chemical classification |
|
triclosan |
| 0‑L |
D08AE05
|
chloroxylenol
|
WHO Anatomical Therapeutic Chemical classification |
|
chloroxylenol |
| 0‑L |
D08AE06
|
biphenylol
|
WHO Anatomical Therapeutic Chemical classification |
|
biphenylol |
| 0‑L |
D08AF
|
Nitrofuran derivatives
|
WHO Anatomical Therapeutic Chemical classification |
|
Nitrofuran derivatives |
| 0‑L |
D08AF01
|
nitrofural
|
WHO Anatomical Therapeutic Chemical classification |
|
nitrofural |
| 0‑L |
D08AG
|
Iodine products
|
WHO Anatomical Therapeutic Chemical classification |
|
Iodine products |
| 0‑L |
D08AG01
|
iodine/octylphenoxypolyglycolether
|
WHO Anatomical Therapeutic Chemical classification |
|
iodine/octylphenoxypolyglycolether |
| 0‑L |
D08AG02
|
povidone-iodine
|
WHO Anatomical Therapeutic Chemical classification |
|
povidone-iodine |
| 0‑L |
D08AG03
|
iodine
|
WHO Anatomical Therapeutic Chemical classification |
|
iodine |
| 0‑L |
D08AG04
|
diiodohydroxypropane
|
WHO Anatomical Therapeutic Chemical classification |
|
diiodohydroxypropane |
| 0‑L |
D08AH
|
Quinoline derivatives
|
WHO Anatomical Therapeutic Chemical classification |
|
Quinoline derivatives |
| 0‑L |
D08AH01
|
dequalinium
|
WHO Anatomical Therapeutic Chemical classification |
|
dequalinium |
| 0‑L |
D08AH02
|
chlorquinaldol
|
WHO Anatomical Therapeutic Chemical classification |
|
chlorquinaldol |
| 0‑L |
D08AH03
|
oxyquinoline
|
WHO Anatomical Therapeutic Chemical classification |
|
oxyquinoline |
| 0‑L |
D08AH30
|
clioquinol
|
WHO Anatomical Therapeutic Chemical classification |
|
clioquinol |
| 0‑L |
D08AJ
|
Quaternary ammonium compounds
|
WHO Anatomical Therapeutic Chemical classification |
|
Quaternary ammonium compounds |
| 0‑L |
D08AJ01
|
benzalkonium
|
WHO Anatomical Therapeutic Chemical classification |
|
benzalkonium |
| 0‑L |
D08AJ02
|
cetrimonium
|
WHO Anatomical Therapeutic Chemical classification |
|
cetrimonium |
| 0‑L |
D08AJ03
|
cetylpyridinium
|
WHO Anatomical Therapeutic Chemical classification |
|
cetylpyridinium |
| 0‑L |
D08AJ04
|
cetrimide
|
WHO Anatomical Therapeutic Chemical classification |
|
cetrimide |
| 0‑L |
D08AJ05
|
benzoxonium chloride
|
WHO Anatomical Therapeutic Chemical classification |
|
benzoxonium chloride |
| 0‑L |
D08AJ06
|
didecyldimethylammonium chloride
|
WHO Anatomical Therapeutic Chemical classification |
|
didecyldimethylammonium chloride |
| 0‑L |
D08AJ08
|
benzethonium chloride
|
WHO Anatomical Therapeutic Chemical classification |
|
benzethonium chloride |
| 0‑L |
D08AJ10
|
decamethoxine
|
WHO Anatomical Therapeutic Chemical classification |
|
decamethoxine |
| 0‑L |
D08AJ57
|
octenidine, combinations
|
WHO Anatomical Therapeutic Chemical classification |
|
octenidine, combinations |
| 0‑L |
D08AJ58
|
benzethonium chloride, combinations
|
WHO Anatomical Therapeutic Chemical classification |
|
benzethonium chloride, combinations |
| 0‑L |
D08AJ59
|
dodeclonium bromide, combinations
|
WHO Anatomical Therapeutic Chemical classification |
|
dodeclonium bromide, combinations |
| 0‑L |
D08AK
|
Mercurial products
|
WHO Anatomical Therapeutic Chemical classification |
|
Mercurial products |
| 0‑L |
D08AK01
|
mercuric amidochloride
|
WHO Anatomical Therapeutic Chemical classification |
|
mercuric amidochloride |
| 0‑L |
D08AK02
|
phenylmercuric borate
|
WHO Anatomical Therapeutic Chemical classification |
|
phenylmercuric borate |
| 0‑L |
D08AK03
|
mercuric chloride
|
WHO Anatomical Therapeutic Chemical classification |
|
mercuric chloride |
| 0‑L |
D08AK04
|
mercurochrome
|
WHO Anatomical Therapeutic Chemical classification |
|
mercurochrome |
| 0‑L |
D08AK05
|
mercury, metallic
|
WHO Anatomical Therapeutic Chemical classification |
|
mercury, metallic |
| 0‑L |
D08AK06
|
thiomersal
|
WHO Anatomical Therapeutic Chemical classification |
|
thiomersal |
| 0‑L |
D08AK30
|
mercuric iodide
|
WHO Anatomical Therapeutic Chemical classification |
|
mercuric iodide |
| 0‑L |
D08AL
|
Silver compounds
|
WHO Anatomical Therapeutic Chemical classification |
|
Silver compounds |
| 0‑L |
D08AL01
|
silver nitrate
|
WHO Anatomical Therapeutic Chemical classification |
|
silver nitrate |
| 0‑L |
D08AL30
|
silver
|
WHO Anatomical Therapeutic Chemical classification |
|
silver |
| 0‑L |
D08AX
|
Other antiseptics and disinfectants
|
WHO Anatomical Therapeutic Chemical classification |
|
Other antiseptics and disinfectants |
| 0‑L |
D08AX01
|
hydrogen peroxide
|
WHO Anatomical Therapeutic Chemical classification |
|
hydrogen peroxide |
| 0‑L |
D08AX02
|
eosin
|
WHO Anatomical Therapeutic Chemical classification |
|
eosin |
| 0‑L |
D08AX03
|
propanol
|
WHO Anatomical Therapeutic Chemical classification |
|
propanol |
| 0‑L |
D08AX04
|
tosylchloramide sodium
|
WHO Anatomical Therapeutic Chemical classification |
|
tosylchloramide sodium |
| 0‑L |
D08AX05
|
isopropanol
|
WHO Anatomical Therapeutic Chemical classification |
|
isopropanol |
| 0‑L |
D08AX06
|
potassium permanganate
|
WHO Anatomical Therapeutic Chemical classification |
|
potassium permanganate |
| 0‑L |
D08AX07
|
sodium hypochlorite
|
WHO Anatomical Therapeutic Chemical classification |
|
sodium hypochlorite |
| 0‑L |
D08AX08
|
ethanol
|
WHO Anatomical Therapeutic Chemical classification |
|
ethanol |
| 0‑L |
D08AX53
|
propanol, combinations
|
WHO Anatomical Therapeutic Chemical classification |
|
propanol, combinations |
| 0‑L |
D09
|
MEDICATED DRESSINGS
|
WHO Anatomical Therapeutic Chemical classification |
|
MEDICATED DRESSINGS |
| 0‑L |
D09A
|
MEDICATED DRESSINGS
|
WHO Anatomical Therapeutic Chemical classification |
|
MEDICATED DRESSINGS |
| 0‑L |
D09AA
|
Medicated dressings with antiinfectives
|
WHO Anatomical Therapeutic Chemical classification |
|
Medicated dressings with antiinfectives |
| 0‑L |
D09AA01
|
framycetin
|
WHO Anatomical Therapeutic Chemical classification |
|
framycetin |
| 0‑L |
D09AA02
|
fusidic acid
|
WHO Anatomical Therapeutic Chemical classification |
|
fusidic acid |
| 0‑L |
D09AA03
|
nitrofural
|
WHO Anatomical Therapeutic Chemical classification |
|
nitrofural |
| 0‑L |
D09AA04
|
phenylmercuric nitrate
|
WHO Anatomical Therapeutic Chemical classification |
|
phenylmercuric nitrate |
| 0‑L |
D09AA05
|
benzododecinium
|
WHO Anatomical Therapeutic Chemical classification |
|
benzododecinium |
| 0‑L |
D09AA06
|
triclosan
|
WHO Anatomical Therapeutic Chemical classification |
|
triclosan |
| 0‑L |
D09AA07
|
cetylpyridinium
|
WHO Anatomical Therapeutic Chemical classification |
|
cetylpyridinium |
| 0‑L |
D09AA08
|
aluminium chlorohydrate
|
WHO Anatomical Therapeutic Chemical classification |
|
aluminium chlorohydrate |
| 0‑L |
D09AA09
|
povidone-iodine
|
WHO Anatomical Therapeutic Chemical classification |
|
povidone-iodine |
| 0‑L |
D09AA10
|
clioquinol
|
WHO Anatomical Therapeutic Chemical classification |
|
clioquinol |
| 0‑L |
D09AA11
|
benzalkonium
|
WHO Anatomical Therapeutic Chemical classification |
|
benzalkonium |
| 0‑L |
D09AA12
|
chlorhexidine
|
WHO Anatomical Therapeutic Chemical classification |
|
chlorhexidine |
| 0‑L |
D09AA13
|
iodoform
|
WHO Anatomical Therapeutic Chemical classification |
|
iodoform |
| 0‑L |
D09AB
|
Zinc bandages
|
WHO Anatomical Therapeutic Chemical classification |
|
Zinc bandages |
| 0‑L |
D09AB01
|
zinc bandage without supplements
|
WHO Anatomical Therapeutic Chemical classification |
|
zinc bandage without supplements |
| 0‑L |
D09AB02
|
zinc bandage with supplements
|
WHO Anatomical Therapeutic Chemical classification |
|
zinc bandage with supplements |
| 0‑L |
D09AX
|
Soft paraffin dressings
|
WHO Anatomical Therapeutic Chemical classification |
|
Soft paraffin dressings |
| 0‑L |
D10
|
ANTI-ACNE PREPARATIONS
|
WHO Anatomical Therapeutic Chemical classification |
|
ANTI-ACNE PREPARATIONS |
| 0‑L |
D10A
|
ANTI-ACNE PREPARATIONS FOR TOPICAL USE
|
WHO Anatomical Therapeutic Chemical classification |
|
ANTI-ACNE PREPARATIONS FOR TOPICAL USE |
| 0‑L |
D10AA
|
Corticosteroids, combinations for treatment of acne
|
WHO Anatomical Therapeutic Chemical classification |
|
Corticosteroids, combinations for treatment of acne |
| 0‑L |
D10AA01
|
fluorometholone
|
WHO Anatomical Therapeutic Chemical classification |
|
fluorometholone |
| 0‑L |
D10AA02
|
methylprednisolone
|
WHO Anatomical Therapeutic Chemical classification |
|
methylprednisolone |
| 0‑L |
D10AA03
|
dexamethasone
|
WHO Anatomical Therapeutic Chemical classification |
|
dexamethasone |
| 0‑L |
D10AB
|
Preparations containing sulfur
|
WHO Anatomical Therapeutic Chemical classification |
|
Preparations containing sulfur |
| 0‑L |
D10AB01
|
bithionol
|
WHO Anatomical Therapeutic Chemical classification |
|
bithionol |
| 0‑L |
D10AB02
|
sulfur
|
WHO Anatomical Therapeutic Chemical classification |
|
sulfur |
| 0‑L |
D10AB03
|
tioxolone
|
WHO Anatomical Therapeutic Chemical classification |
|
tioxolone |
| 0‑L |
D10AB05
|
mesulfen
|
WHO Anatomical Therapeutic Chemical classification |
|
mesulfen |
| 0‑L |
D10AD
|
Retinoids for topical use in acne
|
WHO Anatomical Therapeutic Chemical classification |
|
Retinoids for topical use in acne |
| 0‑L |
D10AD01
|
tretinoin
|
WHO Anatomical Therapeutic Chemical classification |
|
tretinoin |
| 0‑L |
D10AD02
|
retinol
|
WHO Anatomical Therapeutic Chemical classification |
|
retinol |
| 0‑L |
D10AD03
|
adapalene
|
WHO Anatomical Therapeutic Chemical classification |
|
adapalene |
| 0‑L |
D10AD04
|
isotretinoin
|
WHO Anatomical Therapeutic Chemical classification |
|
isotretinoin |
| 0‑L |
D10AD05
|
motretinide
|
WHO Anatomical Therapeutic Chemical classification |
|
motretinide |
| 0‑L |
D10AD51
|
tretinoin, combinations
|
WHO Anatomical Therapeutic Chemical classification |
|
tretinoin, combinations |
| 0‑L |
D10AD53
|
adapalene, combinations
|
WHO Anatomical Therapeutic Chemical classification |
|
adapalene, combinations |
| 0‑L |
D10AD54
|
isotretinoin, combinations
|
WHO Anatomical Therapeutic Chemical classification |
|
isotretinoin, combinations |
| 0‑L |
D10AE
|
Peroxides
|
WHO Anatomical Therapeutic Chemical classification |
|
Peroxides |
| 0‑L |
D10AE01
|
benzoyl peroxide
|
WHO Anatomical Therapeutic Chemical classification |
|
benzoyl peroxide |
| 0‑L |
D10AE51
|
benzoyl peroxide, combinations
|
WHO Anatomical Therapeutic Chemical classification |
|
benzoyl peroxide, combinations |
| 0‑L |
D10AF
|
Antiinfectives for treatment of acne
|
WHO Anatomical Therapeutic Chemical classification |
|
Antiinfectives for treatment of acne |
| 0‑L |
D10AF01
|
clindamycin
|
WHO Anatomical Therapeutic Chemical classification |
|
clindamycin |
| 0‑L |
D10AF02
|
erythromycin
|
WHO Anatomical Therapeutic Chemical classification |
|
erythromycin |
| 0‑L |
D10AF03
|
chloramphenicol
|
WHO Anatomical Therapeutic Chemical classification |
|
chloramphenicol |
| 0‑L |
D10AF04
|
meclocycline
|
WHO Anatomical Therapeutic Chemical classification |
|
meclocycline |
| 0‑L |
D10AF05
|
nadifloxacin
|
WHO Anatomical Therapeutic Chemical classification |
|
nadifloxacin |
| 0‑L |
D10AF06
|
sulfacetamide
|
WHO Anatomical Therapeutic Chemical classification |
|
sulfacetamide |
| 0‑L |
D10AF51
|
clindamycin, combinations
|
WHO Anatomical Therapeutic Chemical classification |
|
clindamycin, combinations |
| 0‑L |
D10AF52
|
erythromycin, combinations
|
WHO Anatomical Therapeutic Chemical classification |
|
erythromycin, combinations |
| 0‑L |
D10AX
|
Other anti-acne preparations for topical use
|
WHO Anatomical Therapeutic Chemical classification |
|
Other anti-acne preparations for topical use |
| 0‑L |
D10AX01
|
aluminium chloride
|
WHO Anatomical Therapeutic Chemical classification |
|
aluminium chloride |
| 0‑L |
D10AX02
|
resorcinol
|
WHO Anatomical Therapeutic Chemical classification |
|
resorcinol |
| 0‑L |
D10AX03
|
azelaic acid
|
WHO Anatomical Therapeutic Chemical classification |
|
azelaic acid |
| 0‑L |
D10AX04
|
aluminium oxide
|
WHO Anatomical Therapeutic Chemical classification |
|
aluminium oxide |
| 0‑L |
D10AX05
|
dapsone
|
WHO Anatomical Therapeutic Chemical classification |
|
dapsone |
| 0‑L |
D10AX30
|
various combinations
|
WHO Anatomical Therapeutic Chemical classification |
|
various combinations |
| 0‑L |
D10B
|
ANTI-ACNE PREPARATIONS FOR SYSTEMIC USE
|
WHO Anatomical Therapeutic Chemical classification |
|
ANTI-ACNE PREPARATIONS FOR SYSTEMIC USE |
| 0‑L |
D10BA
|
Retinoids for treatment of acne
|
WHO Anatomical Therapeutic Chemical classification |
|
Retinoids for treatment of acne |
| 0‑L |
D10BA01
|
isotretinoin
|
WHO Anatomical Therapeutic Chemical classification |
|
isotretinoin |
| 0‑L |
D10BX
|
Other anti-acne preparations for systemic use
|
WHO Anatomical Therapeutic Chemical classification |
|
Other anti-acne preparations for systemic use |
| 0‑L |
D10BX01
|
ichtasol
|
WHO Anatomical Therapeutic Chemical classification |
|
ichtasol |
| 0‑L |
D11
|
OTHER DERMATOLOGICAL PREPARATIONS
|
WHO Anatomical Therapeutic Chemical classification |
|
OTHER DERMATOLOGICAL PREPARATIONS |
| 0‑L |
D11A
|
OTHER DERMATOLOGICAL PREPARATIONS
|
WHO Anatomical Therapeutic Chemical classification |
|
OTHER DERMATOLOGICAL PREPARATIONS |
| 0‑L |
D11AA
|
Antihidrotics
|
WHO Anatomical Therapeutic Chemical classification |
|
Antihidrotics |
| 0‑L |
D11AC
|
Medicated shampoos
|
WHO Anatomical Therapeutic Chemical classification |
|
Medicated shampoos |
| 0‑L |
D11AC01
|
cetrimide
|
WHO Anatomical Therapeutic Chemical classification |
|
cetrimide |
| 0‑L |
D11AC02
|
cadmium compounds
|
WHO Anatomical Therapeutic Chemical classification |
|
cadmium compounds |
| 0‑L |
D11AC03
|
selenium compounds
|
WHO Anatomical Therapeutic Chemical classification |
|
selenium compounds |
| 0‑L |
D11AC06
|
povidone-iodine
|
WHO Anatomical Therapeutic Chemical classification |
|
povidone-iodine |
| 0‑L |
D11AC08
|
sulfur compounds
|
WHO Anatomical Therapeutic Chemical classification |
|
sulfur compounds |
| 0‑L |
D11AC09
|
xenysalate
|
WHO Anatomical Therapeutic Chemical classification |
|
xenysalate |
| 0‑L |
D11AC30
|
others
|
WHO Anatomical Therapeutic Chemical classification |
|
others |
| 0‑L |
D11AE
|
Androgens for topical use
|
WHO Anatomical Therapeutic Chemical classification |
|
Androgens for topical use |
| 0‑L |
D11AE01
|
metandienone
|
WHO Anatomical Therapeutic Chemical classification |
|
metandienone |
| 0‑L |
D11AF
|
Wart and anti-corn preparations
|
WHO Anatomical Therapeutic Chemical classification |
|
Wart and anti-corn preparations |
| 0‑L |
D11AH
|
Agents for dermatitis, excluding corticosteroids
|
WHO Anatomical Therapeutic Chemical classification |
|
Agents for dermatitis, excluding corticosteroids |
| 0‑L |
D11AH01
|
tacrolimus
|
WHO Anatomical Therapeutic Chemical classification |
|
tacrolimus |
| 0‑L |
D11AH02
|
pimecrolimus
|
WHO Anatomical Therapeutic Chemical classification |
|
pimecrolimus |
| 0‑L |
D11AH03
|
cromoglicic acid
|
WHO Anatomical Therapeutic Chemical classification |
|
cromoglicic acid |
| 0‑L |
D11AH04
|
alitretinoin
|
WHO Anatomical Therapeutic Chemical classification |
|
alitretinoin |
| 0‑L |
D11AX
|
Other dermatologicals
|
WHO Anatomical Therapeutic Chemical classification |
|
Other dermatologicals |
| 0‑L |
D11AX01
|
minoxidil
|
WHO Anatomical Therapeutic Chemical classification |
|
minoxidil |
| 0‑L |
D11AX02
|
gamolenic acid
|
WHO Anatomical Therapeutic Chemical classification |
|
gamolenic acid |
| 0‑L |
D11AX03
|
calcium gluconate
|
WHO Anatomical Therapeutic Chemical classification |
|
calcium gluconate |
| 0‑L |
D11AX04
|
lithium succinate
|
WHO Anatomical Therapeutic Chemical classification |
|
lithium succinate |
| 0‑L |
D11AX05
|
magnesium sulfate
|
WHO Anatomical Therapeutic Chemical classification |
|
magnesium sulfate |
| 0‑L |
D11AX06
|
mequinol
|
WHO Anatomical Therapeutic Chemical classification |
|
mequinol |
| 0‑L |
D11AX08
|
tiratricol
|
WHO Anatomical Therapeutic Chemical classification |
|
tiratricol |
| 0‑L |
D11AX09
|
oxaceprol
|
WHO Anatomical Therapeutic Chemical classification |
|
oxaceprol |
| 0‑L |
D11AX10
|
finasteride
|
WHO Anatomical Therapeutic Chemical classification |
|
finasteride |
| 0‑L |
D11AX11
|
hydroquinone
|
WHO Anatomical Therapeutic Chemical classification |
|
hydroquinone |
| 0‑L |
D11AX12
|
pyrithione zinc
|
WHO Anatomical Therapeutic Chemical classification |
|
pyrithione zinc |
| 0‑L |
D11AX13
|
monobenzone
|
WHO Anatomical Therapeutic Chemical classification |
|
monobenzone |
| 0‑L |
D11AX16
|
eflornithine
|
WHO Anatomical Therapeutic Chemical classification |
|
eflornithine |
| 0‑L |
D11AX18
|
diclofenac
|
WHO Anatomical Therapeutic Chemical classification |
|
diclofenac |
| 0‑L |
D11AX21
|
brimonidine
|
WHO Anatomical Therapeutic Chemical classification |
|
brimonidine |
| 0‑L |
D11AX22
|
ivermectin
|
WHO Anatomical Therapeutic Chemical classification |
|
ivermectin |
| 0‑L |
D11AX23
|
aminobenzoate potassium
|
WHO Anatomical Therapeutic Chemical classification |
|
aminobenzoate potassium |
| 0‑L |
D11AX24
|
deoxycholic acid
|
WHO Anatomical Therapeutic Chemical classification |
|
deoxycholic acid |
| 0‑L |
D11AX52
|
gamolenic acid, combinations
|
WHO Anatomical Therapeutic Chemical classification |
|
gamolenic acid, combinations |
| 0‑L |
D11AX57
|
collagen, combinations
|
WHO Anatomical Therapeutic Chemical classification |
|
collagen, combinations |
| 0‑L |
G
|
GENITO URINARY SYSTEM AND SEX HORMONES
|
WHO Anatomical Therapeutic Chemical classification |
|
GENITO URINARY SYSTEM AND SEX HORMONES |
| 0‑L |
G01
|
GYNECOLOGICAL ANTIINFECTIVES AND ANTISEPTICS
|
WHO Anatomical Therapeutic Chemical classification |
|
GYNECOLOGICAL ANTIINFECTIVES AND ANTISEPTICS |
| 0‑L |
G01A
|
ANTIINFECTIVES AND ANTISEPTICS, EXCL. COMBINATIONS WITH CORTICOSTEROIDS
|
WHO Anatomical Therapeutic Chemical classification |
|
ANTIINFECTIVES AND ANTISEPTICS, EXCL. COMBINATIONS WITH CORTICOSTEROIDS |
| 0‑L |
G01AA
|
Antibiotics
|
WHO Anatomical Therapeutic Chemical classification |
|
Antibiotics |
| 0‑L |
G01AA01
|
nystatin
|
WHO Anatomical Therapeutic Chemical classification |
|
nystatin |
| 0‑L |
G01AA02
|
natamycin
|
WHO Anatomical Therapeutic Chemical classification |
|
natamycin |
| 0‑L |
G01AA03
|
amphotericin B
|
WHO Anatomical Therapeutic Chemical classification |
|
amphotericin B |
| 0‑L |
G01AA04
|
candicidin
|
WHO Anatomical Therapeutic Chemical classification |
|
candicidin |
| 0‑L |
G01AA05
|
chloramphenicol
|
WHO Anatomical Therapeutic Chemical classification |
|
chloramphenicol |
| 0‑L |
G01AA06
|
hachimycin
|
WHO Anatomical Therapeutic Chemical classification |
|
hachimycin |
| 0‑L |
G01AA07
|
oxytetracycline
|
WHO Anatomical Therapeutic Chemical classification |
|
oxytetracycline |
| 0‑L |
G01AA08
|
carfecillin
|
WHO Anatomical Therapeutic Chemical classification |
|
carfecillin |
| 0‑L |
G01AA09
|
mepartricin
|
WHO Anatomical Therapeutic Chemical classification |
|
mepartricin |
| 0‑L |
G01AA10
|
clindamycin
|
WHO Anatomical Therapeutic Chemical classification |
|
clindamycin |
| 0‑L |
G01AA11
|
pentamycin
|
WHO Anatomical Therapeutic Chemical classification |
|
pentamycin |
| 0‑L |
G01AA51
|
nystatin, combinations
|
WHO Anatomical Therapeutic Chemical classification |
|
nystatin, combinations |
| 0‑L |
G01AB
|
Arsenic compounds
|
WHO Anatomical Therapeutic Chemical classification |
|
Arsenic compounds |
| 0‑L |
G01AB01
|
acetarsol
|
WHO Anatomical Therapeutic Chemical classification |
|
acetarsol |
| 0‑L |
G01AC
|
Quinoline derivatives
|
WHO Anatomical Therapeutic Chemical classification |
|
Quinoline derivatives |
| 0‑L |
G01AC01
|
diiodohydroxyquinoline
|
WHO Anatomical Therapeutic Chemical classification |
|
diiodohydroxyquinoline |
| 0‑L |
G01AC02
|
clioquinol
|
WHO Anatomical Therapeutic Chemical classification |
|
clioquinol |
| 0‑L |
G01AC03
|
chlorquinaldol
|
WHO Anatomical Therapeutic Chemical classification |
|
chlorquinaldol |
| 0‑L |
G01AC05
|
dequalinium
|
WHO Anatomical Therapeutic Chemical classification |
|
dequalinium |
| 0‑L |
G01AC06
|
broxyquinoline
|
WHO Anatomical Therapeutic Chemical classification |
|
broxyquinoline |
| 0‑L |
G01AC30
|
oxyquinoline
|
WHO Anatomical Therapeutic Chemical classification |
|
oxyquinoline |
| 0‑L |
G01AD
|
Organic acids
|
WHO Anatomical Therapeutic Chemical classification |
|
Organic acids |
| 0‑L |
G01AD01
|
lactic acid
|
WHO Anatomical Therapeutic Chemical classification |
|
lactic acid |
| 0‑L |
G01AD02
|
acetic acid
|
WHO Anatomical Therapeutic Chemical classification |
|
acetic acid |
| 0‑L |
G01AD03
|
ascorbic acid
|
WHO Anatomical Therapeutic Chemical classification |
|
ascorbic acid |
| 0‑L |
G01AE
|
Sulfonamides
|
WHO Anatomical Therapeutic Chemical classification |
|
Sulfonamides |
| 0‑L |
G01AE01
|
sulfatolamide
|
WHO Anatomical Therapeutic Chemical classification |
|
sulfatolamide |
| 0‑L |
G01AE10
|
combinations of sulfonamides
|
WHO Anatomical Therapeutic Chemical classification |
|
combinations of sulfonamides |
| 0‑L |
G01AF
|
Imidazole derivatives
|
WHO Anatomical Therapeutic Chemical classification |
|
Imidazole derivatives |
| 0‑L |
G01AF01
|
metronidazole
|
WHO Anatomical Therapeutic Chemical classification |
|
metronidazole |
| 0‑L |
G01AF02
|
clotrimazole
|
WHO Anatomical Therapeutic Chemical classification |
|
clotrimazole |
| 0‑L |
G01AF04
|
miconazole
|
WHO Anatomical Therapeutic Chemical classification |
|
miconazole |
| 0‑L |
G01AF05
|
econazole
|
WHO Anatomical Therapeutic Chemical classification |
|
econazole |
| 0‑L |
G01AF06
|
ornidazole
|
WHO Anatomical Therapeutic Chemical classification |
|
ornidazole |
| 0‑L |
G01AF07
|
isoconazole
|
WHO Anatomical Therapeutic Chemical classification |
|
isoconazole |
| 0‑L |
G01AF08
|
tioconazole
|
WHO Anatomical Therapeutic Chemical classification |
|
tioconazole |
| 0‑L |
G01AF11
|
ketoconazole
|
WHO Anatomical Therapeutic Chemical classification |
|
ketoconazole |
| 0‑L |
G01AF12
|
fenticonazole
|
WHO Anatomical Therapeutic Chemical classification |
|
fenticonazole |
| 0‑L |
G01AF13
|
azanidazole
|
WHO Anatomical Therapeutic Chemical classification |
|
azanidazole |
| 0‑L |
G01AF14
|
propenidazole
|
WHO Anatomical Therapeutic Chemical classification |
|
propenidazole |
| 0‑L |
G01AF15
|
butoconazole
|
WHO Anatomical Therapeutic Chemical classification |
|
butoconazole |
| 0‑L |
G01AF16
|
omoconazole
|
WHO Anatomical Therapeutic Chemical classification |
|
omoconazole |
| 0‑L |
G01AF17
|
oxiconazole
|
WHO Anatomical Therapeutic Chemical classification |
|
oxiconazole |
| 0‑L |
G01AF18
|
flutrimazole
|
WHO Anatomical Therapeutic Chemical classification |
|
flutrimazole |
| 0‑L |
G01AF19
|
sertaconazole
|
WHO Anatomical Therapeutic Chemical classification |
|
sertaconazole |
| 0‑L |
G01AF20
|
combinations of imidazole derivatives
|
WHO Anatomical Therapeutic Chemical classification |
|
combinations of imidazole derivatives |
| 0‑L |
G01AG
|
Triazole derivatives
|
WHO Anatomical Therapeutic Chemical classification |
|
Triazole derivatives |
| 0‑L |
G01AG02
|
terconazole
|
WHO Anatomical Therapeutic Chemical classification |
|
terconazole |
| 0‑L |
G01AX
|
Other antiinfectives and antiseptics
|
WHO Anatomical Therapeutic Chemical classification |
|
Other antiinfectives and antiseptics |
| 0‑L |
G01AX01
|
clodantoin
|
WHO Anatomical Therapeutic Chemical classification |
|
clodantoin |
| 0‑L |
G01AX02
|
inosine
|
WHO Anatomical Therapeutic Chemical classification |
|
inosine |
| 0‑L |
G01AX03
|
policresulen
|
WHO Anatomical Therapeutic Chemical classification |
|
policresulen |
| 0‑L |
G01AX05
|
nifuratel
|
WHO Anatomical Therapeutic Chemical classification |
|
nifuratel |
| 0‑L |
G01AX06
|
furazolidone
|
WHO Anatomical Therapeutic Chemical classification |
|
furazolidone |
| 0‑L |
G01AX09
|
methylrosaniline
|
WHO Anatomical Therapeutic Chemical classification |
|
methylrosaniline |
| 0‑L |
G01AX11
|
povidone-iodine
|
WHO Anatomical Therapeutic Chemical classification |
|
povidone-iodine |
| 0‑L |
G01AX12
|
ciclopirox
|
WHO Anatomical Therapeutic Chemical classification |
|
ciclopirox |
| 0‑L |
G01AX13
|
protiofate
|
WHO Anatomical Therapeutic Chemical classification |
|
protiofate |
| 0‑L |
G01AX14
|
lactobacillus fermentum
|
WHO Anatomical Therapeutic Chemical classification |
|
lactobacillus fermentum |
| 0‑L |
G01AX15
|
copper usnate
|
WHO Anatomical Therapeutic Chemical classification |
|
copper usnate |
| 0‑L |
G01AX16
|
hexetidine
|
WHO Anatomical Therapeutic Chemical classification |
|
hexetidine |
| 0‑L |
G01AX66
|
octenidine, combinations
|
WHO Anatomical Therapeutic Chemical classification |
|
octenidine, combinations |
| 0‑L |
G01B
|
ANTIINFECTIVES/ANTISEPTICS IN COMBINATION WITH CORTICOSTEROIDS
|
WHO Anatomical Therapeutic Chemical classification |
|
ANTIINFECTIVES/ANTISEPTICS IN COMBINATION WITH CORTICOSTEROIDS |
| 0‑L |
G01BA
|
Antibiotics and corticosteroids
|
WHO Anatomical Therapeutic Chemical classification |
|
Antibiotics and corticosteroids |
| 0‑L |
G01BC
|
Quinoline derivatives and corticosteroids
|
WHO Anatomical Therapeutic Chemical classification |
|
Quinoline derivatives and corticosteroids |
| 0‑L |
G01BD
|
Antiseptics and corticosteroids
|
WHO Anatomical Therapeutic Chemical classification |
|
Antiseptics and corticosteroids |
| 0‑L |
G01BE
|
Sulfonamides and corticosteroids
|
WHO Anatomical Therapeutic Chemical classification |
|
Sulfonamides and corticosteroids |
| 0‑L |
G01BF
|
Imidazole derivatives and corticosteroids
|
WHO Anatomical Therapeutic Chemical classification |
|
Imidazole derivatives and corticosteroids |
| 0‑L |
G02
|
OTHER GYNECOLOGICALS
|
WHO Anatomical Therapeutic Chemical classification |
|
OTHER GYNECOLOGICALS |
| 0‑L |
G02A
|
UTEROTONICS
|
WHO Anatomical Therapeutic Chemical classification |
|
UTEROTONICS |
| 0‑L |
G02AB
|
Ergot alkaloids
|
WHO Anatomical Therapeutic Chemical classification |
|
Ergot alkaloids |
| 0‑L |
G02AB01
|
methylergometrine
|
WHO Anatomical Therapeutic Chemical classification |
|
methylergometrine |
| 0‑L |
G02AB02
|
ergot alkaloids
|
WHO Anatomical Therapeutic Chemical classification |
|
ergot alkaloids |
| 0‑L |
G02AB03
|
ergometrine
|
WHO Anatomical Therapeutic Chemical classification |
|
ergometrine |
| 0‑L |
G02AC
|
Ergot alkaloids and oxytocin incl. analogues, in combination
|
WHO Anatomical Therapeutic Chemical classification |
|
Ergot alkaloids and oxytocin incl. analogues, in combination |
| 0‑L |
G02AC01
|
methylergometrine and oxytocin
|
WHO Anatomical Therapeutic Chemical classification |
|
methylergometrine and oxytocin |
| 0‑L |
G02AD
|
Prostaglandins
|
WHO Anatomical Therapeutic Chemical classification |
|
Prostaglandins |
| 0‑L |
G02AD01
|
dinoprost
|
WHO Anatomical Therapeutic Chemical classification |
|
dinoprost |
| 0‑L |
G02AD02
|
dinoprostone
|
WHO Anatomical Therapeutic Chemical classification |
|
dinoprostone |
| 0‑L |
G02AD03
|
gemeprost
|
WHO Anatomical Therapeutic Chemical classification |
|
gemeprost |
| 0‑L |
G02AD04
|
carboprost
|
WHO Anatomical Therapeutic Chemical classification |
|
carboprost |
| 0‑L |
G02AD05
|
sulprostone
|
WHO Anatomical Therapeutic Chemical classification |
|
sulprostone |
| 0‑L |
G02AD06
|
misoprostol
|
WHO Anatomical Therapeutic Chemical classification |
|
misoprostol |
| 0‑L |
G02AX
|
Other uterotonics
|
WHO Anatomical Therapeutic Chemical classification |
|
Other uterotonics |
| 0‑L |
G02B
|
CONTRACEPTIVES FOR TOPICAL USE
|
WHO Anatomical Therapeutic Chemical classification |
|
CONTRACEPTIVES FOR TOPICAL USE |
| 0‑L |
G02BA
|
Intrauterine contraceptives
|
WHO Anatomical Therapeutic Chemical classification |
|
Intrauterine contraceptives |
| 0‑L |
G02BA01
|
plastic IUD
|
WHO Anatomical Therapeutic Chemical classification |
|
plastic IUD |
| 0‑L |
G02BA02
|
plastic IUD with copper
|
WHO Anatomical Therapeutic Chemical classification |
|
plastic IUD with copper |
| 0‑L |
G02BA03
|
plastic IUD with progestogen
|
WHO Anatomical Therapeutic Chemical classification |
|
plastic IUD with progestogen |
| 0‑L |
G02BB
|
Intravaginal contraceptives
|
WHO Anatomical Therapeutic Chemical classification |
|
Intravaginal contraceptives |
| 0‑L |
G02BB01
|
vaginal ring with progestogen and estrogen
|
WHO Anatomical Therapeutic Chemical classification |
|
vaginal ring with progestogen and estrogen |
| 0‑L |
G02C
|
OTHER GYNECOLOGICALS
|
WHO Anatomical Therapeutic Chemical classification |
|
OTHER GYNECOLOGICALS |
| 0‑L |
G02CA
|
Sympathomimetics, labour repressants
|
WHO Anatomical Therapeutic Chemical classification |
|
Sympathomimetics, labour repressants |
| 0‑L |
G02CA01
|
ritodrine
|
WHO Anatomical Therapeutic Chemical classification |
|
ritodrine |
| 0‑L |
G02CA02
|
buphenine
|
WHO Anatomical Therapeutic Chemical classification |
|
buphenine |
| 0‑L |
G02CA03
|
fenoterol
|
WHO Anatomical Therapeutic Chemical classification |
|
fenoterol |
| 0‑L |
G02CB
|
Prolactine inhibitors
|
WHO Anatomical Therapeutic Chemical classification |
|
Prolactine inhibitors |
| 0‑L |
G02CB01
|
bromocriptine
|
WHO Anatomical Therapeutic Chemical classification |
|
bromocriptine |
| 0‑L |
G02CB02
|
lisuride
|
WHO Anatomical Therapeutic Chemical classification |
|
lisuride |
| 0‑L |
G02CB03
|
cabergoline
|
WHO Anatomical Therapeutic Chemical classification |
|
cabergoline |
| 0‑L |
G02CB04
|
quinagolide
|
WHO Anatomical Therapeutic Chemical classification |
|
quinagolide |
| 0‑L |
G02CB05
|
metergoline
|
WHO Anatomical Therapeutic Chemical classification |
|
metergoline |
| 0‑L |
G02CB06
|
terguride
|
WHO Anatomical Therapeutic Chemical classification |
|
terguride |
| 0‑L |
G02CC
|
Antiinflammatory products for vaginal administration
|
WHO Anatomical Therapeutic Chemical classification |
|
Antiinflammatory products for vaginal administration |
| 0‑L |
G02CC01
|
ibuprofen
|
WHO Anatomical Therapeutic Chemical classification |
|
ibuprofen |
| 0‑L |
G02CC02
|
naproxen
|
WHO Anatomical Therapeutic Chemical classification |
|
naproxen |
| 0‑L |
G02CC03
|
benzydamine
|
WHO Anatomical Therapeutic Chemical classification |
|
benzydamine |
| 0‑L |
G02CC04
|
flunoxaprofen
|
WHO Anatomical Therapeutic Chemical classification |
|
flunoxaprofen |
| 0‑L |
G02CX
|
Other gynecologicals
|
WHO Anatomical Therapeutic Chemical classification |
|
Other gynecologicals |
| 0‑L |
G02CX01
|
atosiban
|
WHO Anatomical Therapeutic Chemical classification |
|
atosiban |
| 0‑L |
G02CX02
|
flibanserin
|
WHO Anatomical Therapeutic Chemical classification |
|
flibanserin |
| 0‑L |
G02CX03
|
Agni casti fructus
|
WHO Anatomical Therapeutic Chemical classification |
|
Agni casti fructus |
| 0‑L |
G02CX04
|
Cimicifugae rhizoma
|
WHO Anatomical Therapeutic Chemical classification |
|
Cimicifugae rhizoma |
| 0‑L |
G03
|
SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM
|
WHO Anatomical Therapeutic Chemical classification |
|
SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM |
| 0‑L |
G03A
|
HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE
|
WHO Anatomical Therapeutic Chemical classification |
|
HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE |
| 0‑L |
G03AA
|
Progestogens and estrogens, fixed combinations
|
WHO Anatomical Therapeutic Chemical classification |
|
Progestogens and estrogens, fixed combinations |
| 0‑L |
G03AA01
|
etynodiol and ethinylestradiol
|
WHO Anatomical Therapeutic Chemical classification |
|
etynodiol and ethinylestradiol |
| 0‑L |
G03AA02
|
quingestanol and ethinylestradiol
|
WHO Anatomical Therapeutic Chemical classification |
|
quingestanol and ethinylestradiol |
| 0‑L |
G03AA03
|
lynestrenol and ethinylestradiol
|
WHO Anatomical Therapeutic Chemical classification |
|
lynestrenol and ethinylestradiol |
| 0‑L |
G03AA04
|
megestrol and ethinylestradiol
|
WHO Anatomical Therapeutic Chemical classification |
|
megestrol and ethinylestradiol |
| 0‑L |
G03AA05
|
norethisterone and ethinylestradiol
|
WHO Anatomical Therapeutic Chemical classification |
|
norethisterone and ethinylestradiol |
| 0‑L |
G03AA06
|
norgestrel and ethinylestradiol
|
WHO Anatomical Therapeutic Chemical classification |
|
norgestrel and ethinylestradiol |
| 0‑L |
G03AA07
|
levonorgestrel and ethinylestradiol
|
WHO Anatomical Therapeutic Chemical classification |
|
levonorgestrel and ethinylestradiol |
| 0‑L |
G03AA08
|
medroxyprogesterone and ethinylestradiol
|
WHO Anatomical Therapeutic Chemical classification |
|
medroxyprogesterone and ethinylestradiol |
| 0‑L |
G03AA09
|
desogestrel and ethinylestradiol
|
WHO Anatomical Therapeutic Chemical classification |
|
desogestrel and ethinylestradiol |
| 0‑L |
G03AA10
|
gestodene and ethinylestradiol
|
WHO Anatomical Therapeutic Chemical classification |
|
gestodene and ethinylestradiol |
| 0‑L |
G03AA11
|
norgestimate and ethinylestradiol
|
WHO Anatomical Therapeutic Chemical classification |
|
norgestimate and ethinylestradiol |
| 0‑L |
G03AA12
|
drospirenone and ethinylestradiol
|
WHO Anatomical Therapeutic Chemical classification |
|
drospirenone and ethinylestradiol |
| 0‑L |
G03AA13
|
norelgestromin and ethinylestradiol
|
WHO Anatomical Therapeutic Chemical classification |
|
norelgestromin and ethinylestradiol |
| 0‑L |
G03AA14
|
nomegestrol and estradiol
|
WHO Anatomical Therapeutic Chemical classification |
|
nomegestrol and estradiol |
| 0‑L |
G03AA15
|
chlormadinone and ethinylestradiol
|
WHO Anatomical Therapeutic Chemical classification |
|
chlormadinone and ethinylestradiol |
| 0‑L |
G03AA16
|
dienogest and ethinylestradiol
|
WHO Anatomical Therapeutic Chemical classification |
|
dienogest and ethinylestradiol |
| 0‑L |
G03AB
|
Progestogens and estrogens, sequential preparations
|
WHO Anatomical Therapeutic Chemical classification |
|
Progestogens and estrogens, sequential preparations |
| 0‑L |
G03AB01
|
megestrol and ethinylestradiol
|
WHO Anatomical Therapeutic Chemical classification |
|
megestrol and ethinylestradiol |
| 0‑L |
G03AB02
|
lynestrenol and ethinylestradiol
|
WHO Anatomical Therapeutic Chemical classification |
|
lynestrenol and ethinylestradiol |
| 0‑L |
G03AB03
|
levonorgestrel and ethinylestradiol
|
WHO Anatomical Therapeutic Chemical classification |
|
levonorgestrel and ethinylestradiol |
| 0‑L |
G03AB04
|
norethisterone and ethinylestradiol
|
WHO Anatomical Therapeutic Chemical classification |
|
norethisterone and ethinylestradiol |
| 0‑L |
G03AB05
|
desogestrel and ethinylestradiol
|
WHO Anatomical Therapeutic Chemical classification |
|
desogestrel and ethinylestradiol |
| 0‑L |
G03AB06
|
gestodene and ethinylestradiol
|
WHO Anatomical Therapeutic Chemical classification |
|
gestodene and ethinylestradiol |
| 0‑L |
G03AB07
|
chlormadinone and ethinylestradiol
|
WHO Anatomical Therapeutic Chemical classification |
|
chlormadinone and ethinylestradiol |
| 0‑L |
G03AB08
|
dienogest and estradiol
|
WHO Anatomical Therapeutic Chemical classification |
|
dienogest and estradiol |
| 0‑L |
G03AC
|
Progestogens
|
WHO Anatomical Therapeutic Chemical classification |
|
Progestogens |
| 0‑L |
G03AC01
|
norethisterone
|
WHO Anatomical Therapeutic Chemical classification |
|
norethisterone |
| 0‑L |
G03AC02
|
lynestrenol
|
WHO Anatomical Therapeutic Chemical classification |
|
lynestrenol |
| 0‑L |
G03AC03
|
levonorgestrel
|
WHO Anatomical Therapeutic Chemical classification |
|
levonorgestrel |
| 0‑L |
G03AC04
|
quingestanol
|
WHO Anatomical Therapeutic Chemical classification |
|
quingestanol |
| 0‑L |
G03AC05
|
megestrol
|
WHO Anatomical Therapeutic Chemical classification |
|
megestrol |
| 0‑L |
G03AC06
|
medroxyprogesterone
|
WHO Anatomical Therapeutic Chemical classification |
|
medroxyprogesterone |
| 0‑L |
G03AC07
|
norgestrienone
|
WHO Anatomical Therapeutic Chemical classification |
|
norgestrienone |
| 0‑L |
G03AC08
|
etonogestrel
|
WHO Anatomical Therapeutic Chemical classification |
|
etonogestrel |
| 0‑L |
G03AC09
|
desogestrel
|
WHO Anatomical Therapeutic Chemical classification |
|
desogestrel |
| 0‑L |
G03AC10
|
drospirenone
|
WHO Anatomical Therapeutic Chemical classification |
|
drospirenone |
| 0‑L |
G03AD
|
Emergency contraceptives
|
WHO Anatomical Therapeutic Chemical classification |
|
Emergency contraceptives |
| 0‑L |
G03AD01
|
levonorgestrel
|
WHO Anatomical Therapeutic Chemical classification |
|
levonorgestrel |
| 0‑L |
G03AD02
|
ulipristal
|
WHO Anatomical Therapeutic Chemical classification |
|
ulipristal |
| 0‑L |
G03B
|
ANDROGENS
|
WHO Anatomical Therapeutic Chemical classification |
|
ANDROGENS |
| 0‑L |
G03BA
|
3-oxoandrosten (4) derivatives
|
WHO Anatomical Therapeutic Chemical classification |
|
3-oxoandrosten (4) derivatives |
| 0‑L |
G03BA01
|
fluoxymesterone
|
WHO Anatomical Therapeutic Chemical classification |
|
fluoxymesterone |
| 0‑L |
G03BA02
|
methyltestosterone
|
WHO Anatomical Therapeutic Chemical classification |
|
methyltestosterone |
| 0‑L |
G03BA03
|
testosterone
|
WHO Anatomical Therapeutic Chemical classification |
|
testosterone |
| 0‑L |
G03BB
|
5-androstanon (3) derivatives
|
WHO Anatomical Therapeutic Chemical classification |
|
5-androstanon (3) derivatives |
| 0‑L |
G03BB01
|
mesterolone
|
WHO Anatomical Therapeutic Chemical classification |
|
mesterolone |
| 0‑L |
G03BB02
|
androstanolone
|
WHO Anatomical Therapeutic Chemical classification |
|
androstanolone |
| 0‑L |
G03C
|
ESTROGENS
|
WHO Anatomical Therapeutic Chemical classification |
|
ESTROGENS |
| 0‑L |
G03CA
|
Natural and semisynthetic estrogens, plain
|
WHO Anatomical Therapeutic Chemical classification |
|
Natural and semisynthetic estrogens, plain |
| 0‑L |
G03CA01
|
ethinylestradiol
|
WHO Anatomical Therapeutic Chemical classification |
|
ethinylestradiol |
| 0‑L |
G03CA03
|
estradiol
|
WHO Anatomical Therapeutic Chemical classification |
|
estradiol |
| 0‑L |
G03CA04
|
estriol
|
WHO Anatomical Therapeutic Chemical classification |
|
estriol |
| 0‑L |
G03CA06
|
chlorotrianisene
|
WHO Anatomical Therapeutic Chemical classification |
|
chlorotrianisene |
| 0‑L |
G03CA07
|
estrone
|
WHO Anatomical Therapeutic Chemical classification |
|
estrone |
| 0‑L |
G03CA09
|
promestriene
|
WHO Anatomical Therapeutic Chemical classification |
|
promestriene |
| 0‑L |
G03CA53
|
estradiol, combinations
|
WHO Anatomical Therapeutic Chemical classification |
|
estradiol, combinations |
| 0‑L |
G03CA57
|
conjugated estrogens
|
WHO Anatomical Therapeutic Chemical classification |
|
conjugated estrogens |
| 0‑L |
G03CB
|
Synthetic estrogens, plain
|
WHO Anatomical Therapeutic Chemical classification |
|
Synthetic estrogens, plain |
| 0‑L |
G03CB01
|
dienestrol
|
WHO Anatomical Therapeutic Chemical classification |
|
dienestrol |
| 0‑L |
G03CB02
|
diethylstilbestrol
|
WHO Anatomical Therapeutic Chemical classification |
|
diethylstilbestrol |
| 0‑L |
G03CB03
|
methallenestril
|
WHO Anatomical Therapeutic Chemical classification |
|
methallenestril |
| 0‑L |
G03CB04
|
moxestrol
|
WHO Anatomical Therapeutic Chemical classification |
|
moxestrol |
| 0‑L |
G03CC
|
Estrogens, combinations with other drugs
|
WHO Anatomical Therapeutic Chemical classification |
|
Estrogens, combinations with other drugs |
| 0‑L |
G03CC02
|
dienestrol
|
WHO Anatomical Therapeutic Chemical classification |
|
dienestrol |
| 0‑L |
G03CC03
|
methallenestril
|
WHO Anatomical Therapeutic Chemical classification |
|
methallenestril |
| 0‑L |
G03CC04
|
estrone
|
WHO Anatomical Therapeutic Chemical classification |
|
estrone |
| 0‑L |
G03CC05
|
diethylstilbestrol
|
WHO Anatomical Therapeutic Chemical classification |
|
diethylstilbestrol |
| 0‑L |
G03CC06
|
estriol
|
WHO Anatomical Therapeutic Chemical classification |
|
estriol |
| 0‑L |
G03CC07
|
conjugated estrogens and bazedoxifene
|
WHO Anatomical Therapeutic Chemical classification |
|
conjugated estrogens and bazedoxifene |
| 0‑L |
G03CX
|
Other estrogens
|
WHO Anatomical Therapeutic Chemical classification |
|
Other estrogens |
| 0‑L |
G03CX01
|
tibolone
|
WHO Anatomical Therapeutic Chemical classification |
|
tibolone |
| 0‑L |
G03D
|
PROGESTOGENS
|
WHO Anatomical Therapeutic Chemical classification |
|
PROGESTOGENS |
| 0‑L |
G03DA
|
Pregnen (4) derivatives
|
WHO Anatomical Therapeutic Chemical classification |
|
Pregnen (4) derivatives |
| 0‑L |
G03DA01
|
gestonorone
|
WHO Anatomical Therapeutic Chemical classification |
|
gestonorone |
| 0‑L |
G03DA02
|
medroxyprogesterone
|
WHO Anatomical Therapeutic Chemical classification |
|
medroxyprogesterone |
| 0‑L |
G03DA03
|
hydroxyprogesterone
|
WHO Anatomical Therapeutic Chemical classification |
|
hydroxyprogesterone |
| 0‑L |
G03DA04
|
progesterone
|
WHO Anatomical Therapeutic Chemical classification |
|
progesterone |
| 0‑L |
G03DB
|
Pregnadien derivatives
|
WHO Anatomical Therapeutic Chemical classification |
|
Pregnadien derivatives |
| 0‑L |
G03DB01
|
dydrogesterone
|
WHO Anatomical Therapeutic Chemical classification |
|
dydrogesterone |
| 0‑L |
G03DB02
|
megestrol
|
WHO Anatomical Therapeutic Chemical classification |
|
megestrol |
| 0‑L |
G03DB03
|
medrogestone
|
WHO Anatomical Therapeutic Chemical classification |
|
medrogestone |
| 0‑L |
G03DB04
|
nomegestrol
|
WHO Anatomical Therapeutic Chemical classification |
|
nomegestrol |
| 0‑L |
G03DB05
|
demegestone
|
WHO Anatomical Therapeutic Chemical classification |
|
demegestone |
| 0‑L |
G03DB06
|
chlormadinone
|
WHO Anatomical Therapeutic Chemical classification |
|
chlormadinone |
| 0‑L |
G03DB07
|
promegestone
|
WHO Anatomical Therapeutic Chemical classification |
|
promegestone |
| 0‑L |
G03DB08
|
dienogest
|
WHO Anatomical Therapeutic Chemical classification |
|
dienogest |
| 0‑L |
G03DC
|
Estren derivatives
|
WHO Anatomical Therapeutic Chemical classification |
|
Estren derivatives |
| 0‑L |
G03DC01
|
allylestrenol
|
WHO Anatomical Therapeutic Chemical classification |
|
allylestrenol |
| 0‑L |
G03DC02
|
norethisterone
|
WHO Anatomical Therapeutic Chemical classification |
|
norethisterone |
| 0‑L |
G03DC03
|
lynestrenol
|
WHO Anatomical Therapeutic Chemical classification |
|
lynestrenol |
| 0‑L |
G03DC04
|
ethisterone
|
WHO Anatomical Therapeutic Chemical classification |
|
ethisterone |
| 0‑L |
G03DC06
|
etynodiol
|
WHO Anatomical Therapeutic Chemical classification |
|
etynodiol |
| 0‑L |
G03DC31
|
methylestrenolone
|
WHO Anatomical Therapeutic Chemical classification |
|
methylestrenolone |
| 0‑L |
G03E
|
ANDROGENS AND FEMALE SEX HORMONES IN COMBINATION
|
WHO Anatomical Therapeutic Chemical classification |
|
ANDROGENS AND FEMALE SEX HORMONES IN COMBINATION |
| 0‑L |
G03EA
|
Androgens and estrogens
|
WHO Anatomical Therapeutic Chemical classification |
|
Androgens and estrogens |
| 0‑L |
G03EA01
|
methyltestosterone and estrogen
|
WHO Anatomical Therapeutic Chemical classification |
|
methyltestosterone and estrogen |
| 0‑L |
G03EA02
|
testosterone and estrogen
|
WHO Anatomical Therapeutic Chemical classification |
|
testosterone and estrogen |
| 0‑L |
G03EA03
|
prasterone and estrogen
|
WHO Anatomical Therapeutic Chemical classification |
|
prasterone and estrogen |
| 0‑L |
G03EB
|
Androgen, progestogen and estrogen in combination
|
WHO Anatomical Therapeutic Chemical classification |
|
Androgen, progestogen and estrogen in combination |
| 0‑L |
G03EK
|
Androgens and female sex hormones in combination with other drugs
|
WHO Anatomical Therapeutic Chemical classification |
|
Androgens and female sex hormones in combination with other drugs |
| 0‑L |
G03EK01
|
methyltestosterone
|
WHO Anatomical Therapeutic Chemical classification |
|
methyltestosterone |
| 0‑L |
G03F
|
PROGESTOGENS AND ESTROGENS IN COMBINATION
|
WHO Anatomical Therapeutic Chemical classification |
|
PROGESTOGENS AND ESTROGENS IN COMBINATION |
| 0‑L |
G03FA
|
Progestogens and estrogens, fixed combinations
|
WHO Anatomical Therapeutic Chemical classification |
|
Progestogens and estrogens, fixed combinations |
| 0‑L |
G03FA01
|
norethisterone and estrogen
|
WHO Anatomical Therapeutic Chemical classification |
|
norethisterone and estrogen |
| 0‑L |
G03FA02
|
hydroxyprogesterone and estrogen
|
WHO Anatomical Therapeutic Chemical classification |
|
hydroxyprogesterone and estrogen |
| 0‑L |
G03FA03
|
ethisterone and estrogen
|
WHO Anatomical Therapeutic Chemical classification |
|
ethisterone and estrogen |
| 0‑L |
G03FA04
|
progesterone and estrogen
|
WHO Anatomical Therapeutic Chemical classification |
|
progesterone and estrogen |
| 0‑L |
G03FA05
|
methylnortestosterone and estrogen
|
WHO Anatomical Therapeutic Chemical classification |
|
methylnortestosterone and estrogen |
| 0‑L |
G03FA06
|
etynodiol and estrogen
|
WHO Anatomical Therapeutic Chemical classification |
|
etynodiol and estrogen |
| 0‑L |
G03FA07
|
lynestrenol and estrogen
|
WHO Anatomical Therapeutic Chemical classification |
|
lynestrenol and estrogen |
| 0‑L |
G03FA08
|
megestrol and estrogen
|
WHO Anatomical Therapeutic Chemical classification |
|
megestrol and estrogen |
| 0‑L |
G03FA09
|
noretynodrel and estrogen
|
WHO Anatomical Therapeutic Chemical classification |
|
noretynodrel and estrogen |
| 0‑L |
G03FA10
|
norgestrel and estrogen
|
WHO Anatomical Therapeutic Chemical classification |
|
norgestrel and estrogen |
| 0‑L |
G03FA11
|
levonorgestrel and estrogen
|
WHO Anatomical Therapeutic Chemical classification |
|
levonorgestrel and estrogen |
| 0‑L |
G03FA12
|
medroxyprogesterone and estrogen
|
WHO Anatomical Therapeutic Chemical classification |
|
medroxyprogesterone and estrogen |
| 0‑L |
G03FA13
|
norgestimate and estrogen
|
WHO Anatomical Therapeutic Chemical classification |
|
norgestimate and estrogen |
| 0‑L |
G03FA14
|
dydrogesterone and estrogen
|
WHO Anatomical Therapeutic Chemical classification |
|
dydrogesterone and estrogen |
| 0‑L |
G03FA15
|
dienogest and estrogen
|
WHO Anatomical Therapeutic Chemical classification |
|
dienogest and estrogen |
| 0‑L |
G03FA16
|
trimegestone and estrogen
|
WHO Anatomical Therapeutic Chemical classification |
|
trimegestone and estrogen |
| 0‑L |
G03FA17
|
drospirenone and estrogen
|
WHO Anatomical Therapeutic Chemical classification |
|
drospirenone and estrogen |
| 0‑L |
G03FB
|
Progestogens and estrogens, sequential preparations
|
WHO Anatomical Therapeutic Chemical classification |
|
Progestogens and estrogens, sequential preparations |
| 0‑L |
G03FB01
|
norgestrel and estrogen
|
WHO Anatomical Therapeutic Chemical classification |
|
norgestrel and estrogen |
| 0‑L |
G03FB02
|
lynestrenol and estrogen
|
WHO Anatomical Therapeutic Chemical classification |
|
lynestrenol and estrogen |
| 0‑L |
G03FB03
|
chlormadinone and estrogen
|
WHO Anatomical Therapeutic Chemical classification |
|
chlormadinone and estrogen |
| 0‑L |
G03FB04
|
megestrol and estrogen
|
WHO Anatomical Therapeutic Chemical classification |
|
megestrol and estrogen |
| 0‑L |
G03FB05
|
norethisterone and estrogen
|
WHO Anatomical Therapeutic Chemical classification |
|
norethisterone and estrogen |
| 0‑L |
G03FB06
|
medroxyprogesterone and estrogen
|
WHO Anatomical Therapeutic Chemical classification |
|
medroxyprogesterone and estrogen |
| 0‑L |
G03FB07
|
medrogestone and estrogen
|
WHO Anatomical Therapeutic Chemical classification |
|
medrogestone and estrogen |
| 0‑L |
G03FB08
|
dydrogesterone and estrogen
|
WHO Anatomical Therapeutic Chemical classification |
|
dydrogesterone and estrogen |
| 0‑L |
G03FB09
|
levonorgestrel and estrogen
|
WHO Anatomical Therapeutic Chemical classification |
|
levonorgestrel and estrogen |
| 0‑L |
G03FB10
|
desogestrel and estrogen
|
WHO Anatomical Therapeutic Chemical classification |
|
desogestrel and estrogen |
| 0‑L |
G03FB11
|
trimegestone and estrogen
|
WHO Anatomical Therapeutic Chemical classification |
|
trimegestone and estrogen |
| 0‑L |
G03FB12
|
nomegestrol and estrogen
|
WHO Anatomical Therapeutic Chemical classification |
|
nomegestrol and estrogen |
| 0‑L |
G03G
|
GONADOTROPINS AND OTHER OVULATION STIMULANTS
|
WHO Anatomical Therapeutic Chemical classification |
|
GONADOTROPINS AND OTHER OVULATION STIMULANTS |
| 0‑L |
G03GA
|
Gonadotropins
|
WHO Anatomical Therapeutic Chemical classification |
|
Gonadotropins |
| 0‑L |
G03GA01
|
chorionic gonadotrophin
|
WHO Anatomical Therapeutic Chemical classification |
|
chorionic gonadotrophin |
| 0‑L |
G03GA02
|
human menopausal gonadotrophin
|
WHO Anatomical Therapeutic Chemical classification |
|
human menopausal gonadotrophin |
| 0‑L |
G03GA03
|
serum gonadotrophin
|
WHO Anatomical Therapeutic Chemical classification |
|
serum gonadotrophin |
| 0‑L |
G03GA04
|
urofollitropin
|
WHO Anatomical Therapeutic Chemical classification |
|
urofollitropin |
| 0‑L |
G03GA05
|
follitropin alfa
|
WHO Anatomical Therapeutic Chemical classification |
|
follitropin alfa |
| 0‑L |
G03GA06
|
follitropin beta
|
WHO Anatomical Therapeutic Chemical classification |
|
follitropin beta |
| 0‑L |
G03GA07
|
lutropin alfa
|
WHO Anatomical Therapeutic Chemical classification |
|
lutropin alfa |
| 0‑L |
G03GA08
|
choriogonadotropin alfa
|
WHO Anatomical Therapeutic Chemical classification |
|
choriogonadotropin alfa |
| 0‑L |
G03GA09
|
corifollitropin alfa
|
WHO Anatomical Therapeutic Chemical classification |
|
corifollitropin alfa |
| 0‑L |
G03GA10
|
follitropin delta
|
WHO Anatomical Therapeutic Chemical classification |
|
follitropin delta |
| 0‑L |
G03GA30
|
combinations
|
WHO Anatomical Therapeutic Chemical classification |
|
combinations |
| 0‑L |
G03GB
|
Ovulation stimulants, synthetic
|
WHO Anatomical Therapeutic Chemical classification |
|
Ovulation stimulants, synthetic |
| 0‑L |
G03GB01
|
cyclofenil
|
WHO Anatomical Therapeutic Chemical classification |
|
cyclofenil |
| 0‑L |
G03GB02
|
clomifene
|
WHO Anatomical Therapeutic Chemical classification |
|
clomifene |
| 0‑L |
G03GB03
|
epimestrol
|
WHO Anatomical Therapeutic Chemical classification |
|
epimestrol |
| 0‑L |
G03H
|
ANTIANDROGENS
|
WHO Anatomical Therapeutic Chemical classification |
|
ANTIANDROGENS |
| 0‑L |
G03HA
|
Antiandrogens, plain
|
WHO Anatomical Therapeutic Chemical classification |
|
Antiandrogens, plain |
| 0‑L |
G03HA01
|
cyproterone
|
WHO Anatomical Therapeutic Chemical classification |
|
cyproterone |
| 0‑L |
G03HB
|
Antiandrogens and estrogens
|
WHO Anatomical Therapeutic Chemical classification |
|
Antiandrogens and estrogens |
| 0‑L |
G03HB01
|
cyproterone and estrogen
|
WHO Anatomical Therapeutic Chemical classification |
|
cyproterone and estrogen |
| 0‑L |
G03X
|
OTHER SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM
|
WHO Anatomical Therapeutic Chemical classification |
|
OTHER SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM |
| 0‑L |
G03XA
|
Antigonadotropins and similar agents
|
WHO Anatomical Therapeutic Chemical classification |
|
Antigonadotropins and similar agents |
| 0‑L |
G03XA01
|
danazol
|
WHO Anatomical Therapeutic Chemical classification |
|
danazol |
| 0‑L |
G03XA02
|
gestrinone
|
WHO Anatomical Therapeutic Chemical classification |
|
gestrinone |
| 0‑L |
G03XB
|
Progesterone receptor modulators
|
WHO Anatomical Therapeutic Chemical classification |
|
Progesterone receptor modulators |
| 0‑L |
G03XB01
|
mifepristone
|
WHO Anatomical Therapeutic Chemical classification |
|
mifepristone |
| 0‑L |
G03XB02
|
ulipristal
|
WHO Anatomical Therapeutic Chemical classification |
|
ulipristal |
| 0‑L |
G03XB51
|
mifepristone, combinations
|
WHO Anatomical Therapeutic Chemical classification |
|
mifepristone, combinations |
| 0‑L |
G03XC
|
Selective estrogen receptor modulators
|
WHO Anatomical Therapeutic Chemical classification |
|
Selective estrogen receptor modulators |
| 0‑L |
G03XC01
|
raloxifene
|
WHO Anatomical Therapeutic Chemical classification |
|
raloxifene |
| 0‑L |
G03XC02
|
bazedoxifene
|
WHO Anatomical Therapeutic Chemical classification |
|
bazedoxifene |
| 0‑L |
G03XC03
|
lasofoxifene
|
WHO Anatomical Therapeutic Chemical classification |
|
lasofoxifene |
| 0‑L |
G03XC04
|
ormeloxifene
|
WHO Anatomical Therapeutic Chemical classification |
|
ormeloxifene |
| 0‑L |
G03XC05
|
ospemifene
|
WHO Anatomical Therapeutic Chemical classification |
|
ospemifene |
| 0‑L |
G04
|
UROLOGICALS
|
WHO Anatomical Therapeutic Chemical classification |
|
UROLOGICALS |
| 0‑L |
G04B
|
UROLOGICALS
|
WHO Anatomical Therapeutic Chemical classification |
|
UROLOGICALS |
| 0‑L |
G04BA
|
Acidifiers
|
WHO Anatomical Therapeutic Chemical classification |
|
Acidifiers |
| 0‑L |
G04BA01
|
ammonium chloride
|
WHO Anatomical Therapeutic Chemical classification |
|
ammonium chloride |
| 0‑L |
G04BA03
|
calcium chloride
|
WHO Anatomical Therapeutic Chemical classification |
|
calcium chloride |
| 0‑L |
G04BC
|
Urinary concrement solvents
|
WHO Anatomical Therapeutic Chemical classification |
|
Urinary concrement solvents |
| 0‑L |
G04BD
|
Drugs for urinary frequency and incontinence
|
WHO Anatomical Therapeutic Chemical classification |
|
Drugs for urinary frequency and incontinence |
| 0‑L |
G04BD01
|
emepronium
|
WHO Anatomical Therapeutic Chemical classification |
|
emepronium |
| 0‑L |
G04BD02
|
flavoxate
|
WHO Anatomical Therapeutic Chemical classification |
|
flavoxate |
| 0‑L |
G04BD03
|
meladrazine
|
WHO Anatomical Therapeutic Chemical classification |
|
meladrazine |
| 0‑L |
G04BD04
|
oxybutynin
|
WHO Anatomical Therapeutic Chemical classification |
|
oxybutynin |
| 0‑L |
G04BD05
|
terodiline
|
WHO Anatomical Therapeutic Chemical classification |
|
terodiline |
| 0‑L |
G04BD06
|
propiverine
|
WHO Anatomical Therapeutic Chemical classification |
|
propiverine |
| 0‑L |
G04BD07
|
tolterodine
|
WHO Anatomical Therapeutic Chemical classification |
|
tolterodine |
| 0‑L |
G04BD08
|
solifenacin
|
WHO Anatomical Therapeutic Chemical classification |
|
solifenacin |
| 0‑L |
G04BD09
|
trospium
|
WHO Anatomical Therapeutic Chemical classification |
|
trospium |
| 0‑L |
G04BD10
|
darifenacin
|
WHO Anatomical Therapeutic Chemical classification |
|
darifenacin |
| 0‑L |
G04BD11
|
fesoterodine
|
WHO Anatomical Therapeutic Chemical classification |
|
fesoterodine |
| 0‑L |
G04BD12
|
mirabegron
|
WHO Anatomical Therapeutic Chemical classification |
|
mirabegron |
| 0‑L |
G04BD13
|
desfesoterodine
|
WHO Anatomical Therapeutic Chemical classification |
|
desfesoterodine |
| 0‑L |
G04BE
|
Drugs used in erectile dysfunction
|
WHO Anatomical Therapeutic Chemical classification |
|
Drugs used in erectile dysfunction |
| 0‑L |
G04BE01
|
alprostadil
|
WHO Anatomical Therapeutic Chemical classification |
|
alprostadil |
| 0‑L |
G04BE02
|
papaverine
|
WHO Anatomical Therapeutic Chemical classification |
|
papaverine |
| 0‑L |
G04BE03
|
sildenafil
|
WHO Anatomical Therapeutic Chemical classification |
|
sildenafil |
| 0‑L |
G04BE04
|
yohimbine
|
WHO Anatomical Therapeutic Chemical classification |
|
yohimbine |
| 0‑L |
G04BE06
|
moxisylyte
|
WHO Anatomical Therapeutic Chemical classification |
|
moxisylyte |
| 0‑L |
G04BE07
|
apomorphine
|
WHO Anatomical Therapeutic Chemical classification |
|
apomorphine |
| 0‑L |
G04BE08
|
tadalafil
|
WHO Anatomical Therapeutic Chemical classification |
|
tadalafil |
| 0‑L |
G04BE09
|
vardenafil
|
WHO Anatomical Therapeutic Chemical classification |
|
vardenafil |
| 0‑L |
G04BE10
|
avanafil
|
WHO Anatomical Therapeutic Chemical classification |
|
avanafil |
| 0‑L |
G04BE11
|
udenafil
|
WHO Anatomical Therapeutic Chemical classification |
|
udenafil |
| 0‑L |
G04BE30
|
combinations
|
WHO Anatomical Therapeutic Chemical classification |
|
combinations |
| 0‑L |
G04BE52
|
papaverine, combinations
|
WHO Anatomical Therapeutic Chemical classification |
|
papaverine, combinations |
| 0‑L |
G04BX
|
Other urologicals
|
WHO Anatomical Therapeutic Chemical classification |
|
Other urologicals |
| 0‑L |
G04BX01
|
magnesium hydroxide
|
WHO Anatomical Therapeutic Chemical classification |
|
magnesium hydroxide |
| 0‑L |
G04BX03
|
acetohydroxamic acid
|
WHO Anatomical Therapeutic Chemical classification |
|
acetohydroxamic acid |
| 0‑L |
G04BX06
|
phenazopyridine
|
WHO Anatomical Therapeutic Chemical classification |
|
phenazopyridine |
| 0‑L |
G04BX10
|
succinimide
|
WHO Anatomical Therapeutic Chemical classification |
|
succinimide |
| 0‑L |
G04BX11
|
collagen
|
WHO Anatomical Therapeutic Chemical classification |
|
collagen |
| 0‑L |
G04BX12
|
phenyl salicylate
|
WHO Anatomical Therapeutic Chemical classification |
|
phenyl salicylate |
| 0‑L |
G04BX13
|
dimethyl sulfoxide
|
WHO Anatomical Therapeutic Chemical classification |
|
dimethyl sulfoxide |
| 0‑L |
G04BX14
|
dapoxetine
|
WHO Anatomical Therapeutic Chemical classification |
|
dapoxetine |
| 0‑L |
G04BX15
|
pentosan polysulfate sodium
|
WHO Anatomical Therapeutic Chemical classification |
|
pentosan polysulfate sodium |
| 0‑L |
G04BX16
|
tiopronin
|
WHO Anatomical Therapeutic Chemical classification |
|
tiopronin |
| 0‑L |
G04C
|
DRUGS USED IN BENIGN PROSTATIC HYPERTROPHY
|
WHO Anatomical Therapeutic Chemical classification |
|
DRUGS USED IN BENIGN PROSTATIC HYPERTROPHY |
| 0‑L |
G04CA
|
Alpha-adrenoreceptor antagonists
|
WHO Anatomical Therapeutic Chemical classification |
|
Alpha-adrenoreceptor antagonists |
| 0‑L |
G04CA01
|
alfuzosin
|
WHO Anatomical Therapeutic Chemical classification |
|
alfuzosin |
| 0‑L |
G04CA02
|
tamsulosin
|
WHO Anatomical Therapeutic Chemical classification |
|
tamsulosin |
| 0‑L |
G04CA03
|
terazosin
|
WHO Anatomical Therapeutic Chemical classification |
|
terazosin |
| 0‑L |
G04CA04
|
silodosin
|
WHO Anatomical Therapeutic Chemical classification |
|
silodosin |
| 0‑L |
G04CA51
|
alfuzosin and finasteride
|
WHO Anatomical Therapeutic Chemical classification |
|
alfuzosin and finasteride |
| 0‑L |
G04CA52
|
tamsulosin and dutasteride
|
WHO Anatomical Therapeutic Chemical classification |
|
tamsulosin and dutasteride |
| 0‑L |
G04CA53
|
tamsulosin and solifenacin
|
WHO Anatomical Therapeutic Chemical classification |
|
tamsulosin and solifenacin |
| 0‑L |
G04CB
|
Testosterone-5-alpha reductase inhibitors
|
WHO Anatomical Therapeutic Chemical classification |
|
Testosterone-5-alpha reductase inhibitors |
| 0‑L |
G04CB01
|
finasteride
|
WHO Anatomical Therapeutic Chemical classification |
|
finasteride |
| 0‑L |
G04CB02
|
dutasteride
|
WHO Anatomical Therapeutic Chemical classification |
|
dutasteride |
| 0‑L |
G04CX
|
Other drugs used in benign prostatic hypertrophy
|
WHO Anatomical Therapeutic Chemical classification |
|
Other drugs used in benign prostatic hypertrophy |
| 0‑L |
G04CX01
|
Prunus africanae cortex
|
WHO Anatomical Therapeutic Chemical classification |
|
Prunus africanae cortex |
| 0‑L |
G04CX02
|
Sabalis serrulatae fructus
|
WHO Anatomical Therapeutic Chemical classification |
|
Sabalis serrulatae fructus |
| 0‑L |
G04CX03
|
mepartricin
|
WHO Anatomical Therapeutic Chemical classification |
|
mepartricin |
| 0‑L |
H
|
SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS
|
WHO Anatomical Therapeutic Chemical classification |
|
SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS |
| 0‑L |
H01
|
PITUITARY AND HYPOTHALAMIC HORMONES AND ANALOGUES
|
WHO Anatomical Therapeutic Chemical classification |
|
PITUITARY AND HYPOTHALAMIC HORMONES AND ANALOGUES |
| 0‑L |
H01A
|
ANTERIOR PITUITARY LOBE HORMONES AND ANALOGUES
|
WHO Anatomical Therapeutic Chemical classification |
|
ANTERIOR PITUITARY LOBE HORMONES AND ANALOGUES |
| 0‑L |
H01AA
|
ACTH
|
WHO Anatomical Therapeutic Chemical classification |
|
ACTH |
| 0‑L |
H01AA01
|
corticotropin
|
WHO Anatomical Therapeutic Chemical classification |
|
corticotropin |
| 0‑L |
H01AA02
|
tetracosactide
|
WHO Anatomical Therapeutic Chemical classification |
|
tetracosactide |
| 0‑L |
H01AB
|
Thyrotropin
|
WHO Anatomical Therapeutic Chemical classification |
|
Thyrotropin |
| 0‑L |
H01AB01
|
thyrotropin alfa
|
WHO Anatomical Therapeutic Chemical classification |
|
thyrotropin alfa |
| 0‑L |
H01AC
|
Somatropin and somatropin agonists
|
WHO Anatomical Therapeutic Chemical classification |
|
Somatropin and somatropin agonists |
| 0‑L |
H01AC01
|
somatropin
|
WHO Anatomical Therapeutic Chemical classification |
|
somatropin |
| 0‑L |
H01AC02
|
somatrem
|
WHO Anatomical Therapeutic Chemical classification |
|
somatrem |
| 0‑L |
H01AC03
|
mecasermin
|
WHO Anatomical Therapeutic Chemical classification |
|
mecasermin |
| 0‑L |
H01AC04
|
sermorelin
|
WHO Anatomical Therapeutic Chemical classification |
|
sermorelin |
| 0‑L |
H01AC05
|
mecasermin rinfabate
|
WHO Anatomical Therapeutic Chemical classification |
|
mecasermin rinfabate |
| 0‑L |
H01AC06
|
tesamorelin
|
WHO Anatomical Therapeutic Chemical classification |
|
tesamorelin |
| 0‑L |
H01AX
|
Other anterior pituitary lobe hormones and analogues
|
WHO Anatomical Therapeutic Chemical classification |
|
Other anterior pituitary lobe hormones and analogues |
| 0‑L |
H01AX01
|
pegvisomant
|
WHO Anatomical Therapeutic Chemical classification |
|
pegvisomant |
| 0‑L |
H01B
|
POSTERIOR PITUITARY LOBE HORMONES
|
WHO Anatomical Therapeutic Chemical classification |
|
POSTERIOR PITUITARY LOBE HORMONES |
| 0‑L |
H01BA
|
Vasopressin and analogues
|
WHO Anatomical Therapeutic Chemical classification |
|
Vasopressin and analogues |
| 0‑L |
H01BA01
|
vasopressin
|
WHO Anatomical Therapeutic Chemical classification |
|
vasopressin |
| 0‑L |
H01BA02
|
desmopressin
|
WHO Anatomical Therapeutic Chemical classification |
|
desmopressin |
| 0‑L |
H01BA03
|
lypressin
|
WHO Anatomical Therapeutic Chemical classification |
|
lypressin |
| 0‑L |
H01BA04
|
terlipressin
|
WHO Anatomical Therapeutic Chemical classification |
|
terlipressin |
| 0‑L |
H01BA05
|
ornipressin
|
WHO Anatomical Therapeutic Chemical classification |
|
ornipressin |
| 0‑L |
H01BA06
|
argipressin
|
WHO Anatomical Therapeutic Chemical classification |
|
argipressin |
| 0‑L |
H01BB
|
Oxytocin and analogues
|
WHO Anatomical Therapeutic Chemical classification |
|
Oxytocin and analogues |
| 0‑L |
H01BB01
|
demoxytocin
|
WHO Anatomical Therapeutic Chemical classification |
|
demoxytocin |
| 0‑L |
H01BB02
|
oxytocin
|
WHO Anatomical Therapeutic Chemical classification |
|
oxytocin |
| 0‑L |
H01BB03
|
carbetocin
|
WHO Anatomical Therapeutic Chemical classification |
|
carbetocin |
| 0‑L |
H01C
|
HYPOTHALAMIC HORMONES
|
WHO Anatomical Therapeutic Chemical classification |
|
HYPOTHALAMIC HORMONES |
| 0‑L |
H01CA
|
Gonadotropin-releasing hormones
|
WHO Anatomical Therapeutic Chemical classification |
|
Gonadotropin-releasing hormones |
| 0‑L |
H01CA01
|
gonadorelin
|
WHO Anatomical Therapeutic Chemical classification |
|
gonadorelin |
| 0‑L |
H01CA02
|
nafarelin
|
WHO Anatomical Therapeutic Chemical classification |
|
nafarelin |
| 0‑L |
H01CB
|
Somatostatin and analogues
|
WHO Anatomical Therapeutic Chemical classification |
|
Somatostatin and analogues |
| 0‑L |
H01CB01
|
somatostatin
|
WHO Anatomical Therapeutic Chemical classification |
|
somatostatin |
| 0‑L |
H01CB02
|
octreotide
|
WHO Anatomical Therapeutic Chemical classification |
|
octreotide |
| 0‑L |
H01CB03
|
lanreotide
|
WHO Anatomical Therapeutic Chemical classification |
|
lanreotide |
| 0‑L |
H01CB04
|
vapreotide
|
WHO Anatomical Therapeutic Chemical classification |
|
vapreotide |
| 0‑L |
H01CB05
|
pasireotide
|
WHO Anatomical Therapeutic Chemical classification |
|
pasireotide |
| 0‑L |
H01CC
|
Anti-gonadotropin-releasing hormones
|
WHO Anatomical Therapeutic Chemical classification |
|
Anti-gonadotropin-releasing hormones |
| 0‑L |
H01CC01
|
ganirelix
|
WHO Anatomical Therapeutic Chemical classification |
|
ganirelix |
| 0‑L |
H01CC02
|
cetrorelix
|
WHO Anatomical Therapeutic Chemical classification |
|
cetrorelix |
| 0‑L |
H02
|
CORTICOSTEROIDS FOR SYSTEMIC USE
|
WHO Anatomical Therapeutic Chemical classification |
|
CORTICOSTEROIDS FOR SYSTEMIC USE |
| 0‑L |
H02A
|
CORTICOSTEROIDS FOR SYSTEMIC USE, PLAIN
|
WHO Anatomical Therapeutic Chemical classification |
|
CORTICOSTEROIDS FOR SYSTEMIC USE, PLAIN |
| 0‑L |
H02AA
|
Mineralocorticoids
|
WHO Anatomical Therapeutic Chemical classification |
|
Mineralocorticoids |
| 0‑L |
H02AA01
|
aldosterone
|
WHO Anatomical Therapeutic Chemical classification |
|
aldosterone |
| 0‑L |
H02AA02
|
fludrocortisone
|
WHO Anatomical Therapeutic Chemical classification |
|
fludrocortisone |
| 0‑L |
H02AA03
|
desoxycortone
|
WHO Anatomical Therapeutic Chemical classification |
|
desoxycortone |
| 0‑L |
H02AB
|
Glucocorticoids
|
WHO Anatomical Therapeutic Chemical classification |
|
Glucocorticoids |
| 0‑L |
H02AB01
|
betamethasone
|
WHO Anatomical Therapeutic Chemical classification |
|
betamethasone |
| 0‑L |
H02AB02
|
dexamethasone
|
WHO Anatomical Therapeutic Chemical classification |
|
dexamethasone |
| 0‑L |
H02AB03
|
fluocortolone
|
WHO Anatomical Therapeutic Chemical classification |
|
fluocortolone |
| 0‑L |
H02AB04
|
methylprednisolone
|
WHO Anatomical Therapeutic Chemical classification |
|
methylprednisolone |
| 0‑L |
H02AB05
|
paramethasone
|
WHO Anatomical Therapeutic Chemical classification |
|
paramethasone |
| 0‑L |
H02AB06
|
prednisolone
|
WHO Anatomical Therapeutic Chemical classification |
|
prednisolone |
| 0‑L |
H02AB07
|
prednisone
|
WHO Anatomical Therapeutic Chemical classification |
|
prednisone |
| 0‑L |
H02AB08
|
triamcinolone
|
WHO Anatomical Therapeutic Chemical classification |
|
triamcinolone |
| 0‑L |
H02AB09
|
hydrocortisone
|
WHO Anatomical Therapeutic Chemical classification |
|
hydrocortisone |
| 0‑L |
H02AB10
|
cortisone
|
WHO Anatomical Therapeutic Chemical classification |
|
cortisone |
| 0‑L |
H02AB11
|
prednylidene
|
WHO Anatomical Therapeutic Chemical classification |
|
prednylidene |
| 0‑L |
H02AB12
|
rimexolone
|
WHO Anatomical Therapeutic Chemical classification |
|
rimexolone |
| 0‑L |
H02AB13
|
deflazacort
|
WHO Anatomical Therapeutic Chemical classification |
|
deflazacort |
| 0‑L |
H02AB14
|
cloprednol
|
WHO Anatomical Therapeutic Chemical classification |
|
cloprednol |
| 0‑L |
H02AB15
|
meprednisone
|
WHO Anatomical Therapeutic Chemical classification |
|
meprednisone |
| 0‑L |
H02AB17
|
cortivazol
|
WHO Anatomical Therapeutic Chemical classification |
|
cortivazol |
| 0‑L |
H02B
|
CORTICOSTEROIDS FOR SYSTEMIC USE, COMBINATIONS
|
WHO Anatomical Therapeutic Chemical classification |
|
CORTICOSTEROIDS FOR SYSTEMIC USE, COMBINATIONS |
| 0‑L |
H02BX
|
Corticosteroids for systemic use, combinations
|
WHO Anatomical Therapeutic Chemical classification |
|
Corticosteroids for systemic use, combinations |
| 0‑L |
H02BX01
|
methylprednisolone, combinations
|
WHO Anatomical Therapeutic Chemical classification |
|
methylprednisolone, combinations |
| 0‑L |
H02C
|
ANTIADRENAL PREPARATIONS
|
WHO Anatomical Therapeutic Chemical classification |
|
ANTIADRENAL PREPARATIONS |
| 0‑L |
H02CA
|
Anticorticosteroids
|
WHO Anatomical Therapeutic Chemical classification |
|
Anticorticosteroids |
| 0‑L |
H02CA01
|
trilostane
|
WHO Anatomical Therapeutic Chemical classification |
|
trilostane |
| 0‑L |
H03
|
THYROID THERAPY
|
WHO Anatomical Therapeutic Chemical classification |
|
THYROID THERAPY |
| 0‑L |
H03A
|
THYROID PREPARATIONS
|
WHO Anatomical Therapeutic Chemical classification |
|
THYROID PREPARATIONS |
| 0‑L |
H03AA
|
Thyroid hormones
|
WHO Anatomical Therapeutic Chemical classification |
|
Thyroid hormones |
| 0‑L |
H03AA01
|
levothyroxine sodium
|
WHO Anatomical Therapeutic Chemical classification |
|
levothyroxine sodium |
| 0‑L |
H03AA02
|
liothyronine sodium
|
WHO Anatomical Therapeutic Chemical classification |
|
liothyronine sodium |
| 0‑L |
H03AA03
|
combinations of levothyroxine and liothyronine
|
WHO Anatomical Therapeutic Chemical classification |
|
combinations of levothyroxine and liothyronine |
| 0‑L |
H03AA04
|
tiratricol
|
WHO Anatomical Therapeutic Chemical classification |
|
tiratricol |
| 0‑L |
H03AA05
|
thyroid gland preparations
|
WHO Anatomical Therapeutic Chemical classification |
|
thyroid gland preparations |
| 0‑L |
H03B
|
ANTITHYROID PREPARATIONS
|
WHO Anatomical Therapeutic Chemical classification |
|
ANTITHYROID PREPARATIONS |
| 0‑L |
H03BA
|
Thiouracils
|
WHO Anatomical Therapeutic Chemical classification |
|
Thiouracils |
| 0‑L |
H03BA01
|
methylthiouracil
|
WHO Anatomical Therapeutic Chemical classification |
|
methylthiouracil |
| 0‑L |
H03BA02
|
propylthiouracil
|
WHO Anatomical Therapeutic Chemical classification |
|
propylthiouracil |
| 0‑L |
H03BA03
|
benzylthiouracil
|
WHO Anatomical Therapeutic Chemical classification |
|
benzylthiouracil |
| 0‑L |
H03BB
|
Sulfur-containing imidazole derivatives
|
WHO Anatomical Therapeutic Chemical classification |
|
Sulfur-containing imidazole derivatives |
| 0‑L |
H03BB01
|
carbimazole
|
WHO Anatomical Therapeutic Chemical classification |
|
carbimazole |
| 0‑L |
H03BB02
|
thiamazole
|
WHO Anatomical Therapeutic Chemical classification |
|
thiamazole |
| 0‑L |
H03BB52
|
thiamazole, combinations
|
WHO Anatomical Therapeutic Chemical classification |
|
thiamazole, combinations |
| 0‑L |
H03BC
|
Perchlorates
|
WHO Anatomical Therapeutic Chemical classification |
|
Perchlorates |
| 0‑L |
H03BC01
|
potassium perchlorate
|
WHO Anatomical Therapeutic Chemical classification |
|
potassium perchlorate |
| 0‑L |
H03BX
|
Other antithyroid preparations
|
WHO Anatomical Therapeutic Chemical classification |
|
Other antithyroid preparations |
| 0‑L |
H03BX01
|
diiodotyrosine
|
WHO Anatomical Therapeutic Chemical classification |
|
diiodotyrosine |
| 0‑L |
H03BX02
|
dibromotyrosine
|
WHO Anatomical Therapeutic Chemical classification |
|
dibromotyrosine |
| 0‑L |
H03C
|
IODINE THERAPY
|
WHO Anatomical Therapeutic Chemical classification |
|
IODINE THERAPY |
| 0‑L |
H03CA
|
Iodine therapy
|
WHO Anatomical Therapeutic Chemical classification |
|
Iodine therapy |
| 0‑L |
H04
|
PANCREATIC HORMONES
|
WHO Anatomical Therapeutic Chemical classification |
|
PANCREATIC HORMONES |
| 0‑L |
H04A
|
GLYCOGENOLYTIC HORMONES
|
WHO Anatomical Therapeutic Chemical classification |
|
GLYCOGENOLYTIC HORMONES |
| 0‑L |
H04AA
|
Glycogenolytic hormones
|
WHO Anatomical Therapeutic Chemical classification |
|
Glycogenolytic hormones |
| 0‑L |
H04AA01
|
glucagon
|
WHO Anatomical Therapeutic Chemical classification |
|
glucagon |
| 0‑L |
H05
|
CALCIUM HOMEOSTASIS
|
WHO Anatomical Therapeutic Chemical classification |
|
CALCIUM HOMEOSTASIS |
| 0‑L |
H05A
|
PARATHYROID HORMONES AND ANALOGUES
|
WHO Anatomical Therapeutic Chemical classification |
|
PARATHYROID HORMONES AND ANALOGUES |
| 0‑L |
H05AA
|
Parathyroid hormones and analogues
|
WHO Anatomical Therapeutic Chemical classification |
|
Parathyroid hormones and analogues |
| 0‑L |
H05AA01
|
parathyroid gland extract
|
WHO Anatomical Therapeutic Chemical classification |
|
parathyroid gland extract |
| 0‑L |
H05AA02
|
teriparatide
|
WHO Anatomical Therapeutic Chemical classification |
|
teriparatide |
| 0‑L |
H05AA03
|
parathyroid hormone
|
WHO Anatomical Therapeutic Chemical classification |
|
parathyroid hormone |
| 0‑L |
H05B
|
ANTI-PARATHYROID AGENTS
|
WHO Anatomical Therapeutic Chemical classification |
|
ANTI-PARATHYROID AGENTS |
| 0‑L |
H05BA
|
Calcitonin preparations
|
WHO Anatomical Therapeutic Chemical classification |
|
Calcitonin preparations |
| 0‑L |
H05BA01
|
calcitonin (salmon synthetic)
|
WHO Anatomical Therapeutic Chemical classification |
|
calcitonin (salmon synthetic) |
| 0‑L |
H05BA02
|
calcitonin (pork natural)
|
WHO Anatomical Therapeutic Chemical classification |
|
calcitonin (pork natural) |
| 0‑L |
H05BA03
|
calcitonin (human synthetic)
|
WHO Anatomical Therapeutic Chemical classification |
|
calcitonin (human synthetic) |
| 0‑L |
H05BA04
|
elcatonin
|
WHO Anatomical Therapeutic Chemical classification |
|
elcatonin |
| 0‑L |
H05BX
|
Other anti-parathyroid agents
|
WHO Anatomical Therapeutic Chemical classification |
|
Other anti-parathyroid agents |
| 0‑L |
H05BX01
|
cinacalcet
|
WHO Anatomical Therapeutic Chemical classification |
|
cinacalcet |
| 0‑L |
H05BX02
|
paricalcitol
|
WHO Anatomical Therapeutic Chemical classification |
|
paricalcitol |
| 0‑L |
H05BX03
|
doxercalciferol
|
WHO Anatomical Therapeutic Chemical classification |
|
doxercalciferol |
| 0‑L |
H05BX04
|
etelcalcetide
|
WHO Anatomical Therapeutic Chemical classification |
|
etelcalcetide |
| 0‑L |
J
|
ANTIINFECTIVES FOR SYSTEMIC USE
|
WHO Anatomical Therapeutic Chemical classification |
|
ANTIINFECTIVES FOR SYSTEMIC USE |
| 0‑L |
J01
|
ANTIBACTERIALS FOR SYSTEMIC USE
|
WHO Anatomical Therapeutic Chemical classification |
|
ANTIBACTERIALS FOR SYSTEMIC USE |
| 0‑L |
J01A
|
TETRACYCLINES
|
WHO Anatomical Therapeutic Chemical classification |
|
TETRACYCLINES |
| 0‑L |
J01AA
|
Tetracyclines
|
WHO Anatomical Therapeutic Chemical classification |
|
Tetracyclines |
| 0‑L |
J01AA01
|
demeclocycline
|
WHO Anatomical Therapeutic Chemical classification |
|
demeclocycline |
| 0‑L |
J01AA02
|
doxycycline
|
WHO Anatomical Therapeutic Chemical classification |
|
doxycycline |
| 0‑L |
J01AA03
|
chlortetracycline
|
WHO Anatomical Therapeutic Chemical classification |
|
chlortetracycline |
| 0‑L |
J01AA04
|
lymecycline
|
WHO Anatomical Therapeutic Chemical classification |
|
lymecycline |
| 0‑L |
J01AA05
|
metacycline
|
WHO Anatomical Therapeutic Chemical classification |
|
metacycline |
| 0‑L |
J01AA06
|
oxytetracycline
|
WHO Anatomical Therapeutic Chemical classification |
|
oxytetracycline |
| 0‑L |
J01AA07
|
tetracycline
|
WHO Anatomical Therapeutic Chemical classification |
|
tetracycline |
| 0‑L |
J01AA08
|
minocycline
|
WHO Anatomical Therapeutic Chemical classification |
|
minocycline |
| 0‑L |
J01AA09
|
rolitetracycline
|
WHO Anatomical Therapeutic Chemical classification |
|
rolitetracycline |
| 0‑L |
J01AA10
|
penimepicycline
|
WHO Anatomical Therapeutic Chemical classification |
|
penimepicycline |
| 0‑L |
J01AA11
|
clomocycline
|
WHO Anatomical Therapeutic Chemical classification |
|
clomocycline |
| 0‑L |
J01AA12
|
tigecycline
|
WHO Anatomical Therapeutic Chemical classification |
|
tigecycline |
| 0‑L |
J01AA20
|
combinations of tetracyclines
|
WHO Anatomical Therapeutic Chemical classification |
|
combinations of tetracyclines |
| 0‑L |
J01AA56
|
oxytetracycline, combinations
|
WHO Anatomical Therapeutic Chemical classification |
|
oxytetracycline, combinations |
| 0‑L |
J01B
|
AMPHENICOLS
|
WHO Anatomical Therapeutic Chemical classification |
|
AMPHENICOLS |
| 0‑L |
J01BA
|
Amphenicols
|
WHO Anatomical Therapeutic Chemical classification |
|
Amphenicols |
| 0‑L |
J01BA01
|
chloramphenicol
|
WHO Anatomical Therapeutic Chemical classification |
|
chloramphenicol |
| 0‑L |
J01BA02
|
thiamphenicol
|
WHO Anatomical Therapeutic Chemical classification |
|
thiamphenicol |
| 0‑L |
J01BA52
|
thiamphenicol, combinations
|
WHO Anatomical Therapeutic Chemical classification |
|
thiamphenicol, combinations |
| 0‑L |
J01C
|
BETA-LACTAM ANTIBACTERIALS, PENICILLINS
|
WHO Anatomical Therapeutic Chemical classification |
|
BETA-LACTAM ANTIBACTERIALS, PENICILLINS |
| 0‑L |
J01CA
|
Penicillins with extended spectrum
|
WHO Anatomical Therapeutic Chemical classification |
|
Penicillins with extended spectrum |
| 0‑L |
J01CA01
|
ampicillin
|
WHO Anatomical Therapeutic Chemical classification |
|
ampicillin |
| 0‑L |
J01CA02
|
pivampicillin
|
WHO Anatomical Therapeutic Chemical classification |
|
pivampicillin |
| 0‑L |
J01CA03
|
carbenicillin
|
WHO Anatomical Therapeutic Chemical classification |
|
carbenicillin |
| 0‑L |
J01CA04
|
amoxicillin
|
WHO Anatomical Therapeutic Chemical classification |
|
amoxicillin |
| 0‑L |
J01CA05
|
carindacillin
|
WHO Anatomical Therapeutic Chemical classification |
|
carindacillin |
| 0‑L |
J01CA06
|
bacampicillin
|
WHO Anatomical Therapeutic Chemical classification |
|
bacampicillin |
| 0‑L |
J01CA07
|
epicillin
|
WHO Anatomical Therapeutic Chemical classification |
|
epicillin |
| 0‑L |
J01CA08
|
pivmecillinam
|
WHO Anatomical Therapeutic Chemical classification |
|
pivmecillinam |
| 0‑L |
J01CA09
|
azlocillin
|
WHO Anatomical Therapeutic Chemical classification |
|
azlocillin |
| 0‑L |
J01CA10
|
mezlocillin
|
WHO Anatomical Therapeutic Chemical classification |
|
mezlocillin |
| 0‑L |
J01CA11
|
mecillinam
|
WHO Anatomical Therapeutic Chemical classification |
|
mecillinam |
| 0‑L |
J01CA12
|
piperacillin
|
WHO Anatomical Therapeutic Chemical classification |
|
piperacillin |
| 0‑L |
J01CA13
|
ticarcillin
|
WHO Anatomical Therapeutic Chemical classification |
|
ticarcillin |
| 0‑L |
J01CA14
|
metampicillin
|
WHO Anatomical Therapeutic Chemical classification |
|
metampicillin |
| 0‑L |
J01CA15
|
talampicillin
|
WHO Anatomical Therapeutic Chemical classification |
|
talampicillin |
| 0‑L |
J01CA16
|
sulbenicillin
|
WHO Anatomical Therapeutic Chemical classification |
|
sulbenicillin |
| 0‑L |
J01CA17
|
temocillin
|
WHO Anatomical Therapeutic Chemical classification |
|
temocillin |
| 0‑L |
J01CA18
|
hetacillin
|
WHO Anatomical Therapeutic Chemical classification |
|
hetacillin |
| 0‑L |
J01CA19
|
aspoxicillin
|
WHO Anatomical Therapeutic Chemical classification |
|
aspoxicillin |
| 0‑L |
J01CA20
|
combinations
|
WHO Anatomical Therapeutic Chemical classification |
|
combinations |
| 0‑L |
J01CA51
|
ampicillin, combinations
|
WHO Anatomical Therapeutic Chemical classification |
|
ampicillin, combinations |
| 0‑L |
J01CE
|
Beta-lactamase sensitive penicillins
|
WHO Anatomical Therapeutic Chemical classification |
|
Beta-lactamase sensitive penicillins |
| 0‑L |
J01CE01
|
benzylpenicillin
|
WHO Anatomical Therapeutic Chemical classification |
|
benzylpenicillin |
| 0‑L |
J01CE02
|
phenoxymethylpenicillin
|
WHO Anatomical Therapeutic Chemical classification |
|
phenoxymethylpenicillin |
| 0‑L |
J01CE03
|
propicillin
|
WHO Anatomical Therapeutic Chemical classification |
|
propicillin |
| 0‑L |
J01CE04
|
azidocillin
|
WHO Anatomical Therapeutic Chemical classification |
|
azidocillin |
| 0‑L |
J01CE05
|
pheneticillin
|
WHO Anatomical Therapeutic Chemical classification |
|
pheneticillin |
| 0‑L |
J01CE06
|
penamecillin
|
WHO Anatomical Therapeutic Chemical classification |
|
penamecillin |
| 0‑L |
J01CE07
|
clometocillin
|
WHO Anatomical Therapeutic Chemical classification |
|
clometocillin |
| 0‑L |
J01CE08
|
benzathine benzylpenicillin
|
WHO Anatomical Therapeutic Chemical classification |
|
benzathine benzylpenicillin |
| 0‑L |
J01CE09
|
procaine benzylpenicillin
|
WHO Anatomical Therapeutic Chemical classification |
|
procaine benzylpenicillin |
| 0‑L |
J01CE10
|
benzathine phenoxymethylpenicillin
|
WHO Anatomical Therapeutic Chemical classification |
|
benzathine phenoxymethylpenicillin |
| 0‑L |
J01CE30
|
combinations
|
WHO Anatomical Therapeutic Chemical classification |
|
combinations |
| 0‑L |
J01CF
|
Beta-lactamase resistant penicillins
|
WHO Anatomical Therapeutic Chemical classification |
|
Beta-lactamase resistant penicillins |
| 0‑L |
J01CF01
|
dicloxacillin
|
WHO Anatomical Therapeutic Chemical classification |
|
dicloxacillin |
| 0‑L |
J01CF02
|
cloxacillin
|
WHO Anatomical Therapeutic Chemical classification |
|
cloxacillin |
| 0‑L |
J01CF03
|
meticillin
|
WHO Anatomical Therapeutic Chemical classification |
|
meticillin |
| 0‑L |
J01CF04
|
oxacillin
|
WHO Anatomical Therapeutic Chemical classification |
|
oxacillin |
| 0‑L |
J01CF05
|
flucloxacillin
|
WHO Anatomical Therapeutic Chemical classification |
|
flucloxacillin |
| 0‑L |
J01CF06
|
nafcillin
|
WHO Anatomical Therapeutic Chemical classification |
|
nafcillin |
| 0‑L |
J01CG
|
Beta-lactamase inhibitors
|
WHO Anatomical Therapeutic Chemical classification |
|
Beta-lactamase inhibitors |
| 0‑L |
J01CG01
|
sulbactam
|
WHO Anatomical Therapeutic Chemical classification |
|
sulbactam |
| 0‑L |
J01CG02
|
tazobactam
|
WHO Anatomical Therapeutic Chemical classification |
|
tazobactam |
| 0‑L |
J01CR
|
Combinations of penicillins, incl. beta-lactamase inhibitors
|
WHO Anatomical Therapeutic Chemical classification |
|
Combinations of penicillins, incl. beta-lactamase inhibitors |
| 0‑L |
J01CR01
|
ampicillin and enzyme inhibitor
|
WHO Anatomical Therapeutic Chemical classification |
|
ampicillin and enzyme inhibitor |
| 0‑L |
J01CR02
|
amoxicillin and enzyme inhibitor
|
WHO Anatomical Therapeutic Chemical classification |
|
amoxicillin and enzyme inhibitor |
| 0‑L |
J01CR03
|
ticarcillin and enzyme inhibitor
|
WHO Anatomical Therapeutic Chemical classification |
|
ticarcillin and enzyme inhibitor |
| 0‑L |
J01CR04
|
sultamicillin
|
WHO Anatomical Therapeutic Chemical classification |
|
sultamicillin |
| 0‑L |
J01CR05
|
piperacillin and enzyme inhibitor
|
WHO Anatomical Therapeutic Chemical classification |
|
piperacillin and enzyme inhibitor |
| 0‑L |
J01CR50
|
combinations of penicillins
|
WHO Anatomical Therapeutic Chemical classification |
|
combinations of penicillins |
| 0‑L |
J01D
|
OTHER BETA-LACTAM ANTIBACTERIALS
|
WHO Anatomical Therapeutic Chemical classification |
|
OTHER BETA-LACTAM ANTIBACTERIALS |
| 0‑L |
J01DB
|
First-generation cephalosporins
|
WHO Anatomical Therapeutic Chemical classification |
|
First-generation cephalosporins |
| 0‑L |
J01DB01
|
cefalexin
|
WHO Anatomical Therapeutic Chemical classification |
|
cefalexin |
| 0‑L |
J01DB02
|
cefaloridine
|
WHO Anatomical Therapeutic Chemical classification |
|
cefaloridine |
| 0‑L |
J01DB03
|
cefalotin
|
WHO Anatomical Therapeutic Chemical classification |
|
cefalotin |
| 0‑L |
J01DB04
|
cefazolin
|
WHO Anatomical Therapeutic Chemical classification |
|
cefazolin |
| 0‑L |
J01DB05
|
cefadroxil
|
WHO Anatomical Therapeutic Chemical classification |
|
cefadroxil |
| 0‑L |
J01DB06
|
cefazedone
|
WHO Anatomical Therapeutic Chemical classification |
|
cefazedone |
| 0‑L |
J01DB07
|
cefatrizine
|
WHO Anatomical Therapeutic Chemical classification |
|
cefatrizine |
| 0‑L |
J01DB08
|
cefapirin
|
WHO Anatomical Therapeutic Chemical classification |
|
cefapirin |
| 0‑L |
J01DB09
|
cefradine
|
WHO Anatomical Therapeutic Chemical classification |
|
cefradine |
| 0‑L |
J01DB10
|
cefacetrile
|
WHO Anatomical Therapeutic Chemical classification |
|
cefacetrile |
| 0‑L |
J01DB11
|
cefroxadine
|
WHO Anatomical Therapeutic Chemical classification |
|
cefroxadine |
| 0‑L |
J01DB12
|
ceftezole
|
WHO Anatomical Therapeutic Chemical classification |
|
ceftezole |
| 0‑L |
J01DC
|
Second-generation cephalosporins
|
WHO Anatomical Therapeutic Chemical classification |
|
Second-generation cephalosporins |
| 0‑L |
J01DC01
|
cefoxitin
|
WHO Anatomical Therapeutic Chemical classification |
|
cefoxitin |
| 0‑L |
J01DC02
|
cefuroxime
|
WHO Anatomical Therapeutic Chemical classification |
|
cefuroxime |
| 0‑L |
J01DC03
|
cefamandole
|
WHO Anatomical Therapeutic Chemical classification |
|
cefamandole |
| 0‑L |
J01DC04
|
cefaclor
|
WHO Anatomical Therapeutic Chemical classification |
|
cefaclor |
| 0‑L |
J01DC05
|
cefotetan
|
WHO Anatomical Therapeutic Chemical classification |
|
cefotetan |
| 0‑L |
J01DC06
|
cefonicid
|
WHO Anatomical Therapeutic Chemical classification |
|
cefonicid |
| 0‑L |
J01DC07
|
cefotiam
|
WHO Anatomical Therapeutic Chemical classification |
|
cefotiam |
| 0‑L |
J01DC08
|
loracarbef
|
WHO Anatomical Therapeutic Chemical classification |
|
loracarbef |
| 0‑L |
J01DC09
|
cefmetazole
|
WHO Anatomical Therapeutic Chemical classification |
|
cefmetazole |
| 0‑L |
J01DC10
|
cefprozil
|
WHO Anatomical Therapeutic Chemical classification |
|
cefprozil |
| 0‑L |
J01DC11
|
ceforanide
|
WHO Anatomical Therapeutic Chemical classification |
|
ceforanide |
| 0‑L |
J01DC12
|
cefminox
|
WHO Anatomical Therapeutic Chemical classification |
|
cefminox |
| 0‑L |
J01DC13
|
cefbuperazone
|
WHO Anatomical Therapeutic Chemical classification |
|
cefbuperazone |
| 0‑L |
J01DC14
|
flomoxef
|
WHO Anatomical Therapeutic Chemical classification |
|
flomoxef |
| 0‑L |
J01DD
|
Third-generation cephalosporins
|
WHO Anatomical Therapeutic Chemical classification |
|
Third-generation cephalosporins |
| 0‑L |
J01DD01
|
cefotaxime
|
WHO Anatomical Therapeutic Chemical classification |
|
cefotaxime |
| 0‑L |
J01DD02
|
ceftazidime
|
WHO Anatomical Therapeutic Chemical classification |
|
ceftazidime |
| 0‑L |
J01DD03
|
cefsulodin
|
WHO Anatomical Therapeutic Chemical classification |
|
cefsulodin |
| 0‑L |
J01DD04
|
ceftriaxone
|
WHO Anatomical Therapeutic Chemical classification |
|
ceftriaxone |
| 0‑L |
J01DD05
|
cefmenoxime
|
WHO Anatomical Therapeutic Chemical classification |
|
cefmenoxime |
| 0‑L |
J01DD06
|
latamoxef
|
WHO Anatomical Therapeutic Chemical classification |
|
latamoxef |
| 0‑L |
J01DD07
|
ceftizoxime
|
WHO Anatomical Therapeutic Chemical classification |
|
ceftizoxime |
| 0‑L |
J01DD08
|
cefixime
|
WHO Anatomical Therapeutic Chemical classification |
|
cefixime |
| 0‑L |
J01DD09
|
cefodizime
|
WHO Anatomical Therapeutic Chemical classification |
|
cefodizime |
| 0‑L |
J01DD10
|
cefetamet
|
WHO Anatomical Therapeutic Chemical classification |
|
cefetamet |
| 0‑L |
J01DD11
|
cefpiramide
|
WHO Anatomical Therapeutic Chemical classification |
|
cefpiramide |
| 0‑L |
J01DD12
|
cefoperazone
|
WHO Anatomical Therapeutic Chemical classification |
|
cefoperazone |
| 0‑L |
J01DD13
|
cefpodoxime
|
WHO Anatomical Therapeutic Chemical classification |
|
cefpodoxime |
| 0‑L |
J01DD14
|
ceftibuten
|
WHO Anatomical Therapeutic Chemical classification |
|
ceftibuten |
| 0‑L |
J01DD15
|
cefdinir
|
WHO Anatomical Therapeutic Chemical classification |
|
cefdinir |
| 0‑L |
J01DD16
|
cefditoren
|
WHO Anatomical Therapeutic Chemical classification |
|
cefditoren |
| 0‑L |
J01DD17
|
cefcapene
|
WHO Anatomical Therapeutic Chemical classification |
|
cefcapene |
| 0‑L |
J01DD51
|
cefotaxime, combinations
|
WHO Anatomical Therapeutic Chemical classification |
|
cefotaxime, combinations |
| 0‑L |
J01DD52
|
ceftazidime, combinations
|
WHO Anatomical Therapeutic Chemical classification |
|
ceftazidime, combinations |
| 0‑L |
J01DD54
|
ceftriaxone, combinations
|
WHO Anatomical Therapeutic Chemical classification |
|
ceftriaxone, combinations |
| 0‑L |
J01DD62
|
cefoperazone, combinations
|
WHO Anatomical Therapeutic Chemical classification |
|
cefoperazone, combinations |
| 0‑L |
J01DE
|
Fourth-generation cephalosporins
|
WHO Anatomical Therapeutic Chemical classification |
|
Fourth-generation cephalosporins |
| 0‑L |
J01DE01
|
cefepime
|
WHO Anatomical Therapeutic Chemical classification |
|
cefepime |
| 0‑L |
J01DE02
|
cefpirome
|
WHO Anatomical Therapeutic Chemical classification |
|
cefpirome |
| 0‑L |
J01DE03
|
cefozopran
|
WHO Anatomical Therapeutic Chemical classification |
|
cefozopran |
| 0‑L |
J01DF
|
Monobactams
|
WHO Anatomical Therapeutic Chemical classification |
|
Monobactams |
| 0‑L |
J01DF01
|
aztreonam
|
WHO Anatomical Therapeutic Chemical classification |
|
aztreonam |
| 0‑L |
J01DF02
|
carumonam
|
WHO Anatomical Therapeutic Chemical classification |
|
carumonam |
| 0‑L |
J01DH
|
Carbapenems
|
WHO Anatomical Therapeutic Chemical classification |
|
Carbapenems |
| 0‑L |
J01DH02
|
meropenem
|
WHO Anatomical Therapeutic Chemical classification |
|
meropenem |
| 0‑L |
J01DH03
|
ertapenem
|
WHO Anatomical Therapeutic Chemical classification |
|
ertapenem |
| 0‑L |
J01DH04
|
doripenem
|
WHO Anatomical Therapeutic Chemical classification |
|
doripenem |
| 0‑L |
J01DH05
|
biapenem
|
WHO Anatomical Therapeutic Chemical classification |
|
biapenem |
| 0‑L |
J01DH51
|
imipenem and enzyme inhibitor
|
WHO Anatomical Therapeutic Chemical classification |
|
imipenem and enzyme inhibitor |
| 0‑L |
J01DH55
|
panipenem and betamipron
|
WHO Anatomical Therapeutic Chemical classification |
|
panipenem and betamipron |
| 0‑L |
J01DI
|
Other cephalosporins and penems
|
WHO Anatomical Therapeutic Chemical classification |
|
Other cephalosporins and penems |
| 0‑L |
J01DI01
|
ceftobiprole medocaril
|
WHO Anatomical Therapeutic Chemical classification |
|
ceftobiprole medocaril |
| 0‑L |
J01DI02
|
ceftaroline fosamil
|
WHO Anatomical Therapeutic Chemical classification |
|
ceftaroline fosamil |
| 0‑L |
J01DI03
|
faropenem
|
WHO Anatomical Therapeutic Chemical classification |
|
faropenem |
| 0‑L |
J01DI54
|
ceftolozane and enzyme inhibitor
|
WHO Anatomical Therapeutic Chemical classification |
|
ceftolozane and enzyme inhibitor |
| 0‑L |
J01E
|
SULFONAMIDES AND TRIMETHOPRIM
|
WHO Anatomical Therapeutic Chemical classification |
|
SULFONAMIDES AND TRIMETHOPRIM |
| 0‑L |
J01EA
|
Trimethoprim and derivatives
|
WHO Anatomical Therapeutic Chemical classification |
|
Trimethoprim and derivatives |
| 0‑L |
J01EA01
|
trimethoprim
|
WHO Anatomical Therapeutic Chemical classification |
|
trimethoprim |
| 0‑L |
J01EA02
|
brodimoprim
|
WHO Anatomical Therapeutic Chemical classification |
|
brodimoprim |
| 0‑L |
J01EA03
|
iclaprim
|
WHO Anatomical Therapeutic Chemical classification |
|
iclaprim |
| 0‑L |
J01EB
|
Short-acting sulfonamides
|
WHO Anatomical Therapeutic Chemical classification |
|
Short-acting sulfonamides |
| 0‑L |
J01EB01
|
sulfaisodimidine
|
WHO Anatomical Therapeutic Chemical classification |
|
sulfaisodimidine |
| 0‑L |
J01EB02
|
sulfamethizole
|
WHO Anatomical Therapeutic Chemical classification |
|
sulfamethizole |
| 0‑L |
J01EB03
|
sulfadimidine
|
WHO Anatomical Therapeutic Chemical classification |
|
sulfadimidine |
| 0‑L |
J01EB04
|
sulfapyridine
|
WHO Anatomical Therapeutic Chemical classification |
|
sulfapyridine |
| 0‑L |
J01EB05
|
sulfafurazole
|
WHO Anatomical Therapeutic Chemical classification |
|
sulfafurazole |
| 0‑L |
J01EB06
|
sulfanilamide
|
WHO Anatomical Therapeutic Chemical classification |
|
sulfanilamide |
| 0‑L |
J01EB07
|
sulfathiazole
|
WHO Anatomical Therapeutic Chemical classification |
|
sulfathiazole |
| 0‑L |
J01EB08
|
sulfathiourea
|
WHO Anatomical Therapeutic Chemical classification |
|
sulfathiourea |
| 0‑L |
J01EB20
|
combinations
|
WHO Anatomical Therapeutic Chemical classification |
|
combinations |
| 0‑L |
J01EC
|
Intermediate-acting sulfonamides
|
WHO Anatomical Therapeutic Chemical classification |
|
Intermediate-acting sulfonamides |
| 0‑L |
J01EC01
|
sulfamethoxazole
|
WHO Anatomical Therapeutic Chemical classification |
|
sulfamethoxazole |
| 0‑L |
J01EC02
|
sulfadiazine
|
WHO Anatomical Therapeutic Chemical classification |
|
sulfadiazine |
| 0‑L |
J01EC03
|
sulfamoxole
|
WHO Anatomical Therapeutic Chemical classification |
|
sulfamoxole |
| 0‑L |
J01EC20
|
combinations
|
WHO Anatomical Therapeutic Chemical classification |
|
combinations |
| 0‑L |
J01ED
|
Long-acting sulfonamides
|
WHO Anatomical Therapeutic Chemical classification |
|
Long-acting sulfonamides |
| 0‑L |
J01ED01
|
sulfadimethoxine
|
WHO Anatomical Therapeutic Chemical classification |
|
sulfadimethoxine |
| 0‑L |
J01ED02
|
sulfalene
|
WHO Anatomical Therapeutic Chemical classification |
|
sulfalene |
| 0‑L |
J01ED03
|
sulfametomidine
|
WHO Anatomical Therapeutic Chemical classification |
|
sulfametomidine |
| 0‑L |
J01ED04
|
sulfametoxydiazine
|
WHO Anatomical Therapeutic Chemical classification |
|
sulfametoxydiazine |
| 0‑L |
J01ED05
|
sulfamethoxypyridazine
|
WHO Anatomical Therapeutic Chemical classification |
|
sulfamethoxypyridazine |
| 0‑L |
J01ED06
|
sulfaperin
|
WHO Anatomical Therapeutic Chemical classification |
|
sulfaperin |
| 0‑L |
J01ED07
|
sulfamerazine
|
WHO Anatomical Therapeutic Chemical classification |
|
sulfamerazine |
| 0‑L |
J01ED08
|
sulfaphenazole
|
WHO Anatomical Therapeutic Chemical classification |
|
sulfaphenazole |
| 0‑L |
J01ED09
|
sulfamazone
|
WHO Anatomical Therapeutic Chemical classification |
|
sulfamazone |
| 0‑L |
J01ED20
|
combinations
|
WHO Anatomical Therapeutic Chemical classification |
|
combinations |
| 0‑L |
J01EE
|
Combinations of sulfonamides and trimethoprim, incl. derivatives
|
WHO Anatomical Therapeutic Chemical classification |
|
Combinations of sulfonamides and trimethoprim, incl. derivatives |
| 0‑L |
J01EE01
|
sulfamethoxazole and trimethoprim
|
WHO Anatomical Therapeutic Chemical classification |
|
sulfamethoxazole and trimethoprim |
| 0‑L |
J01EE02
|
sulfadiazine and trimethoprim
|
WHO Anatomical Therapeutic Chemical classification |
|
sulfadiazine and trimethoprim |
| 0‑L |
J01EE03
|
sulfametrole and trimethoprim
|
WHO Anatomical Therapeutic Chemical classification |
|
sulfametrole and trimethoprim |
| 0‑L |
J01EE04
|
sulfamoxole and trimethoprim
|
WHO Anatomical Therapeutic Chemical classification |
|
sulfamoxole and trimethoprim |
| 0‑L |
J01EE05
|
sulfadimidine and trimethoprim
|
WHO Anatomical Therapeutic Chemical classification |
|
sulfadimidine and trimethoprim |
| 0‑L |
J01EE06
|
sulfadiazine and tetroxoprim
|
WHO Anatomical Therapeutic Chemical classification |
|
sulfadiazine and tetroxoprim |
| 0‑L |
J01EE07
|
sulfamerazine and trimethoprim
|
WHO Anatomical Therapeutic Chemical classification |
|
sulfamerazine and trimethoprim |
| 0‑L |
J01F
|
MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS
|
WHO Anatomical Therapeutic Chemical classification |
|
MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS |
| 0‑L |
J01FA
|
Macrolides
|
WHO Anatomical Therapeutic Chemical classification |
|
Macrolides |
| 0‑L |
J01FA01
|
erythromycin
|
WHO Anatomical Therapeutic Chemical classification |
|
erythromycin |
| 0‑L |
J01FA02
|
spiramycin
|
WHO Anatomical Therapeutic Chemical classification |
|
spiramycin |
| 0‑L |
J01FA03
|
midecamycin
|
WHO Anatomical Therapeutic Chemical classification |
|
midecamycin |
| 0‑L |
J01FA05
|
oleandomycin
|
WHO Anatomical Therapeutic Chemical classification |
|
oleandomycin |
| 0‑L |
J01FA06
|
roxithromycin
|
WHO Anatomical Therapeutic Chemical classification |
|
roxithromycin |
| 0‑L |
J01FA07
|
josamycin
|
WHO Anatomical Therapeutic Chemical classification |
|
josamycin |
| 0‑L |
J01FA08
|
troleandomycin
|
WHO Anatomical Therapeutic Chemical classification |
|
troleandomycin |
| 0‑L |
J01FA09
|
clarithromycin
|
WHO Anatomical Therapeutic Chemical classification |
|
clarithromycin |
| 0‑L |
J01FA10
|
azithromycin
|
WHO Anatomical Therapeutic Chemical classification |
|
azithromycin |
| 0‑L |
J01FA11
|
miocamycin
|
WHO Anatomical Therapeutic Chemical classification |
|
miocamycin |
| 0‑L |
J01FA12
|
rokitamycin
|
WHO Anatomical Therapeutic Chemical classification |
|
rokitamycin |
| 0‑L |
J01FA13
|
dirithromycin
|
WHO Anatomical Therapeutic Chemical classification |
|
dirithromycin |
| 0‑L |
J01FA14
|
flurithromycin
|
WHO Anatomical Therapeutic Chemical classification |
|
flurithromycin |
| 0‑L |
J01FA15
|
telithromycin
|
WHO Anatomical Therapeutic Chemical classification |
|
telithromycin |
| 0‑L |
J01FA16
|
solithromycin
|
WHO Anatomical Therapeutic Chemical classification |
|
solithromycin |
| 0‑L |
J01FF
|
Lincosamides
|
WHO Anatomical Therapeutic Chemical classification |
|
Lincosamides |
| 0‑L |
J01FF01
|
clindamycin
|
WHO Anatomical Therapeutic Chemical classification |
|
clindamycin |
| 0‑L |
J01FF02
|
lincomycin
|
WHO Anatomical Therapeutic Chemical classification |
|
lincomycin |
| 0‑L |
J01FG
|
Streptogramins
|
WHO Anatomical Therapeutic Chemical classification |
|
Streptogramins |
| 0‑L |
J01FG01
|
pristinamycin
|
WHO Anatomical Therapeutic Chemical classification |
|
pristinamycin |
| 0‑L |
J01FG02
|
quinupristin/dalfopristin
|
WHO Anatomical Therapeutic Chemical classification |
|
quinupristin/dalfopristin |
| 0‑L |
J01G
|
AMINOGLYCOSIDE ANTIBACTERIALS
|
WHO Anatomical Therapeutic Chemical classification |
|
AMINOGLYCOSIDE ANTIBACTERIALS |
| 0‑L |
J01GA
|
Streptomycins
|
WHO Anatomical Therapeutic Chemical classification |
|
Streptomycins |
| 0‑L |
J01GA01
|
streptomycin
|
WHO Anatomical Therapeutic Chemical classification |
|
streptomycin |
| 0‑L |
J01GA02
|
streptoduocin
|
WHO Anatomical Therapeutic Chemical classification |
|
streptoduocin |
| 0‑L |
J01GB
|
Other aminoglycosides
|
WHO Anatomical Therapeutic Chemical classification |
|
Other aminoglycosides |
| 0‑L |
J01GB01
|
tobramycin
|
WHO Anatomical Therapeutic Chemical classification |
|
tobramycin |
| 0‑L |
J01GB03
|
gentamicin
|
WHO Anatomical Therapeutic Chemical classification |
|
gentamicin |
| 0‑L |
J01GB04
|
kanamycin
|
WHO Anatomical Therapeutic Chemical classification |
|
kanamycin |
| 0‑L |
J01GB05
|
neomycin
|
WHO Anatomical Therapeutic Chemical classification |
|
neomycin |
| 0‑L |
J01GB06
|
amikacin
|
WHO Anatomical Therapeutic Chemical classification |
|
amikacin |
| 0‑L |
J01GB07
|
netilmicin
|
WHO Anatomical Therapeutic Chemical classification |
|
netilmicin |
| 0‑L |
J01GB08
|
sisomicin
|
WHO Anatomical Therapeutic Chemical classification |
|
sisomicin |
| 0‑L |
J01GB09
|
dibekacin
|
WHO Anatomical Therapeutic Chemical classification |
|
dibekacin |
| 0‑L |
J01GB10
|
ribostamycin
|
WHO Anatomical Therapeutic Chemical classification |
|
ribostamycin |
| 0‑L |
J01GB11
|
isepamicin
|
WHO Anatomical Therapeutic Chemical classification |
|
isepamicin |
| 0‑L |
J01GB12
|
arbekacin
|
WHO Anatomical Therapeutic Chemical classification |
|
arbekacin |
| 0‑L |
J01GB13
|
bekanamycin
|
WHO Anatomical Therapeutic Chemical classification |
|
bekanamycin |
| 0‑L |
J01M
|
QUINOLONE ANTIBACTERIALS
|
WHO Anatomical Therapeutic Chemical classification |
|
QUINOLONE ANTIBACTERIALS |
| 0‑L |
J01MA
|
Fluoroquinolones
|
WHO Anatomical Therapeutic Chemical classification |
|
Fluoroquinolones |
| 0‑L |
J01MA01
|
ofloxacin
|
WHO Anatomical Therapeutic Chemical classification |
|
ofloxacin |
| 0‑L |
J01MA02
|
ciprofloxacin
|
WHO Anatomical Therapeutic Chemical classification |
|
ciprofloxacin |
| 0‑L |
J01MA03
|
pefloxacin
|
WHO Anatomical Therapeutic Chemical classification |
|
pefloxacin |
| 0‑L |
J01MA04
|
enoxacin
|
WHO Anatomical Therapeutic Chemical classification |
|
enoxacin |
| 0‑L |
J01MA05
|
temafloxacin
|
WHO Anatomical Therapeutic Chemical classification |
|
temafloxacin |
| 0‑L |
J01MA06
|
norfloxacin
|
WHO Anatomical Therapeutic Chemical classification |
|
norfloxacin |
| 0‑L |
J01MA07
|
lomefloxacin
|
WHO Anatomical Therapeutic Chemical classification |
|
lomefloxacin |
| 0‑L |
J01MA08
|
fleroxacin
|
WHO Anatomical Therapeutic Chemical classification |
|
fleroxacin |
| 0‑L |
J01MA09
|
sparfloxacin
|
WHO Anatomical Therapeutic Chemical classification |
|
sparfloxacin |
| 0‑L |
J01MA10
|
rufloxacin
|
WHO Anatomical Therapeutic Chemical classification |
|
rufloxacin |
| 0‑L |
J01MA11
|
grepafloxacin
|
WHO Anatomical Therapeutic Chemical classification |
|
grepafloxacin |
| 0‑L |
J01MA12
|
levofloxacin
|
WHO Anatomical Therapeutic Chemical classification |
|
levofloxacin |
| 0‑L |
J01MA13
|
trovafloxacin
|
WHO Anatomical Therapeutic Chemical classification |
|
trovafloxacin |
| 0‑L |
J01MA14
|
moxifloxacin
|
WHO Anatomical Therapeutic Chemical classification |
|
moxifloxacin |
| 0‑L |
J01MA15
|
gemifloxacin
|
WHO Anatomical Therapeutic Chemical classification |
|
gemifloxacin |
| 0‑L |
J01MA16
|
gatifloxacin
|
WHO Anatomical Therapeutic Chemical classification |
|
gatifloxacin |
| 0‑L |
J01MA17
|
prulifloxacin
|
WHO Anatomical Therapeutic Chemical classification |
|
prulifloxacin |
| 0‑L |
J01MA18
|
pazufloxacin
|
WHO Anatomical Therapeutic Chemical classification |
|
pazufloxacin |
| 0‑L |
J01MA19
|
garenoxacin
|
WHO Anatomical Therapeutic Chemical classification |
|
garenoxacin |
| 0‑L |
J01MA21
|
sitafloxacin
|
WHO Anatomical Therapeutic Chemical classification |
|
sitafloxacin |
| 0‑L |
J01MB
|
Other quinolones
|
WHO Anatomical Therapeutic Chemical classification |
|
Other quinolones |
| 0‑L |
J01MB01
|
rosoxacin
|
WHO Anatomical Therapeutic Chemical classification |
|
rosoxacin |
| 0‑L |
J01MB02
|
nalidixic acid
|
WHO Anatomical Therapeutic Chemical classification |
|
nalidixic acid |
| 0‑L |
J01MB03
|
piromidic acid
|
WHO Anatomical Therapeutic Chemical classification |
|
piromidic acid |
| 0‑L |
J01MB04
|
pipemidic acid
|
WHO Anatomical Therapeutic Chemical classification |
|
pipemidic acid |
| 0‑L |
J01MB05
|
oxolinic acid
|
WHO Anatomical Therapeutic Chemical classification |
|
oxolinic acid |
| 0‑L |
J01MB06
|
cinoxacin
|
WHO Anatomical Therapeutic Chemical classification |
|
cinoxacin |
| 0‑L |
J01MB07
|
flumequine
|
WHO Anatomical Therapeutic Chemical classification |
|
flumequine |
| 0‑L |
J01MB08
|
nemonoxacin
|
WHO Anatomical Therapeutic Chemical classification |
|
nemonoxacin |
| 0‑L |
J01R
|
COMBINATIONS OF ANTIBACTERIALS
|
WHO Anatomical Therapeutic Chemical classification |
|
COMBINATIONS OF ANTIBACTERIALS |
| 0‑L |
J01RA
|
Combinations of antibacterials
|
WHO Anatomical Therapeutic Chemical classification |
|
Combinations of antibacterials |
| 0‑L |
J01RA01
|
penicillins, combinations with other antibacterials
|
WHO Anatomical Therapeutic Chemical classification |
|
penicillins, combinations with other antibacterials |
| 0‑L |
J01RA02
|
sulfonamides, combinations with other antibacterials (excl. trimethoprim)
|
WHO Anatomical Therapeutic Chemical classification |
|
sulfonamides, combinations with other antibacterials (excl. trimethoprim) |
| 0‑L |
J01RA03
|
cefuroxime and metronidazole
|
WHO Anatomical Therapeutic Chemical classification |
|
cefuroxime and metronidazole |
| 0‑L |
J01RA04
|
spiramycin and metronidazole
|
WHO Anatomical Therapeutic Chemical classification |
|
spiramycin and metronidazole |
| 0‑L |
J01RA05
|
levofloxacin and ornidazole
|
WHO Anatomical Therapeutic Chemical classification |
|
levofloxacin and ornidazole |
| 0‑L |
J01RA06
|
cefepime and amikacin
|
WHO Anatomical Therapeutic Chemical classification |
|
cefepime and amikacin |
| 0‑L |
J01RA07
|
azithromycin, fluconazole and secnidazole
|
WHO Anatomical Therapeutic Chemical classification |
|
azithromycin, fluconazole and secnidazole |
| 0‑L |
J01RA08
|
tetracycline and oleandomycin
|
WHO Anatomical Therapeutic Chemical classification |
|
tetracycline and oleandomycin |
| 0‑L |
J01RA09
|
ofloxacin and ornidazole
|
WHO Anatomical Therapeutic Chemical classification |
|
ofloxacin and ornidazole |
| 0‑L |
J01RA10
|
ciprofloxacin and metronidazole
|
WHO Anatomical Therapeutic Chemical classification |
|
ciprofloxacin and metronidazole |
| 0‑L |
J01RA11
|
ciprofloxacin and tinidazole
|
WHO Anatomical Therapeutic Chemical classification |
|
ciprofloxacin and tinidazole |
| 0‑L |
J01RA12
|
ciprofloxacin and ornidazole
|
WHO Anatomical Therapeutic Chemical classification |
|
ciprofloxacin and ornidazole |
| 0‑L |
J01RA13
|
norfloxacin and tinidazole
|
WHO Anatomical Therapeutic Chemical classification |
|
norfloxacin and tinidazole |
| 0‑L |
J01X
|
OTHER ANTIBACTERIALS
|
WHO Anatomical Therapeutic Chemical classification |
|
OTHER ANTIBACTERIALS |
| 0‑L |
J01XA
|
Glycopeptide antibacterials
|
WHO Anatomical Therapeutic Chemical classification |
|
Glycopeptide antibacterials |
| 0‑L |
J01XA01
|
vancomycin
|
WHO Anatomical Therapeutic Chemical classification |
|
vancomycin |
| 0‑L |
J01XA02
|
teicoplanin
|
WHO Anatomical Therapeutic Chemical classification |
|
teicoplanin |
| 0‑L |
J01XA03
|
telavancin
|
WHO Anatomical Therapeutic Chemical classification |
|
telavancin |
| 0‑L |
J01XA04
|
dalbavancin
|
WHO Anatomical Therapeutic Chemical classification |
|
dalbavancin |
| 0‑L |
J01XA05
|
oritavancin
|
WHO Anatomical Therapeutic Chemical classification |
|
oritavancin |
| 0‑L |
J01XB
|
Polymyxins
|
WHO Anatomical Therapeutic Chemical classification |
|
Polymyxins |
| 0‑L |
J01XB01
|
colistin
|
WHO Anatomical Therapeutic Chemical classification |
|
colistin |
| 0‑L |
J01XB02
|
polymyxin B
|
WHO Anatomical Therapeutic Chemical classification |
|
polymyxin B |
| 0‑L |
J01XC
|
Steroid antibacterials
|
WHO Anatomical Therapeutic Chemical classification |
|
Steroid antibacterials |
| 0‑L |
J01XC01
|
fusidic acid
|
WHO Anatomical Therapeutic Chemical classification |
|
fusidic acid |
| 0‑L |
J01XD
|
Imidazole derivatives
|
WHO Anatomical Therapeutic Chemical classification |
|
Imidazole derivatives |
| 0‑L |
J01XD01
|
metronidazole
|
WHO Anatomical Therapeutic Chemical classification |
|
metronidazole |
| 0‑L |
J01XD02
|
tinidazole
|
WHO Anatomical Therapeutic Chemical classification |
|
tinidazole |
| 0‑L |
J01XD03
|
ornidazole
|
WHO Anatomical Therapeutic Chemical classification |
|
ornidazole |
| 0‑L |
J01XE
|
Nitrofuran derivatives
|
WHO Anatomical Therapeutic Chemical classification |
|
Nitrofuran derivatives |
| 0‑L |
J01XE01
|
nitrofurantoin
|
WHO Anatomical Therapeutic Chemical classification |
|
nitrofurantoin |
| 0‑L |
J01XE02
|
nifurtoinol
|
WHO Anatomical Therapeutic Chemical classification |
|
nifurtoinol |
| 0‑L |
J01XE03
|
furazidin
|
WHO Anatomical Therapeutic Chemical classification |
|
furazidin |
| 0‑L |
J01XE51
|
nitrofurantoin, combinations
|
WHO Anatomical Therapeutic Chemical classification |
|
nitrofurantoin, combinations |
| 0‑L |
J01XX
|
Other antibacterials
|
WHO Anatomical Therapeutic Chemical classification |
|
Other antibacterials |
| 0‑L |
J01XX01
|
fosfomycin
|
WHO Anatomical Therapeutic Chemical classification |
|
fosfomycin |
| 0‑L |
J01XX02
|
xibornol
|
WHO Anatomical Therapeutic Chemical classification |
|
xibornol |
| 0‑L |
J01XX03
|
clofoctol
|
WHO Anatomical Therapeutic Chemical classification |
|
clofoctol |
| 0‑L |
J01XX04
|
spectinomycin
|
WHO Anatomical Therapeutic Chemical classification |
|
spectinomycin |
| 0‑L |
J01XX05
|
methenamine
|
WHO Anatomical Therapeutic Chemical classification |
|
methenamine |
| 0‑L |
J01XX06
|
mandelic acid
|
WHO Anatomical Therapeutic Chemical classification |
|
mandelic acid |
| 0‑L |
J01XX07
|
nitroxoline
|
WHO Anatomical Therapeutic Chemical classification |
|
nitroxoline |
| 0‑L |
J01XX08
|
linezolid
|
WHO Anatomical Therapeutic Chemical classification |
|
linezolid |
| 0‑L |
J01XX09
|
daptomycin
|
WHO Anatomical Therapeutic Chemical classification |
|
daptomycin |
| 0‑L |
J01XX10
|
bacitracin
|
WHO Anatomical Therapeutic Chemical classification |
|
bacitracin |
| 0‑L |
J01XX11
|
tedizolid
|
WHO Anatomical Therapeutic Chemical classification |
|
tedizolid |
| 0‑L |
J02
|
ANTIMYCOTICS FOR SYSTEMIC USE
|
WHO Anatomical Therapeutic Chemical classification |
|
ANTIMYCOTICS FOR SYSTEMIC USE |
| 0‑L |
J02A
|
ANTIMYCOTICS FOR SYSTEMIC USE
|
WHO Anatomical Therapeutic Chemical classification |
|
ANTIMYCOTICS FOR SYSTEMIC USE |
| 0‑L |
J02AA
|
Antibiotics
|
WHO Anatomical Therapeutic Chemical classification |
|
Antibiotics |
| 0‑L |
J02AA01
|
amphotericin B
|
WHO Anatomical Therapeutic Chemical classification |
|
amphotericin B |
| 0‑L |
J02AA02
|
hachimycin
|
WHO Anatomical Therapeutic Chemical classification |
|
hachimycin |
| 0‑L |
J02AB
|
Imidazole derivatives
|
WHO Anatomical Therapeutic Chemical classification |
|
Imidazole derivatives |
| 0‑L |
J02AB01
|
miconazole
|
WHO Anatomical Therapeutic Chemical classification |
|
miconazole |
| 0‑L |
J02AB02
|
ketoconazole
|
WHO Anatomical Therapeutic Chemical classification |
|
ketoconazole |
| 0‑L |
J02AC
|
Triazole derivatives
|
WHO Anatomical Therapeutic Chemical classification |
|
Triazole derivatives |
| 0‑L |
J02AC01
|
fluconazole
|
WHO Anatomical Therapeutic Chemical classification |
|
fluconazole |
| 0‑L |
J02AC02
|
itraconazole
|
WHO Anatomical Therapeutic Chemical classification |
|
itraconazole |
| 0‑L |
J02AC03
|
voriconazole
|
WHO Anatomical Therapeutic Chemical classification |
|
voriconazole |
| 0‑L |
J02AC04
|
posaconazole
|
WHO Anatomical Therapeutic Chemical classification |
|
posaconazole |
| 0‑L |
J02AC05
|
isavuconazole
|
WHO Anatomical Therapeutic Chemical classification |
|
isavuconazole |
| 0‑L |
J02AX
|
Other antimycotics for systemic use
|
WHO Anatomical Therapeutic Chemical classification |
|
Other antimycotics for systemic use |
| 0‑L |
J02AX01
|
flucytosine
|
WHO Anatomical Therapeutic Chemical classification |
|
flucytosine |
| 0‑L |
J02AX04
|
caspofungin
|
WHO Anatomical Therapeutic Chemical classification |
|
caspofungin |
| 0‑L |
J02AX05
|
micafungin
|
WHO Anatomical Therapeutic Chemical classification |
|
micafungin |
| 0‑L |
J02AX06
|
anidulafungin
|
WHO Anatomical Therapeutic Chemical classification |
|
anidulafungin |
| 0‑L |
J04
|
ANTIMYCOBACTERIALS
|
WHO Anatomical Therapeutic Chemical classification |
|
ANTIMYCOBACTERIALS |
| 0‑L |
J04A
|
DRUGS FOR TREATMENT OF TUBERCULOSIS
|
WHO Anatomical Therapeutic Chemical classification |
|
DRUGS FOR TREATMENT OF TUBERCULOSIS |
| 0‑L |
J04AA
|
Aminosalicylic acid and derivatives
|
WHO Anatomical Therapeutic Chemical classification |
|
Aminosalicylic acid and derivatives |
| 0‑L |
J04AA01
|
4-aminosalicylic acid
|
WHO Anatomical Therapeutic Chemical classification |
|
4-aminosalicylic acid |
| 0‑L |
J04AA02
|
sodium aminosalicylate
|
WHO Anatomical Therapeutic Chemical classification |
|
sodium aminosalicylate |
| 0‑L |
J04AA03
|
calcium aminosalicylate
|
WHO Anatomical Therapeutic Chemical classification |
|
calcium aminosalicylate |
| 0‑L |
J04AB
|
Antibiotics
|
WHO Anatomical Therapeutic Chemical classification |
|
Antibiotics |
| 0‑L |
J04AB01
|
cycloserine
|
WHO Anatomical Therapeutic Chemical classification |
|
cycloserine |
| 0‑L |
J04AB02
|
rifampicin
|
WHO Anatomical Therapeutic Chemical classification |
|
rifampicin |
| 0‑L |
J04AB03
|
rifamycin
|
WHO Anatomical Therapeutic Chemical classification |
|
rifamycin |
| 0‑L |
J04AB04
|
rifabutin
|
WHO Anatomical Therapeutic Chemical classification |
|
rifabutin |
| 0‑L |
J04AB05
|
rifapentine
|
WHO Anatomical Therapeutic Chemical classification |
|
rifapentine |
| 0‑L |
J04AB30
|
capreomycin
|
WHO Anatomical Therapeutic Chemical classification |
|
capreomycin |
| 0‑L |
J04AC
|
Hydrazides
|
WHO Anatomical Therapeutic Chemical classification |
|
Hydrazides |
| 0‑L |
J04AC01
|
isoniazid
|
WHO Anatomical Therapeutic Chemical classification |
|
isoniazid |
| 0‑L |
J04AC51
|
isoniazid, combinations
|
WHO Anatomical Therapeutic Chemical classification |
|
isoniazid, combinations |
| 0‑L |
J04AD
|
Thiocarbamide derivatives
|
WHO Anatomical Therapeutic Chemical classification |
|
Thiocarbamide derivatives |
| 0‑L |
J04AD01
|
protionamide
|
WHO Anatomical Therapeutic Chemical classification |
|
protionamide |
| 0‑L |
J04AD02
|
tiocarlide
|
WHO Anatomical Therapeutic Chemical classification |
|
tiocarlide |
| 0‑L |
J04AD03
|
ethionamide
|
WHO Anatomical Therapeutic Chemical classification |
|
ethionamide |
| 0‑L |
J04AK
|
Other drugs for treatment of tuberculosis
|
WHO Anatomical Therapeutic Chemical classification |
|
Other drugs for treatment of tuberculosis |
| 0‑L |
J04AK01
|
pyrazinamide
|
WHO Anatomical Therapeutic Chemical classification |
|
pyrazinamide |
| 0‑L |
J04AK02
|
ethambutol
|
WHO Anatomical Therapeutic Chemical classification |
|
ethambutol |
| 0‑L |
J04AK03
|
terizidone
|
WHO Anatomical Therapeutic Chemical classification |
|
terizidone |
| 0‑L |
J04AK04
|
morinamide
|
WHO Anatomical Therapeutic Chemical classification |
|
morinamide |
| 0‑L |
J04AK05
|
bedaquiline
|
WHO Anatomical Therapeutic Chemical classification |
|
bedaquiline |
| 0‑L |
J04AK06
|
delamanid
|
WHO Anatomical Therapeutic Chemical classification |
|
delamanid |
| 0‑L |
J04AK07
|
thioacetazone
|
WHO Anatomical Therapeutic Chemical classification |
|
thioacetazone |
| 0‑L |
J04AM
|
Combinations of drugs for treatment of tuberculosis
|
WHO Anatomical Therapeutic Chemical classification |
|
Combinations of drugs for treatment of tuberculosis |
| 0‑L |
J04AM01
|
streptomycin and isoniazid
|
WHO Anatomical Therapeutic Chemical classification |
|
streptomycin and isoniazid |
| 0‑L |
J04AM02
|
rifampicin and isoniazid
|
WHO Anatomical Therapeutic Chemical classification |
|
rifampicin and isoniazid |
| 0‑L |
J04AM03
|
ethambutol and isoniazid
|
WHO Anatomical Therapeutic Chemical classification |
|
ethambutol and isoniazid |
| 0‑L |
J04AM04
|
thioacetazone and isoniazid
|
WHO Anatomical Therapeutic Chemical classification |
|
thioacetazone and isoniazid |
| 0‑L |
J04AM05
|
rifampicin, pyrazinamide and isoniazid
|
WHO Anatomical Therapeutic Chemical classification |
|
rifampicin, pyrazinamide and isoniazid |
| 0‑L |
J04AM06
|
rifampicin, pyrazinamide, ethambutol and isoniazid
|
WHO Anatomical Therapeutic Chemical classification |
|
rifampicin, pyrazinamide, ethambutol and isoniazid |
| 0‑L |
J04B
|
DRUGS FOR TREATMENT OF LEPRA
|
WHO Anatomical Therapeutic Chemical classification |
|
DRUGS FOR TREATMENT OF LEPRA |
| 0‑L |
J04BA
|
Drugs for treatment of lepra
|
WHO Anatomical Therapeutic Chemical classification |
|
Drugs for treatment of lepra |
| 0‑L |
J04BA01
|
clofazimine
|
WHO Anatomical Therapeutic Chemical classification |
|
clofazimine |
| 0‑L |
J04BA02
|
dapsone
|
WHO Anatomical Therapeutic Chemical classification |
|
dapsone |
| 0‑L |
J04BA03
|
aldesulfone sodium
|
WHO Anatomical Therapeutic Chemical classification |
|
aldesulfone sodium |
| 0‑L |
J05
|
ANTIVIRALS FOR SYSTEMIC USE
|
WHO Anatomical Therapeutic Chemical classification |
|
ANTIVIRALS FOR SYSTEMIC USE |
| 0‑L |
J05A
|
DIRECT ACTING ANTIVIRALS
|
WHO Anatomical Therapeutic Chemical classification |
|
DIRECT ACTING ANTIVIRALS |
| 0‑L |
J05AA
|
Thiosemicarbazones
|
WHO Anatomical Therapeutic Chemical classification |
|
Thiosemicarbazones |
| 0‑L |
J05AA01
|
metisazone
|
WHO Anatomical Therapeutic Chemical classification |
|
metisazone |
| 0‑L |
J05AB
|
Nucleosides and nucleotides excl. reverse transcriptase inhibitors
|
WHO Anatomical Therapeutic Chemical classification |
|
Nucleosides and nucleotides excl. reverse transcriptase inhibitors |
| 0‑L |
J05AB01
|
aciclovir
|
WHO Anatomical Therapeutic Chemical classification |
|
aciclovir |
| 0‑L |
J05AB02
|
idoxuridine
|
WHO Anatomical Therapeutic Chemical classification |
|
idoxuridine |
| 0‑L |
J05AB03
|
vidarabine
|
WHO Anatomical Therapeutic Chemical classification |
|
vidarabine |
| 0‑L |
J05AB04
|
ribavirin
|
WHO Anatomical Therapeutic Chemical classification |
|
ribavirin |
| 0‑L |
J05AB06
|
ganciclovir
|
WHO Anatomical Therapeutic Chemical classification |
|
ganciclovir |
| 0‑L |
J05AB09
|
famciclovir
|
WHO Anatomical Therapeutic Chemical classification |
|
famciclovir |
| 0‑L |
J05AB11
|
valaciclovir
|
WHO Anatomical Therapeutic Chemical classification |
|
valaciclovir |
| 0‑L |
J05AB12
|
cidofovir
|
WHO Anatomical Therapeutic Chemical classification |
|
cidofovir |
| 0‑L |
J05AB13
|
penciclovir
|
WHO Anatomical Therapeutic Chemical classification |
|
penciclovir |
| 0‑L |
J05AB14
|
valganciclovir
|
WHO Anatomical Therapeutic Chemical classification |
|
valganciclovir |
| 0‑L |
J05AB15
|
brivudine
|
WHO Anatomical Therapeutic Chemical classification |
|
brivudine |
| 0‑L |
J05AC
|
Cyclic amines
|
WHO Anatomical Therapeutic Chemical classification |
|
Cyclic amines |
| 0‑L |
J05AC02
|
rimantadine
|
WHO Anatomical Therapeutic Chemical classification |
|
rimantadine |
| 0‑L |
J05AC03
|
tromantadine
|
WHO Anatomical Therapeutic Chemical classification |
|
tromantadine |
| 0‑L |
J05AD
|
Phosphonic acid derivatives
|
WHO Anatomical Therapeutic Chemical classification |
|
Phosphonic acid derivatives |
| 0‑L |
J05AD01
|
foscarnet
|
WHO Anatomical Therapeutic Chemical classification |
|
foscarnet |
| 0‑L |
J05AD02
|
fosfonet
|
WHO Anatomical Therapeutic Chemical classification |
|
fosfonet |
| 0‑L |
J05AE
|
Protease inhibitors
|
WHO Anatomical Therapeutic Chemical classification |
|
Protease inhibitors |
| 0‑L |
J05AE01
|
saquinavir
|
WHO Anatomical Therapeutic Chemical classification |
|
saquinavir |
| 0‑L |
J05AE02
|
indinavir
|
WHO Anatomical Therapeutic Chemical classification |
|
indinavir |
| 0‑L |
J05AE03
|
ritonavir
|
WHO Anatomical Therapeutic Chemical classification |
|
ritonavir |
| 0‑L |
J05AE04
|
nelfinavir
|
WHO Anatomical Therapeutic Chemical classification |
|
nelfinavir |
| 0‑L |
J05AE05
|
amprenavir
|
WHO Anatomical Therapeutic Chemical classification |
|
amprenavir |
| 0‑L |
J05AE07
|
fosamprenavir
|
WHO Anatomical Therapeutic Chemical classification |
|
fosamprenavir |
| 0‑L |
J05AE08
|
atazanavir
|
WHO Anatomical Therapeutic Chemical classification |
|
atazanavir |
| 0‑L |
J05AE09
|
tipranavir
|
WHO Anatomical Therapeutic Chemical classification |
|
tipranavir |
| 0‑L |
J05AE10
|
darunavir
|
WHO Anatomical Therapeutic Chemical classification |
|
darunavir |
| 0‑L |
J05AE11
|
telaprevir
|
WHO Anatomical Therapeutic Chemical classification |
|
telaprevir |
| 0‑L |
J05AE12
|
boceprevir
|
WHO Anatomical Therapeutic Chemical classification |
|
boceprevir |
| 0‑L |
J05AE13
|
faldaprevir
|
WHO Anatomical Therapeutic Chemical classification |
|
faldaprevir |
| 0‑L |
J05AE14
|
simeprevir
|
WHO Anatomical Therapeutic Chemical classification |
|
simeprevir |
| 0‑L |
J05AE15
|
asunaprevir
|
WHO Anatomical Therapeutic Chemical classification |
|
asunaprevir |
| 0‑L |
J05AF
|
Nucleoside and nucleotide reverse transcriptase inhibitors
|
WHO Anatomical Therapeutic Chemical classification |
|
Nucleoside and nucleotide reverse transcriptase inhibitors |
| 0‑L |
J05AF01
|
zidovudine
|
WHO Anatomical Therapeutic Chemical classification |
|
zidovudine |
| 0‑L |
J05AF02
|
didanosine
|
WHO Anatomical Therapeutic Chemical classification |
|
didanosine |
| 0‑L |
J05AF03
|
zalcitabine
|
WHO Anatomical Therapeutic Chemical classification |
|
zalcitabine |
| 0‑L |
J05AF04
|
stavudine
|
WHO Anatomical Therapeutic Chemical classification |
|
stavudine |
| 0‑L |
J05AF05
|
lamivudine
|
WHO Anatomical Therapeutic Chemical classification |
|
lamivudine |
| 0‑L |
J05AF06
|
abacavir
|
WHO Anatomical Therapeutic Chemical classification |
|
abacavir |
| 0‑L |
J05AF07
|
tenofovir disoproxil
|
WHO Anatomical Therapeutic Chemical classification |
|
tenofovir disoproxil |
| 0‑L |
J05AF08
|
adefovir dipivoxil
|
WHO Anatomical Therapeutic Chemical classification |
|
adefovir dipivoxil |
| 0‑L |
J05AF09
|
emtricitabine
|
WHO Anatomical Therapeutic Chemical classification |
|
emtricitabine |
| 0‑L |
J05AF10
|
entecavir
|
WHO Anatomical Therapeutic Chemical classification |
|
entecavir |
| 0‑L |
J05AF11
|
telbivudine
|
WHO Anatomical Therapeutic Chemical classification |
|
telbivudine |
| 0‑L |
J05AF12
|
clevudine
|
WHO Anatomical Therapeutic Chemical classification |
|
clevudine |
| 0‑L |
J05AF13
|
tenofovir alafenamide
|
WHO Anatomical Therapeutic Chemical classification |
|
tenofovir alafenamide |
| 0‑L |
J05AG
|
Non-nucleoside reverse transcriptase inhibitors
|
WHO Anatomical Therapeutic Chemical classification |
|
Non-nucleoside reverse transcriptase inhibitors |
| 0‑L |
J05AG01
|
nevirapine
|
WHO Anatomical Therapeutic Chemical classification |
|
nevirapine |
| 0‑L |
J05AG02
|
delavirdine
|
WHO Anatomical Therapeutic Chemical classification |
|
delavirdine |
| 0‑L |
J05AG03
|
efavirenz
|
WHO Anatomical Therapeutic Chemical classification |
|
efavirenz |
| 0‑L |
J05AG04
|
etravirine
|
WHO Anatomical Therapeutic Chemical classification |
|
etravirine |
| 0‑L |
J05AG05
|
rilpivirine
|
WHO Anatomical Therapeutic Chemical classification |
|
rilpivirine |
| 0‑L |
J05AH
|
Neuraminidase inhibitors
|
WHO Anatomical Therapeutic Chemical classification |
|
Neuraminidase inhibitors |
| 0‑L |
J05AH01
|
zanamivir
|
WHO Anatomical Therapeutic Chemical classification |
|
zanamivir |
| 0‑L |
J05AH02
|
oseltamivir
|
WHO Anatomical Therapeutic Chemical classification |
|
oseltamivir |
| 0‑L |
J05AR
|
Antivirals for treatment of HIV infections, combinations
|
WHO Anatomical Therapeutic Chemical classification |
|
Antivirals for treatment of HIV infections, combinations |
| 0‑L |
J05AR01
|
zidovudine and lamivudine
|
WHO Anatomical Therapeutic Chemical classification |
|
zidovudine and lamivudine |
| 0‑L |
J05AR02
|
lamivudine and abacavir
|
WHO Anatomical Therapeutic Chemical classification |
|
lamivudine and abacavir |
| 0‑L |
J05AR03
|
tenofovir disoproxil and emtricitabine
|
WHO Anatomical Therapeutic Chemical classification |
|
tenofovir disoproxil and emtricitabine |
| 0‑L |
J05AR04
|
zidovudine, lamivudine and abacavir
|
WHO Anatomical Therapeutic Chemical classification |
|
zidovudine, lamivudine and abacavir |
| 0‑L |
J05AR05
|
zidovudine, lamivudine and nevirapine
|
WHO Anatomical Therapeutic Chemical classification |
|
zidovudine, lamivudine and nevirapine |
| 0‑L |
J05AR06
|
emtricitabine, tenofovir disoproxil and efavirenz
|
WHO Anatomical Therapeutic Chemical classification |
|
emtricitabine, tenofovir disoproxil and efavirenz |
| 0‑L |
J05AR07
|
stavudine, lamivudine and nevirapine
|
WHO Anatomical Therapeutic Chemical classification |
|
stavudine, lamivudine and nevirapine |
| 0‑L |
J05AR08
|
emtricitabine, tenofovir disoproxil and rilpivirine
|
WHO Anatomical Therapeutic Chemical classification |
|
emtricitabine, tenofovir disoproxil and rilpivirine |
| 0‑L |
J05AR09
|
emtricitabine, tenofovir disoproxil, elvitegravir and cobicistat
|
WHO Anatomical Therapeutic Chemical classification |
|
emtricitabine, tenofovir disoproxil, elvitegravir and cobicistat |
| 0‑L |
J05AR10
|
lopinavir and ritonavir
|
WHO Anatomical Therapeutic Chemical classification |
|
lopinavir and ritonavir |
| 0‑L |
J05AR11
|
lamivudine, tenofovir disoproxil and efavirenz
|
WHO Anatomical Therapeutic Chemical classification |
|
lamivudine, tenofovir disoproxil and efavirenz |
| 0‑L |
J05AR12
|
lamivudine and tenofovir disoproxil
|
WHO Anatomical Therapeutic Chemical classification |
|
lamivudine and tenofovir disoproxil |
| 0‑L |
J05AR13
|
lamivudine, abacavir and dolutegravir
|
WHO Anatomical Therapeutic Chemical classification |
|
lamivudine, abacavir and dolutegravir |
| 0‑L |
J05AR14
|
darunavir and cobicistat
|
WHO Anatomical Therapeutic Chemical classification |
|
darunavir and cobicistat |
| 0‑L |
J05AR15
|
atazanavir and cobicistat
|
WHO Anatomical Therapeutic Chemical classification |
|
atazanavir and cobicistat |
| 0‑L |
J05AR16
|
lamivudine and raltegravir
|
WHO Anatomical Therapeutic Chemical classification |
|
lamivudine and raltegravir |
| 0‑L |
J05AR17
|
emtricitabine and tenofovir alafenamide
|
WHO Anatomical Therapeutic Chemical classification |
|
emtricitabine and tenofovir alafenamide |
| 0‑L |
J05AR18
|
emtricitabine, tenofovir alafenamide, elvitegravir and cobicistat
|
WHO Anatomical Therapeutic Chemical classification |
|
emtricitabine, tenofovir alafenamide, elvitegravir and cobicistat |
| 0‑L |
J05AR19
|
emtricitabine, tenofovir alafenamide and rilpivirine
|
WHO Anatomical Therapeutic Chemical classification |
|
emtricitabine, tenofovir alafenamide and rilpivirine |
| 0‑L |
J05AX
|
Other antivirals
|
WHO Anatomical Therapeutic Chemical classification |
|
Other antivirals |
| 0‑L |
J05AX01
|
moroxydine
|
WHO Anatomical Therapeutic Chemical classification |
|
moroxydine |
| 0‑L |
J05AX02
|
lysozyme
|
WHO Anatomical Therapeutic Chemical classification |
|
lysozyme |
| 0‑L |
J05AX05
|
inosine pranobex
|
WHO Anatomical Therapeutic Chemical classification |
|
inosine pranobex |
| 0‑L |
J05AX06
|
pleconaril
|
WHO Anatomical Therapeutic Chemical classification |
|
pleconaril |
| 0‑L |
J05AX07
|
enfuvirtide
|
WHO Anatomical Therapeutic Chemical classification |
|
enfuvirtide |
| 0‑L |
J05AX08
|
raltegravir
|
WHO Anatomical Therapeutic Chemical classification |
|
raltegravir |
| 0‑L |
J05AX09
|
maraviroc
|
WHO Anatomical Therapeutic Chemical classification |
|
maraviroc |
| 0‑L |
J05AX10
|
maribavir
|
WHO Anatomical Therapeutic Chemical classification |
|
maribavir |
| 0‑L |
J05AX11
|
elvitegravir
|
WHO Anatomical Therapeutic Chemical classification |
|
elvitegravir |
| 0‑L |
J05AX12
|
dolutegravir
|
WHO Anatomical Therapeutic Chemical classification |
|
dolutegravir |
| 0‑L |
J05AX13
|
umifenovir
|
WHO Anatomical Therapeutic Chemical classification |
|
umifenovir |
| 0‑L |
J05AX14
|
daclatasvir
|
WHO Anatomical Therapeutic Chemical classification |
|
daclatasvir |
| 0‑L |
J05AX15
|
sofosbuvir
|
WHO Anatomical Therapeutic Chemical classification |
|
sofosbuvir |
| 0‑L |
J05AX16
|
dasabuvir
|
WHO Anatomical Therapeutic Chemical classification |
|
dasabuvir |
| 0‑L |
J05AX65
|
sofosbuvir and ledipasvir
|
WHO Anatomical Therapeutic Chemical classification |
|
sofosbuvir and ledipasvir |
| 0‑L |
J05AX66
|
dasabuvir, ombitasvir, paritaprevir and ritonavir
|
WHO Anatomical Therapeutic Chemical classification |
|
dasabuvir, ombitasvir, paritaprevir and ritonavir |
| 0‑L |
J05AX67
|
ombitasvir, paritaprevir and ritonavir
|
WHO Anatomical Therapeutic Chemical classification |
|
ombitasvir, paritaprevir and ritonavir |
| 0‑L |
J05AX68
|
elbasvir and grazoprevir
|
WHO Anatomical Therapeutic Chemical classification |
|
elbasvir and grazoprevir |
| 0‑L |
J06
|
IMMUNE SERA AND IMMUNOGLOBULINS
|
WHO Anatomical Therapeutic Chemical classification |
|
IMMUNE SERA AND IMMUNOGLOBULINS |
| 0‑L |
J06A
|
IMMUNE SERA
|
WHO Anatomical Therapeutic Chemical classification |
|
IMMUNE SERA |
| 0‑L |
J06AA
|
Immune sera
|
WHO Anatomical Therapeutic Chemical classification |
|
Immune sera |
| 0‑L |
J06AA01
|
diphtheria antitoxin
|
WHO Anatomical Therapeutic Chemical classification |
|
diphtheria antitoxin |
| 0‑L |
J06AA02
|
tetanus antitoxin
|
WHO Anatomical Therapeutic Chemical classification |
|
tetanus antitoxin |
| 0‑L |
J06AA03
|
snake venom antiserum
|
WHO Anatomical Therapeutic Chemical classification |
|
snake venom antiserum |
| 0‑L |
J06AA04
|
botulinum antitoxin
|
WHO Anatomical Therapeutic Chemical classification |
|
botulinum antitoxin |
| 0‑L |
J06AA05
|
gas-gangrene sera
|
WHO Anatomical Therapeutic Chemical classification |
|
gas-gangrene sera |
| 0‑L |
J06AA06
|
rabies serum
|
WHO Anatomical Therapeutic Chemical classification |
|
rabies serum |
| 0‑L |
J06B
|
IMMUNOGLOBULINS
|
WHO Anatomical Therapeutic Chemical classification |
|
IMMUNOGLOBULINS |
| 0‑L |
J06BA
|
Immunoglobulins, normal human
|
WHO Anatomical Therapeutic Chemical classification |
|
Immunoglobulins, normal human |
| 0‑L |
J06BA01
|
immunoglobulins, normal human, for extravascular adm.
|
WHO Anatomical Therapeutic Chemical classification |
|
immunoglobulins, normal human, for extravascular adm. |
| 0‑L |
J06BA02
|
immunoglobulins, normal human, for intravascular adm.
|
WHO Anatomical Therapeutic Chemical classification |
|
immunoglobulins, normal human, for intravascular adm. |
| 0‑L |
J06BB
|
Specific immunoglobulins
|
WHO Anatomical Therapeutic Chemical classification |
|
Specific immunoglobulins |
| 0‑L |
J06BB01
|
anti-D (rh) immunoglobulin
|
WHO Anatomical Therapeutic Chemical classification |
|
anti-D (rh) immunoglobulin |
| 0‑L |
J06BB02
|
tetanus immunoglobulin
|
WHO Anatomical Therapeutic Chemical classification |
|
tetanus immunoglobulin |
| 0‑L |
J06BB03
|
varicella/zoster immunoglobulin
|
WHO Anatomical Therapeutic Chemical classification |
|
varicella/zoster immunoglobulin |
| 0‑L |
J06BB04
|
hepatitis B immunoglobulin
|
WHO Anatomical Therapeutic Chemical classification |
|
hepatitis B immunoglobulin |
| 0‑L |
J06BB05
|
rabies immunoglobulin
|
WHO Anatomical Therapeutic Chemical classification |
|
rabies immunoglobulin |
| 0‑L |
J06BB06
|
rubella immunoglobulin
|
WHO Anatomical Therapeutic Chemical classification |
|
rubella immunoglobulin |
| 0‑L |
J06BB07
|
vaccinia immunoglobulin
|
WHO Anatomical Therapeutic Chemical classification |
|
vaccinia immunoglobulin |
| 0‑L |
J06BB08
|
staphylococcus immunoglobulin
|
WHO Anatomical Therapeutic Chemical classification |
|
staphylococcus immunoglobulin |
| 0‑L |
J06BB09
|
cytomegalovirus immunoglobulin
|
WHO Anatomical Therapeutic Chemical classification |
|
cytomegalovirus immunoglobulin |
| 0‑L |
J06BB10
|
diphtheria immunoglobulin
|
WHO Anatomical Therapeutic Chemical classification |
|
diphtheria immunoglobulin |
| 0‑L |
J06BB11
|
hepatitis A immunoglobulin
|
WHO Anatomical Therapeutic Chemical classification |
|
hepatitis A immunoglobulin |
| 0‑L |
J06BB12
|
encephalitis, tick borne immunoglobulin
|
WHO Anatomical Therapeutic Chemical classification |
|
encephalitis, tick borne immunoglobulin |
| 0‑L |
J06BB13
|
pertussis immunoglobulin
|
WHO Anatomical Therapeutic Chemical classification |
|
pertussis immunoglobulin |
| 0‑L |
J06BB14
|
measles immunoglobulin
|
WHO Anatomical Therapeutic Chemical classification |
|
measles immunoglobulin |
| 0‑L |
J06BB15
|
mumps immunoglobulin
|
WHO Anatomical Therapeutic Chemical classification |
|
mumps immunoglobulin |
| 0‑L |
J06BB16
|
palivizumab
|
WHO Anatomical Therapeutic Chemical classification |
|
palivizumab |
| 0‑L |
J06BB17
|
motavizumab
|
WHO Anatomical Therapeutic Chemical classification |
|
motavizumab |
| 0‑L |
J06BB18
|
raxibacumab
|
WHO Anatomical Therapeutic Chemical classification |
|
raxibacumab |
| 0‑L |
J06BB19
|
anthrax immunoglobulin
|
WHO Anatomical Therapeutic Chemical classification |
|
anthrax immunoglobulin |
| 0‑L |
J06BB21
|
bezlotoxumab
|
WHO Anatomical Therapeutic Chemical classification |
|
bezlotoxumab |
| 0‑L |
J06BB30
|
combinations
|
WHO Anatomical Therapeutic Chemical classification |
|
combinations |
| 0‑L |
J06BC
|
Other immunoglobulins
|
WHO Anatomical Therapeutic Chemical classification |
|
Other immunoglobulins |
| 0‑L |
J06BC01
|
nebacumab
|
WHO Anatomical Therapeutic Chemical classification |
|
nebacumab |
| 0‑L |
J07
|
VACCINES
|
WHO Anatomical Therapeutic Chemical classification |
|
VACCINES |
| 0‑L |
J07A
|
BACTERIAL VACCINES
|
WHO Anatomical Therapeutic Chemical classification |
|
BACTERIAL VACCINES |
| 0‑L |
J07AC
|
Anthrax vaccines
|
WHO Anatomical Therapeutic Chemical classification |
|
Anthrax vaccines |
| 0‑L |
J07AC01
|
anthrax antigen
|
WHO Anatomical Therapeutic Chemical classification |
|
anthrax antigen |
| 0‑L |
J07AD
|
Brucellosis vaccines
|
WHO Anatomical Therapeutic Chemical classification |
|
Brucellosis vaccines |
| 0‑L |
J07AD01
|
brucella antigen
|
WHO Anatomical Therapeutic Chemical classification |
|
brucella antigen |
| 0‑L |
J07AE
|
Cholera vaccines
|
WHO Anatomical Therapeutic Chemical classification |
|
Cholera vaccines |
| 0‑L |
J07AE01
|
cholera, inactivated, whole cell
|
WHO Anatomical Therapeutic Chemical classification |
|
cholera, inactivated, whole cell |
| 0‑L |
J07AE02
|
cholera, live attenuated
|
WHO Anatomical Therapeutic Chemical classification |
|
cholera, live attenuated |
| 0‑L |
J07AE51
|
cholera, combinations with typhoid vaccine, inactivated, whole cell
|
WHO Anatomical Therapeutic Chemical classification |
|
cholera, combinations with typhoid vaccine, inactivated, whole cell |
| 0‑L |
J07AF
|
Diphtheria vaccines
|
WHO Anatomical Therapeutic Chemical classification |
|
Diphtheria vaccines |
| 0‑L |
J07AF01
|
diphtheria toxoid
|
WHO Anatomical Therapeutic Chemical classification |
|
diphtheria toxoid |
| 0‑L |
J07AG
|
Hemophilus influenzae B vaccines
|
WHO Anatomical Therapeutic Chemical classification |
|
Hemophilus influenzae B vaccines |
| 0‑L |
J07AG01
|
hemophilus influenzae B, purified antigen conjugated
|
WHO Anatomical Therapeutic Chemical classification |
|
hemophilus influenzae B, purified antigen conjugated |
| 0‑L |
J07AG51
|
hemophilus influenzae B, combinations with toxoids
|
WHO Anatomical Therapeutic Chemical classification |
|
hemophilus influenzae B, combinations with toxoids |
| 0‑L |
J07AG52
|
hemophilus influenzae B, combinations with pertussis and toxoids
|
WHO Anatomical Therapeutic Chemical classification |
|
hemophilus influenzae B, combinations with pertussis and toxoids |
| 0‑L |
J07AG53
|
hemophilus influenzae B, combinations with meningococcus C, conjugated
|
WHO Anatomical Therapeutic Chemical classification |
|
hemophilus influenzae B, combinations with meningococcus C, conjugated |
| 0‑L |
J07AH
|
Meningococcal vaccines
|
WHO Anatomical Therapeutic Chemical classification |
|
Meningococcal vaccines |
| 0‑L |
J07AH01
|
meningococcus A, purified polysaccharides antigen
|
WHO Anatomical Therapeutic Chemical classification |
|
meningococcus A, purified polysaccharides antigen |
| 0‑L |
J07AH02
|
other meningococcal monovalent purified polysaccharides antigen
|
WHO Anatomical Therapeutic Chemical classification |
|
other meningococcal monovalent purified polysaccharides antigen |
| 0‑L |
J07AH03
|
meningococcus A,C, bivalent purified polysaccharides antigen
|
WHO Anatomical Therapeutic Chemical classification |
|
meningococcus A,C, bivalent purified polysaccharides antigen |
| 0‑L |
J07AH04
|
meningococcus A,C,Y,W-135, tetravalent purified polysaccharides antigen
|
WHO Anatomical Therapeutic Chemical classification |
|
meningococcus A,C,Y,W-135, tetravalent purified polysaccharides antigen |
| 0‑L |
J07AH05
|
other meningococcal polyvalent purified polysaccharides antigen
|
WHO Anatomical Therapeutic Chemical classification |
|
other meningococcal polyvalent purified polysaccharides antigen |
| 0‑L |
J07AH06
|
meningococcus B, outer membrane vesicle vaccine
|
WHO Anatomical Therapeutic Chemical classification |
|
meningococcus B, outer membrane vesicle vaccine |
| 0‑L |
J07AH07
|
meningococcus C, purified polysaccharides antigen conjugated
|
WHO Anatomical Therapeutic Chemical classification |
|
meningococcus C, purified polysaccharides antigen conjugated |
| 0‑L |
J07AH08
|
meningococcus A,C,Y,W-135, tetravalent purified polysaccharides antigen conjugated
|
WHO Anatomical Therapeutic Chemical classification |
|
meningococcus A,C,Y,W-135, tetravalent purified polysaccharides antigen conjugated |
| 0‑L |
J07AH09
|
meningococcus B, multicomponent vaccine
|
WHO Anatomical Therapeutic Chemical classification |
|
meningococcus B, multicomponent vaccine |
| 0‑L |
J07AH10
|
meningococcus A, purified polysaccharides antigen conjugated
|
WHO Anatomical Therapeutic Chemical classification |
|
meningococcus A, purified polysaccharides antigen conjugated |
| 0‑L |
J07AJ
|
Pertussis vaccines
|
WHO Anatomical Therapeutic Chemical classification |
|
Pertussis vaccines |
| 0‑L |
J07AJ01
|
pertussis, inactivated, whole cell
|
WHO Anatomical Therapeutic Chemical classification |
|
pertussis, inactivated, whole cell |
| 0‑L |
J07AJ02
|
pertussis, purified antigen
|
WHO Anatomical Therapeutic Chemical classification |
|
pertussis, purified antigen |
| 0‑L |
J07AJ51
|
pertussis, inactivated, whole cell, combinations with toxoids
|
WHO Anatomical Therapeutic Chemical classification |
|
pertussis, inactivated, whole cell, combinations with toxoids |
| 0‑L |
J07AJ52
|
pertussis, purified antigen, combinations with toxoids
|
WHO Anatomical Therapeutic Chemical classification |
|
pertussis, purified antigen, combinations with toxoids |
| 0‑L |
J07AK
|
Plague vaccines
|
WHO Anatomical Therapeutic Chemical classification |
|
Plague vaccines |
| 0‑L |
J07AK01
|
plague, inactivated, whole cell
|
WHO Anatomical Therapeutic Chemical classification |
|
plague, inactivated, whole cell |
| 0‑L |
J07AL
|
Pneumococcal vaccines
|
WHO Anatomical Therapeutic Chemical classification |
|
Pneumococcal vaccines |
| 0‑L |
J07AL01
|
pneumococcus, purified polysaccharides antigen
|
WHO Anatomical Therapeutic Chemical classification |
|
pneumococcus, purified polysaccharides antigen |
| 0‑L |
J07AL02
|
pneumococcus, purified polysaccharides antigen conjugated
|
WHO Anatomical Therapeutic Chemical classification |
|
pneumococcus, purified polysaccharides antigen conjugated |
| 0‑L |
J07AL52
|
pneumococcus purified polysaccharides antigen and haemophilus influenzae, conjugated
|
WHO Anatomical Therapeutic Chemical classification |
|
pneumococcus purified polysaccharides antigen and haemophilus influenzae, conjugated |
| 0‑L |
J07AM
|
Tetanus vaccines
|
WHO Anatomical Therapeutic Chemical classification |
|
Tetanus vaccines |
| 0‑L |
J07AM01
|
tetanus toxoid
|
WHO Anatomical Therapeutic Chemical classification |
|
tetanus toxoid |
| 0‑L |
J07AM51
|
tetanus toxoid, combinations with diphtheria toxoid
|
WHO Anatomical Therapeutic Chemical classification |
|
tetanus toxoid, combinations with diphtheria toxoid |
| 0‑L |
J07AM52
|
tetanus toxoid, combinations with tetanus immunoglobulin
|
WHO Anatomical Therapeutic Chemical classification |
|
tetanus toxoid, combinations with tetanus immunoglobulin |
| 0‑L |
J07AN
|
Tuberculosis vaccines
|
WHO Anatomical Therapeutic Chemical classification |
|
Tuberculosis vaccines |
| 0‑L |
J07AN01
|
tuberculosis, live attenuated
|
WHO Anatomical Therapeutic Chemical classification |
|
tuberculosis, live attenuated |
| 0‑L |
J07AP
|
Typhoid vaccines
|
WHO Anatomical Therapeutic Chemical classification |
|
Typhoid vaccines |
| 0‑L |
J07AP01
|
typhoid, oral, live attenuated
|
WHO Anatomical Therapeutic Chemical classification |
|
typhoid, oral, live attenuated |
| 0‑L |
J07AP02
|
typhoid, inactivated, whole cell
|
WHO Anatomical Therapeutic Chemical classification |
|
typhoid, inactivated, whole cell |
| 0‑L |
J07AP03
|
typhoid, purified polysaccharide antigen
|
WHO Anatomical Therapeutic Chemical classification |
|
typhoid, purified polysaccharide antigen |
| 0‑L |
J07AP10
|
typhoid, combinations with paratyphi types
|
WHO Anatomical Therapeutic Chemical classification |
|
typhoid, combinations with paratyphi types |
| 0‑L |
J07AR
|
Typhus (exanthematicus) vaccines
|
WHO Anatomical Therapeutic Chemical classification |
|
Typhus (exanthematicus) vaccines |
| 0‑L |
J07AR01
|
typhus exanthematicus, inactivated, whole cell
|
WHO Anatomical Therapeutic Chemical classification |
|
typhus exanthematicus, inactivated, whole cell |
| 0‑L |
J07AX
|
Other bacterial vaccines
|
WHO Anatomical Therapeutic Chemical classification |
|
Other bacterial vaccines |
| 0‑L |
J07B
|
VIRAL VACCINES
|
WHO Anatomical Therapeutic Chemical classification |
|
VIRAL VACCINES |
| 0‑L |
J07BA
|
Encephalitis vaccines
|
WHO Anatomical Therapeutic Chemical classification |
|
Encephalitis vaccines |
| 0‑L |
J07BA01
|
encephalitis, tick borne, inactivated, whole virus
|
WHO Anatomical Therapeutic Chemical classification |
|
encephalitis, tick borne, inactivated, whole virus |
| 0‑L |
J07BA02
|
encephalitis, Japanese, inactivated, whole virus
|
WHO Anatomical Therapeutic Chemical classification |
|
encephalitis, Japanese, inactivated, whole virus |
| 0‑L |
J07BA03
|
encephalitis, Japanese, live attenuated
|
WHO Anatomical Therapeutic Chemical classification |
|
encephalitis, Japanese, live attenuated |
| 0‑L |
J07BB
|
Influenza vaccines
|
WHO Anatomical Therapeutic Chemical classification |
|
Influenza vaccines |
| 0‑L |
J07BB01
|
influenza, inactivated, whole virus
|
WHO Anatomical Therapeutic Chemical classification |
|
influenza, inactivated, whole virus |
| 0‑L |
J07BB02
|
influenza, inactivated, split virus or surface antigen
|
WHO Anatomical Therapeutic Chemical classification |
|
influenza, inactivated, split virus or surface antigen |
| 0‑L |
J07BB03
|
influenza, live attenuated
|
WHO Anatomical Therapeutic Chemical classification |
|
influenza, live attenuated |
| 0‑L |
J07BC
|
Hepatitis vaccines
|
WHO Anatomical Therapeutic Chemical classification |
|
Hepatitis vaccines |
| 0‑L |
J07BC01
|
hepatitis B, purified antigen
|
WHO Anatomical Therapeutic Chemical classification |
|
hepatitis B, purified antigen |
| 0‑L |
J07BC02
|
hepatitis A, inactivated, whole virus
|
WHO Anatomical Therapeutic Chemical classification |
|
hepatitis A, inactivated, whole virus |
| 0‑L |
J07BC20
|
combinations
|
WHO Anatomical Therapeutic Chemical classification |
|
combinations |
| 0‑L |
J07BD
|
Measles vaccines
|
WHO Anatomical Therapeutic Chemical classification |
|
Measles vaccines |
| 0‑L |
J07BD01
|
measles, live attenuated
|
WHO Anatomical Therapeutic Chemical classification |
|
measles, live attenuated |
| 0‑L |
J07BD51
|
measles, combinations with mumps, live attenuated
|
WHO Anatomical Therapeutic Chemical classification |
|
measles, combinations with mumps, live attenuated |
| 0‑L |
J07BD52
|
measles, combinations with mumps and rubella, live attenuated
|
WHO Anatomical Therapeutic Chemical classification |
|
measles, combinations with mumps and rubella, live attenuated |
| 0‑L |
J07BD53
|
measles, combinations with rubella, live attenuated
|
WHO Anatomical Therapeutic Chemical classification |
|
measles, combinations with rubella, live attenuated |
| 0‑L |
J07BD54
|
measles, combinations with mumps, rubella and varicella, live attenuated
|
WHO Anatomical Therapeutic Chemical classification |
|
measles, combinations with mumps, rubella and varicella, live attenuated |
| 0‑L |
J07BE
|
Mumps vaccines
|
WHO Anatomical Therapeutic Chemical classification |
|
Mumps vaccines |
| 0‑L |
J07BE01
|
mumps, live attenuated
|
WHO Anatomical Therapeutic Chemical classification |
|
mumps, live attenuated |
| 0‑L |
J07BF
|
Poliomyelitis vaccines
|
WHO Anatomical Therapeutic Chemical classification |
|
Poliomyelitis vaccines |
| 0‑L |
J07BF01
|
poliomyelitis oral, monovalent, live attenuated
|
WHO Anatomical Therapeutic Chemical classification |
|
poliomyelitis oral, monovalent, live attenuated |
| 0‑L |
J07BF02
|
poliomyelitis oral, trivalent, live attenuated
|
WHO Anatomical Therapeutic Chemical classification |
|
poliomyelitis oral, trivalent, live attenuated |
| 0‑L |
J07BF03
|
poliomyelitis, trivalent, inactivated, whole virus
|
WHO Anatomical Therapeutic Chemical classification |
|
poliomyelitis, trivalent, inactivated, whole virus |
| 0‑L |
J07BF04
|
poliomyelitis oral, bivalent, live attenuated
|
WHO Anatomical Therapeutic Chemical classification |
|
poliomyelitis oral, bivalent, live attenuated |
| 0‑L |
J07BG
|
Rabies vaccines
|
WHO Anatomical Therapeutic Chemical classification |
|
Rabies vaccines |
| 0‑L |
J07BG01
|
rabies, inactivated, whole virus
|
WHO Anatomical Therapeutic Chemical classification |
|
rabies, inactivated, whole virus |
| 0‑L |
J07BH
|
Rota virus diarrhea vaccines
|
WHO Anatomical Therapeutic Chemical classification |
|
Rota virus diarrhea vaccines |
| 0‑L |
J07BH01
|
rota virus, live attenuated
|
WHO Anatomical Therapeutic Chemical classification |
|
rota virus, live attenuated |
| 0‑L |
J07BH02
|
rota virus, pentavalent, live, reassorted
|
WHO Anatomical Therapeutic Chemical classification |
|
rota virus, pentavalent, live, reassorted |
| 0‑L |
J07BJ
|
Rubella vaccines
|
WHO Anatomical Therapeutic Chemical classification |
|
Rubella vaccines |
| 0‑L |
J07BJ01
|
rubella, live attenuated
|
WHO Anatomical Therapeutic Chemical classification |
|
rubella, live attenuated |
| 0‑L |
J07BJ51
|
rubella, combinations with mumps, live attenuated
|
WHO Anatomical Therapeutic Chemical classification |
|
rubella, combinations with mumps, live attenuated |
| 0‑L |
J07BK
|
Varicella zoster vaccines
|
WHO Anatomical Therapeutic Chemical classification |
|
Varicella zoster vaccines |
| 0‑L |
J07BK01
|
varicella, live attenuated
|
WHO Anatomical Therapeutic Chemical classification |
|
varicella, live attenuated |
| 0‑L |
J07BK02
|
zoster, live attenuated
|
WHO Anatomical Therapeutic Chemical classification |
|
zoster, live attenuated |
| 0‑L |
J07BL
|
Yellow fever vaccines
|
WHO Anatomical Therapeutic Chemical classification |
|
Yellow fever vaccines |
| 0‑L |
J07BL01
|
yellow fever, live attenuated
|
WHO Anatomical Therapeutic Chemical classification |
|
yellow fever, live attenuated |
| 0‑L |
J07BM
|
Papillomavirus vaccines
|
WHO Anatomical Therapeutic Chemical classification |
|
Papillomavirus vaccines |
| 0‑L |
J07BM01
|
papillomavirus (human types 6, 11, 16, 18)
|
WHO Anatomical Therapeutic Chemical classification |
|
papillomavirus (human types 6, 11, 16, 18) |
| 0‑L |
J07BM02
|
papillomavirus (human types 16, 18)
|
WHO Anatomical Therapeutic Chemical classification |
|
papillomavirus (human types 16, 18) |
| 0‑L |
J07BM03
|
papillomavirus (human types 6, 11, 16, 18, 31, 33, 45, 52, 58)
|
WHO Anatomical Therapeutic Chemical classification |
|
papillomavirus (human types 6, 11, 16, 18, 31, 33, 45, 52, 58) |
| 0‑L |
J07BX
|
Other viral vaccines
|
WHO Anatomical Therapeutic Chemical classification |
|
Other viral vaccines |
| 0‑L |
J07BX01
|
smallpox, live attenuated
|
WHO Anatomical Therapeutic Chemical classification |
|
smallpox, live attenuated |
| 0‑L |
J07C
|
BACTERIAL AND VIRAL VACCINES, COMBINED
|
WHO Anatomical Therapeutic Chemical classification |
|
BACTERIAL AND VIRAL VACCINES, COMBINED |
| 0‑L |
J07CA
|
Bacterial and viral vaccines, combined
|
WHO Anatomical Therapeutic Chemical classification |
|
Bacterial and viral vaccines, combined |
| 0‑L |
J07CA01
|
diphtheria-poliomyelitis-tetanus
|
WHO Anatomical Therapeutic Chemical classification |
|
diphtheria-poliomyelitis-tetanus |
| 0‑L |
J07CA02
|
diphtheria-pertussis-poliomyelitis-tetanus
|
WHO Anatomical Therapeutic Chemical classification |
|
diphtheria-pertussis-poliomyelitis-tetanus |
| 0‑L |
J07CA03
|
diphtheria-rubella-tetanus
|
WHO Anatomical Therapeutic Chemical classification |
|
diphtheria-rubella-tetanus |
| 0‑L |
J07CA04
|
hemophilus influenzae B and poliomyelitis
|
WHO Anatomical Therapeutic Chemical classification |
|
hemophilus influenzae B and poliomyelitis |
| 0‑L |
J07CA05
|
diphtheria-hepatitis B-pertussis-tetanus
|
WHO Anatomical Therapeutic Chemical classification |
|
diphtheria-hepatitis B-pertussis-tetanus |
| 0‑L |
J07CA06
|
diphtheria-hemophilus influenzae B-pertussis-poliomyelitis-tetanus
|
WHO Anatomical Therapeutic Chemical classification |
|
diphtheria-hemophilus influenzae B-pertussis-poliomyelitis-tetanus |
| 0‑L |
J07CA07
|
diphtheria-hepatitis B-tetanus
|
WHO Anatomical Therapeutic Chemical classification |
|
diphtheria-hepatitis B-tetanus |
| 0‑L |
J07CA08
|
hemophilus influenzae B and hepatitis B
|
WHO Anatomical Therapeutic Chemical classification |
|
hemophilus influenzae B and hepatitis B |
| 0‑L |
J07CA09
|
diphtheria-hemophilus influenzae B-pertussis-poliomyelitis-tetanus-hepatitis B
|
WHO Anatomical Therapeutic Chemical classification |
|
diphtheria-hemophilus influenzae B-pertussis-poliomyelitis-tetanus-hepatitis B |
| 0‑L |
J07CA10
|
typhoid-hepatitis A
|
WHO Anatomical Therapeutic Chemical classification |
|
typhoid-hepatitis A |
| 0‑L |
J07CA11
|
diphtheria-hemophilus influenzae B-pertussis-tetanus-hepatitis B
|
WHO Anatomical Therapeutic Chemical classification |
|
diphtheria-hemophilus influenzae B-pertussis-tetanus-hepatitis B |
| 0‑L |
J07CA12
|
diphtheria-pertussis-poliomyelitis-tetanus-hepatitis B
|
WHO Anatomical Therapeutic Chemical classification |
|
diphtheria-pertussis-poliomyelitis-tetanus-hepatitis B |
| 0‑L |
J07CA13
|
diphtheria-hemophilus influenzae B-pertussis-tetanus-hepatitis B-meningococcus A +
C
|
WHO Anatomical Therapeutic Chemical classification |
|
diphtheria-hemophilus influenzae B-pertussis-tetanus-hepatitis B-meningococcus A +
C
|
| 0‑L |
J07X
|
OTHER VACCINES
|
WHO Anatomical Therapeutic Chemical classification |
|
OTHER VACCINES |
| 0‑L |
L
|
ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
|
WHO Anatomical Therapeutic Chemical classification |
|
ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS |
| 0‑L |
L01
|
ANTINEOPLASTIC AGENTS
|
WHO Anatomical Therapeutic Chemical classification |
|
ANTINEOPLASTIC AGENTS |
| 0‑L |
L01A
|
ALKYLATING AGENTS
|
WHO Anatomical Therapeutic Chemical classification |
|
ALKYLATING AGENTS |
| 0‑L |
L01AA
|
Nitrogen mustard analogues
|
WHO Anatomical Therapeutic Chemical classification |
|
Nitrogen mustard analogues |
| 0‑L |
L01AA01
|
cyclophosphamide
|
WHO Anatomical Therapeutic Chemical classification |
|
cyclophosphamide |
| 0‑L |
L01AA02
|
chlorambucil
|
WHO Anatomical Therapeutic Chemical classification |
|
chlorambucil |
| 0‑L |
L01AA03
|
melphalan
|
WHO Anatomical Therapeutic Chemical classification |
|
melphalan |
| 0‑L |
L01AA05
|
chlormethine
|
WHO Anatomical Therapeutic Chemical classification |
|
chlormethine |
| 0‑L |
L01AA06
|
ifosfamide
|
WHO Anatomical Therapeutic Chemical classification |
|
ifosfamide |
| 0‑L |
L01AA07
|
trofosfamide
|
WHO Anatomical Therapeutic Chemical classification |
|
trofosfamide |
| 0‑L |
L01AA08
|
prednimustine
|
WHO Anatomical Therapeutic Chemical classification |
|
prednimustine |
| 0‑L |
L01AA09
|
bendamustine
|
WHO Anatomical Therapeutic Chemical classification |
|
bendamustine |
| 0‑L |
L01AB
|
Alkyl sulfonates
|
WHO Anatomical Therapeutic Chemical classification |
|
Alkyl sulfonates |
| 0‑L |
L01AB01
|
busulfan
|
WHO Anatomical Therapeutic Chemical classification |
|
busulfan |
| 0‑L |
L01AB02
|
treosulfan
|
WHO Anatomical Therapeutic Chemical classification |
|
treosulfan |
| 0‑L |
L01AB03
|
mannosulfan
|
WHO Anatomical Therapeutic Chemical classification |
|
mannosulfan |
| 0‑L |
L01AC
|
Ethylene imines
|
WHO Anatomical Therapeutic Chemical classification |
|
Ethylene imines |
| 0‑L |
L01AC01
|
thiotepa
|
WHO Anatomical Therapeutic Chemical classification |
|
thiotepa |
| 0‑L |
L01AC02
|
triaziquone
|
WHO Anatomical Therapeutic Chemical classification |
|
triaziquone |
| 0‑L |
L01AC03
|
carboquone
|
WHO Anatomical Therapeutic Chemical classification |
|
carboquone |
| 0‑L |
L01AD
|
Nitrosoureas
|
WHO Anatomical Therapeutic Chemical classification |
|
Nitrosoureas |
| 0‑L |
L01AD01
|
carmustine
|
WHO Anatomical Therapeutic Chemical classification |
|
carmustine |
| 0‑L |
L01AD02
|
lomustine
|
WHO Anatomical Therapeutic Chemical classification |
|
lomustine |
| 0‑L |
L01AD03
|
semustine
|
WHO Anatomical Therapeutic Chemical classification |
|
semustine |
| 0‑L |
L01AD04
|
streptozocin
|
WHO Anatomical Therapeutic Chemical classification |
|
streptozocin |
| 0‑L |
L01AD05
|
fotemustine
|
WHO Anatomical Therapeutic Chemical classification |
|
fotemustine |
| 0‑L |
L01AD06
|
nimustine
|
WHO Anatomical Therapeutic Chemical classification |
|
nimustine |
| 0‑L |
L01AD07
|
ranimustine
|
WHO Anatomical Therapeutic Chemical classification |
|
ranimustine |
| 0‑L |
L01AG
|
Epoxides
|
WHO Anatomical Therapeutic Chemical classification |
|
Epoxides |
| 0‑L |
L01AG01
|
etoglucid
|
WHO Anatomical Therapeutic Chemical classification |
|
etoglucid |
| 0‑L |
L01AX
|
Other alkylating agents
|
WHO Anatomical Therapeutic Chemical classification |
|
Other alkylating agents |
| 0‑L |
L01AX01
|
mitobronitol
|
WHO Anatomical Therapeutic Chemical classification |
|
mitobronitol |
| 0‑L |
L01AX02
|
pipobroman
|
WHO Anatomical Therapeutic Chemical classification |
|
pipobroman |
| 0‑L |
L01AX03
|
temozolomide
|
WHO Anatomical Therapeutic Chemical classification |
|
temozolomide |
| 0‑L |
L01AX04
|
dacarbazine
|
WHO Anatomical Therapeutic Chemical classification |
|
dacarbazine |
| 0‑L |
L01B
|
ANTIMETABOLITES
|
WHO Anatomical Therapeutic Chemical classification |
|
ANTIMETABOLITES |
| 0‑L |
L01BA
|
Folic acid analogues
|
WHO Anatomical Therapeutic Chemical classification |
|
Folic acid analogues |
| 0‑L |
L01BA01
|
methotrexate
|
WHO Anatomical Therapeutic Chemical classification |
|
methotrexate |
| 0‑L |
L01BA03
|
raltitrexed
|
WHO Anatomical Therapeutic Chemical classification |
|
raltitrexed |
| 0‑L |
L01BA04
|
pemetrexed
|
WHO Anatomical Therapeutic Chemical classification |
|
pemetrexed |
| 0‑L |
L01BA05
|
pralatrexate
|
WHO Anatomical Therapeutic Chemical classification |
|
pralatrexate |
| 0‑L |
L01BB
|
Purine analogues
|
WHO Anatomical Therapeutic Chemical classification |
|
Purine analogues |
| 0‑L |
L01BB02
|
mercaptopurine
|
WHO Anatomical Therapeutic Chemical classification |
|
mercaptopurine |
| 0‑L |
L01BB03
|
tioguanine
|
WHO Anatomical Therapeutic Chemical classification |
|
tioguanine |
| 0‑L |
L01BB04
|
cladribine
|
WHO Anatomical Therapeutic Chemical classification |
|
cladribine |
| 0‑L |
L01BB05
|
fludarabine
|
WHO Anatomical Therapeutic Chemical classification |
|
fludarabine |
| 0‑L |
L01BB06
|
clofarabine
|
WHO Anatomical Therapeutic Chemical classification |
|
clofarabine |
| 0‑L |
L01BB07
|
nelarabine
|
WHO Anatomical Therapeutic Chemical classification |
|
nelarabine |
| 0‑L |
L01BC
|
Pyrimidine analogues
|
WHO Anatomical Therapeutic Chemical classification |
|
Pyrimidine analogues |
| 0‑L |
L01BC01
|
cytarabine
|
WHO Anatomical Therapeutic Chemical classification |
|
cytarabine |
| 0‑L |
L01BC02
|
fluorouracil
|
WHO Anatomical Therapeutic Chemical classification |
|
fluorouracil |
| 0‑L |
L01BC03
|
tegafur
|
WHO Anatomical Therapeutic Chemical classification |
|
tegafur |
| 0‑L |
L01BC04
|
carmofur
|
WHO Anatomical Therapeutic Chemical classification |
|
carmofur |
| 0‑L |
L01BC05
|
gemcitabine
|
WHO Anatomical Therapeutic Chemical classification |
|
gemcitabine |
| 0‑L |
L01BC06
|
capecitabine
|
WHO Anatomical Therapeutic Chemical classification |
|
capecitabine |
| 0‑L |
L01BC07
|
azacitidine
|
WHO Anatomical Therapeutic Chemical classification |
|
azacitidine |
| 0‑L |
L01BC08
|
decitabine
|
WHO Anatomical Therapeutic Chemical classification |
|
decitabine |
| 0‑L |
L01BC52
|
fluorouracil, combinations
|
WHO Anatomical Therapeutic Chemical classification |
|
fluorouracil, combinations |
| 0‑L |
L01BC53
|
tegafur, combinations
|
WHO Anatomical Therapeutic Chemical classification |
|
tegafur, combinations |
| 0‑L |
L01BC59
|
trifluridine, combinations
|
WHO Anatomical Therapeutic Chemical classification |
|
trifluridine, combinations |
| 0‑L |
L01C
|
PLANT ALKALOIDS AND OTHER NATURAL PRODUCTS
|
WHO Anatomical Therapeutic Chemical classification |
|
PLANT ALKALOIDS AND OTHER NATURAL PRODUCTS |
| 0‑L |
L01CA
|
Vinca alkaloids and analogues
|
WHO Anatomical Therapeutic Chemical classification |
|
Vinca alkaloids and analogues |
| 0‑L |
L01CA01
|
vinblastine
|
WHO Anatomical Therapeutic Chemical classification |
|
vinblastine |
| 0‑L |
L01CA02
|
vincristine
|
WHO Anatomical Therapeutic Chemical classification |
|
vincristine |
| 0‑L |
L01CA03
|
vindesine
|
WHO Anatomical Therapeutic Chemical classification |
|
vindesine |
| 0‑L |
L01CA04
|
vinorelbine
|
WHO Anatomical Therapeutic Chemical classification |
|
vinorelbine |
| 0‑L |
L01CA05
|
vinflunine
|
WHO Anatomical Therapeutic Chemical classification |
|
vinflunine |
| 0‑L |
L01CA06
|
vintafolide
|
WHO Anatomical Therapeutic Chemical classification |
|
vintafolide |
| 0‑L |
L01CB
|
Podophyllotoxin derivatives
|
WHO Anatomical Therapeutic Chemical classification |
|
Podophyllotoxin derivatives |
| 0‑L |
L01CB01
|
etoposide
|
WHO Anatomical Therapeutic Chemical classification |
|
etoposide |
| 0‑L |
L01CB02
|
teniposide
|
WHO Anatomical Therapeutic Chemical classification |
|
teniposide |
| 0‑L |
L01CC
|
Colchicine derivatives
|
WHO Anatomical Therapeutic Chemical classification |
|
Colchicine derivatives |
| 0‑L |
L01CC01
|
demecolcine
|
WHO Anatomical Therapeutic Chemical classification |
|
demecolcine |
| 0‑L |
L01CD
|
Taxanes
|
WHO Anatomical Therapeutic Chemical classification |
|
Taxanes |
| 0‑L |
L01CD01
|
paclitaxel
|
WHO Anatomical Therapeutic Chemical classification |
|
paclitaxel |
| 0‑L |
L01CD02
|
docetaxel
|
WHO Anatomical Therapeutic Chemical classification |
|
docetaxel |
| 0‑L |
L01CD03
|
paclitaxel poliglumex
|
WHO Anatomical Therapeutic Chemical classification |
|
paclitaxel poliglumex |
| 0‑L |
L01CD04
|
cabazitaxel
|
WHO Anatomical Therapeutic Chemical classification |
|
cabazitaxel |
| 0‑L |
L01CX
|
Other plant alkaloids and natural products
|
WHO Anatomical Therapeutic Chemical classification |
|
Other plant alkaloids and natural products |
| 0‑L |
L01CX01
|
trabectedin
|
WHO Anatomical Therapeutic Chemical classification |
|
trabectedin |
| 0‑L |
L01D
|
CYTOTOXIC ANTIBIOTICS AND RELATED SUBSTANCES
|
WHO Anatomical Therapeutic Chemical classification |
|
CYTOTOXIC ANTIBIOTICS AND RELATED SUBSTANCES |
| 0‑L |
L01DA
|
Actinomycines
|
WHO Anatomical Therapeutic Chemical classification |
|
Actinomycines |
| 0‑L |
L01DA01
|
dactinomycin
|
WHO Anatomical Therapeutic Chemical classification |
|
dactinomycin |
| 0‑L |
L01DB
|
Anthracyclines and related substances
|
WHO Anatomical Therapeutic Chemical classification |
|
Anthracyclines and related substances |
| 0‑L |
L01DB01
|
doxorubicin
|
WHO Anatomical Therapeutic Chemical classification |
|
doxorubicin |
| 0‑L |
L01DB02
|
daunorubicin
|
WHO Anatomical Therapeutic Chemical classification |
|
daunorubicin |
| 0‑L |
L01DB03
|
epirubicin
|
WHO Anatomical Therapeutic Chemical classification |
|
epirubicin |
| 0‑L |
L01DB04
|
aclarubicin
|
WHO Anatomical Therapeutic Chemical classification |
|
aclarubicin |
| 0‑L |
L01DB05
|
zorubicin
|
WHO Anatomical Therapeutic Chemical classification |
|
zorubicin |
| 0‑L |
L01DB06
|
idarubicin
|
WHO Anatomical Therapeutic Chemical classification |
|
idarubicin |
| 0‑L |
L01DB07
|
mitoxantrone
|
WHO Anatomical Therapeutic Chemical classification |
|
mitoxantrone |
| 0‑L |
L01DB08
|
pirarubicin
|
WHO Anatomical Therapeutic Chemical classification |
|
pirarubicin |
| 0‑L |
L01DB09
|
valrubicin
|
WHO Anatomical Therapeutic Chemical classification |
|
valrubicin |
| 0‑L |
L01DB10
|
amrubicin
|
WHO Anatomical Therapeutic Chemical classification |
|
amrubicin |
| 0‑L |
L01DB11
|
pixantrone
|
WHO Anatomical Therapeutic Chemical classification |
|
pixantrone |
| 0‑L |
L01DC
|
Other cytotoxic antibiotics
|
WHO Anatomical Therapeutic Chemical classification |
|
Other cytotoxic antibiotics |
| 0‑L |
L01DC01
|
bleomycin
|
WHO Anatomical Therapeutic Chemical classification |
|
bleomycin |
| 0‑L |
L01DC02
|
plicamycin
|
WHO Anatomical Therapeutic Chemical classification |
|
plicamycin |
| 0‑L |
L01DC03
|
mitomycin
|
WHO Anatomical Therapeutic Chemical classification |
|
mitomycin |
| 0‑L |
L01DC04
|
ixabepilone
|
WHO Anatomical Therapeutic Chemical classification |
|
ixabepilone |
| 0‑L |
L01X
|
OTHER ANTINEOPLASTIC AGENTS
|
WHO Anatomical Therapeutic Chemical classification |
|
OTHER ANTINEOPLASTIC AGENTS |
| 0‑L |
L01XA
|
Platinum compounds
|
WHO Anatomical Therapeutic Chemical classification |
|
Platinum compounds |
| 0‑L |
L01XA01
|
cisplatin
|
WHO Anatomical Therapeutic Chemical classification |
|
cisplatin |
| 0‑L |
L01XA02
|
carboplatin
|
WHO Anatomical Therapeutic Chemical classification |
|
carboplatin |
| 0‑L |
L01XA03
|
oxaliplatin
|
WHO Anatomical Therapeutic Chemical classification |
|
oxaliplatin |
| 0‑L |
L01XA04
|
satraplatin
|
WHO Anatomical Therapeutic Chemical classification |
|
satraplatin |
| 0‑L |
L01XA05
|
polyplatillen
|
WHO Anatomical Therapeutic Chemical classification |
|
polyplatillen |
| 0‑L |
L01XB
|
Methylhydrazines
|
WHO Anatomical Therapeutic Chemical classification |
|
Methylhydrazines |
| 0‑L |
L01XB01
|
procarbazine
|
WHO Anatomical Therapeutic Chemical classification |
|
procarbazine |
| 0‑L |
L01XC
|
Monoclonal antibodies
|
WHO Anatomical Therapeutic Chemical classification |
|
Monoclonal antibodies |
| 0‑L |
L01XC01
|
edrecolomab
|
WHO Anatomical Therapeutic Chemical classification |
|
edrecolomab |
| 0‑L |
L01XC02
|
rituximab
|
WHO Anatomical Therapeutic Chemical classification |
|
rituximab |
| 0‑L |
L01XC03
|
trastuzumab
|
WHO Anatomical Therapeutic Chemical classification |
|
trastuzumab |
| 0‑L |
L01XC05
|
gemtuzumab
|
WHO Anatomical Therapeutic Chemical classification |
|
gemtuzumab |
| 0‑L |
L01XC06
|
cetuximab
|
WHO Anatomical Therapeutic Chemical classification |
|
cetuximab |
| 0‑L |
L01XC07
|
bevacizumab
|
WHO Anatomical Therapeutic Chemical classification |
|
bevacizumab |
| 0‑L |
L01XC08
|
panitumumab
|
WHO Anatomical Therapeutic Chemical classification |
|
panitumumab |
| 0‑L |
L01XC09
|
catumaxomab
|
WHO Anatomical Therapeutic Chemical classification |
|
catumaxomab |
| 0‑L |
L01XC10
|
ofatumumab
|
WHO Anatomical Therapeutic Chemical classification |
|
ofatumumab |
| 0‑L |
L01XC11
|
ipilimumab
|
WHO Anatomical Therapeutic Chemical classification |
|
ipilimumab |
| 0‑L |
L01XC12
|
brentuximab vedotin
|
WHO Anatomical Therapeutic Chemical classification |
|
brentuximab vedotin |
| 0‑L |
L01XC13
|
pertuzumab
|
WHO Anatomical Therapeutic Chemical classification |
|
pertuzumab |
| 0‑L |
L01XC14
|
trastuzumab emtansine
|
WHO Anatomical Therapeutic Chemical classification |
|
trastuzumab emtansine |
| 0‑L |
L01XC15
|
obinutuzumab
|
WHO Anatomical Therapeutic Chemical classification |
|
obinutuzumab |
| 0‑L |
L01XC16
|
dinutuximab
|
WHO Anatomical Therapeutic Chemical classification |
|
dinutuximab |
| 0‑L |
L01XC17
|
nivolumab
|
WHO Anatomical Therapeutic Chemical classification |
|
nivolumab |
| 0‑L |
L01XC18
|
pembrolizumab
|
WHO Anatomical Therapeutic Chemical classification |
|
pembrolizumab |
| 0‑L |
L01XC19
|
blinatumomab
|
WHO Anatomical Therapeutic Chemical classification |
|
blinatumomab |
| 0‑L |
L01XC21
|
ramucirumab
|
WHO Anatomical Therapeutic Chemical classification |
|
ramucirumab |
| 0‑L |
L01XC22
|
necitumumab
|
WHO Anatomical Therapeutic Chemical classification |
|
necitumumab |
| 0‑L |
L01XC23
|
elotuzumab
|
WHO Anatomical Therapeutic Chemical classification |
|
elotuzumab |
| 0‑L |
L01XC24
|
daratumumab
|
WHO Anatomical Therapeutic Chemical classification |
|
daratumumab |
| 0‑L |
L01XC25
|
mogamulizumab
|
WHO Anatomical Therapeutic Chemical classification |
|
mogamulizumab |
| 0‑L |
L01XC26
|
inotuzumab ozogamicin
|
WHO Anatomical Therapeutic Chemical classification |
|
inotuzumab ozogamicin |
| 0‑L |
L01XD
|
Sensitizers used in photodynamic/radiation therapy
|
WHO Anatomical Therapeutic Chemical classification |
|
Sensitizers used in photodynamic/radiation therapy |
| 0‑L |
L01XD01
|
porfimer sodium
|
WHO Anatomical Therapeutic Chemical classification |
|
porfimer sodium |
| 0‑L |
L01XD03
|
methyl aminolevulinate
|
WHO Anatomical Therapeutic Chemical classification |
|
methyl aminolevulinate |
| 0‑L |
L01XD04
|
aminolevulinic acid
|
WHO Anatomical Therapeutic Chemical classification |
|
aminolevulinic acid |
| 0‑L |
L01XD05
|
temoporfin
|
WHO Anatomical Therapeutic Chemical classification |
|
temoporfin |
| 0‑L |
L01XD06
|
efaproxiral
|
WHO Anatomical Therapeutic Chemical classification |
|
efaproxiral |
| 0‑L |
L01XE
|
Protein kinase inhibitors
|
WHO Anatomical Therapeutic Chemical classification |
|
Protein kinase inhibitors |
| 0‑L |
L01XE01
|
imatinib
|
WHO Anatomical Therapeutic Chemical classification |
|
imatinib |
| 0‑L |
L01XE02
|
gefitinib
|
WHO Anatomical Therapeutic Chemical classification |
|
gefitinib |
| 0‑L |
L01XE03
|
erlotinib
|
WHO Anatomical Therapeutic Chemical classification |
|
erlotinib |
| 0‑L |
L01XE04
|
sunitinib
|
WHO Anatomical Therapeutic Chemical classification |
|
sunitinib |
| 0‑L |
L01XE05
|
sorafenib
|
WHO Anatomical Therapeutic Chemical classification |
|
sorafenib |
| 0‑L |
L01XE06
|
dasatinib
|
WHO Anatomical Therapeutic Chemical classification |
|
dasatinib |
| 0‑L |
L01XE07
|
lapatinib
|
WHO Anatomical Therapeutic Chemical classification |
|
lapatinib |
| 0‑L |
L01XE08
|
nilotinib
|
WHO Anatomical Therapeutic Chemical classification |
|
nilotinib |
| 0‑L |
L01XE09
|
temsirolimus
|
WHO Anatomical Therapeutic Chemical classification |
|
temsirolimus |
| 0‑L |
L01XE10
|
everolimus
|
WHO Anatomical Therapeutic Chemical classification |
|
everolimus |
| 0‑L |
L01XE11
|
pazopanib
|
WHO Anatomical Therapeutic Chemical classification |
|
pazopanib |
| 0‑L |
L01XE12
|
vandetanib
|
WHO Anatomical Therapeutic Chemical classification |
|
vandetanib |
| 0‑L |
L01XE13
|
afatinib
|
WHO Anatomical Therapeutic Chemical classification |
|
afatinib |
| 0‑L |
L01XE14
|
bosutinib
|
WHO Anatomical Therapeutic Chemical classification |
|
bosutinib |
| 0‑L |
L01XE15
|
vemurafenib
|
WHO Anatomical Therapeutic Chemical classification |
|
vemurafenib |
| 0‑L |
L01XE16
|
crizotinib
|
WHO Anatomical Therapeutic Chemical classification |
|
crizotinib |
| 0‑L |
L01XE17
|
axitinib
|
WHO Anatomical Therapeutic Chemical classification |
|
axitinib |
| 0‑L |
L01XE18
|
ruxolitinib
|
WHO Anatomical Therapeutic Chemical classification |
|
ruxolitinib |
| 0‑L |
L01XE19
|
ridaforolimus
|
WHO Anatomical Therapeutic Chemical classification |
|
ridaforolimus |
| 0‑L |
L01XE21
|
regorafenib
|
WHO Anatomical Therapeutic Chemical classification |
|
regorafenib |
| 0‑L |
L01XE22
|
masitinib
|
WHO Anatomical Therapeutic Chemical classification |
|
masitinib |
| 0‑L |
L01XE23
|
dabrafenib
|
WHO Anatomical Therapeutic Chemical classification |
|
dabrafenib |
| 0‑L |
L01XE24
|
ponatinib
|
WHO Anatomical Therapeutic Chemical classification |
|
ponatinib |
| 0‑L |
L01XE25
|
trametinib
|
WHO Anatomical Therapeutic Chemical classification |
|
trametinib |
| 0‑L |
L01XE26
|
cabozantinib
|
WHO Anatomical Therapeutic Chemical classification |
|
cabozantinib |
| 0‑L |
L01XE27
|
ibrutinib
|
WHO Anatomical Therapeutic Chemical classification |
|
ibrutinib |
| 0‑L |
L01XE28
|
ceritinib
|
WHO Anatomical Therapeutic Chemical classification |
|
ceritinib |
| 0‑L |
L01XE29
|
lenvatinib
|
WHO Anatomical Therapeutic Chemical classification |
|
lenvatinib |
| 0‑L |
L01XE31
|
nintedanib
|
WHO Anatomical Therapeutic Chemical classification |
|
nintedanib |
| 0‑L |
L01XE32
|
cediranib
|
WHO Anatomical Therapeutic Chemical classification |
|
cediranib |
| 0‑L |
L01XE33
|
palbociclib
|
WHO Anatomical Therapeutic Chemical classification |
|
palbociclib |
| 0‑L |
L01XE34
|
tivozanib
|
WHO Anatomical Therapeutic Chemical classification |
|
tivozanib |
| 0‑L |
L01XE35
|
osimertinib
|
WHO Anatomical Therapeutic Chemical classification |
|
osimertinib |
| 0‑L |
L01XE36
|
alectinib
|
WHO Anatomical Therapeutic Chemical classification |
|
alectinib |
| 0‑L |
L01XE37
|
rociletinib
|
WHO Anatomical Therapeutic Chemical classification |
|
rociletinib |
| 0‑L |
L01XE38
|
cobimetinib
|
WHO Anatomical Therapeutic Chemical classification |
|
cobimetinib |
| 0‑L |
L01XE39
|
midostaurin
|
WHO Anatomical Therapeutic Chemical classification |
|
midostaurin |
| 0‑L |
L01XE40
|
olmutinib
|
WHO Anatomical Therapeutic Chemical classification |
|
olmutinib |
| 0‑L |
L01XX
|
Other antineoplastic agents
|
WHO Anatomical Therapeutic Chemical classification |
|
Other antineoplastic agents |
| 0‑L |
L01XX01
|
amsacrine
|
WHO Anatomical Therapeutic Chemical classification |
|
amsacrine |
| 0‑L |
L01XX02
|
asparaginase
|
WHO Anatomical Therapeutic Chemical classification |
|
asparaginase |
| 0‑L |
L01XX03
|
altretamine
|
WHO Anatomical Therapeutic Chemical classification |
|
altretamine |
| 0‑L |
L01XX05
|
hydroxycarbamide
|
WHO Anatomical Therapeutic Chemical classification |
|
hydroxycarbamide |
| 0‑L |
L01XX07
|
lonidamine
|
WHO Anatomical Therapeutic Chemical classification |
|
lonidamine |
| 0‑L |
L01XX08
|
pentostatin
|
WHO Anatomical Therapeutic Chemical classification |
|
pentostatin |
| 0‑L |
L01XX09
|
miltefosine
|
WHO Anatomical Therapeutic Chemical classification |
|
miltefosine |
| 0‑L |
L01XX10
|
masoprocol
|
WHO Anatomical Therapeutic Chemical classification |
|
masoprocol |
| 0‑L |
L01XX11
|
estramustine
|
WHO Anatomical Therapeutic Chemical classification |
|
estramustine |
| 0‑L |
L01XX14
|
tretinoin
|
WHO Anatomical Therapeutic Chemical classification |
|
tretinoin |
| 0‑L |
L01XX16
|
mitoguazone
|
WHO Anatomical Therapeutic Chemical classification |
|
mitoguazone |
| 0‑L |
L01XX17
|
topotecan
|
WHO Anatomical Therapeutic Chemical classification |
|
topotecan |
| 0‑L |
L01XX18
|
tiazofurine
|
WHO Anatomical Therapeutic Chemical classification |
|
tiazofurine |
| 0‑L |
L01XX19
|
irinotecan
|
WHO Anatomical Therapeutic Chemical classification |
|
irinotecan |
| 0‑L |
L01XX22
|
alitretinoin
|
WHO Anatomical Therapeutic Chemical classification |
|
alitretinoin |
| 0‑L |
L01XX23
|
mitotane
|
WHO Anatomical Therapeutic Chemical classification |
|
mitotane |
| 0‑L |
L01XX24
|
pegaspargase
|
WHO Anatomical Therapeutic Chemical classification |
|
pegaspargase |
| 0‑L |
L01XX25
|
bexarotene
|
WHO Anatomical Therapeutic Chemical classification |
|
bexarotene |
| 0‑L |
L01XX27
|
arsenic trioxide
|
WHO Anatomical Therapeutic Chemical classification |
|
arsenic trioxide |
| 0‑L |
L01XX29
|
denileukin diftitox
|
WHO Anatomical Therapeutic Chemical classification |
|
denileukin diftitox |
| 0‑L |
L01XX32
|
bortezomib
|
WHO Anatomical Therapeutic Chemical classification |
|
bortezomib |
| 0‑L |
L01XX33
|
celecoxib
|
WHO Anatomical Therapeutic Chemical classification |
|
celecoxib |
| 0‑L |
L01XX35
|
anagrelide
|
WHO Anatomical Therapeutic Chemical classification |
|
anagrelide |
| 0‑L |
L01XX36
|
oblimersen
|
WHO Anatomical Therapeutic Chemical classification |
|
oblimersen |
| 0‑L |
L01XX37
|
sitimagene ceradenovec
|
WHO Anatomical Therapeutic Chemical classification |
|
sitimagene ceradenovec |
| 0‑L |
L01XX38
|
vorinostat
|
WHO Anatomical Therapeutic Chemical classification |
|
vorinostat |
| 0‑L |
L01XX39
|
romidepsin
|
WHO Anatomical Therapeutic Chemical classification |
|
romidepsin |
| 0‑L |
L01XX40
|
omacetaxine mepesuccinate
|
WHO Anatomical Therapeutic Chemical classification |
|
omacetaxine mepesuccinate |
| 0‑L |
L01XX41
|
eribulin
|
WHO Anatomical Therapeutic Chemical classification |
|
eribulin |
| 0‑L |
L01XX42
|
panobinostat
|
WHO Anatomical Therapeutic Chemical classification |
|
panobinostat |
| 0‑L |
L01XX43
|
vismodegib
|
WHO Anatomical Therapeutic Chemical classification |
|
vismodegib |
| 0‑L |
L01XX44
|
aflibercept
|
WHO Anatomical Therapeutic Chemical classification |
|
aflibercept |
| 0‑L |
L01XX45
|
carfilzomib
|
WHO Anatomical Therapeutic Chemical classification |
|
carfilzomib |
| 0‑L |
L01XX46
|
olaparib
|
WHO Anatomical Therapeutic Chemical classification |
|
olaparib |
| 0‑L |
L01XX47
|
idelalisib
|
WHO Anatomical Therapeutic Chemical classification |
|
idelalisib |
| 0‑L |
L01XX48
|
sonidegib
|
WHO Anatomical Therapeutic Chemical classification |
|
sonidegib |
| 0‑L |
L01XX49
|
belinostat
|
WHO Anatomical Therapeutic Chemical classification |
|
belinostat |
| 0‑L |
L01XX50
|
ixazomib
|
WHO Anatomical Therapeutic Chemical classification |
|
ixazomib |
| 0‑L |
L01XX51
|
talimogene laherparepvec
|
WHO Anatomical Therapeutic Chemical classification |
|
talimogene laherparepvec |
| 0‑L |
L01XX52
|
venetoclax
|
WHO Anatomical Therapeutic Chemical classification |
|
venetoclax |
| 0‑L |
L01XX53
|
vosaroxin
|
WHO Anatomical Therapeutic Chemical classification |
|
vosaroxin |
| 0‑L |
L01XY
|
Combinations of antineoplastic agents
|
WHO Anatomical Therapeutic Chemical classification |
|
Combinations of antineoplastic agents |
| 0‑L |
L02
|
ENDOCRINE THERAPY
|
WHO Anatomical Therapeutic Chemical classification |
|
ENDOCRINE THERAPY |
| 0‑L |
L02A
|
HORMONES AND RELATED AGENTS
|
WHO Anatomical Therapeutic Chemical classification |
|
HORMONES AND RELATED AGENTS |
| 0‑L |
L02AA
|
Estrogens
|
WHO Anatomical Therapeutic Chemical classification |
|
Estrogens |
| 0‑L |
L02AA01
|
diethylstilbestrol
|
WHO Anatomical Therapeutic Chemical classification |
|
diethylstilbestrol |
| 0‑L |
L02AA02
|
polyestradiol phosphate
|
WHO Anatomical Therapeutic Chemical classification |
|
polyestradiol phosphate |
| 0‑L |
L02AA03
|
ethinylestradiol
|
WHO Anatomical Therapeutic Chemical classification |
|
ethinylestradiol |
| 0‑L |
L02AA04
|
fosfestrol
|
WHO Anatomical Therapeutic Chemical classification |
|
fosfestrol |
| 0‑L |
L02AB
|
Progestogens
|
WHO Anatomical Therapeutic Chemical classification |
|
Progestogens |
| 0‑L |
L02AB01
|
megestrol
|
WHO Anatomical Therapeutic Chemical classification |
|
megestrol |
| 0‑L |
L02AB02
|
medroxyprogesterone
|
WHO Anatomical Therapeutic Chemical classification |
|
medroxyprogesterone |
| 0‑L |
L02AB03
|
gestonorone
|
WHO Anatomical Therapeutic Chemical classification |
|
gestonorone |
| 0‑L |
L02AE
|
Gonadotropin releasing hormone analogues
|
WHO Anatomical Therapeutic Chemical classification |
|
Gonadotropin releasing hormone analogues |
| 0‑L |
L02AE01
|
buserelin
|
WHO Anatomical Therapeutic Chemical classification |
|
buserelin |
| 0‑L |
L02AE02
|
leuprorelin
|
WHO Anatomical Therapeutic Chemical classification |
|
leuprorelin |
| 0‑L |
L02AE03
|
goserelin
|
WHO Anatomical Therapeutic Chemical classification |
|
goserelin |
| 0‑L |
L02AE04
|
triptorelin
|
WHO Anatomical Therapeutic Chemical classification |
|
triptorelin |
| 0‑L |
L02AE05
|
histrelin
|
WHO Anatomical Therapeutic Chemical classification |
|
histrelin |
| 0‑L |
L02AX
|
Other hormones
|
WHO Anatomical Therapeutic Chemical classification |
|
Other hormones |
| 0‑L |
L02B
|
HORMONE ANTAGONISTS AND RELATED AGENTS
|
WHO Anatomical Therapeutic Chemical classification |
|
HORMONE ANTAGONISTS AND RELATED AGENTS |
| 0‑L |
L02BA
|
Anti-estrogens
|
WHO Anatomical Therapeutic Chemical classification |
|
Anti-estrogens |
| 0‑L |
L02BA01
|
tamoxifen
|
WHO Anatomical Therapeutic Chemical classification |
|
tamoxifen |
| 0‑L |
L02BA02
|
toremifene
|
WHO Anatomical Therapeutic Chemical classification |
|
toremifene |
| 0‑L |
L02BA03
|
fulvestrant
|
WHO Anatomical Therapeutic Chemical classification |
|
fulvestrant |
| 0‑L |
L02BB
|
Anti-androgens
|
WHO Anatomical Therapeutic Chemical classification |
|
Anti-androgens |
| 0‑L |
L02BB01
|
flutamide
|
WHO Anatomical Therapeutic Chemical classification |
|
flutamide |
| 0‑L |
L02BB02
|
nilutamide
|
WHO Anatomical Therapeutic Chemical classification |
|
nilutamide |
| 0‑L |
L02BB03
|
bicalutamide
|
WHO Anatomical Therapeutic Chemical classification |
|
bicalutamide |
| 0‑L |
L02BB04
|
enzalutamide
|
WHO Anatomical Therapeutic Chemical classification |
|
enzalutamide |
| 0‑L |
L02BG
|
Aromatase inhibitors
|
WHO Anatomical Therapeutic Chemical classification |
|
Aromatase inhibitors |
| 0‑L |
L02BG01
|
aminoglutethimide
|
WHO Anatomical Therapeutic Chemical classification |
|
aminoglutethimide |
| 0‑L |
L02BG02
|
formestane
|
WHO Anatomical Therapeutic Chemical classification |
|
formestane |
| 0‑L |
L02BG03
|
anastrozole
|
WHO Anatomical Therapeutic Chemical classification |
|
anastrozole |
| 0‑L |
L02BG04
|
letrozole
|
WHO Anatomical Therapeutic Chemical classification |
|
letrozole |
| 0‑L |
L02BG05
|
vorozole
|
WHO Anatomical Therapeutic Chemical classification |
|
vorozole |
| 0‑L |
L02BG06
|
exemestane
|
WHO Anatomical Therapeutic Chemical classification |
|
exemestane |
| 0‑L |
L02BX
|
Other hormone antagonists and related agents
|
WHO Anatomical Therapeutic Chemical classification |
|
Other hormone antagonists and related agents |
| 0‑L |
L02BX01
|
abarelix
|
WHO Anatomical Therapeutic Chemical classification |
|
abarelix |
| 0‑L |
L02BX02
|
degarelix
|
WHO Anatomical Therapeutic Chemical classification |
|
degarelix |
| 0‑L |
L02BX03
|
abiraterone
|
WHO Anatomical Therapeutic Chemical classification |
|
abiraterone |
| 0‑L |
L03
|
IMMUNOSTIMULANTS
|
WHO Anatomical Therapeutic Chemical classification |
|
IMMUNOSTIMULANTS |
| 0‑L |
L03A
|
IMMUNOSTIMULANTS
|
WHO Anatomical Therapeutic Chemical classification |
|
IMMUNOSTIMULANTS |
| 0‑L |
L03AA
|
Colony stimulating factors
|
WHO Anatomical Therapeutic Chemical classification |
|
Colony stimulating factors |
| 0‑L |
L03AA02
|
filgrastim
|
WHO Anatomical Therapeutic Chemical classification |
|
filgrastim |
| 0‑L |
L03AA03
|
molgramostim
|
WHO Anatomical Therapeutic Chemical classification |
|
molgramostim |
| 0‑L |
L03AA09
|
sargramostim
|
WHO Anatomical Therapeutic Chemical classification |
|
sargramostim |
| 0‑L |
L03AA10
|
lenograstim
|
WHO Anatomical Therapeutic Chemical classification |
|
lenograstim |
| 0‑L |
L03AA12
|
ancestim
|
WHO Anatomical Therapeutic Chemical classification |
|
ancestim |
| 0‑L |
L03AA13
|
pegfilgrastim
|
WHO Anatomical Therapeutic Chemical classification |
|
pegfilgrastim |
| 0‑L |
L03AA14
|
lipegfilgrastim
|
WHO Anatomical Therapeutic Chemical classification |
|
lipegfilgrastim |
| 0‑L |
L03AA15
|
balugrastim
|
WHO Anatomical Therapeutic Chemical classification |
|
balugrastim |
| 0‑L |
L03AA16
|
empegfilgrastim
|
WHO Anatomical Therapeutic Chemical classification |
|
empegfilgrastim |
| 0‑L |
L03AB
|
Interferons
|
WHO Anatomical Therapeutic Chemical classification |
|
Interferons |
| 0‑L |
L03AB01
|
interferon alfa natural
|
WHO Anatomical Therapeutic Chemical classification |
|
interferon alfa natural |
| 0‑L |
L03AB02
|
interferon beta natural
|
WHO Anatomical Therapeutic Chemical classification |
|
interferon beta natural |
| 0‑L |
L03AB03
|
interferon gamma
|
WHO Anatomical Therapeutic Chemical classification |
|
interferon gamma |
| 0‑L |
L03AB04
|
interferon alfa-2a
|
WHO Anatomical Therapeutic Chemical classification |
|
interferon alfa-2a |
| 0‑L |
L03AB05
|
interferon alfa-2b
|
WHO Anatomical Therapeutic Chemical classification |
|
interferon alfa-2b |
| 0‑L |
L03AB06
|
interferon alfa-n1
|
WHO Anatomical Therapeutic Chemical classification |
|
interferon alfa-n1 |
| 0‑L |
L03AB07
|
interferon beta-1a
|
WHO Anatomical Therapeutic Chemical classification |
|
interferon beta-1a |
| 0‑L |
L03AB08
|
interferon beta-1b
|
WHO Anatomical Therapeutic Chemical classification |
|
interferon beta-1b |
| 0‑L |
L03AB09
|
interferon alfacon-1
|
WHO Anatomical Therapeutic Chemical classification |
|
interferon alfacon-1 |
| 0‑L |
L03AB10
|
peginterferon alfa-2b
|
WHO Anatomical Therapeutic Chemical classification |
|
peginterferon alfa-2b |
| 0‑L |
L03AB11
|
peginterferon alfa-2a
|
WHO Anatomical Therapeutic Chemical classification |
|
peginterferon alfa-2a |
| 0‑L |
L03AB12
|
albinterferon alfa-2b
|
WHO Anatomical Therapeutic Chemical classification |
|
albinterferon alfa-2b |
| 0‑L |
L03AB13
|
peginterferon beta-1a
|
WHO Anatomical Therapeutic Chemical classification |
|
peginterferon beta-1a |
| 0‑L |
L03AB14
|
cepeginterferon alfa-2b
|
WHO Anatomical Therapeutic Chemical classification |
|
cepeginterferon alfa-2b |
| 0‑L |
L03AB60
|
peginterferon alfa-2b, combinations
|
WHO Anatomical Therapeutic Chemical classification |
|
peginterferon alfa-2b, combinations |
| 0‑L |
L03AB61
|
peginterferon alfa-2a, combinations
|
WHO Anatomical Therapeutic Chemical classification |
|
peginterferon alfa-2a, combinations |
| 0‑L |
L03AC
|
Interleukins
|
WHO Anatomical Therapeutic Chemical classification |
|
Interleukins |
| 0‑L |
L03AC01
|
aldesleukin
|
WHO Anatomical Therapeutic Chemical classification |
|
aldesleukin |
| 0‑L |
L03AC02
|
oprelvekin
|
WHO Anatomical Therapeutic Chemical classification |
|
oprelvekin |
| 0‑L |
L03AX
|
Other immunostimulants
|
WHO Anatomical Therapeutic Chemical classification |
|
Other immunostimulants |
| 0‑L |
L03AX01
|
lentinan
|
WHO Anatomical Therapeutic Chemical classification |
|
lentinan |
| 0‑L |
L03AX02
|
roquinimex
|
WHO Anatomical Therapeutic Chemical classification |
|
roquinimex |
| 0‑L |
L03AX03
|
BCG vaccine
|
WHO Anatomical Therapeutic Chemical classification |
|
BCG vaccine |
| 0‑L |
L03AX04
|
pegademase
|
WHO Anatomical Therapeutic Chemical classification |
|
pegademase |
| 0‑L |
L03AX05
|
pidotimod
|
WHO Anatomical Therapeutic Chemical classification |
|
pidotimod |
| 0‑L |
L03AX07
|
poly I:C
|
WHO Anatomical Therapeutic Chemical classification |
|
poly I:C |
| 0‑L |
L03AX08
|
poly ICLC
|
WHO Anatomical Therapeutic Chemical classification |
|
poly ICLC |
| 0‑L |
L03AX09
|
thymopentin
|
WHO Anatomical Therapeutic Chemical classification |
|
thymopentin |
| 0‑L |
L03AX10
|
immunocyanin
|
WHO Anatomical Therapeutic Chemical classification |
|
immunocyanin |
| 0‑L |
L03AX11
|
tasonermin
|
WHO Anatomical Therapeutic Chemical classification |
|
tasonermin |
| 0‑L |
L03AX12
|
melanoma vaccine
|
WHO Anatomical Therapeutic Chemical classification |
|
melanoma vaccine |
| 0‑L |
L03AX13
|
glatiramer acetate
|
WHO Anatomical Therapeutic Chemical classification |
|
glatiramer acetate |
| 0‑L |
L03AX14
|
histamine dihydrochloride
|
WHO Anatomical Therapeutic Chemical classification |
|
histamine dihydrochloride |
| 0‑L |
L03AX15
|
mifamurtide
|
WHO Anatomical Therapeutic Chemical classification |
|
mifamurtide |
| 0‑L |
L03AX16
|
plerixafor
|
WHO Anatomical Therapeutic Chemical classification |
|
plerixafor |
| 0‑L |
L03AX17
|
sipuleucel-T
|
WHO Anatomical Therapeutic Chemical classification |
|
sipuleucel-T |
| 0‑L |
L03AX18
|
cridanimod
|
WHO Anatomical Therapeutic Chemical classification |
|
cridanimod |
| 0‑L |
L03AX19
|
dasiprotimut-T
|
WHO Anatomical Therapeutic Chemical classification |
|
dasiprotimut-T |
| 0‑L |
L04
|
IMMUNOSUPPRESSANTS
|
WHO Anatomical Therapeutic Chemical classification |
|
IMMUNOSUPPRESSANTS |
| 0‑L |
L04A
|
IMMUNOSUPPRESSANTS
|
WHO Anatomical Therapeutic Chemical classification |
|
IMMUNOSUPPRESSANTS |
| 0‑L |
L04AA
|
Selective immunosuppressants
|
WHO Anatomical Therapeutic Chemical classification |
|
Selective immunosuppressants |
| 0‑L |
L04AA02
|
muromonab-CD3
|
WHO Anatomical Therapeutic Chemical classification |
|
muromonab-CD3 |
| 0‑L |
L04AA03
|
antilymphocyte immunoglobulin (horse)
|
WHO Anatomical Therapeutic Chemical classification |
|
antilymphocyte immunoglobulin (horse) |
| 0‑L |
L04AA04
|
antithymocyte immunoglobulin (rabbit)
|
WHO Anatomical Therapeutic Chemical classification |
|
antithymocyte immunoglobulin (rabbit) |
| 0‑L |
L04AA06
|
mycophenolic acid
|
WHO Anatomical Therapeutic Chemical classification |
|
mycophenolic acid |
| 0‑L |
L04AA10
|
sirolimus
|
WHO Anatomical Therapeutic Chemical classification |
|
sirolimus |
| 0‑L |
L04AA13
|
leflunomide
|
WHO Anatomical Therapeutic Chemical classification |
|
leflunomide |
| 0‑L |
L04AA15
|
alefacept
|
WHO Anatomical Therapeutic Chemical classification |
|
alefacept |
| 0‑L |
L04AA18
|
everolimus
|
WHO Anatomical Therapeutic Chemical classification |
|
everolimus |
| 0‑L |
L04AA19
|
gusperimus
|
WHO Anatomical Therapeutic Chemical classification |
|
gusperimus |
| 0‑L |
L04AA21
|
efalizumab
|
WHO Anatomical Therapeutic Chemical classification |
|
efalizumab |
| 0‑L |
L04AA22
|
abetimus
|
WHO Anatomical Therapeutic Chemical classification |
|
abetimus |
| 0‑L |
L04AA23
|
natalizumab
|
WHO Anatomical Therapeutic Chemical classification |
|
natalizumab |
| 0‑L |
L04AA24
|
abatacept
|
WHO Anatomical Therapeutic Chemical classification |
|
abatacept |
| 0‑L |
L04AA25
|
eculizumab
|
WHO Anatomical Therapeutic Chemical classification |
|
eculizumab |
| 0‑L |
L04AA26
|
belimumab
|
WHO Anatomical Therapeutic Chemical classification |
|
belimumab |
| 0‑L |
L04AA27
|
fingolimod
|
WHO Anatomical Therapeutic Chemical classification |
|
fingolimod |
| 0‑L |
L04AA28
|
belatacept
|
WHO Anatomical Therapeutic Chemical classification |
|
belatacept |
| 0‑L |
L04AA29
|
tofacitinib
|
WHO Anatomical Therapeutic Chemical classification |
|
tofacitinib |
| 0‑L |
L04AA31
|
teriflunomide
|
WHO Anatomical Therapeutic Chemical classification |
|
teriflunomide |
| 0‑L |
L04AA32
|
apremilast
|
WHO Anatomical Therapeutic Chemical classification |
|
apremilast |
| 0‑L |
L04AA33
|
vedolizumab
|
WHO Anatomical Therapeutic Chemical classification |
|
vedolizumab |
| 0‑L |
L04AA34
|
alemtuzumab
|
WHO Anatomical Therapeutic Chemical classification |
|
alemtuzumab |
| 0‑L |
L04AA35
|
begelomab
|
WHO Anatomical Therapeutic Chemical classification |
|
begelomab |
| 0‑L |
L04AA36
|
ocrelizumab
|
WHO Anatomical Therapeutic Chemical classification |
|
ocrelizumab |
| 0‑L |
L04AA37
|
baricitinib
|
WHO Anatomical Therapeutic Chemical classification |
|
baricitinib |
| 0‑L |
L04AB
|
Tumor necrosis factor alpha (TNF-) inhibitors
|
WHO Anatomical Therapeutic Chemical classification |
|
Tumor necrosis factor alpha (TNF-) inhibitors |
| 0‑L |
L04AB01
|
etanercept
|
WHO Anatomical Therapeutic Chemical classification |
|
etanercept |
| 0‑L |
L04AB02
|
infliximab
|
WHO Anatomical Therapeutic Chemical classification |
|
infliximab |
| 0‑L |
L04AB03
|
afelimomab
|
WHO Anatomical Therapeutic Chemical classification |
|
afelimomab |
| 0‑L |
L04AB04
|
adalimumab
|
WHO Anatomical Therapeutic Chemical classification |
|
adalimumab |
| 0‑L |
L04AB05
|
certolizumab pegol
|
WHO Anatomical Therapeutic Chemical classification |
|
certolizumab pegol |
| 0‑L |
L04AB06
|
golimumab
|
WHO Anatomical Therapeutic Chemical classification |
|
golimumab |
| 0‑L |
L04AC
|
Interleukin inhibitors
|
WHO Anatomical Therapeutic Chemical classification |
|
Interleukin inhibitors |
| 0‑L |
L04AC01
|
daclizumab
|
WHO Anatomical Therapeutic Chemical classification |
|
daclizumab |
| 0‑L |
L04AC02
|
basiliximab
|
WHO Anatomical Therapeutic Chemical classification |
|
basiliximab |
| 0‑L |
L04AC03
|
anakinra
|
WHO Anatomical Therapeutic Chemical classification |
|
anakinra |
| 0‑L |
L04AC04
|
rilonacept
|
WHO Anatomical Therapeutic Chemical classification |
|
rilonacept |
| 0‑L |
L04AC05
|
ustekinumab
|
WHO Anatomical Therapeutic Chemical classification |
|
ustekinumab |
| 0‑L |
L04AC07
|
tocilizumab
|
WHO Anatomical Therapeutic Chemical classification |
|
tocilizumab |
| 0‑L |
L04AC08
|
canakinumab
|
WHO Anatomical Therapeutic Chemical classification |
|
canakinumab |
| 0‑L |
L04AC09
|
briakinumab
|
WHO Anatomical Therapeutic Chemical classification |
|
briakinumab |
| 0‑L |
L04AC10
|
secukinumab
|
WHO Anatomical Therapeutic Chemical classification |
|
secukinumab |
| 0‑L |
L04AC11
|
siltuximab
|
WHO Anatomical Therapeutic Chemical classification |
|
siltuximab |
| 0‑L |
L04AC12
|
brodalumab
|
WHO Anatomical Therapeutic Chemical classification |
|
brodalumab |
| 0‑L |
L04AC13
|
ixekizumab
|
WHO Anatomical Therapeutic Chemical classification |
|
ixekizumab |
| 0‑L |
L04AC14
|
sarilumab
|
WHO Anatomical Therapeutic Chemical classification |
|
sarilumab |
| 0‑L |
L04AD
|
Calcineurin inhibitors
|
WHO Anatomical Therapeutic Chemical classification |
|
Calcineurin inhibitors |
| 0‑L |
L04AD01
|
ciclosporin
|
WHO Anatomical Therapeutic Chemical classification |
|
ciclosporin |
| 0‑L |
L04AD02
|
tacrolimus
|
WHO Anatomical Therapeutic Chemical classification |
|
tacrolimus |
| 0‑L |
L04AD03
|
voclosporin
|
WHO Anatomical Therapeutic Chemical classification |
|
voclosporin |
| 0‑L |
L04AX
|
Other immunosuppressants
|
WHO Anatomical Therapeutic Chemical classification |
|
Other immunosuppressants |
| 0‑L |
L04AX01
|
azathioprine
|
WHO Anatomical Therapeutic Chemical classification |
|
azathioprine |
| 0‑L |
L04AX02
|
thalidomide
|
WHO Anatomical Therapeutic Chemical classification |
|
thalidomide |
| 0‑L |
L04AX03
|
methotrexate
|
WHO Anatomical Therapeutic Chemical classification |
|
methotrexate |
| 0‑L |
L04AX04
|
lenalidomide
|
WHO Anatomical Therapeutic Chemical classification |
|
lenalidomide |
| 0‑L |
L04AX05
|
pirfenidone
|
WHO Anatomical Therapeutic Chemical classification |
|
pirfenidone |
| 0‑L |
L04AX06
|
pomalidomide
|
WHO Anatomical Therapeutic Chemical classification |
|
pomalidomide |
| 0‑L |
M
|
MUSCULO-SKELETAL SYSTEM
|
WHO Anatomical Therapeutic Chemical classification |
|
MUSCULO-SKELETAL SYSTEM |
| 0‑L |
M01
|
ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS
|
WHO Anatomical Therapeutic Chemical classification |
|
ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS |
| 0‑L |
M01A
|
ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS
|
WHO Anatomical Therapeutic Chemical classification |
|
ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS |
| 0‑L |
M01AA
|
Butylpyrazolidines
|
WHO Anatomical Therapeutic Chemical classification |
|
Butylpyrazolidines |
| 0‑L |
M01AA01
|
phenylbutazone
|
WHO Anatomical Therapeutic Chemical classification |
|
phenylbutazone |
| 0‑L |
M01AA02
|
mofebutazone
|
WHO Anatomical Therapeutic Chemical classification |
|
mofebutazone |
| 0‑L |
M01AA03
|
oxyphenbutazone
|
WHO Anatomical Therapeutic Chemical classification |
|
oxyphenbutazone |
| 0‑L |
M01AA05
|
clofezone
|
WHO Anatomical Therapeutic Chemical classification |
|
clofezone |
| 0‑L |
M01AA06
|
kebuzone
|
WHO Anatomical Therapeutic Chemical classification |
|
kebuzone |
| 0‑L |
M01AB
|
Acetic acid derivatives and related substances
|
WHO Anatomical Therapeutic Chemical classification |
|
Acetic acid derivatives and related substances |
| 0‑L |
M01AB01
|
indometacin
|
WHO Anatomical Therapeutic Chemical classification |
|
indometacin |
| 0‑L |
M01AB02
|
sulindac
|
WHO Anatomical Therapeutic Chemical classification |
|
sulindac |
| 0‑L |
M01AB03
|
tolmetin
|
WHO Anatomical Therapeutic Chemical classification |
|
tolmetin |
| 0‑L |
M01AB04
|
zomepirac
|
WHO Anatomical Therapeutic Chemical classification |
|
zomepirac |
| 0‑L |
M01AB05
|
diclofenac
|
WHO Anatomical Therapeutic Chemical classification |
|
diclofenac |
| 0‑L |
M01AB06
|
alclofenac
|
WHO Anatomical Therapeutic Chemical classification |
|
alclofenac |
| 0‑L |
M01AB07
|
bumadizone
|
WHO Anatomical Therapeutic Chemical classification |
|
bumadizone |
| 0‑L |
M01AB08
|
etodolac
|
WHO Anatomical Therapeutic Chemical classification |
|
etodolac |
| 0‑L |
M01AB09
|
lonazolac
|
WHO Anatomical Therapeutic Chemical classification |
|
lonazolac |
| 0‑L |
M01AB10
|
fentiazac
|
WHO Anatomical Therapeutic Chemical classification |
|
fentiazac |
| 0‑L |
M01AB11
|
acemetacin
|
WHO Anatomical Therapeutic Chemical classification |
|
acemetacin |
| 0‑L |
M01AB12
|
difenpiramide
|
WHO Anatomical Therapeutic Chemical classification |
|
difenpiramide |
| 0‑L |
M01AB13
|
oxametacin
|
WHO Anatomical Therapeutic Chemical classification |
|
oxametacin |
| 0‑L |
M01AB14
|
proglumetacin
|
WHO Anatomical Therapeutic Chemical classification |
|
proglumetacin |
| 0‑L |
M01AB15
|
ketorolac
|
WHO Anatomical Therapeutic Chemical classification |
|
ketorolac |
| 0‑L |
M01AB16
|
aceclofenac
|
WHO Anatomical Therapeutic Chemical classification |
|
aceclofenac |
| 0‑L |
M01AB17
|
bufexamac
|
WHO Anatomical Therapeutic Chemical classification |
|
bufexamac |
| 0‑L |
M01AB51
|
indometacin, combinations
|
WHO Anatomical Therapeutic Chemical classification |
|
indometacin, combinations |
| 0‑L |
M01AB55
|
diclofenac, combinations
|
WHO Anatomical Therapeutic Chemical classification |
|
diclofenac, combinations |
| 0‑L |
M01AC
|
Oxicams
|
WHO Anatomical Therapeutic Chemical classification |
|
Oxicams |
| 0‑L |
M01AC01
|
piroxicam
|
WHO Anatomical Therapeutic Chemical classification |
|
piroxicam |
| 0‑L |
M01AC02
|
tenoxicam
|
WHO Anatomical Therapeutic Chemical classification |
|
tenoxicam |
| 0‑L |
M01AC04
|
droxicam
|
WHO Anatomical Therapeutic Chemical classification |
|
droxicam |
| 0‑L |
M01AC05
|
lornoxicam
|
WHO Anatomical Therapeutic Chemical classification |
|
lornoxicam |
| 0‑L |
M01AC06
|
meloxicam
|
WHO Anatomical Therapeutic Chemical classification |
|
meloxicam |
| 0‑L |
M01AC56
|
meloxicam, combinations
|
WHO Anatomical Therapeutic Chemical classification |
|
meloxicam, combinations |
| 0‑L |
M01AE
|
Propionic acid derivatives
|
WHO Anatomical Therapeutic Chemical classification |
|
Propionic acid derivatives |
| 0‑L |
M01AE01
|
ibuprofen
|
WHO Anatomical Therapeutic Chemical classification |
|
ibuprofen |
| 0‑L |
M01AE02
|
naproxen
|
WHO Anatomical Therapeutic Chemical classification |
|
naproxen |
| 0‑L |
M01AE03
|
ketoprofen
|
WHO Anatomical Therapeutic Chemical classification |
|
ketoprofen |
| 0‑L |
M01AE04
|
fenoprofen
|
WHO Anatomical Therapeutic Chemical classification |
|
fenoprofen |
| 0‑L |
M01AE05
|
fenbufen
|
WHO Anatomical Therapeutic Chemical classification |
|
fenbufen |
| 0‑L |
M01AE06
|
benoxaprofen
|
WHO Anatomical Therapeutic Chemical classification |
|
benoxaprofen |
| 0‑L |
M01AE07
|
suprofen
|
WHO Anatomical Therapeutic Chemical classification |
|
suprofen |
| 0‑L |
M01AE08
|
pirprofen
|
WHO Anatomical Therapeutic Chemical classification |
|
pirprofen |
| 0‑L |
M01AE09
|
flurbiprofen
|
WHO Anatomical Therapeutic Chemical classification |
|
flurbiprofen |
| 0‑L |
M01AE10
|
indoprofen
|
WHO Anatomical Therapeutic Chemical classification |
|
indoprofen |
| 0‑L |
M01AE11
|
tiaprofenic acid
|
WHO Anatomical Therapeutic Chemical classification |
|
tiaprofenic acid |
| 0‑L |
M01AE12
|
oxaprozin
|
WHO Anatomical Therapeutic Chemical classification |
|
oxaprozin |
| 0‑L |
M01AE13
|
ibuproxam
|
WHO Anatomical Therapeutic Chemical classification |
|
ibuproxam |
| 0‑L |
M01AE14
|
dexibuprofen
|
WHO Anatomical Therapeutic Chemical classification |
|
dexibuprofen |
| 0‑L |
M01AE15
|
flunoxaprofen
|
WHO Anatomical Therapeutic Chemical classification |
|
flunoxaprofen |
| 0‑L |
M01AE16
|
alminoprofen
|
WHO Anatomical Therapeutic Chemical classification |
|
alminoprofen |
| 0‑L |
M01AE17
|
dexketoprofen
|
WHO Anatomical Therapeutic Chemical classification |
|
dexketoprofen |
| 0‑L |
M01AE18
|
naproxcinod
|
WHO Anatomical Therapeutic Chemical classification |
|
naproxcinod |
| 0‑L |
M01AE51
|
ibuprofen, combinations
|
WHO Anatomical Therapeutic Chemical classification |
|
ibuprofen, combinations |
| 0‑L |
M01AE52
|
naproxen and esomeprazole
|
WHO Anatomical Therapeutic Chemical classification |
|
naproxen and esomeprazole |
| 0‑L |
M01AE53
|
ketoprofen, combinations
|
WHO Anatomical Therapeutic Chemical classification |
|
ketoprofen, combinations |
| 0‑L |
M01AE56
|
naproxen and misoprostol
|
WHO Anatomical Therapeutic Chemical classification |
|
naproxen and misoprostol |
| 0‑L |
M01AG
|
Fenamates
|
WHO Anatomical Therapeutic Chemical classification |
|
Fenamates |
| 0‑L |
M01AG01
|
mefenamic acid
|
WHO Anatomical Therapeutic Chemical classification |
|
mefenamic acid |
| 0‑L |
M01AG02
|
tolfenamic acid
|
WHO Anatomical Therapeutic Chemical classification |
|
tolfenamic acid |
| 0‑L |
M01AG03
|
flufenamic acid
|
WHO Anatomical Therapeutic Chemical classification |
|
flufenamic acid |
| 0‑L |
M01AG04
|
meclofenamic acid
|
WHO Anatomical Therapeutic Chemical classification |
|
meclofenamic acid |
| 0‑L |
M01AH
|
Coxibs
|
WHO Anatomical Therapeutic Chemical classification |
|
Coxibs |
| 0‑L |
M01AH01
|
celecoxib
|
WHO Anatomical Therapeutic Chemical classification |
|
celecoxib |
| 0‑L |
M01AH02
|
rofecoxib
|
WHO Anatomical Therapeutic Chemical classification |
|
rofecoxib |
| 0‑L |
M01AH03
|
valdecoxib
|
WHO Anatomical Therapeutic Chemical classification |
|
valdecoxib |
| 0‑L |
M01AH04
|
parecoxib
|
WHO Anatomical Therapeutic Chemical classification |
|
parecoxib |
| 0‑L |
M01AH05
|
etoricoxib
|
WHO Anatomical Therapeutic Chemical classification |
|
etoricoxib |
| 0‑L |
M01AH06
|
lumiracoxib
|
WHO Anatomical Therapeutic Chemical classification |
|
lumiracoxib |
| 0‑L |
M01AX
|
Other antiinflammatory and antirheumatic agents, non-steroids
|
WHO Anatomical Therapeutic Chemical classification |
|
Other antiinflammatory and antirheumatic agents, non-steroids |
| 0‑L |
M01AX01
|
nabumetone
|
WHO Anatomical Therapeutic Chemical classification |
|
nabumetone |
| 0‑L |
M01AX02
|
niflumic acid
|
WHO Anatomical Therapeutic Chemical classification |
|
niflumic acid |
| 0‑L |
M01AX04
|
azapropazone
|
WHO Anatomical Therapeutic Chemical classification |
|
azapropazone |
| 0‑L |
M01AX05
|
glucosamine
|
WHO Anatomical Therapeutic Chemical classification |
|
glucosamine |
| 0‑L |
M01AX07
|
benzydamine
|
WHO Anatomical Therapeutic Chemical classification |
|
benzydamine |
| 0‑L |
M01AX12
|
glucosaminoglycan polysulfate
|
WHO Anatomical Therapeutic Chemical classification |
|
glucosaminoglycan polysulfate |
| 0‑L |
M01AX13
|
proquazone
|
WHO Anatomical Therapeutic Chemical classification |
|
proquazone |
| 0‑L |
M01AX14
|
orgotein
|
WHO Anatomical Therapeutic Chemical classification |
|
orgotein |
| 0‑L |
M01AX17
|
nimesulide
|
WHO Anatomical Therapeutic Chemical classification |
|
nimesulide |
| 0‑L |
M01AX18
|
feprazone
|
WHO Anatomical Therapeutic Chemical classification |
|
feprazone |
| 0‑L |
M01AX21
|
diacerein
|
WHO Anatomical Therapeutic Chemical classification |
|
diacerein |
| 0‑L |
M01AX22
|
morniflumate
|
WHO Anatomical Therapeutic Chemical classification |
|
morniflumate |
| 0‑L |
M01AX23
|
tenidap
|
WHO Anatomical Therapeutic Chemical classification |
|
tenidap |
| 0‑L |
M01AX24
|
oxaceprol
|
WHO Anatomical Therapeutic Chemical classification |
|
oxaceprol |
| 0‑L |
M01AX25
|
chondroitin sulfate
|
WHO Anatomical Therapeutic Chemical classification |
|
chondroitin sulfate |
| 0‑L |
M01AX26
|
avocado and soyabean oil, unsaponifiables
|
WHO Anatomical Therapeutic Chemical classification |
|
avocado and soyabean oil, unsaponifiables |
| 0‑L |
M01AX68
|
feprazone, combinations
|
WHO Anatomical Therapeutic Chemical classification |
|
feprazone, combinations |
| 0‑L |
M01B
|
ANTIINFLAMMATORY/ANTIRHEUMATIC AGENTS IN COMBINATION
|
WHO Anatomical Therapeutic Chemical classification |
|
ANTIINFLAMMATORY/ANTIRHEUMATIC AGENTS IN COMBINATION |
| 0‑L |
M01BA
|
Antiinflammatory/antirheumatic agents in combination with corticosteroids
|
WHO Anatomical Therapeutic Chemical classification |
|
Antiinflammatory/antirheumatic agents in combination with corticosteroids |
| 0‑L |
M01BA01
|
phenylbutazone and corticosteroids
|
WHO Anatomical Therapeutic Chemical classification |
|
phenylbutazone and corticosteroids |
| 0‑L |
M01BA02
|
dipyrocetyl and corticosteroids
|
WHO Anatomical Therapeutic Chemical classification |
|
dipyrocetyl and corticosteroids |
| 0‑L |
M01BA03
|
acetylsalicylic acid and corticosteroids
|
WHO Anatomical Therapeutic Chemical classification |
|
acetylsalicylic acid and corticosteroids |
| 0‑L |
M01BX
|
Other antiinflammatory/antirheumatic agents in combination with other drugs
|
WHO Anatomical Therapeutic Chemical classification |
|
Other antiinflammatory/antirheumatic agents in combination with other drugs |
| 0‑L |
M01C
|
SPECIFIC ANTIRHEUMATIC AGENTS
|
WHO Anatomical Therapeutic Chemical classification |
|
SPECIFIC ANTIRHEUMATIC AGENTS |
| 0‑L |
M01CA
|
Quinolines
|
WHO Anatomical Therapeutic Chemical classification |
|
Quinolines |
| 0‑L |
M01CA03
|
oxycinchophen
|
WHO Anatomical Therapeutic Chemical classification |
|
oxycinchophen |
| 0‑L |
M01CB
|
Gold preparations
|
WHO Anatomical Therapeutic Chemical classification |
|
Gold preparations |
| 0‑L |
M01CB01
|
sodium aurothiomalate
|
WHO Anatomical Therapeutic Chemical classification |
|
sodium aurothiomalate |
| 0‑L |
M01CB02
|
sodium aurotiosulfate
|
WHO Anatomical Therapeutic Chemical classification |
|
sodium aurotiosulfate |
| 0‑L |
M01CB03
|
auranofin
|
WHO Anatomical Therapeutic Chemical classification |
|
auranofin |
| 0‑L |
M01CB04
|
aurothioglucose
|
WHO Anatomical Therapeutic Chemical classification |
|
aurothioglucose |
| 0‑L |
M01CB05
|
aurotioprol
|
WHO Anatomical Therapeutic Chemical classification |
|
aurotioprol |
| 0‑L |
M01CC
|
Penicillamine and similar agents
|
WHO Anatomical Therapeutic Chemical classification |
|
Penicillamine and similar agents |
| 0‑L |
M01CC01
|
penicillamine
|
WHO Anatomical Therapeutic Chemical classification |
|
penicillamine |
| 0‑L |
M01CC02
|
bucillamine
|
WHO Anatomical Therapeutic Chemical classification |
|
bucillamine |
| 0‑L |
M01CX
|
Other specific antirheumatic agents
|
WHO Anatomical Therapeutic Chemical classification |
|
Other specific antirheumatic agents |
| 0‑L |
M02
|
TOPICAL PRODUCTS FOR JOINT AND MUSCULAR PAIN
|
WHO Anatomical Therapeutic Chemical classification |
|
TOPICAL PRODUCTS FOR JOINT AND MUSCULAR PAIN |
| 0‑L |
M02A
|
TOPICAL PRODUCTS FOR JOINT AND MUSCULAR PAIN
|
WHO Anatomical Therapeutic Chemical classification |
|
TOPICAL PRODUCTS FOR JOINT AND MUSCULAR PAIN |
| 0‑L |
M02AA
|
Antiinflammatory preparations, non-steroids for topical use
|
WHO Anatomical Therapeutic Chemical classification |
|
Antiinflammatory preparations, non-steroids for topical use |
| 0‑L |
M02AA01
|
phenylbutazone
|
WHO Anatomical Therapeutic Chemical classification |
|
phenylbutazone |
| 0‑L |
M02AA02
|
mofebutazone
|
WHO Anatomical Therapeutic Chemical classification |
|
mofebutazone |
| 0‑L |
M02AA03
|
clofezone
|
WHO Anatomical Therapeutic Chemical classification |
|
clofezone |
| 0‑L |
M02AA04
|
oxyphenbutazone
|
WHO Anatomical Therapeutic Chemical classification |
|
oxyphenbutazone |
| 0‑L |
M02AA05
|
benzydamine
|
WHO Anatomical Therapeutic Chemical classification |
|
benzydamine |
| 0‑L |
M02AA06
|
etofenamate
|
WHO Anatomical Therapeutic Chemical classification |
|
etofenamate |
| 0‑L |
M02AA07
|
piroxicam
|
WHO Anatomical Therapeutic Chemical classification |
|
piroxicam |
| 0‑L |
M02AA08
|
felbinac
|
WHO Anatomical Therapeutic Chemical classification |
|
felbinac |
| 0‑L |
M02AA09
|
bufexamac
|
WHO Anatomical Therapeutic Chemical classification |
|
bufexamac |
| 0‑L |
M02AA10
|
ketoprofen
|
WHO Anatomical Therapeutic Chemical classification |
|
ketoprofen |
| 0‑L |
M02AA11
|
bendazac
|
WHO Anatomical Therapeutic Chemical classification |
|
bendazac |
| 0‑L |
M02AA12
|
naproxen
|
WHO Anatomical Therapeutic Chemical classification |
|
naproxen |
| 0‑L |
M02AA13
|
ibuprofen
|
WHO Anatomical Therapeutic Chemical classification |
|
ibuprofen |
| 0‑L |
M02AA14
|
fentiazac
|
WHO Anatomical Therapeutic Chemical classification |
|
fentiazac |
| 0‑L |
M02AA15
|
diclofenac
|
WHO Anatomical Therapeutic Chemical classification |
|
diclofenac |
| 0‑L |
M02AA16
|
feprazone
|
WHO Anatomical Therapeutic Chemical classification |
|
feprazone |
| 0‑L |
M02AA17
|
niflumic acid
|
WHO Anatomical Therapeutic Chemical classification |
|
niflumic acid |
| 0‑L |
M02AA18
|
meclofenamic acid
|
WHO Anatomical Therapeutic Chemical classification |
|
meclofenamic acid |
| 0‑L |
M02AA19
|
flurbiprofen
|
WHO Anatomical Therapeutic Chemical classification |
|
flurbiprofen |
| 0‑L |
M02AA21
|
tolmetin
|
WHO Anatomical Therapeutic Chemical classification |
|
tolmetin |
| 0‑L |
M02AA22
|
suxibuzone
|
WHO Anatomical Therapeutic Chemical classification |
|
suxibuzone |
| 0‑L |
M02AA23
|
indometacin
|
WHO Anatomical Therapeutic Chemical classification |
|
indometacin |
| 0‑L |
M02AA24
|
nifenazone
|
WHO Anatomical Therapeutic Chemical classification |
|
nifenazone |
| 0‑L |
M02AA25
|
aceclofenac
|
WHO Anatomical Therapeutic Chemical classification |
|
aceclofenac |
| 0‑L |
M02AA26
|
nimesulide
|
WHO Anatomical Therapeutic Chemical classification |
|
nimesulide |
| 0‑L |
M02AA27
|
dexketoprofen
|
WHO Anatomical Therapeutic Chemical classification |
|
dexketoprofen |
| 0‑L |
M02AA28
|
piketoprofen
|
WHO Anatomical Therapeutic Chemical classification |
|
piketoprofen |
| 0‑L |
M02AB
|
Capsaicin and similar agents
|
WHO Anatomical Therapeutic Chemical classification |
|
Capsaicin and similar agents |
| 0‑L |
M02AB01
|
capsaicin
|
WHO Anatomical Therapeutic Chemical classification |
|
capsaicin |
| 0‑L |
M02AB02
|
zucapsaicin
|
WHO Anatomical Therapeutic Chemical classification |
|
zucapsaicin |
| 0‑L |
M02AC
|
Preparations with salicylic acid derivatives
|
WHO Anatomical Therapeutic Chemical classification |
|
Preparations with salicylic acid derivatives |
| 0‑L |
M02AX
|
Other topical products for joint and muscular pain
|
WHO Anatomical Therapeutic Chemical classification |
|
Other topical products for joint and muscular pain |
| 0‑L |
M02AX02
|
tolazoline
|
WHO Anatomical Therapeutic Chemical classification |
|
tolazoline |
| 0‑L |
M02AX03
|
dimethyl sulfoxide
|
WHO Anatomical Therapeutic Chemical classification |
|
dimethyl sulfoxide |
| 0‑L |
M02AX05
|
idrocilamide
|
WHO Anatomical Therapeutic Chemical classification |
|
idrocilamide |
| 0‑L |
M02AX06
|
tolperisone
|
WHO Anatomical Therapeutic Chemical classification |
|
tolperisone |
| 0‑L |
M02AX10
|
various
|
WHO Anatomical Therapeutic Chemical classification |
|
various |
| 0‑L |
M03
|
MUSCLE RELAXANTS
|
WHO Anatomical Therapeutic Chemical classification |
|
MUSCLE RELAXANTS |
| 0‑L |
M03A
|
MUSCLE RELAXANTS, PERIPHERALLY ACTING AGENTS
|
WHO Anatomical Therapeutic Chemical classification |
|
MUSCLE RELAXANTS, PERIPHERALLY ACTING AGENTS |
| 0‑L |
M03AA
|
Curare alkaloids
|
WHO Anatomical Therapeutic Chemical classification |
|
Curare alkaloids |
| 0‑L |
M03AA01
|
alcuronium
|
WHO Anatomical Therapeutic Chemical classification |
|
alcuronium |
| 0‑L |
M03AA02
|
tubocurarine
|
WHO Anatomical Therapeutic Chemical classification |
|
tubocurarine |
| 0‑L |
M03AA04
|
dimethyltubocurarine
|
WHO Anatomical Therapeutic Chemical classification |
|
dimethyltubocurarine |
| 0‑L |
M03AB
|
Choline derivatives
|
WHO Anatomical Therapeutic Chemical classification |
|
Choline derivatives |
| 0‑L |
M03AB01
|
suxamethonium
|
WHO Anatomical Therapeutic Chemical classification |
|
suxamethonium |
| 0‑L |
M03AC
|
Other quaternary ammonium compounds
|
WHO Anatomical Therapeutic Chemical classification |
|
Other quaternary ammonium compounds |
| 0‑L |
M03AC01
|
pancuronium
|
WHO Anatomical Therapeutic Chemical classification |
|
pancuronium |
| 0‑L |
M03AC02
|
gallamine
|
WHO Anatomical Therapeutic Chemical classification |
|
gallamine |
| 0‑L |
M03AC03
|
vecuronium
|
WHO Anatomical Therapeutic Chemical classification |
|
vecuronium |
| 0‑L |
M03AC04
|
atracurium
|
WHO Anatomical Therapeutic Chemical classification |
|
atracurium |
| 0‑L |
M03AC05
|
hexafluronium
|
WHO Anatomical Therapeutic Chemical classification |
|
hexafluronium |
| 0‑L |
M03AC06
|
pipecuronium bromide
|
WHO Anatomical Therapeutic Chemical classification |
|
pipecuronium bromide |
| 0‑L |
M03AC07
|
doxacurium chloride
|
WHO Anatomical Therapeutic Chemical classification |
|
doxacurium chloride |
| 0‑L |
M03AC08
|
fazadinium bromide
|
WHO Anatomical Therapeutic Chemical classification |
|
fazadinium bromide |
| 0‑L |
M03AC09
|
rocuronium bromide
|
WHO Anatomical Therapeutic Chemical classification |
|
rocuronium bromide |
| 0‑L |
M03AC10
|
mivacurium chloride
|
WHO Anatomical Therapeutic Chemical classification |
|
mivacurium chloride |
| 0‑L |
M03AC11
|
cisatracurium
|
WHO Anatomical Therapeutic Chemical classification |
|
cisatracurium |
| 0‑L |
M03AX
|
Other muscle relaxants, peripherally acting agents
|
WHO Anatomical Therapeutic Chemical classification |
|
Other muscle relaxants, peripherally acting agents |
| 0‑L |
M03AX01
|
botulinum toxin
|
WHO Anatomical Therapeutic Chemical classification |
|
botulinum toxin |
| 0‑L |
M03B
|
MUSCLE RELAXANTS, CENTRALLY ACTING AGENTS
|
WHO Anatomical Therapeutic Chemical classification |
|
MUSCLE RELAXANTS, CENTRALLY ACTING AGENTS |
| 0‑L |
M03BA
|
Carbamic acid esters
|
WHO Anatomical Therapeutic Chemical classification |
|
Carbamic acid esters |
| 0‑L |
M03BA01
|
phenprobamate
|
WHO Anatomical Therapeutic Chemical classification |
|
phenprobamate |
| 0‑L |
M03BA02
|
carisoprodol
|
WHO Anatomical Therapeutic Chemical classification |
|
carisoprodol |
| 0‑L |
M03BA03
|
methocarbamol
|
WHO Anatomical Therapeutic Chemical classification |
|
methocarbamol |
| 0‑L |
M03BA04
|
styramate
|
WHO Anatomical Therapeutic Chemical classification |
|
styramate |
| 0‑L |
M03BA05
|
febarbamate
|
WHO Anatomical Therapeutic Chemical classification |
|
febarbamate |
| 0‑L |
M03BA51
|
phenprobamate, combinations excl. psycholeptics
|
WHO Anatomical Therapeutic Chemical classification |
|
phenprobamate, combinations excl. psycholeptics |
| 0‑L |
M03BA52
|
carisoprodol, combinations excl. psycholeptics
|
WHO Anatomical Therapeutic Chemical classification |
|
carisoprodol, combinations excl. psycholeptics |
| 0‑L |
M03BA53
|
methocarbamol, combinations excl. psycholeptics
|
WHO Anatomical Therapeutic Chemical classification |
|
methocarbamol, combinations excl. psycholeptics |
| 0‑L |
M03BA71
|
phenprobamate, combinations with psycholeptics
|
WHO Anatomical Therapeutic Chemical classification |
|
phenprobamate, combinations with psycholeptics |
| 0‑L |
M03BA72
|
carisoprodol, combinations with psycholeptics
|
WHO Anatomical Therapeutic Chemical classification |
|
carisoprodol, combinations with psycholeptics |
| 0‑L |
M03BA73
|
methocarbamol, combinations with psycholeptics
|
WHO Anatomical Therapeutic Chemical classification |
|
methocarbamol, combinations with psycholeptics |
| 0‑L |
M03BB
|
Oxazol, thiazine, and triazine derivatives
|
WHO Anatomical Therapeutic Chemical classification |
|
Oxazol, thiazine, and triazine derivatives |
| 0‑L |
M03BB02
|
chlormezanone
|
WHO Anatomical Therapeutic Chemical classification |
|
chlormezanone |
| 0‑L |
M03BB03
|
chlorzoxazone
|
WHO Anatomical Therapeutic Chemical classification |
|
chlorzoxazone |
| 0‑L |
M03BB52
|
chlormezanone, combinations excl. psycholeptics
|
WHO Anatomical Therapeutic Chemical classification |
|
chlormezanone, combinations excl. psycholeptics |
| 0‑L |
M03BB53
|
chlorzoxazone, combinations excl. psycholeptics
|
WHO Anatomical Therapeutic Chemical classification |
|
chlorzoxazone, combinations excl. psycholeptics |
| 0‑L |
M03BB72
|
chlormezanone, combinations with psycholeptics
|
WHO Anatomical Therapeutic Chemical classification |
|
chlormezanone, combinations with psycholeptics |
| 0‑L |
M03BB73
|
chlorzoxazone, combinations with psycholeptics
|
WHO Anatomical Therapeutic Chemical classification |
|
chlorzoxazone, combinations with psycholeptics |
| 0‑L |
M03BC
|
Ethers, chemically close to antihistamines
|
WHO Anatomical Therapeutic Chemical classification |
|
Ethers, chemically close to antihistamines |
| 0‑L |
M03BC01
|
orphenadrine (citrate)
|
WHO Anatomical Therapeutic Chemical classification |
|
orphenadrine (citrate) |
| 0‑L |
M03BC51
|
orphenadrine, combinations
|
WHO Anatomical Therapeutic Chemical classification |
|
orphenadrine, combinations |
| 0‑L |
M03BX
|
Other centrally acting agents
|
WHO Anatomical Therapeutic Chemical classification |
|
Other centrally acting agents |
| 0‑L |
M03BX01
|
baclofen
|
WHO Anatomical Therapeutic Chemical classification |
|
baclofen |
| 0‑L |
M03BX02
|
tizanidine
|
WHO Anatomical Therapeutic Chemical classification |
|
tizanidine |
| 0‑L |
M03BX03
|
pridinol
|
WHO Anatomical Therapeutic Chemical classification |
|
pridinol |
| 0‑L |
M03BX04
|
tolperisone
|
WHO Anatomical Therapeutic Chemical classification |
|
tolperisone |
| 0‑L |
M03BX05
|
thiocolchicoside
|
WHO Anatomical Therapeutic Chemical classification |
|
thiocolchicoside |
| 0‑L |
M03BX06
|
mephenesin
|
WHO Anatomical Therapeutic Chemical classification |
|
mephenesin |
| 0‑L |
M03BX07
|
tetrazepam
|
WHO Anatomical Therapeutic Chemical classification |
|
tetrazepam |
| 0‑L |
M03BX08
|
cyclobenzaprine
|
WHO Anatomical Therapeutic Chemical classification |
|
cyclobenzaprine |
| 0‑L |
M03BX09
|
eperisone
|
WHO Anatomical Therapeutic Chemical classification |
|
eperisone |
| 0‑L |
M03BX30
|
fenyramidol
|
WHO Anatomical Therapeutic Chemical classification |
|
fenyramidol |
| 0‑L |
M03BX55
|
thiocolchicoside, combinations
|
WHO Anatomical Therapeutic Chemical classification |
|
thiocolchicoside, combinations |
| 0‑L |
M03C
|
MUSCLE RELAXANTS, DIRECTLY ACTING AGENTS
|
WHO Anatomical Therapeutic Chemical classification |
|
MUSCLE RELAXANTS, DIRECTLY ACTING AGENTS |
| 0‑L |
M03CA
|
Dantrolene and derivatives
|
WHO Anatomical Therapeutic Chemical classification |
|
Dantrolene and derivatives |
| 0‑L |
M03CA01
|
dantrolene
|
WHO Anatomical Therapeutic Chemical classification |
|
dantrolene |
| 0‑L |
M04
|
ANTIGOUT PREPARATIONS
|
WHO Anatomical Therapeutic Chemical classification |
|
ANTIGOUT PREPARATIONS |
| 0‑L |
M04A
|
ANTIGOUT PREPARATIONS
|
WHO Anatomical Therapeutic Chemical classification |
|
ANTIGOUT PREPARATIONS |
| 0‑L |
M04AA
|
Preparations inhibiting uric acid production
|
WHO Anatomical Therapeutic Chemical classification |
|
Preparations inhibiting uric acid production |
| 0‑L |
M04AA01
|
allopurinol
|
WHO Anatomical Therapeutic Chemical classification |
|
allopurinol |
| 0‑L |
M04AA02
|
tisopurine
|
WHO Anatomical Therapeutic Chemical classification |
|
tisopurine |
| 0‑L |
M04AA03
|
febuxostat
|
WHO Anatomical Therapeutic Chemical classification |
|
febuxostat |
| 0‑L |
M04AA51
|
allopurinol, combinations
|
WHO Anatomical Therapeutic Chemical classification |
|
allopurinol, combinations |
| 0‑L |
M04AB
|
Preparations increasing uric acid excretion
|
WHO Anatomical Therapeutic Chemical classification |
|
Preparations increasing uric acid excretion |
| 0‑L |
M04AB01
|
probenecid
|
WHO Anatomical Therapeutic Chemical classification |
|
probenecid |
| 0‑L |
M04AB02
|
sulfinpyrazone
|
WHO Anatomical Therapeutic Chemical classification |
|
sulfinpyrazone |
| 0‑L |
M04AB03
|
benzbromarone
|
WHO Anatomical Therapeutic Chemical classification |
|
benzbromarone |
| 0‑L |
M04AB04
|
isobromindione
|
WHO Anatomical Therapeutic Chemical classification |
|
isobromindione |
| 0‑L |
M04AB05
|
lesinurad
|
WHO Anatomical Therapeutic Chemical classification |
|
lesinurad |
| 0‑L |
M04AC
|
Preparations with no effect on uric acid metabolism
|
WHO Anatomical Therapeutic Chemical classification |
|
Preparations with no effect on uric acid metabolism |
| 0‑L |
M04AC01
|
colchicine
|
WHO Anatomical Therapeutic Chemical classification |
|
colchicine |
| 0‑L |
M04AC02
|
cinchophen
|
WHO Anatomical Therapeutic Chemical classification |
|
cinchophen |
| 0‑L |
M04AX
|
Other antigout preparations
|
WHO Anatomical Therapeutic Chemical classification |
|
Other antigout preparations |
| 0‑L |
M04AX01
|
urate oxidase
|
WHO Anatomical Therapeutic Chemical classification |
|
urate oxidase |
| 0‑L |
M04AX02
|
pegloticase
|
WHO Anatomical Therapeutic Chemical classification |
|
pegloticase |
| 0‑L |
M05
|
DRUGS FOR TREATMENT OF BONE DISEASES
|
WHO Anatomical Therapeutic Chemical classification |
|
DRUGS FOR TREATMENT OF BONE DISEASES |
| 0‑L |
M05B
|
DRUGS AFFECTING BONE STRUCTURE AND MINERALIZATION
|
WHO Anatomical Therapeutic Chemical classification |
|
DRUGS AFFECTING BONE STRUCTURE AND MINERALIZATION |
| 0‑L |
M05BA
|
Bisphosphonates
|
WHO Anatomical Therapeutic Chemical classification |
|
Bisphosphonates |
| 0‑L |
M05BA01
|
etidronic acid
|
WHO Anatomical Therapeutic Chemical classification |
|
etidronic acid |
| 0‑L |
M05BA02
|
clodronic acid
|
WHO Anatomical Therapeutic Chemical classification |
|
clodronic acid |
| 0‑L |
M05BA03
|
pamidronic acid
|
WHO Anatomical Therapeutic Chemical classification |
|
pamidronic acid |
| 0‑L |
M05BA04
|
alendronic acid
|
WHO Anatomical Therapeutic Chemical classification |
|
alendronic acid |
| 0‑L |
M05BA05
|
tiludronic acid
|
WHO Anatomical Therapeutic Chemical classification |
|
tiludronic acid |
| 0‑L |
M05BA06
|
ibandronic acid
|
WHO Anatomical Therapeutic Chemical classification |
|
ibandronic acid |
| 0‑L |
M05BA07
|
risedronic acid
|
WHO Anatomical Therapeutic Chemical classification |
|
risedronic acid |
| 0‑L |
M05BA08
|
zoledronic acid
|
WHO Anatomical Therapeutic Chemical classification |
|
zoledronic acid |
| 0‑L |
M05BB
|
Bisphosphonates, combinations
|
WHO Anatomical Therapeutic Chemical classification |
|
Bisphosphonates, combinations |
| 0‑L |
M05BB01
|
etidronic acid and calcium, sequential
|
WHO Anatomical Therapeutic Chemical classification |
|
etidronic acid and calcium, sequential |
| 0‑L |
M05BB02
|
risedronic acid and calcium, sequential
|
WHO Anatomical Therapeutic Chemical classification |
|
risedronic acid and calcium, sequential |
| 0‑L |
M05BB03
|
alendronic acid and colecalciferol
|
WHO Anatomical Therapeutic Chemical classification |
|
alendronic acid and colecalciferol |
| 0‑L |
M05BB04
|
risedronic acid, calcium and colecalciferol, sequential
|
WHO Anatomical Therapeutic Chemical classification |
|
risedronic acid, calcium and colecalciferol, sequential |
| 0‑L |
M05BB05
|
alendronic acid, calcium and colecalciferol, sequential
|
WHO Anatomical Therapeutic Chemical classification |
|
alendronic acid, calcium and colecalciferol, sequential |
| 0‑L |
M05BB06
|
alendronic acid and alfacalcidol, sequential
|
WHO Anatomical Therapeutic Chemical classification |
|
alendronic acid and alfacalcidol, sequential |
| 0‑L |
M05BB07
|
risedronic acid and colecalciferol
|
WHO Anatomical Therapeutic Chemical classification |
|
risedronic acid and colecalciferol |
| 0‑L |
M05BB08
|
zoledronic acid, calcium and colecalciferol, sequential
|
WHO Anatomical Therapeutic Chemical classification |
|
zoledronic acid, calcium and colecalciferol, sequential |
| 0‑L |
M05BC
|
Bone morphogenetic proteins
|
WHO Anatomical Therapeutic Chemical classification |
|
Bone morphogenetic proteins |
| 0‑L |
M05BC01
|
dibotermin alfa
|
WHO Anatomical Therapeutic Chemical classification |
|
dibotermin alfa |
| 0‑L |
M05BC02
|
eptotermin alfa
|
WHO Anatomical Therapeutic Chemical classification |
|
eptotermin alfa |
| 0‑L |
M05BX
|
Other drugs affecting bone structure and mineralization
|
WHO Anatomical Therapeutic Chemical classification |
|
Other drugs affecting bone structure and mineralization |
| 0‑L |
M05BX01
|
ipriflavone
|
WHO Anatomical Therapeutic Chemical classification |
|
ipriflavone |
| 0‑L |
M05BX02
|
aluminium chlorohydrate
|
WHO Anatomical Therapeutic Chemical classification |
|
aluminium chlorohydrate |
| 0‑L |
M05BX03
|
strontium ranelate
|
WHO Anatomical Therapeutic Chemical classification |
|
strontium ranelate |
| 0‑L |
M05BX04
|
denosumab
|
WHO Anatomical Therapeutic Chemical classification |
|
denosumab |
| 0‑L |
M05BX05
|
burosumab
|
WHO Anatomical Therapeutic Chemical classification |
|
burosumab |
| 0‑L |
M05BX53
|
strontium ranelate and colecalciferol
|
WHO Anatomical Therapeutic Chemical classification |
|
strontium ranelate and colecalciferol |
| 0‑L |
M09
|
OTHER DRUGS FOR DISORDERS OF THE MUSCULO-SKELETAL SYSTEM
|
WHO Anatomical Therapeutic Chemical classification |
|
OTHER DRUGS FOR DISORDERS OF THE MUSCULO-SKELETAL SYSTEM |
| 0‑L |
M09A
|
OTHER DRUGS FOR DISORDERS OF THE MUSCULO-SKELETAL SYSTEM
|
WHO Anatomical Therapeutic Chemical classification |
|
OTHER DRUGS FOR DISORDERS OF THE MUSCULO-SKELETAL SYSTEM |
| 0‑L |
M09AA
|
Quinine and derivatives
|
WHO Anatomical Therapeutic Chemical classification |
|
Quinine and derivatives |
| 0‑L |
M09AA01
|
hydroquinine
|
WHO Anatomical Therapeutic Chemical classification |
|
hydroquinine |
| 0‑L |
M09AA72
|
quinine, combinations with psycholeptics
|
WHO Anatomical Therapeutic Chemical classification |
|
quinine, combinations with psycholeptics |
| 0‑L |
M09AB
|
Enzymes
|
WHO Anatomical Therapeutic Chemical classification |
|
Enzymes |
| 0‑L |
M09AB01
|
chymopapain
|
WHO Anatomical Therapeutic Chemical classification |
|
chymopapain |
| 0‑L |
M09AB02
|
collagenase clostridium histolyticum
|
WHO Anatomical Therapeutic Chemical classification |
|
collagenase clostridium histolyticum |
| 0‑L |
M09AB03
|
bromelains
|
WHO Anatomical Therapeutic Chemical classification |
|
bromelains |
| 0‑L |
M09AB52
|
trypsin, combinations
|
WHO Anatomical Therapeutic Chemical classification |
|
trypsin, combinations |
| 0‑L |
M09AX
|
Other drugs for disorders of the musculo-skeletal system
|
WHO Anatomical Therapeutic Chemical classification |
|
Other drugs for disorders of the musculo-skeletal system |
| 0‑L |
M09AX01
|
hyaluronic acid
|
WHO Anatomical Therapeutic Chemical classification |
|
hyaluronic acid |
| 0‑L |
M09AX02
|
chondrocytes, autologous
|
WHO Anatomical Therapeutic Chemical classification |
|
chondrocytes, autologous |
| 0‑L |
M09AX03
|
ataluren
|
WHO Anatomical Therapeutic Chemical classification |
|
ataluren |
| 0‑L |
M09AX04
|
drisapersen
|
WHO Anatomical Therapeutic Chemical classification |
|
drisapersen |
| 0‑L |
M09AX05
|
aceneuramic acid
|
WHO Anatomical Therapeutic Chemical classification |
|
aceneuramic acid |
| 0‑L |
N
|
NERVOUS SYSTEM
|
WHO Anatomical Therapeutic Chemical classification |
|
NERVOUS SYSTEM |
| 0‑L |
N01
|
ANESTHETICS
|
WHO Anatomical Therapeutic Chemical classification |
|
ANESTHETICS |
| 0‑L |
N01A
|
ANESTHETICS, GENERAL
|
WHO Anatomical Therapeutic Chemical classification |
|
ANESTHETICS, GENERAL |
| 0‑L |
N01AA
|
Ethers
|
WHO Anatomical Therapeutic Chemical classification |
|
Ethers |
| 0‑L |
N01AA01
|
diethyl ether
|
WHO Anatomical Therapeutic Chemical classification |
|
diethyl ether |
| 0‑L |
N01AA02
|
vinyl ether
|
WHO Anatomical Therapeutic Chemical classification |
|
vinyl ether |
| 0‑L |
N01AB
|
Halogenated hydrocarbons
|
WHO Anatomical Therapeutic Chemical classification |
|
Halogenated hydrocarbons |
| 0‑L |
N01AB01
|
halothane
|
WHO Anatomical Therapeutic Chemical classification |
|
halothane |
| 0‑L |
N01AB02
|
chloroform
|
WHO Anatomical Therapeutic Chemical classification |
|
chloroform |
| 0‑L |
N01AB04
|
enflurane
|
WHO Anatomical Therapeutic Chemical classification |
|
enflurane |
| 0‑L |
N01AB05
|
trichloroethylene
|
WHO Anatomical Therapeutic Chemical classification |
|
trichloroethylene |
| 0‑L |
N01AB06
|
isoflurane
|
WHO Anatomical Therapeutic Chemical classification |
|
isoflurane |
| 0‑L |
N01AB07
|
desflurane
|
WHO Anatomical Therapeutic Chemical classification |
|
desflurane |
| 0‑L |
N01AB08
|
sevoflurane
|
WHO Anatomical Therapeutic Chemical classification |
|
sevoflurane |
| 0‑L |
N01AF
|
Barbiturates, plain
|
WHO Anatomical Therapeutic Chemical classification |
|
Barbiturates, plain |
| 0‑L |
N01AF01
|
methohexital
|
WHO Anatomical Therapeutic Chemical classification |
|
methohexital |
| 0‑L |
N01AF02
|
hexobarbital
|
WHO Anatomical Therapeutic Chemical classification |
|
hexobarbital |
| 0‑L |
N01AF03
|
thiopental
|
WHO Anatomical Therapeutic Chemical classification |
|
thiopental |
| 0‑L |
N01AG
|
Barbiturates in combination with other drugs
|
WHO Anatomical Therapeutic Chemical classification |
|
Barbiturates in combination with other drugs |
| 0‑L |
N01AG01
|
narcobarbital
|
WHO Anatomical Therapeutic Chemical classification |
|
narcobarbital |
| 0‑L |
N01AH
|
Opioid anesthetics
|
WHO Anatomical Therapeutic Chemical classification |
|
Opioid anesthetics |
| 0‑L |
N01AH01
|
fentanyl
|
WHO Anatomical Therapeutic Chemical classification |
|
fentanyl |
| 0‑L |
N01AH02
|
alfentanil
|
WHO Anatomical Therapeutic Chemical classification |
|
alfentanil |
| 0‑L |
N01AH03
|
sufentanil
|
WHO Anatomical Therapeutic Chemical classification |
|
sufentanil |
| 0‑L |
N01AH04
|
phenoperidine
|
WHO Anatomical Therapeutic Chemical classification |
|
phenoperidine |
| 0‑L |
N01AH05
|
anileridine
|
WHO Anatomical Therapeutic Chemical classification |
|
anileridine |
| 0‑L |
N01AH06
|
remifentanil
|
WHO Anatomical Therapeutic Chemical classification |
|
remifentanil |
| 0‑L |
N01AH51
|
fentanyl, combinations
|
WHO Anatomical Therapeutic Chemical classification |
|
fentanyl, combinations |
| 0‑L |
N01AX
|
Other general anesthetics
|
WHO Anatomical Therapeutic Chemical classification |
|
Other general anesthetics |
| 0‑L |
N01AX03
|
ketamine
|
WHO Anatomical Therapeutic Chemical classification |
|
ketamine |
| 0‑L |
N01AX04
|
propanidid
|
WHO Anatomical Therapeutic Chemical classification |
|
propanidid |
| 0‑L |
N01AX05
|
alfaxalone
|
WHO Anatomical Therapeutic Chemical classification |
|
alfaxalone |
| 0‑L |
N01AX07
|
etomidate
|
WHO Anatomical Therapeutic Chemical classification |
|
etomidate |
| 0‑L |
N01AX10
|
propofol
|
WHO Anatomical Therapeutic Chemical classification |
|
propofol |
| 0‑L |
N01AX11
|
sodium oxybate
|
WHO Anatomical Therapeutic Chemical classification |
|
sodium oxybate |
| 0‑L |
N01AX13
|
nitrous oxide
|
WHO Anatomical Therapeutic Chemical classification |
|
nitrous oxide |
| 0‑L |
N01AX14
|
esketamine
|
WHO Anatomical Therapeutic Chemical classification |
|
esketamine |
| 0‑L |
N01AX15
|
xenon
|
WHO Anatomical Therapeutic Chemical classification |
|
xenon |
| 0‑L |
N01AX63
|
nitrous oxide, combinations
|
WHO Anatomical Therapeutic Chemical classification |
|
nitrous oxide, combinations |
| 0‑L |
N01B
|
ANESTHETICS, LOCAL
|
WHO Anatomical Therapeutic Chemical classification |
|
ANESTHETICS, LOCAL |
| 0‑L |
N01BA
|
Esters of aminobenzoic acid
|
WHO Anatomical Therapeutic Chemical classification |
|
Esters of aminobenzoic acid |
| 0‑L |
N01BA01
|
metabutethamine
|
WHO Anatomical Therapeutic Chemical classification |
|
metabutethamine |
| 0‑L |
N01BA02
|
procaine
|
WHO Anatomical Therapeutic Chemical classification |
|
procaine |
| 0‑L |
N01BA03
|
tetracaine
|
WHO Anatomical Therapeutic Chemical classification |
|
tetracaine |
| 0‑L |
N01BA04
|
chloroprocaine
|
WHO Anatomical Therapeutic Chemical classification |
|
chloroprocaine |
| 0‑L |
N01BA05
|
benzocaine
|
WHO Anatomical Therapeutic Chemical classification |
|
benzocaine |
| 0‑L |
N01BA52
|
procaine, combinations
|
WHO Anatomical Therapeutic Chemical classification |
|
procaine, combinations |
| 0‑L |
N01BB
|
Amides
|
WHO Anatomical Therapeutic Chemical classification |
|
Amides |
| 0‑L |
N01BB01
|
bupivacaine
|
WHO Anatomical Therapeutic Chemical classification |
|
bupivacaine |
| 0‑L |
N01BB02
|
lidocaine
|
WHO Anatomical Therapeutic Chemical classification |
|
lidocaine |
| 0‑L |
N01BB03
|
mepivacaine
|
WHO Anatomical Therapeutic Chemical classification |
|
mepivacaine |
| 0‑L |
N01BB04
|
prilocaine
|
WHO Anatomical Therapeutic Chemical classification |
|
prilocaine |
| 0‑L |
N01BB05
|
butanilicaine
|
WHO Anatomical Therapeutic Chemical classification |
|
butanilicaine |
| 0‑L |
N01BB06
|
cinchocaine
|
WHO Anatomical Therapeutic Chemical classification |
|
cinchocaine |
| 0‑L |
N01BB07
|
etidocaine
|
WHO Anatomical Therapeutic Chemical classification |
|
etidocaine |
| 0‑L |
N01BB08
|
articaine
|
WHO Anatomical Therapeutic Chemical classification |
|
articaine |
| 0‑L |
N01BB09
|
ropivacaine
|
WHO Anatomical Therapeutic Chemical classification |
|
ropivacaine |
| 0‑L |
N01BB10
|
levobupivacaine
|
WHO Anatomical Therapeutic Chemical classification |
|
levobupivacaine |
| 0‑L |
N01BB20
|
combinations
|
WHO Anatomical Therapeutic Chemical classification |
|
combinations |
| 0‑L |
N01BB51
|
bupivacaine, combinations
|
WHO Anatomical Therapeutic Chemical classification |
|
bupivacaine, combinations |
| 0‑L |
N01BB52
|
lidocaine, combinations
|
WHO Anatomical Therapeutic Chemical classification |
|
lidocaine, combinations |
| 0‑L |
N01BB53
|
mepivacaine, combinations
|
WHO Anatomical Therapeutic Chemical classification |
|
mepivacaine, combinations |
| 0‑L |
N01BB54
|
prilocaine, combinations
|
WHO Anatomical Therapeutic Chemical classification |
|
prilocaine, combinations |
| 0‑L |
N01BB57
|
etidocaine, combinations
|
WHO Anatomical Therapeutic Chemical classification |
|
etidocaine, combinations |
| 0‑L |
N01BB58
|
articaine, combinations
|
WHO Anatomical Therapeutic Chemical classification |
|
articaine, combinations |
| 0‑L |
N01BC
|
Esters of benzoic acid
|
WHO Anatomical Therapeutic Chemical classification |
|
Esters of benzoic acid |
| 0‑L |
N01BC01
|
cocaine
|
WHO Anatomical Therapeutic Chemical classification |
|
cocaine |
| 0‑L |
N01BX
|
Other local anesthetics
|
WHO Anatomical Therapeutic Chemical classification |
|
Other local anesthetics |
| 0‑L |
N01BX01
|
ethyl chloride
|
WHO Anatomical Therapeutic Chemical classification |
|
ethyl chloride |
| 0‑L |
N01BX02
|
dyclonine
|
WHO Anatomical Therapeutic Chemical classification |
|
dyclonine |
| 0‑L |
N01BX03
|
phenol
|
WHO Anatomical Therapeutic Chemical classification |
|
phenol |
| 0‑L |
N01BX04
|
capsaicin
|
WHO Anatomical Therapeutic Chemical classification |
|
capsaicin |
| 0‑L |
N02
|
ANALGESICS
|
WHO Anatomical Therapeutic Chemical classification |
|
ANALGESICS |
| 0‑L |
N02A
|
OPIOIDS
|
WHO Anatomical Therapeutic Chemical classification |
|
OPIOIDS |
| 0‑L |
N02AA
|
Natural opium alkaloids
|
WHO Anatomical Therapeutic Chemical classification |
|
Natural opium alkaloids |
| 0‑L |
N02AA01
|
morphine
|
WHO Anatomical Therapeutic Chemical classification |
|
morphine |
| 0‑L |
N02AA02
|
opium
|
WHO Anatomical Therapeutic Chemical classification |
|
opium |
| 0‑L |
N02AA03
|
hydromorphone
|
WHO Anatomical Therapeutic Chemical classification |
|
hydromorphone |
| 0‑L |
N02AA04
|
nicomorphine
|
WHO Anatomical Therapeutic Chemical classification |
|
nicomorphine |
| 0‑L |
N02AA05
|
oxycodone
|
WHO Anatomical Therapeutic Chemical classification |
|
oxycodone |
| 0‑L |
N02AA08
|
dihydrocodeine
|
WHO Anatomical Therapeutic Chemical classification |
|
dihydrocodeine |
| 0‑L |
N02AA10
|
papaveretum
|
WHO Anatomical Therapeutic Chemical classification |
|
papaveretum |
| 0‑L |
N02AA51
|
morphine, combinations
|
WHO Anatomical Therapeutic Chemical classification |
|
morphine, combinations |
| 0‑L |
N02AA55
|
oxycodone and naloxone
|
WHO Anatomical Therapeutic Chemical classification |
|
oxycodone and naloxone |
| 0‑L |
N02AA58
|
dihydrocodeine, combinations
|
WHO Anatomical Therapeutic Chemical classification |
|
dihydrocodeine, combinations |
| 0‑L |
N02AA59
|
codeine, combinations excl. psycholeptics
|
WHO Anatomical Therapeutic Chemical classification |
|
codeine, combinations excl. psycholeptics |
| 0‑L |
N02AA79
|
codeine, combinations with psycholeptics
|
WHO Anatomical Therapeutic Chemical classification |
|
codeine, combinations with psycholeptics |
| 0‑L |
N02AB
|
Phenylpiperidine derivatives
|
WHO Anatomical Therapeutic Chemical classification |
|
Phenylpiperidine derivatives |
| 0‑L |
N02AB01
|
ketobemidone
|
WHO Anatomical Therapeutic Chemical classification |
|
ketobemidone |
| 0‑L |
N02AB02
|
pethidine
|
WHO Anatomical Therapeutic Chemical classification |
|
pethidine |
| 0‑L |
N02AB03
|
fentanyl
|
WHO Anatomical Therapeutic Chemical classification |
|
fentanyl |
| 0‑L |
N02AB52
|
pethidine, combinations excl. psycholeptics
|
WHO Anatomical Therapeutic Chemical classification |
|
pethidine, combinations excl. psycholeptics |
| 0‑L |
N02AB72
|
pethidine, combinations with psycholeptics
|
WHO Anatomical Therapeutic Chemical classification |
|
pethidine, combinations with psycholeptics |
| 0‑L |
N02AC
|
Diphenylpropylamine derivatives
|
WHO Anatomical Therapeutic Chemical classification |
|
Diphenylpropylamine derivatives |
| 0‑L |
N02AC01
|
dextromoramide
|
WHO Anatomical Therapeutic Chemical classification |
|
dextromoramide |
| 0‑L |
N02AC03
|
piritramide
|
WHO Anatomical Therapeutic Chemical classification |
|
piritramide |
| 0‑L |
N02AC04
|
dextropropoxyphene
|
WHO Anatomical Therapeutic Chemical classification |
|
dextropropoxyphene |
| 0‑L |
N02AC05
|
bezitramide
|
WHO Anatomical Therapeutic Chemical classification |
|
bezitramide |
| 0‑L |
N02AC52
|
methadone, combinations excl. psycholeptics
|
WHO Anatomical Therapeutic Chemical classification |
|
methadone, combinations excl. psycholeptics |
| 0‑L |
N02AC54
|
dextropropoxyphene, combinations excl. psycholeptics
|
WHO Anatomical Therapeutic Chemical classification |
|
dextropropoxyphene, combinations excl. psycholeptics |
| 0‑L |
N02AC74
|
dextropropoxyphene, combinations with psycholeptics
|
WHO Anatomical Therapeutic Chemical classification |
|
dextropropoxyphene, combinations with psycholeptics |
| 0‑L |
N02AD
|
Benzomorphan derivatives
|
WHO Anatomical Therapeutic Chemical classification |
|
Benzomorphan derivatives |
| 0‑L |
N02AD01
|
pentazocine
|
WHO Anatomical Therapeutic Chemical classification |
|
pentazocine |
| 0‑L |
N02AD02
|
phenazocine
|
WHO Anatomical Therapeutic Chemical classification |
|
phenazocine |
| 0‑L |
N02AE
|
Oripavine derivatives
|
WHO Anatomical Therapeutic Chemical classification |
|
Oripavine derivatives |
| 0‑L |
N02AE01
|
buprenorphine
|
WHO Anatomical Therapeutic Chemical classification |
|
buprenorphine |
| 0‑L |
N02AF
|
Morphinan derivatives
|
WHO Anatomical Therapeutic Chemical classification |
|
Morphinan derivatives |
| 0‑L |
N02AF01
|
butorphanol
|
WHO Anatomical Therapeutic Chemical classification |
|
butorphanol |
| 0‑L |
N02AF02
|
nalbuphine
|
WHO Anatomical Therapeutic Chemical classification |
|
nalbuphine |
| 0‑L |
N02AG
|
Opioids in combination with antispasmodics
|
WHO Anatomical Therapeutic Chemical classification |
|
Opioids in combination with antispasmodics |
| 0‑L |
N02AG01
|
morphine and antispasmodics
|
WHO Anatomical Therapeutic Chemical classification |
|
morphine and antispasmodics |
| 0‑L |
N02AG02
|
ketobemidone and antispasmodics
|
WHO Anatomical Therapeutic Chemical classification |
|
ketobemidone and antispasmodics |
| 0‑L |
N02AG03
|
pethidine and antispasmodics
|
WHO Anatomical Therapeutic Chemical classification |
|
pethidine and antispasmodics |
| 0‑L |
N02AG04
|
hydromorphone and antispasmodics
|
WHO Anatomical Therapeutic Chemical classification |
|
hydromorphone and antispasmodics |
| 0‑L |
N02AJ
|
Opioids in combination with non-opioid analgesics
|
WHO Anatomical Therapeutic Chemical classification |
|
Opioids in combination with non-opioid analgesics |
| 0‑L |
N02AJ01
|
dihydrocodeine and paracetamol
|
WHO Anatomical Therapeutic Chemical classification |
|
dihydrocodeine and paracetamol |
| 0‑L |
N02AJ02
|
dihydrocodeine and acetylsalicylic acid
|
WHO Anatomical Therapeutic Chemical classification |
|
dihydrocodeine and acetylsalicylic acid |
| 0‑L |
N02AJ03
|
dihydrocodeine and other non-opioid analgesics
|
WHO Anatomical Therapeutic Chemical classification |
|
dihydrocodeine and other non-opioid analgesics |
| 0‑L |
N02AJ06
|
codeine and paracetamol
|
WHO Anatomical Therapeutic Chemical classification |
|
codeine and paracetamol |
| 0‑L |
N02AJ07
|
codeine and acetylsalicylic acid
|
WHO Anatomical Therapeutic Chemical classification |
|
codeine and acetylsalicylic acid |
| 0‑L |
N02AJ08
|
codeine and ibuprofen
|
WHO Anatomical Therapeutic Chemical classification |
|
codeine and ibuprofen |
| 0‑L |
N02AJ09
|
codeine and other non-opioid analgesics
|
WHO Anatomical Therapeutic Chemical classification |
|
codeine and other non-opioid analgesics |
| 0‑L |
N02AJ13
|
tramadol and paracetamol
|
WHO Anatomical Therapeutic Chemical classification |
|
tramadol and paracetamol |
| 0‑L |
N02AJ14
|
tramadol and dexketoprofen
|
WHO Anatomical Therapeutic Chemical classification |
|
tramadol and dexketoprofen |
| 0‑L |
N02AJ15
|
tramadol and other non-opioid analgesics
|
WHO Anatomical Therapeutic Chemical classification |
|
tramadol and other non-opioid analgesics |
| 0‑L |
N02AJ17
|
oxycodone and paracetamol
|
WHO Anatomical Therapeutic Chemical classification |
|
oxycodone and paracetamol |
| 0‑L |
N02AJ18
|
oxycodone and acetylsalicylic acid
|
WHO Anatomical Therapeutic Chemical classification |
|
oxycodone and acetylsalicylic acid |
| 0‑L |
N02AJ19
|
oxycodone and ibuprofen
|
WHO Anatomical Therapeutic Chemical classification |
|
oxycodone and ibuprofen |
| 0‑L |
N02AX
|
Other opioids
|
WHO Anatomical Therapeutic Chemical classification |
|
Other opioids |
| 0‑L |
N02AX01
|
tilidine
|
WHO Anatomical Therapeutic Chemical classification |
|
tilidine |
| 0‑L |
N02AX02
|
tramadol
|
WHO Anatomical Therapeutic Chemical classification |
|
tramadol |
| 0‑L |
N02AX03
|
dezocine
|
WHO Anatomical Therapeutic Chemical classification |
|
dezocine |
| 0‑L |
N02AX05
|
meptazinol
|
WHO Anatomical Therapeutic Chemical classification |
|
meptazinol |
| 0‑L |
N02AX06
|
tapentadol
|
WHO Anatomical Therapeutic Chemical classification |
|
tapentadol |
| 0‑L |
N02B
|
OTHER ANALGESICS AND ANTIPYRETICS
|
WHO Anatomical Therapeutic Chemical classification |
|
OTHER ANALGESICS AND ANTIPYRETICS |
| 0‑L |
N02BA
|
Salicylic acid and derivatives
|
WHO Anatomical Therapeutic Chemical classification |
|
Salicylic acid and derivatives |
| 0‑L |
N02BA01
|
acetylsalicylic acid
|
WHO Anatomical Therapeutic Chemical classification |
|
acetylsalicylic acid |
| 0‑L |
N02BA02
|
aloxiprin
|
WHO Anatomical Therapeutic Chemical classification |
|
aloxiprin |
| 0‑L |
N02BA03
|
choline salicylate
|
WHO Anatomical Therapeutic Chemical classification |
|
choline salicylate |
| 0‑L |
N02BA04
|
sodium salicylate
|
WHO Anatomical Therapeutic Chemical classification |
|
sodium salicylate |
| 0‑L |
N02BA05
|
salicylamide
|
WHO Anatomical Therapeutic Chemical classification |
|
salicylamide |
| 0‑L |
N02BA06
|
salsalate
|
WHO Anatomical Therapeutic Chemical classification |
|
salsalate |
| 0‑L |
N02BA07
|
ethenzamide
|
WHO Anatomical Therapeutic Chemical classification |
|
ethenzamide |
| 0‑L |
N02BA08
|
morpholine salicylate
|
WHO Anatomical Therapeutic Chemical classification |
|
morpholine salicylate |
| 0‑L |
N02BA09
|
dipyrocetyl
|
WHO Anatomical Therapeutic Chemical classification |
|
dipyrocetyl |
| 0‑L |
N02BA10
|
benorilate
|
WHO Anatomical Therapeutic Chemical classification |
|
benorilate |
| 0‑L |
N02BA11
|
diflunisal
|
WHO Anatomical Therapeutic Chemical classification |
|
diflunisal |
| 0‑L |
N02BA12
|
potassium salicylate
|
WHO Anatomical Therapeutic Chemical classification |
|
potassium salicylate |
| 0‑L |
N02BA14
|
guacetisal
|
WHO Anatomical Therapeutic Chemical classification |
|
guacetisal |
| 0‑L |
N02BA15
|
carbasalate calcium
|
WHO Anatomical Therapeutic Chemical classification |
|
carbasalate calcium |
| 0‑L |
N02BA16
|
imidazole salicylate
|
WHO Anatomical Therapeutic Chemical classification |
|
imidazole salicylate |
| 0‑L |
N02BA51
|
acetylsalicylic acid, combinations excl. psycholeptics
|
WHO Anatomical Therapeutic Chemical classification |
|
acetylsalicylic acid, combinations excl. psycholeptics |
| 0‑L |
N02BA55
|
salicylamide, combinations excl. psycholeptics
|
WHO Anatomical Therapeutic Chemical classification |
|
salicylamide, combinations excl. psycholeptics |
| 0‑L |
N02BA57
|
ethenzamide, combinations excl. psycholeptics
|
WHO Anatomical Therapeutic Chemical classification |
|
ethenzamide, combinations excl. psycholeptics |
| 0‑L |
N02BA59
|
dipyrocetyl, combinations excl. psycholeptics
|
WHO Anatomical Therapeutic Chemical classification |
|
dipyrocetyl, combinations excl. psycholeptics |
| 0‑L |
N02BA65
|
carbasalate calcium combinations excl. psycholeptics
|
WHO Anatomical Therapeutic Chemical classification |
|
carbasalate calcium combinations excl. psycholeptics |
| 0‑L |
N02BA71
|
acetylsalicylic acid, combinations with psycholeptics
|
WHO Anatomical Therapeutic Chemical classification |
|
acetylsalicylic acid, combinations with psycholeptics |
| 0‑L |
N02BA75
|
salicylamide, combinations with psycholeptics
|
WHO Anatomical Therapeutic Chemical classification |
|
salicylamide, combinations with psycholeptics |
| 0‑L |
N02BA77
|
ethenzamide, combinations with psycholeptics
|
WHO Anatomical Therapeutic Chemical classification |
|
ethenzamide, combinations with psycholeptics |
| 0‑L |
N02BA79
|
dipyrocetyl, combinations with psycholeptics
|
WHO Anatomical Therapeutic Chemical classification |
|
dipyrocetyl, combinations with psycholeptics |
| 0‑L |
N02BB
|
Pyrazolones
|
WHO Anatomical Therapeutic Chemical classification |
|
Pyrazolones |
| 0‑L |
N02BB01
|
phenazone
|
WHO Anatomical Therapeutic Chemical classification |
|
phenazone |
| 0‑L |
N02BB02
|
metamizole sodium
|
WHO Anatomical Therapeutic Chemical classification |
|
metamizole sodium |
| 0‑L |
N02BB03
|
aminophenazone
|
WHO Anatomical Therapeutic Chemical classification |
|
aminophenazone |
| 0‑L |
N02BB04
|
propyphenazone
|
WHO Anatomical Therapeutic Chemical classification |
|
propyphenazone |
| 0‑L |
N02BB05
|
nifenazone
|
WHO Anatomical Therapeutic Chemical classification |
|
nifenazone |
| 0‑L |
N02BB51
|
phenazone, combinations excl. psycholeptics
|
WHO Anatomical Therapeutic Chemical classification |
|
phenazone, combinations excl. psycholeptics |
| 0‑L |
N02BB52
|
metamizole sodium, combinations excl. psycholeptics
|
WHO Anatomical Therapeutic Chemical classification |
|
metamizole sodium, combinations excl. psycholeptics |
| 0‑L |
N02BB53
|
aminophenazone, combinations excl. psycholeptics
|
WHO Anatomical Therapeutic Chemical classification |
|
aminophenazone, combinations excl. psycholeptics |
| 0‑L |
N02BB54
|
propyphenazone, combinations excl. psycholeptics
|
WHO Anatomical Therapeutic Chemical classification |
|
propyphenazone, combinations excl. psycholeptics |
| 0‑L |
N02BB71
|
phenazone, combinations with psycholeptics
|
WHO Anatomical Therapeutic Chemical classification |
|
phenazone, combinations with psycholeptics |
| 0‑L |
N02BB72
|
metamizole sodium, combinations with psycholeptics
|
WHO Anatomical Therapeutic Chemical classification |
|
metamizole sodium, combinations with psycholeptics |
| 0‑L |
N02BB73
|
aminophenazone, combinations with psycholeptics
|
WHO Anatomical Therapeutic Chemical classification |
|
aminophenazone, combinations with psycholeptics |
| 0‑L |
N02BB74
|
propyphenazone, combinations with psycholeptics
|
WHO Anatomical Therapeutic Chemical classification |
|
propyphenazone, combinations with psycholeptics |
| 0‑L |
N02BE
|
Anilides
|
WHO Anatomical Therapeutic Chemical classification |
|
Anilides |
| 0‑L |
N02BE01
|
paracetamol
|
WHO Anatomical Therapeutic Chemical classification |
|
paracetamol |
| 0‑L |
N02BE03
|
phenacetin
|
WHO Anatomical Therapeutic Chemical classification |
|
phenacetin |
| 0‑L |
N02BE04
|
bucetin
|
WHO Anatomical Therapeutic Chemical classification |
|
bucetin |
| 0‑L |
N02BE05
|
propacetamol
|
WHO Anatomical Therapeutic Chemical classification |
|
propacetamol |
| 0‑L |
N02BE51
|
paracetamol, combinations excl. psycholeptics
|
WHO Anatomical Therapeutic Chemical classification |
|
paracetamol, combinations excl. psycholeptics |
| 0‑L |
N02BE53
|
phenacetin, combinations excl. psycholeptics
|
WHO Anatomical Therapeutic Chemical classification |
|
phenacetin, combinations excl. psycholeptics |
| 0‑L |
N02BE54
|
bucetin, combinations excl. psycholeptics
|
WHO Anatomical Therapeutic Chemical classification |
|
bucetin, combinations excl. psycholeptics |
| 0‑L |
N02BE71
|
paracetamol, combinations with psycholeptics
|
WHO Anatomical Therapeutic Chemical classification |
|
paracetamol, combinations with psycholeptics |
| 0‑L |
N02BE73
|
phenacetin, combinations with psycholeptics
|
WHO Anatomical Therapeutic Chemical classification |
|
phenacetin, combinations with psycholeptics |
| 0‑L |
N02BE74
|
bucetin, combinations with psycholeptics
|
WHO Anatomical Therapeutic Chemical classification |
|
bucetin, combinations with psycholeptics |
| 0‑L |
N02BG
|
Other analgesics and antipyretics
|
WHO Anatomical Therapeutic Chemical classification |
|
Other analgesics and antipyretics |
| 0‑L |
N02BG02
|
rimazolium
|
WHO Anatomical Therapeutic Chemical classification |
|
rimazolium |
| 0‑L |
N02BG03
|
glafenine
|
WHO Anatomical Therapeutic Chemical classification |
|
glafenine |
| 0‑L |
N02BG04
|
floctafenine
|
WHO Anatomical Therapeutic Chemical classification |
|
floctafenine |
| 0‑L |
N02BG05
|
viminol
|
WHO Anatomical Therapeutic Chemical classification |
|
viminol |
| 0‑L |
N02BG06
|
nefopam
|
WHO Anatomical Therapeutic Chemical classification |
|
nefopam |
| 0‑L |
N02BG07
|
flupirtine
|
WHO Anatomical Therapeutic Chemical classification |
|
flupirtine |
| 0‑L |
N02BG08
|
ziconotide
|
WHO Anatomical Therapeutic Chemical classification |
|
ziconotide |
| 0‑L |
N02BG09
|
methoxyflurane
|
WHO Anatomical Therapeutic Chemical classification |
|
methoxyflurane |
| 0‑L |
N02BG10
|
cannabinoids
|
WHO Anatomical Therapeutic Chemical classification |
|
cannabinoids |
| 0‑L |
N02C
|
ANTIMIGRAINE PREPARATIONS
|
WHO Anatomical Therapeutic Chemical classification |
|
ANTIMIGRAINE PREPARATIONS |
| 0‑L |
N02CA
|
Ergot alkaloids
|
WHO Anatomical Therapeutic Chemical classification |
|
Ergot alkaloids |
| 0‑L |
N02CA01
|
dihydroergotamine
|
WHO Anatomical Therapeutic Chemical classification |
|
dihydroergotamine |
| 0‑L |
N02CA02
|
ergotamine
|
WHO Anatomical Therapeutic Chemical classification |
|
ergotamine |
| 0‑L |
N02CA04
|
methysergide
|
WHO Anatomical Therapeutic Chemical classification |
|
methysergide |
| 0‑L |
N02CA07
|
lisuride
|
WHO Anatomical Therapeutic Chemical classification |
|
lisuride |
| 0‑L |
N02CA51
|
dihydroergotamine, combinations
|
WHO Anatomical Therapeutic Chemical classification |
|
dihydroergotamine, combinations |
| 0‑L |
N02CA52
|
ergotamine, combinations excl. psycholeptics
|
WHO Anatomical Therapeutic Chemical classification |
|
ergotamine, combinations excl. psycholeptics |
| 0‑L |
N02CA72
|
ergotamine, combinations with psycholeptics
|
WHO Anatomical Therapeutic Chemical classification |
|
ergotamine, combinations with psycholeptics |
| 0‑L |
N02CB
|
Corticosteroid derivatives
|
WHO Anatomical Therapeutic Chemical classification |
|
Corticosteroid derivatives |
| 0‑L |
N02CB01
|
flumedroxone
|
WHO Anatomical Therapeutic Chemical classification |
|
flumedroxone |
| 0‑L |
N02CC
|
Selective serotonin (5HT1) agonists
|
WHO Anatomical Therapeutic Chemical classification |
|
Selective serotonin (5HT1) agonists |
| 0‑L |
N02CC01
|
sumatriptan
|
WHO Anatomical Therapeutic Chemical classification |
|
sumatriptan |
| 0‑L |
N02CC02
|
naratriptan
|
WHO Anatomical Therapeutic Chemical classification |
|
naratriptan |
| 0‑L |
N02CC03
|
zolmitriptan
|
WHO Anatomical Therapeutic Chemical classification |
|
zolmitriptan |
| 0‑L |
N02CC04
|
rizatriptan
|
WHO Anatomical Therapeutic Chemical classification |
|
rizatriptan |
| 0‑L |
N02CC05
|
almotriptan
|
WHO Anatomical Therapeutic Chemical classification |
|
almotriptan |
| 0‑L |
N02CC06
|
eletriptan
|
WHO Anatomical Therapeutic Chemical classification |
|
eletriptan |
| 0‑L |
N02CC07
|
frovatriptan
|
WHO Anatomical Therapeutic Chemical classification |
|
frovatriptan |
| 0‑L |
N02CX
|
Other antimigraine preparations
|
WHO Anatomical Therapeutic Chemical classification |
|
Other antimigraine preparations |
| 0‑L |
N02CX01
|
pizotifen
|
WHO Anatomical Therapeutic Chemical classification |
|
pizotifen |
| 0‑L |
N02CX02
|
clonidine
|
WHO Anatomical Therapeutic Chemical classification |
|
clonidine |
| 0‑L |
N02CX03
|
iprazochrome
|
WHO Anatomical Therapeutic Chemical classification |
|
iprazochrome |
| 0‑L |
N02CX05
|
dimetotiazine
|
WHO Anatomical Therapeutic Chemical classification |
|
dimetotiazine |
| 0‑L |
N02CX06
|
oxetorone
|
WHO Anatomical Therapeutic Chemical classification |
|
oxetorone |
| 0‑L |
N03
|
ANTIEPILEPTICS
|
WHO Anatomical Therapeutic Chemical classification |
|
ANTIEPILEPTICS |
| 0‑L |
N03A
|
ANTIEPILEPTICS
|
WHO Anatomical Therapeutic Chemical classification |
|
ANTIEPILEPTICS |
| 0‑L |
N03AA
|
Barbiturates and derivatives
|
WHO Anatomical Therapeutic Chemical classification |
|
Barbiturates and derivatives |
| 0‑L |
N03AA01
|
methylphenobarbital
|
WHO Anatomical Therapeutic Chemical classification |
|
methylphenobarbital |
| 0‑L |
N03AA02
|
phenobarbital
|
WHO Anatomical Therapeutic Chemical classification |
|
phenobarbital |
| 0‑L |
N03AA03
|
primidone
|
WHO Anatomical Therapeutic Chemical classification |
|
primidone |
| 0‑L |
N03AA04
|
barbexaclone
|
WHO Anatomical Therapeutic Chemical classification |
|
barbexaclone |
| 0‑L |
N03AA30
|
metharbital
|
WHO Anatomical Therapeutic Chemical classification |
|
metharbital |
| 0‑L |
N03AB
|
Hydantoin derivatives
|
WHO Anatomical Therapeutic Chemical classification |
|
Hydantoin derivatives |
| 0‑L |
N03AB01
|
ethotoin
|
WHO Anatomical Therapeutic Chemical classification |
|
ethotoin |
| 0‑L |
N03AB02
|
phenytoin
|
WHO Anatomical Therapeutic Chemical classification |
|
phenytoin |
| 0‑L |
N03AB03
|
amino(diphenylhydantoin) valeric acid
|
WHO Anatomical Therapeutic Chemical classification |
|
amino(diphenylhydantoin) valeric acid |
| 0‑L |
N03AB04
|
mephenytoin
|
WHO Anatomical Therapeutic Chemical classification |
|
mephenytoin |
| 0‑L |
N03AB05
|
fosphenytoin
|
WHO Anatomical Therapeutic Chemical classification |
|
fosphenytoin |
| 0‑L |
N03AB52
|
phenytoin, combinations
|
WHO Anatomical Therapeutic Chemical classification |
|
phenytoin, combinations |
| 0‑L |
N03AB54
|
mephenytoin, combinations
|
WHO Anatomical Therapeutic Chemical classification |
|
mephenytoin, combinations |
| 0‑L |
N03AC
|
Oxazolidine derivatives
|
WHO Anatomical Therapeutic Chemical classification |
|
Oxazolidine derivatives |
| 0‑L |
N03AC01
|
paramethadione
|
WHO Anatomical Therapeutic Chemical classification |
|
paramethadione |
| 0‑L |
N03AC02
|
trimethadione
|
WHO Anatomical Therapeutic Chemical classification |
|
trimethadione |
| 0‑L |
N03AC03
|
ethadione
|
WHO Anatomical Therapeutic Chemical classification |
|
ethadione |
| 0‑L |
N03AD
|
Succinimide derivatives
|
WHO Anatomical Therapeutic Chemical classification |
|
Succinimide derivatives |
| 0‑L |
N03AD01
|
ethosuximide
|
WHO Anatomical Therapeutic Chemical classification |
|
ethosuximide |
| 0‑L |
N03AD02
|
phensuximide
|
WHO Anatomical Therapeutic Chemical classification |
|
phensuximide |
| 0‑L |
N03AD03
|
mesuximide
|
WHO Anatomical Therapeutic Chemical classification |
|
mesuximide |
| 0‑L |
N03AD51
|
ethosuximide, combinations
|
WHO Anatomical Therapeutic Chemical classification |
|
ethosuximide, combinations |
| 0‑L |
N03AE
|
Benzodiazepine derivatives
|
WHO Anatomical Therapeutic Chemical classification |
|
Benzodiazepine derivatives |
| 0‑L |
N03AE01
|
clonazepam
|
WHO Anatomical Therapeutic Chemical classification |
|
clonazepam |
| 0‑L |
N03AF
|
Carboxamide derivatives
|
WHO Anatomical Therapeutic Chemical classification |
|
Carboxamide derivatives |
| 0‑L |
N03AF01
|
carbamazepine
|
WHO Anatomical Therapeutic Chemical classification |
|
carbamazepine |
| 0‑L |
N03AF02
|
oxcarbazepine
|
WHO Anatomical Therapeutic Chemical classification |
|
oxcarbazepine |
| 0‑L |
N03AF03
|
rufinamide
|
WHO Anatomical Therapeutic Chemical classification |
|
rufinamide |
| 0‑L |
N03AF04
|
eslicarbazepine
|
WHO Anatomical Therapeutic Chemical classification |
|
eslicarbazepine |
| 0‑L |
N03AG
|
Fatty acid derivatives
|
WHO Anatomical Therapeutic Chemical classification |
|
Fatty acid derivatives |
| 0‑L |
N03AG01
|
valproic acid
|
WHO Anatomical Therapeutic Chemical classification |
|
valproic acid |
| 0‑L |
N03AG02
|
valpromide
|
WHO Anatomical Therapeutic Chemical classification |
|
valpromide |
| 0‑L |
N03AG03
|
aminobutyric acid
|
WHO Anatomical Therapeutic Chemical classification |
|
aminobutyric acid |
| 0‑L |
N03AG04
|
vigabatrin
|
WHO Anatomical Therapeutic Chemical classification |
|
vigabatrin |
| 0‑L |
N03AG05
|
progabide
|
WHO Anatomical Therapeutic Chemical classification |
|
progabide |
| 0‑L |
N03AG06
|
tiagabine
|
WHO Anatomical Therapeutic Chemical classification |
|
tiagabine |
| 0‑L |
N03AX
|
Other antiepileptics
|
WHO Anatomical Therapeutic Chemical classification |
|
Other antiepileptics |
| 0‑L |
N03AX03
|
sultiame
|
WHO Anatomical Therapeutic Chemical classification |
|
sultiame |
| 0‑L |
N03AX07
|
phenacemide
|
WHO Anatomical Therapeutic Chemical classification |
|
phenacemide |
| 0‑L |
N03AX09
|
lamotrigine
|
WHO Anatomical Therapeutic Chemical classification |
|
lamotrigine |
| 0‑L |
N03AX10
|
felbamate
|
WHO Anatomical Therapeutic Chemical classification |
|
felbamate |
| 0‑L |
N03AX11
|
topiramate
|
WHO Anatomical Therapeutic Chemical classification |
|
topiramate |
| 0‑L |
N03AX12
|
gabapentin
|
WHO Anatomical Therapeutic Chemical classification |
|
gabapentin |
| 0‑L |
N03AX13
|
pheneturide
|
WHO Anatomical Therapeutic Chemical classification |
|
pheneturide |
| 0‑L |
N03AX14
|
levetiracetam
|
WHO Anatomical Therapeutic Chemical classification |
|
levetiracetam |
| 0‑L |
N03AX15
|
zonisamide
|
WHO Anatomical Therapeutic Chemical classification |
|
zonisamide |
| 0‑L |
N03AX16
|
pregabalin
|
WHO Anatomical Therapeutic Chemical classification |
|
pregabalin |
| 0‑L |
N03AX17
|
stiripentol
|
WHO Anatomical Therapeutic Chemical classification |
|
stiripentol |
| 0‑L |
N03AX18
|
lacosamide
|
WHO Anatomical Therapeutic Chemical classification |
|
lacosamide |
| 0‑L |
N03AX19
|
carisbamate
|
WHO Anatomical Therapeutic Chemical classification |
|
carisbamate |
| 0‑L |
N03AX21
|
retigabine
|
WHO Anatomical Therapeutic Chemical classification |
|
retigabine |
| 0‑L |
N03AX22
|
perampanel
|
WHO Anatomical Therapeutic Chemical classification |
|
perampanel |
| 0‑L |
N03AX23
|
brivaracetam
|
WHO Anatomical Therapeutic Chemical classification |
|
brivaracetam |
| 0‑L |
N03AX30
|
beclamide
|
WHO Anatomical Therapeutic Chemical classification |
|
beclamide |
| 0‑L |
N04
|
ANTI-PARKINSON DRUGS
|
WHO Anatomical Therapeutic Chemical classification |
|
ANTI-PARKINSON DRUGS |
| 0‑L |
N04A
|
ANTICHOLINERGIC AGENTS
|
WHO Anatomical Therapeutic Chemical classification |
|
ANTICHOLINERGIC AGENTS |
| 0‑L |
N04AA
|
Tertiary amines
|
WHO Anatomical Therapeutic Chemical classification |
|
Tertiary amines |
| 0‑L |
N04AA01
|
trihexyphenidyl
|
WHO Anatomical Therapeutic Chemical classification |
|
trihexyphenidyl |
| 0‑L |
N04AA02
|
biperiden
|
WHO Anatomical Therapeutic Chemical classification |
|
biperiden |
| 0‑L |
N04AA03
|
metixene
|
WHO Anatomical Therapeutic Chemical classification |
|
metixene |
| 0‑L |
N04AA04
|
procyclidine
|
WHO Anatomical Therapeutic Chemical classification |
|
procyclidine |
| 0‑L |
N04AA05
|
profenamine
|
WHO Anatomical Therapeutic Chemical classification |
|
profenamine |
| 0‑L |
N04AA08
|
dexetimide
|
WHO Anatomical Therapeutic Chemical classification |
|
dexetimide |
| 0‑L |
N04AA09
|
phenglutarimide
|
WHO Anatomical Therapeutic Chemical classification |
|
phenglutarimide |
| 0‑L |
N04AA10
|
mazaticol
|
WHO Anatomical Therapeutic Chemical classification |
|
mazaticol |
| 0‑L |
N04AA11
|
bornaprine
|
WHO Anatomical Therapeutic Chemical classification |
|
bornaprine |
| 0‑L |
N04AA12
|
tropatepine
|
WHO Anatomical Therapeutic Chemical classification |
|
tropatepine |
| 0‑L |
N04AB
|
Ethers chemically close to antihistamines
|
WHO Anatomical Therapeutic Chemical classification |
|
Ethers chemically close to antihistamines |
| 0‑L |
N04AB01
|
etanautine
|
WHO Anatomical Therapeutic Chemical classification |
|
etanautine |
| 0‑L |
N04AB02
|
orphenadrine (chloride)
|
WHO Anatomical Therapeutic Chemical classification |
|
orphenadrine (chloride) |
| 0‑L |
N04AC
|
Ethers of tropine or tropine derivatives
|
WHO Anatomical Therapeutic Chemical classification |
|
Ethers of tropine or tropine derivatives |
| 0‑L |
N04AC01
|
benzatropine
|
WHO Anatomical Therapeutic Chemical classification |
|
benzatropine |
| 0‑L |
N04AC30
|
etybenzatropine
|
WHO Anatomical Therapeutic Chemical classification |
|
etybenzatropine |
| 0‑L |
N04B
|
DOPAMINERGIC AGENTS
|
WHO Anatomical Therapeutic Chemical classification |
|
DOPAMINERGIC AGENTS |
| 0‑L |
N04BA
|
Dopa and dopa derivatives
|
WHO Anatomical Therapeutic Chemical classification |
|
Dopa and dopa derivatives |
| 0‑L |
N04BA01
|
levodopa
|
WHO Anatomical Therapeutic Chemical classification |
|
levodopa |
| 0‑L |
N04BA02
|
levodopa and decarboxylase inhibitor
|
WHO Anatomical Therapeutic Chemical classification |
|
levodopa and decarboxylase inhibitor |
| 0‑L |
N04BA03
|
levodopa, decarboxylase inhibitor and COMT inhibitor
|
WHO Anatomical Therapeutic Chemical classification |
|
levodopa, decarboxylase inhibitor and COMT inhibitor |
| 0‑L |
N04BA04
|
melevodopa
|
WHO Anatomical Therapeutic Chemical classification |
|
melevodopa |
| 0‑L |
N04BA05
|
melevodopa and decarboxylase inhibitor
|
WHO Anatomical Therapeutic Chemical classification |
|
melevodopa and decarboxylase inhibitor |
| 0‑L |
N04BA06
|
etilevodopa and decarboxylase inhibitor
|
WHO Anatomical Therapeutic Chemical classification |
|
etilevodopa and decarboxylase inhibitor |
| 0‑L |
N04BB
|
Adamantane derivatives
|
WHO Anatomical Therapeutic Chemical classification |
|
Adamantane derivatives |
| 0‑L |
N04BB01
|
amantadine
|
WHO Anatomical Therapeutic Chemical classification |
|
amantadine |
| 0‑L |
N04BC
|
Dopamine agonists
|
WHO Anatomical Therapeutic Chemical classification |
|
Dopamine agonists |
| 0‑L |
N04BC01
|
bromocriptine
|
WHO Anatomical Therapeutic Chemical classification |
|
bromocriptine |
| 0‑L |
N04BC02
|
pergolide
|
WHO Anatomical Therapeutic Chemical classification |
|
pergolide |
| 0‑L |
N04BC03
|
dihydroergocryptine mesylate
|
WHO Anatomical Therapeutic Chemical classification |
|
dihydroergocryptine mesylate |
| 0‑L |
N04BC04
|
ropinirole
|
WHO Anatomical Therapeutic Chemical classification |
|
ropinirole |
| 0‑L |
N04BC05
|
pramipexole
|
WHO Anatomical Therapeutic Chemical classification |
|
pramipexole |
| 0‑L |
N04BC06
|
cabergoline
|
WHO Anatomical Therapeutic Chemical classification |
|
cabergoline |
| 0‑L |
N04BC07
|
apomorphine
|
WHO Anatomical Therapeutic Chemical classification |
|
apomorphine |
| 0‑L |
N04BC08
|
piribedil
|
WHO Anatomical Therapeutic Chemical classification |
|
piribedil |
| 0‑L |
N04BC09
|
rotigotine
|
WHO Anatomical Therapeutic Chemical classification |
|
rotigotine |
| 0‑L |
N04BD
|
Monoamine oxidase B inhibitors
|
WHO Anatomical Therapeutic Chemical classification |
|
Monoamine oxidase B inhibitors |
| 0‑L |
N04BD01
|
selegiline
|
WHO Anatomical Therapeutic Chemical classification |
|
selegiline |
| 0‑L |
N04BD02
|
rasagiline
|
WHO Anatomical Therapeutic Chemical classification |
|
rasagiline |
| 0‑L |
N04BD03
|
safinamide
|
WHO Anatomical Therapeutic Chemical classification |
|
safinamide |
| 0‑L |
N04BX
|
Other dopaminergic agents
|
WHO Anatomical Therapeutic Chemical classification |
|
Other dopaminergic agents |
| 0‑L |
N04BX01
|
tolcapone
|
WHO Anatomical Therapeutic Chemical classification |
|
tolcapone |
| 0‑L |
N04BX02
|
entacapone
|
WHO Anatomical Therapeutic Chemical classification |
|
entacapone |
| 0‑L |
N04BX03
|
budipine
|
WHO Anatomical Therapeutic Chemical classification |
|
budipine |
| 0‑L |
N05
|
PSYCHOLEPTICS
|
WHO Anatomical Therapeutic Chemical classification |
|
PSYCHOLEPTICS |
| 0‑L |
N05A
|
ANTIPSYCHOTICS
|
WHO Anatomical Therapeutic Chemical classification |
|
ANTIPSYCHOTICS |
| 0‑L |
N05AA
|
Phenothiazines with aliphatic side-chain
|
WHO Anatomical Therapeutic Chemical classification |
|
Phenothiazines with aliphatic side-chain |
| 0‑L |
N05AA01
|
chlorpromazine
|
WHO Anatomical Therapeutic Chemical classification |
|
chlorpromazine |
| 0‑L |
N05AA02
|
levomepromazine
|
WHO Anatomical Therapeutic Chemical classification |
|
levomepromazine |
| 0‑L |
N05AA03
|
promazine
|
WHO Anatomical Therapeutic Chemical classification |
|
promazine |
| 0‑L |
N05AA04
|
acepromazine
|
WHO Anatomical Therapeutic Chemical classification |
|
acepromazine |
| 0‑L |
N05AA05
|
triflupromazine
|
WHO Anatomical Therapeutic Chemical classification |
|
triflupromazine |
| 0‑L |
N05AA06
|
cyamemazine
|
WHO Anatomical Therapeutic Chemical classification |
|
cyamemazine |
| 0‑L |
N05AA07
|
chlorproethazine
|
WHO Anatomical Therapeutic Chemical classification |
|
chlorproethazine |
| 0‑L |
N05AB
|
Phenothiazines with piperazine structure
|
WHO Anatomical Therapeutic Chemical classification |
|
Phenothiazines with piperazine structure |
| 0‑L |
N05AB01
|
dixyrazine
|
WHO Anatomical Therapeutic Chemical classification |
|
dixyrazine |
| 0‑L |
N05AB02
|
fluphenazine
|
WHO Anatomical Therapeutic Chemical classification |
|
fluphenazine |
| 0‑L |
N05AB03
|
perphenazine
|
WHO Anatomical Therapeutic Chemical classification |
|
perphenazine |
| 0‑L |
N05AB04
|
prochlorperazine
|
WHO Anatomical Therapeutic Chemical classification |
|
prochlorperazine |
| 0‑L |
N05AB05
|
thiopropazate
|
WHO Anatomical Therapeutic Chemical classification |
|
thiopropazate |
| 0‑L |
N05AB06
|
trifluoperazine
|
WHO Anatomical Therapeutic Chemical classification |
|
trifluoperazine |
| 0‑L |
N05AB07
|
acetophenazine
|
WHO Anatomical Therapeutic Chemical classification |
|
acetophenazine |
| 0‑L |
N05AB08
|
thioproperazine
|
WHO Anatomical Therapeutic Chemical classification |
|
thioproperazine |
| 0‑L |
N05AB09
|
butaperazine
|
WHO Anatomical Therapeutic Chemical classification |
|
butaperazine |
| 0‑L |
N05AB10
|
perazine
|
WHO Anatomical Therapeutic Chemical classification |
|
perazine |
| 0‑L |
N05AC
|
Phenothiazines with piperidine structure
|
WHO Anatomical Therapeutic Chemical classification |
|
Phenothiazines with piperidine structure |
| 0‑L |
N05AC01
|
periciazine
|
WHO Anatomical Therapeutic Chemical classification |
|
periciazine |
| 0‑L |
N05AC02
|
thioridazine
|
WHO Anatomical Therapeutic Chemical classification |
|
thioridazine |
| 0‑L |
N05AC03
|
mesoridazine
|
WHO Anatomical Therapeutic Chemical classification |
|
mesoridazine |
| 0‑L |
N05AC04
|
pipotiazine
|
WHO Anatomical Therapeutic Chemical classification |
|
pipotiazine |
| 0‑L |
N05AD
|
Butyrophenone derivatives
|
WHO Anatomical Therapeutic Chemical classification |
|
Butyrophenone derivatives |
| 0‑L |
N05AD01
|
haloperidol
|
WHO Anatomical Therapeutic Chemical classification |
|
haloperidol |
| 0‑L |
N05AD02
|
trifluperidol
|
WHO Anatomical Therapeutic Chemical classification |
|
trifluperidol |
| 0‑L |
N05AD03
|
melperone
|
WHO Anatomical Therapeutic Chemical classification |
|
melperone |
| 0‑L |
N05AD04
|
moperone
|
WHO Anatomical Therapeutic Chemical classification |
|
moperone |
| 0‑L |
N05AD05
|
pipamperone
|
WHO Anatomical Therapeutic Chemical classification |
|
pipamperone |
| 0‑L |
N05AD06
|
bromperidol
|
WHO Anatomical Therapeutic Chemical classification |
|
bromperidol |
| 0‑L |
N05AD07
|
benperidol
|
WHO Anatomical Therapeutic Chemical classification |
|
benperidol |
| 0‑L |
N05AD08
|
droperidol
|
WHO Anatomical Therapeutic Chemical classification |
|
droperidol |
| 0‑L |
N05AD09
|
fluanisone
|
WHO Anatomical Therapeutic Chemical classification |
|
fluanisone |
| 0‑L |
N05AE
|
Indole derivatives
|
WHO Anatomical Therapeutic Chemical classification |
|
Indole derivatives |
| 0‑L |
N05AE01
|
oxypertine
|
WHO Anatomical Therapeutic Chemical classification |
|
oxypertine |
| 0‑L |
N05AE02
|
molindone
|
WHO Anatomical Therapeutic Chemical classification |
|
molindone |
| 0‑L |
N05AE03
|
sertindole
|
WHO Anatomical Therapeutic Chemical classification |
|
sertindole |
| 0‑L |
N05AE04
|
ziprasidone
|
WHO Anatomical Therapeutic Chemical classification |
|
ziprasidone |
| 0‑L |
N05AE05
|
lurasidone
|
WHO Anatomical Therapeutic Chemical classification |
|
lurasidone |
| 0‑L |
N05AF
|
Thioxanthene derivatives
|
WHO Anatomical Therapeutic Chemical classification |
|
Thioxanthene derivatives |
| 0‑L |
N05AF01
|
flupentixol
|
WHO Anatomical Therapeutic Chemical classification |
|
flupentixol |
| 0‑L |
N05AF02
|
clopenthixol
|
WHO Anatomical Therapeutic Chemical classification |
|
clopenthixol |
| 0‑L |
N05AF03
|
chlorprothixene
|
WHO Anatomical Therapeutic Chemical classification |
|
chlorprothixene |
| 0‑L |
N05AF04
|
tiotixene
|
WHO Anatomical Therapeutic Chemical classification |
|
tiotixene |
| 0‑L |
N05AF05
|
zuclopenthixol
|
WHO Anatomical Therapeutic Chemical classification |
|
zuclopenthixol |
| 0‑L |
N05AG
|
Diphenylbutylpiperidine derivatives
|
WHO Anatomical Therapeutic Chemical classification |
|
Diphenylbutylpiperidine derivatives |
| 0‑L |
N05AG01
|
fluspirilene
|
WHO Anatomical Therapeutic Chemical classification |
|
fluspirilene |
| 0‑L |
N05AG02
|
pimozide
|
WHO Anatomical Therapeutic Chemical classification |
|
pimozide |
| 0‑L |
N05AG03
|
penfluridol
|
WHO Anatomical Therapeutic Chemical classification |
|
penfluridol |
| 0‑L |
N05AH
|
Diazepines, oxazepines, thiazepines and oxepines
|
WHO Anatomical Therapeutic Chemical classification |
|
Diazepines, oxazepines, thiazepines and oxepines |
| 0‑L |
N05AH01
|
loxapine
|
WHO Anatomical Therapeutic Chemical classification |
|
loxapine |
| 0‑L |
N05AH02
|
clozapine
|
WHO Anatomical Therapeutic Chemical classification |
|
clozapine |
| 0‑L |
N05AH03
|
olanzapine
|
WHO Anatomical Therapeutic Chemical classification |
|
olanzapine |
| 0‑L |
N05AH04
|
quetiapine
|
WHO Anatomical Therapeutic Chemical classification |
|
quetiapine |
| 0‑L |
N05AH05
|
asenapine
|
WHO Anatomical Therapeutic Chemical classification |
|
asenapine |
| 0‑L |
N05AH06
|
clotiapine
|
WHO Anatomical Therapeutic Chemical classification |
|
clotiapine |
| 0‑L |
N05AL
|
Benzamides
|
WHO Anatomical Therapeutic Chemical classification |
|
Benzamides |
| 0‑L |
N05AL01
|
sulpiride
|
WHO Anatomical Therapeutic Chemical classification |
|
sulpiride |
| 0‑L |
N05AL02
|
sultopride
|
WHO Anatomical Therapeutic Chemical classification |
|
sultopride |
| 0‑L |
N05AL03
|
tiapride
|
WHO Anatomical Therapeutic Chemical classification |
|
tiapride |
| 0‑L |
N05AL04
|
remoxipride
|
WHO Anatomical Therapeutic Chemical classification |
|
remoxipride |
| 0‑L |
N05AL05
|
amisulpride
|
WHO Anatomical Therapeutic Chemical classification |
|
amisulpride |
| 0‑L |
N05AL06
|
veralipride
|
WHO Anatomical Therapeutic Chemical classification |
|
veralipride |
| 0‑L |
N05AL07
|
levosulpiride
|
WHO Anatomical Therapeutic Chemical classification |
|
levosulpiride |
| 0‑L |
N05AN
|
Lithium
|
WHO Anatomical Therapeutic Chemical classification |
|
Lithium |
| 0‑L |
N05AN01
|
lithium
|
WHO Anatomical Therapeutic Chemical classification |
|
lithium |
| 0‑L |
N05AX
|
Other antipsychotics
|
WHO Anatomical Therapeutic Chemical classification |
|
Other antipsychotics |
| 0‑L |
N05AX07
|
prothipendyl
|
WHO Anatomical Therapeutic Chemical classification |
|
prothipendyl |
| 0‑L |
N05AX08
|
risperidone
|
WHO Anatomical Therapeutic Chemical classification |
|
risperidone |
| 0‑L |
N05AX10
|
mosapramine
|
WHO Anatomical Therapeutic Chemical classification |
|
mosapramine |
| 0‑L |
N05AX11
|
zotepine
|
WHO Anatomical Therapeutic Chemical classification |
|
zotepine |
| 0‑L |
N05AX12
|
aripiprazole
|
WHO Anatomical Therapeutic Chemical classification |
|
aripiprazole |
| 0‑L |
N05AX13
|
paliperidone
|
WHO Anatomical Therapeutic Chemical classification |
|
paliperidone |
| 0‑L |
N05AX14
|
iloperidone
|
WHO Anatomical Therapeutic Chemical classification |
|
iloperidone |
| 0‑L |
N05AX15
|
cariprazine
|
WHO Anatomical Therapeutic Chemical classification |
|
cariprazine |
| 0‑L |
N05AX16
|
brexpiprazole
|
WHO Anatomical Therapeutic Chemical classification |
|
brexpiprazole |
| 0‑L |
N05AX17
|
pimavanserin
|
WHO Anatomical Therapeutic Chemical classification |
|
pimavanserin |
| 0‑L |
N05B
|
ANXIOLYTICS
|
WHO Anatomical Therapeutic Chemical classification |
|
ANXIOLYTICS |
| 0‑L |
N05BA
|
Benzodiazepine derivatives
|
WHO Anatomical Therapeutic Chemical classification |
|
Benzodiazepine derivatives |
| 0‑L |
N05BA01
|
diazepam
|
WHO Anatomical Therapeutic Chemical classification |
|
diazepam |
| 0‑L |
N05BA02
|
chlordiazepoxide
|
WHO Anatomical Therapeutic Chemical classification |
|
chlordiazepoxide |
| 0‑L |
N05BA03
|
medazepam
|
WHO Anatomical Therapeutic Chemical classification |
|
medazepam |
| 0‑L |
N05BA04
|
oxazepam
|
WHO Anatomical Therapeutic Chemical classification |
|
oxazepam |
| 0‑L |
N05BA05
|
potassium clorazepate
|
WHO Anatomical Therapeutic Chemical classification |
|
potassium clorazepate |
| 0‑L |
N05BA06
|
lorazepam
|
WHO Anatomical Therapeutic Chemical classification |
|
lorazepam |
| 0‑L |
N05BA07
|
adinazolam
|
WHO Anatomical Therapeutic Chemical classification |
|
adinazolam |
| 0‑L |
N05BA08
|
bromazepam
|
WHO Anatomical Therapeutic Chemical classification |
|
bromazepam |
| 0‑L |
N05BA09
|
clobazam
|
WHO Anatomical Therapeutic Chemical classification |
|
clobazam |
| 0‑L |
N05BA10
|
ketazolam
|
WHO Anatomical Therapeutic Chemical classification |
|
ketazolam |
| 0‑L |
N05BA11
|
prazepam
|
WHO Anatomical Therapeutic Chemical classification |
|
prazepam |
| 0‑L |
N05BA12
|
alprazolam
|
WHO Anatomical Therapeutic Chemical classification |
|
alprazolam |
| 0‑L |
N05BA13
|
halazepam
|
WHO Anatomical Therapeutic Chemical classification |
|
halazepam |
| 0‑L |
N05BA14
|
pinazepam
|
WHO Anatomical Therapeutic Chemical classification |
|
pinazepam |
| 0‑L |
N05BA15
|
camazepam
|
WHO Anatomical Therapeutic Chemical classification |
|
camazepam |
| 0‑L |
N05BA16
|
nordazepam
|
WHO Anatomical Therapeutic Chemical classification |
|
nordazepam |
| 0‑L |
N05BA17
|
fludiazepam
|
WHO Anatomical Therapeutic Chemical classification |
|
fludiazepam |
| 0‑L |
N05BA18
|
ethyl loflazepate
|
WHO Anatomical Therapeutic Chemical classification |
|
ethyl loflazepate |
| 0‑L |
N05BA19
|
etizolam
|
WHO Anatomical Therapeutic Chemical classification |
|
etizolam |
| 0‑L |
N05BA21
|
clotiazepam
|
WHO Anatomical Therapeutic Chemical classification |
|
clotiazepam |
| 0‑L |
N05BA22
|
cloxazolam
|
WHO Anatomical Therapeutic Chemical classification |
|
cloxazolam |
| 0‑L |
N05BA23
|
tofisopam
|
WHO Anatomical Therapeutic Chemical classification |
|
tofisopam |
| 0‑L |
N05BA24
|
bentazepam
|
WHO Anatomical Therapeutic Chemical classification |
|
bentazepam |
| 0‑L |
N05BA56
|
lorazepam, combinations
|
WHO Anatomical Therapeutic Chemical classification |
|
lorazepam, combinations |
| 0‑L |
N05BB
|
Diphenylmethane derivatives
|
WHO Anatomical Therapeutic Chemical classification |
|
Diphenylmethane derivatives |
| 0‑L |
N05BB01
|
hydroxyzine
|
WHO Anatomical Therapeutic Chemical classification |
|
hydroxyzine |
| 0‑L |
N05BB02
|
captodiame
|
WHO Anatomical Therapeutic Chemical classification |
|
captodiame |
| 0‑L |
N05BB51
|
hydroxyzine, combinations
|
WHO Anatomical Therapeutic Chemical classification |
|
hydroxyzine, combinations |
| 0‑L |
N05BC
|
Carbamates
|
WHO Anatomical Therapeutic Chemical classification |
|
Carbamates |
| 0‑L |
N05BC01
|
meprobamate
|
WHO Anatomical Therapeutic Chemical classification |
|
meprobamate |
| 0‑L |
N05BC03
|
emylcamate
|
WHO Anatomical Therapeutic Chemical classification |
|
emylcamate |
| 0‑L |
N05BC04
|
mebutamate
|
WHO Anatomical Therapeutic Chemical classification |
|
mebutamate |
| 0‑L |
N05BC51
|
meprobamate, combinations
|
WHO Anatomical Therapeutic Chemical classification |
|
meprobamate, combinations |
| 0‑L |
N05BD
|
Dibenzo-bicyclo-octadiene derivatives
|
WHO Anatomical Therapeutic Chemical classification |
|
Dibenzo-bicyclo-octadiene derivatives |
| 0‑L |
N05BD01
|
benzoctamine
|
WHO Anatomical Therapeutic Chemical classification |
|
benzoctamine |
| 0‑L |
N05BE
|
Azaspirodecanedione derivatives
|
WHO Anatomical Therapeutic Chemical classification |
|
Azaspirodecanedione derivatives |
| 0‑L |
N05BE01
|
buspirone
|
WHO Anatomical Therapeutic Chemical classification |
|
buspirone |
| 0‑L |
N05BX
|
Other anxiolytics
|
WHO Anatomical Therapeutic Chemical classification |
|
Other anxiolytics |
| 0‑L |
N05BX01
|
mephenoxalone
|
WHO Anatomical Therapeutic Chemical classification |
|
mephenoxalone |
| 0‑L |
N05BX02
|
gedocarnil
|
WHO Anatomical Therapeutic Chemical classification |
|
gedocarnil |
| 0‑L |
N05BX03
|
etifoxine
|
WHO Anatomical Therapeutic Chemical classification |
|
etifoxine |
| 0‑L |
N05BX04
|
fabomotizole
|
WHO Anatomical Therapeutic Chemical classification |
|
fabomotizole |
| 0‑L |
N05C
|
HYPNOTICS AND SEDATIVES
|
WHO Anatomical Therapeutic Chemical classification |
|
HYPNOTICS AND SEDATIVES |
| 0‑L |
N05CA
|
Barbiturates, plain
|
WHO Anatomical Therapeutic Chemical classification |
|
Barbiturates, plain |
| 0‑L |
N05CA01
|
pentobarbital
|
WHO Anatomical Therapeutic Chemical classification |
|
pentobarbital |
| 0‑L |
N05CA02
|
amobarbital
|
WHO Anatomical Therapeutic Chemical classification |
|
amobarbital |
| 0‑L |
N05CA03
|
butobarbital
|
WHO Anatomical Therapeutic Chemical classification |
|
butobarbital |
| 0‑L |
N05CA04
|
barbital
|
WHO Anatomical Therapeutic Chemical classification |
|
barbital |
| 0‑L |
N05CA05
|
aprobarbital
|
WHO Anatomical Therapeutic Chemical classification |
|
aprobarbital |
| 0‑L |
N05CA06
|
secobarbital
|
WHO Anatomical Therapeutic Chemical classification |
|
secobarbital |
| 0‑L |
N05CA07
|
talbutal
|
WHO Anatomical Therapeutic Chemical classification |
|
talbutal |
| 0‑L |
N05CA08
|
vinylbital
|
WHO Anatomical Therapeutic Chemical classification |
|
vinylbital |
| 0‑L |
N05CA09
|
vinbarbital
|
WHO Anatomical Therapeutic Chemical classification |
|
vinbarbital |
| 0‑L |
N05CA10
|
cyclobarbital
|
WHO Anatomical Therapeutic Chemical classification |
|
cyclobarbital |
| 0‑L |
N05CA11
|
heptabarbital
|
WHO Anatomical Therapeutic Chemical classification |
|
heptabarbital |
| 0‑L |
N05CA12
|
reposal
|
WHO Anatomical Therapeutic Chemical classification |
|
reposal |
| 0‑L |
N05CA15
|
methohexital
|
WHO Anatomical Therapeutic Chemical classification |
|
methohexital |
| 0‑L |
N05CA16
|
hexobarbital
|
WHO Anatomical Therapeutic Chemical classification |
|
hexobarbital |
| 0‑L |
N05CA19
|
thiopental
|
WHO Anatomical Therapeutic Chemical classification |
|
thiopental |
| 0‑L |
N05CA20
|
etallobarbital
|
WHO Anatomical Therapeutic Chemical classification |
|
etallobarbital |
| 0‑L |
N05CA21
|
allobarbital
|
WHO Anatomical Therapeutic Chemical classification |
|
allobarbital |
| 0‑L |
N05CA22
|
proxibarbal
|
WHO Anatomical Therapeutic Chemical classification |
|
proxibarbal |
| 0‑L |
N05CB
|
Barbiturates, combinations
|
WHO Anatomical Therapeutic Chemical classification |
|
Barbiturates, combinations |
| 0‑L |
N05CB01
|
combinations of barbiturates
|
WHO Anatomical Therapeutic Chemical classification |
|
combinations of barbiturates |
| 0‑L |
N05CB02
|
barbiturates in combination with other drugs
|
WHO Anatomical Therapeutic Chemical classification |
|
barbiturates in combination with other drugs |
| 0‑L |
N05CC
|
Aldehydes and derivatives
|
WHO Anatomical Therapeutic Chemical classification |
|
Aldehydes and derivatives |
| 0‑L |
N05CC01
|
chloral hydrate
|
WHO Anatomical Therapeutic Chemical classification |
|
chloral hydrate |
| 0‑L |
N05CC02
|
chloralodol
|
WHO Anatomical Therapeutic Chemical classification |
|
chloralodol |
| 0‑L |
N05CC03
|
acetylglycinamide chloral hydrate
|
WHO Anatomical Therapeutic Chemical classification |
|
acetylglycinamide chloral hydrate |
| 0‑L |
N05CC04
|
dichloralphenazone
|
WHO Anatomical Therapeutic Chemical classification |
|
dichloralphenazone |
| 0‑L |
N05CC05
|
paraldehyde
|
WHO Anatomical Therapeutic Chemical classification |
|
paraldehyde |
| 0‑L |
N05CD
|
Benzodiazepine derivatives
|
WHO Anatomical Therapeutic Chemical classification |
|
Benzodiazepine derivatives |
| 0‑L |
N05CD01
|
flurazepam
|
WHO Anatomical Therapeutic Chemical classification |
|
flurazepam |
| 0‑L |
N05CD02
|
nitrazepam
|
WHO Anatomical Therapeutic Chemical classification |
|
nitrazepam |
| 0‑L |
N05CD03
|
flunitrazepam
|
WHO Anatomical Therapeutic Chemical classification |
|
flunitrazepam |
| 0‑L |
N05CD04
|
estazolam
|
WHO Anatomical Therapeutic Chemical classification |
|
estazolam |
| 0‑L |
N05CD05
|
triazolam
|
WHO Anatomical Therapeutic Chemical classification |
|
triazolam |
| 0‑L |
N05CD06
|
lormetazepam
|
WHO Anatomical Therapeutic Chemical classification |
|
lormetazepam |
| 0‑L |
N05CD07
|
temazepam
|
WHO Anatomical Therapeutic Chemical classification |
|
temazepam |
| 0‑L |
N05CD08
|
midazolam
|
WHO Anatomical Therapeutic Chemical classification |
|
midazolam |
| 0‑L |
N05CD09
|
brotizolam
|
WHO Anatomical Therapeutic Chemical classification |
|
brotizolam |
| 0‑L |
N05CD10
|
quazepam
|
WHO Anatomical Therapeutic Chemical classification |
|
quazepam |
| 0‑L |
N05CD11
|
loprazolam
|
WHO Anatomical Therapeutic Chemical classification |
|
loprazolam |
| 0‑L |
N05CD12
|
doxefazepam
|
WHO Anatomical Therapeutic Chemical classification |
|
doxefazepam |
| 0‑L |
N05CD13
|
cinolazepam
|
WHO Anatomical Therapeutic Chemical classification |
|
cinolazepam |
| 0‑L |
N05CE
|
Piperidinedione derivatives
|
WHO Anatomical Therapeutic Chemical classification |
|
Piperidinedione derivatives |
| 0‑L |
N05CE01
|
glutethimide
|
WHO Anatomical Therapeutic Chemical classification |
|
glutethimide |
| 0‑L |
N05CE02
|
methyprylon
|
WHO Anatomical Therapeutic Chemical classification |
|
methyprylon |
| 0‑L |
N05CE03
|
pyrithyldione
|
WHO Anatomical Therapeutic Chemical classification |
|
pyrithyldione |
| 0‑L |
N05CF
|
Benzodiazepine related drugs
|
WHO Anatomical Therapeutic Chemical classification |
|
Benzodiazepine related drugs |
| 0‑L |
N05CF01
|
zopiclone
|
WHO Anatomical Therapeutic Chemical classification |
|
zopiclone |
| 0‑L |
N05CF02
|
zolpidem
|
WHO Anatomical Therapeutic Chemical classification |
|
zolpidem |
| 0‑L |
N05CF03
|
zaleplon
|
WHO Anatomical Therapeutic Chemical classification |
|
zaleplon |
| 0‑L |
N05CF04
|
eszopiclone
|
WHO Anatomical Therapeutic Chemical classification |
|
eszopiclone |
| 0‑L |
N05CH
|
Melatonin receptor agonists
|
WHO Anatomical Therapeutic Chemical classification |
|
Melatonin receptor agonists |
| 0‑L |
N05CH01
|
melatonin
|
WHO Anatomical Therapeutic Chemical classification |
|
melatonin |
| 0‑L |
N05CH02
|
ramelteon
|
WHO Anatomical Therapeutic Chemical classification |
|
ramelteon |
| 0‑L |
N05CH03
|
tasimelteon
|
WHO Anatomical Therapeutic Chemical classification |
|
tasimelteon |
| 0‑L |
N05CM
|
Other hypnotics and sedatives
|
WHO Anatomical Therapeutic Chemical classification |
|
Other hypnotics and sedatives |
| 0‑L |
N05CM01
|
methaqualone
|
WHO Anatomical Therapeutic Chemical classification |
|
methaqualone |
| 0‑L |
N05CM02
|
clomethiazole
|
WHO Anatomical Therapeutic Chemical classification |
|
clomethiazole |
| 0‑L |
N05CM03
|
bromisoval
|
WHO Anatomical Therapeutic Chemical classification |
|
bromisoval |
| 0‑L |
N05CM04
|
carbromal
|
WHO Anatomical Therapeutic Chemical classification |
|
carbromal |
| 0‑L |
N05CM05
|
scopolamine
|
WHO Anatomical Therapeutic Chemical classification |
|
scopolamine |
| 0‑L |
N05CM06
|
propiomazine
|
WHO Anatomical Therapeutic Chemical classification |
|
propiomazine |
| 0‑L |
N05CM07
|
triclofos
|
WHO Anatomical Therapeutic Chemical classification |
|
triclofos |
| 0‑L |
N05CM08
|
ethchlorvynol
|
WHO Anatomical Therapeutic Chemical classification |
|
ethchlorvynol |
| 0‑L |
N05CM09
|
Valerianae radix
|
WHO Anatomical Therapeutic Chemical classification |
|
Valerianae radix |
| 0‑L |
N05CM10
|
hexapropymate
|
WHO Anatomical Therapeutic Chemical classification |
|
hexapropymate |
| 0‑L |
N05CM11
|
bromides
|
WHO Anatomical Therapeutic Chemical classification |
|
bromides |
| 0‑L |
N05CM12
|
apronal
|
WHO Anatomical Therapeutic Chemical classification |
|
apronal |
| 0‑L |
N05CM13
|
valnoctamide
|
WHO Anatomical Therapeutic Chemical classification |
|
valnoctamide |
| 0‑L |
N05CM15
|
methylpentynol
|
WHO Anatomical Therapeutic Chemical classification |
|
methylpentynol |
| 0‑L |
N05CM16
|
niaprazine
|
WHO Anatomical Therapeutic Chemical classification |
|
niaprazine |
| 0‑L |
N05CM18
|
dexmedetomidine
|
WHO Anatomical Therapeutic Chemical classification |
|
dexmedetomidine |
| 0‑L |
N05CX
|
Hypnotics and sedatives in combination, excl. barbiturates
|
WHO Anatomical Therapeutic Chemical classification |
|
Hypnotics and sedatives in combination, excl. barbiturates |
| 0‑L |
N05CX01
|
meprobamate, combinations
|
WHO Anatomical Therapeutic Chemical classification |
|
meprobamate, combinations |
| 0‑L |
N05CX02
|
methaqualone, combinations
|
WHO Anatomical Therapeutic Chemical classification |
|
methaqualone, combinations |
| 0‑L |
N05CX03
|
methylpentynol, combinations
|
WHO Anatomical Therapeutic Chemical classification |
|
methylpentynol, combinations |
| 0‑L |
N05CX04
|
clomethiazole, combinations
|
WHO Anatomical Therapeutic Chemical classification |
|
clomethiazole, combinations |
| 0‑L |
N05CX05
|
emepronium, combinations
|
WHO Anatomical Therapeutic Chemical classification |
|
emepronium, combinations |
| 0‑L |
N05CX06
|
dipiperonylaminoethanol, combinations
|
WHO Anatomical Therapeutic Chemical classification |
|
dipiperonylaminoethanol, combinations |
| 0‑L |
N06
|
PSYCHOANALEPTICS
|
WHO Anatomical Therapeutic Chemical classification |
|
PSYCHOANALEPTICS |
| 0‑L |
N06A
|
ANTIDEPRESSANTS
|
WHO Anatomical Therapeutic Chemical classification |
|
ANTIDEPRESSANTS |
| 0‑L |
N06AA
|
Non-selective monoamine reuptake inhibitors
|
WHO Anatomical Therapeutic Chemical classification |
|
Non-selective monoamine reuptake inhibitors |
| 0‑L |
N06AA01
|
desipramine
|
WHO Anatomical Therapeutic Chemical classification |
|
desipramine |
| 0‑L |
N06AA02
|
imipramine
|
WHO Anatomical Therapeutic Chemical classification |
|
imipramine |
| 0‑L |
N06AA03
|
imipramine oxide
|
WHO Anatomical Therapeutic Chemical classification |
|
imipramine oxide |
| 0‑L |
N06AA04
|
clomipramine
|
WHO Anatomical Therapeutic Chemical classification |
|
clomipramine |
| 0‑L |
N06AA05
|
opipramol
|
WHO Anatomical Therapeutic Chemical classification |
|
opipramol |
| 0‑L |
N06AA06
|
trimipramine
|
WHO Anatomical Therapeutic Chemical classification |
|
trimipramine |
| 0‑L |
N06AA07
|
lofepramine
|
WHO Anatomical Therapeutic Chemical classification |
|
lofepramine |
| 0‑L |
N06AA08
|
dibenzepin
|
WHO Anatomical Therapeutic Chemical classification |
|
dibenzepin |
| 0‑L |
N06AA09
|
amitriptyline
|
WHO Anatomical Therapeutic Chemical classification |
|
amitriptyline |
| 0‑L |
N06AA10
|
nortriptyline
|
WHO Anatomical Therapeutic Chemical classification |
|
nortriptyline |
| 0‑L |
N06AA11
|
protriptyline
|
WHO Anatomical Therapeutic Chemical classification |
|
protriptyline |
| 0‑L |
N06AA12
|
doxepin
|
WHO Anatomical Therapeutic Chemical classification |
|
doxepin |
| 0‑L |
N06AA13
|
iprindole
|
WHO Anatomical Therapeutic Chemical classification |
|
iprindole |
| 0‑L |
N06AA14
|
melitracen
|
WHO Anatomical Therapeutic Chemical classification |
|
melitracen |
| 0‑L |
N06AA15
|
butriptyline
|
WHO Anatomical Therapeutic Chemical classification |
|
butriptyline |
| 0‑L |
N06AA16
|
dosulepin
|
WHO Anatomical Therapeutic Chemical classification |
|
dosulepin |
| 0‑L |
N06AA17
|
amoxapine
|
WHO Anatomical Therapeutic Chemical classification |
|
amoxapine |
| 0‑L |
N06AA18
|
dimetacrine
|
WHO Anatomical Therapeutic Chemical classification |
|
dimetacrine |
| 0‑L |
N06AA19
|
amineptine
|
WHO Anatomical Therapeutic Chemical classification |
|
amineptine |
| 0‑L |
N06AA21
|
maprotiline
|
WHO Anatomical Therapeutic Chemical classification |
|
maprotiline |
| 0‑L |
N06AA23
|
quinupramine
|
WHO Anatomical Therapeutic Chemical classification |
|
quinupramine |
| 0‑L |
N06AB
|
Selective serotonin reuptake inhibitors
|
WHO Anatomical Therapeutic Chemical classification |
|
Selective serotonin reuptake inhibitors |
| 0‑L |
N06AB02
|
zimeldine
|
WHO Anatomical Therapeutic Chemical classification |
|
zimeldine |
| 0‑L |
N06AB03
|
fluoxetine
|
WHO Anatomical Therapeutic Chemical classification |
|
fluoxetine |
| 0‑L |
N06AB04
|
citalopram
|
WHO Anatomical Therapeutic Chemical classification |
|
citalopram |
| 0‑L |
N06AB05
|
paroxetine
|
WHO Anatomical Therapeutic Chemical classification |
|
paroxetine |
| 0‑L |
N06AB06
|
sertraline
|
WHO Anatomical Therapeutic Chemical classification |
|
sertraline |
| 0‑L |
N06AB07
|
alaproclate
|
WHO Anatomical Therapeutic Chemical classification |
|
alaproclate |
| 0‑L |
N06AB08
|
fluvoxamine
|
WHO Anatomical Therapeutic Chemical classification |
|
fluvoxamine |
| 0‑L |
N06AB09
|
etoperidone
|
WHO Anatomical Therapeutic Chemical classification |
|
etoperidone |
| 0‑L |
N06AB10
|
escitalopram
|
WHO Anatomical Therapeutic Chemical classification |
|
escitalopram |
| 0‑L |
N06AF
|
Monoamine oxidase inhibitors, non-selective
|
WHO Anatomical Therapeutic Chemical classification |
|
Monoamine oxidase inhibitors, non-selective |
| 0‑L |
N06AF01
|
isocarboxazid
|
WHO Anatomical Therapeutic Chemical classification |
|
isocarboxazid |
| 0‑L |
N06AF02
|
nialamide
|
WHO Anatomical Therapeutic Chemical classification |
|
nialamide |
| 0‑L |
N06AF03
|
phenelzine
|
WHO Anatomical Therapeutic Chemical classification |
|
phenelzine |
| 0‑L |
N06AF04
|
tranylcypromine
|
WHO Anatomical Therapeutic Chemical classification |
|
tranylcypromine |
| 0‑L |
N06AF05
|
iproniazide
|
WHO Anatomical Therapeutic Chemical classification |
|
iproniazide |
| 0‑L |
N06AF06
|
iproclozide
|
WHO Anatomical Therapeutic Chemical classification |
|
iproclozide |
| 0‑L |
N06AG
|
Monoamine oxidase A inhibitors
|
WHO Anatomical Therapeutic Chemical classification |
|
Monoamine oxidase A inhibitors |
| 0‑L |
N06AG02
|
moclobemide
|
WHO Anatomical Therapeutic Chemical classification |
|
moclobemide |
| 0‑L |
N06AG03
|
toloxatone
|
WHO Anatomical Therapeutic Chemical classification |
|
toloxatone |
| 0‑L |
N06AX
|
Other antidepressants
|
WHO Anatomical Therapeutic Chemical classification |
|
Other antidepressants |
| 0‑L |
N06AX01
|
oxitriptan
|
WHO Anatomical Therapeutic Chemical classification |
|
oxitriptan |
| 0‑L |
N06AX02
|
tryptophan
|
WHO Anatomical Therapeutic Chemical classification |
|
tryptophan |
| 0‑L |
N06AX03
|
mianserin
|
WHO Anatomical Therapeutic Chemical classification |
|
mianserin |
| 0‑L |
N06AX04
|
nomifensine
|
WHO Anatomical Therapeutic Chemical classification |
|
nomifensine |
| 0‑L |
N06AX05
|
trazodone
|
WHO Anatomical Therapeutic Chemical classification |
|
trazodone |
| 0‑L |
N06AX06
|
nefazodone
|
WHO Anatomical Therapeutic Chemical classification |
|
nefazodone |
| 0‑L |
N06AX07
|
minaprine
|
WHO Anatomical Therapeutic Chemical classification |
|
minaprine |
| 0‑L |
N06AX08
|
bifemelane
|
WHO Anatomical Therapeutic Chemical classification |
|
bifemelane |
| 0‑L |
N06AX09
|
viloxazine
|
WHO Anatomical Therapeutic Chemical classification |
|
viloxazine |
| 0‑L |
N06AX10
|
oxaflozane
|
WHO Anatomical Therapeutic Chemical classification |
|
oxaflozane |
| 0‑L |
N06AX11
|
mirtazapine
|
WHO Anatomical Therapeutic Chemical classification |
|
mirtazapine |
| 0‑L |
N06AX12
|
bupropion
|
WHO Anatomical Therapeutic Chemical classification |
|
bupropion |
| 0‑L |
N06AX13
|
medifoxamine
|
WHO Anatomical Therapeutic Chemical classification |
|
medifoxamine |
| 0‑L |
N06AX14
|
tianeptine
|
WHO Anatomical Therapeutic Chemical classification |
|
tianeptine |
| 0‑L |
N06AX15
|
pivagabine
|
WHO Anatomical Therapeutic Chemical classification |
|
pivagabine |
| 0‑L |
N06AX16
|
venlafaxine
|
WHO Anatomical Therapeutic Chemical classification |
|
venlafaxine |
| 0‑L |
N06AX17
|
milnacipran
|
WHO Anatomical Therapeutic Chemical classification |
|
milnacipran |
| 0‑L |
N06AX18
|
reboxetine
|
WHO Anatomical Therapeutic Chemical classification |
|
reboxetine |
| 0‑L |
N06AX19
|
gepirone
|
WHO Anatomical Therapeutic Chemical classification |
|
gepirone |
| 0‑L |
N06AX21
|
duloxetine
|
WHO Anatomical Therapeutic Chemical classification |
|
duloxetine |
| 0‑L |
N06AX22
|
agomelatine
|
WHO Anatomical Therapeutic Chemical classification |
|
agomelatine |
| 0‑L |
N06AX23
|
desvenlafaxine
|
WHO Anatomical Therapeutic Chemical classification |
|
desvenlafaxine |
| 0‑L |
N06AX24
|
vilazodone
|
WHO Anatomical Therapeutic Chemical classification |
|
vilazodone |
| 0‑L |
N06AX25
|
Hyperici herba
|
WHO Anatomical Therapeutic Chemical classification |
|
Hyperici herba |
| 0‑L |
N06AX26
|
vortioxetine
|
WHO Anatomical Therapeutic Chemical classification |
|
vortioxetine |
| 0‑L |
N06B
|
PSYCHOSTIMULANTS, AGENTS USED FOR ADHD AND NOOTROPICS
|
WHO Anatomical Therapeutic Chemical classification |
|
PSYCHOSTIMULANTS, AGENTS USED FOR ADHD AND NOOTROPICS |
| 0‑L |
N06BA
|
Centrally acting sympathomimetics
|
WHO Anatomical Therapeutic Chemical classification |
|
Centrally acting sympathomimetics |
| 0‑L |
N06BA01
|
amfetamine
|
WHO Anatomical Therapeutic Chemical classification |
|
amfetamine |
| 0‑L |
N06BA02
|
dexamfetamine
|
WHO Anatomical Therapeutic Chemical classification |
|
dexamfetamine |
| 0‑L |
N06BA03
|
metamfetamine
|
WHO Anatomical Therapeutic Chemical classification |
|
metamfetamine |
| 0‑L |
N06BA04
|
methylphenidate
|
WHO Anatomical Therapeutic Chemical classification |
|
methylphenidate |
| 0‑L |
N06BA05
|
pemoline
|
WHO Anatomical Therapeutic Chemical classification |
|
pemoline |
| 0‑L |
N06BA06
|
fencamfamin
|
WHO Anatomical Therapeutic Chemical classification |
|
fencamfamin |
| 0‑L |
N06BA07
|
modafinil
|
WHO Anatomical Therapeutic Chemical classification |
|
modafinil |
| 0‑L |
N06BA08
|
fenozolone
|
WHO Anatomical Therapeutic Chemical classification |
|
fenozolone |
| 0‑L |
N06BA09
|
atomoxetine
|
WHO Anatomical Therapeutic Chemical classification |
|
atomoxetine |
| 0‑L |
N06BA10
|
fenetylline
|
WHO Anatomical Therapeutic Chemical classification |
|
fenetylline |
| 0‑L |
N06BA11
|
dexmethylphenidate
|
WHO Anatomical Therapeutic Chemical classification |
|
dexmethylphenidate |
| 0‑L |
N06BA12
|
lisdexamfetamine
|
WHO Anatomical Therapeutic Chemical classification |
|
lisdexamfetamine |
| 0‑L |
N06BA13
|
armodafinil
|
WHO Anatomical Therapeutic Chemical classification |
|
armodafinil |
| 0‑L |
N06BC
|
Xanthine derivatives
|
WHO Anatomical Therapeutic Chemical classification |
|
Xanthine derivatives |
| 0‑L |
N06BC01
|
caffeine
|
WHO Anatomical Therapeutic Chemical classification |
|
caffeine |
| 0‑L |
N06BC02
|
propentofylline
|
WHO Anatomical Therapeutic Chemical classification |
|
propentofylline |
| 0‑L |
N06BX
|
Other psychostimulants and nootropics
|
WHO Anatomical Therapeutic Chemical classification |
|
Other psychostimulants and nootropics |
| 0‑L |
N06BX01
|
meclofenoxate
|
WHO Anatomical Therapeutic Chemical classification |
|
meclofenoxate |
| 0‑L |
N06BX02
|
pyritinol
|
WHO Anatomical Therapeutic Chemical classification |
|
pyritinol |
| 0‑L |
N06BX03
|
piracetam
|
WHO Anatomical Therapeutic Chemical classification |
|
piracetam |
| 0‑L |
N06BX04
|
deanol
|
WHO Anatomical Therapeutic Chemical classification |
|
deanol |
| 0‑L |
N06BX05
|
fipexide
|
WHO Anatomical Therapeutic Chemical classification |
|
fipexide |
| 0‑L |
N06BX06
|
citicoline
|
WHO Anatomical Therapeutic Chemical classification |
|
citicoline |
| 0‑L |
N06BX07
|
oxiracetam
|
WHO Anatomical Therapeutic Chemical classification |
|
oxiracetam |
| 0‑L |
N06BX08
|
pirisudanol
|
WHO Anatomical Therapeutic Chemical classification |
|
pirisudanol |
| 0‑L |
N06BX09
|
linopirdine
|
WHO Anatomical Therapeutic Chemical classification |
|
linopirdine |
| 0‑L |
N06BX10
|
nizofenone
|
WHO Anatomical Therapeutic Chemical classification |
|
nizofenone |
| 0‑L |
N06BX11
|
aniracetam
|
WHO Anatomical Therapeutic Chemical classification |
|
aniracetam |
| 0‑L |
N06BX12
|
acetylcarnitine
|
WHO Anatomical Therapeutic Chemical classification |
|
acetylcarnitine |
| 0‑L |
N06BX13
|
idebenone
|
WHO Anatomical Therapeutic Chemical classification |
|
idebenone |
| 0‑L |
N06BX14
|
prolintane
|
WHO Anatomical Therapeutic Chemical classification |
|
prolintane |
| 0‑L |
N06BX15
|
pipradrol
|
WHO Anatomical Therapeutic Chemical classification |
|
pipradrol |
| 0‑L |
N06BX16
|
pramiracetam
|
WHO Anatomical Therapeutic Chemical classification |
|
pramiracetam |
| 0‑L |
N06BX17
|
adrafinil
|
WHO Anatomical Therapeutic Chemical classification |
|
adrafinil |
| 0‑L |
N06BX18
|
vinpocetine
|
WHO Anatomical Therapeutic Chemical classification |
|
vinpocetine |
| 0‑L |
N06BX21
|
mebicar
|
WHO Anatomical Therapeutic Chemical classification |
|
mebicar |
| 0‑L |
N06BX22
|
phenibut
|
WHO Anatomical Therapeutic Chemical classification |
|
phenibut |
| 0‑L |
N06C
|
PSYCHOLEPTICS AND PSYCHOANALEPTICS IN COMBINATION
|
WHO Anatomical Therapeutic Chemical classification |
|
PSYCHOLEPTICS AND PSYCHOANALEPTICS IN COMBINATION |
| 0‑L |
N06CA
|
Antidepressants in combination with psycholeptics
|
WHO Anatomical Therapeutic Chemical classification |
|
Antidepressants in combination with psycholeptics |
| 0‑L |
N06CA01
|
amitriptyline and psycholeptics
|
WHO Anatomical Therapeutic Chemical classification |
|
amitriptyline and psycholeptics |
| 0‑L |
N06CA02
|
melitracen and psycholeptics
|
WHO Anatomical Therapeutic Chemical classification |
|
melitracen and psycholeptics |
| 0‑L |
N06CA03
|
fluoxetine and psycholeptics
|
WHO Anatomical Therapeutic Chemical classification |
|
fluoxetine and psycholeptics |
| 0‑L |
N06CB
|
Psychostimulants in combination with psycholeptics
|
WHO Anatomical Therapeutic Chemical classification |
|
Psychostimulants in combination with psycholeptics |
| 0‑L |
N06D
|
ANTI-DEMENTIA DRUGS
|
WHO Anatomical Therapeutic Chemical classification |
|
ANTI-DEMENTIA DRUGS |
| 0‑L |
N06DA
|
Anticholinesterases
|
WHO Anatomical Therapeutic Chemical classification |
|
Anticholinesterases |
| 0‑L |
N06DA01
|
tacrine
|
WHO Anatomical Therapeutic Chemical classification |
|
tacrine |
| 0‑L |
N06DA02
|
donepezil
|
WHO Anatomical Therapeutic Chemical classification |
|
donepezil |
| 0‑L |
N06DA03
|
rivastigmine
|
WHO Anatomical Therapeutic Chemical classification |
|
rivastigmine |
| 0‑L |
N06DA04
|
galantamine
|
WHO Anatomical Therapeutic Chemical classification |
|
galantamine |
| 0‑L |
N06DA05
|
ipidacrine
|
WHO Anatomical Therapeutic Chemical classification |
|
ipidacrine |
| 0‑L |
N06DA52
|
donepezil and memantine
|
WHO Anatomical Therapeutic Chemical classification |
|
donepezil and memantine |
| 0‑L |
N06DA53
|
donepezil, memantine and Ginkgo folium
|
WHO Anatomical Therapeutic Chemical classification |
|
donepezil, memantine and Ginkgo folium |
| 0‑L |
N06DX
|
Other anti-dementia drugs
|
WHO Anatomical Therapeutic Chemical classification |
|
Other anti-dementia drugs |
| 0‑L |
N06DX01
|
memantine
|
WHO Anatomical Therapeutic Chemical classification |
|
memantine |
| 0‑L |
N06DX02
|
Ginkgo folium
|
WHO Anatomical Therapeutic Chemical classification |
|
Ginkgo folium |
| 0‑L |
N06DX30
|
combinations
|
WHO Anatomical Therapeutic Chemical classification |
|
combinations |
| 0‑L |
N07
|
OTHER NERVOUS SYSTEM DRUGS
|
WHO Anatomical Therapeutic Chemical classification |
|
OTHER NERVOUS SYSTEM DRUGS |
| 0‑L |
N07A
|
PARASYMPATHOMIMETICS
|
WHO Anatomical Therapeutic Chemical classification |
|
PARASYMPATHOMIMETICS |
| 0‑L |
N07AA
|
Anticholinesterases
|
WHO Anatomical Therapeutic Chemical classification |
|
Anticholinesterases |
| 0‑L |
N07AA01
|
neostigmine
|
WHO Anatomical Therapeutic Chemical classification |
|
neostigmine |
| 0‑L |
N07AA02
|
pyridostigmine
|
WHO Anatomical Therapeutic Chemical classification |
|
pyridostigmine |
| 0‑L |
N07AA03
|
distigmine
|
WHO Anatomical Therapeutic Chemical classification |
|
distigmine |
| 0‑L |
N07AA30
|
ambenonium
|
WHO Anatomical Therapeutic Chemical classification |
|
ambenonium |
| 0‑L |
N07AA51
|
neostigmine, combinations
|
WHO Anatomical Therapeutic Chemical classification |
|
neostigmine, combinations |
| 0‑L |
N07AB
|
Choline esters
|
WHO Anatomical Therapeutic Chemical classification |
|
Choline esters |
| 0‑L |
N07AB01
|
carbachol
|
WHO Anatomical Therapeutic Chemical classification |
|
carbachol |
| 0‑L |
N07AB02
|
bethanechol
|
WHO Anatomical Therapeutic Chemical classification |
|
bethanechol |
| 0‑L |
N07AX
|
Other parasympathomimetics
|
WHO Anatomical Therapeutic Chemical classification |
|
Other parasympathomimetics |
| 0‑L |
N07AX01
|
pilocarpine
|
WHO Anatomical Therapeutic Chemical classification |
|
pilocarpine |
| 0‑L |
N07AX02
|
choline alfoscerate
|
WHO Anatomical Therapeutic Chemical classification |
|
choline alfoscerate |
| 0‑L |
N07AX03
|
cevimeline
|
WHO Anatomical Therapeutic Chemical classification |
|
cevimeline |
| 0‑L |
N07B
|
DRUGS USED IN ADDICTIVE DISORDERS
|
WHO Anatomical Therapeutic Chemical classification |
|
DRUGS USED IN ADDICTIVE DISORDERS |
| 0‑L |
N07BA
|
Drugs used in nicotine dependence
|
WHO Anatomical Therapeutic Chemical classification |
|
Drugs used in nicotine dependence |
| 0‑L |
N07BA01
|
nicotine
|
WHO Anatomical Therapeutic Chemical classification |
|
nicotine |
| 0‑L |
N07BA03
|
varenicline
|
WHO Anatomical Therapeutic Chemical classification |
|
varenicline |
| 0‑L |
N07BB
|
Drugs used in alcohol dependence
|
WHO Anatomical Therapeutic Chemical classification |
|
Drugs used in alcohol dependence |
| 0‑L |
N07BB01
|
disulfiram
|
WHO Anatomical Therapeutic Chemical classification |
|
disulfiram |
| 0‑L |
N07BB02
|
calcium carbimide
|
WHO Anatomical Therapeutic Chemical classification |
|
calcium carbimide |
| 0‑L |
N07BB03
|
acamprosate
|
WHO Anatomical Therapeutic Chemical classification |
|
acamprosate |
| 0‑L |
N07BB04
|
naltrexone
|
WHO Anatomical Therapeutic Chemical classification |
|
naltrexone |
| 0‑L |
N07BB05
|
nalmefene
|
WHO Anatomical Therapeutic Chemical classification |
|
nalmefene |
| 0‑L |
N07BC
|
Drugs used in opioid dependence
|
WHO Anatomical Therapeutic Chemical classification |
|
Drugs used in opioid dependence |
| 0‑L |
N07BC01
|
buprenorphine
|
WHO Anatomical Therapeutic Chemical classification |
|
buprenorphine |
| 0‑L |
N07BC02
|
methadone
|
WHO Anatomical Therapeutic Chemical classification |
|
methadone |
| 0‑L |
N07BC03
|
levacetylmethadol
|
WHO Anatomical Therapeutic Chemical classification |
|
levacetylmethadol |
| 0‑L |
N07BC04
|
lofexidine
|
WHO Anatomical Therapeutic Chemical classification |
|
lofexidine |
| 0‑L |
N07BC05
|
levomethadone
|
WHO Anatomical Therapeutic Chemical classification |
|
levomethadone |
| 0‑L |
N07BC06
|
diamorphine
|
WHO Anatomical Therapeutic Chemical classification |
|
diamorphine |
| 0‑L |
N07BC51
|
buprenorphine, combinations
|
WHO Anatomical Therapeutic Chemical classification |
|
buprenorphine, combinations |
| 0‑L |
N07C
|
ANTIVERTIGO PREPARATIONS
|
WHO Anatomical Therapeutic Chemical classification |
|
ANTIVERTIGO PREPARATIONS |
| 0‑L |
N07CA
|
Antivertigo preparations
|
WHO Anatomical Therapeutic Chemical classification |
|
Antivertigo preparations |
| 0‑L |
N07CA01
|
betahistine
|
WHO Anatomical Therapeutic Chemical classification |
|
betahistine |
| 0‑L |
N07CA02
|
cinnarizine
|
WHO Anatomical Therapeutic Chemical classification |
|
cinnarizine |
| 0‑L |
N07CA03
|
flunarizine
|
WHO Anatomical Therapeutic Chemical classification |
|
flunarizine |
| 0‑L |
N07CA04
|
acetylleucine
|
WHO Anatomical Therapeutic Chemical classification |
|
acetylleucine |
| 0‑L |
N07CA52
|
cinnarizine, combinations
|
WHO Anatomical Therapeutic Chemical classification |
|
cinnarizine, combinations |
| 0‑L |
N07X
|
OTHER NERVOUS SYSTEM DRUGS
|
WHO Anatomical Therapeutic Chemical classification |
|
OTHER NERVOUS SYSTEM DRUGS |
| 0‑L |
N07XA
|
Gangliosides and ganglioside derivatives
|
WHO Anatomical Therapeutic Chemical classification |
|
Gangliosides and ganglioside derivatives |
| 0‑L |
N07XX
|
Other nervous system drugs
|
WHO Anatomical Therapeutic Chemical classification |
|
Other nervous system drugs |
| 0‑L |
N07XX01
|
tirilazad
|
WHO Anatomical Therapeutic Chemical classification |
|
tirilazad |
| 0‑L |
N07XX02
|
riluzole
|
WHO Anatomical Therapeutic Chemical classification |
|
riluzole |
| 0‑L |
N07XX03
|
xaliproden
|
WHO Anatomical Therapeutic Chemical classification |
|
xaliproden |
| 0‑L |
N07XX04
|
sodium oxybate
|
WHO Anatomical Therapeutic Chemical classification |
|
sodium oxybate |
| 0‑L |
N07XX05
|
amifampridine
|
WHO Anatomical Therapeutic Chemical classification |
|
amifampridine |
| 0‑L |
N07XX06
|
tetrabenazine
|
WHO Anatomical Therapeutic Chemical classification |
|
tetrabenazine |
| 0‑L |
N07XX07
|
fampridine
|
WHO Anatomical Therapeutic Chemical classification |
|
fampridine |
| 0‑L |
N07XX08
|
tafamidis
|
WHO Anatomical Therapeutic Chemical classification |
|
tafamidis |
| 0‑L |
N07XX09
|
dimethyl fumarate
|
WHO Anatomical Therapeutic Chemical classification |
|
dimethyl fumarate |
| 0‑L |
N07XX10
|
laquinimod
|
WHO Anatomical Therapeutic Chemical classification |
|
laquinimod |
| 0‑L |
N07XX11
|
pitolisant
|
WHO Anatomical Therapeutic Chemical classification |
|
pitolisant |
| 0‑L |
N07XX59
|
dextromethorphan, combinations
|
WHO Anatomical Therapeutic Chemical classification |
|
dextromethorphan, combinations |
| 0‑L |
P
|
ANTIPARASITIC PRODUCTS, INSECTICIDES AND REPELLENTS
|
WHO Anatomical Therapeutic Chemical classification |
|
ANTIPARASITIC PRODUCTS, INSECTICIDES AND REPELLENTS |
| 0‑L |
P01
|
ANTIPROTOZOALS
|
WHO Anatomical Therapeutic Chemical classification |
|
ANTIPROTOZOALS |
| 0‑L |
P01A
|
AGENTS AGAINST AMOEBIASIS AND OTHER PROTOZOAL DISEASES
|
WHO Anatomical Therapeutic Chemical classification |
|
AGENTS AGAINST AMOEBIASIS AND OTHER PROTOZOAL DISEASES |
| 0‑L |
P01AA
|
Hydroxyquinoline derivatives
|
WHO Anatomical Therapeutic Chemical classification |
|
Hydroxyquinoline derivatives |
| 0‑L |
P01AA01
|
broxyquinoline
|
WHO Anatomical Therapeutic Chemical classification |
|
broxyquinoline |
| 0‑L |
P01AA02
|
clioquinol
|
WHO Anatomical Therapeutic Chemical classification |
|
clioquinol |
| 0‑L |
P01AA04
|
chlorquinaldol
|
WHO Anatomical Therapeutic Chemical classification |
|
chlorquinaldol |
| 0‑L |
P01AA05
|
tilbroquinol
|
WHO Anatomical Therapeutic Chemical classification |
|
tilbroquinol |
| 0‑L |
P01AA52
|
clioquinol, combinations
|
WHO Anatomical Therapeutic Chemical classification |
|
clioquinol, combinations |
| 0‑L |
P01AB
|
Nitroimidazole derivatives
|
WHO Anatomical Therapeutic Chemical classification |
|
Nitroimidazole derivatives |
| 0‑L |
P01AB01
|
metronidazole
|
WHO Anatomical Therapeutic Chemical classification |
|
metronidazole |
| 0‑L |
P01AB02
|
tinidazole
|
WHO Anatomical Therapeutic Chemical classification |
|
tinidazole |
| 0‑L |
P01AB03
|
ornidazole
|
WHO Anatomical Therapeutic Chemical classification |
|
ornidazole |
| 0‑L |
P01AB04
|
azanidazole
|
WHO Anatomical Therapeutic Chemical classification |
|
azanidazole |
| 0‑L |
P01AB05
|
propenidazole
|
WHO Anatomical Therapeutic Chemical classification |
|
propenidazole |
| 0‑L |
P01AB06
|
nimorazole
|
WHO Anatomical Therapeutic Chemical classification |
|
nimorazole |
| 0‑L |
P01AB07
|
secnidazole
|
WHO Anatomical Therapeutic Chemical classification |
|
secnidazole |
| 0‑L |
P01AB51
|
metronidazole, combinations
|
WHO Anatomical Therapeutic Chemical classification |
|
metronidazole, combinations |
| 0‑L |
P01AC
|
Dichloroacetamide derivatives
|
WHO Anatomical Therapeutic Chemical classification |
|
Dichloroacetamide derivatives |
| 0‑L |
P01AC01
|
diloxanide
|
WHO Anatomical Therapeutic Chemical classification |
|
diloxanide |
| 0‑L |
P01AC02
|
clefamide
|
WHO Anatomical Therapeutic Chemical classification |
|
clefamide |
| 0‑L |
P01AC03
|
etofamide
|
WHO Anatomical Therapeutic Chemical classification |
|
etofamide |
| 0‑L |
P01AC04
|
teclozan
|
WHO Anatomical Therapeutic Chemical classification |
|
teclozan |
| 0‑L |
P01AR
|
Arsenic compounds
|
WHO Anatomical Therapeutic Chemical classification |
|
Arsenic compounds |
| 0‑L |
P01AR01
|
arsthinol
|
WHO Anatomical Therapeutic Chemical classification |
|
arsthinol |
| 0‑L |
P01AR02
|
difetarsone
|
WHO Anatomical Therapeutic Chemical classification |
|
difetarsone |
| 0‑L |
P01AR03
|
glycobiarsol
|
WHO Anatomical Therapeutic Chemical classification |
|
glycobiarsol |
| 0‑L |
P01AR53
|
glycobiarsol, combinations
|
WHO Anatomical Therapeutic Chemical classification |
|
glycobiarsol, combinations |
| 0‑L |
P01AX
|
Other agents against amoebiasis and other protozoal diseases
|
WHO Anatomical Therapeutic Chemical classification |
|
Other agents against amoebiasis and other protozoal diseases |
| 0‑L |
P01AX01
|
chiniofon
|
WHO Anatomical Therapeutic Chemical classification |
|
chiniofon |
| 0‑L |
P01AX02
|
emetine
|
WHO Anatomical Therapeutic Chemical classification |
|
emetine |
| 0‑L |
P01AX04
|
phanquinone
|
WHO Anatomical Therapeutic Chemical classification |
|
phanquinone |
| 0‑L |
P01AX05
|
mepacrine
|
WHO Anatomical Therapeutic Chemical classification |
|
mepacrine |
| 0‑L |
P01AX06
|
atovaquone
|
WHO Anatomical Therapeutic Chemical classification |
|
atovaquone |
| 0‑L |
P01AX07
|
trimetrexate
|
WHO Anatomical Therapeutic Chemical classification |
|
trimetrexate |
| 0‑L |
P01AX08
|
tenonitrozole
|
WHO Anatomical Therapeutic Chemical classification |
|
tenonitrozole |
| 0‑L |
P01AX09
|
dehydroemetine
|
WHO Anatomical Therapeutic Chemical classification |
|
dehydroemetine |
| 0‑L |
P01AX10
|
fumagillin
|
WHO Anatomical Therapeutic Chemical classification |
|
fumagillin |
| 0‑L |
P01AX11
|
nitazoxanide
|
WHO Anatomical Therapeutic Chemical classification |
|
nitazoxanide |
| 0‑L |
P01AX52
|
emetine, combinations
|
WHO Anatomical Therapeutic Chemical classification |
|
emetine, combinations |
| 0‑L |
P01B
|
ANTIMALARIALS
|
WHO Anatomical Therapeutic Chemical classification |
|
ANTIMALARIALS |
| 0‑L |
P01BA
|
Aminoquinolines
|
WHO Anatomical Therapeutic Chemical classification |
|
Aminoquinolines |
| 0‑L |
P01BA01
|
chloroquine
|
WHO Anatomical Therapeutic Chemical classification |
|
chloroquine |
| 0‑L |
P01BA02
|
hydroxychloroquine
|
WHO Anatomical Therapeutic Chemical classification |
|
hydroxychloroquine |
| 0‑L |
P01BA03
|
primaquine
|
WHO Anatomical Therapeutic Chemical classification |
|
primaquine |
| 0‑L |
P01BA06
|
amodiaquine
|
WHO Anatomical Therapeutic Chemical classification |
|
amodiaquine |
| 0‑L |
P01BB
|
Biguanides
|
WHO Anatomical Therapeutic Chemical classification |
|
Biguanides |
| 0‑L |
P01BB01
|
proguanil
|
WHO Anatomical Therapeutic Chemical classification |
|
proguanil |
| 0‑L |
P01BB02
|
cycloguanil embonate
|
WHO Anatomical Therapeutic Chemical classification |
|
cycloguanil embonate |
| 0‑L |
P01BB51
|
proguanil, combinations
|
WHO Anatomical Therapeutic Chemical classification |
|
proguanil, combinations |
| 0‑L |
P01BC
|
Methanolquinolines
|
WHO Anatomical Therapeutic Chemical classification |
|
Methanolquinolines |
| 0‑L |
P01BC01
|
quinine
|
WHO Anatomical Therapeutic Chemical classification |
|
quinine |
| 0‑L |
P01BC02
|
mefloquine
|
WHO Anatomical Therapeutic Chemical classification |
|
mefloquine |
| 0‑L |
P01BD
|
Diaminopyrimidines
|
WHO Anatomical Therapeutic Chemical classification |
|
Diaminopyrimidines |
| 0‑L |
P01BD01
|
pyrimethamine
|
WHO Anatomical Therapeutic Chemical classification |
|
pyrimethamine |
| 0‑L |
P01BD51
|
pyrimethamine, combinations
|
WHO Anatomical Therapeutic Chemical classification |
|
pyrimethamine, combinations |
| 0‑L |
P01BE
|
Artemisinin and derivatives, plain
|
WHO Anatomical Therapeutic Chemical classification |
|
Artemisinin and derivatives, plain |
| 0‑L |
P01BE01
|
artemisinin
|
WHO Anatomical Therapeutic Chemical classification |
|
artemisinin |
| 0‑L |
P01BE02
|
artemether
|
WHO Anatomical Therapeutic Chemical classification |
|
artemether |
| 0‑L |
P01BE03
|
artesunate
|
WHO Anatomical Therapeutic Chemical classification |
|
artesunate |
| 0‑L |
P01BE04
|
artemotil
|
WHO Anatomical Therapeutic Chemical classification |
|
artemotil |
| 0‑L |
P01BE05
|
artenimol
|
WHO Anatomical Therapeutic Chemical classification |
|
artenimol |
| 0‑L |
P01BF
|
Artemisinin and derivatives, combinations
|
WHO Anatomical Therapeutic Chemical classification |
|
Artemisinin and derivatives, combinations |
| 0‑L |
P01BF01
|
artemether and lumefantrine
|
WHO Anatomical Therapeutic Chemical classification |
|
artemether and lumefantrine |
| 0‑L |
P01BF02
|
artesunate and mefloquine
|
WHO Anatomical Therapeutic Chemical classification |
|
artesunate and mefloquine |
| 0‑L |
P01BF03
|
artesunate and amodiaquine
|
WHO Anatomical Therapeutic Chemical classification |
|
artesunate and amodiaquine |
| 0‑L |
P01BF04
|
artesunate, sulphamethopyrazine and pyrimethamine
|
WHO Anatomical Therapeutic Chemical classification |
|
artesunate, sulphamethopyrazine and pyrimethamine |
| 0‑L |
P01BF05
|
artenimol and piperaquine
|
WHO Anatomical Therapeutic Chemical classification |
|
artenimol and piperaquine |
| 0‑L |
P01BF06
|
artesunate and pyronaridine
|
WHO Anatomical Therapeutic Chemical classification |
|
artesunate and pyronaridine |
| 0‑L |
P01BX
|
Other antimalarials
|
WHO Anatomical Therapeutic Chemical classification |
|
Other antimalarials |
| 0‑L |
P01BX01
|
halofantrine
|
WHO Anatomical Therapeutic Chemical classification |
|
halofantrine |
| 0‑L |
P01BX02
|
arterolane and piperaquine
|
WHO Anatomical Therapeutic Chemical classification |
|
arterolane and piperaquine |
| 0‑L |
P01C
|
AGENTS AGAINST LEISHMANIASIS AND TRYPANOSOMIASIS
|
WHO Anatomical Therapeutic Chemical classification |
|
AGENTS AGAINST LEISHMANIASIS AND TRYPANOSOMIASIS |
| 0‑L |
P01CA
|
Nitroimidazole derivatives
|
WHO Anatomical Therapeutic Chemical classification |
|
Nitroimidazole derivatives |
| 0‑L |
P01CA02
|
benznidazole
|
WHO Anatomical Therapeutic Chemical classification |
|
benznidazole |
| 0‑L |
P01CB
|
Antimony compounds
|
WHO Anatomical Therapeutic Chemical classification |
|
Antimony compounds |
| 0‑L |
P01CB01
|
meglumine antimonate
|
WHO Anatomical Therapeutic Chemical classification |
|
meglumine antimonate |
| 0‑L |
P01CB02
|
sodium stibogluconate
|
WHO Anatomical Therapeutic Chemical classification |
|
sodium stibogluconate |
| 0‑L |
P01CC
|
Nitrofuran derivatives
|
WHO Anatomical Therapeutic Chemical classification |
|
Nitrofuran derivatives |
| 0‑L |
P01CC01
|
nifurtimox
|
WHO Anatomical Therapeutic Chemical classification |
|
nifurtimox |
| 0‑L |
P01CC02
|
nitrofural
|
WHO Anatomical Therapeutic Chemical classification |
|
nitrofural |
| 0‑L |
P01CD
|
Arsenic compounds
|
WHO Anatomical Therapeutic Chemical classification |
|
Arsenic compounds |
| 0‑L |
P01CD01
|
melarsoprol
|
WHO Anatomical Therapeutic Chemical classification |
|
melarsoprol |
| 0‑L |
P01CD02
|
acetarsol
|
WHO Anatomical Therapeutic Chemical classification |
|
acetarsol |
| 0‑L |
P01CX
|
Other agents against leishmaniasis and trypanosomiasis
|
WHO Anatomical Therapeutic Chemical classification |
|
Other agents against leishmaniasis and trypanosomiasis |
| 0‑L |
P01CX01
|
pentamidine isethionate
|
WHO Anatomical Therapeutic Chemical classification |
|
pentamidine isethionate |
| 0‑L |
P01CX02
|
suramin sodium
|
WHO Anatomical Therapeutic Chemical classification |
|
suramin sodium |
| 0‑L |
P01CX03
|
eflornithine
|
WHO Anatomical Therapeutic Chemical classification |
|
eflornithine |
| 0‑L |
P02
|
ANTHELMINTICS
|
WHO Anatomical Therapeutic Chemical classification |
|
ANTHELMINTICS |
| 0‑L |
P02B
|
ANTITREMATODALS
|
WHO Anatomical Therapeutic Chemical classification |
|
ANTITREMATODALS |
| 0‑L |
P02BA
|
Quinoline derivatives and related substances
|
WHO Anatomical Therapeutic Chemical classification |
|
Quinoline derivatives and related substances |
| 0‑L |
P02BA01
|
praziquantel
|
WHO Anatomical Therapeutic Chemical classification |
|
praziquantel |
| 0‑L |
P02BA02
|
oxamniquine
|
WHO Anatomical Therapeutic Chemical classification |
|
oxamniquine |
| 0‑L |
P02BB
|
Organophosphorous compounds
|
WHO Anatomical Therapeutic Chemical classification |
|
Organophosphorous compounds |
| 0‑L |
P02BB01
|
metrifonate
|
WHO Anatomical Therapeutic Chemical classification |
|
metrifonate |
| 0‑L |
P02BX
|
Other antitrematodal agents
|
WHO Anatomical Therapeutic Chemical classification |
|
Other antitrematodal agents |
| 0‑L |
P02BX01
|
bithionol
|
WHO Anatomical Therapeutic Chemical classification |
|
bithionol |
| 0‑L |
P02BX02
|
niridazole
|
WHO Anatomical Therapeutic Chemical classification |
|
niridazole |
| 0‑L |
P02BX03
|
stibophen
|
WHO Anatomical Therapeutic Chemical classification |
|
stibophen |
| 0‑L |
P02BX04
|
triclabendazole
|
WHO Anatomical Therapeutic Chemical classification |
|
triclabendazole |
| 0‑L |
P02C
|
ANTINEMATODAL AGENTS
|
WHO Anatomical Therapeutic Chemical classification |
|
ANTINEMATODAL AGENTS |
| 0‑L |
P02CA
|
Benzimidazole derivatives
|
WHO Anatomical Therapeutic Chemical classification |
|
Benzimidazole derivatives |
| 0‑L |
P02CA01
|
mebendazole
|
WHO Anatomical Therapeutic Chemical classification |
|
mebendazole |
| 0‑L |
P02CA02
|
tiabendazole
|
WHO Anatomical Therapeutic Chemical classification |
|
tiabendazole |
| 0‑L |
P02CA03
|
albendazole
|
WHO Anatomical Therapeutic Chemical classification |
|
albendazole |
| 0‑L |
P02CA04
|
ciclobendazole
|
WHO Anatomical Therapeutic Chemical classification |
|
ciclobendazole |
| 0‑L |
P02CA05
|
flubendazole
|
WHO Anatomical Therapeutic Chemical classification |
|
flubendazole |
| 0‑L |
P02CA06
|
fenbendazole
|
WHO Anatomical Therapeutic Chemical classification |
|
fenbendazole |
| 0‑L |
P02CA51
|
mebendazole, combinations
|
WHO Anatomical Therapeutic Chemical classification |
|
mebendazole, combinations |
| 0‑L |
P02CB
|
Piperazine and derivatives
|
WHO Anatomical Therapeutic Chemical classification |
|
Piperazine and derivatives |
| 0‑L |
P02CB01
|
piperazine
|
WHO Anatomical Therapeutic Chemical classification |
|
piperazine |
| 0‑L |
P02CB02
|
diethylcarbamazine
|
WHO Anatomical Therapeutic Chemical classification |
|
diethylcarbamazine |
| 0‑L |
P02CC
|
Tetrahydropyrimidine derivatives
|
WHO Anatomical Therapeutic Chemical classification |
|
Tetrahydropyrimidine derivatives |
| 0‑L |
P02CC01
|
pyrantel
|
WHO Anatomical Therapeutic Chemical classification |
|
pyrantel |
| 0‑L |
P02CC02
|
oxantel
|
WHO Anatomical Therapeutic Chemical classification |
|
oxantel |
| 0‑L |
P02CE
|
Imidazothiazole derivatives
|
WHO Anatomical Therapeutic Chemical classification |
|
Imidazothiazole derivatives |
| 0‑L |
P02CE01
|
levamisole
|
WHO Anatomical Therapeutic Chemical classification |
|
levamisole |
| 0‑L |
P02CF
|
Avermectines
|
WHO Anatomical Therapeutic Chemical classification |
|
Avermectines |
| 0‑L |
P02CF01
|
ivermectin
|
WHO Anatomical Therapeutic Chemical classification |
|
ivermectin |
| 0‑L |
P02CX
|
Other antinematodals
|
WHO Anatomical Therapeutic Chemical classification |
|
Other antinematodals |
| 0‑L |
P02CX01
|
pyrvinium
|
WHO Anatomical Therapeutic Chemical classification |
|
pyrvinium |
| 0‑L |
P02CX02
|
bephenium
|
WHO Anatomical Therapeutic Chemical classification |
|
bephenium |
| 0‑L |
P02D
|
ANTICESTODALS
|
WHO Anatomical Therapeutic Chemical classification |
|
ANTICESTODALS |
| 0‑L |
P02DA
|
Salicylic acid derivatives
|
WHO Anatomical Therapeutic Chemical classification |
|
Salicylic acid derivatives |
| 0‑L |
P02DA01
|
niclosamide
|
WHO Anatomical Therapeutic Chemical classification |
|
niclosamide |
| 0‑L |
P02DX
|
Other anticestodals
|
WHO Anatomical Therapeutic Chemical classification |
|
Other anticestodals |
| 0‑L |
P02DX01
|
desaspidin
|
WHO Anatomical Therapeutic Chemical classification |
|
desaspidin |
| 0‑L |
P02DX02
|
dichlorophen
|
WHO Anatomical Therapeutic Chemical classification |
|
dichlorophen |
| 0‑L |
P03
|
ECTOPARASITICIDES, INCL. SCABICIDES, INSECTICIDES AND REPELLENTS
|
WHO Anatomical Therapeutic Chemical classification |
|
ECTOPARASITICIDES, INCL. SCABICIDES, INSECTICIDES AND REPELLENTS |
| 0‑L |
P03A
|
ECTOPARASITICIDES, INCL. SCABICIDES
|
WHO Anatomical Therapeutic Chemical classification |
|
ECTOPARASITICIDES, INCL. SCABICIDES |
| 0‑L |
P03AA
|
Sulfur containing products
|
WHO Anatomical Therapeutic Chemical classification |
|
Sulfur containing products |
| 0‑L |
P03AA01
|
dixanthogen
|
WHO Anatomical Therapeutic Chemical classification |
|
dixanthogen |
| 0‑L |
P03AA02
|
potassium polysulfide
|
WHO Anatomical Therapeutic Chemical classification |
|
potassium polysulfide |
| 0‑L |
P03AA03
|
mesulfen
|
WHO Anatomical Therapeutic Chemical classification |
|
mesulfen |
| 0‑L |
P03AA04
|
disulfiram
|
WHO Anatomical Therapeutic Chemical classification |
|
disulfiram |
| 0‑L |
P03AA05
|
thiram
|
WHO Anatomical Therapeutic Chemical classification |
|
thiram |
| 0‑L |
P03AA54
|
disulfiram, combinations
|
WHO Anatomical Therapeutic Chemical classification |
|
disulfiram, combinations |
| 0‑L |
P03AB
|
Chlorine containing products
|
WHO Anatomical Therapeutic Chemical classification |
|
Chlorine containing products |
| 0‑L |
P03AB01
|
clofenotane
|
WHO Anatomical Therapeutic Chemical classification |
|
clofenotane |
| 0‑L |
P03AB02
|
lindane
|
WHO Anatomical Therapeutic Chemical classification |
|
lindane |
| 0‑L |
P03AB51
|
clofenotane, combinations
|
WHO Anatomical Therapeutic Chemical classification |
|
clofenotane, combinations |
| 0‑L |
P03AC
|
Pyrethrines, incl. synthetic compounds
|
WHO Anatomical Therapeutic Chemical classification |
|
Pyrethrines, incl. synthetic compounds |
| 0‑L |
P03AC01
|
pyrethrum
|
WHO Anatomical Therapeutic Chemical classification |
|
pyrethrum |
| 0‑L |
P03AC02
|
bioallethrin
|
WHO Anatomical Therapeutic Chemical classification |
|
bioallethrin |
| 0‑L |
P03AC03
|
phenothrin
|
WHO Anatomical Therapeutic Chemical classification |
|
phenothrin |
| 0‑L |
P03AC04
|
permethrin
|
WHO Anatomical Therapeutic Chemical classification |
|
permethrin |
| 0‑L |
P03AC51
|
pyrethrum, combinations
|
WHO Anatomical Therapeutic Chemical classification |
|
pyrethrum, combinations |
| 0‑L |
P03AC52
|
bioallethrin, combinations
|
WHO Anatomical Therapeutic Chemical classification |
|
bioallethrin, combinations |
| 0‑L |
P03AC53
|
phenothrin, combinations
|
WHO Anatomical Therapeutic Chemical classification |
|
phenothrin, combinations |
| 0‑L |
P03AC54
|
permethrin, combinations
|
WHO Anatomical Therapeutic Chemical classification |
|
permethrin, combinations |
| 0‑L |
P03AX
|
Other ectoparasiticides, incl. scabicides
|
WHO Anatomical Therapeutic Chemical classification |
|
Other ectoparasiticides, incl. scabicides |
| 0‑L |
P03AX01
|
benzyl benzoate
|
WHO Anatomical Therapeutic Chemical classification |
|
benzyl benzoate |
| 0‑L |
P03AX02
|
copper oleinate
|
WHO Anatomical Therapeutic Chemical classification |
|
copper oleinate |
| 0‑L |
P03AX03
|
malathion
|
WHO Anatomical Therapeutic Chemical classification |
|
malathion |
| 0‑L |
P03AX04
|
quassia
|
WHO Anatomical Therapeutic Chemical classification |
|
quassia |
| 0‑L |
P03AX05
|
dimeticone
|
WHO Anatomical Therapeutic Chemical classification |
|
dimeticone |
| 0‑L |
P03AX06
|
benzyl alcohol
|
WHO Anatomical Therapeutic Chemical classification |
|
benzyl alcohol |
| 0‑L |
P03B
|
INSECTICIDES AND REPELLENTS
|
WHO Anatomical Therapeutic Chemical classification |
|
INSECTICIDES AND REPELLENTS |
| 0‑L |
P03BA
|
Pyrethrines
|
WHO Anatomical Therapeutic Chemical classification |
|
Pyrethrines |
| 0‑L |
P03BA01
|
cyfluthrin
|
WHO Anatomical Therapeutic Chemical classification |
|
cyfluthrin |
| 0‑L |
P03BA02
|
cypermethrin
|
WHO Anatomical Therapeutic Chemical classification |
|
cypermethrin |
| 0‑L |
P03BA03
|
decamethrin
|
WHO Anatomical Therapeutic Chemical classification |
|
decamethrin |
| 0‑L |
P03BA04
|
tetramethrin
|
WHO Anatomical Therapeutic Chemical classification |
|
tetramethrin |
| 0‑L |
P03BX
|
Other insecticides and repellents
|
WHO Anatomical Therapeutic Chemical classification |
|
Other insecticides and repellents |
| 0‑L |
P03BX01
|
diethyltoluamide
|
WHO Anatomical Therapeutic Chemical classification |
|
diethyltoluamide |
| 0‑L |
P03BX02
|
dimethylphthalate
|
WHO Anatomical Therapeutic Chemical classification |
|
dimethylphthalate |
| 0‑L |
P03BX03
|
dibutylphthalate
|
WHO Anatomical Therapeutic Chemical classification |
|
dibutylphthalate |
| 0‑L |
P03BX04
|
dibutylsuccinate
|
WHO Anatomical Therapeutic Chemical classification |
|
dibutylsuccinate |
| 0‑L |
P03BX05
|
dimethylcarbate
|
WHO Anatomical Therapeutic Chemical classification |
|
dimethylcarbate |
| 0‑L |
P03BX06
|
etohexadiol
|
WHO Anatomical Therapeutic Chemical classification |
|
etohexadiol |
| 0‑L |
R
|
RESPIRATORY SYSTEM
|
WHO Anatomical Therapeutic Chemical classification |
|
RESPIRATORY SYSTEM |
| 0‑L |
R01
|
NASAL PREPARATIONS
|
WHO Anatomical Therapeutic Chemical classification |
|
NASAL PREPARATIONS |
| 0‑L |
R01A
|
DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE
|
WHO Anatomical Therapeutic Chemical classification |
|
DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE |
| 0‑L |
R01AA
|
Sympathomimetics, plain
|
WHO Anatomical Therapeutic Chemical classification |
|
Sympathomimetics, plain |
| 0‑L |
R01AA02
|
cyclopentamine
|
WHO Anatomical Therapeutic Chemical classification |
|
cyclopentamine |
| 0‑L |
R01AA03
|
ephedrine
|
WHO Anatomical Therapeutic Chemical classification |
|
ephedrine |
| 0‑L |
R01AA04
|
phenylephrine
|
WHO Anatomical Therapeutic Chemical classification |
|
phenylephrine |
| 0‑L |
R01AA05
|
oxymetazoline
|
WHO Anatomical Therapeutic Chemical classification |
|
oxymetazoline |
| 0‑L |
R01AA06
|
tetryzoline
|
WHO Anatomical Therapeutic Chemical classification |
|
tetryzoline |
| 0‑L |
R01AA07
|
xylometazoline
|
WHO Anatomical Therapeutic Chemical classification |
|
xylometazoline |
| 0‑L |
R01AA08
|
naphazoline
|
WHO Anatomical Therapeutic Chemical classification |
|
naphazoline |
| 0‑L |
R01AA09
|
tramazoline
|
WHO Anatomical Therapeutic Chemical classification |
|
tramazoline |
| 0‑L |
R01AA10
|
metizoline
|
WHO Anatomical Therapeutic Chemical classification |
|
metizoline |
| 0‑L |
R01AA11
|
tuaminoheptane
|
WHO Anatomical Therapeutic Chemical classification |
|
tuaminoheptane |
| 0‑L |
R01AA12
|
fenoxazoline
|
WHO Anatomical Therapeutic Chemical classification |
|
fenoxazoline |
| 0‑L |
R01AA13
|
tymazoline
|
WHO Anatomical Therapeutic Chemical classification |
|
tymazoline |
| 0‑L |
R01AA14
|
epinephrine
|
WHO Anatomical Therapeutic Chemical classification |
|
epinephrine |
| 0‑L |
R01AA15
|
indanazoline
|
WHO Anatomical Therapeutic Chemical classification |
|
indanazoline |
| 0‑L |
R01AB
|
Sympathomimetics, combinations excl. corticosteroids
|
WHO Anatomical Therapeutic Chemical classification |
|
Sympathomimetics, combinations excl. corticosteroids |
| 0‑L |
R01AB01
|
phenylephrine
|
WHO Anatomical Therapeutic Chemical classification |
|
phenylephrine |
| 0‑L |
R01AB02
|
naphazoline
|
WHO Anatomical Therapeutic Chemical classification |
|
naphazoline |
| 0‑L |
R01AB03
|
tetryzoline
|
WHO Anatomical Therapeutic Chemical classification |
|
tetryzoline |
| 0‑L |
R01AB05
|
ephedrine
|
WHO Anatomical Therapeutic Chemical classification |
|
ephedrine |
| 0‑L |
R01AB06
|
xylometazoline
|
WHO Anatomical Therapeutic Chemical classification |
|
xylometazoline |
| 0‑L |
R01AB07
|
oxymetazoline
|
WHO Anatomical Therapeutic Chemical classification |
|
oxymetazoline |
| 0‑L |
R01AB08
|
tuaminoheptane
|
WHO Anatomical Therapeutic Chemical classification |
|
tuaminoheptane |
| 0‑L |
R01AC
|
Antiallergic agents, excl. corticosteroids
|
WHO Anatomical Therapeutic Chemical classification |
|
Antiallergic agents, excl. corticosteroids |
| 0‑L |
R01AC01
|
cromoglicic acid
|
WHO Anatomical Therapeutic Chemical classification |
|
cromoglicic acid |
| 0‑L |
R01AC02
|
levocabastine
|
WHO Anatomical Therapeutic Chemical classification |
|
levocabastine |
| 0‑L |
R01AC03
|
azelastine
|
WHO Anatomical Therapeutic Chemical classification |
|
azelastine |
| 0‑L |
R01AC04
|
antazoline
|
WHO Anatomical Therapeutic Chemical classification |
|
antazoline |
| 0‑L |
R01AC05
|
spaglumic acid
|
WHO Anatomical Therapeutic Chemical classification |
|
spaglumic acid |
| 0‑L |
R01AC06
|
thonzylamine
|
WHO Anatomical Therapeutic Chemical classification |
|
thonzylamine |
| 0‑L |
R01AC07
|
nedocromil
|
WHO Anatomical Therapeutic Chemical classification |
|
nedocromil |
| 0‑L |
R01AC08
|
olopatadine
|
WHO Anatomical Therapeutic Chemical classification |
|
olopatadine |
| 0‑L |
R01AC51
|
cromoglicic acid, combinations
|
WHO Anatomical Therapeutic Chemical classification |
|
cromoglicic acid, combinations |
| 0‑L |
R01AD
|
Corticosteroids
|
WHO Anatomical Therapeutic Chemical classification |
|
Corticosteroids |
| 0‑L |
R01AD01
|
beclometasone
|
WHO Anatomical Therapeutic Chemical classification |
|
beclometasone |
| 0‑L |
R01AD02
|
prednisolone
|
WHO Anatomical Therapeutic Chemical classification |
|
prednisolone |
| 0‑L |
R01AD03
|
dexamethasone
|
WHO Anatomical Therapeutic Chemical classification |
|
dexamethasone |
| 0‑L |
R01AD04
|
flunisolide
|
WHO Anatomical Therapeutic Chemical classification |
|
flunisolide |
| 0‑L |
R01AD05
|
budesonide
|
WHO Anatomical Therapeutic Chemical classification |
|
budesonide |
| 0‑L |
R01AD06
|
betamethasone
|
WHO Anatomical Therapeutic Chemical classification |
|
betamethasone |
| 0‑L |
R01AD07
|
tixocortol
|
WHO Anatomical Therapeutic Chemical classification |
|
tixocortol |
| 0‑L |
R01AD08
|
fluticasone
|
WHO Anatomical Therapeutic Chemical classification |
|
fluticasone |
| 0‑L |
R01AD09
|
mometasone
|
WHO Anatomical Therapeutic Chemical classification |
|
mometasone |
| 0‑L |
R01AD11
|
triamcinolone
|
WHO Anatomical Therapeutic Chemical classification |
|
triamcinolone |
| 0‑L |
R01AD12
|
fluticasone furoate
|
WHO Anatomical Therapeutic Chemical classification |
|
fluticasone furoate |
| 0‑L |
R01AD13
|
ciclesonide
|
WHO Anatomical Therapeutic Chemical classification |
|
ciclesonide |
| 0‑L |
R01AD52
|
prednisolone, combinations
|
WHO Anatomical Therapeutic Chemical classification |
|
prednisolone, combinations |
| 0‑L |
R01AD53
|
dexamethasone, combinations
|
WHO Anatomical Therapeutic Chemical classification |
|
dexamethasone, combinations |
| 0‑L |
R01AD57
|
tixocortol, combinations
|
WHO Anatomical Therapeutic Chemical classification |
|
tixocortol, combinations |
| 0‑L |
R01AD58
|
fluticasone, combinations
|
WHO Anatomical Therapeutic Chemical classification |
|
fluticasone, combinations |
| 0‑L |
R01AD60
|
hydrocortisone, combinations
|
WHO Anatomical Therapeutic Chemical classification |
|
hydrocortisone, combinations |
| 0‑L |
R01AX
|
Other nasal preparations
|
WHO Anatomical Therapeutic Chemical classification |
|
Other nasal preparations |
| 0‑L |
R01AX01
|
calcium hexamine thiocyanate
|
WHO Anatomical Therapeutic Chemical classification |
|
calcium hexamine thiocyanate |
| 0‑L |
R01AX02
|
retinol
|
WHO Anatomical Therapeutic Chemical classification |
|
retinol |
| 0‑L |
R01AX03
|
ipratropium bromide
|
WHO Anatomical Therapeutic Chemical classification |
|
ipratropium bromide |
| 0‑L |
R01AX05
|
ritiometan
|
WHO Anatomical Therapeutic Chemical classification |
|
ritiometan |
| 0‑L |
R01AX06
|
mupirocin
|
WHO Anatomical Therapeutic Chemical classification |
|
mupirocin |
| 0‑L |
R01AX07
|
hexamidine
|
WHO Anatomical Therapeutic Chemical classification |
|
hexamidine |
| 0‑L |
R01AX08
|
framycetin
|
WHO Anatomical Therapeutic Chemical classification |
|
framycetin |
| 0‑L |
R01AX09
|
hyaluronic acid
|
WHO Anatomical Therapeutic Chemical classification |
|
hyaluronic acid |
| 0‑L |
R01AX10
|
various
|
WHO Anatomical Therapeutic Chemical classification |
|
various |
| 0‑L |
R01AX30
|
combinations
|
WHO Anatomical Therapeutic Chemical classification |
|
combinations |
| 0‑L |
R01B
|
NASAL DECONGESTANTS FOR SYSTEMIC USE
|
WHO Anatomical Therapeutic Chemical classification |
|
NASAL DECONGESTANTS FOR SYSTEMIC USE |
| 0‑L |
R01BA
|
Sympathomimetics
|
WHO Anatomical Therapeutic Chemical classification |
|
Sympathomimetics |
| 0‑L |
R01BA01
|
phenylpropanolamine
|
WHO Anatomical Therapeutic Chemical classification |
|
phenylpropanolamine |
| 0‑L |
R01BA02
|
pseudoephedrine
|
WHO Anatomical Therapeutic Chemical classification |
|
pseudoephedrine |
| 0‑L |
R01BA03
|
phenylephrine
|
WHO Anatomical Therapeutic Chemical classification |
|
phenylephrine |
| 0‑L |
R01BA51
|
phenylpropanolamine, combinations
|
WHO Anatomical Therapeutic Chemical classification |
|
phenylpropanolamine, combinations |
| 0‑L |
R01BA52
|
pseudoephedrine, combinations
|
WHO Anatomical Therapeutic Chemical classification |
|
pseudoephedrine, combinations |
| 0‑L |
R01BA53
|
phenylephrine, combinations
|
WHO Anatomical Therapeutic Chemical classification |
|
phenylephrine, combinations |
| 0‑L |
R02
|
THROAT PREPARATIONS
|
WHO Anatomical Therapeutic Chemical classification |
|
THROAT PREPARATIONS |
| 0‑L |
R02A
|
THROAT PREPARATIONS
|
WHO Anatomical Therapeutic Chemical classification |
|
THROAT PREPARATIONS |
| 0‑L |
R02AA
|
Antiseptics
|
WHO Anatomical Therapeutic Chemical classification |
|
Antiseptics |
| 0‑L |
R02AA01
|
ambazone
|
WHO Anatomical Therapeutic Chemical classification |
|
ambazone |
| 0‑L |
R02AA02
|
dequalinium
|
WHO Anatomical Therapeutic Chemical classification |
|
dequalinium |
| 0‑L |
R02AA03
|
dichlorobenzyl alcohol
|
WHO Anatomical Therapeutic Chemical classification |
|
dichlorobenzyl alcohol |
| 0‑L |
R02AA05
|
chlorhexidine
|
WHO Anatomical Therapeutic Chemical classification |
|
chlorhexidine |
| 0‑L |
R02AA06
|
cetylpyridinium
|
WHO Anatomical Therapeutic Chemical classification |
|
cetylpyridinium |
| 0‑L |
R02AA09
|
benzethonium
|
WHO Anatomical Therapeutic Chemical classification |
|
benzethonium |
| 0‑L |
R02AA10
|
myristyl-benzalkonium
|
WHO Anatomical Therapeutic Chemical classification |
|
myristyl-benzalkonium |
| 0‑L |
R02AA11
|
chlorquinaldol
|
WHO Anatomical Therapeutic Chemical classification |
|
chlorquinaldol |
| 0‑L |
R02AA12
|
hexylresorcinol
|
WHO Anatomical Therapeutic Chemical classification |
|
hexylresorcinol |
| 0‑L |
R02AA13
|
acriflavinium chloride
|
WHO Anatomical Therapeutic Chemical classification |
|
acriflavinium chloride |
| 0‑L |
R02AA14
|
oxyquinoline
|
WHO Anatomical Therapeutic Chemical classification |
|
oxyquinoline |
| 0‑L |
R02AA15
|
povidone-iodine
|
WHO Anatomical Therapeutic Chemical classification |
|
povidone-iodine |
| 0‑L |
R02AA16
|
benzalkonium
|
WHO Anatomical Therapeutic Chemical classification |
|
benzalkonium |
| 0‑L |
R02AA17
|
cetrimonium
|
WHO Anatomical Therapeutic Chemical classification |
|
cetrimonium |
| 0‑L |
R02AA18
|
hexamidine
|
WHO Anatomical Therapeutic Chemical classification |
|
hexamidine |
| 0‑L |
R02AA19
|
phenol
|
WHO Anatomical Therapeutic Chemical classification |
|
phenol |
| 0‑L |
R02AA20
|
various
|
WHO Anatomical Therapeutic Chemical classification |
|
various |
| 0‑L |
R02AA21
|
octenidine
|
WHO Anatomical Therapeutic Chemical classification |
|
octenidine |
| 0‑L |
R02AB
|
Antibiotics
|
WHO Anatomical Therapeutic Chemical classification |
|
Antibiotics |
| 0‑L |
R02AB01
|
neomycin
|
WHO Anatomical Therapeutic Chemical classification |
|
neomycin |
| 0‑L |
R02AB02
|
tyrothricin
|
WHO Anatomical Therapeutic Chemical classification |
|
tyrothricin |
| 0‑L |
R02AB03
|
fusafungine
|
WHO Anatomical Therapeutic Chemical classification |
|
fusafungine |
| 0‑L |
R02AB04
|
bacitracin
|
WHO Anatomical Therapeutic Chemical classification |
|
bacitracin |
| 0‑L |
R02AB30
|
gramicidin
|
WHO Anatomical Therapeutic Chemical classification |
|
gramicidin |
| 0‑L |
R02AD
|
Anesthetics, local
|
WHO Anatomical Therapeutic Chemical classification |
|
Anesthetics, local |
| 0‑L |
R02AD01
|
benzocaine
|
WHO Anatomical Therapeutic Chemical classification |
|
benzocaine |
| 0‑L |
R02AD02
|
lidocaine
|
WHO Anatomical Therapeutic Chemical classification |
|
lidocaine |
| 0‑L |
R02AD03
|
cocaine
|
WHO Anatomical Therapeutic Chemical classification |
|
cocaine |
| 0‑L |
R02AD04
|
dyclonine
|
WHO Anatomical Therapeutic Chemical classification |
|
dyclonine |
| 0‑L |
R02AX
|
Other throat preparations
|
WHO Anatomical Therapeutic Chemical classification |
|
Other throat preparations |
| 0‑L |
R02AX01
|
flurbiprofen
|
WHO Anatomical Therapeutic Chemical classification |
|
flurbiprofen |
| 0‑L |
R02AX02
|
ibuprofen
|
WHO Anatomical Therapeutic Chemical classification |
|
ibuprofen |
| 0‑L |
R03
|
DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES
|
WHO Anatomical Therapeutic Chemical classification |
|
DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES |
| 0‑L |
R03A
|
ADRENERGICS, INHALANTS
|
WHO Anatomical Therapeutic Chemical classification |
|
ADRENERGICS, INHALANTS |
| 0‑L |
R03AA
|
Alpha- and beta-adrenoreceptor agonists
|
WHO Anatomical Therapeutic Chemical classification |
|
Alpha- and beta-adrenoreceptor agonists |
| 0‑L |
R03AA01
|
epinephrine
|
WHO Anatomical Therapeutic Chemical classification |
|
epinephrine |
| 0‑L |
R03AB
|
Non-selective beta-adrenoreceptor agonists
|
WHO Anatomical Therapeutic Chemical classification |
|
Non-selective beta-adrenoreceptor agonists |
| 0‑L |
R03AB02
|
isoprenaline
|
WHO Anatomical Therapeutic Chemical classification |
|
isoprenaline |
| 0‑L |
R03AB03
|
orciprenaline
|
WHO Anatomical Therapeutic Chemical classification |
|
orciprenaline |
| 0‑L |
R03AC
|
Selective beta-2-adrenoreceptor agonists
|
WHO Anatomical Therapeutic Chemical classification |
|
Selective beta-2-adrenoreceptor agonists |
| 0‑L |
R03AC02
|
salbutamol
|
WHO Anatomical Therapeutic Chemical classification |
|
salbutamol |
| 0‑L |
R03AC03
|
terbutaline
|
WHO Anatomical Therapeutic Chemical classification |
|
terbutaline |
| 0‑L |
R03AC04
|
fenoterol
|
WHO Anatomical Therapeutic Chemical classification |
|
fenoterol |
| 0‑L |
R03AC05
|
rimiterol
|
WHO Anatomical Therapeutic Chemical classification |
|
rimiterol |
| 0‑L |
R03AC06
|
hexoprenaline
|
WHO Anatomical Therapeutic Chemical classification |
|
hexoprenaline |
| 0‑L |
R03AC07
|
isoetarine
|
WHO Anatomical Therapeutic Chemical classification |
|
isoetarine |
| 0‑L |
R03AC08
|
pirbuterol
|
WHO Anatomical Therapeutic Chemical classification |
|
pirbuterol |
| 0‑L |
R03AC09
|
tretoquinol
|
WHO Anatomical Therapeutic Chemical classification |
|
tretoquinol |
| 0‑L |
R03AC10
|
carbuterol
|
WHO Anatomical Therapeutic Chemical classification |
|
carbuterol |
| 0‑L |
R03AC11
|
tulobuterol
|
WHO Anatomical Therapeutic Chemical classification |
|
tulobuterol |
| 0‑L |
R03AC12
|
salmeterol
|
WHO Anatomical Therapeutic Chemical classification |
|
salmeterol |
| 0‑L |
R03AC13
|
formoterol
|
WHO Anatomical Therapeutic Chemical classification |
|
formoterol |
| 0‑L |
R03AC14
|
clenbuterol
|
WHO Anatomical Therapeutic Chemical classification |
|
clenbuterol |
| 0‑L |
R03AC15
|
reproterol
|
WHO Anatomical Therapeutic Chemical classification |
|
reproterol |
| 0‑L |
R03AC16
|
procaterol
|
WHO Anatomical Therapeutic Chemical classification |
|
procaterol |
| 0‑L |
R03AC17
|
bitolterol
|
WHO Anatomical Therapeutic Chemical classification |
|
bitolterol |
| 0‑L |
R03AC18
|
indacaterol
|
WHO Anatomical Therapeutic Chemical classification |
|
indacaterol |
| 0‑L |
R03AC19
|
olodaterol
|
WHO Anatomical Therapeutic Chemical classification |
|
olodaterol |
| 0‑L |
R03AH
|
Combinations of adrenergics
|
WHO Anatomical Therapeutic Chemical classification |
|
Combinations of adrenergics |
| 0‑L |
R03AK
|
Adrenergics in combination with corticosteroids or other drugs, excl. anticholinergics
|
WHO Anatomical Therapeutic Chemical classification |
|
Adrenergics in combination with corticosteroids or other drugs, excl. anticholinergics |
| 0‑L |
R03AK01
|
epinephrine and other drugs for obstructive airway diseases
|
WHO Anatomical Therapeutic Chemical classification |
|
epinephrine and other drugs for obstructive airway diseases |
| 0‑L |
R03AK02
|
isoprenaline and other drugs for obstructive airway diseases
|
WHO Anatomical Therapeutic Chemical classification |
|
isoprenaline and other drugs for obstructive airway diseases |
| 0‑L |
R03AK04
|
salbutamol and sodium cromoglicate
|
WHO Anatomical Therapeutic Chemical classification |
|
salbutamol and sodium cromoglicate |
| 0‑L |
R03AK05
|
reproterol and sodium cromoglicate
|
WHO Anatomical Therapeutic Chemical classification |
|
reproterol and sodium cromoglicate |
| 0‑L |
R03AK06
|
salmeterol and fluticasone
|
WHO Anatomical Therapeutic Chemical classification |
|
salmeterol and fluticasone |
| 0‑L |
R03AK07
|
formoterol and budesonide
|
WHO Anatomical Therapeutic Chemical classification |
|
formoterol and budesonide |
| 0‑L |
R03AK08
|
formoterol and beclometasone
|
WHO Anatomical Therapeutic Chemical classification |
|
formoterol and beclometasone |
| 0‑L |
R03AK09
|
formoterol and mometasone
|
WHO Anatomical Therapeutic Chemical classification |
|
formoterol and mometasone |
| 0‑L |
R03AK10
|
vilanterol and fluticasone furoate
|
WHO Anatomical Therapeutic Chemical classification |
|
vilanterol and fluticasone furoate |
| 0‑L |
R03AK11
|
formoterol and fluticasone
|
WHO Anatomical Therapeutic Chemical classification |
|
formoterol and fluticasone |
| 0‑L |
R03AK12
|
salmeterol and budesonide
|
WHO Anatomical Therapeutic Chemical classification |
|
salmeterol and budesonide |
| 0‑L |
R03AK13
|
salbutamol and beclometasone
|
WHO Anatomical Therapeutic Chemical classification |
|
salbutamol and beclometasone |
| 0‑L |
R03AL
|
Adrenergics in combination with anticholinergics
|
WHO Anatomical Therapeutic Chemical classification |
|
Adrenergics in combination with anticholinergics |
| 0‑L |
R03AL01
|
fenoterol and ipratropium bromide
|
WHO Anatomical Therapeutic Chemical classification |
|
fenoterol and ipratropium bromide |
| 0‑L |
R03AL02
|
salbutamol and ipratropium bromide
|
WHO Anatomical Therapeutic Chemical classification |
|
salbutamol and ipratropium bromide |
| 0‑L |
R03AL03
|
vilanterol and umeclidinium bromide
|
WHO Anatomical Therapeutic Chemical classification |
|
vilanterol and umeclidinium bromide |
| 0‑L |
R03AL04
|
indacaterol and glycopyrronium bromide
|
WHO Anatomical Therapeutic Chemical classification |
|
indacaterol and glycopyrronium bromide |
| 0‑L |
R03AL05
|
formoterol and aclidinium bromide
|
WHO Anatomical Therapeutic Chemical classification |
|
formoterol and aclidinium bromide |
| 0‑L |
R03AL06
|
olodaterol and tiotropium bromide
|
WHO Anatomical Therapeutic Chemical classification |
|
olodaterol and tiotropium bromide |
| 0‑L |
R03AL07
|
formoterol and glycopyrronium bromide
|
WHO Anatomical Therapeutic Chemical classification |
|
formoterol and glycopyrronium bromide |
| 0‑L |
R03B
|
OTHER DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES, INHALANTS
|
WHO Anatomical Therapeutic Chemical classification |
|
OTHER DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES, INHALANTS |
| 0‑L |
R03BA
|
Glucocorticoids
|
WHO Anatomical Therapeutic Chemical classification |
|
Glucocorticoids |
| 0‑L |
R03BA01
|
beclometasone
|
WHO Anatomical Therapeutic Chemical classification |
|
beclometasone |
| 0‑L |
R03BA02
|
budesonide
|
WHO Anatomical Therapeutic Chemical classification |
|
budesonide |
| 0‑L |
R03BA03
|
flunisolide
|
WHO Anatomical Therapeutic Chemical classification |
|
flunisolide |
| 0‑L |
R03BA04
|
betamethasone
|
WHO Anatomical Therapeutic Chemical classification |
|
betamethasone |
| 0‑L |
R03BA05
|
fluticasone
|
WHO Anatomical Therapeutic Chemical classification |
|
fluticasone |
| 0‑L |
R03BA06
|
triamcinolone
|
WHO Anatomical Therapeutic Chemical classification |
|
triamcinolone |
| 0‑L |
R03BA07
|
mometasone
|
WHO Anatomical Therapeutic Chemical classification |
|
mometasone |
| 0‑L |
R03BA08
|
ciclesonide
|
WHO Anatomical Therapeutic Chemical classification |
|
ciclesonide |
| 0‑L |
R03BA09
|
fluticasone furoate
|
WHO Anatomical Therapeutic Chemical classification |
|
fluticasone furoate |
| 0‑L |
R03BB
|
Anticholinergics
|
WHO Anatomical Therapeutic Chemical classification |
|
Anticholinergics |
| 0‑L |
R03BB01
|
ipratropium bromide
|
WHO Anatomical Therapeutic Chemical classification |
|
ipratropium bromide |
| 0‑L |
R03BB02
|
oxitropium bromide
|
WHO Anatomical Therapeutic Chemical classification |
|
oxitropium bromide |
| 0‑L |
R03BB03
|
stramoni preparations
|
WHO Anatomical Therapeutic Chemical classification |
|
stramoni preparations |
| 0‑L |
R03BB04
|
tiotropium bromide
|
WHO Anatomical Therapeutic Chemical classification |
|
tiotropium bromide |
| 0‑L |
R03BB05
|
aclidinium bromide
|
WHO Anatomical Therapeutic Chemical classification |
|
aclidinium bromide |
| 0‑L |
R03BB06
|
glycopyrronium bromide
|
WHO Anatomical Therapeutic Chemical classification |
|
glycopyrronium bromide |
| 0‑L |
R03BB07
|
umeclidinium bromide
|
WHO Anatomical Therapeutic Chemical classification |
|
umeclidinium bromide |
| 0‑L |
R03BB54
|
tiotropium bromide, combinations
|
WHO Anatomical Therapeutic Chemical classification |
|
tiotropium bromide, combinations |
| 0‑L |
R03BC
|
Antiallergic agents, excl. corticosteroids
|
WHO Anatomical Therapeutic Chemical classification |
|
Antiallergic agents, excl. corticosteroids |
| 0‑L |
R03BC01
|
cromoglicic acid
|
WHO Anatomical Therapeutic Chemical classification |
|
cromoglicic acid |
| 0‑L |
R03BC03
|
nedocromil
|
WHO Anatomical Therapeutic Chemical classification |
|
nedocromil |
| 0‑L |
R03BX
|
Other drugs for obstructive airway diseases, inhalants
|
WHO Anatomical Therapeutic Chemical classification |
|
Other drugs for obstructive airway diseases, inhalants |
| 0‑L |
R03BX01
|
fenspiride
|
WHO Anatomical Therapeutic Chemical classification |
|
fenspiride |
| 0‑L |
R03C
|
ADRENERGICS FOR SYSTEMIC USE
|
WHO Anatomical Therapeutic Chemical classification |
|
ADRENERGICS FOR SYSTEMIC USE |
| 0‑L |
R03CA
|
Alpha- and beta-adrenoreceptor agonists
|
WHO Anatomical Therapeutic Chemical classification |
|
Alpha- and beta-adrenoreceptor agonists |
| 0‑L |
R03CA02
|
ephedrine
|
WHO Anatomical Therapeutic Chemical classification |
|
ephedrine |
| 0‑L |
R03CB
|
Non-selective beta-adrenoreceptor agonists
|
WHO Anatomical Therapeutic Chemical classification |
|
Non-selective beta-adrenoreceptor agonists |
| 0‑L |
R03CB01
|
isoprenaline
|
WHO Anatomical Therapeutic Chemical classification |
|
isoprenaline |
| 0‑L |
R03CB02
|
methoxyphenamine
|
WHO Anatomical Therapeutic Chemical classification |
|
methoxyphenamine |
| 0‑L |
R03CB03
|
orciprenaline
|
WHO Anatomical Therapeutic Chemical classification |
|
orciprenaline |
| 0‑L |
R03CB51
|
isoprenaline, combinations
|
WHO Anatomical Therapeutic Chemical classification |
|
isoprenaline, combinations |
| 0‑L |
R03CB53
|
orciprenaline, combinations
|
WHO Anatomical Therapeutic Chemical classification |
|
orciprenaline, combinations |
| 0‑L |
R03CC
|
Selective beta-2-adrenoreceptor agonists
|
WHO Anatomical Therapeutic Chemical classification |
|
Selective beta-2-adrenoreceptor agonists |
| 0‑L |
R03CC02
|
salbutamol
|
WHO Anatomical Therapeutic Chemical classification |
|
salbutamol |
| 0‑L |
R03CC03
|
terbutaline
|
WHO Anatomical Therapeutic Chemical classification |
|
terbutaline |
| 0‑L |
R03CC04
|
fenoterol
|
WHO Anatomical Therapeutic Chemical classification |
|
fenoterol |
| 0‑L |
R03CC05
|
hexoprenaline
|
WHO Anatomical Therapeutic Chemical classification |
|
hexoprenaline |
| 0‑L |
R03CC06
|
isoetarine
|
WHO Anatomical Therapeutic Chemical classification |
|
isoetarine |
| 0‑L |
R03CC07
|
pirbuterol
|
WHO Anatomical Therapeutic Chemical classification |
|
pirbuterol |
| 0‑L |
R03CC08
|
procaterol
|
WHO Anatomical Therapeutic Chemical classification |
|
procaterol |
| 0‑L |
R03CC09
|
tretoquinol
|
WHO Anatomical Therapeutic Chemical classification |
|
tretoquinol |
| 0‑L |
R03CC10
|
carbuterol
|
WHO Anatomical Therapeutic Chemical classification |
|
carbuterol |
| 0‑L |
R03CC11
|
tulobuterol
|
WHO Anatomical Therapeutic Chemical classification |
|
tulobuterol |
| 0‑L |
R03CC12
|
bambuterol
|
WHO Anatomical Therapeutic Chemical classification |
|
bambuterol |
| 0‑L |
R03CC13
|
clenbuterol
|
WHO Anatomical Therapeutic Chemical classification |
|
clenbuterol |
| 0‑L |
R03CC14
|
reproterol
|
WHO Anatomical Therapeutic Chemical classification |
|
reproterol |
| 0‑L |
R03CC53
|
terbutaline, combinations
|
WHO Anatomical Therapeutic Chemical classification |
|
terbutaline, combinations |
| 0‑L |
R03CK
|
Adrenergics and other drugs for obstructive airway diseases
|
WHO Anatomical Therapeutic Chemical classification |
|
Adrenergics and other drugs for obstructive airway diseases |
| 0‑L |
R03D
|
OTHER SYSTEMIC DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES
|
WHO Anatomical Therapeutic Chemical classification |
|
OTHER SYSTEMIC DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES |
| 0‑L |
R03DA
|
Xanthines
|
WHO Anatomical Therapeutic Chemical classification |
|
Xanthines |
| 0‑L |
R03DA01
|
diprophylline
|
WHO Anatomical Therapeutic Chemical classification |
|
diprophylline |
| 0‑L |
R03DA02
|
choline theophyllinate
|
WHO Anatomical Therapeutic Chemical classification |
|
choline theophyllinate |
| 0‑L |
R03DA03
|
proxyphylline
|
WHO Anatomical Therapeutic Chemical classification |
|
proxyphylline |
| 0‑L |
R03DA04
|
theophylline
|
WHO Anatomical Therapeutic Chemical classification |
|
theophylline |
| 0‑L |
R03DA05
|
aminophylline
|
WHO Anatomical Therapeutic Chemical classification |
|
aminophylline |
| 0‑L |
R03DA06
|
etamiphylline
|
WHO Anatomical Therapeutic Chemical classification |
|
etamiphylline |
| 0‑L |
R03DA07
|
theobromine
|
WHO Anatomical Therapeutic Chemical classification |
|
theobromine |
| 0‑L |
R03DA08
|
bamifylline
|
WHO Anatomical Therapeutic Chemical classification |
|
bamifylline |
| 0‑L |
R03DA09
|
acefylline piperazine
|
WHO Anatomical Therapeutic Chemical classification |
|
acefylline piperazine |
| 0‑L |
R03DA10
|
bufylline
|
WHO Anatomical Therapeutic Chemical classification |
|
bufylline |
| 0‑L |
R03DA11
|
doxofylline
|
WHO Anatomical Therapeutic Chemical classification |
|
doxofylline |
| 0‑L |
R03DA20
|
combinations of xanthines
|
WHO Anatomical Therapeutic Chemical classification |
|
combinations of xanthines |
| 0‑L |
R03DA51
|
diprophylline, combinations
|
WHO Anatomical Therapeutic Chemical classification |
|
diprophylline, combinations |
| 0‑L |
R03DA54
|
theophylline, combinations excl. psycholeptics
|
WHO Anatomical Therapeutic Chemical classification |
|
theophylline, combinations excl. psycholeptics |
| 0‑L |
R03DA55
|
aminophylline, combinations
|
WHO Anatomical Therapeutic Chemical classification |
|
aminophylline, combinations |
| 0‑L |
R03DA57
|
theobromine, combinations
|
WHO Anatomical Therapeutic Chemical classification |
|
theobromine, combinations |
| 0‑L |
R03DA74
|
theophylline, combinations with psycholeptics
|
WHO Anatomical Therapeutic Chemical classification |
|
theophylline, combinations with psycholeptics |
| 0‑L |
R03DB
|
Xanthines and adrenergics
|
WHO Anatomical Therapeutic Chemical classification |
|
Xanthines and adrenergics |
| 0‑L |
R03DB01
|
diprophylline and adrenergics
|
WHO Anatomical Therapeutic Chemical classification |
|
diprophylline and adrenergics |
| 0‑L |
R03DB02
|
choline theophyllinate and adrenergics
|
WHO Anatomical Therapeutic Chemical classification |
|
choline theophyllinate and adrenergics |
| 0‑L |
R03DB03
|
proxyphylline and adrenergics
|
WHO Anatomical Therapeutic Chemical classification |
|
proxyphylline and adrenergics |
| 0‑L |
R03DB04
|
theophylline and adrenergics
|
WHO Anatomical Therapeutic Chemical classification |
|
theophylline and adrenergics |
| 0‑L |
R03DB05
|
aminophylline and adrenergics
|
WHO Anatomical Therapeutic Chemical classification |
|
aminophylline and adrenergics |
| 0‑L |
R03DB06
|
etamiphylline and adrenergics
|
WHO Anatomical Therapeutic Chemical classification |
|
etamiphylline and adrenergics |
| 0‑L |
R03DC
|
Leukotriene receptor antagonists
|
WHO Anatomical Therapeutic Chemical classification |
|
Leukotriene receptor antagonists |
| 0‑L |
R03DC01
|
zafirlukast
|
WHO Anatomical Therapeutic Chemical classification |
|
zafirlukast |
| 0‑L |
R03DC02
|
pranlukast
|
WHO Anatomical Therapeutic Chemical classification |
|
pranlukast |
| 0‑L |
R03DC03
|
montelukast
|
WHO Anatomical Therapeutic Chemical classification |
|
montelukast |
| 0‑L |
R03DC04
|
ibudilast
|
WHO Anatomical Therapeutic Chemical classification |
|
ibudilast |
| 0‑L |
R03DC53
|
montelukast, combinations
|
WHO Anatomical Therapeutic Chemical classification |
|
montelukast, combinations |
| 0‑L |
R03DX
|
Other systemic drugs for obstructive airway diseases
|
WHO Anatomical Therapeutic Chemical classification |
|
Other systemic drugs for obstructive airway diseases |
| 0‑L |
R03DX01
|
amlexanox
|
WHO Anatomical Therapeutic Chemical classification |
|
amlexanox |
| 0‑L |
R03DX02
|
eprozinol
|
WHO Anatomical Therapeutic Chemical classification |
|
eprozinol |
| 0‑L |
R03DX03
|
fenspiride
|
WHO Anatomical Therapeutic Chemical classification |
|
fenspiride |
| 0‑L |
R03DX05
|
omalizumab
|
WHO Anatomical Therapeutic Chemical classification |
|
omalizumab |
| 0‑L |
R03DX06
|
seratrodast
|
WHO Anatomical Therapeutic Chemical classification |
|
seratrodast |
| 0‑L |
R03DX07
|
roflumilast
|
WHO Anatomical Therapeutic Chemical classification |
|
roflumilast |
| 0‑L |
R03DX08
|
reslizumab
|
WHO Anatomical Therapeutic Chemical classification |
|
reslizumab |
| 0‑L |
R03DX09
|
mepolizumab
|
WHO Anatomical Therapeutic Chemical classification |
|
mepolizumab |
| 0‑L |
R05
|
COUGH AND COLD PREPARATIONS
|
WHO Anatomical Therapeutic Chemical classification |
|
COUGH AND COLD PREPARATIONS |
| 0‑L |
R05C
|
EXPECTORANTS, EXCL. COMBINATIONS WITH COUGH SUPPRESSANTS
|
WHO Anatomical Therapeutic Chemical classification |
|
EXPECTORANTS, EXCL. COMBINATIONS WITH COUGH SUPPRESSANTS |
| 0‑L |
R05CA
|
Expectorants
|
WHO Anatomical Therapeutic Chemical classification |
|
Expectorants |
| 0‑L |
R05CA01
|
tyloxapol
|
WHO Anatomical Therapeutic Chemical classification |
|
tyloxapol |
| 0‑L |
R05CA02
|
potassium iodide
|
WHO Anatomical Therapeutic Chemical classification |
|
potassium iodide |
| 0‑L |
R05CA03
|
guaifenesin
|
WHO Anatomical Therapeutic Chemical classification |
|
guaifenesin |
| 0‑L |
R05CA04
|
ipecacuanha
|
WHO Anatomical Therapeutic Chemical classification |
|
ipecacuanha |
| 0‑L |
R05CA05
|
althea root
|
WHO Anatomical Therapeutic Chemical classification |
|
althea root |
| 0‑L |
R05CA06
|
senega
|
WHO Anatomical Therapeutic Chemical classification |
|
senega |
| 0‑L |
R05CA07
|
antimony pentasulfide
|
WHO Anatomical Therapeutic Chemical classification |
|
antimony pentasulfide |
| 0‑L |
R05CA08
|
creosote
|
WHO Anatomical Therapeutic Chemical classification |
|
creosote |
| 0‑L |
R05CA09
|
guaiacolsulfonate
|
WHO Anatomical Therapeutic Chemical classification |
|
guaiacolsulfonate |
| 0‑L |
R05CA10
|
combinations
|
WHO Anatomical Therapeutic Chemical classification |
|
combinations |
| 0‑L |
R05CA11
|
levoverbenone
|
WHO Anatomical Therapeutic Chemical classification |
|
levoverbenone |
| 0‑L |
R05CA12
|
Hederae helicis folium
|
WHO Anatomical Therapeutic Chemical classification |
|
Hederae helicis folium |
| 0‑L |
R05CA13
|
cineole
|
WHO Anatomical Therapeutic Chemical classification |
|
cineole |
| 0‑L |
R05CB
|
Mucolytics
|
WHO Anatomical Therapeutic Chemical classification |
|
Mucolytics |
| 0‑L |
R05CB01
|
acetylcysteine
|
WHO Anatomical Therapeutic Chemical classification |
|
acetylcysteine |
| 0‑L |
R05CB02
|
bromhexine
|
WHO Anatomical Therapeutic Chemical classification |
|
bromhexine |
| 0‑L |
R05CB03
|
carbocisteine
|
WHO Anatomical Therapeutic Chemical classification |
|
carbocisteine |
| 0‑L |
R05CB04
|
eprazinone
|
WHO Anatomical Therapeutic Chemical classification |
|
eprazinone |
| 0‑L |
R05CB05
|
mesna
|
WHO Anatomical Therapeutic Chemical classification |
|
mesna |
| 0‑L |
R05CB06
|
ambroxol
|
WHO Anatomical Therapeutic Chemical classification |
|
ambroxol |
| 0‑L |
R05CB07
|
sobrerol
|
WHO Anatomical Therapeutic Chemical classification |
|
sobrerol |
| 0‑L |
R05CB08
|
domiodol
|
WHO Anatomical Therapeutic Chemical classification |
|
domiodol |
| 0‑L |
R05CB09
|
letosteine
|
WHO Anatomical Therapeutic Chemical classification |
|
letosteine |
| 0‑L |
R05CB10
|
combinations
|
WHO Anatomical Therapeutic Chemical classification |
|
combinations |
| 0‑L |
R05CB11
|
stepronin
|
WHO Anatomical Therapeutic Chemical classification |
|
stepronin |
| 0‑L |
R05CB13
|
dornase alfa (desoxyribonuclease)
|
WHO Anatomical Therapeutic Chemical classification |
|
dornase alfa (desoxyribonuclease) |
| 0‑L |
R05CB14
|
neltenexine
|
WHO Anatomical Therapeutic Chemical classification |
|
neltenexine |
| 0‑L |
R05CB15
|
erdosteine
|
WHO Anatomical Therapeutic Chemical classification |
|
erdosteine |
| 0‑L |
R05CB16
|
mannitol
|
WHO Anatomical Therapeutic Chemical classification |
|
mannitol |
| 0‑L |
R05D
|
COUGH SUPPRESSANTS, EXCL. COMBINATIONS WITH EXPECTORANTS
|
WHO Anatomical Therapeutic Chemical classification |
|
COUGH SUPPRESSANTS, EXCL. COMBINATIONS WITH EXPECTORANTS |
| 0‑L |
R05DA
|
Opium alkaloids and derivatives
|
WHO Anatomical Therapeutic Chemical classification |
|
Opium alkaloids and derivatives |
| 0‑L |
R05DA01
|
ethylmorphine
|
WHO Anatomical Therapeutic Chemical classification |
|
ethylmorphine |
| 0‑L |
R05DA03
|
hydrocodone
|
WHO Anatomical Therapeutic Chemical classification |
|
hydrocodone |
| 0‑L |
R05DA04
|
codeine
|
WHO Anatomical Therapeutic Chemical classification |
|
codeine |
| 0‑L |
R05DA05
|
opium alkaloids with morphine
|
WHO Anatomical Therapeutic Chemical classification |
|
opium alkaloids with morphine |
| 0‑L |
R05DA06
|
normethadone
|
WHO Anatomical Therapeutic Chemical classification |
|
normethadone |
| 0‑L |
R05DA07
|
noscapine
|
WHO Anatomical Therapeutic Chemical classification |
|
noscapine |
| 0‑L |
R05DA08
|
pholcodine
|
WHO Anatomical Therapeutic Chemical classification |
|
pholcodine |
| 0‑L |
R05DA09
|
dextromethorphan
|
WHO Anatomical Therapeutic Chemical classification |
|
dextromethorphan |
| 0‑L |
R05DA10
|
thebacon
|
WHO Anatomical Therapeutic Chemical classification |
|
thebacon |
| 0‑L |
R05DA11
|
dimemorfan
|
WHO Anatomical Therapeutic Chemical classification |
|
dimemorfan |
| 0‑L |
R05DA12
|
acetyldihydrocodeine
|
WHO Anatomical Therapeutic Chemical classification |
|
acetyldihydrocodeine |
| 0‑L |
R05DA20
|
combinations
|
WHO Anatomical Therapeutic Chemical classification |
|
combinations |
| 0‑L |
R05DB
|
Other cough suppressants
|
WHO Anatomical Therapeutic Chemical classification |
|
Other cough suppressants |
| 0‑L |
R05DB01
|
benzonatate
|
WHO Anatomical Therapeutic Chemical classification |
|
benzonatate |
| 0‑L |
R05DB02
|
benproperine
|
WHO Anatomical Therapeutic Chemical classification |
|
benproperine |
| 0‑L |
R05DB03
|
clobutinol
|
WHO Anatomical Therapeutic Chemical classification |
|
clobutinol |
| 0‑L |
R05DB04
|
isoaminile
|
WHO Anatomical Therapeutic Chemical classification |
|
isoaminile |
| 0‑L |
R05DB05
|
pentoxyverine
|
WHO Anatomical Therapeutic Chemical classification |
|
pentoxyverine |
| 0‑L |
R05DB07
|
oxolamine
|
WHO Anatomical Therapeutic Chemical classification |
|
oxolamine |
| 0‑L |
R05DB09
|
oxeladin
|
WHO Anatomical Therapeutic Chemical classification |
|
oxeladin |
| 0‑L |
R05DB10
|
clofedanol
|
WHO Anatomical Therapeutic Chemical classification |
|
clofedanol |
| 0‑L |
R05DB11
|
pipazetate
|
WHO Anatomical Therapeutic Chemical classification |
|
pipazetate |
| 0‑L |
R05DB12
|
bibenzonium bromide
|
WHO Anatomical Therapeutic Chemical classification |
|
bibenzonium bromide |
| 0‑L |
R05DB13
|
butamirate
|
WHO Anatomical Therapeutic Chemical classification |
|
butamirate |
| 0‑L |
R05DB14
|
fedrilate
|
WHO Anatomical Therapeutic Chemical classification |
|
fedrilate |
| 0‑L |
R05DB15
|
zipeprol
|
WHO Anatomical Therapeutic Chemical classification |
|
zipeprol |
| 0‑L |
R05DB16
|
dibunate
|
WHO Anatomical Therapeutic Chemical classification |
|
dibunate |
| 0‑L |
R05DB17
|
droxypropine
|
WHO Anatomical Therapeutic Chemical classification |
|
droxypropine |
| 0‑L |
R05DB18
|
prenoxdiazine
|
WHO Anatomical Therapeutic Chemical classification |
|
prenoxdiazine |
| 0‑L |
R05DB19
|
dropropizine
|
WHO Anatomical Therapeutic Chemical classification |
|
dropropizine |
| 0‑L |
R05DB20
|
combinations
|
WHO Anatomical Therapeutic Chemical classification |
|
combinations |
| 0‑L |
R05DB21
|
cloperastine
|
WHO Anatomical Therapeutic Chemical classification |
|
cloperastine |
| 0‑L |
R05DB22
|
meprotixol
|
WHO Anatomical Therapeutic Chemical classification |
|
meprotixol |
| 0‑L |
R05DB23
|
piperidione
|
WHO Anatomical Therapeutic Chemical classification |
|
piperidione |
| 0‑L |
R05DB24
|
tipepidine
|
WHO Anatomical Therapeutic Chemical classification |
|
tipepidine |
| 0‑L |
R05DB25
|
morclofone
|
WHO Anatomical Therapeutic Chemical classification |
|
morclofone |
| 0‑L |
R05DB26
|
nepinalone
|
WHO Anatomical Therapeutic Chemical classification |
|
nepinalone |
| 0‑L |
R05DB27
|
levodropropizine
|
WHO Anatomical Therapeutic Chemical classification |
|
levodropropizine |
| 0‑L |
R05DB28
|
dimethoxanate
|
WHO Anatomical Therapeutic Chemical classification |
|
dimethoxanate |
| 0‑L |
R05F
|
COUGH SUPPRESSANTS AND EXPECTORANTS, COMBINATIONS
|
WHO Anatomical Therapeutic Chemical classification |
|
COUGH SUPPRESSANTS AND EXPECTORANTS, COMBINATIONS |
| 0‑L |
R05FA
|
Opium derivatives and expectorants
|
WHO Anatomical Therapeutic Chemical classification |
|
Opium derivatives and expectorants |
| 0‑L |
R05FA01
|
opium derivatives and mucolytics
|
WHO Anatomical Therapeutic Chemical classification |
|
opium derivatives and mucolytics |
| 0‑L |
R05FA02
|
opium derivatives and expectorants
|
WHO Anatomical Therapeutic Chemical classification |
|
opium derivatives and expectorants |
| 0‑L |
R05FB
|
Other cough suppressants and expectorants
|
WHO Anatomical Therapeutic Chemical classification |
|
Other cough suppressants and expectorants |
| 0‑L |
R05FB01
|
cough suppressants and mucolytics
|
WHO Anatomical Therapeutic Chemical classification |
|
cough suppressants and mucolytics |
| 0‑L |
R05FB02
|
cough suppressants and expectorants
|
WHO Anatomical Therapeutic Chemical classification |
|
cough suppressants and expectorants |
| 0‑L |
R05X
|
OTHER COLD PREPARATIONS
|
WHO Anatomical Therapeutic Chemical classification |
|
OTHER COLD PREPARATIONS |
| 0‑L |
R06
|
ANTIHISTAMINES FOR SYSTEMIC USE
|
WHO Anatomical Therapeutic Chemical classification |
|
ANTIHISTAMINES FOR SYSTEMIC USE |
| 0‑L |
R06A
|
ANTIHISTAMINES FOR SYSTEMIC USE
|
WHO Anatomical Therapeutic Chemical classification |
|
ANTIHISTAMINES FOR SYSTEMIC USE |
| 0‑L |
R06AA
|
Aminoalkyl ethers
|
WHO Anatomical Therapeutic Chemical classification |
|
Aminoalkyl ethers |
| 0‑L |
R06AA01
|
bromazine
|
WHO Anatomical Therapeutic Chemical classification |
|
bromazine |
| 0‑L |
R06AA02
|
diphenhydramine
|
WHO Anatomical Therapeutic Chemical classification |
|
diphenhydramine |
| 0‑L |
R06AA04
|
clemastine
|
WHO Anatomical Therapeutic Chemical classification |
|
clemastine |
| 0‑L |
R06AA06
|
chlorphenoxamine
|
WHO Anatomical Therapeutic Chemical classification |
|
chlorphenoxamine |
| 0‑L |
R06AA07
|
diphenylpyraline
|
WHO Anatomical Therapeutic Chemical classification |
|
diphenylpyraline |
| 0‑L |
R06AA08
|
carbinoxamine
|
WHO Anatomical Therapeutic Chemical classification |
|
carbinoxamine |
| 0‑L |
R06AA09
|
doxylamine
|
WHO Anatomical Therapeutic Chemical classification |
|
doxylamine |
| 0‑L |
R06AA10
|
trimethobenzamide
|
WHO Anatomical Therapeutic Chemical classification |
|
trimethobenzamide |
| 0‑L |
R06AA52
|
diphenhydramine, combinations
|
WHO Anatomical Therapeutic Chemical classification |
|
diphenhydramine, combinations |
| 0‑L |
R06AA54
|
clemastine, combinations
|
WHO Anatomical Therapeutic Chemical classification |
|
clemastine, combinations |
| 0‑L |
R06AA56
|
chlorphenoxamine, combinations
|
WHO Anatomical Therapeutic Chemical classification |
|
chlorphenoxamine, combinations |
| 0‑L |
R06AA57
|
diphenylpyraline, combinations
|
WHO Anatomical Therapeutic Chemical classification |
|
diphenylpyraline, combinations |
| 0‑L |
R06AA59
|
doxylamine, combinations
|
WHO Anatomical Therapeutic Chemical classification |
|
doxylamine, combinations |
| 0‑L |
R06AB
|
Substituted alkylamines
|
WHO Anatomical Therapeutic Chemical classification |
|
Substituted alkylamines |
| 0‑L |
R06AB01
|
brompheniramine
|
WHO Anatomical Therapeutic Chemical classification |
|
brompheniramine |
| 0‑L |
R06AB02
|
dexchlorpheniramine
|
WHO Anatomical Therapeutic Chemical classification |
|
dexchlorpheniramine |
| 0‑L |
R06AB03
|
dimetindene
|
WHO Anatomical Therapeutic Chemical classification |
|
dimetindene |
| 0‑L |
R06AB04
|
chlorphenamine
|
WHO Anatomical Therapeutic Chemical classification |
|
chlorphenamine |
| 0‑L |
R06AB05
|
pheniramine
|
WHO Anatomical Therapeutic Chemical classification |
|
pheniramine |
| 0‑L |
R06AB06
|
dexbrompheniramine
|
WHO Anatomical Therapeutic Chemical classification |
|
dexbrompheniramine |
| 0‑L |
R06AB07
|
talastine
|
WHO Anatomical Therapeutic Chemical classification |
|
talastine |
| 0‑L |
R06AB51
|
brompheniramine, combinations
|
WHO Anatomical Therapeutic Chemical classification |
|
brompheniramine, combinations |
| 0‑L |
R06AB52
|
dexchlorpheniramine, combinations
|
WHO Anatomical Therapeutic Chemical classification |
|
dexchlorpheniramine, combinations |
| 0‑L |
R06AB54
|
chlorphenamine, combinations
|
WHO Anatomical Therapeutic Chemical classification |
|
chlorphenamine, combinations |
| 0‑L |
R06AB56
|
dexbrompheniramine, combinations
|
WHO Anatomical Therapeutic Chemical classification |
|
dexbrompheniramine, combinations |
| 0‑L |
R06AC
|
Substituted ethylene diamines
|
WHO Anatomical Therapeutic Chemical classification |
|
Substituted ethylene diamines |
| 0‑L |
R06AC01
|
mepyramine
|
WHO Anatomical Therapeutic Chemical classification |
|
mepyramine |
| 0‑L |
R06AC02
|
histapyrrodine
|
WHO Anatomical Therapeutic Chemical classification |
|
histapyrrodine |
| 0‑L |
R06AC03
|
chloropyramine
|
WHO Anatomical Therapeutic Chemical classification |
|
chloropyramine |
| 0‑L |
R06AC04
|
tripelennamine
|
WHO Anatomical Therapeutic Chemical classification |
|
tripelennamine |
| 0‑L |
R06AC05
|
methapyrilene
|
WHO Anatomical Therapeutic Chemical classification |
|
methapyrilene |
| 0‑L |
R06AC06
|
thonzylamine
|
WHO Anatomical Therapeutic Chemical classification |
|
thonzylamine |
| 0‑L |
R06AC52
|
histapyrrodine, combinations
|
WHO Anatomical Therapeutic Chemical classification |
|
histapyrrodine, combinations |
| 0‑L |
R06AC53
|
chloropyramine, combinations
|
WHO Anatomical Therapeutic Chemical classification |
|
chloropyramine, combinations |
| 0‑L |
R06AD
|
Phenothiazine derivatives
|
WHO Anatomical Therapeutic Chemical classification |
|
Phenothiazine derivatives |
| 0‑L |
R06AD01
|
alimemazine
|
WHO Anatomical Therapeutic Chemical classification |
|
alimemazine |
| 0‑L |
R06AD02
|
promethazine
|
WHO Anatomical Therapeutic Chemical classification |
|
promethazine |
| 0‑L |
R06AD03
|
thiethylperazine
|
WHO Anatomical Therapeutic Chemical classification |
|
thiethylperazine |
| 0‑L |
R06AD04
|
methdilazine
|
WHO Anatomical Therapeutic Chemical classification |
|
methdilazine |
| 0‑L |
R06AD05
|
hydroxyethylpromethazine
|
WHO Anatomical Therapeutic Chemical classification |
|
hydroxyethylpromethazine |
| 0‑L |
R06AD06
|
thiazinam
|
WHO Anatomical Therapeutic Chemical classification |
|
thiazinam |
| 0‑L |
R06AD07
|
mequitazine
|
WHO Anatomical Therapeutic Chemical classification |
|
mequitazine |
| 0‑L |
R06AD08
|
oxomemazine
|
WHO Anatomical Therapeutic Chemical classification |
|
oxomemazine |
| 0‑L |
R06AD09
|
isothipendyl
|
WHO Anatomical Therapeutic Chemical classification |
|
isothipendyl |
| 0‑L |
R06AD52
|
promethazine, combinations
|
WHO Anatomical Therapeutic Chemical classification |
|
promethazine, combinations |
| 0‑L |
R06AD55
|
hydroxyethylpromethazine, combinations
|
WHO Anatomical Therapeutic Chemical classification |
|
hydroxyethylpromethazine, combinations |
| 0‑L |
R06AE
|
Piperazine derivatives
|
WHO Anatomical Therapeutic Chemical classification |
|
Piperazine derivatives |
| 0‑L |
R06AE01
|
buclizine
|
WHO Anatomical Therapeutic Chemical classification |
|
buclizine |
| 0‑L |
R06AE03
|
cyclizine
|
WHO Anatomical Therapeutic Chemical classification |
|
cyclizine |
| 0‑L |
R06AE04
|
chlorcyclizine
|
WHO Anatomical Therapeutic Chemical classification |
|
chlorcyclizine |
| 0‑L |
R06AE05
|
meclozine
|
WHO Anatomical Therapeutic Chemical classification |
|
meclozine |
| 0‑L |
R06AE06
|
oxatomide
|
WHO Anatomical Therapeutic Chemical classification |
|
oxatomide |
| 0‑L |
R06AE07
|
cetirizine
|
WHO Anatomical Therapeutic Chemical classification |
|
cetirizine |
| 0‑L |
R06AE09
|
levocetirizine
|
WHO Anatomical Therapeutic Chemical classification |
|
levocetirizine |
| 0‑L |
R06AE51
|
buclizine, combinations
|
WHO Anatomical Therapeutic Chemical classification |
|
buclizine, combinations |
| 0‑L |
R06AE53
|
cyclizine, combinations
|
WHO Anatomical Therapeutic Chemical classification |
|
cyclizine, combinations |
| 0‑L |
R06AE55
|
meclozine, combinations
|
WHO Anatomical Therapeutic Chemical classification |
|
meclozine, combinations |
| 0‑L |
R06AK
|
Combinations of antihistamines
|
WHO Anatomical Therapeutic Chemical classification |
|
Combinations of antihistamines |
| 0‑L |
R06AX
|
Other antihistamines for systemic use
|
WHO Anatomical Therapeutic Chemical classification |
|
Other antihistamines for systemic use |
| 0‑L |
R06AX01
|
bamipine
|
WHO Anatomical Therapeutic Chemical classification |
|
bamipine |
| 0‑L |
R06AX02
|
cyproheptadine
|
WHO Anatomical Therapeutic Chemical classification |
|
cyproheptadine |
| 0‑L |
R06AX03
|
thenalidine
|
WHO Anatomical Therapeutic Chemical classification |
|
thenalidine |
| 0‑L |
R06AX04
|
phenindamine
|
WHO Anatomical Therapeutic Chemical classification |
|
phenindamine |
| 0‑L |
R06AX05
|
antazoline
|
WHO Anatomical Therapeutic Chemical classification |
|
antazoline |
| 0‑L |
R06AX07
|
triprolidine
|
WHO Anatomical Therapeutic Chemical classification |
|
triprolidine |
| 0‑L |
R06AX08
|
pyrrobutamine
|
WHO Anatomical Therapeutic Chemical classification |
|
pyrrobutamine |
| 0‑L |
R06AX09
|
azatadine
|
WHO Anatomical Therapeutic Chemical classification |
|
azatadine |
| 0‑L |
R06AX11
|
astemizole
|
WHO Anatomical Therapeutic Chemical classification |
|
astemizole |
| 0‑L |
R06AX12
|
terfenadine
|
WHO Anatomical Therapeutic Chemical classification |
|
terfenadine |
| 0‑L |
R06AX13
|
loratadine
|
WHO Anatomical Therapeutic Chemical classification |
|
loratadine |
| 0‑L |
R06AX15
|
mebhydrolin
|
WHO Anatomical Therapeutic Chemical classification |
|
mebhydrolin |
| 0‑L |
R06AX16
|
deptropine
|
WHO Anatomical Therapeutic Chemical classification |
|
deptropine |
| 0‑L |
R06AX17
|
ketotifen
|
WHO Anatomical Therapeutic Chemical classification |
|
ketotifen |
| 0‑L |
R06AX18
|
acrivastine
|
WHO Anatomical Therapeutic Chemical classification |
|
acrivastine |
| 0‑L |
R06AX19
|
azelastine
|
WHO Anatomical Therapeutic Chemical classification |
|
azelastine |
| 0‑L |
R06AX21
|
tritoqualine
|
WHO Anatomical Therapeutic Chemical classification |
|
tritoqualine |
| 0‑L |
R06AX22
|
ebastine
|
WHO Anatomical Therapeutic Chemical classification |
|
ebastine |
| 0‑L |
R06AX23
|
pimethixene
|
WHO Anatomical Therapeutic Chemical classification |
|
pimethixene |
| 0‑L |
R06AX24
|
epinastine
|
WHO Anatomical Therapeutic Chemical classification |
|
epinastine |
| 0‑L |
R06AX25
|
mizolastine
|
WHO Anatomical Therapeutic Chemical classification |
|
mizolastine |
| 0‑L |
R06AX26
|
fexofenadine
|
WHO Anatomical Therapeutic Chemical classification |
|
fexofenadine |
| 0‑L |
R06AX27
|
desloratadine
|
WHO Anatomical Therapeutic Chemical classification |
|
desloratadine |
| 0‑L |
R06AX28
|
rupatadine
|
WHO Anatomical Therapeutic Chemical classification |
|
rupatadine |
| 0‑L |
R06AX29
|
bilastine
|
WHO Anatomical Therapeutic Chemical classification |
|
bilastine |
| 0‑L |
R06AX31
|
quifenadine
|
WHO Anatomical Therapeutic Chemical classification |
|
quifenadine |
| 0‑L |
R06AX32
|
sequifenadine
|
WHO Anatomical Therapeutic Chemical classification |
|
sequifenadine |
| 0‑L |
R06AX53
|
thenalidine, combinations
|
WHO Anatomical Therapeutic Chemical classification |
|
thenalidine, combinations |
| 0‑L |
R06AX58
|
pyrrobutamine, combinations
|
WHO Anatomical Therapeutic Chemical classification |
|
pyrrobutamine, combinations |
| 0‑L |
R07
|
OTHER RESPIRATORY SYSTEM PRODUCTS
|
WHO Anatomical Therapeutic Chemical classification |
|
OTHER RESPIRATORY SYSTEM PRODUCTS |
| 0‑L |
R07A
|
OTHER RESPIRATORY SYSTEM PRODUCTS
|
WHO Anatomical Therapeutic Chemical classification |
|
OTHER RESPIRATORY SYSTEM PRODUCTS |
| 0‑L |
R07AA
|
Lung surfactants
|
WHO Anatomical Therapeutic Chemical classification |
|
Lung surfactants |
| 0‑L |
R07AA01
|
colfosceril palmitate
|
WHO Anatomical Therapeutic Chemical classification |
|
colfosceril palmitate |
| 0‑L |
R07AA02
|
natural phospholipids
|
WHO Anatomical Therapeutic Chemical classification |
|
natural phospholipids |
| 0‑L |
R07AA30
|
combinations
|
WHO Anatomical Therapeutic Chemical classification |
|
combinations |
| 0‑L |
R07AB
|
Respiratory stimulants
|
WHO Anatomical Therapeutic Chemical classification |
|
Respiratory stimulants |
| 0‑L |
R07AB01
|
doxapram
|
WHO Anatomical Therapeutic Chemical classification |
|
doxapram |
| 0‑L |
R07AB02
|
nikethamide
|
WHO Anatomical Therapeutic Chemical classification |
|
nikethamide |
| 0‑L |
R07AB03
|
pentetrazol
|
WHO Anatomical Therapeutic Chemical classification |
|
pentetrazol |
| 0‑L |
R07AB04
|
etamivan
|
WHO Anatomical Therapeutic Chemical classification |
|
etamivan |
| 0‑L |
R07AB05
|
bemegride
|
WHO Anatomical Therapeutic Chemical classification |
|
bemegride |
| 0‑L |
R07AB06
|
prethcamide
|
WHO Anatomical Therapeutic Chemical classification |
|
prethcamide |
| 0‑L |
R07AB07
|
almitrine
|
WHO Anatomical Therapeutic Chemical classification |
|
almitrine |
| 0‑L |
R07AB08
|
dimefline
|
WHO Anatomical Therapeutic Chemical classification |
|
dimefline |
| 0‑L |
R07AB09
|
mepixanox
|
WHO Anatomical Therapeutic Chemical classification |
|
mepixanox |
| 0‑L |
R07AB52
|
nikethamide, combinations
|
WHO Anatomical Therapeutic Chemical classification |
|
nikethamide, combinations |
| 0‑L |
R07AB53
|
pentetrazol, combinations
|
WHO Anatomical Therapeutic Chemical classification |
|
pentetrazol, combinations |
| 0‑L |
R07AX
|
Other respiratory system products
|
WHO Anatomical Therapeutic Chemical classification |
|
Other respiratory system products |
| 0‑L |
R07AX01
|
nitric oxide
|
WHO Anatomical Therapeutic Chemical classification |
|
nitric oxide |
| 0‑L |
R07AX02
|
ivacaftor
|
WHO Anatomical Therapeutic Chemical classification |
|
ivacaftor |
| 0‑L |
R07AX30
|
ivacaftor and lumacaftor
|
WHO Anatomical Therapeutic Chemical classification |
|
ivacaftor and lumacaftor |
| 0‑L |
S
|
SENSORY ORGANS
|
WHO Anatomical Therapeutic Chemical classification |
|
SENSORY ORGANS |
| 0‑L |
S01
|
OPHTHALMOLOGICALS
|
WHO Anatomical Therapeutic Chemical classification |
|
OPHTHALMOLOGICALS |
| 0‑L |
S01A
|
ANTIINFECTIVES
|
WHO Anatomical Therapeutic Chemical classification |
|
ANTIINFECTIVES |
| 0‑L |
S01AA
|
Antibiotics
|
WHO Anatomical Therapeutic Chemical classification |
|
Antibiotics |
| 0‑L |
S01AA01
|
chloramphenicol
|
WHO Anatomical Therapeutic Chemical classification |
|
chloramphenicol |
| 0‑L |
S01AA02
|
chlortetracycline
|
WHO Anatomical Therapeutic Chemical classification |
|
chlortetracycline |
| 0‑L |
S01AA03
|
neomycin
|
WHO Anatomical Therapeutic Chemical classification |
|
neomycin |
| 0‑L |
S01AA04
|
oxytetracycline
|
WHO Anatomical Therapeutic Chemical classification |
|
oxytetracycline |
| 0‑L |
S01AA05
|
tyrothricin
|
WHO Anatomical Therapeutic Chemical classification |
|
tyrothricin |
| 0‑L |
S01AA07
|
framycetin
|
WHO Anatomical Therapeutic Chemical classification |
|
framycetin |
| 0‑L |
S01AA09
|
tetracycline
|
WHO Anatomical Therapeutic Chemical classification |
|
tetracycline |
| 0‑L |
S01AA10
|
natamycin
|
WHO Anatomical Therapeutic Chemical classification |
|
natamycin |
| 0‑L |
S01AA11
|
gentamicin
|
WHO Anatomical Therapeutic Chemical classification |
|
gentamicin |
| 0‑L |
S01AA12
|
tobramycin
|
WHO Anatomical Therapeutic Chemical classification |
|
tobramycin |
| 0‑L |
S01AA13
|
fusidic acid
|
WHO Anatomical Therapeutic Chemical classification |
|
fusidic acid |
| 0‑L |
S01AA14
|
benzylpenicillin
|
WHO Anatomical Therapeutic Chemical classification |
|
benzylpenicillin |
| 0‑L |
S01AA15
|
dihydrostreptomycin
|
WHO Anatomical Therapeutic Chemical classification |
|
dihydrostreptomycin |
| 0‑L |
S01AA16
|
rifamycin
|
WHO Anatomical Therapeutic Chemical classification |
|
rifamycin |
| 0‑L |
S01AA17
|
erythromycin
|
WHO Anatomical Therapeutic Chemical classification |
|
erythromycin |
| 0‑L |
S01AA18
|
polymyxin B
|
WHO Anatomical Therapeutic Chemical classification |
|
polymyxin B |
| 0‑L |
S01AA19
|
ampicillin
|
WHO Anatomical Therapeutic Chemical classification |
|
ampicillin |
| 0‑L |
S01AA20
|
antibiotics in combination with other drugs
|
WHO Anatomical Therapeutic Chemical classification |
|
antibiotics in combination with other drugs |
| 0‑L |
S01AA21
|
amikacin
|
WHO Anatomical Therapeutic Chemical classification |
|
amikacin |
| 0‑L |
S01AA22
|
micronomicin
|
WHO Anatomical Therapeutic Chemical classification |
|
micronomicin |
| 0‑L |
S01AA23
|
netilmicin
|
WHO Anatomical Therapeutic Chemical classification |
|
netilmicin |
| 0‑L |
S01AA24
|
kanamycin
|
WHO Anatomical Therapeutic Chemical classification |
|
kanamycin |
| 0‑L |
S01AA25
|
azidamfenicol
|
WHO Anatomical Therapeutic Chemical classification |
|
azidamfenicol |
| 0‑L |
S01AA26
|
azithromycin
|
WHO Anatomical Therapeutic Chemical classification |
|
azithromycin |
| 0‑L |
S01AA27
|
cefuroxime
|
WHO Anatomical Therapeutic Chemical classification |
|
cefuroxime |
| 0‑L |
S01AA30
|
combinations of different antibiotics
|
WHO Anatomical Therapeutic Chemical classification |
|
combinations of different antibiotics |
| 0‑L |
S01AB
|
Sulfonamides
|
WHO Anatomical Therapeutic Chemical classification |
|
Sulfonamides |
| 0‑L |
S01AB01
|
sulfamethizole
|
WHO Anatomical Therapeutic Chemical classification |
|
sulfamethizole |
| 0‑L |
S01AB02
|
sulfafurazole
|
WHO Anatomical Therapeutic Chemical classification |
|
sulfafurazole |
| 0‑L |
S01AB03
|
sulfadicramide
|
WHO Anatomical Therapeutic Chemical classification |
|
sulfadicramide |
| 0‑L |
S01AB04
|
sulfacetamide
|
WHO Anatomical Therapeutic Chemical classification |
|
sulfacetamide |
| 0‑L |
S01AB05
|
sulfafenazol
|
WHO Anatomical Therapeutic Chemical classification |
|
sulfafenazol |
| 0‑L |
S01AD
|
Antivirals
|
WHO Anatomical Therapeutic Chemical classification |
|
Antivirals |
| 0‑L |
S01AD01
|
idoxuridine
|
WHO Anatomical Therapeutic Chemical classification |
|
idoxuridine |
| 0‑L |
S01AD02
|
trifluridine
|
WHO Anatomical Therapeutic Chemical classification |
|
trifluridine |
| 0‑L |
S01AD03
|
aciclovir
|
WHO Anatomical Therapeutic Chemical classification |
|
aciclovir |
| 0‑L |
S01AD05
|
interferon
|
WHO Anatomical Therapeutic Chemical classification |
|
interferon |
| 0‑L |
S01AD06
|
vidarabine
|
WHO Anatomical Therapeutic Chemical classification |
|
vidarabine |
| 0‑L |
S01AD07
|
famciclovir
|
WHO Anatomical Therapeutic Chemical classification |
|
famciclovir |
| 0‑L |
S01AD08
|
fomivirsen
|
WHO Anatomical Therapeutic Chemical classification |
|
fomivirsen |
| 0‑L |
S01AD09
|
ganciclovir
|
WHO Anatomical Therapeutic Chemical classification |
|
ganciclovir |
| 0‑L |
S01AE
|
Fluoroquinolones
|
WHO Anatomical Therapeutic Chemical classification |
|
Fluoroquinolones |
| 0‑L |
S01AE01
|
ofloxacin
|
WHO Anatomical Therapeutic Chemical classification |
|
ofloxacin |
| 0‑L |
S01AE02
|
norfloxacin
|
WHO Anatomical Therapeutic Chemical classification |
|
norfloxacin |
| 0‑L |
S01AE03
|
ciprofloxacin
|
WHO Anatomical Therapeutic Chemical classification |
|
ciprofloxacin |
| 0‑L |
S01AE04
|
lomefloxacin
|
WHO Anatomical Therapeutic Chemical classification |
|
lomefloxacin |
| 0‑L |
S01AE05
|
levofloxacin
|
WHO Anatomical Therapeutic Chemical classification |
|
levofloxacin |
| 0‑L |
S01AE06
|
gatifloxacin
|
WHO Anatomical Therapeutic Chemical classification |
|
gatifloxacin |
| 0‑L |
S01AE07
|
moxifloxacin
|
WHO Anatomical Therapeutic Chemical classification |
|
moxifloxacin |
| 0‑L |
S01AE08
|
besifloxacin
|
WHO Anatomical Therapeutic Chemical classification |
|
besifloxacin |
| 0‑L |
S01AX
|
Other antiinfectives
|
WHO Anatomical Therapeutic Chemical classification |
|
Other antiinfectives |
| 0‑L |
S01AX01
|
mercury compounds
|
WHO Anatomical Therapeutic Chemical classification |
|
mercury compounds |
| 0‑L |
S01AX02
|
silver compounds
|
WHO Anatomical Therapeutic Chemical classification |
|
silver compounds |
| 0‑L |
S01AX03
|
zinc compounds
|
WHO Anatomical Therapeutic Chemical classification |
|
zinc compounds |
| 0‑L |
S01AX04
|
nitrofural
|
WHO Anatomical Therapeutic Chemical classification |
|
nitrofural |
| 0‑L |
S01AX05
|
bibrocathol
|
WHO Anatomical Therapeutic Chemical classification |
|
bibrocathol |
| 0‑L |
S01AX06
|
resorcinol
|
WHO Anatomical Therapeutic Chemical classification |
|
resorcinol |
| 0‑L |
S01AX07
|
sodium borate
|
WHO Anatomical Therapeutic Chemical classification |
|
sodium borate |
| 0‑L |
S01AX08
|
hexamidine
|
WHO Anatomical Therapeutic Chemical classification |
|
hexamidine |
| 0‑L |
S01AX09
|
chlorhexidine
|
WHO Anatomical Therapeutic Chemical classification |
|
chlorhexidine |
| 0‑L |
S01AX10
|
sodium propionate
|
WHO Anatomical Therapeutic Chemical classification |
|
sodium propionate |
| 0‑L |
S01AX14
|
dibrompropamidine
|
WHO Anatomical Therapeutic Chemical classification |
|
dibrompropamidine |
| 0‑L |
S01AX15
|
propamidine
|
WHO Anatomical Therapeutic Chemical classification |
|
propamidine |
| 0‑L |
S01AX16
|
picloxydine
|
WHO Anatomical Therapeutic Chemical classification |
|
picloxydine |
| 0‑L |
S01AX18
|
povidone-iodine
|
WHO Anatomical Therapeutic Chemical classification |
|
povidone-iodine |
| 0‑L |
S01B
|
ANTIINFLAMMATORY AGENTS
|
WHO Anatomical Therapeutic Chemical classification |
|
ANTIINFLAMMATORY AGENTS |
| 0‑L |
S01BA
|
Corticosteroids, plain
|
WHO Anatomical Therapeutic Chemical classification |
|
Corticosteroids, plain |
| 0‑L |
S01BA01
|
dexamethasone
|
WHO Anatomical Therapeutic Chemical classification |
|
dexamethasone |
| 0‑L |
S01BA02
|
hydrocortisone
|
WHO Anatomical Therapeutic Chemical classification |
|
hydrocortisone |
| 0‑L |
S01BA03
|
cortisone
|
WHO Anatomical Therapeutic Chemical classification |
|
cortisone |
| 0‑L |
S01BA04
|
prednisolone
|
WHO Anatomical Therapeutic Chemical classification |
|
prednisolone |
| 0‑L |
S01BA05
|
triamcinolone
|
WHO Anatomical Therapeutic Chemical classification |
|
triamcinolone |
| 0‑L |
S01BA06
|
betamethasone
|
WHO Anatomical Therapeutic Chemical classification |
|
betamethasone |
| 0‑L |
S01BA07
|
fluorometholone
|
WHO Anatomical Therapeutic Chemical classification |
|
fluorometholone |
| 0‑L |
S01BA08
|
medrysone
|
WHO Anatomical Therapeutic Chemical classification |
|
medrysone |
| 0‑L |
S01BA09
|
clobetasone
|
WHO Anatomical Therapeutic Chemical classification |
|
clobetasone |
| 0‑L |
S01BA10
|
alclometasone
|
WHO Anatomical Therapeutic Chemical classification |
|
alclometasone |
| 0‑L |
S01BA11
|
desonide
|
WHO Anatomical Therapeutic Chemical classification |
|
desonide |
| 0‑L |
S01BA12
|
formocortal
|
WHO Anatomical Therapeutic Chemical classification |
|
formocortal |
| 0‑L |
S01BA13
|
rimexolone
|
WHO Anatomical Therapeutic Chemical classification |
|
rimexolone |
| 0‑L |
S01BA14
|
loteprednol
|
WHO Anatomical Therapeutic Chemical classification |
|
loteprednol |
| 0‑L |
S01BA15
|
fluocinolone acetonide
|
WHO Anatomical Therapeutic Chemical classification |
|
fluocinolone acetonide |
| 0‑L |
S01BB
|
Corticosteroids and mydriatics in combination
|
WHO Anatomical Therapeutic Chemical classification |
|
Corticosteroids and mydriatics in combination |
| 0‑L |
S01BB01
|
hydrocortisone and mydriatics
|
WHO Anatomical Therapeutic Chemical classification |
|
hydrocortisone and mydriatics |
| 0‑L |
S01BB02
|
prednisolone and mydriatics
|
WHO Anatomical Therapeutic Chemical classification |
|
prednisolone and mydriatics |
| 0‑L |
S01BB03
|
fluorometholone and mydriatics
|
WHO Anatomical Therapeutic Chemical classification |
|
fluorometholone and mydriatics |
| 0‑L |
S01BB04
|
betamethasone and mydriatics
|
WHO Anatomical Therapeutic Chemical classification |
|
betamethasone and mydriatics |
| 0‑L |
S01BC
|
Antiinflammatory agents, non-steroids
|
WHO Anatomical Therapeutic Chemical classification |
|
Antiinflammatory agents, non-steroids |
| 0‑L |
S01BC01
|
indometacin
|
WHO Anatomical Therapeutic Chemical classification |
|
indometacin |
| 0‑L |
S01BC02
|
oxyphenbutazone
|
WHO Anatomical Therapeutic Chemical classification |
|
oxyphenbutazone |
| 0‑L |
S01BC03
|
diclofenac
|
WHO Anatomical Therapeutic Chemical classification |
|
diclofenac |
| 0‑L |
S01BC04
|
flurbiprofen
|
WHO Anatomical Therapeutic Chemical classification |
|
flurbiprofen |
| 0‑L |
S01BC05
|
ketorolac
|
WHO Anatomical Therapeutic Chemical classification |
|
ketorolac |
| 0‑L |
S01BC06
|
piroxicam
|
WHO Anatomical Therapeutic Chemical classification |
|
piroxicam |
| 0‑L |
S01BC07
|
bendazac
|
WHO Anatomical Therapeutic Chemical classification |
|
bendazac |
| 0‑L |
S01BC08
|
salicylic acid
|
WHO Anatomical Therapeutic Chemical classification |
|
salicylic acid |
| 0‑L |
S01BC09
|
pranoprofen
|
WHO Anatomical Therapeutic Chemical classification |
|
pranoprofen |
| 0‑L |
S01BC10
|
nepafenac
|
WHO Anatomical Therapeutic Chemical classification |
|
nepafenac |
| 0‑L |
S01BC11
|
bromfenac
|
WHO Anatomical Therapeutic Chemical classification |
|
bromfenac |
| 0‑L |
S01C
|
ANTIINFLAMMATORY AGENTS AND ANTIINFECTIVES IN COMBINATION
|
WHO Anatomical Therapeutic Chemical classification |
|
ANTIINFLAMMATORY AGENTS AND ANTIINFECTIVES IN COMBINATION |
| 0‑L |
S01CA
|
Corticosteroids and antiinfectives in combination
|
WHO Anatomical Therapeutic Chemical classification |
|
Corticosteroids and antiinfectives in combination |
| 0‑L |
S01CA01
|
dexamethasone and antiinfectives
|
WHO Anatomical Therapeutic Chemical classification |
|
dexamethasone and antiinfectives |
| 0‑L |
S01CA02
|
prednisolone and antiinfectives
|
WHO Anatomical Therapeutic Chemical classification |
|
prednisolone and antiinfectives |
| 0‑L |
S01CA03
|
hydrocortisone and antiinfectives
|
WHO Anatomical Therapeutic Chemical classification |
|
hydrocortisone and antiinfectives |
| 0‑L |
S01CA04
|
fluocortolone and antiinfectives
|
WHO Anatomical Therapeutic Chemical classification |
|
fluocortolone and antiinfectives |
| 0‑L |
S01CA05
|
betamethasone and antiinfectives
|
WHO Anatomical Therapeutic Chemical classification |
|
betamethasone and antiinfectives |
| 0‑L |
S01CA06
|
fludrocortisone and antiinfectives
|
WHO Anatomical Therapeutic Chemical classification |
|
fludrocortisone and antiinfectives |
| 0‑L |
S01CA07
|
fluorometholone and antiinfectives
|
WHO Anatomical Therapeutic Chemical classification |
|
fluorometholone and antiinfectives |
| 0‑L |
S01CA08
|
methylprednisolone and antiinfectives
|
WHO Anatomical Therapeutic Chemical classification |
|
methylprednisolone and antiinfectives |
| 0‑L |
S01CA09
|
chloroprednisone and antiinfectives
|
WHO Anatomical Therapeutic Chemical classification |
|
chloroprednisone and antiinfectives |
| 0‑L |
S01CA10
|
fluocinolone acetonide and antiinfectives
|
WHO Anatomical Therapeutic Chemical classification |
|
fluocinolone acetonide and antiinfectives |
| 0‑L |
S01CA11
|
clobetasone and antiinfectives
|
WHO Anatomical Therapeutic Chemical classification |
|
clobetasone and antiinfectives |
| 0‑L |
S01CB
|
Corticosteroids/antiinfectives/mydriatics in combination
|
WHO Anatomical Therapeutic Chemical classification |
|
Corticosteroids/antiinfectives/mydriatics in combination |
| 0‑L |
S01CB01
|
dexamethasone
|
WHO Anatomical Therapeutic Chemical classification |
|
dexamethasone |
| 0‑L |
S01CB02
|
prednisolone
|
WHO Anatomical Therapeutic Chemical classification |
|
prednisolone |
| 0‑L |
S01CB03
|
hydrocortisone
|
WHO Anatomical Therapeutic Chemical classification |
|
hydrocortisone |
| 0‑L |
S01CB04
|
betamethasone
|
WHO Anatomical Therapeutic Chemical classification |
|
betamethasone |
| 0‑L |
S01CB05
|
fluorometholone
|
WHO Anatomical Therapeutic Chemical classification |
|
fluorometholone |
| 0‑L |
S01CC
|
Antiinflammatory agents, non-steroids and antiinfectives in combination
|
WHO Anatomical Therapeutic Chemical classification |
|
Antiinflammatory agents, non-steroids and antiinfectives in combination |
| 0‑L |
S01CC01
|
diclofenac and antiinfectives
|
WHO Anatomical Therapeutic Chemical classification |
|
diclofenac and antiinfectives |
| 0‑L |
S01CC02
|
indometacin and antiinfectives
|
WHO Anatomical Therapeutic Chemical classification |
|
indometacin and antiinfectives |
| 0‑L |
S01E
|
ANTIGLAUCOMA PREPARATIONS AND MIOTICS
|
WHO Anatomical Therapeutic Chemical classification |
|
ANTIGLAUCOMA PREPARATIONS AND MIOTICS |
| 0‑L |
S01EA
|
Sympathomimetics in glaucoma therapy1)
|
WHO Anatomical Therapeutic Chemical classification |
|
Sympathomimetics in glaucoma therapy1) |
| 0‑L |
S01EA01
|
epinephrine
|
WHO Anatomical Therapeutic Chemical classification |
|
epinephrine |
| 0‑L |
S01EA02
|
dipivefrine
|
WHO Anatomical Therapeutic Chemical classification |
|
dipivefrine |
| 0‑L |
S01EA03
|
apraclonidine
|
WHO Anatomical Therapeutic Chemical classification |
|
apraclonidine |
| 0‑L |
S01EA04
|
clonidine
|
WHO Anatomical Therapeutic Chemical classification |
|
clonidine |
| 0‑L |
S01EA05
|
brimonidine
|
WHO Anatomical Therapeutic Chemical classification |
|
brimonidine |
| 0‑L |
S01EA51
|
epinephrine, combinations
|
WHO Anatomical Therapeutic Chemical classification |
|
epinephrine, combinations |
| 0‑L |
S01EB
|
Parasympathomimetics
|
WHO Anatomical Therapeutic Chemical classification |
|
Parasympathomimetics |
| 0‑L |
S01EB01
|
pilocarpine
|
WHO Anatomical Therapeutic Chemical classification |
|
pilocarpine |
| 0‑L |
S01EB02
|
carbachol
|
WHO Anatomical Therapeutic Chemical classification |
|
carbachol |
| 0‑L |
S01EB03
|
ecothiopate
|
WHO Anatomical Therapeutic Chemical classification |
|
ecothiopate |
| 0‑L |
S01EB04
|
demecarium
|
WHO Anatomical Therapeutic Chemical classification |
|
demecarium |
| 0‑L |
S01EB05
|
physostigmine
|
WHO Anatomical Therapeutic Chemical classification |
|
physostigmine |
| 0‑L |
S01EB06
|
neostigmine
|
WHO Anatomical Therapeutic Chemical classification |
|
neostigmine |
| 0‑L |
S01EB07
|
fluostigmine
|
WHO Anatomical Therapeutic Chemical classification |
|
fluostigmine |
| 0‑L |
S01EB08
|
aceclidine
|
WHO Anatomical Therapeutic Chemical classification |
|
aceclidine |
| 0‑L |
S01EB09
|
acetylcholine
|
WHO Anatomical Therapeutic Chemical classification |
|
acetylcholine |
| 0‑L |
S01EB10
|
paraoxon
|
WHO Anatomical Therapeutic Chemical classification |
|
paraoxon |
| 0‑L |
S01EB51
|
pilocarpine, combinations
|
WHO Anatomical Therapeutic Chemical classification |
|
pilocarpine, combinations |
| 0‑L |
S01EB58
|
aceclidine, combinations
|
WHO Anatomical Therapeutic Chemical classification |
|
aceclidine, combinations |
| 0‑L |
S01EC
|
Carbonic anhydrase inhibitors
|
WHO Anatomical Therapeutic Chemical classification |
|
Carbonic anhydrase inhibitors |
| 0‑L |
S01EC01
|
acetazolamide
|
WHO Anatomical Therapeutic Chemical classification |
|
acetazolamide |
| 0‑L |
S01EC02
|
diclofenamide
|
WHO Anatomical Therapeutic Chemical classification |
|
diclofenamide |
| 0‑L |
S01EC03
|
dorzolamide
|
WHO Anatomical Therapeutic Chemical classification |
|
dorzolamide |
| 0‑L |
S01EC04
|
brinzolamide
|
WHO Anatomical Therapeutic Chemical classification |
|
brinzolamide |
| 0‑L |
S01EC05
|
methazolamide
|
WHO Anatomical Therapeutic Chemical classification |
|
methazolamide |
| 0‑L |
S01EC54
|
brinzolamide, combinations
|
WHO Anatomical Therapeutic Chemical classification |
|
brinzolamide, combinations |
| 0‑L |
S01ED
|
Beta blocking agents1)
|
WHO Anatomical Therapeutic Chemical classification |
|
Beta blocking agents1) |
| 0‑L |
S01ED01
|
timolol
|
WHO Anatomical Therapeutic Chemical classification |
|
timolol |
| 0‑L |
S01ED02
|
betaxolol
|
WHO Anatomical Therapeutic Chemical classification |
|
betaxolol |
| 0‑L |
S01ED03
|
levobunolol
|
WHO Anatomical Therapeutic Chemical classification |
|
levobunolol |
| 0‑L |
S01ED04
|
metipranolol
|
WHO Anatomical Therapeutic Chemical classification |
|
metipranolol |
| 0‑L |
S01ED05
|
carteolol
|
WHO Anatomical Therapeutic Chemical classification |
|
carteolol |
| 0‑L |
S01ED06
|
befunolol
|
WHO Anatomical Therapeutic Chemical classification |
|
befunolol |
| 0‑L |
S01ED51
|
timolol, combinations
|
WHO Anatomical Therapeutic Chemical classification |
|
timolol, combinations |
| 0‑L |
S01ED52
|
betaxolol, combinations
|
WHO Anatomical Therapeutic Chemical classification |
|
betaxolol, combinations |
| 0‑L |
S01ED54
|
metipranolol, combinations
|
WHO Anatomical Therapeutic Chemical classification |
|
metipranolol, combinations |
| 0‑L |
S01ED55
|
carteolol, combinations
|
WHO Anatomical Therapeutic Chemical classification |
|
carteolol, combinations |
| 0‑L |
S01EE
|
Prostaglandin analogues1)
|
WHO Anatomical Therapeutic Chemical classification |
|
Prostaglandin analogues1) |
| 0‑L |
S01EE01
|
latanoprost
|
WHO Anatomical Therapeutic Chemical classification |
|
latanoprost |
| 0‑L |
S01EE02
|
unoprostone
|
WHO Anatomical Therapeutic Chemical classification |
|
unoprostone |
| 0‑L |
S01EE03
|
bimatoprost
|
WHO Anatomical Therapeutic Chemical classification |
|
bimatoprost |
| 0‑L |
S01EE04
|
travoprost
|
WHO Anatomical Therapeutic Chemical classification |
|
travoprost |
| 0‑L |
S01EE05
|
tafluprost
|
WHO Anatomical Therapeutic Chemical classification |
|
tafluprost |
| 0‑L |
S01EX
|
Other antiglaucoma preparations
|
WHO Anatomical Therapeutic Chemical classification |
|
Other antiglaucoma preparations |
| 0‑L |
S01EX01
|
guanethidine
|
WHO Anatomical Therapeutic Chemical classification |
|
guanethidine |
| 0‑L |
S01EX02
|
dapiprazole
|
WHO Anatomical Therapeutic Chemical classification |
|
dapiprazole |
| 0‑L |
S01F
|
MYDRIATICS AND CYCLOPLEGICS
|
WHO Anatomical Therapeutic Chemical classification |
|
MYDRIATICS AND CYCLOPLEGICS |
| 0‑L |
S01FA
|
Anticholinergics
|
WHO Anatomical Therapeutic Chemical classification |
|
Anticholinergics |
| 0‑L |
S01FA01
|
atropine
|
WHO Anatomical Therapeutic Chemical classification |
|
atropine |
| 0‑L |
S01FA02
|
scopolamine
|
WHO Anatomical Therapeutic Chemical classification |
|
scopolamine |
| 0‑L |
S01FA03
|
methylscopolamine
|
WHO Anatomical Therapeutic Chemical classification |
|
methylscopolamine |
| 0‑L |
S01FA04
|
cyclopentolate
|
WHO Anatomical Therapeutic Chemical classification |
|
cyclopentolate |
| 0‑L |
S01FA05
|
homatropine
|
WHO Anatomical Therapeutic Chemical classification |
|
homatropine |
| 0‑L |
S01FA06
|
tropicamide
|
WHO Anatomical Therapeutic Chemical classification |
|
tropicamide |
| 0‑L |
S01FA54
|
cyclopentolate, combinations
|
WHO Anatomical Therapeutic Chemical classification |
|
cyclopentolate, combinations |
| 0‑L |
S01FA56
|
tropicamide, combinations
|
WHO Anatomical Therapeutic Chemical classification |
|
tropicamide, combinations |
| 0‑L |
S01FB
|
Sympathomimetics excl. antiglaucoma preparations
|
WHO Anatomical Therapeutic Chemical classification |
|
Sympathomimetics excl. antiglaucoma preparations |
| 0‑L |
S01FB01
|
phenylephrine
|
WHO Anatomical Therapeutic Chemical classification |
|
phenylephrine |
| 0‑L |
S01FB02
|
ephedrine
|
WHO Anatomical Therapeutic Chemical classification |
|
ephedrine |
| 0‑L |
S01FB03
|
ibopamine
|
WHO Anatomical Therapeutic Chemical classification |
|
ibopamine |
| 0‑L |
S01FB51
|
phenylephrine and ketorolac
|
WHO Anatomical Therapeutic Chemical classification |
|
phenylephrine and ketorolac |
| 0‑L |
S01G
|
DECONGESTANTS AND ANTIALLERGICS
|
WHO Anatomical Therapeutic Chemical classification |
|
DECONGESTANTS AND ANTIALLERGICS |
| 0‑L |
S01GA
|
Sympathomimetics used as decongestants
|
WHO Anatomical Therapeutic Chemical classification |
|
Sympathomimetics used as decongestants |
| 0‑L |
S01GA01
|
naphazoline
|
WHO Anatomical Therapeutic Chemical classification |
|
naphazoline |
| 0‑L |
S01GA02
|
tetryzoline
|
WHO Anatomical Therapeutic Chemical classification |
|
tetryzoline |
| 0‑L |
S01GA03
|
xylometazoline
|
WHO Anatomical Therapeutic Chemical classification |
|
xylometazoline |
| 0‑L |
S01GA04
|
oxymetazoline
|
WHO Anatomical Therapeutic Chemical classification |
|
oxymetazoline |
| 0‑L |
S01GA05
|
phenylephrine
|
WHO Anatomical Therapeutic Chemical classification |
|
phenylephrine |
| 0‑L |
S01GA06
|
oxedrine
|
WHO Anatomical Therapeutic Chemical classification |
|
oxedrine |
| 0‑L |
S01GA51
|
naphazoline, combinations
|
WHO Anatomical Therapeutic Chemical classification |
|
naphazoline, combinations |
| 0‑L |
S01GA52
|
tetryzoline, combinations
|
WHO Anatomical Therapeutic Chemical classification |
|
tetryzoline, combinations |
| 0‑L |
S01GA53
|
xylometazoline, combinations
|
WHO Anatomical Therapeutic Chemical classification |
|
xylometazoline, combinations |
| 0‑L |
S01GA55
|
phenylephrine, combinations
|
WHO Anatomical Therapeutic Chemical classification |
|
phenylephrine, combinations |
| 0‑L |
S01GA56
|
oxedrine, combinations
|
WHO Anatomical Therapeutic Chemical classification |
|
oxedrine, combinations |
| 0‑L |
S01GX
|
Other antiallergics
|
WHO Anatomical Therapeutic Chemical classification |
|
Other antiallergics |
| 0‑L |
S01GX01
|
cromoglicic acid
|
WHO Anatomical Therapeutic Chemical classification |
|
cromoglicic acid |
| 0‑L |
S01GX02
|
levocabastine
|
WHO Anatomical Therapeutic Chemical classification |
|
levocabastine |
| 0‑L |
S01GX03
|
spaglumic acid
|
WHO Anatomical Therapeutic Chemical classification |
|
spaglumic acid |
| 0‑L |
S01GX04
|
nedocromil
|
WHO Anatomical Therapeutic Chemical classification |
|
nedocromil |
| 0‑L |
S01GX05
|
lodoxamide
|
WHO Anatomical Therapeutic Chemical classification |
|
lodoxamide |
| 0‑L |
S01GX06
|
emedastine
|
WHO Anatomical Therapeutic Chemical classification |
|
emedastine |
| 0‑L |
S01GX07
|
azelastine
|
WHO Anatomical Therapeutic Chemical classification |
|
azelastine |
| 0‑L |
S01GX08
|
ketotifen
|
WHO Anatomical Therapeutic Chemical classification |
|
ketotifen |
| 0‑L |
S01GX09
|
olopatadine
|
WHO Anatomical Therapeutic Chemical classification |
|
olopatadine |
| 0‑L |
S01GX10
|
epinastine
|
WHO Anatomical Therapeutic Chemical classification |
|
epinastine |
| 0‑L |
S01GX11
|
alcaftadine
|
WHO Anatomical Therapeutic Chemical classification |
|
alcaftadine |
| 0‑L |
S01GX51
|
cromoglicic acid, combinations
|
WHO Anatomical Therapeutic Chemical classification |
|
cromoglicic acid, combinations |
| 0‑L |
S01H
|
LOCAL ANESTHETICS
|
WHO Anatomical Therapeutic Chemical classification |
|
LOCAL ANESTHETICS |
| 0‑L |
S01HA
|
Local anesthetics
|
WHO Anatomical Therapeutic Chemical classification |
|
Local anesthetics |
| 0‑L |
S01HA01
|
cocaine
|
WHO Anatomical Therapeutic Chemical classification |
|
cocaine |
| 0‑L |
S01HA02
|
oxybuprocaine
|
WHO Anatomical Therapeutic Chemical classification |
|
oxybuprocaine |
| 0‑L |
S01HA03
|
tetracaine
|
WHO Anatomical Therapeutic Chemical classification |
|
tetracaine |
| 0‑L |
S01HA04
|
proxymetacaine
|
WHO Anatomical Therapeutic Chemical classification |
|
proxymetacaine |
| 0‑L |
S01HA05
|
procaine
|
WHO Anatomical Therapeutic Chemical classification |
|
procaine |
| 0‑L |
S01HA06
|
cinchocaine
|
WHO Anatomical Therapeutic Chemical classification |
|
cinchocaine |
| 0‑L |
S01HA07
|
lidocaine
|
WHO Anatomical Therapeutic Chemical classification |
|
lidocaine |
| 0‑L |
S01HA30
|
combinations
|
WHO Anatomical Therapeutic Chemical classification |
|
combinations |
| 0‑L |
S01J
|
DIAGNOSTIC AGENTS
|
WHO Anatomical Therapeutic Chemical classification |
|
DIAGNOSTIC AGENTS |
| 0‑L |
S01JA
|
Colouring agents
|
WHO Anatomical Therapeutic Chemical classification |
|
Colouring agents |
| 0‑L |
S01JA01
|
fluorescein
|
WHO Anatomical Therapeutic Chemical classification |
|
fluorescein |
| 0‑L |
S01JA02
|
rose bengal sodium
|
WHO Anatomical Therapeutic Chemical classification |
|
rose bengal sodium |
| 0‑L |
S01JA51
|
fluorescein, combinations
|
WHO Anatomical Therapeutic Chemical classification |
|
fluorescein, combinations |
| 0‑L |
S01JX
|
Other ophthalmological diagnostic agents
|
WHO Anatomical Therapeutic Chemical classification |
|
Other ophthalmological diagnostic agents |
| 0‑L |
S01K
|
SURGICAL AIDS
|
WHO Anatomical Therapeutic Chemical classification |
|
SURGICAL AIDS |
| 0‑L |
S01KA
|
Viscoelastic substances
|
WHO Anatomical Therapeutic Chemical classification |
|
Viscoelastic substances |
| 0‑L |
S01KA01
|
hyaluronic acid
|
WHO Anatomical Therapeutic Chemical classification |
|
hyaluronic acid |
| 0‑L |
S01KA02
|
hypromellose
|
WHO Anatomical Therapeutic Chemical classification |
|
hypromellose |
| 0‑L |
S01KA51
|
hyaluronic acid, combinations
|
WHO Anatomical Therapeutic Chemical classification |
|
hyaluronic acid, combinations |
| 0‑L |
S01KX
|
Other surgical aids
|
WHO Anatomical Therapeutic Chemical classification |
|
Other surgical aids |
| 0‑L |
S01KX01
|
chymotrypsin
|
WHO Anatomical Therapeutic Chemical classification |
|
chymotrypsin |
| 0‑L |
S01L
|
OCULAR VASCULAR DISORDER AGENTS
|
WHO Anatomical Therapeutic Chemical classification |
|
OCULAR VASCULAR DISORDER AGENTS |
| 0‑L |
S01LA
|
Antineovascularisation agents
|
WHO Anatomical Therapeutic Chemical classification |
|
Antineovascularisation agents |
| 0‑L |
S01LA01
|
verteporfin
|
WHO Anatomical Therapeutic Chemical classification |
|
verteporfin |
| 0‑L |
S01LA02
|
anecortave
|
WHO Anatomical Therapeutic Chemical classification |
|
anecortave |
| 0‑L |
S01LA03
|
pegaptanib
|
WHO Anatomical Therapeutic Chemical classification |
|
pegaptanib |
| 0‑L |
S01LA04
|
ranibizumab
|
WHO Anatomical Therapeutic Chemical classification |
|
ranibizumab |
| 0‑L |
S01LA05
|
aflibercept
|
WHO Anatomical Therapeutic Chemical classification |
|
aflibercept |
| 0‑L |
S01X
|
OTHER OPHTHALMOLOGICALS
|
WHO Anatomical Therapeutic Chemical classification |
|
OTHER OPHTHALMOLOGICALS |
| 0‑L |
S01XA
|
Other ophthalmologicals
|
WHO Anatomical Therapeutic Chemical classification |
|
Other ophthalmologicals |
| 0‑L |
S01XA01
|
guaiazulen
|
WHO Anatomical Therapeutic Chemical classification |
|
guaiazulen |
| 0‑L |
S01XA02
|
retinol
|
WHO Anatomical Therapeutic Chemical classification |
|
retinol |
| 0‑L |
S01XA03
|
sodium chloride, hypertonic
|
WHO Anatomical Therapeutic Chemical classification |
|
sodium chloride, hypertonic |
| 0‑L |
S01XA04
|
potassium iodide
|
WHO Anatomical Therapeutic Chemical classification |
|
potassium iodide |
| 0‑L |
S01XA05
|
sodium edetate
|
WHO Anatomical Therapeutic Chemical classification |
|
sodium edetate |
| 0‑L |
S01XA06
|
ethylmorphine
|
WHO Anatomical Therapeutic Chemical classification |
|
ethylmorphine |
| 0‑L |
S01XA07
|
alum
|
WHO Anatomical Therapeutic Chemical classification |
|
alum |
| 0‑L |
S01XA08
|
acetylcysteine
|
WHO Anatomical Therapeutic Chemical classification |
|
acetylcysteine |
| 0‑L |
S01XA09
|
iodoheparinate
|
WHO Anatomical Therapeutic Chemical classification |
|
iodoheparinate |
| 0‑L |
S01XA10
|
inosine
|
WHO Anatomical Therapeutic Chemical classification |
|
inosine |
| 0‑L |
S01XA11
|
nandrolone
|
WHO Anatomical Therapeutic Chemical classification |
|
nandrolone |
| 0‑L |
S01XA12
|
dexpanthenol
|
WHO Anatomical Therapeutic Chemical classification |
|
dexpanthenol |
| 0‑L |
S01XA13
|
alteplase
|
WHO Anatomical Therapeutic Chemical classification |
|
alteplase |
| 0‑L |
S01XA14
|
heparin
|
WHO Anatomical Therapeutic Chemical classification |
|
heparin |
| 0‑L |
S01XA15
|
ascorbic acid
|
WHO Anatomical Therapeutic Chemical classification |
|
ascorbic acid |
| 0‑L |
S01XA18
|
ciclosporin
|
WHO Anatomical Therapeutic Chemical classification |
|
ciclosporin |
| 0‑L |
S01XA19
|
limbal stems cells, autologous
|
WHO Anatomical Therapeutic Chemical classification |
|
limbal stems cells, autologous |
| 0‑L |
S01XA20
|
artificial tears and other indifferent preparations
|
WHO Anatomical Therapeutic Chemical classification |
|
artificial tears and other indifferent preparations |
| 0‑L |
S01XA21
|
mercaptamine
|
WHO Anatomical Therapeutic Chemical classification |
|
mercaptamine |
| 0‑L |
S01XA22
|
ocriplasmin
|
WHO Anatomical Therapeutic Chemical classification |
|
ocriplasmin |
| 0‑L |
S01XA23
|
sirolimus
|
WHO Anatomical Therapeutic Chemical classification |
|
sirolimus |
| 0‑L |
S02
|
OTOLOGICALS
|
WHO Anatomical Therapeutic Chemical classification |
|
OTOLOGICALS |
| 0‑L |
S02A
|
ANTIINFECTIVES
|
WHO Anatomical Therapeutic Chemical classification |
|
ANTIINFECTIVES |
| 0‑L |
S02AA
|
Antiinfectives
|
WHO Anatomical Therapeutic Chemical classification |
|
Antiinfectives |
| 0‑L |
S02AA01
|
chloramphenicol
|
WHO Anatomical Therapeutic Chemical classification |
|
chloramphenicol |
| 0‑L |
S02AA02
|
nitrofural
|
WHO Anatomical Therapeutic Chemical classification |
|
nitrofural |
| 0‑L |
S02AA03
|
boric acid
|
WHO Anatomical Therapeutic Chemical classification |
|
boric acid |
| 0‑L |
S02AA04
|
aluminium acetotartrate
|
WHO Anatomical Therapeutic Chemical classification |
|
aluminium acetotartrate |
| 0‑L |
S02AA05
|
clioquinol
|
WHO Anatomical Therapeutic Chemical classification |
|
clioquinol |
| 0‑L |
S02AA06
|
hydrogen peroxide
|
WHO Anatomical Therapeutic Chemical classification |
|
hydrogen peroxide |
| 0‑L |
S02AA07
|
neomycin
|
WHO Anatomical Therapeutic Chemical classification |
|
neomycin |
| 0‑L |
S02AA08
|
tetracycline
|
WHO Anatomical Therapeutic Chemical classification |
|
tetracycline |
| 0‑L |
S02AA09
|
chlorhexidine
|
WHO Anatomical Therapeutic Chemical classification |
|
chlorhexidine |
| 0‑L |
S02AA10
|
acetic acid
|
WHO Anatomical Therapeutic Chemical classification |
|
acetic acid |
| 0‑L |
S02AA11
|
polymyxin B
|
WHO Anatomical Therapeutic Chemical classification |
|
polymyxin B |
| 0‑L |
S02AA12
|
rifamycin
|
WHO Anatomical Therapeutic Chemical classification |
|
rifamycin |
| 0‑L |
S02AA13
|
miconazole
|
WHO Anatomical Therapeutic Chemical classification |
|
miconazole |
| 0‑L |
S02AA14
|
gentamicin
|
WHO Anatomical Therapeutic Chemical classification |
|
gentamicin |
| 0‑L |
S02AA15
|
ciprofloxacin
|
WHO Anatomical Therapeutic Chemical classification |
|
ciprofloxacin |
| 0‑L |
S02AA16
|
ofloxacin
|
WHO Anatomical Therapeutic Chemical classification |
|
ofloxacin |
| 0‑L |
S02AA30
|
antiinfectives, combinations
|
WHO Anatomical Therapeutic Chemical classification |
|
antiinfectives, combinations |
| 0‑L |
S02B
|
CORTICOSTEROIDS
|
WHO Anatomical Therapeutic Chemical classification |
|
CORTICOSTEROIDS |
| 0‑L |
S02BA
|
Corticosteroids
|
WHO Anatomical Therapeutic Chemical classification |
|
Corticosteroids |
| 0‑L |
S02BA01
|
hydrocortisone
|
WHO Anatomical Therapeutic Chemical classification |
|
hydrocortisone |
| 0‑L |
S02BA03
|
prednisolone
|
WHO Anatomical Therapeutic Chemical classification |
|
prednisolone |
| 0‑L |
S02BA06
|
dexamethasone
|
WHO Anatomical Therapeutic Chemical classification |
|
dexamethasone |
| 0‑L |
S02BA07
|
betamethasone
|
WHO Anatomical Therapeutic Chemical classification |
|
betamethasone |
| 0‑L |
S02BA08
|
fluocinolone acetonide
|
WHO Anatomical Therapeutic Chemical classification |
|
fluocinolone acetonide |
| 0‑L |
S02C
|
CORTICOSTEROIDS AND ANTIINFECTIVES IN COMBINATION
|
WHO Anatomical Therapeutic Chemical classification |
|
CORTICOSTEROIDS AND ANTIINFECTIVES IN COMBINATION |
| 0‑L |
S02CA
|
Corticosteroids and antiinfectives in combination
|
WHO Anatomical Therapeutic Chemical classification |
|
Corticosteroids and antiinfectives in combination |
| 0‑L |
S02CA01
|
prednisolone and antiinfectives
|
WHO Anatomical Therapeutic Chemical classification |
|
prednisolone and antiinfectives |
| 0‑L |
S02CA02
|
flumetasone and antiinfectives
|
WHO Anatomical Therapeutic Chemical classification |
|
flumetasone and antiinfectives |
| 0‑L |
S02CA03
|
hydrocortisone and antiinfectives
|
WHO Anatomical Therapeutic Chemical classification |
|
hydrocortisone and antiinfectives |
| 0‑L |
S02CA04
|
triamcinolone and antiinfectives
|
WHO Anatomical Therapeutic Chemical classification |
|
triamcinolone and antiinfectives |
| 0‑L |
S02CA05
|
fluocinolone acetonide and antiinfectives
|
WHO Anatomical Therapeutic Chemical classification |
|
fluocinolone acetonide and antiinfectives |
| 0‑L |
S02CA06
|
dexamethasone and antiinfectives
|
WHO Anatomical Therapeutic Chemical classification |
|
dexamethasone and antiinfectives |
| 0‑L |
S02CA07
|
fludrocortisone and antiinfectives
|
WHO Anatomical Therapeutic Chemical classification |
|
fludrocortisone and antiinfectives |
| 0‑L |
S02D
|
OTHER OTOLOGICALS
|
WHO Anatomical Therapeutic Chemical classification |
|
OTHER OTOLOGICALS |
| 0‑L |
S02DA
|
Analgesics and anesthetics
|
WHO Anatomical Therapeutic Chemical classification |
|
Analgesics and anesthetics |
| 0‑L |
S02DA01
|
lidocaine
|
WHO Anatomical Therapeutic Chemical classification |
|
lidocaine |
| 0‑L |
S02DA02
|
cocaine
|
WHO Anatomical Therapeutic Chemical classification |
|
cocaine |
| 0‑L |
S02DA03
|
phenazone
|
WHO Anatomical Therapeutic Chemical classification |
|
phenazone |
| 0‑L |
S02DA04
|
cinchocaine
|
WHO Anatomical Therapeutic Chemical classification |
|
cinchocaine |
| 0‑L |
S02DA30
|
combinations
|
WHO Anatomical Therapeutic Chemical classification |
|
combinations |
| 0‑L |
S02DC
|
Indifferent preparations
|
WHO Anatomical Therapeutic Chemical classification |
|
Indifferent preparations |
| 0‑L |
S03
|
OPHTHALMOLOGICAL AND OTOLOGICAL PREPARATIONS
|
WHO Anatomical Therapeutic Chemical classification |
|
OPHTHALMOLOGICAL AND OTOLOGICAL PREPARATIONS |
| 0‑L |
S03A
|
ANTIINFECTIVES
|
WHO Anatomical Therapeutic Chemical classification |
|
ANTIINFECTIVES |
| 0‑L |
S03AA
|
Antiinfectives
|
WHO Anatomical Therapeutic Chemical classification |
|
Antiinfectives |
| 0‑L |
S03AA01
|
neomycin
|
WHO Anatomical Therapeutic Chemical classification |
|
neomycin |
| 0‑L |
S03AA02
|
tetracycline
|
WHO Anatomical Therapeutic Chemical classification |
|
tetracycline |
| 0‑L |
S03AA03
|
polymyxin B
|
WHO Anatomical Therapeutic Chemical classification |
|
polymyxin B |
| 0‑L |
S03AA04
|
chlorhexidine
|
WHO Anatomical Therapeutic Chemical classification |
|
chlorhexidine |
| 0‑L |
S03AA05
|
hexamidine
|
WHO Anatomical Therapeutic Chemical classification |
|
hexamidine |
| 0‑L |
S03AA06
|
gentamicin
|
WHO Anatomical Therapeutic Chemical classification |
|
gentamicin |
| 0‑L |
S03AA07
|
ciprofloxacin
|
WHO Anatomical Therapeutic Chemical classification |
|
ciprofloxacin |
| 0‑L |
S03AA08
|
chloramphenicol
|
WHO Anatomical Therapeutic Chemical classification |
|
chloramphenicol |
| 0‑L |
S03AA30
|
antiinfectives, combinations
|
WHO Anatomical Therapeutic Chemical classification |
|
antiinfectives, combinations |
| 0‑L |
S03B
|
CORTICOSTEROIDS
|
WHO Anatomical Therapeutic Chemical classification |
|
CORTICOSTEROIDS |
| 0‑L |
S03BA
|
Corticosteroids
|
WHO Anatomical Therapeutic Chemical classification |
|
Corticosteroids |
| 0‑L |
S03BA01
|
dexamethasone
|
WHO Anatomical Therapeutic Chemical classification |
|
dexamethasone |
| 0‑L |
S03BA02
|
prednisolone
|
WHO Anatomical Therapeutic Chemical classification |
|
prednisolone |
| 0‑L |
S03BA03
|
betamethasone
|
WHO Anatomical Therapeutic Chemical classification |
|
betamethasone |
| 0‑L |
S03C
|
CORTICOSTEROIDS AND ANTIINFECTIVES IN COMBINATION
|
WHO Anatomical Therapeutic Chemical classification |
|
CORTICOSTEROIDS AND ANTIINFECTIVES IN COMBINATION |
| 0‑L |
S03CA
|
Corticosteroids and antiinfectives in combination
|
WHO Anatomical Therapeutic Chemical classification |
|
Corticosteroids and antiinfectives in combination |
| 0‑L |
S03CA01
|
dexamethasone and antiinfectives
|
WHO Anatomical Therapeutic Chemical classification |
|
dexamethasone and antiinfectives |
| 0‑L |
S03CA02
|
prednisolone and antiinfectives
|
WHO Anatomical Therapeutic Chemical classification |
|
prednisolone and antiinfectives |
| 0‑L |
S03CA04
|
hydrocortisone and antiinfectives
|
WHO Anatomical Therapeutic Chemical classification |
|
hydrocortisone and antiinfectives |
| 0‑L |
S03CA05
|
fludrocortisone and antiinfectives
|
WHO Anatomical Therapeutic Chemical classification |
|
fludrocortisone and antiinfectives |
| 0‑L |
S03CA06
|
betamethasone and antiinfectives
|
WHO Anatomical Therapeutic Chemical classification |
|
betamethasone and antiinfectives |
| 0‑L |
S03D
|
OTHER OPHTHALMOLOGICAL AND OTOLOGICAL PREPARATIONS
|
WHO Anatomical Therapeutic Chemical classification |
|
OTHER OPHTHALMOLOGICAL AND OTOLOGICAL PREPARATIONS |
| 0‑L |
V
|
VARIOUS
|
WHO Anatomical Therapeutic Chemical classification |
|
VARIOUS |
| 0‑L |
V01
|
ALLERGENS
|
WHO Anatomical Therapeutic Chemical classification |
|
ALLERGENS |
| 0‑L |
V01A
|
ALLERGENS
|
WHO Anatomical Therapeutic Chemical classification |
|
ALLERGENS |
| 0‑L |
V01AA
|
Allergen extracts
|
WHO Anatomical Therapeutic Chemical classification |
|
Allergen extracts |
| 0‑L |
V01AA01
|
feather
|
WHO Anatomical Therapeutic Chemical classification |
|
feather |
| 0‑L |
V01AA02
|
grass pollen
|
WHO Anatomical Therapeutic Chemical classification |
|
grass pollen |
| 0‑L |
V01AA03
|
house dust mites
|
WHO Anatomical Therapeutic Chemical classification |
|
house dust mites |
| 0‑L |
V01AA04
|
mould fungus and yeast fungus
|
WHO Anatomical Therapeutic Chemical classification |
|
mould fungus and yeast fungus |
| 0‑L |
V01AA05
|
tree pollen
|
WHO Anatomical Therapeutic Chemical classification |
|
tree pollen |
| 0‑L |
V01AA07
|
insects
|
WHO Anatomical Therapeutic Chemical classification |
|
insects |
| 0‑L |
V01AA08
|
food
|
WHO Anatomical Therapeutic Chemical classification |
|
food |
| 0‑L |
V01AA09
|
textiles
|
WHO Anatomical Therapeutic Chemical classification |
|
textiles |
| 0‑L |
V01AA10
|
flowers
|
WHO Anatomical Therapeutic Chemical classification |
|
flowers |
| 0‑L |
V01AA11
|
animals
|
WHO Anatomical Therapeutic Chemical classification |
|
animals |
| 0‑L |
V01AA20
|
various
|
WHO Anatomical Therapeutic Chemical classification |
|
various |
| 0‑L |
V03
|
ALL OTHER THERAPEUTIC PRODUCTS
|
WHO Anatomical Therapeutic Chemical classification |
|
ALL OTHER THERAPEUTIC PRODUCTS |
| 0‑L |
V03A
|
ALL OTHER THERAPEUTIC PRODUCTS
|
WHO Anatomical Therapeutic Chemical classification |
|
ALL OTHER THERAPEUTIC PRODUCTS |
| 0‑L |
V03AB
|
Antidotes
|
WHO Anatomical Therapeutic Chemical classification |
|
Antidotes |
| 0‑L |
V03AB01
|
ipecacuanha
|
WHO Anatomical Therapeutic Chemical classification |
|
ipecacuanha |
| 0‑L |
V03AB02
|
nalorphine
|
WHO Anatomical Therapeutic Chemical classification |
|
nalorphine |
| 0‑L |
V03AB03
|
edetates
|
WHO Anatomical Therapeutic Chemical classification |
|
edetates |
| 0‑L |
V03AB04
|
pralidoxime
|
WHO Anatomical Therapeutic Chemical classification |
|
pralidoxime |
| 0‑L |
V03AB05
|
prednisolone and promethazine
|
WHO Anatomical Therapeutic Chemical classification |
|
prednisolone and promethazine |
| 0‑L |
V03AB06
|
thiosulfate
|
WHO Anatomical Therapeutic Chemical classification |
|
thiosulfate |
| 0‑L |
V03AB08
|
sodium nitrite
|
WHO Anatomical Therapeutic Chemical classification |
|
sodium nitrite |
| 0‑L |
V03AB09
|
dimercaprol
|
WHO Anatomical Therapeutic Chemical classification |
|
dimercaprol |
| 0‑L |
V03AB13
|
obidoxime
|
WHO Anatomical Therapeutic Chemical classification |
|
obidoxime |
| 0‑L |
V03AB14
|
protamine
|
WHO Anatomical Therapeutic Chemical classification |
|
protamine |
| 0‑L |
V03AB15
|
naloxone
|
WHO Anatomical Therapeutic Chemical classification |
|
naloxone |
| 0‑L |
V03AB16
|
ethanol
|
WHO Anatomical Therapeutic Chemical classification |
|
ethanol |
| 0‑L |
V03AB17
|
methylthioninium chloride
|
WHO Anatomical Therapeutic Chemical classification |
|
methylthioninium chloride |
| 0‑L |
V03AB18
|
potassium permanganate
|
WHO Anatomical Therapeutic Chemical classification |
|
potassium permanganate |
| 0‑L |
V03AB19
|
physostigmine
|
WHO Anatomical Therapeutic Chemical classification |
|
physostigmine |
| 0‑L |
V03AB20
|
copper sulfate
|
WHO Anatomical Therapeutic Chemical classification |
|
copper sulfate |
| 0‑L |
V03AB21
|
potassium iodide
|
WHO Anatomical Therapeutic Chemical classification |
|
potassium iodide |
| 0‑L |
V03AB22
|
amyl nitrite
|
WHO Anatomical Therapeutic Chemical classification |
|
amyl nitrite |
| 0‑L |
V03AB23
|
acetylcysteine
|
WHO Anatomical Therapeutic Chemical classification |
|
acetylcysteine |
| 0‑L |
V03AB24
|
digitalis antitoxin
|
WHO Anatomical Therapeutic Chemical classification |
|
digitalis antitoxin |
| 0‑L |
V03AB25
|
flumazenil
|
WHO Anatomical Therapeutic Chemical classification |
|
flumazenil |
| 0‑L |
V03AB26
|
methionine
|
WHO Anatomical Therapeutic Chemical classification |
|
methionine |
| 0‑L |
V03AB27
|
4-dimethylaminophenol
|
WHO Anatomical Therapeutic Chemical classification |
|
4-dimethylaminophenol |
| 0‑L |
V03AB29
|
cholinesterase
|
WHO Anatomical Therapeutic Chemical classification |
|
cholinesterase |
| 0‑L |
V03AB31
|
prussian blue
|
WHO Anatomical Therapeutic Chemical classification |
|
prussian blue |
| 0‑L |
V03AB32
|
glutathione
|
WHO Anatomical Therapeutic Chemical classification |
|
glutathione |
| 0‑L |
V03AB33
|
hydroxocobalamin
|
WHO Anatomical Therapeutic Chemical classification |
|
hydroxocobalamin |
| 0‑L |
V03AB34
|
fomepizole
|
WHO Anatomical Therapeutic Chemical classification |
|
fomepizole |
| 0‑L |
V03AB35
|
sugammadex
|
WHO Anatomical Therapeutic Chemical classification |
|
sugammadex |
| 0‑L |
V03AB36
|
phentolamine
|
WHO Anatomical Therapeutic Chemical classification |
|
phentolamine |
| 0‑L |
V03AB37
|
idarucizumab
|
WHO Anatomical Therapeutic Chemical classification |
|
idarucizumab |
| 0‑L |
V03AC
|
Iron chelating agents
|
WHO Anatomical Therapeutic Chemical classification |
|
Iron chelating agents |
| 0‑L |
V03AC01
|
deferoxamine
|
WHO Anatomical Therapeutic Chemical classification |
|
deferoxamine |
| 0‑L |
V03AC02
|
deferiprone
|
WHO Anatomical Therapeutic Chemical classification |
|
deferiprone |
| 0‑L |
V03AC03
|
deferasirox
|
WHO Anatomical Therapeutic Chemical classification |
|
deferasirox |
| 0‑L |
V03AE
|
Drugs for treatment of hyperkalemia and hyperphosphatemia
|
WHO Anatomical Therapeutic Chemical classification |
|
Drugs for treatment of hyperkalemia and hyperphosphatemia |
| 0‑L |
V03AE01
|
polystyrene sulfonate
|
WHO Anatomical Therapeutic Chemical classification |
|
polystyrene sulfonate |
| 0‑L |
V03AE02
|
sevelamer
|
WHO Anatomical Therapeutic Chemical classification |
|
sevelamer |
| 0‑L |
V03AE03
|
lanthanum carbonate
|
WHO Anatomical Therapeutic Chemical classification |
|
lanthanum carbonate |
| 0‑L |
V03AE04
|
calcium acetate and magnesium carbonate
|
WHO Anatomical Therapeutic Chemical classification |
|
calcium acetate and magnesium carbonate |
| 0‑L |
V03AE05
|
sucroferric oxyhydroxide
|
WHO Anatomical Therapeutic Chemical classification |
|
sucroferric oxyhydroxide |
| 0‑L |
V03AE06
|
colestilan
|
WHO Anatomical Therapeutic Chemical classification |
|
colestilan |
| 0‑L |
V03AE07
|
calcium acetate
|
WHO Anatomical Therapeutic Chemical classification |
|
calcium acetate |
| 0‑L |
V03AE08
|
ferric citrate
|
WHO Anatomical Therapeutic Chemical classification |
|
ferric citrate |
| 0‑L |
V03AE09
|
patiromer calcium
|
WHO Anatomical Therapeutic Chemical classification |
|
patiromer calcium |
| 0‑L |
V03AF
|
Detoxifying agents for antineoplastic treatment
|
WHO Anatomical Therapeutic Chemical classification |
|
Detoxifying agents for antineoplastic treatment |
| 0‑L |
V03AF01
|
mesna
|
WHO Anatomical Therapeutic Chemical classification |
|
mesna |
| 0‑L |
V03AF02
|
dexrazoxane
|
WHO Anatomical Therapeutic Chemical classification |
|
dexrazoxane |
| 0‑L |
V03AF03
|
calcium folinate
|
WHO Anatomical Therapeutic Chemical classification |
|
calcium folinate |
| 0‑L |
V03AF04
|
calcium levofolinate
|
WHO Anatomical Therapeutic Chemical classification |
|
calcium levofolinate |
| 0‑L |
V03AF05
|
amifostine
|
WHO Anatomical Therapeutic Chemical classification |
|
amifostine |
| 0‑L |
V03AF06
|
sodium folinate
|
WHO Anatomical Therapeutic Chemical classification |
|
sodium folinate |
| 0‑L |
V03AF07
|
rasburicase
|
WHO Anatomical Therapeutic Chemical classification |
|
rasburicase |
| 0‑L |
V03AF08
|
palifermin
|
WHO Anatomical Therapeutic Chemical classification |
|
palifermin |
| 0‑L |
V03AF09
|
glucarpidase
|
WHO Anatomical Therapeutic Chemical classification |
|
glucarpidase |
| 0‑L |
V03AF10
|
sodium levofolinate
|
WHO Anatomical Therapeutic Chemical classification |
|
sodium levofolinate |
| 0‑L |
V03AG
|
Drugs for treatment of hypercalcemia
|
WHO Anatomical Therapeutic Chemical classification |
|
Drugs for treatment of hypercalcemia |
| 0‑L |
V03AG01
|
sodium cellulose phosphate
|
WHO Anatomical Therapeutic Chemical classification |
|
sodium cellulose phosphate |
| 0‑L |
V03AH
|
Drugs for treatment of hypoglycemia
|
WHO Anatomical Therapeutic Chemical classification |
|
Drugs for treatment of hypoglycemia |
| 0‑L |
V03AH01
|
diazoxide
|
WHO Anatomical Therapeutic Chemical classification |
|
diazoxide |
| 0‑L |
V03AK
|
Tissue adhesives
|
WHO Anatomical Therapeutic Chemical classification |
|
Tissue adhesives |
| 0‑L |
V03AM
|
Drugs for embolisation
|
WHO Anatomical Therapeutic Chemical classification |
|
Drugs for embolisation |
| 0‑L |
V03AN
|
Medical gases
|
WHO Anatomical Therapeutic Chemical classification |
|
Medical gases |
| 0‑L |
V03AN01
|
oxygen
|
WHO Anatomical Therapeutic Chemical classification |
|
oxygen |
| 0‑L |
V03AN02
|
carbon dioxide
|
WHO Anatomical Therapeutic Chemical classification |
|
carbon dioxide |
| 0‑L |
V03AN03
|
helium
|
WHO Anatomical Therapeutic Chemical classification |
|
helium |
| 0‑L |
V03AN04
|
nitrogen
|
WHO Anatomical Therapeutic Chemical classification |
|
nitrogen |
| 0‑L |
V03AN05
|
medical air
|
WHO Anatomical Therapeutic Chemical classification |
|
medical air |
| 0‑L |
V03AX
|
Other therapeutic products
|
WHO Anatomical Therapeutic Chemical classification |
|
Other therapeutic products |
| 0‑L |
V03AX02
|
nalfurafine
|
WHO Anatomical Therapeutic Chemical classification |
|
nalfurafine |
| 0‑L |
V03AX03
|
cobicistat
|
WHO Anatomical Therapeutic Chemical classification |
|
cobicistat |
| 0‑L |
V03AZ
|
Nerve depressants
|
WHO Anatomical Therapeutic Chemical classification |
|
Nerve depressants |
| 0‑L |
V03AZ01
|
ethanol
|
WHO Anatomical Therapeutic Chemical classification |
|
ethanol |
| 0‑L |
V04
|
DIAGNOSTIC AGENTS
|
WHO Anatomical Therapeutic Chemical classification |
|
DIAGNOSTIC AGENTS |
| 0‑L |
V04B
|
URINE TESTS
|
WHO Anatomical Therapeutic Chemical classification |
|
URINE TESTS |
| 0‑L |
V04C
|
OTHER DIAGNOSTIC AGENTS
|
WHO Anatomical Therapeutic Chemical classification |
|
OTHER DIAGNOSTIC AGENTS |
| 0‑L |
V04CA
|
Tests for diabetes
|
WHO Anatomical Therapeutic Chemical classification |
|
Tests for diabetes |
| 0‑L |
V04CA01
|
tolbutamide
|
WHO Anatomical Therapeutic Chemical classification |
|
tolbutamide |
| 0‑L |
V04CA02
|
glucose
|
WHO Anatomical Therapeutic Chemical classification |
|
glucose |
| 0‑L |
V04CB
|
Tests for fat absorption
|
WHO Anatomical Therapeutic Chemical classification |
|
Tests for fat absorption |
| 0‑L |
V04CB01
|
vitamin A concentrates
|
WHO Anatomical Therapeutic Chemical classification |
|
vitamin A concentrates |
| 0‑L |
V04CC
|
Tests for bile duct patency
|
WHO Anatomical Therapeutic Chemical classification |
|
Tests for bile duct patency |
| 0‑L |
V04CC01
|
sorbitol
|
WHO Anatomical Therapeutic Chemical classification |
|
sorbitol |
| 0‑L |
V04CC02
|
magnesium sulfate
|
WHO Anatomical Therapeutic Chemical classification |
|
magnesium sulfate |
| 0‑L |
V04CC03
|
sincalide
|
WHO Anatomical Therapeutic Chemical classification |
|
sincalide |
| 0‑L |
V04CC04
|
ceruletide
|
WHO Anatomical Therapeutic Chemical classification |
|
ceruletide |
| 0‑L |
V04CD
|
Tests for pituitary function
|
WHO Anatomical Therapeutic Chemical classification |
|
Tests for pituitary function |
| 0‑L |
V04CD01
|
metyrapone
|
WHO Anatomical Therapeutic Chemical classification |
|
metyrapone |
| 0‑L |
V04CD03
|
sermorelin
|
WHO Anatomical Therapeutic Chemical classification |
|
sermorelin |
| 0‑L |
V04CD04
|
corticorelin
|
WHO Anatomical Therapeutic Chemical classification |
|
corticorelin |
| 0‑L |
V04CD05
|
somatorelin
|
WHO Anatomical Therapeutic Chemical classification |
|
somatorelin |
| 0‑L |
V04CD06
|
macimorelin
|
WHO Anatomical Therapeutic Chemical classification |
|
macimorelin |
| 0‑L |
V04CE
|
Tests for liver functional capacity
|
WHO Anatomical Therapeutic Chemical classification |
|
Tests for liver functional capacity |
| 0‑L |
V04CE01
|
galactose
|
WHO Anatomical Therapeutic Chemical classification |
|
galactose |
| 0‑L |
V04CE02
|
sulfobromophthalein
|
WHO Anatomical Therapeutic Chemical classification |
|
sulfobromophthalein |
| 0‑L |
V04CE03
|
methacetin (13C)
|
WHO Anatomical Therapeutic Chemical classification |
|
methacetin (13C) |
| 0‑L |
V04CF
|
Tuberculosis diagnostics
|
WHO Anatomical Therapeutic Chemical classification |
|
Tuberculosis diagnostics |
| 0‑L |
V04CF01
|
tuberculin
|
WHO Anatomical Therapeutic Chemical classification |
|
tuberculin |
| 0‑L |
V04CG
|
Tests for gastric secretion
|
WHO Anatomical Therapeutic Chemical classification |
|
Tests for gastric secretion |
| 0‑L |
V04CG01
|
cation exchange resins
|
WHO Anatomical Therapeutic Chemical classification |
|
cation exchange resins |
| 0‑L |
V04CG02
|
betazole
|
WHO Anatomical Therapeutic Chemical classification |
|
betazole |
| 0‑L |
V04CG03
|
histamine phosphate
|
WHO Anatomical Therapeutic Chemical classification |
|
histamine phosphate |
| 0‑L |
V04CG04
|
pentagastrin
|
WHO Anatomical Therapeutic Chemical classification |
|
pentagastrin |
| 0‑L |
V04CG05
|
methylthioninium chloride
|
WHO Anatomical Therapeutic Chemical classification |
|
methylthioninium chloride |
| 0‑L |
V04CG30
|
caffeine and sodium benzoate
|
WHO Anatomical Therapeutic Chemical classification |
|
caffeine and sodium benzoate |
| 0‑L |
V04CH
|
Tests for renal function and ureteral injuries
|
WHO Anatomical Therapeutic Chemical classification |
|
Tests for renal function and ureteral injuries |
| 0‑L |
V04CH01
|
inulin and other polyfructosans
|
WHO Anatomical Therapeutic Chemical classification |
|
inulin and other polyfructosans |
| 0‑L |
V04CH02
|
indigo carmine
|
WHO Anatomical Therapeutic Chemical classification |
|
indigo carmine |
| 0‑L |
V04CH03
|
phenolsulfonphthalein
|
WHO Anatomical Therapeutic Chemical classification |
|
phenolsulfonphthalein |
| 0‑L |
V04CH04
|
alsactide
|
WHO Anatomical Therapeutic Chemical classification |
|
alsactide |
| 0‑L |
V04CH30
|
aminohippuric acid
|
WHO Anatomical Therapeutic Chemical classification |
|
aminohippuric acid |
| 0‑L |
V04CJ
|
Tests for thyreoidea function
|
WHO Anatomical Therapeutic Chemical classification |
|
Tests for thyreoidea function |
| 0‑L |
V04CJ01
|
thyrotropin
|
WHO Anatomical Therapeutic Chemical classification |
|
thyrotropin |
| 0‑L |
V04CJ02
|
protirelin
|
WHO Anatomical Therapeutic Chemical classification |
|
protirelin |
| 0‑L |
V04CK
|
Tests for pancreatic function
|
WHO Anatomical Therapeutic Chemical classification |
|
Tests for pancreatic function |
| 0‑L |
V04CK01
|
secretin
|
WHO Anatomical Therapeutic Chemical classification |
|
secretin |
| 0‑L |
V04CK02
|
pancreozymin (cholecystokinin)
|
WHO Anatomical Therapeutic Chemical classification |
|
pancreozymin (cholecystokinin) |
| 0‑L |
V04CK03
|
bentiromide
|
WHO Anatomical Therapeutic Chemical classification |
|
bentiromide |
| 0‑L |
V04CL
|
Tests for allergic diseases
|
WHO Anatomical Therapeutic Chemical classification |
|
Tests for allergic diseases |
| 0‑L |
V04CM
|
Tests for fertility disturbances
|
WHO Anatomical Therapeutic Chemical classification |
|
Tests for fertility disturbances |
| 0‑L |
V04CM01
|
gonadorelin
|
WHO Anatomical Therapeutic Chemical classification |
|
gonadorelin |
| 0‑L |
V04CX
|
Other diagnostic agents
|
WHO Anatomical Therapeutic Chemical classification |
|
Other diagnostic agents |
| 0‑L |
V06
|
GENERAL NUTRIENTS
|
WHO Anatomical Therapeutic Chemical classification |
|
GENERAL NUTRIENTS |
| 0‑L |
V06A
|
DIET FORMULATIONS FOR TREATMENT OF OBESITY
|
WHO Anatomical Therapeutic Chemical classification |
|
DIET FORMULATIONS FOR TREATMENT OF OBESITY |
| 0‑L |
V06AA
|
Low-energy diets
|
WHO Anatomical Therapeutic Chemical classification |
|
Low-energy diets |
| 0‑L |
V06B
|
PROTEIN SUPPLEMENTS
|
WHO Anatomical Therapeutic Chemical classification |
|
PROTEIN SUPPLEMENTS |
| 0‑L |
V06C
|
INFANT FORMULAS
|
WHO Anatomical Therapeutic Chemical classification |
|
INFANT FORMULAS |
| 0‑L |
V06CA
|
Nutrients without phenylalanine
|
WHO Anatomical Therapeutic Chemical classification |
|
Nutrients without phenylalanine |
| 0‑L |
V06D
|
OTHER NUTRIENTS
|
WHO Anatomical Therapeutic Chemical classification |
|
OTHER NUTRIENTS |
| 0‑L |
V06DA
|
Carbohydrates/proteins/minerals/vitamins, combinations
|
WHO Anatomical Therapeutic Chemical classification |
|
Carbohydrates/proteins/minerals/vitamins, combinations |
| 0‑L |
V06DB
|
Fat/carbohydrates/proteins/minerals/vitamins, combinations
|
WHO Anatomical Therapeutic Chemical classification |
|
Fat/carbohydrates/proteins/minerals/vitamins, combinations |
| 0‑L |
V06DC
|
Carbohydrates
|
WHO Anatomical Therapeutic Chemical classification |
|
Carbohydrates |
| 0‑L |
V06DC01
|
glucose
|
WHO Anatomical Therapeutic Chemical classification |
|
glucose |
| 0‑L |
V06DC02
|
fructose
|
WHO Anatomical Therapeutic Chemical classification |
|
fructose |
| 0‑L |
V06DD
|
Amino acids, incl. combinations with polypeptides
|
WHO Anatomical Therapeutic Chemical classification |
|
Amino acids, incl. combinations with polypeptides |
| 0‑L |
V06DE
|
Amino acids/carbohydrates/minerals/vitamins, combinations
|
WHO Anatomical Therapeutic Chemical classification |
|
Amino acids/carbohydrates/minerals/vitamins, combinations |
| 0‑L |
V06DF
|
Milk substitutes
|
WHO Anatomical Therapeutic Chemical classification |
|
Milk substitutes |
| 0‑L |
V06DX
|
Other combinations of nutrients
|
WHO Anatomical Therapeutic Chemical classification |
|
Other combinations of nutrients |
| 0‑L |
V07
|
ALL OTHER NON-THERAPEUTIC PRODUCTS
|
WHO Anatomical Therapeutic Chemical classification |
|
ALL OTHER NON-THERAPEUTIC PRODUCTS |
| 0‑L |
V07A
|
ALL OTHER NON-THERAPEUTIC PRODUCTS
|
WHO Anatomical Therapeutic Chemical classification |
|
ALL OTHER NON-THERAPEUTIC PRODUCTS |
| 0‑L |
V07AA
|
Plasters
|
WHO Anatomical Therapeutic Chemical classification |
|
Plasters |
| 0‑L |
V07AB
|
Solvents and diluting agents, incl. irrigating solutions
|
WHO Anatomical Therapeutic Chemical classification |
|
Solvents and diluting agents, incl. irrigating solutions |
| 0‑L |
V07AC
|
Blood transfusion, auxiliary products
|
WHO Anatomical Therapeutic Chemical classification |
|
Blood transfusion, auxiliary products |
| 0‑L |
V07AD
|
Blood tests, auxiliary products
|
WHO Anatomical Therapeutic Chemical classification |
|
Blood tests, auxiliary products |
| 0‑L |
V07AN
|
Incontinence equipment
|
WHO Anatomical Therapeutic Chemical classification |
|
Incontinence equipment |
| 0‑L |
V07AR
|
Sensitivity tests, discs and tablets
|
WHO Anatomical Therapeutic Chemical classification |
|
Sensitivity tests, discs and tablets |
| 0‑L |
V07AS
|
Stomi equipment
|
WHO Anatomical Therapeutic Chemical classification |
|
Stomi equipment |
| 0‑L |
V07AT
|
Cosmetics
|
WHO Anatomical Therapeutic Chemical classification |
|
Cosmetics |
| 0‑L |
V07AV
|
Technical disinfectants
|
WHO Anatomical Therapeutic Chemical classification |
|
Technical disinfectants |
| 0‑L |
V07AX
|
Washing agents etc.
|
WHO Anatomical Therapeutic Chemical classification |
|
Washing agents etc. |
| 0‑L |
V07AY
|
Other non-therapeutic auxiliary products
|
WHO Anatomical Therapeutic Chemical classification |
|
Other non-therapeutic auxiliary products |
| 0‑L |
V07AZ
|
Chemicals and reagents for analysis
|
WHO Anatomical Therapeutic Chemical classification |
|
Chemicals and reagents for analysis |
| 0‑L |
V08
|
CONTRAST MEDIA
|
WHO Anatomical Therapeutic Chemical classification |
|
CONTRAST MEDIA |
| 0‑L |
V08A
|
X-RAY CONTRAST MEDIA, IODINATED
|
WHO Anatomical Therapeutic Chemical classification |
|
X-RAY CONTRAST MEDIA, IODINATED |
| 0‑L |
V08AA
|
Watersoluble, nephrotropic, high osmolar X-ray contrast media
|
WHO Anatomical Therapeutic Chemical classification |
|
Watersoluble, nephrotropic, high osmolar X-ray contrast media |
| 0‑L |
V08AA01
|
diatrizoic acid
|
WHO Anatomical Therapeutic Chemical classification |
|
diatrizoic acid |
| 0‑L |
V08AA02
|
metrizoic acid
|
WHO Anatomical Therapeutic Chemical classification |
|
metrizoic acid |
| 0‑L |
V08AA03
|
iodamide
|
WHO Anatomical Therapeutic Chemical classification |
|
iodamide |
| 0‑L |
V08AA04
|
iotalamic acid
|
WHO Anatomical Therapeutic Chemical classification |
|
iotalamic acid |
| 0‑L |
V08AA05
|
ioxitalamic acid
|
WHO Anatomical Therapeutic Chemical classification |
|
ioxitalamic acid |
| 0‑L |
V08AA06
|
ioglicic acid
|
WHO Anatomical Therapeutic Chemical classification |
|
ioglicic acid |
| 0‑L |
V08AA07
|
acetrizoic acid
|
WHO Anatomical Therapeutic Chemical classification |
|
acetrizoic acid |
| 0‑L |
V08AA08
|
iocarmic acid
|
WHO Anatomical Therapeutic Chemical classification |
|
iocarmic acid |
| 0‑L |
V08AA09
|
methiodal
|
WHO Anatomical Therapeutic Chemical classification |
|
methiodal |
| 0‑L |
V08AA10
|
diodone
|
WHO Anatomical Therapeutic Chemical classification |
|
diodone |
| 0‑L |
V08AB
|
Watersoluble, nephrotropic, low osmolar X-ray contrast media
|
WHO Anatomical Therapeutic Chemical classification |
|
Watersoluble, nephrotropic, low osmolar X-ray contrast media |
| 0‑L |
V08AB01
|
metrizamide
|
WHO Anatomical Therapeutic Chemical classification |
|
metrizamide |
| 0‑L |
V08AB02
|
iohexol
|
WHO Anatomical Therapeutic Chemical classification |
|
iohexol |
| 0‑L |
V08AB03
|
ioxaglic acid
|
WHO Anatomical Therapeutic Chemical classification |
|
ioxaglic acid |
| 0‑L |
V08AB04
|
iopamidol
|
WHO Anatomical Therapeutic Chemical classification |
|
iopamidol |
| 0‑L |
V08AB05
|
iopromide
|
WHO Anatomical Therapeutic Chemical classification |
|
iopromide |
| 0‑L |
V08AB06
|
iotrolan
|
WHO Anatomical Therapeutic Chemical classification |
|
iotrolan |
| 0‑L |
V08AB07
|
ioversol
|
WHO Anatomical Therapeutic Chemical classification |
|
ioversol |
| 0‑L |
V08AB08
|
iopentol
|
WHO Anatomical Therapeutic Chemical classification |
|
iopentol |
| 0‑L |
V08AB09
|
iodixanol
|
WHO Anatomical Therapeutic Chemical classification |
|
iodixanol |
| 0‑L |
V08AB10
|
iomeprol
|
WHO Anatomical Therapeutic Chemical classification |
|
iomeprol |
| 0‑L |
V08AB11
|
iobitridol
|
WHO Anatomical Therapeutic Chemical classification |
|
iobitridol |
| 0‑L |
V08AB12
|
ioxilan
|
WHO Anatomical Therapeutic Chemical classification |
|
ioxilan |
| 0‑L |
V08AC
|
Watersoluble, hepatotropic X-ray contrast media
|
WHO Anatomical Therapeutic Chemical classification |
|
Watersoluble, hepatotropic X-ray contrast media |
| 0‑L |
V08AC01
|
iodoxamic acid
|
WHO Anatomical Therapeutic Chemical classification |
|
iodoxamic acid |
| 0‑L |
V08AC02
|
iotroxic acid
|
WHO Anatomical Therapeutic Chemical classification |
|
iotroxic acid |
| 0‑L |
V08AC03
|
ioglycamic acid
|
WHO Anatomical Therapeutic Chemical classification |
|
ioglycamic acid |
| 0‑L |
V08AC04
|
adipiodone
|
WHO Anatomical Therapeutic Chemical classification |
|
adipiodone |
| 0‑L |
V08AC05
|
iobenzamic acid
|
WHO Anatomical Therapeutic Chemical classification |
|
iobenzamic acid |
| 0‑L |
V08AC06
|
iopanoic acid
|
WHO Anatomical Therapeutic Chemical classification |
|
iopanoic acid |
| 0‑L |
V08AC07
|
iocetamic acid
|
WHO Anatomical Therapeutic Chemical classification |
|
iocetamic acid |
| 0‑L |
V08AC08
|
sodium iopodate
|
WHO Anatomical Therapeutic Chemical classification |
|
sodium iopodate |
| 0‑L |
V08AC09
|
tyropanoic acid
|
WHO Anatomical Therapeutic Chemical classification |
|
tyropanoic acid |
| 0‑L |
V08AC10
|
calcium iopodate
|
WHO Anatomical Therapeutic Chemical classification |
|
calcium iopodate |
| 0‑L |
V08AD
|
Non-watersoluble X-ray contrast media
|
WHO Anatomical Therapeutic Chemical classification |
|
Non-watersoluble X-ray contrast media |
| 0‑L |
V08AD01
|
ethyl esters of iodised fatty acids
|
WHO Anatomical Therapeutic Chemical classification |
|
ethyl esters of iodised fatty acids |
| 0‑L |
V08AD02
|
iopydol
|
WHO Anatomical Therapeutic Chemical classification |
|
iopydol |
| 0‑L |
V08AD03
|
propyliodone
|
WHO Anatomical Therapeutic Chemical classification |
|
propyliodone |
| 0‑L |
V08AD04
|
iofendylate
|
WHO Anatomical Therapeutic Chemical classification |
|
iofendylate |
| 0‑L |
V08B
|
X-RAY CONTRAST MEDIA, NON-IODINATED
|
WHO Anatomical Therapeutic Chemical classification |
|
X-RAY CONTRAST MEDIA, NON-IODINATED |
| 0‑L |
V08BA
|
Barium sulfate containing X-ray contrast media
|
WHO Anatomical Therapeutic Chemical classification |
|
Barium sulfate containing X-ray contrast media |
| 0‑L |
V08BA01
|
barium sulfate with suspending agents
|
WHO Anatomical Therapeutic Chemical classification |
|
barium sulfate with suspending agents |
| 0‑L |
V08BA02
|
barium sulfate without suspending agents
|
WHO Anatomical Therapeutic Chemical classification |
|
barium sulfate without suspending agents |
| 0‑L |
V08C
|
MAGNETIC RESONANCE IMAGING CONTRAST MEDIA
|
WHO Anatomical Therapeutic Chemical classification |
|
MAGNETIC RESONANCE IMAGING CONTRAST MEDIA |
| 0‑L |
V08CA
|
Paramagnetic contrast media
|
WHO Anatomical Therapeutic Chemical classification |
|
Paramagnetic contrast media |
| 0‑L |
V08CA01
|
gadopentetic acid
|
WHO Anatomical Therapeutic Chemical classification |
|
gadopentetic acid |
| 0‑L |
V08CA02
|
gadoteric acid
|
WHO Anatomical Therapeutic Chemical classification |
|
gadoteric acid |
| 0‑L |
V08CA03
|
gadodiamide
|
WHO Anatomical Therapeutic Chemical classification |
|
gadodiamide |
| 0‑L |
V08CA04
|
gadoteridol
|
WHO Anatomical Therapeutic Chemical classification |
|
gadoteridol |
| 0‑L |
V08CA05
|
mangafodipir
|
WHO Anatomical Therapeutic Chemical classification |
|
mangafodipir |
| 0‑L |
V08CA06
|
gadoversetamide
|
WHO Anatomical Therapeutic Chemical classification |
|
gadoversetamide |
| 0‑L |
V08CA07
|
ferric ammonium citrate
|
WHO Anatomical Therapeutic Chemical classification |
|
ferric ammonium citrate |
| 0‑L |
V08CA08
|
gadobenic acid
|
WHO Anatomical Therapeutic Chemical classification |
|
gadobenic acid |
| 0‑L |
V08CA09
|
gadobutrol
|
WHO Anatomical Therapeutic Chemical classification |
|
gadobutrol |
| 0‑L |
V08CA10
|
gadoxetic acid
|
WHO Anatomical Therapeutic Chemical classification |
|
gadoxetic acid |
| 0‑L |
V08CA11
|
gadofosveset
|
WHO Anatomical Therapeutic Chemical classification |
|
gadofosveset |
| 0‑L |
V08CB
|
Superparamagnetic contrast media
|
WHO Anatomical Therapeutic Chemical classification |
|
Superparamagnetic contrast media |
| 0‑L |
V08CB01
|
ferumoxsil
|
WHO Anatomical Therapeutic Chemical classification |
|
ferumoxsil |
| 0‑L |
V08CB02
|
ferristene
|
WHO Anatomical Therapeutic Chemical classification |
|
ferristene |
| 0‑L |
V08CB03
|
iron oxide, nanoparticles
|
WHO Anatomical Therapeutic Chemical classification |
|
iron oxide, nanoparticles |
| 0‑L |
V08CX
|
Other magnetic resonance imaging contrast media
|
WHO Anatomical Therapeutic Chemical classification |
|
Other magnetic resonance imaging contrast media |
| 0‑L |
V08CX01
|
perflubron
|
WHO Anatomical Therapeutic Chemical classification |
|
perflubron |
| 0‑L |
V08D
|
ULTRASOUND CONTRAST MEDIA
|
WHO Anatomical Therapeutic Chemical classification |
|
ULTRASOUND CONTRAST MEDIA |
| 0‑L |
V08DA
|
Ultrasound contrast media
|
WHO Anatomical Therapeutic Chemical classification |
|
Ultrasound contrast media |
| 0‑L |
V08DA01
|
microspheres of human albumin
|
WHO Anatomical Therapeutic Chemical classification |
|
microspheres of human albumin |
| 0‑L |
V08DA02
|
microparticles of galactose
|
WHO Anatomical Therapeutic Chemical classification |
|
microparticles of galactose |
| 0‑L |
V08DA03
|
perflenapent
|
WHO Anatomical Therapeutic Chemical classification |
|
perflenapent |
| 0‑L |
V08DA04
|
microspheres of phospholipids
|
WHO Anatomical Therapeutic Chemical classification |
|
microspheres of phospholipids |
| 0‑L |
V08DA05
|
sulfur hexafluoride
|
WHO Anatomical Therapeutic Chemical classification |
|
sulfur hexafluoride |
| 0‑L |
V08DA06
|
perflubutane polymer microspheres
|
WHO Anatomical Therapeutic Chemical classification |
|
perflubutane polymer microspheres |
| 0‑L |
V09
|
DIAGNOSTIC RADIOPHARMACEUTICALS
|
WHO Anatomical Therapeutic Chemical classification |
|
DIAGNOSTIC RADIOPHARMACEUTICALS |
| 0‑L |
V09A
|
CENTRAL NERVOUS SYSTEM
|
WHO Anatomical Therapeutic Chemical classification |
|
CENTRAL NERVOUS SYSTEM |
| 0‑L |
V09AA
|
Technetium (99mTc) compounds
|
WHO Anatomical Therapeutic Chemical classification |
|
Technetium (99mTc) compounds |
| 0‑L |
V09AA01
|
technetium (99mTc) exametazime
|
WHO Anatomical Therapeutic Chemical classification |
|
technetium (99mTc) exametazime |
| 0‑L |
V09AA02
|
technetium (99mTc) bicisate
|
WHO Anatomical Therapeutic Chemical classification |
|
technetium (99mTc) bicisate |
| 0‑L |
V09AB
|
Iodine (123I) compounds
|
WHO Anatomical Therapeutic Chemical classification |
|
Iodine (123I) compounds |
| 0‑L |
V09AB01
|
iodine iofetamine (123I)
|
WHO Anatomical Therapeutic Chemical classification |
|
iodine iofetamine (123I) |
| 0‑L |
V09AB02
|
iodine iolopride (123I)
|
WHO Anatomical Therapeutic Chemical classification |
|
iodine iolopride (123I) |
| 0‑L |
V09AB03
|
iodine ioflupane (123I)
|
WHO Anatomical Therapeutic Chemical classification |
|
iodine ioflupane (123I) |
| 0‑L |
V09AX
|
Other central nervous system diagnostic radiopharmaceuticals
|
WHO Anatomical Therapeutic Chemical classification |
|
Other central nervous system diagnostic radiopharmaceuticals |
| 0‑L |
V09AX01
|
indium (111In) pentetic acid
|
WHO Anatomical Therapeutic Chemical classification |
|
indium (111In) pentetic acid |
| 0‑L |
V09AX03
|
iodine (124I) 2beta-carbomethoxy-3beta-(4 iodophenyl)-tropane
|
WHO Anatomical Therapeutic Chemical classification |
|
iodine (124I) 2beta-carbomethoxy-3beta-(4 iodophenyl)-tropane |
| 0‑L |
V09AX04
|
flutemetamol (18F)
|
WHO Anatomical Therapeutic Chemical classification |
|
flutemetamol (18F) |
| 0‑L |
V09AX05
|
florbetapir (18F)
|
WHO Anatomical Therapeutic Chemical classification |
|
florbetapir (18F) |
| 0‑L |
V09AX06
|
florbetaben (18F)
|
WHO Anatomical Therapeutic Chemical classification |
|
florbetaben (18F) |
| 0‑L |
V09B
|
SKELETON
|
WHO Anatomical Therapeutic Chemical classification |
|
SKELETON |
| 0‑L |
V09BA
|
Technetium (99mTc) compounds
|
WHO Anatomical Therapeutic Chemical classification |
|
Technetium (99mTc) compounds |
| 0‑L |
V09BA01
|
technetium (99mTc) oxidronic acid
|
WHO Anatomical Therapeutic Chemical classification |
|
technetium (99mTc) oxidronic acid |
| 0‑L |
V09BA02
|
technetium (99mTc) medronic acid
|
WHO Anatomical Therapeutic Chemical classification |
|
technetium (99mTc) medronic acid |
| 0‑L |
V09BA03
|
technetium (99mTc) pyrophosphate
|
WHO Anatomical Therapeutic Chemical classification |
|
technetium (99mTc) pyrophosphate |
| 0‑L |
V09BA04
|
technetium (99mTc) butedronic acid
|
WHO Anatomical Therapeutic Chemical classification |
|
technetium (99mTc) butedronic acid |
| 0‑L |
V09C
|
RENAL SYSTEM
|
WHO Anatomical Therapeutic Chemical classification |
|
RENAL SYSTEM |
| 0‑L |
V09CA
|
Technetium (99mTc) compounds
|
WHO Anatomical Therapeutic Chemical classification |
|
Technetium (99mTc) compounds |
| 0‑L |
V09CA01
|
technetium (99mTc) pentetic acid
|
WHO Anatomical Therapeutic Chemical classification |
|
technetium (99mTc) pentetic acid |
| 0‑L |
V09CA02
|
technetium (99mTc) succimer
|
WHO Anatomical Therapeutic Chemical classification |
|
technetium (99mTc) succimer |
| 0‑L |
V09CA03
|
technetium (99mTc) mertiatide
|
WHO Anatomical Therapeutic Chemical classification |
|
technetium (99mTc) mertiatide |
| 0‑L |
V09CA04
|
technetium (99mTc) gluceptate
|
WHO Anatomical Therapeutic Chemical classification |
|
technetium (99mTc) gluceptate |
| 0‑L |
V09CA05
|
technetium (99mTc) gluconate
|
WHO Anatomical Therapeutic Chemical classification |
|
technetium (99mTc) gluconate |
| 0‑L |
V09CA06
|
technetium (99mTc) ethylenedicysteine
|
WHO Anatomical Therapeutic Chemical classification |
|
technetium (99mTc) ethylenedicysteine |
| 0‑L |
V09CX
|
Other renal system diagnostic radiopharmaceuticals
|
WHO Anatomical Therapeutic Chemical classification |
|
Other renal system diagnostic radiopharmaceuticals |
| 0‑L |
V09CX01
|
sodium iodohippurate (123I)
|
WHO Anatomical Therapeutic Chemical classification |
|
sodium iodohippurate (123I) |
| 0‑L |
V09CX02
|
sodium iodohippurate (131I)
|
WHO Anatomical Therapeutic Chemical classification |
|
sodium iodohippurate (131I) |
| 0‑L |
V09CX03
|
sodium iothalamate (125I)
|
WHO Anatomical Therapeutic Chemical classification |
|
sodium iothalamate (125I) |
| 0‑L |
V09CX04
|
chromium (51Cr) edetate
|
WHO Anatomical Therapeutic Chemical classification |
|
chromium (51Cr) edetate |
| 0‑L |
V09D
|
HEPATIC AND RETICULO ENDOTHELIAL SYSTEM
|
WHO Anatomical Therapeutic Chemical classification |
|
HEPATIC AND RETICULO ENDOTHELIAL SYSTEM |
| 0‑L |
V09DA
|
Technetium (99mTc) compounds
|
WHO Anatomical Therapeutic Chemical classification |
|
Technetium (99mTc) compounds |
| 0‑L |
V09DA01
|
technetium (99mTc) disofenin
|
WHO Anatomical Therapeutic Chemical classification |
|
technetium (99mTc) disofenin |
| 0‑L |
V09DA02
|
technetium (99mTc) etifenin
|
WHO Anatomical Therapeutic Chemical classification |
|
technetium (99mTc) etifenin |
| 0‑L |
V09DA03
|
technetium (99mTc) lidofenin
|
WHO Anatomical Therapeutic Chemical classification |
|
technetium (99mTc) lidofenin |
| 0‑L |
V09DA04
|
technetium (99mTc) mebrofenin
|
WHO Anatomical Therapeutic Chemical classification |
|
technetium (99mTc) mebrofenin |
| 0‑L |
V09DA05
|
technetium (99mTc) galtifenin
|
WHO Anatomical Therapeutic Chemical classification |
|
technetium (99mTc) galtifenin |
| 0‑L |
V09DB
|
Technetium (99mTc), particles and colloids
|
WHO Anatomical Therapeutic Chemical classification |
|
Technetium (99mTc), particles and colloids |
| 0‑L |
V09DB01
|
technetium (99mTc) nanocolloid
|
WHO Anatomical Therapeutic Chemical classification |
|
technetium (99mTc) nanocolloid |
| 0‑L |
V09DB02
|
technetium (99mTc) microcolloid
|
WHO Anatomical Therapeutic Chemical classification |
|
technetium (99mTc) microcolloid |
| 0‑L |
V09DB03
|
technetium (99mTc) millimicrospheres
|
WHO Anatomical Therapeutic Chemical classification |
|
technetium (99mTc) millimicrospheres |
| 0‑L |
V09DB04
|
technetium (99mTc) tin colloid
|
WHO Anatomical Therapeutic Chemical classification |
|
technetium (99mTc) tin colloid |
| 0‑L |
V09DB05
|
technetium (99mTc) sulfur colloid
|
WHO Anatomical Therapeutic Chemical classification |
|
technetium (99mTc) sulfur colloid |
| 0‑L |
V09DB06
|
technetium (99mTc) rheniumsulfide colloid
|
WHO Anatomical Therapeutic Chemical classification |
|
technetium (99mTc) rheniumsulfide colloid |
| 0‑L |
V09DB07
|
technetium (99mTc) phytate
|
WHO Anatomical Therapeutic Chemical classification |
|
technetium (99mTc) phytate |
| 0‑L |
V09DX
|
Other hepatic and reticulo endothelial system diagnostic radiopharmaceuticals
|
WHO Anatomical Therapeutic Chemical classification |
|
Other hepatic and reticulo endothelial system diagnostic radiopharmaceuticals |
| 0‑L |
V09DX01
|
selenium (75Se) tauroselcholic acid
|
WHO Anatomical Therapeutic Chemical classification |
|
selenium (75Se) tauroselcholic acid |
| 0‑L |
V09E
|
RESPIRATORY SYSTEM
|
WHO Anatomical Therapeutic Chemical classification |
|
RESPIRATORY SYSTEM |
| 0‑L |
V09EA
|
Technetium (99mTc), inhalants
|
WHO Anatomical Therapeutic Chemical classification |
|
Technetium (99mTc), inhalants |
| 0‑L |
V09EA01
|
technetium (99mTc) pentetic acid
|
WHO Anatomical Therapeutic Chemical classification |
|
technetium (99mTc) pentetic acid |
| 0‑L |
V09EA02
|
technetium (99mTc) technegas
|
WHO Anatomical Therapeutic Chemical classification |
|
technetium (99mTc) technegas |
| 0‑L |
V09EA03
|
technetium (99mTc) nanocolloid
|
WHO Anatomical Therapeutic Chemical classification |
|
technetium (99mTc) nanocolloid |
| 0‑L |
V09EB
|
Technetium (99mTc), particles for injection
|
WHO Anatomical Therapeutic Chemical classification |
|
Technetium (99mTc), particles for injection |
| 0‑L |
V09EB01
|
technetium (99mTc) macrosalb
|
WHO Anatomical Therapeutic Chemical classification |
|
technetium (99mTc) macrosalb |
| 0‑L |
V09EB02
|
technetium (99mTc) microspheres
|
WHO Anatomical Therapeutic Chemical classification |
|
technetium (99mTc) microspheres |
| 0‑L |
V09EX
|
Other respiratory system diagnostic radiopharmaceuticals
|
WHO Anatomical Therapeutic Chemical classification |
|
Other respiratory system diagnostic radiopharmaceuticals |
| 0‑L |
V09EX01
|
krypton (81mKr) gas
|
WHO Anatomical Therapeutic Chemical classification |
|
krypton (81mKr) gas |
| 0‑L |
V09EX02
|
xenon (127Xe) gas
|
WHO Anatomical Therapeutic Chemical classification |
|
xenon (127Xe) gas |
| 0‑L |
V09EX03
|
xenon (133Xe) gas
|
WHO Anatomical Therapeutic Chemical classification |
|
xenon (133Xe) gas |
| 0‑L |
V09F
|
THYROID
|
WHO Anatomical Therapeutic Chemical classification |
|
THYROID |
| 0‑L |
V09FX
|
Various thyroid diagnostic radiopharmaceuticals
|
WHO Anatomical Therapeutic Chemical classification |
|
Various thyroid diagnostic radiopharmaceuticals |
| 0‑L |
V09FX01
|
technetium (99mTc) pertechnetate
|
WHO Anatomical Therapeutic Chemical classification |
|
technetium (99mTc) pertechnetate |
| 0‑L |
V09FX02
|
sodium iodide (123I)
|
WHO Anatomical Therapeutic Chemical classification |
|
sodium iodide (123I) |
| 0‑L |
V09FX03
|
sodium iodide (131I)
|
WHO Anatomical Therapeutic Chemical classification |
|
sodium iodide (131I) |
| 0‑L |
V09FX04
|
sodium iodide (124I)
|
WHO Anatomical Therapeutic Chemical classification |
|
sodium iodide (124I) |
| 0‑L |
V09G
|
CARDIOVASCULAR SYSTEM
|
WHO Anatomical Therapeutic Chemical classification |
|
CARDIOVASCULAR SYSTEM |
| 0‑L |
V09GA
|
Technetium (99mTc) compounds
|
WHO Anatomical Therapeutic Chemical classification |
|
Technetium (99mTc) compounds |
| 0‑L |
V09GA01
|
technetium (99mTc) sestamibi
|
WHO Anatomical Therapeutic Chemical classification |
|
technetium (99mTc) sestamibi |
| 0‑L |
V09GA02
|
technetium (99mTc) tetrofosmin
|
WHO Anatomical Therapeutic Chemical classification |
|
technetium (99mTc) tetrofosmin |
| 0‑L |
V09GA03
|
technetium (99mTc) teboroxime
|
WHO Anatomical Therapeutic Chemical classification |
|
technetium (99mTc) teboroxime |
| 0‑L |
V09GA04
|
technetium (99mTc) human albumin
|
WHO Anatomical Therapeutic Chemical classification |
|
technetium (99mTc) human albumin |
| 0‑L |
V09GA05
|
technetium (99mTc) furifosmin
|
WHO Anatomical Therapeutic Chemical classification |
|
technetium (99mTc) furifosmin |
| 0‑L |
V09GA06
|
technetium (99mTc) stannous agent labelled cells
|
WHO Anatomical Therapeutic Chemical classification |
|
technetium (99mTc) stannous agent labelled cells |
| 0‑L |
V09GA07
|
technetium (99mTc) apcitide
|
WHO Anatomical Therapeutic Chemical classification |
|
technetium (99mTc) apcitide |
| 0‑L |
V09GB
|
Iodine (125I) compounds
|
WHO Anatomical Therapeutic Chemical classification |
|
Iodine (125I) compounds |
| 0‑L |
V09GB01
|
fibrinogen (125I)
|
WHO Anatomical Therapeutic Chemical classification |
|
fibrinogen (125I) |
| 0‑L |
V09GB02
|
iodine (125I) human albumin
|
WHO Anatomical Therapeutic Chemical classification |
|
iodine (125I) human albumin |
| 0‑L |
V09GX
|
Other cardiovascular system diagnostic radiopharmaceuticals
|
WHO Anatomical Therapeutic Chemical classification |
|
Other cardiovascular system diagnostic radiopharmaceuticals |
| 0‑L |
V09GX01
|
thallium (201Tl) chloride
|
WHO Anatomical Therapeutic Chemical classification |
|
thallium (201Tl) chloride |
| 0‑L |
V09GX02
|
indium (111In) imciromab
|
WHO Anatomical Therapeutic Chemical classification |
|
indium (111In) imciromab |
| 0‑L |
V09GX03
|
chromium (51Cr) chromate labelled cells
|
WHO Anatomical Therapeutic Chemical classification |
|
chromium (51Cr) chromate labelled cells |
| 0‑L |
V09GX04
|
rubidium (82Rb) chloride
|
WHO Anatomical Therapeutic Chemical classification |
|
rubidium (82Rb) chloride |
| 0‑L |
V09H
|
INFLAMMATION AND INFECTION DETECTION
|
WHO Anatomical Therapeutic Chemical classification |
|
INFLAMMATION AND INFECTION DETECTION |
| 0‑L |
V09HA
|
Technetium (99mTc) compounds
|
WHO Anatomical Therapeutic Chemical classification |
|
Technetium (99mTc) compounds |
| 0‑L |
V09HA01
|
technetium (99mTc) human immunoglobulin
|
WHO Anatomical Therapeutic Chemical classification |
|
technetium (99mTc) human immunoglobulin |
| 0‑L |
V09HA02
|
technetium (99mTc) exametazime labelled cells
|
WHO Anatomical Therapeutic Chemical classification |
|
technetium (99mTc) exametazime labelled cells |
| 0‑L |
V09HA03
|
technetium (99mTc) antigranulocyte antibody
|
WHO Anatomical Therapeutic Chemical classification |
|
technetium (99mTc) antigranulocyte antibody |
| 0‑L |
V09HA04
|
technetium (99mTc) sulesomab
|
WHO Anatomical Therapeutic Chemical classification |
|
technetium (99mTc) sulesomab |
| 0‑L |
V09HB
|
Indium (111In) compounds
|
WHO Anatomical Therapeutic Chemical classification |
|
Indium (111In) compounds |
| 0‑L |
V09HB01
|
indium (111In) oxinate labelled cells
|
WHO Anatomical Therapeutic Chemical classification |
|
indium (111In) oxinate labelled cells |
| 0‑L |
V09HB02
|
indium (111In) tropolonate labelled cells
|
WHO Anatomical Therapeutic Chemical classification |
|
indium (111In) tropolonate labelled cells |
| 0‑L |
V09HX
|
Other diagnostic radiopharmaceuticals for inflammation and infection detection
|
WHO Anatomical Therapeutic Chemical classification |
|
Other diagnostic radiopharmaceuticals for inflammation and infection detection |
| 0‑L |
V09HX01
|
gallium (67Ga) citrate
|
WHO Anatomical Therapeutic Chemical classification |
|
gallium (67Ga) citrate |
| 0‑L |
V09I
|
TUMOUR DETECTION
|
WHO Anatomical Therapeutic Chemical classification |
|
TUMOUR DETECTION |
| 0‑L |
V09IA
|
Technetium (99mTc) compounds
|
WHO Anatomical Therapeutic Chemical classification |
|
Technetium (99mTc) compounds |
| 0‑L |
V09IA01
|
technetium (99mTc) antiCarcinoEmbryonicAntigen antibody
|
WHO Anatomical Therapeutic Chemical classification |
|
technetium (99mTc) antiCarcinoEmbryonicAntigen antibody |
| 0‑L |
V09IA02
|
technetium (99mTc) antimelanoma antibody
|
WHO Anatomical Therapeutic Chemical classification |
|
technetium (99mTc) antimelanoma antibody |
| 0‑L |
V09IA03
|
technetium (99mTc) pentavalent succimer
|
WHO Anatomical Therapeutic Chemical classification |
|
technetium (99mTc) pentavalent succimer |
| 0‑L |
V09IA04
|
technetium (99mTc) votumumab
|
WHO Anatomical Therapeutic Chemical classification |
|
technetium (99mTc) votumumab |
| 0‑L |
V09IA05
|
technetium (99mTc) depreotide
|
WHO Anatomical Therapeutic Chemical classification |
|
technetium (99mTc) depreotide |
| 0‑L |
V09IA06
|
technetium (99mTc) arcitumomab
|
WHO Anatomical Therapeutic Chemical classification |
|
technetium (99mTc) arcitumomab |
| 0‑L |
V09IA07
|
technetium (99mTc) hynic-octreotide
|
WHO Anatomical Therapeutic Chemical classification |
|
technetium (99mTc) hynic-octreotide |
| 0‑L |
V09IA08
|
technetium (99mTc) etarfolatide
|
WHO Anatomical Therapeutic Chemical classification |
|
technetium (99mTc) etarfolatide |
| 0‑L |
V09IA09
|
technetium (99mTc) tilmanocept
|
WHO Anatomical Therapeutic Chemical classification |
|
technetium (99mTc) tilmanocept |
| 0‑L |
V09IB
|
Indium (111In) compounds
|
WHO Anatomical Therapeutic Chemical classification |
|
Indium (111In) compounds |
| 0‑L |
V09IB01
|
indium (111In) pentetreotide
|
WHO Anatomical Therapeutic Chemical classification |
|
indium (111In) pentetreotide |
| 0‑L |
V09IB02
|
indium (111In) satumomab pendetide
|
WHO Anatomical Therapeutic Chemical classification |
|
indium (111In) satumomab pendetide |
| 0‑L |
V09IB03
|
indium (111In) antiovariumcarcinoma antibody
|
WHO Anatomical Therapeutic Chemical classification |
|
indium (111In) antiovariumcarcinoma antibody |
| 0‑L |
V09IB04
|
indium (111In) capromab pendetide
|
WHO Anatomical Therapeutic Chemical classification |
|
indium (111In) capromab pendetide |
| 0‑L |
V09IX
|
Other diagnostic radiopharmaceuticals for tumour detection
|
WHO Anatomical Therapeutic Chemical classification |
|
Other diagnostic radiopharmaceuticals for tumour detection |
| 0‑L |
V09IX01
|
iobenguane (123I)
|
WHO Anatomical Therapeutic Chemical classification |
|
iobenguane (123I) |
| 0‑L |
V09IX02
|
iobenguane (131I)
|
WHO Anatomical Therapeutic Chemical classification |
|
iobenguane (131I) |
| 0‑L |
V09IX03
|
iodine (125I) CC49-monoclonal antibody
|
WHO Anatomical Therapeutic Chemical classification |
|
iodine (125I) CC49-monoclonal antibody |
| 0‑L |
V09IX04
|
fludeoxyglucose (18F)
|
WHO Anatomical Therapeutic Chemical classification |
|
fludeoxyglucose (18F) |
| 0‑L |
V09IX05
|
fluorodopa (18F)
|
WHO Anatomical Therapeutic Chemical classification |
|
fluorodopa (18F) |
| 0‑L |
V09IX06
|
sodium fluoride (18F)
|
WHO Anatomical Therapeutic Chemical classification |
|
sodium fluoride (18F) |
| 0‑L |
V09IX07
|
fluoromethylcholine (18F)
|
WHO Anatomical Therapeutic Chemical classification |
|
fluoromethylcholine (18F) |
| 0‑L |
V09IX08
|
fluoroethylcholine (18F)
|
WHO Anatomical Therapeutic Chemical classification |
|
fluoroethylcholine (18F) |
| 0‑L |
V09IX09
|
gallium (68Ga) edotreotide
|
WHO Anatomical Therapeutic Chemical classification |
|
gallium (68Ga) edotreotide |
| 0‑L |
V09IX10
|
fluoroethyl-L-tyrosine (18F)
|
WHO Anatomical Therapeutic Chemical classification |
|
fluoroethyl-L-tyrosine (18F) |
| 0‑L |
V09IX11
|
fluoroestradiol (18F)
|
WHO Anatomical Therapeutic Chemical classification |
|
fluoroestradiol (18F) |
| 0‑L |
V09IX12
|
fluciclovine (18F)
|
WHO Anatomical Therapeutic Chemical classification |
|
fluciclovine (18F) |
| 0‑L |
V09X
|
OTHER DIAGNOSTIC RADIOPHARMACEUTICALS
|
WHO Anatomical Therapeutic Chemical classification |
|
OTHER DIAGNOSTIC RADIOPHARMACEUTICALS |
| 0‑L |
V09XA
|
Iodine (131I) compounds
|
WHO Anatomical Therapeutic Chemical classification |
|
Iodine (131I) compounds |
| 0‑L |
V09XA01
|
iodine (131I) norcholesterol
|
WHO Anatomical Therapeutic Chemical classification |
|
iodine (131I) norcholesterol |
| 0‑L |
V09XA02
|
iodocholesterol (131I)
|
WHO Anatomical Therapeutic Chemical classification |
|
iodocholesterol (131I) |
| 0‑L |
V09XA03
|
iodine (131I) human albumin
|
WHO Anatomical Therapeutic Chemical classification |
|
iodine (131I) human albumin |
| 0‑L |
V09XX
|
Various diagnostic radiopharmaceuticals
|
WHO Anatomical Therapeutic Chemical classification |
|
Various diagnostic radiopharmaceuticals |
| 0‑L |
V09XX01
|
cobalt (57Co) cyanocobalamine
|
WHO Anatomical Therapeutic Chemical classification |
|
cobalt (57Co) cyanocobalamine |
| 0‑L |
V09XX02
|
cobalt (58Co) cyanocobalamine
|
WHO Anatomical Therapeutic Chemical classification |
|
cobalt (58Co) cyanocobalamine |
| 0‑L |
V09XX03
|
selenium (75Se) norcholesterol
|
WHO Anatomical Therapeutic Chemical classification |
|
selenium (75Se) norcholesterol |
| 0‑L |
V09XX04
|
ferric (59Fe) citrate
|
WHO Anatomical Therapeutic Chemical classification |
|
ferric (59Fe) citrate |
| 0‑L |
V10
|
THERAPEUTIC RADIOPHARMACEUTICALS
|
WHO Anatomical Therapeutic Chemical classification |
|
THERAPEUTIC RADIOPHARMACEUTICALS |
| 0‑L |
V10A
|
ANTIINFLAMMATORY AGENTS
|
WHO Anatomical Therapeutic Chemical classification |
|
ANTIINFLAMMATORY AGENTS |
| 0‑L |
V10AA
|
Yttrium (90Y) compounds
|
WHO Anatomical Therapeutic Chemical classification |
|
Yttrium (90Y) compounds |
| 0‑L |
V10AA01
|
yttrium (90Y) citrate colloid
|
WHO Anatomical Therapeutic Chemical classification |
|
yttrium (90Y) citrate colloid |
| 0‑L |
V10AA02
|
yttrium (90Y) ferrihydroxide colloid
|
WHO Anatomical Therapeutic Chemical classification |
|
yttrium (90Y) ferrihydroxide colloid |
| 0‑L |
V10AA03
|
yttrium (90Y) silicate colloid
|
WHO Anatomical Therapeutic Chemical classification |
|
yttrium (90Y) silicate colloid |
| 0‑L |
V10AX
|
Other antiinflammatory therapeutic radiopharmaceuticals
|
WHO Anatomical Therapeutic Chemical classification |
|
Other antiinflammatory therapeutic radiopharmaceuticals |
| 0‑L |
V10AX01
|
phosphorous (32P) chromicphosphate colloid
|
WHO Anatomical Therapeutic Chemical classification |
|
phosphorous (32P) chromicphosphate colloid |
| 0‑L |
V10AX02
|
samarium (153Sm) hydroxyapatite colloid
|
WHO Anatomical Therapeutic Chemical classification |
|
samarium (153Sm) hydroxyapatite colloid |
| 0‑L |
V10AX03
|
dysprosium (165Dy) colloid
|
WHO Anatomical Therapeutic Chemical classification |
|
dysprosium (165Dy) colloid |
| 0‑L |
V10AX04
|
erbium (169Er) citrate colloid
|
WHO Anatomical Therapeutic Chemical classification |
|
erbium (169Er) citrate colloid |
| 0‑L |
V10AX05
|
rhenium (186Re) sulfide colloid
|
WHO Anatomical Therapeutic Chemical classification |
|
rhenium (186Re) sulfide colloid |
| 0‑L |
V10AX06
|
gold (198Au) colloidal
|
WHO Anatomical Therapeutic Chemical classification |
|
gold (198Au) colloidal |
| 0‑L |
V10B
|
PAIN PALLIATION (BONE SEEKING AGENTS)
|
WHO Anatomical Therapeutic Chemical classification |
|
PAIN PALLIATION (BONE SEEKING AGENTS) |
| 0‑L |
V10BX
|
Various pain palliation radiopharmaceuticals
|
WHO Anatomical Therapeutic Chemical classification |
|
Various pain palliation radiopharmaceuticals |
| 0‑L |
V10BX01
|
strontium (89Sr) chloride
|
WHO Anatomical Therapeutic Chemical classification |
|
strontium (89Sr) chloride |
| 0‑L |
V10BX02
|
samarium (153Sm) lexidronam
|
WHO Anatomical Therapeutic Chemical classification |
|
samarium (153Sm) lexidronam |
| 0‑L |
V10BX03
|
rhenium (186Re) etidronic acid
|
WHO Anatomical Therapeutic Chemical classification |
|
rhenium (186Re) etidronic acid |
| 0‑L |
V10X
|
OTHER THERAPEUTIC RADIOPHARMACEUTICALS
|
WHO Anatomical Therapeutic Chemical classification |
|
OTHER THERAPEUTIC RADIOPHARMACEUTICALS |
| 0‑L |
V10XA
|
Iodine (131I) compounds
|
WHO Anatomical Therapeutic Chemical classification |
|
Iodine (131I) compounds |
| 0‑L |
V10XA01
|
sodium iodide (131I)
|
WHO Anatomical Therapeutic Chemical classification |
|
sodium iodide (131I) |
| 0‑L |
V10XA02
|
iobenguane (131I)
|
WHO Anatomical Therapeutic Chemical classification |
|
iobenguane (131I) |
| 0‑L |
V10XA53
|
tositumomab/iodine (131I) tositumomab
|
WHO Anatomical Therapeutic Chemical classification |
|
tositumomab/iodine (131I) tositumomab |
| 0‑L |
V10XX
|
Various therapeutic radiopharmaceuticals
|
WHO Anatomical Therapeutic Chemical classification |
|
Various therapeutic radiopharmaceuticals |
| 0‑L |
V10XX01
|
sodium phosphate (32P)
|
WHO Anatomical Therapeutic Chemical classification |
|
sodium phosphate (32P) |
| 0‑L |
V10XX02
|
ibritumomab tiuxetan (90Y)
|
WHO Anatomical Therapeutic Chemical classification |
|
ibritumomab tiuxetan (90Y) |
| 0‑L |
V10XX03
|
radium (223Ra) dichloride
|
WHO Anatomical Therapeutic Chemical classification |
|
radium (223Ra) dichloride |
| 0‑L |
V20
|
SURGICAL DRESSINGS
|
WHO Anatomical Therapeutic Chemical classification |
|
SURGICAL DRESSINGS |
| This value set has 6082 codes in it. In order to keep the publication size manageable,
only a selection (500 codes) of the whole set of codes is shown.
|
|